Ticker,Drug,Indication,Stage,Date,Catalyst,Shares_Millions,Market_Cap,Volatility,Share_Price_D-1,Share_Price_D1,Share_Price_D5,Perc_Return_D1,Perc_Return_D5,XBI_Return_D1,XBI_Return_D5,Short_Interest_Pct,Year_Beta,Daily_Volum_Traded,row_id,has_endpoint,has_pvalue,has_effect,has_safety,has_sample,has_phase,has_partner,has_regulatory,has_financial,has_enrollment,has_clinical,has_catalyst,pos_count,neg_count,neu_count,headline_sentiment
SNDX,Niktimvo (axatilimab-csfr),Chronic Graft versus host disease (cGvHD)Â ,BLA Filing,1/2/2024,"BLA submitteed to the FDA, noted January 2, 2024.",86.0,1853.94083,47.8089,21.61,21.86,22.64,0.011502312,0.046562083,0.012282537,-0.047140884,12.18667,0.3223,27.4223,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
INCY,Niktimvo (axatilimab-csfr),Chronic Graft versus host disease (cGvHD)Â ,BLA Filing,1/2/2024,"BLA submitteed to the FDA, noted January 2, 2024.",195.0,14667.94963,26.2121,62.79,65.45,64.38,0.041490667,0.025007201,0.012282537,-0.047140884,3.11092,0.29539,95.47892,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
ATAI,EMP-01,Post-Traumatic Stress Disorder (PTSD)Â ,Phase 1,1/2/2024,"Phase 1 was well-tolerated, and treatment-related adverse events (AEs) were all expected and generally dose-dependent, noted on January 2, 2024.",214.0,280.5577,76.7738,1.41,1.69,2.19,0.181138825,0.440311839,0.012282537,-0.047140884,2.72094,0.19038,5.22094,2,0,0,0,1,0,1,0,0,0,0,0,0,2,0,0,1
AVXL,ANAVEX 2-73-RS-003 - (EXCELLENCE),Pediatric Rett SyndromeÂ ,Phase 2/3,1/2/2024,"Phase 2/3 results missed a primary endpoint on the LS Mean difference (SE) points between treated and placebo, noted January 2, 2024.",85.0,496.21296,88.6481,9.31,6.045,6.41,-0.431857607,-0.37322982,0.012282537,-0.047140884,22.07637,0.2929,56.00573,3,1,0,1,0,0,1,0,0,0,0,0,0,0,3,0,-1
ATXI,AJ201,Spinal and bulbar muscular atrophy (SBMA)Â ,Phase 1/2,1/2/2024,"Phase 1b/2 enrollment completed, noted January 2, 2024.",3.0,2.11961,106.4138,12.07503,12.00003,14.13754,-0.006230534,0.157693987,0.012282537,-0.047140884,1.7293,0.0,0.16552,4,0,0,0,0,0,1,0,0,0,1,0,0,2,0,0,1
SPRO,Tebipenem HBr (SPR994) - (PIVOT-PO),"Complicated urinary tract infection (cUTI), including acute pyelonephritis (AP)Â ",Phase 3,1/2/2024,"Phase 3 dosing initiated, noted January 2, 2024.",56.0,80.55896,48.2975,1.47,1.52,1.46,0.033447934,-0.006825965,0.012282537,-0.047140884,1.84249,0.13337,0.65182,5,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1
CTXR,Mino-Lok,Catheter related blood stream infection (CRBSI)Â ,Phase 3,1/2/2024,"Phase 3 enrollment was completed, noted January 2, 2024.",17.0,128.55627,58.412,18.9125,20.2175,18.6625,0.066725487,-0.013306916,0.012282537,-0.047140884,8.46801,0.03937,0.5833,6,0,0,0,0,0,1,0,0,0,1,0,0,2,0,0,1
NVS,Farabursen (RGLS8429) (MAD),Autosomal Dominant Polycystic Kidney Disease (ADPKD)Â ,Phase 1b,1/2/2024,"Phase 1b third cohort completed, noted January 2, 2024.",0.0,1411.16675,47.7725,4.52,4.4,4.45,-0.026907453,-0.015607898,0.012282537,-0.047140884,0.0,0.01319,0.03078,7,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1
AGIO,PYRUKYND (Mitapivat) - (ENERGIZE),ThalassemiaÂ ,Phase 3,1/3/2024,"Phase 3 data reported that the trial met its primary endpoint and key secondary endpoints, noted January 3, 2024.",58.0,1342.50864,35.5535,22.83,24.02,23.4,0.050811356,0.024660562,0.008682156,-0.02517095,12.29495,0.42335,64.6156,8,1,0,0,0,0,1,0,0,1,0,0,0,3,0,0,1
TEVA,AVT06 - (EYLEA biosimilar),Eye disordersÂ ,Phase 3,1/3/2024,"Phase 3 data reported that the trial met its primary endpoint, noted January 3, 2024.",0.0,12274.63466,37.7228,10.67,10.95,11.49,0.025903391,0.074041027,0.008682156,-0.02517095,1.25926,0.10705,159.06765,9,1,0,0,0,0,1,0,0,0,0,0,0,2,0,0,1
ALVO,AVT06 - (EYLEA biosimilar),Eye disordersÂ ,Phase 3,1/3/2024,"Phase 3 data reported that the trial met its primary endpoint, noted January 3, 2024.",301.0,3101.38715,40.855,11.36,11.68,12.21,0.027779564,0.072156875,0.008682156,-0.02517095,0.02756,0.03281,0.63091,10,1,0,0,0,0,1,0,0,0,0,0,0,2,0,0,1
DYN,DYNE-101 - (ACHIEVE),Myotonic Dystrophy Type 1 (DM1)Â ,Phase 1/2,1/3/2024,"Phase 1/2 MAD data reported a dose-dependent splicing correction and increase in muscle delivery and DMPK knockdown while also showing functional improvement in myotonia, noted January 3, 2024.",142.0,906.63648,83.4003,13.06,14.77,17.34,0.123043973,0.283461848,0.008682156,-0.02517095,15.85134,0.17516,309.23751,11,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
DYN,DYNE-251 - (DELIVER),Duchenne muscular dystrophy (DMD)Â ,Phase 1/2,1/3/2024,"Phase 1/2 initial data reported a mean absolute dystrophin level of 0.88% of normal and a 0.28% change from baseline at 6 months, noted January 3, 2024.",142.0,906.63648,83.4003,13.06,14.77,17.34,0.123043973,0.283461848,0.008682156,-0.02517095,15.85134,0.17516,309.23751,12,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ATHA,Fosgonimeton (ATH-1017) - (LIFT-AD),Alzheimerâ€™s diseaseÂ ,Phase 2/3,1/3/2024,"Phase 2/3 trial enrollment completed, noted January 3, 2024.",3.0,115.30538,69.7535,28.9,30.3,28.8,0.047306117,-0.003466208,0.008682156,-0.02517095,1.29185,0.13226,2.42009,13,0,0,0,0,0,1,0,0,0,1,0,0,2,0,0,1
APLM,Uproleselan,Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)Â ,Phase 3,1/3/2024,"Phase 3 enrollment completed, noted January 3, 2024.",1.0,85.50182,138.9394,91.93,95.5,94.7399,0.03809883,0.030107824,0.008682156,-0.02517095,0.08805,0.08805,0.65609,14,0,0,0,0,0,1,0,0,0,1,0,0,2,0,0,1
CMMB,nebokitug (CM-101) - (SPRING),Primary Sclerosing CholangitisÂ ,Phase 2,1/3/2024,"Phase 2 early enrollment completed, noted January 3, 2023.",5.0,6.32064,82.6604,2.1512,2.1388,2.18,-0.005780902,0.013299051,0.008682156,-0.02517095,0.1516,0.11831,0.08527,15,0,0,0,0,0,1,0,0,0,1,0,0,2,0,0,1
SLRX,Seclidemstat,Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)Â ,Phase 1/2,1/3/2024,"Additional Phase 1/2 data reported that an additional Ewing sarcoma patient treated with seclidemstat, topotecan and cyclophosphamide (TC) has achieved a partial response as demonstrated by at least a",0.0,2.51585,77.5817,76.81196,76.65596,79.07996,-0.002032999,0.029099135,0.008682156,-0.02517095,0.17692,0.00028,0.01679,16,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1
INTS,INT230-6,Advanced Soft Tissue SarcomaÂ ,Phase 3,1/3/2024,"FDA provided ""Study May Proceed"" letter, noted January 3, 2024.",47.0,109.53792,139.0833,8.67,7.99,6.0,-0.081678031,-0.368109322,0.008682156,-0.02517095,0.6222,0.00328,0.44293,17,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ENVB,EB-003 (EVM301 series),Mental health disordersÂ ,Preclinical,1/3/2024,"Preclinical development to commence in early 2024, with IND submission planned in 2024, noted January 3, 2024.",3.0,3.06409,88.0568,226.79998,237.59998,232.19998,0.04652002,0.023530499,0.008682156,-0.02517095,0.51747,0.0259,0.07746,18,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
IFRX,INF904,Chronic Autoimmune and Inflammatory DiseasesÂ ,Phase 1,1/4/2024,Phase 1 MAD results from 24 healthy volunteers showed that study was well tolerated in participants over the entire dose range and resulted in no safety signals of concern. The overall percentage of A,59.0,107.75639,81.2025,1.6,1.83,1.75,0.134312338,0.089612159,-0.012394525,-0.025411341,1.07199,0.00094,1.89428,19,0,0,0,1,0,1,0,0,0,0,0,0,2,0,0,1
ADCT,ADCT-601 (mipasetamab uzoptirine),"Soft tissue sarcomas, pancreatic cancer and AXL-expressing non-small cell lung cancer (NSCLC)Â ",Phase 1b,1/4/2024,"Preliminary Phase 1 data shows the maximum-tolerated dose has been reached, and the study is currently in dose optimization, noted Janaury 4, 2024.",112.0,151.86847,138.0034,1.66,1.88,2.07,0.124454174,0.220731005,-0.012394525,-0.025411341,5.01402,0.04643,2.46834,20,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ADCT,ADCT-901,Solid tumorsÂ ,Phase 1,1/4/2024,"Program discontinued due to limited signs of efficacy in the dose escalation phase and to reallocate capital to prioritized programs, noted January 4, 2024.",112.0,151.86847,138.0034,1.66,1.88,2.07,0.124454174,0.220731005,-0.012394525,-0.025411341,5.01402,0.04643,2.46834,21,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ALDX,ADX-629,SjÃ¶gren-Larsson Syndrome (SLS)Â ,Phase 1/2,1/4/2024,Phase 2 biomarker results observed in adult cohort proposed expansion to include pediatric patients expected to be submitted to the FDA in the 1H 2024.,59.0,196.46576,180.3384,3.35,3.34,3.2,-0.002989539,-0.045809536,-0.012394525,-0.025411341,6.04079,0.25004,1.83975,22,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ALDX,ADX-246,Systemic Immune-Mediated Diseases and atopic dermatitisÂ ,Phase 1,1/4/2024,"Phase 1 expanded to include patients with atopic dermatitis, noted Janaury 4, 2024.",59.0,196.46576,180.3384,3.35,3.34,3.2,-0.002989539,-0.045809536,-0.012394525,-0.025411341,6.04079,0.25004,1.83975,23,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
KNSA,Abiprubart (KPL-404),Rheumatoid arthritisÂ ,Phase 2,1/4/2024,"Phase 2 trial met its primary endpoint, noted January 4, 2024.",74.0,1345.22102,58.665,19.98,19.125,19.28,-0.043735394,-0.035663484,-0.012394525,-0.025411341,4.65689,0.02271,26.4366,24,1,0,0,0,0,1,0,0,0,0,0,0,2,0,0,1
RYTM,Bivamelagon (LB54640),Healthy overweight adultsÂ ,Phase 1,1/4/2024,"Phase 1 has shown targeted effect on MC4 receptor without hyperpigmentation, noted January 4, 2024.",66.0,2559.46742,63.5507,43.88,43.31,41.51,-0.01307508,-0.055524273,-0.012394525,-0.025411341,14.61566,0.13496,58.38885,25,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
SNGX,SGX302/hypericin sodium,PsoriasisÂ ,Phase 2a,1/4/2024,"Phase 2a data reported that two patients reached a disease status of ""Almost Clear"" represented by an Investigator Global Assessment (IGA) score of 1, noted January 4, 2024.",4.0,9.41616,145.0268,14.68,14.5168,13.8608,-0.011179424,-0.057421311,-0.012394525,-0.025411341,0.38244,0.0002,2.15457,26,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
MRK,IMM60 - (PORT-2),Refractory NSCLC & MelanomaÂ ,Phase 1,1/4/2024,"Phase 2 paused after a review of Portage's funding requirements, noted January 4, 2024.",0.0,296506.0411,18.1863,114.77,117.01,118.43,0.019329276,0.031391943,-0.012394525,-0.025411341,0.53146,0.00786,1344.70361,27,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
IMMP,Eftilagimod alpha - INSIGHT-004,Solid tumorsÂ ,Phase 1,1/4/2024,"Phase 1 dosing initiated, noted January 4, 2024.",145.0,398.25958,47.012,2.31,2.41,2.56,0.042379223,0.102759734,-0.012394525,-0.025411341,0.0,0.0,0.38981,28,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1
APLT,AT-001 - (ARISE-HF),Diabetic cardiomyopathy (DbCM)Â ,Phase 3,1/4/2024,"Phase 3 topline data demonstrated that while a trend favored active treatment, the difference between active and placebo treated groups (0.30 ml/kg/min) was not statistically significant, noted Januar",144.0,292.6987,115.7805,3.59,3.79,2.44,0.054213817,-0.386154163,-0.012394525,-0.025411341,2.77586,0.02185,15.36482,29,0,0,0,0,0,1,0,0,0,0,1,0,0,0,2,0
APLT,AT-001 - (ARISE-HF),Diabetic cardiomyopathy (DbCM)Â ,Phase 3,1/4/2024,"Phase 3 topline data demonstrated that while a trend favored active treatment, the difference between active and placebo treated groups (0.30 ml/kg/min) was not statistically significant, noted Januar",144.0,292.6987,115.7805,3.59,3.79,2.44,0.054213817,-0.386154163,-0.012394525,-0.025411341,2.77586,0.02185,15.36482,30,0,0,0,0,0,1,0,0,0,0,1,0,0,0,2,0
TBPH,YUPELRI (revefenacin) - (PIFR-2),Chronic obstructive pulmonary disease (COPD)Â ,Phase 3,1/5/2024,"Phase 4 data reported that the trial did not show a statistically significant difference between YUPELRI and Spiriva HandiHaler on the primary endpoint, noted January 5, 2024.",50.0,516.40387,33.7589,11.52,10.37,9.83,-0.105167633,-0.158645721,-0.043425645,-0.010785672,18.72446,0.07479,14.80076,31,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1
CVAC,CV0601,COVID-19 vaccineÂ ,Phase 2,1/5/2024,"Phase 2 data reported a meaningful immune responses and favorable reactogenicity profiles across all tested doses, including the lowest tested dose, noted January 5, 2024.",224.0,971.82889,66.8964,4.22,4.34,3.88,0.02803922,-0.083999974,-0.043425645,-0.010785672,1.6726,0.08841,8.8193,32,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
GSK,XMT-2056,HER2-Expressing TumorsÂ ,Phase 1,1/5/2024,"Phase 1 clinical trial restarting; plan to advance dose escalation in 2024, noted January 5, 2024.",0.0,62822.05247,17.5791,15.398,15.412,15.73,0.000908796,0.021332086,-0.043425645,-0.010785672,0.0,0.00274,97.31924,33,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
MRSN,XMT-2056,HER2-Expressing TumorsÂ ,Phase 1,1/5/2024,"Phase 1 clinical trial restarting; plan to advance dose escalation in 2024, noted January 5, 2024.",4.0,273.72137,200.1738,57.75,56.75,75.5,-0.017467693,0.268009307,-0.043425645,-0.010785672,7.01236,0.01324,2.06218,34,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
FBIO,"Emrosi (Minocycline Hydrochloride ER Capsules, 40 mg) (DFD-29) - (MVOR-2)",Papulopustular RosaceaÂ ,NDA Filing,1/5/2024,"NDA submitted to the FDA, noted January 5, 2024.",29.0,44.47174,153.9349,2.5,2.42,1.92,-0.032523192,-0.263965546,-0.043425645,-0.010785672,4.93768,0.11582,1.86287,35,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
DERM,"Emrosi (Minocycline Hydrochloride ER Capsules, 40 mg) (DFD-29) - (MVOR-2)",Papulopustular RosaceaÂ ,NDA Filing,1/5/2024,"NDA submitted to the FDA, noted January 5, 2024.",24.0,93.46767,107.6582,4.97,5.05,4.82,0.015968403,-0.030645912,-0.043425645,-0.010785672,0.94107,0.0194,1.55421,36,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
NOVN,ZELSUVMI (berdazimer topical gel),Molluscum ContagiosumÂ ,Approved,1/5/2024,"FDA Approved on January 5, 2023.",28.0,185834.1823,17.9254,89.84,90.41,91.43,0.00632457,0.017543342,-0.043425645,-0.010785672,0.0,0.03559,239.20642,37,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
LGND,ZELSUVMI (berdazimer topical gel),Molluscum ContagiosumÂ ,Approved,1/5/2024,"FDA Approved on January 5, 2023.",19.0,1234.98891,29.5135,70.36,70.83,72.6,0.00665772,0.031340002,-0.043425645,-0.010785672,5.12487,0.4139,9.88709,38,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
VINC,VIP236,Solid tumorsÂ ,Phase 1,1/8/2024,"Phase 1 update observed that 15 patients have been treated, showing a promising safety profile and preliminary evidence of clinical activity with once every 3-week dosing, noted January 8, 2024.",5.0,29.07756,95.4296,23.6,27.2,27.4,0.141970261,0.149296301,-0.047028896,-0.012463994,0.57629,0.02201,31.69311,39,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
VINC,VIP943 (anti-CD123),Hematologic malignanciesÂ ,Phase 1,1/8/2024,"Phase 1 enrollment in the second cohort of the VIP943 trial is nearly complete. Preliminary pharmacokinetic results from the first cohort trial showed very little free payload in circulation, consiste",5.0,29.07756,95.4296,23.6,27.2,27.4,0.141970261,0.149296301,-0.047028896,-0.012463994,0.57629,0.02201,31.69311,40,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
VINC,Enitociclib (VIP152) in combination with venetoclax and prednisone - (NIH trial),Peripheral T-cell lymphoma (PTCL) and 2 double-hit diffuse large b-cell lymphoma (DH-DLBCL)Â ,Phase 1,1/8/2024,"Phase 1 preliminary data from investigators from the National Institutes of Health (NIH) reported 2 partial responses (PR) in 3 PTCL patients and 1 PR in DH-DLBCL in ongoing dose-escalation trial, not",5.0,29.07756,95.4296,23.6,27.2,27.4,0.141970261,0.149296301,-0.047028896,-0.012463994,0.57629,0.02201,31.69311,41,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ARGX,Empasiprubart (ARGX-117) - (ARDA),Multifocal motor neuropathy (MMN)Â ,Phase 2,1/8/2024,"Phase 2 topline data reported that treatment demonstrated a 91% reduction in the need for IVIg rescue compared to placebo, noted January 8, 2024.",60.0,21610.92518,66.0046,353.0,365.8,348.0,0.035618679,-0.014265577,-0.047028896,-0.012463994,0.0,0.00064,21.21896,42,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ABSI,ABS-101,Inflammatory bowel disease (IBD)Â ,Preclinical,1/8/2024,"Preclinical data support profile for development of a potential best-in-class drug. IND submission expected in 1Q 2025; Phase 1 trials anticipated to initiate shortly after, noted January 8, 2024.",149.0,388.48283,99.6955,3.62,4.18,3.99,0.143837221,0.097317205,-0.047028896,-0.012463994,2.20066,0.22448,6.27638,43,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
VERU,Enobosarm with semaglutide (Wegovy) - (PLATEAU),ObesityÂ ,IND-Enabling,1/8/2024,"IND submitted to the FDA, noted January 8, 2024.",14.0,77.84445,90.1866,5.86,5.58,4.592,-0.048960827,-0.243833945,-0.047028896,-0.012463994,9.00548,0.00894,1.07315,44,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ALT,Pemvidutide - (MOMENTUM),"Non-alcoholic steatohepatitis (NASH)/ (MASH) - Healthy, Overweight and Obese VolunteersÂ ",Phase 2,1/8/2024,"Phase 2 results presented at NASH-TAG Conference reported that treatment resulted in reductions of up to 76.4% in relative LFC, 15.2 IU/L in serum ALT, and 149.7ms in cT1 at 24 weeks January 6, 2024.",88.0,611.97184,100.7755,11.19,11.39,12.0,0.017715255,0.069886127,-0.047028896,-0.012463994,20.64737,0.03152,93.50513,45,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CLRB,Iopofosine (CLR 131) - (CLOVER-WaM),Waldenstromâ€™s macroglobulinemiaÂ ,Phase 2b,1/8/2024,"Phase 2b trial met its primary endpoint, noted January 8, 2024.",3.0,39.3226,83.7134,81.30008,96.0001,105.30011,0.166202233,0.258667463,-0.047028896,-0.012463994,4.88196,0.06612,99.21629,46,1,0,0,0,0,1,0,0,0,0,0,0,2,0,0,1
BMY,Belrestotug (EOS-448/GSK4428859A) - (TIG-007) + iberdomide,Relapsed/refractory multiple myeloma (r/r MM)Â ,Phase 1/2,1/8/2024,"Phase 1/2 was deprioritized after trial assessment, noted January 8, 2024.",0.0,105380.1035,21.5968,52.23,51.79,50.31,-0.008459962,-0.037453178,-0.047028896,-0.012463994,1.18445,0.11643,970.84887,47,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
GSK,Belrestotug (EOS-448/GSK4428859A) - (TIG-007) + iberdomide,Relapsed/refractory multiple myeloma (r/r MM)Â ,Phase 1/2,1/8/2024,"Phase 1/2 was deprioritized after trial assessment, noted January 8, 2024.",0.0,63139.99434,17.1917,15.412,15.49,15.8,0.005048228,0.024863513,-0.047028896,-0.012463994,0.0,0.00274,120.40073,48,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CLNN,CNM-Au8 - (VISIONARY-MS),Multiple SclerosisÂ ,Phase 2,1/8/2024,"Phase 2 long term data demonstrated improvement of vision as measured by low contrast visual acuity (LCLA), noted Janaury 8, 2024.",9.0,45.45912,105.0572,5.8,7.08,9.596,0.19941599,0.503488427,-0.047028896,-0.012463994,0.34407,0.07394,1.23283,49,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ABBV,lutikizumab (ABT-981),Hidradenitis suppurativa (HS)Â ,Phase 2,1/8/2024,"Phase 2 300 mg weekly or 300 mg dose every other week showed higher response rates in HiSCR 50 at week 16 than those treated with placebo, noted January 8, 2024.",0.0,285010.7059,17.7657,162.14,161.43,162.4,-0.004388547,0.001602268,-0.047028896,-0.012463994,0.77534,0.01816,968.84345,50,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
OKYO,urcosimod (OK-101),Dry Eye Disease (DED)Â ,Phase 2,1/8/2024,Phase 2 data presented at the Biotech Showcase showed that dose was statistically significant drug effects were observed in FDA-recognized efficacy endpoints as early as the 15-day first visit after d,33.0,62.81614,116.6185,1.864,1.89,1.73,0.013852113,-0.074603308,-0.047028896,-0.012463994,0.14343,0.00061,2.14728,51,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1
NVO,Icosema - (COMBINE 3),Type 2 diabetesÂ ,Phase 3,1/8/2024,"Phase 3a trial completed, noted January 8, 2024",0.0,3209643.321,35.0538,105.98,106.4,107.16,0.00395518,0.011072648,-0.047028896,-0.012463994,0.0,0.0,306.50116,52,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
MNMD,MM-120 (LSD),Attention Deficit Hyperactivity Disorder (ADHD)Â ,Phase 2a,1/8/2024,"Phase 2a trial did not meet its primary endpoint, noted January 8, 2024.",75.0,176.01577,75.8599,4.09,4.39,3.96,0.070784257,-0.032300945,-0.047028896,-0.012463994,7.00672,0.24783,5.82284,53,1,0,0,0,0,1,0,0,0,0,0,0,0,2,0,-1
NRIX,NX-2127,"B-cell malignancies, chronic lymphocytic leukemia (CLL)Â ",Phase 1b,1/8/2024,"The company expects to resolve partial hold to enable the introduction of newly manufactured drug product into the ongoing Phase 1 clinical trial., noted January 8, 2024.",76.0,483.09753,77.1659,9.87,9.96,9.37,0.009077218,-0.051986757,-0.047028896,-0.012463994,18.20078,0.22696,7.33795,54,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
INCY,INCB123667,"Late-stage cancers, ovarian cancerÂ ",Phase 1,1/8/2024,"Phase 1 early clinical activity was observed with several patients with amplified/overexpression of CCNE1, a cell cycle regulator and potential predictive biomarker, achieving partial response (PR), n",195.0,14750.87005,26.2469,65.26,65.82,62.74,0.008544452,-0.039380088,-0.047028896,-0.012463994,3.11092,0.25653,138.35943,55,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
INCY,Ruxolitinib Cream (Opzelura),Adults with hidradenitis suppurativa (HS)Â ,Phase 2,1/8/2024,"Phase 2 primary endpoint was met in its randomized, placebo-controlled study, noted on January 8, 2024.",195.0,14750.87005,26.2469,65.26,65.82,62.74,0.008544452,-0.039380088,-0.047028896,-0.012463994,3.11092,0.25653,138.35943,56,1,0,0,0,0,1,0,0,0,0,0,0,2,0,0,1
NVS,Scemblix - (ASC4FIRST),1L Chronic myeloid leukemia (CML)Â ,Phase 3,1/8/2024,"Phase 3 trial met its primary endpoint, noted January 8, 2024.",0.0,1411.16675,48.0192,4.44,4.4,4.54,-0.009049836,0.022272636,-0.047028896,-0.012463994,0.0,0.02267,0.52289,57,1,0,0,0,0,1,0,0,0,0,0,0,2,0,0,1
CYBN,CYB004 (IV) and SPL028 (IM),Generalized anxiety disorder (GAD)Â ,Phase 1,1/8/2024,"Intravenous (IV) CYB004 demonstrated robust and rapid-onset psychedelic effects at lower doses compared to native DMT, suggesting potential as a short-acting, scalable treatment. Intramuscular (IM) do",23.0,161.0576,99.6434,15.38999,14.88079,15.38999,-0.033646179,0.0,-0.047028896,-0.012463994,2.46092,0.0154,1.83134,58,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
FATE,FT825/ONO-8250,Solid TumorsÂ ,Phase 1,1/8/2024,"Phase 1 trial initiated, noted January 8, 2024.",115.0,406.2401,85.4495,3.77,4.12,4.55,0.088778162,0.188052232,-0.047028896,-0.012463994,10.93577,0.39694,14.51773,59,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
SMMT,Ivonescimab plus chemotherapy - (AK112-201),Non-small cell lung cancer (NSCLC)Â ,Phase 2,1/8/2024,"Phase 2 data reported that the 1-year overall survival rate was 85.6%, and the 2-year overall survival rate was 64.8% for patients in Cohort 1 with squamous histology NSCLC, noted January 8, 2024.",744.0,2081.50341,81.4745,2.55,2.97,3.1,0.152468594,0.195308752,-0.047028896,-0.012463994,1.34685,0.00269,6.82331,60,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ORIC,ORIC-944,Metastatic castration resistant prostate cancer (mCRPC)Â ,Phase 1b,1/8/2024,"Phase 1b data demonstrated potential best-in-class profile, including half-life >10 hours, robust target engagement and well tolerated safety profile, supporting advancement for combination developmen",97.0,449.5074,65.973,8.42,8.24,8.6,-0.021609484,0.021152375,-0.047028896,-0.012463994,15.89094,0.13745,3.16223,61,0,0,0,1,0,1,0,0,0,0,0,0,2,0,0,1
BMEA,Icovamenib (BMF-219) - (COVALENT-112),Type 1 diabetes (T1D)Â ,Phase 2,1/8/2024,"Phase 2 was initiated, noted January 8, 2024.",59.0,569.15023,104.567,14.71,15.94,15.21,0.080304139,0.033425572,-0.047028896,-0.012463994,30.63348,0.02657,16.21399,62,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
NUVB,NUV-1511,Advanced solid tumorsÂ ,IND-Enabling,1/8/2024,"IND cleared by FDA, noted January 8, 2024.",342.0,339.36328,63.5128,1.49,1.55,1.58,0.039478811,0.058648727,-0.047028896,-0.012463994,1.00643,0.28384,0.87455,63,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
AVIR,Bemnifosbuvir (AT-527) - (SUNRISE-3),COVID-19Â ,Phase 3,1/8/2024,"Phase 3 8-week study showed a 98% SVR4, which exceeds our efficacy criterion of >90% for continuing the study, noted January 8, 2024",79.0,258.65009,38.8628,3.09,3.1,3.56,0.003231021,0.141589454,-0.047028896,-0.012463994,4.21518,0.03812,2.29262,64,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ELTX,ELI-002 (AMPLIFY-201),Solid TumorsÂ ,Phase 1/2,1/9/2024,"Phase 1/2 data presented in a paper on Nature Medicine showed that ELI-002 administered as a monotherapy induced robust, polyfunctional, and durable KRAS specific CD4+ and CD8+ T cell responses. Tumor",16.0,52.3508,115.2223,7.82,5.45,5.28,-0.361068946,-0.392758457,0.009572539,0.047795155,0.07055,0.02185,16.85986,65,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
VCEL,NexoBrid (CIDS),Severe burns - pediatricÂ ,BLA Filing,1/9/2024,"sBLA filing review and accepted by the FDA, noted January 9, 2024.",50.0,1780.6027,48.4414,34.79,37.31,39.2,0.069931398,0.119346758,0.009572539,0.047795155,12.32144,0.16761,41.97603,66,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
MDWD,NexoBrid (CIDS),Severe burns - pediatricÂ ,BLA Filing,1/9/2024,"sBLA filing review and accepted by the FDA, noted January 9, 2024.",11.0,115.14857,54.0844,11.82,12.49,12.87,0.055135312,0.08510601,0.009572539,0.047795155,0.36552,0.09114,1.29993,67,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CRBP,CRB-601,Solid tumorsÂ ,IND-Enabling,1/9/2024,"IND cleared by the FDA, noted January 9, 2024",12.0,31.93899,98.165,7.16,7.22,6.09,0.008344972,-0.161861899,0.009572539,0.047795155,1.07707,0.0247,0.24508,68,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
ALC,TRYPTYR (acoltremon ophthalmic solution) 0.003%,Dry eye disease (DED)Â ,Phase 3,1/9/2024,"Phase 3 pivotal efficacy and safety study met the primary endpoint , noted January 9, 2024.",494.0,93.97313,75.3808,0.0685,0.07,0.065,0.021661497,-0.052446475,0.009572539,0.047795155,0.0,0.00094,0.15775,69,1,0,0,1,0,1,0,0,0,0,0,0,3,0,0,1
ALC,AR-15512 (AVX-012) - (COMET-2),Dry eye diseaseÂ ,Phase 3,1/9/2024,"Phase 3 pivotal efficacy and safety study met the primary endpoint , noted January 9, 2024.",494.0,93.97313,75.3808,0.0685,0.07,0.065,0.021661497,-0.052446475,0.009572539,0.047795155,0.0,0.00094,0.15775,70,1,0,0,1,0,1,0,0,0,0,0,0,3,0,0,1
MRSN,Emiltatug Ledadotin (XMT-1660) - (Emi-Le),Metastatic triple-negative breast cancer (TNBC)Â ,Phase 1,1/10/2024,"Phase 1 data reported that treatment was generally well tolerated, with no Grade 4 or 5 treatment-related adverse events (TRAEs) reported, noted January 10, 2025.",4.0,391.89183,203.0704,80.75,81.25,72.25,0.006172859,-0.111225635,0.034012079,0.057837377,6.9619,0.01324,22.86529,71,0,0,0,1,0,1,0,0,0,0,0,0,2,0,0,1
FDMT,4D-150 - (SPECTRA),Wet Age-Related Macular Degeneration (wet AMD)Â ,Phase 2,1/10/2024,"Phase 2 32-week interim data reported that 3E10 vg/eye achieved an 86% reduction in injection burden vs. projected on-label aflibercept 2mg Q8W and dose response with 61% reduction vs. 1E10 vg/eye, wi",46.0,818.30404,55.3857,19.49,19.14,17.75,-0.018121127,-0.093515998,0.034012079,0.057837377,7.53187,0.1473,4.44385,72,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1
CMND,CMND-100,Alcohol use disorder (AUD)Â ,IND-Enabling,1/10/2024,"IND submitted March 16, 2023. Phase 1/2a trial sites selected noted May 22, 2023. Type A meeting completed, noted January 10, 2024.",5.0,4.96092,168.1399,2.07,2.93,1.12,0.347453816,-0.614219922,0.034012079,0.057837377,0.85309,0.00013,140.14555,73,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ACRS,ATI-1777-AD-202,Atopic dermatitisÂ ,Phase 2b,1/10/2024,"Phase 2b topline data on ATI-1777 2% QD showed a trend toward significance, ATI-1777 2% BID achieved a statistically significant result in the primary efficacy endpoint at week 4, noted January 10, 2",108.0,71.19038,289.9477,1.28,1.005,1.18,-0.241872536,-0.081345639,0.034012079,0.057837377,8.16841,0.07865,8.51035,74,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1
VYNE,Repibresib Gel (VYN201),VitiligoÂ ,Phase 1b,1/10/2024,"Phase 1b biomarker data reported a median reduction in MMP-9 of 40.8% in lesional skin compared to baseline for subjects in the 2.0% cohort, noted January 10, 2024.",25.0,31.26441,98.3706,2.27,2.24,1.99,-0.013303966,-0.131645193,0.034012079,0.057837377,0.63039,0.06882,0.63224,75,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
EYPT,EYP-1901 - (VERONA),Diabetic macular edema (DME)Â ,Phase 2,1/10/2024,"Phase 2 dosing initiated, noted January 10, 2024.",68.0,952.30981,171.9504,21.47,20.23,21.87,-0.059489961,0.018459223,0.034012079,0.057837377,11.32262,0.0603,12.44754,76,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1
BPTH,BP1002,Refractory/relapsed lymphoma and chronic lymphocytic leukemiaÂ ,Phase 1,1/10/2024,"Phase 1 first cohort completed, noted January 10, 2024.",8.0,6.91749,167.7256,10.602,11.2,8.694,0.054871116,-0.19840953,0.034012079,0.057837377,3.03726,0.01488,0.1395,77,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1
SANA,SC291 - (ARDENT),"Solid tumors, B-cell lymphomas and leukemiasÂ ",Phase 1,1/10/2024,Phase 1 early data discussed at the JPMorgan Healthcare Conference showed in a presentation that three patients saw at least a reduction in their disease while two patients had no detectable disease a,237.0,1415.40439,91.0515,5.155,7.18,6.12,0.331332266,0.171594979,0.034012079,0.057837377,11.18588,0.19181,454.9816,78,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
MRK,KEYTRUDA with external beam radiotherapy (EBRT) plus concurrent chemotherapy - (KEYNOTE-A18),Cervical cancerÂ ,Approved,1/12/2024,"FDA Approved on January 12, 2024.",0.0,300611.1585,17.4969,118.43,118.63,118.89,0.001687337,0.003876627,0.000552822,0.038535638,0.70507,0.01668,809.44808,79,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
ARQT,"ZORYVE (roflumilast) cream, 0.15%",Atopic dermatitisÂ ,Phase 3,1/15/2024,"Additional Phase 3 data reported that at Week 4, a statistically significant greater percentage of patients achieved a 50% reduction in EASI scores (EASI-50), with 69.2% of patients treated with roflu",119.0,343.55075,95.5498,3.64,3.64,3.54,0.0,-0.027856955,0.015155182,0.015716759,21.3847,0.18356,0.0,80,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1
ANIP,Indomethacin Oral Suspension - (Indocin generic),"Rheumatoid arthritis, ankylosing spondylitis, osteoarthritis, acute gouty arthritis, bursitis, and tendinitisÂ ",Approved,1/16/2024,"Approved January 16, 2024.",21.0,1057.37147,37.8793,56.74,55.41,56.62,-0.023719347,-0.00211715,0.023272476,0.013248176,1.3833,0.13493,4.76532,81,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1
CLRB,CLR 121225 (225Ac-CLR 121225),PLE cancerÂ ,Preclinical,1/16/2024,"Preclinical data reported tumor volume reduction in a dose dependent manner with the highest dose providing near complete eradication of the tumor, noted January 16, 2024.",3.0,45.46676,85.3388,105.30011,111.00011,110.70011,0.052716729,0.05001037,0.023272476,0.013248176,4.40363,0.09403,9.54823,82,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
HALO,HYQVIA (Immune Globulin Infusion 10% with Recombinant Human Hyaluronidase),Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)Â ,Approved,1/16/2024,"Approved January 16, 2024.",116.0,4803.08728,39.0462,34.43,36.36,34.75,0.054540992,0.009251295,0.023272476,0.013248176,5.56369,0.1562,96.22947,83,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1
TAK,HYQVIA (Immune Globulin Infusion 10% with Recombinant Human Hyaluronidase),Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)Â ,Approved,1/16/2024,"Approved January 16, 2024.",0.0,6904763.012,18.8962,15.04,15.01,14.73,-0.001996673,-0.020827088,0.023272476,0.013248176,0.0,0.0,48.77124,84,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1
CRSP,CASGEVY (exagamglogene autotemcel [exa-cel],Beta-thalassemiaÂ ,Approved,1/16/2024,"FDA Approved on January 16, 2024.",90.0,5038.40005,63.7025,64.25,63.43,66.19,-0.012844788,0.02974767,0.023272476,0.013248176,20.4581,0.35855,111.08039,85,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
VRTX,CASGEVY (exagamglogene autotemcel [exa-cel],Beta-thalassemiaÂ ,Approved,1/16/2024,"FDA Approved on January 16, 2024.",256.0,112733.8162,26.2754,433.4,437.49,439.7,0.009392759,0.014431587,0.023272476,0.013248176,1.26358,0.15752,781.85982,86,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
SRPT,SRP-9003-301 - (EMERGENE),Limb-girdle muscular dystrophy type 2E (LGMD2E)Â ,Phase 3,1/16/2024,"Phase 3 screening initiated, noted January 16, 2024.",97.0,10794.35152,79.6483,116.8,115.39,121.13,-0.012145375,0.036401279,0.023272476,0.013248176,5.01534,0.00434,111.95392,87,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ONC,DKN-01 with bevacizumab - (DeFianCe),Colorectal cancerÂ ,Phase 2,1/16/2024,"Phase 2 part B data due at ASCO GI on January 20, 2024. Phase 2 part A data showed a 30% ORR and 93% DCR across heterogenous second-line CRC patients. Subgroup analysis reveals greatest benefit in lef",110.0,18118.12811,50.2043,175.21,173.25,162.27,-0.011249616,-0.07672364,0.023272476,0.013248176,1.75222,0.2117,51.24319,88,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
LPTX,DKN-01 with bevacizumab - (DeFianCe),Colorectal cancerÂ ,Phase 2,1/16/2024,"Phase 2 part B data due at ASCO GI on January 20, 2024. Phase 2 part A data showed a 30% ORR and 93% DCR across heterogenous second-line CRC patients. Subgroup analysis reveals greatest benefit in lef",41.0,88.71199,109.0559,3.51,3.47,2.85,-0.011461444,-0.208297043,0.023272476,0.013248176,2.21894,0.13506,0.96607,89,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
RCUS,AB680 + Zimberelimab (AB122) - (ARC-8),Pancreatic CancerÂ ,Phase 1b,1/16/2024,"Phase 1 data showed a median overall survival was 15.7 months for all patients treated with 100 mg quemliclustat-based regimens in the ARC-8 study, which exceeds the historical benchmark data for chem",106.0,1265.05905,62.104,17.51,16.9,15.44,-0.035458524,-0.125810602,0.023272476,0.013248176,9.70927,0.10653,9.51293,90,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ADAG,muzastotug (ADG126) combined with KEYTRUDA (pembrolizumab) - (ADG126-P001/KEYNOTE-C98),Solid tumorsÂ ,Phase 1/2,1/16/2024,"Phase 1/2 data from first tranche of MSS CRC patients treated with ADG126 10 mg/kg every three weeks (Q3W) in dose expansion showed clinical benefit including confirmed responses at higher, more freq",47.0,165.69506,98.6314,3.17,3.78,3.245,0.175992422,0.023383762,0.023272476,0.013248176,0.05744,0.0423,2.20217,91,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ACXP,Ibezapolstat,C. difficile InfectionÂ ,Phase 2b,1/17/2024,"Phase 2b data showed that that ibezapolstat outperformed vancomycin, a standard of care to treat patients with CDI, with eradication of fecal C. difficile at Day 3 of treatment in 15 of 16 patients (9",1.0,62.23118,132.0725,95.0,90.4,80.4,-0.049632624,-0.166862715,0.022712764,0.015160376,2.16989,0.00897,13.53894,92,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
EVGN,BMC128 with Opdivo,"Non-small cell lung cancer (NSCLC), melanoma or renal cell carcinomaÂ ",Phase 1,1/17/2024,"Phase 1 first patient dosed July 26, 2022. Phase 1 trial enrollment completed, noted January 17, 2024",6.0,32.51785,44.2229,2.35,2.34,2.3,-0.004264399,-0.021506205,0.022712764,0.015160376,0.0,0.0988,0.02129,93,0,0,0,0,0,1,0,0,0,1,0,0,2,0,0,1
BMY,BMC128 with Opdivo,"Non-small cell lung cancer (NSCLC), melanoma or renal cell carcinomaÂ ",Phase 1,1/17/2024,"Phase 1 first patient dosed July 26, 2022. Phase 1 trial enrollment completed, noted January 17, 2024",0.0,101697.192,21.6711,50.0,49.98,50.24,-0.00040008,0.004788517,0.022712764,0.015160376,1.09669,0.10386,820.94294,94,0,0,0,0,0,1,0,0,0,1,0,0,2,0,0,1
REGN,Ateganosine (THIO-101),Non-small cell lung cancer (NSCLC)Â ,Phase 2,1/17/2024,"Phase 2 data reported a 100% preliminary disease control rate (DCR) in second-line and 88% in third-line, in highly difficult-to-treat patients who already progressed through previous lines of treatme",105.0,98810.17324,18.8661,937.32,929.13,948.24,-0.008776075,0.011582895,0.022712764,0.015160376,0.99899,0.14736,489.40808,95,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
MAIA,Ateganosine (THIO-101),Non-small cell lung cancer (NSCLC)Â ,Phase 2,1/17/2024,"Phase 2 data reported a 100% preliminary disease control rate (DCR) in second-line and 88% in third-line, in highly difficult-to-treat patients who already progressed through previous lines of treatme",32.0,25.07676,117.8391,1.23,1.48,1.41,0.185027918,0.136575535,0.022712764,0.015160376,0.55698,2e-05,5.5153,96,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
LSTA,LSTA1,Glioblastoma multiforme (GBM)Â ,Phase 2a,1/17/2024,"Phase 2a trial initiated, noted January 17, 2024.",8.0,23.92998,67.9985,3.02,2.94,2.75,-0.02684725,-0.09365592,0.022712764,0.015160376,0.73303,0.06336,0.04005,97,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CATX,212Pb-VMT01,MC1R-positive metastatic melanomaÂ ,Phase 1/2,1/17/2024,"Phase 1/2 second dose escalation cohorts recruitment commenced, noted January 17, 2024.",74.0,122.35702,140.7214,4.521,4.361,4.886,-0.036031819,0.077640765,0.022712764,0.015160376,0.68891,0.00198,0.37533,98,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CNSP,Berubicin,Glioblastoma (GBM) (adult)Â ,Phase 2,1/17/2024,"Enrollment completed, noted January 17, 2024.",0.0,3.68793,142.0622,21612.02161,21195.0212,16869.01687,-0.019483411,-0.247771098,0.022712764,0.015160376,4.13206,0.01076,0.12717,99,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1
PFE,CRDF-004,Metastatic colorectal cancer (mCRC)Â ,Phase 1b,1/17/2024,"Phase 1b findings highlight the safety and promising efficacy of onvansertib in combination with standard-of-care, noted January 17, 2024.",0.0,158946.5342,25.801,28.32,28.15,28.33,-0.006020914,0.000353045,0.022712764,0.015160376,1.01004,0.08557,937.74921,100,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CRDF,CRDF-004,Metastatic colorectal cancer (mCRC)Â ,Phase 1b,1/17/2024,"Phase 1b findings highlight the safety and promising efficacy of onvansertib in combination with standard-of-care, noted January 17, 2024.",66.0,65.67544,91.7946,1.63,1.47,1.515,-0.103317614,-0.073164576,0.022712764,0.015160376,2.9479,0.07918,0.36656,101,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
IXHL,IHL-42X - (RePOSA),Obstructive sleep apnea (OSA)Â ,Phase 2/3,1/17/2024,"Phase 2/3 IRB approved protocol to asses drug in patients, noted January 17, 2024.",347.0,70.95282,157.8562,4.45,4.47,4.03,0.004484312,-0.09913772,0.022712764,0.015160376,0.58984,0.06711,0.09744,102,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1
PBLA,CPP-1X (eflornithine),NeuroblastomaÂ ,Phase 1,1/18/2024,"Phase 1 data reported that 2 partial responses (PR), 4 minor responses (MR), 10 Stable disease (SD), 7 progressive disease (PD) and 1 unevaluable patient, noted January 18, 2024.",4.0,3.19469,186.1696,8.676,6.65,3.25,-0.265943738,-0.981905597,0.01471034,-0.001809546,14.07482,0.00251,0.89986,103,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
MTVA,DA-1241,Metabolic dysfunction-associated steatohepatitis (MASH)Â ,Preclinical,1/18/2024,"Pre-clinical results demonstrated that once daily oral administration in rats, of sitagliptin alone (180 mg/kg/day), DA-1241 alone (100 mg/kg/day), or sitagliptin in combination with DA-1241 (up to 18",24.0,16.64087,82.9529,3.38,3.43,3.1199,0.014684552,-0.080074759,0.01471034,-0.001809546,0.14051,0.03597,0.30424,104,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CLDX,Barzolvolimab - (CindU),"Chronic inducible urticaria (CIndU), cold urticaria (ColdU) and symptomatic dermographism (SD), Chronic Spontaneous Urticaria (CSU)Â ",Phase 2,1/18/2024,"Phase 2 data reported that the trial met primary endpoint with clinically meaningful and statistically significant decreases in urticaria disease activity across multiple dose groups, noted January 18",66.0,2168.97355,49.6952,39.71,39.66,37.34,-0.001259922,-0.061537907,0.01471034,-0.001809546,12.04683,0.16446,16.69563,105,1,0,0,0,0,1,0,0,0,0,0,0,2,0,0,1
CHRS,Casdozokitug (casdozo),Non-small cell lung cancer (NSCLC)Â ,Phase 2,1/18/2024,"Phase 2 data presented at ASCO GI demonstrated early activity with 38% objective response rate including three complete responses, noted January 18, 2024.",116.0,267.27397,115.9607,2.46,2.4,2.37,-0.024692613,-0.037271395,0.01471034,-0.001809546,21.75374,0.08676,7.42351,106,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1
ZLAB,QINLOCK (ripretinib) - (INTRIGUE),Gastrointestinal Stromal Tumors (GIST) - second-lineÂ ,Phase 3,1/18/2024,"Phase 3 long term data median overall survival of 35.5 months versus 31.5 months for sunitinib in the all-Patient intent-to treat-population, noted Janaury 18, 2024.",109.0,2325.82977,58.0974,23.42,23.56,23.03,0.005960001,-0.016792644,0.01471034,-0.001809546,4.25406,0.24629,16.56475,107,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
NVS,LUTATHERA (lutetium Lu 177) - (NETTER-P),Gastroenteropancreatic neuroendocrine tumors (GEP-NETs)Â ,Phase 3,1/19/2024,Phase 3 data reported that treatment reduced the risk of disease progression or death by 72% as first-line therapy in patients with somatostatin receptor-positive (SSTR+) well-differentiated grade 2/3,0.0,1371.44091,47.2033,4.5,4.42,4.75,-0.017937701,0.054067221,-0.022151187,-0.013462839,0.0,0.00472,0.26782,108,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
AZN,IMFINZI (Durvalumab) + TACE - (EMERALD-1),Locoregional Hepatocellular carcinoma (HCC)Â ,Phase 3,1/19/2024,"Phase 3 data presented at ASCO GI reported that treatment reduced the risk of disease progression or death by 23% compared to TACE alone, noted January 19, 2024.",0.0,162891.0887,21.9162,104.32,105.08,105.46,0.007258867,0.010868636,-0.022151187,-0.013462839,0.0,0.11419,269.92971,109,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1
TEVA,SIMLANDI (adalimumab-ryvk) - (Humira biosimilar),Inflammatory diseasesÂ ,BsUFA,1/19/2024,"FDA facility reinspection in Iceland has concluded, the company also received a form 483 with one observation, noted January 19, 2024. Alvotech believes it is in position to receive approval on BsUFA",0.0,12532.45804,36.9243,10.99,11.18,11.91,0.017140699,0.080392615,-0.022151187,-0.013462839,1.45841,0.05885,112.00724,110,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
ALVO,SIMLANDI (adalimumab-ryvk) - (Humira biosimilar),Inflammatory diseasesÂ ,BsUFA,1/19/2024,"FDA facility reinspection in Iceland has concluded, the company also received a form 483 with one observation, noted January 19, 2024. Alvotech believes it is in position to receive approval on BsUFA",301.0,3754.59027,41.0179,12.265,14.14,14.65,0.142257983,0.177690658,-0.022151187,-0.013462839,0.0371,0.00996,33.93642,111,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
TEVA,SELARSDI (ustekinumab-aekn) - (STELARA biosimilar),moderate to severe plaque psoriasis and for active psoriatic arthritis in adults and pediatric patients 6 years and older.Â ,BsUFA,1/19/2024,"FDA facility reinspection in Iceland has concluded, the company also received a form 483 with one observation, noted January 19, 2024. Alvotech believes it is in position to receive approval on BsUFA",0.0,12532.45804,36.9243,10.99,11.18,11.91,0.017140699,0.080392615,-0.022151187,-0.013462839,1.45841,0.05885,112.00724,112,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
ALVO,SELARSDI (ustekinumab-aekn) - (STELARA biosimilar),moderate to severe plaque psoriasis and for active psoriatic arthritis in adults and pediatric patients 6 years and older.Â ,BsUFA,1/19/2024,"FDA facility reinspection in Iceland has concluded, the company also received a form 483 with one observation, noted January 19, 2024. Alvotech believes it is in position to receive approval on BsUFA",301.0,3754.59027,41.0179,12.265,14.14,14.65,0.142257983,0.177690658,-0.022151187,-0.013462839,0.0371,0.00996,33.93642,113,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
RCUS,AB680 + Zimberelimab (AB122) - (ARC-8),Pancreatic CancerÂ ,Phase 1b,1/19/2024,"Phase 1b results presented at the ASCO Gastrointestinal Cancers Symposium reported that a 37% reduction in risk of death and a 5.9-month improvement in mOS, noted January 19, 2024.",106.0,1148.28437,61.9759,16.37,15.34,15.13,-0.064986595,-0.078770864,-0.022151187,-0.013462839,9.70927,0.0988,28.67026,114,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
BMY,Opdivo (nivolumab) plus Yervoy - (CheckMate -8HW),Microsatellite Instabilityâ€“High or Mismatch Repair Deficient Metastatic Colorectal CancerÂ ,Phase 3,1/20/2024,"Presentation of data reported that it demonstrated significant efficacy benefit compared to chemotherapy as first-line treatment in MSI-H/dMMR mCRC, noted January 20, 2023.",0.0,101961.7105,21.6679,50.11,50.11,49.7,0.0,-0.008215656,-0.022266057,-0.013577709,1.09669,0.11558,0.0,115,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
AZN,Ampligen (rintatolimod) with Imfinzi (durvalumab) - (DURIPANC),Pancreatic CancerÂ ,Phase 1/2,1/22/2024,"Phase 1b/2 trial approved by Netherlands, noted June 27, 2023. Phase 1b/2 enrollment commenced January 22, 2024.",0.0,164162.2221,21.8561,105.08,105.9,105.68,0.007773288,0.005693695,-0.02473464,-0.042176619,0.0,0.11419,479.68009,116,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1
AIM,Ampligen (rintatolimod) with Imfinzi (durvalumab) - (DURIPANC),Pancreatic CancerÂ ,Phase 1/2,1/22/2024,"Phase 1b/2 trial approved by Netherlands, noted June 27, 2023. Phase 1b/2 enrollment commenced January 22, 2024.",2.0,62.64421,61.7909,0.3,0.3,0.28,0.0,-0.068992871,-0.02473464,-0.042176619,0.0,0.00817,0.01581,117,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1
CLRB,Iopofosine (CLR 131) - (CLOVER-WaM),Waldenstromâ€™s macroglobulinemiaÂ ,Phase 2b,1/22/2024,"Phase 2b complete CNS clearance reported in one patient, noted January 22, 2024.",3.0,44.72946,85.2281,104.4001,109.20011,126.30013,0.044951437,0.190430425,-0.02473464,-0.042176619,4.40363,0.08706,11.26323,118,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
SGMT,Denifanstat - (FASCINATE-3),Nonalcoholic steatohepatitis (NASH)Â ,Phase 2b,1/22/2024,"Phase 2b topline data reported NASH resolution without worsening of fibrosis with â‰¥2-point reduction in NAS (NAFLD Activity Score) in 36% of denifanstat-treated patients vs 13% with placebo (p=0.002),",32.0,421.74233,190.8988,6.82,18.42,10.6,0.993577559,0.440994529,-0.02473464,-0.042176619,2.71571,0.19401,666.24046,119,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
AGEN,Neoadjuvant botensilimab plus balstilimab - (NEST-1),Colorectal cancerÂ ,Phase 2,1/22/2024,"Phase 2 trial data presented at ASCO-GI showed a major tumor regression in 67.5% of patients. The study achieved durable elimination of ctDNA, a critical biomarker for cancer clearance and long-term d",31.0,224.51008,82.6161,11.56,11.77,13.89,0.018003058,0.183618294,-0.02473464,-0.042176619,10.39595,0.07856,8.68774,120,0,0,0,0,0,1,0,0,0,0,1,1,3,0,0,1
IONS,DAWNZERA (Donidalorsen),Hereditary Angioedema (HAE)Â ,Phase 3,1/22/2024,"Phase 3 topline data met the primary endpoint with a statistically significant reduction in the rate of HAE attacks in patients treated every 4 weeks or patients treated every 8 weeks, noted January 2",159.0,7318.51279,36.1749,50.98,51.01,52.01,0.000588293,0.020002609,-0.02473464,-0.042176619,5.74523,0.27791,73.53872,121,1,0,0,0,0,1,0,0,0,0,1,0,3,0,0,1
SPRB,Tildacerfont - (CAHmelia-204),Congenital Adrenal Hyperplasia (good disease control)Â ,Phase 2b,1/22/2024,"Phase 2b enrollment completed exceeding target enrollment (100/90), noted January 22, 2024.",0.0,99.3343,76.943,179.25045,183.00046,266.25067,0.020704677,0.395654244,-0.02473464,-0.042176619,0.18902,0.05994,0.43152,122,0,0,0,0,0,1,0,0,0,1,0,0,2,0,0,1
SXTP,ARAKODA (tafenoquine),BabesiosisÂ ,Phase 2,1/22/2024,"Type C meeting with FDA on January 17, 2024, concluded that the company now plans to conduct a pivotal clinical study in support of a future indication, noted January 22, 2024.",4.0,4.35541,129.6486,37.56002,45.06002,31.03201,0.182055192,-0.190920934,-0.02473464,-0.042176619,6.26427,0.0399,0.34512,123,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
GILD,Trodelvy (sacituzumab govitecan-hziy; SG) vs. docetaxel - (EVOKE-01),Non-small cell lung cancer (NSCLC)Â ,Phase 3,1/22/2024,"Phase 3 trial did not meet its primary endpoint, noted January 22, 2024.",0.0,97727.06583,25.6097,87.29,78.43,79.07,-0.107029402,-0.098902373,-0.02473464,-0.042176619,1.36744,0.14949,1598.28976,124,1,0,0,0,0,1,0,0,0,0,0,0,0,2,0,-1
CRBP,CRB-701 (SYS6002) with Pembrolizumab,"Solid tumors, Locally advanced or metastatic urothelial carcinomaÂ ",Phase 1,1/23/2024,"Phase 1 dose escalation data from 2024 ASCO GU reported an anti tumor responses across multiple doses were observed, with the first confirmed stable disease at 0.6mg/kg and the first confirmed partial",12.0,32.29289,101.5123,7.6,7.3,25.16,-0.040273899,1.197107185,0.014598799,0.002699968,0.90025,0.02547,0.63361,125,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ARTL,ART26.12,Chemotherapy-Induced PainÂ ,Preclinical,1/23/2024,"Preclinical data reported that ART26.12 (10 and 25 mg/kg BID for 15 days) with oxaliplatin prevented thermal hyperalgesia, mitigated mechanical allodynia, and attenuated OXA-induced weight loss, noted",1.0,4.40076,77.3003,8.34,8.28,8.28,-0.007220248,-0.007220248,0.014598799,0.002699968,0.45607,0.01361,0.01197,126,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
LLY,AK-OTOF,Hearing lossÂ ,Phase 1/2,1/23/2024,"Phase 1/2 clinical trial showed that hearing restoration was observed within 30 days of a single administration of AK-OTOF in the initial AK-OTOF-101 study participant, noted January 23, 2024.",946.0,566275.781,32.1303,630.88,629.68,644.98,-0.001903916,0.022103638,0.014598799,0.002699968,0.56637,0.0074,1589.9313,127,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
VNDA,VCA-894A,"Charcot-Marie-Tooth disease, axonal, type 2S (CMT2S), caused by cryptic splice site variants within IGHMBP2Â ",IND-Enabling,1/23/2024,"Orphan drug designation, noted June 2, 2023. IND clearance by the FDA on January 23, 2024.",59.0,213.44372,58.2792,3.79,3.71,3.65,-0.021334142,-0.037638851,0.014598799,0.002699968,3.01072,0.01812,4.21039,128,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
HRTX,ZYNRELEF (bupivacaine and meloxicam) extended-release,Soft tissue and orthopedic surgical proceduresÂ ,Approved,1/23/2024,"FDA Approved on January 23, 2024.",153.0,330.15981,117.6731,2.34,2.2,2.49,-0.061693569,0.062131781,0.014598799,0.002699968,13.46927,0.05273,8.9777,129,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
URGN,ZUSDURI (VesiGel UGN-102 (mitomycin)) - (ENVISION),Low grade non-muscle invasive bladder cancer (LG-NMIBC)Â ,NDA Filing,1/24/2024,"NDA was submitted to FDA on January 24, 2024",46.0,464.22945,115.3267,15.11,15.04,15.7,-0.004643458,0.038303936,0.008214754,0.020378833,10.98551,0.0257,3.1923,130,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ANVS,Buntanetap,Parkinson's Disease (PD)Â ,Phase 3,1/24/2024,"Phase 3 data release postponed due to ongoing data cleaning efforts to ensure the accuracy and reliability of the study results, noted January 24, 2024.",19.0,93.28406,110.1817,11.64,9.09,11.05,-0.247272534,-0.052017014,0.008214754,0.020378833,9.55138,0.02488,11.25504,131,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ENSC,PF614-MPAR-102 - (MPAR),Overdose ProtectionÂ ,Phase 1,1/25/2024,"Phase 1 data presented at the HEAL Initiative Scientific Meeting reported that the trial successfully met its overdose protection endpoints, noted January 25, 2024.",2.0,4.7191,111.4355,19.94999,22.49999,22.19999,0.120286223,0.106863196,-0.005910451,-0.014149311,7.82831,0.0115,4.17841,132,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1
PBLA,SBP-101 in combination with Gemcitabine and Nab-Paclitaxel - (ASPIRE),Pancreatic Ductal Adenocarcinoma (PDA)Â ,Phase 2/3,1/25/2024,"Phase 2/3 enrollment exceeded 50% moving faster than expected, full enrollment anticipated 1Q 2025, noted January 25, 2024.",4.0,1.56131,197.3261,3.65,3.25,1.26,-0.116072171,-1.063615447,-0.005910451,-0.014149311,9.6494,0.00104,1.08064,133,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
VERA,Atacicept - (ORIGIN 3),IgA NephropathyÂ ,Phase 2b,1/25/2024,"Phase 2b OLE data reported a 59% reduction in Gd-IgA1, a reduction in the percentage of participants with hematuria to 41%, and a 47% reduction in UPCR in the PP analysis, noted January 25, 2024.",63.0,1124.59784,88.7161,17.02,25.31,38.0,0.396810451,0.803197037,-0.005910451,-0.014149311,13.61666,0.06404,291.27745,134,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CYTK,Aficamten - (FOREST-HCM) (OLE),Non-obstructive hypertrophic cardiomyopathy (HCM)Â ,Phase 2,1/25/2024,"Phase 2 sub-study data reported statistically significant improvements in measures of cardiac structure and function including left ventricular mass index (-11.4 g/m2 Â±19.4, p=0.03), maximum left vent",119.0,8129.62787,107.8795,81.77,82.91,81.25,0.013845254,-0.006379607,-0.005910451,-0.014149311,14.02121,0.02117,144.08456,135,0,1,0,0,0,1,0,0,0,0,0,0,2,0,0,1
EXEL,CABOMETYX (cabozantinib) and TECENTRIQ (atezolizumab) - (CONTACT-02),Castration-Resistant Prostate CancerÂ ,Phase 3,1/25/2024,"Phase 3 data presented at ASCO GU showed a reduction of the risk of disease progression or death by 35% in patients. While a trend toward OS improvement was observed, the data were immature and did no",269.0,6869.41816,28.8653,22.11,22.09,21.75,-0.000904977,-0.016416237,-0.005910451,-0.014149311,2.75382,0.12204,66.65898,136,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1
SRRK,SRK-439 with apitegromab - (EMBRAZE),ObesityÂ ,Preclinical,1/25/2024,"Preclinical data supports the potential of SRK-439 to preserve lean muscle mass as part of healthy weight loss, noted January 25, 2024.",96.0,1075.65598,83.5031,14.74,14.91,14.94,0.011467242,0.013477293,-0.005910451,-0.014149311,16.01552,0.01525,7.92558,137,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
PCSA,NGC-Capecitabine (PCS6422),Gastrointestinal CancerÂ ,Phase 1b,1/25/2024,"Phase 1b preliminary efficacy data reported that of the 11 cancer patients receiving one of the two highest doses of NGC-Cap, five have completed an efficacy evaluation at this time, and four of these",50.0,6.28155,232.81,2.05,5.1,2.34,0.911400747,0.132311136,-0.005910451,-0.014149311,0.72189,0.02387,377.50898,138,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
REGN,Dupixent (dupilumab),Eosinophilic esophagitis (EoE) in 1-11 year oldsÂ ,Approved,1/25/2024,"Approved January 25, 2024.",105.0,100909.4627,18.7144,948.24,948.87,957.78,0.000664168,0.010010472,-0.005910451,-0.014149311,1.00364,0.14522,374.03127,139,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1
SNY,Dupixent (dupilumab),Eosinophilic esophagitis (EoE) in 1-11 year oldsÂ ,Approved,1/25/2024,"Approved January 25, 2024.",0.0,114957.327,34.4925,49.89,49.88,48.41,-0.000200461,-0.030114178,-0.005910451,-0.014149311,0.0,0.0,143.86749,140,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1
BMY,BMS-986365 (CC-94676) - (rechARge),Metastatic CRPCÂ ,Phase 1,1/25/2024,"Phase 1 data reported that treatment induces effective and durable suppression of AR signaling, overcomes resistance to existing AR pathway inhibitors (ARPI) therapies and shows promising clinical act",0.0,100944.3316,21.2537,50.24,49.61,48.67,-0.012619096,-0.031748698,-0.005910451,-0.014149311,1.43437,0.11558,875.10259,141,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CRBP,CRB-701 (SYS6002) with Pembrolizumab,"Solid tumors, Locally advanced or metastatic urothelial carcinomaÂ ",Phase 1,1/26/2024,"Phase 1 dose escalation data from 2024 ASCO GU reported an ORR of 43% in the mixed tumor population, with no dose discontinuations or reductions in the study to date, noted January 26, 2024.",12.0,130.45441,202.9898,8.44,29.49,26.72,1.251068914,1.15243004,-0.025656734,0.006006705,0.634,0.01837,981.74354,142,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
MRK,KEYTRUDA (pembrolizumab) - (AMBASSADOR (A031501) KEYNOTE-123),Localized muscle-invasive urothelial carcinoma (MIUC)Â ,Phase 3,1/26/2024,"Phase 3 data reported that treatment doubled median DFS as adjuvant therapy versus observation â€“ 29 months versus 14 months, noted January 26, 2024.",0.0,306160.669,16.7063,120.13,120.82,126.41,0.005727345,0.050956103,-0.025656734,0.006006705,0.82139,0.01027,1002.84273,143,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
BMY,Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) Injection,"Solid tumors, Metastatic clear cell renal cell carcinoma (ccRCC)Â ",Phase 3,1/27/2024,"Phase 3 results presented at ASCO GU reported that with subcutaneous nivolumab demonstrating an ORR of 24.2% vs. 18.2% with IV Opdivo, noted January 27, 2024.",0.0,101127.4598,21.2552,49.7,49.7,48.71,0.0,-0.020120585,-0.028598911,0.003064528,1.43437,0.12831,0.0,144,1,0,0,0,0,1,0,0,0,0,1,0,3,0,0,1
HALO,Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) Injection,"Solid tumors, Metastatic clear cell renal cell carcinoma (ccRCC)Â ",Phase 3,1/27/2024,"Phase 3 results presented at ASCO GU reported that with subcutaneous nivolumab demonstrating an ORR of 24.2% vs. 18.2% with IV Opdivo, noted January 27, 2024.",116.0,4519.07634,38.9055,34.21,34.21,33.68,0.0,-0.01561381,-0.028598911,0.003064528,5.42454,0.16901,0.0,145,1,0,0,0,0,1,0,0,0,0,1,0,3,0,0,1
MRK,KEYTRUDA (KEYNOTE-564),Renal cell carcinoma (RCC)Â ,Phase 3,1/29/2024,"Additional Phase 3 data reported that treatment reduced the risk of disease recurrence or death by 32%, noted January 29, 2024.",0.0,307326.3196,16.5213,120.82,121.28,126.18,0.003800087,0.043407624,-0.00598838,-0.00192471,0.82139,0.01027,1108.3054,146,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
NNVC,NV-CoV-2 (NV-387),"RSV (Respiratory Syncytial Virus), Coronavirus, Smallpox/Mpox related Ectromelia virus infectionÂ ",Phase 1b,1/29/2024,"Phase 1a/1b healthy subjects section of trial completed with no adverse events reported, noted January 29, 2024.",17.0,13.74229,65.6805,1.07,1.17,1.12,0.0893451,0.045670037,-0.00598838,-0.00192471,2.6085,0.01672,0.49076,147,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
AZN,GC012F,Early-line treatment of multiple myeloma (ELMM).Â ,IND-Enabling,1/29/2024,"IND was cleared by the FDA on January 29, 2024.",0.0,163821.1863,21.4466,105.46,105.68,103.6,0.002083926,-0.017794404,-0.00598838,-0.00192471,0.0,0.14005,189.76324,148,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
ACXP,Ibezapolstat,C. difficile InfectionÂ ,Phase 2b,1/29/2024,"Phase 2b trial showed that 100% (5 of 5) of ibezapolstat-treated patients who agreed to observation for up to three months following Clinical Cure of CDI experienced no recurrence of infection, noted",1.0,50.66609,133.4118,77.4,73.6,62.8,-0.050341755,-0.209031707,-0.00598838,-0.00192471,1.7692,0.00866,0.98344,149,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
SRPT,SRP-5051 - (MOMENTUM),Duchenne muscular dystrophyÂ ,Phase 2,1/29/2024,"Phase 2 data at target dose (~30 mg/kg), SRP-5051 dosed monthly resulted in mean dystrophin expression of 5.17% and mean exon skipping of 11.11% at 28 weeks (n=20), noted January 29, 2024.",97.0,11272.37506,79.8127,118.73,120.5,125.55,0.014797745,0.055852078,-0.00598838,-0.00192471,6.06663,0.00742,139.49092,150,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
PALI,PALI-2108,Moderate-to-severe ulcerative colitis (UC)Â ,Preclinical,1/29/2024,"Preclinical data demonstrated PALI-2108 to be safe and well tolerated, noted January 29, 2024.",9.0,8.90477,220.9784,7.8,14.39999,7.65,0.613103778,-0.019418086,-0.00598838,-0.00192471,1.39091,0.10296,130.57946,151,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1
TAK,GAMMAGARD LIQUID [Immune Globulin Infusion (Human) 10% solution],Adults with chronic inflammatory demyelinating polyneuropathy (CIDP)Â ,Approved,1/29/2024,"FDA Approved on January 29, 2024.",0.0,6843576.482,18.6116,14.6,14.77,13.92,0.011576568,-0.047694874,-0.00598838,-0.00192471,0.0,0.0,23.55418,152,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
LIXT,LB-100 with doxorubicin,Ovarian clear cell carcinoma (OCCC)Â ,Phase 1/2,1/29/2024,"Phase 1b/2 dosing was initiated, noted January 29, 2024.",4.0,4.83597,98.6014,1.99,2.15,2.02,0.077333203,0.014962873,-0.00598838,-0.00192471,0.21087,0.05041,0.08262,153,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
IKT,Risvodetinib - (IkT-148009) - (201 trial),Parkinsonâ€™s diseaseÂ ,Phase 1,1/29/2024,Phase 1 study published at Journal of Parkinson's Disease showed that data demonstrated that Risvodetinib was well tolerated up to 7 days of daily dosing with no serious adverse events in healthy volu,74.0,19.81944,133.7881,2.96,3.21,2.55,0.081081669,-0.149095909,-0.00598838,-0.00192471,0.1422,0.04909,0.92391,154,0,0,0,1,0,1,0,0,0,0,0,0,0,0,2,0
ALVO,"AVT03-GL-P01 (denosumab) - (PROLIA Biosimilar, Xgeva Biosimilar)",Osteoporosis in postmenopausal women and for bone loss in adult men and womenÂ ,Phase 1,1/29/2024,"Pk trial met its primary endpoints, noted January 29, 2024.",301.0,4049.32826,41.2867,14.65,15.25,15.49,0.040139168,0.055754319,-0.00598838,-0.00192471,0.04286,0.00989,7.90885,155,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1
RCUS,Domvanalimab + zimberelimab vs. zimberelimab vs. chemotherapy - (ARC-10),Non Small Cell Lung Cancer (NSCLC)Â ,Phase 3,1/30/2024,"Phase 3 trial discontinued January 30, 2024.",106.0,1416.27234,62.2273,15.3,15.72,15.32,0.027080959,0.001306336,0.037820812,0.011519844,7.9399,0.08764,33.25142,156,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
KURA,Ziftomenib (in combination with SoC cytarabine/daunorubicin (7+3) and venetoclax/azacitidine (ven/aza))- (KOMET-007),Acute myeloid leukemia (AML)Â ,Phase 1,1/30/2024,"Phase 1 combinations demonstrated encouraging preliminary evidence of clinical activity in patients with refractory/relapsed disease after failure of other agents, including venetoclax, a setting with",86.0,1577.28007,77.6561,18.6,20.85,20.97,0.114192368,0.119931264,0.037820812,0.011519844,12.38782,0.08526,233.79362,157,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
SCYX,SCY-247,Pulmonary mucormycosisÂ ,Preclinical,1/30/2024,"Preclinical data reported that SCY-247 resulted in 40% and 50% survival at 21 days post infection for the intermediate (32 mg/kg) and high doses (48 mg/kg), respectively, compared to 0% survival in th",41.0,72.74125,89.5288,1.95,1.955,1.995,0.002560821,0.022814678,0.037820812,0.011519844,3.78207,0.16682,0.19114,158,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ITRM,ORLYNVAH (Oral Sulopenem),Uncomplicated urinary tract infections (uUTI)Â ,Phase 3,1/30/2024,"Phase 3 data met the primary endpoint of non-inferiority to augmentin; and demonstrated statistical superiority, noted January 30, 2024.",44.0,21.22791,121.0978,1.79,1.58,1.58,-0.124790773,-0.124790773,0.037820812,0.011519844,0.35615,0.11428,38.76491,159,1,0,0,0,0,1,0,0,0,0,0,0,2,0,0,1
VRTX,Suzetrigine (VX-548),Acute Pain following bunionectomy or abdominoplasty surgeryÂ ,Phase 3,1/30/2024,"Phase 3 trial data reported a statistically significant improvement on the primary endpoint of the time-weighted sum of the pain intensity difference from 0 to 48 hours (SPID48) compared to placebo, n",256.0,114947.3147,26.5742,435.82,446.08,416.13,0.023268994,-0.046231603,0.037820812,0.011519844,1.30151,0.15104,1485.48075,160,1,0,0,0,0,1,0,0,0,0,1,0,3,0,0,1
NVS,Sabatolimab (MBG453) - (STIMULUS),Myelodysplastic syndromes (MDS)Â ,Phase 3,1/31/2024,"Phase 3 trial did not meet its primary endpoint, noted January 31, 2024.",0.0,1473.83355,46.5677,4.8,4.75,4.94,-0.0104713,0.028749413,-0.002250479,0.007916802,0.0,0.00875,0.13899,161,1,0,0,0,0,1,0,0,0,0,0,0,0,2,0,-1
OTLK,ONS-5010 / LYTENAVA (bevacizumab-vikg) - (NORSE EIGHT),Wet age-related macular degeneration (wet AMD)Â ,Phase 3,1/31/2024,"Special Protocol Assessment (SPA) dosing initiated, noted January 31, 2024.",44.0,100.4594,277.1926,8.3,7.72,8.416,-0.072441151,0.013879141,-0.002250479,0.007916802,4.65973,0.01979,0.69519,162,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1
NVO,Semaglutide - (STEP HFpEF),"Heart failure with preserved ejection fraction (HFpEF) and obesity, Type 2 diabetesÂ ",Phase 3,1/31/2024,"Phase 3 reported that KCCQ-CSS estimated treatment difference between semaglutide 2.4 mg and placebo of 7.8, noted January 31, 2024.",0.0,3452603.284,34.9479,109.02,114.74,118.66,0.051137348,0.084730909,-0.002250479,0.007916802,0.0,0.0,1459.04795,163,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
EDAP,Transrectal High-intensity focused ultrasound (TR-HIFU),Rectal Deep Infiltrating EndometriosisÂ ,Phase 3,2/1/2024,"Phase 3 enrolment completed, noted February 1, 2024.",37.0,234.11949,74.3167,6.65,6.34,6.4,-0.047738086,-0.038318864,-0.006157374,-0.020266757,0.18503,0.02299,0.48112,164,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
AZN,Attruby (Acoramidis) - (ATTRibute-CM),Amyloid cardiomyopathy (ATTR-CM)Â ,Phase 3,2/2/2024,"Additional Phase 3 data reported improved functions and quality of life at 30 months, noted February 2, 2024.",0.0,160599.6154,21.328,104.3,103.6,97.61,-0.006734032,-0.066291415,0.006314149,-0.022999736,0.0,0.13986,304.91842,165,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
BBIO,Attruby (Acoramidis) - (ATTRibute-CM),Amyloid cardiomyopathy (ATTR-CM)Â ,Phase 3,2/2/2024,"Additional Phase 3 data reported improved functions and quality of life at 30 months, noted February 2, 2024.",191.0,5899.22273,52.0258,33.31,33.91,34.47,0.017852304,0.034231728,0.006314149,-0.022999736,9.26687,0.02659,56.43187,166,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
LQDA,L606 (liposomal treprostinil),Pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD)Â ,Phase 2,2/2/2024,"Open-label trial data presented at the Pulmonary Vascular Research Institute (PVRI) reported that treatment demonstrate sustained plasma levels up to 12 hours, supporting twice daily administration, n",86.0,1029.52841,62.3854,13.6,13.58,14.81,-0.001471671,0.085232836,0.006314149,-0.022999736,7.27268,0.031,7.84219,167,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
FDMT,4D-150 - (PRISM),Wet age-related macular degeneration (AMD)Â ,Phase 2,2/3/2024,"Phase 2 data reported that the high dose 4D-150 resulted in an 89% reduction in the annualized anti-VEGF injection rate; 84% of patients received 0 or 1 injection, and 63% were injection-free through",46.0,747.76059,59.3496,17.49,17.49,28.63,0.0,0.49282583,-0.004989238,-0.034303123,6.73732,0.13273,0.0,168,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
LCTX,RG6501 - (OpRegen),Geographic atrophy (GA)Â ,Phase 1/2,2/3/2024,"Additional Phase 1/2a data presented at the Angiogenesis, Exudation, and Degeneration Meeting reported that all patients with extensive delivery to GA showed improvement in outer retinal structure on",228.0,171.48694,65.4291,0.98,0.98,1.08,0.0,0.097163748,-0.004989238,-0.034303123,4.50364,0.02338,0.0,169,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
KOD,KSI-501 (KSI-501ABC) - (DAYBREAK),Retinal diseases w/ inflammatory componentÂ ,Phase 1,2/3/2024,"Phase 1 trial initial data presented at the Angiogenesis, Exudation, and Degeneration reported that monthly dosing of KSI-501 was safe and well-tolerated, noted February 3, 2024.",52.0,210.71268,109.8718,4.03,4.03,5.38,0.0,0.288921998,-0.004989238,-0.034303123,2.60877,0.18385,0.0,170,0,0,0,1,0,1,0,0,0,0,0,0,2,0,0,1
BRTX,BRTX-100,Chronic lumbar disc diseaseÂ ,Phase 2,2/4/2024,"Phase 2 initial data presented at ORS reported that Visual Analog Scale, Oswestry Disability Index, Roland Morris Disability Questionnaire, and Functional Rating Index collected at weeks 26 and 52 pos",7.0,13.17937,91.6412,2.8,2.8,1.35,0.0,-0.729514825,-0.004989238,-0.034303123,0.19429,0.04439,0.0,171,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
EYPT,DURAVYU (EYP-1901) - (LUGANO),Wet age-related macular degeneration (AMD)Â ,Phase 2,2/5/2024,"Phase 2 subgroup analysis reported numerical superiority in change in BCVA along with strong anatomic control compared to the aflibercept control group, noted February 5, 2024.",68.0,1308.1903,171.8556,28.7,27.79,29.71,-0.032220879,0.034586567,-0.020143595,-0.056678337,11.05685,0.04709,47.87358,172,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
PLRX,Bexotegrast (PLN-74809) - (INTEGRIS-PSC),Primary sclerosing cholangitis (PSC)Â ,Phase 2a,2/5/2024,"Phase 2a data reported that 320 mg group met its primary and secondary endpoints demonstrating that bexotegrast was well tolerated over a 12-week treatment period, noted February 5, 2024.",61.0,946.35614,58.9844,17.4,15.8,17.27,-0.096460266,-0.007499314,-0.020143595,-0.056678337,10.62835,0.0995,33.26628,173,1,0,0,1,0,1,0,0,1,0,0,0,4,0,0,1
RANI,"RT-111 (RaniPill Containing Ustekinumab Biosimilar, CT-P43)","Plaque psoriasis, active psoriatic arthritis, moderate to severe Crohn's disease, and moderate to severe ulcerative colitisÂ ",Phase 1,2/5/2024,Phase 1 data showed that it well-tolerated and delivered ustekinumab with high bioavailability. Data provided clinical validation of our ability to successfully transform an injectable large molecule,71.0,95.49744,84.5308,3.49,3.69,3.57,0.055724722,0.02266386,-0.020143595,-0.056678337,5.86019,0.0,0.66708,174,0,0,0,1,0,1,0,0,0,0,0,0,2,0,0,1
THAR,TH104 (AV104),Primary biliary cholangitis (PBC)Â ,Phase 1,2/5/2024,"Phase 1 dosing of first patient completed, noted February 5, 2024.",4.0,1.03595,234.4007,6.6,6.153,5.775,-0.070129881,-0.133531393,-0.020143595,-0.056678337,1.68519,0.00266,0.22004,175,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ARCT,Kostaive (ARCT-154),COVID-19 variant vaccineÂ ,Phase 3,2/5/2024,"Phase 3 results demonstrated continuous advantage of sa-mRNA over conventional mRNA vaccine in terms of duration of immune response, noted February 5, 2024.",27.0,937.18725,73.8582,34.72,35.07,41.62,0.010030174,0.181264931,-0.020143595,-0.056678337,15.52033,0.28856,9.8856,176,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
AIMD,VELDONA,Mild COVID-19Â ,Phase 2,2/5/2024,"Company submitted the clinical hold complete response to the FDA for conducting a Phase 2 trial of its low-dose oral interferon (IFN)-alpha formulation, noted February 5, 2024.",4.0,5.05203,135.7597,5.15,5.4,4.7405,0.047402239,-0.082854099,-0.020143595,-0.056678337,0.78231,0.00382,0.03284,177,0,0,0,0,0,1,0,1,0,0,0,0,0,2,0,-1
VRTX,VX-121/tezacaftor/VX-561 - (SKYLINE-102),Cystic FibrosisÂ ,Phase 3,2/5/2024,"Phase 3 study met all primary and key secondary endpoints in two randomized controlled trials in people with CF ages 12 years and older, noted February 5, 2024.",256.0,110517.7408,26.1837,424.68,428.89,418.53,0.009864532,-0.014587372,-0.020143595,-0.056678337,1.30151,0.18016,823.4821,178,1,0,0,0,0,1,0,0,1,0,0,0,3,0,0,1
GSK,Blenrep,Multiple myelomaÂ ,Phase 3,2/6/2024,"Additional Phase 3 data reported a 59% reduction in risk of disease progression or death, noted February 6, 2024.",0.0,67076.70063,17.7752,16.626,16.53,16.418,-0.005790823,-0.012589441,0.003853133,-0.003500258,0.0,0.00204,83.34578,179,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
SGMO,Civaparvovec (ST-920) - (STAAR),Fabry diseaseÂ ,Phase 1/2,2/6/2024,Phase 1/2 clinical data reported a statistically significant improvements in disease severity were reported in the Fabry Outcome Survey adaptation of the Mainz Severity Score Index (FOS-MSSI) age-adju,301.0,92.34457,111.845,0.56,0.5207,0.6701,-0.072762724,0.179490171,0.003853133,-0.003500258,5.16767,0.13793,1.32188,180,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1
LLY,Tirzepatide - (SYNERGY-NASH),"Nonalcoholic steatohepatitis (NASH), Metabolic dysfunction-associated steatohepatitis (MASH)Â ",Phase 2,2/6/2024,"Phase 2 trial met its primary endpoint, noted February 6, 2024.",946.0,634038.5813,33.0806,706.2,705.03,742.97,-0.001658128,0.050757184,0.003853133,-0.003500258,0.54335,0.01369,5781.17691,181,1,0,0,0,0,1,0,0,0,0,0,0,2,0,0,1
GANX,"GT-02287, GT-02329",GBA1 and Idiopathic Parkinson's DiseaseÂ ,Preclinical,2/6/2024,"Preclinical data presented at the WORLDSymposium reported that GT-02287 restored motor function in a mouse model, even following a delayed administration of the drug candidate after the initial toxic",35.0,72.41118,74.6424,4.39,4.47,4.51,0.018059182,0.026967926,0.003853133,-0.003500258,0.63891,9e-05,1.03206,182,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
LLY,VERZENIO (Abemaciclib) - (CYCLONE-2),Prostate CancerÂ ,Phase 3,2/6/2024,"Phase 3 trial was not successful, noted February 6, 2024.",946.0,634038.5813,33.0806,706.2,705.03,742.97,-0.001658128,0.050757184,0.003853133,-0.003500258,0.54335,0.01369,5781.17691,183,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1
ABEO,UX111 - (ABO-102),Sanfilippo syndrome type A (MPS IIIA)Â ,Phase 1/2,2/6/2024,"Phase 1/2 presented at the WORLDSymposium demonstrated treatment resulted in rapid and sustained decreased levels of heparan sulfate, noted February 6, 2024.",51.0,106.52526,62.5767,4.29,4.3,6.31,0.00232829,0.385848944,0.003853133,-0.003500258,2.67242,0.00726,0.54458,184,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
RARE,UX111 - (ABO-102),Sanfilippo syndrome type A (MPS IIIA)Â ,Phase 1/2,2/6/2024,"Phase 1/2 presented at the WORLDSymposium demonstrated treatment resulted in rapid and sustained decreased levels of heparan sulfate, noted February 6, 2024.",96.0,3767.84003,52.9302,44.76,45.89,43.98,0.024932345,-0.017579898,0.003853133,-0.003500258,5.01329,0.20905,33.65444,185,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
INKT,AGENT-797,Acute respiratory distress (ARDS) secondary to COVID-19Â ,Phase 1/2,2/6/2024,"Phase 1/2 data showed that agenT-797 holds significant promise in improving patient survival and reducing secondary infections, all while maintaining a favorable safety profile, noted February 6, 2024",4.0,32.44837,80.2507,8.526,9.4,9.277,0.097589371,0.0844179,0.003853133,-0.003500258,0.50656,0.09106,0.08395,186,0,0,0,1,0,1,0,0,1,0,0,0,3,0,0,1
REGN,Libtayo (cemiplimab-rwlc),High-risk cutaneous squamous cell carcinoma (CSCC) after surgeryÂ ,Phase 3,2/6/2024,"Phase 3 data from ASCO reported a 68% reduction in the risk of disease recurrence or death, noted June 2, 2025.",105.0,100778.8407,17.7404,936.33,937.81,940.48,0.001579391,0.004422405,0.003853133,-0.003500258,0.99323,0.1296,431.79117,187,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
HCM,Fruquintinib and Paclitaxel - (FRUTIGA),Gastric CancerÂ ,Phase 3,2/7/2024,"Phase 3 data presented at ASCO plenary series noted that the median PFS for patients who received fruquintinib plus paclitaxel was 5.6 months, compared to 2.7 months for those who received paclitaxel",174.0,1860.4344,52.9492,2.15,2.18,2.185,0.013857035,0.016147986,0.006034212,-0.015257344,0.0,0.13842,0.21694,188,1,0,0,0,0,1,0,0,0,0,1,0,3,0,0,1
RGNX,RGX-202 - (AFFINITY DUCHENNE),Duchenne Muscular Dystrophy (DMD)Â ,Phase 1/2,2/7/2024,"Phase 1/2 dose 2 levels completed; additionally, the company reported interim safety and efficacy data where the third patient at dose level 1 demonstrates the largest increase in microdystrophin expr",50.0,640.96315,57.2356,13.05,14.57,16.79,0.110176486,0.251995337,0.006034212,-0.015257344,10.03045,0.23949,26.84477,189,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
VRPX,Probudur,Post-operative painÂ ,Phase 2,2/7/2024,"Phase 2 initial data reported that two doses of Probudur showed reduction in incision-induced pain behaviors, noted February 7, 2023.",1.0,4.46079,122.2015,103.6,95.2,96.5,-0.084557388,-0.070994321,0.006034212,-0.015257344,0.43943,0.0098,0.17993,190,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
BCTX,Bria-IMT - (BRIA-ABC),Advanced breast cancerÂ ,Phase 2,2/7/2024,"Additional Phase 2 data reported a disease control rate of 50%, noted February 7, 2024.",1.0,84.38281,74.0242,620.99969,590.2497,497.99975,-0.050784915,-0.220731008,0.006034212,-0.015257344,0.0,0.0,0.61209,191,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ALEC,Latozinemab (AL001) - (INFRONT-3),Frontotemporal DementiaÂ ,Phase 3,2/7/2024,"Breakthrough Therapy Designation granted by the FDA, noted February 7, 2024",101.0,608.03806,82.6857,6.04,6.4,6.27,0.057893978,0.037372343,0.006034212,-0.015257344,5.68428,0.01202,9.33201,192,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
GSK,Latozinemab (AL001) - (INFRONT-3),Frontotemporal DementiaÂ ,Phase 3,2/7/2024,"Breakthrough Therapy Designation granted by the FDA, noted February 7, 2024",0.0,67872.04445,17.7625,16.53,16.726,16.68,0.011787483,0.009033485,0.006034212,-0.015257344,0.0,0.00204,127.44694,193,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
SAVA,Simufilam (PTI-125) - (RETHINK-ALZ),Alzheimerâ€™s diseaseÂ ,Phase 3,2/7/2024,"Phase 3 24-month data reported that treated patients scores declined by an average of 1.04 points on ADAS-Cog11, noted February 7, 2024.",48.0,1072.81774,84.2715,23.66,25.4,24.1,0.070963315,0.018425982,0.006034212,-0.015257344,31.56632,0.03158,30.61305,194,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
RGNX,clemidsogene lanparvovec (RGX-121) - (CAMPSIITE),MPS II (Hunter Syndrome)Â ,Phase 3,2/7/2024,"Phase 3 topline data reported that trial met primary endpoint, noted February 7, 2024.",50.0,640.96315,57.2356,13.05,14.57,16.79,0.110176486,0.251995337,0.006034212,-0.015257344,10.03045,0.23949,26.84477,195,1,0,0,0,0,1,0,0,0,0,1,0,3,0,0,1
DNLI,DNL126,MPS IIIA (Sanfilippo syndrome Type A)Â ,Preclinical,2/7/2024,"Preclinical mouse-model data shared at the WORLDSymposium reported that ETV:SGSH lowered substrate accumulation in the CNS and improved cognitive deficits, noted February 7, 2024.",146.0,2342.43657,59.892,16.63,16.95,17.89,0.019059541,0.073033604,0.006034212,-0.015257344,7.15183,0.29766,14.66151,196,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
DNLI,Tividenofusp alfa (DNL310) - (COMPASS),Hunter syndrome MPS IIÂ ,Phase 1/2,2/7/2024,"Phase 1/2 data at WORLDSymposium showed additional improvement and stabilization in clinical outcomes in MPS II with 104 weeks of tividenofusp alfa (DNL310) treatment in the open-label, single-arm stu",146.0,2342.43657,59.892,16.63,16.95,17.89,0.019059541,0.073033604,0.006034212,-0.015257344,7.15183,0.29766,14.66151,197,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ALEC,AL101/GSK4527226 - (PROGRESS-AD),Early Alzheimer's disease (AD)Â ,Phase 2,2/8/2024,"Phase 2 dosing initiated, noted February 8, 2024.",101.0,593.78717,82.7363,6.4,6.25,6.49,-0.023716527,0.01396454,-0.033167018,-0.05736656,5.68428,0.01202,3.75396,198,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1
GSK,AL101/GSK4527226 - (PROGRESS-AD),Early Alzheimer's disease (AD)Â ,Phase 2,2/8/2024,"Phase 2 dosing initiated, noted February 8, 2024.",0.0,66995.5431,17.8447,16.726,16.51,16.63,-0.012998137,-0.005756102,-0.033167018,-0.05736656,0.0,0.00204,124.32012,199,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1
ADVM,"Ixo-vec (ixoberogene soroparvovec, ADVM-022) - (ARTEMIS)",Wet age-related macular degeneration (AMD)Â ,Phase 2,2/8/2024,"Phase 2 data presented at the Macula Society Annual Meeting on the 2E11 and 6E10 doses demonstrated maintenance of visual and anatomic outcomes, noted February 8, 2024.",20.0,199.02353,114.0871,28.1,19.7,20.0,-0.355150941,-0.340037303,-0.033167018,-0.05736656,1.63607,0.01339,29.91266,200,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
AIM,Ampligen (AMP-518),Post-COVID conditionsÂ ,Phase 2,2/8/2024,ase 2 efficacy results offer preliminary evidence that Ampligen may reduce fatigue in subjects with Post-COVID conditions. Safety results showed Ampligen is generally well tolerated in the treatment o,2.0,57.42386,57.2609,0.275,0.275,0.285,0.0,0.035718083,-0.033167018,-0.05736656,0.0,0.00592,0.0,201,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1
BDRX,MTX110 - (MAGIC-G1),Recurrent Glioblastoma (GBM)Â ,Phase 1,2/8/2024,"Phase 1 PFS data reported that one patient had a survival rate of 12 months from the start of treatment, while 3 patients remain in the study, noted February 8, 2024.",0.0,3.40535,164.0147,337.5,325.0,397.5,-0.037740328,0.163629424,-0.033167018,-0.05736656,1.73144,0.00063,1.84633,202,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
AMLX,AMX0035 - (HELIOS),Wolfram SyndromeÂ ,Phase 2,2/8/2024,"Phase 2 enrollment completed, noted February 8, 2024.",89.0,1043.82446,69.2839,15.12,15.46,15.38,0.022237672,0.017049593,-0.033167018,-0.05736656,8.48478,0.08282,8.50014,203,0,0,0,0,0,1,0,0,0,1,0,0,2,0,0,1
ATHA,ATH-1105,Amyotrophic Lateral Sclerosis (ALS)Â ,Preclinical,2/8/2024,"Preclinical data reported that ATH-1105 treatment results in significant, consistent beneficial effects both in cell culture and in vivo models of ALS, noted February 8, 2024.",3.0,120.63302,74.9017,31.0,31.7,36.6,0.022329476,0.166061036,-0.033167018,-0.05736656,1.3503,0.07189,0.55282,204,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
TAK,Oveporexton (TAK-861-2001),Narcolepsy type 1 (NT1)Â ,Phase 2b,2/9/2024,"Phase 2b trial met its primary and secondary endpoints, noted February 9, 2024.",0.0,6682008.776,19.4101,14.0,14.24,14.62,0.016997576,0.043333125,-0.042568955,-0.043105867,0.0,0.0,17.17975,205,1,0,0,0,0,1,0,0,1,0,0,0,3,0,0,1
CNTA,SerpinPC - (PRESent-3),Hemophilia BÂ ,Phase 2a,2/9/2024,"Phase 2a data presented at EAHAD reinforce confidence in SerpinPC's novel mechanism of action as we continue to advance the registrational studies, noted February 9, 2024.",134.0,904.04774,78.2521,7.46,9.26,11.75,0.216148634,0.454297826,-0.042568955,-0.043105867,1.13865,0.16504,28.10975,206,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
OKYO,Urcosimod (OK-101),Neuropathic corneal pain (NCP)Â ,IND-Enabling,2/9/2024,"IND cleared by the FDA, noted February 9, 2024.",33.0,56.83365,106.8312,1.43,1.71,1.41,0.178818926,-0.01408474,-0.042568955,-0.043105867,0.15403,0.00086,9.83294,207,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
NRXP,NRX-101,Bipolar Depression and Suicidal IdeationÂ ,Phase 2/3,2/9/2024,"hase 2b/3 enrollment completed, noted February 9, 2024.",19.0,42.62548,89.7755,4.64,5.12,4.708,0.098440073,0.014548823,-0.042568955,-0.043105867,3.45232,0.02952,1.14597,208,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1
IRON,MWTX-003 - (DISC-3405),Polycythemia vera (PV)Â ,Phase 1,2/9/2024,"Orphan drug designation granted by the FDA on February 9, 2024",34.0,1648.54983,48.1994,66.73,68.29,65.92,0.023108716,-0.012212741,-0.042568955,-0.043105867,5.46485,0.0461,7.88586,209,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ANTX,EBO-301,Treatment-Refractory MAC Lung DiseaseÂ ,Phase 2/3,2/12/2024,"Phase 2/3 enrollment voluntary pause enables time to evaluate study data further and for the independent DSMB to conduct an unblinded assessment and recommend next steps, which could include changes t",27.0,151.68137,207.3869,20.0,5.1,3.64,-1.366491734,-1.703748592,0.025813627,-0.022912127,0.94252,0.02616,29.07324,210,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
LRMR,Nomlabofusp (CTI-1601),Friedreichâ€™s ataxia (FA)Â ,Phase 2,2/12/2024,"Phase 2 study showed that treatment was generally well tolerated following repeated subcutaneous injections in patients in the 25 and 50 mg cohorts with no serious adverse events, noted February 12, 2",85.0,343.78322,83.6802,7.76,7.83,12.78,0.008980176,0.498899115,0.025813627,-0.022912127,0.7737,0.05605,16.92701,211,0,0,0,1,0,1,0,0,0,0,0,0,0,0,2,0
BTAI,BXCL701 and KEYTRUDA (pembrolizumab),Neuroendocrine Prostate Cancer (NEPC)Â ,Phase 2a,2/12/2024,"Fast Track designation granted by the FDA on February 12, 2024.",14.0,59.24471,149.9362,33.76,31.2,56.16,-0.078858575,0.50892809,0.025813627,-0.022912127,8.08295,0.04641,19.98635,212,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
PYPD,D-PLEX100 - (SHIELD II),Surgical Site InfectionÂ ,Phase 3,2/12/2024,"Phase 3 trial 100th patient enrollment, noted February 12, 2024.",10.0,32.8132,111.0529,6.92,6.84,6.4,-0.011628038,-0.078117779,0.025813627,-0.022912127,0.10798,8e-05,0.03391,213,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
NUVL,Neladalkib (NVL-655) - (ALKove-1),ALK non-small cell lung cancer (NSCLC)Â ,Phase 1/2,2/12/2024,"Phase 1/2 trial initiated, noted February 12, 2024.",72.0,5232.74444,59.8129,82.45,83.55,86.21,0.013253206,0.044594131,0.025813627,-0.022912127,10.05736,0.12256,47.13607,214,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
TAK,EOHILIA (budesonide oral suspension),People 11 years and older with eosinophilic esophagitis (EoE)Â ,Approved,2/12/2024,"FDA approved on February 12, 2024.",0.0,6682008.776,19.4686,14.24,14.31,14.62,0.004903688,0.026335548,0.025813627,-0.022912127,0.0,0.0,16.30825,215,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
JAGX,Mytesi (crofelemer),Moderate-to-severe diarrhea including Vibrio choleraeÂ ,Phase 1,2/12/2024,"Orphan Drug Designation (ODD) submited to the FDA, noted February 12, 2024.",2.0,4.53753,126.8627,125.54975,134.09973,117.14977,0.065881682,-0.069248893,0.025813627,-0.022912127,8.1002,0.00026,2.06956,216,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
SGMO,Civaparvovec (ST-920) - (STAAR),Fabry diseaseÂ ,Phase 1/2,2/12/2024,"Type-D meeting with the FDA agreed in a that data from a single, adequate, and well-controlled study may form the primary basis of approval of a BLA for isaralgagene civaparvovec, noted February 12, 2",301.0,142.76432,123.1802,0.5744,0.805,1.38,0.33751626,0.87651276,0.025813627,-0.022912127,5.62785,0.13686,6.84376,217,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
TNXP,TNX-102 SL - (OASIS),"Acute stress reaction (ASR), acute stress disorder (ASD), and posttraumatic stress disorder (PTSD)Â ",Phase 2,2/12/2024,"FDA Cleared IND on February 12, 2024.",8.0,21.68733,108.3839,1056.0,1184.0,1220.8,0.114410351,0.145018196,0.025813627,-0.022912127,1.08885,0.13187,1.19229,218,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
ANIX,Chimeric endocrine receptor T-cell (CER-T),Ovarian CancerÂ ,Phase 1,2/12/2024,"Phase 1 2nd cohort dosing initiated, noted February 12, 2024.",32.0,141.43442,62.5941,4.51,4.46,4.05,-0.011148387,-0.107580272,0.025813627,-0.022912127,2.14893,0.08749,0.61229,219,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1
FDMT,4D-310 - (INGLAXA),Fabry DiseaseÂ ,Phase 1/2,2/12/2024,"Phase 1/2 interim data presented at the WORLDSymposium 2024 demonstrated clinically meaningful cardiac endpoint improvements through 12-24 months in contractility (echocardiography), peak VO2 (cardiop",46.0,1374.10847,107.0605,28.63,27.85,27.26,-0.027622153,-0.049034693,0.025813627,-0.022912127,7.77293,0.09494,53.76899,220,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
BMRN,Valoctocogene roxaparvovec (BMN 270-303) - (GENEr8-3),Hemophilia AÂ ,Phase 3,2/12/2024,"Phase 3 trial data presented at EAHAD after liver biopsy analysis suggests efficient hepatocyte transduction occurred, noted February 9, 2024.",192.0,16610.30532,29.6906,88.46,88.18,88.77,-0.003170293,0.003498283,0.025813627,-0.022912127,1.68528,0.20091,112.83954,221,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
KRYS,KB707 - (KYANITE-1),Solid TumorsÂ ,IND-Enabling,2/13/2024,"The FDA cleared IND and granted fast-track designation on February 13, 2024.",28.0,3066.87426,48.201,115.88,108.73,111.64,-0.063687428,-0.037275764,0.021277398,0.007763679,7.19433,0.05328,36.54861,222,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
KALV,EKTERLY (sebetralstat),Hereditary Angioedema (HAE)Â ,Phase 3,2/13/2024,"Phase 3 clinical trial met all primary and key secondary endpoints and demonstrated a favorable safety profile, noted February 13, 2024.",50.0,513.19683,59.3196,16.04,14.85,13.8,-0.077085737,-0.15041701,0.021277398,0.007763679,7.15732,0.16326,66.19045,223,1,0,0,1,0,1,0,0,1,0,0,0,4,0,0,1
CADL,CAN-3110,GliomaÂ ,Phase 1,2/13/2024,"Fast track designation granted by the FDA on February 13, 2024.",54.0,52.05566,110.743,1.39,1.8,1.72,0.258482918,0.213020544,0.021277398,0.007763679,0.57462,0.00027,3.47868,224,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
LCTX,AST-OPC1 SCiSTAR - (DOSED),Cervical spinal cord injuryÂ ,IND-Enabling,2/13/2024,"INDa cleared by the FDA on February 13, 2024.",228.0,192.24778,67.6221,1.08,1.02,1.09,-0.057158414,0.009216655,0.021277398,0.007763679,4.48602,0.02434,0.96536,225,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
RCKT,KRESLADI (marnetegragene autotemcel),Leukocyte Adhesion Deficiency-I (LAD-I)Â ,PDUFA,2/13/2024,"PDUFA date extended by 3 months to June 30, 2024.",107.0,2611.90319,68.7179,29.99,28.97,28.64,-0.034603181,-0.046059651,0.021277398,0.007763679,9.36909,0.11126,51.99901,226,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CALC,Auxora - (KOURAGE),Acute kidney injury (AKI) with associated acute hypoxemic respiratory failure (AHRF)Â ,IND-Enabling,2/13/2024,"IND cleared by the FDA, noted February 13, 2024.",13.0,56.1708,116.7181,5.6977,5.23,4.36,-0.085651307,-0.267590527,0.021277398,0.007763679,0.20184,0.03414,0.11315,227,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
ROIV,RVT-2001,Transfusion-Dependent Anemia in Patients with Lower-Risk MDSÂ ,Phase 1/2,2/13/2024,Phase 1/2 development discontinued after interim data analysis.,682.0,8703.13687,57.2451,10.87,10.8,11.54,-0.006460567,0.05981256,0.021277398,0.007763679,3.1901,0.09307,66.98586,228,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
PBYI,Alisertib - (PUMA-ALI-4201) - (ALISCA-Lung1),Small Cell Lung Cancer (SCLC)Â ,Phase 2,2/13/2024,"Phase 2 was initiated, noted on February 13, 2024.",50.0,295.41797,67.3613,6.36,6.21,6.79,-0.023867481,0.065422564,0.021277398,0.007763679,6.74136,0.17585,5.63545,229,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
OCUL,AXPAXLI (OTX-TKI) - (SOL-1),Wet Age-related Macular Degeneration (AMD)Â ,Phase 3,2/13/2024,"Phase 3 first three subjects have been screened and dosed with first aflibercept injection, noted February 13, 2024.",174.0,619.42868,88.9074,5.88,5.62,7.52,-0.045225098,0.246009376,0.021277398,0.007763679,3.59266,0.04326,7.49006,230,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
TAK,Eohilia (formerly TAK-721),Eosinophilic esophagitisÂ ,Approved,2/13/2024,"Approved February 13, 2024.",0.0,6824780.037,19.4638,14.31,14.34,14.82,0.002094242,0.035019026,0.021277398,0.007763679,0.0,0.0,30.03886,231,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1
OPT,Sozinibercept (OPT-302) with Aflibercept - (COAST),Age-related macular degeneration (AMD)Â ,Phase 3,2/14/2024,"Phase 3 patient enrollment completed, noted February 14, 2024.",171.0,377.80092,89.5415,0.57,0.57,0.59,0.0,0.034486176,-0.05001317,-0.041398925,0.0,0.00614,0.11814,232,0,0,0,0,0,1,0,0,0,1,0,0,2,0,0,1
DTIL,PBGENE-HBV - (ELIMINATE-B),Chronic Hepatitis B Virus (HBV)Â ,Preclinical,2/14/2024,"Pre-IND meeting with FDA provided feedback on overall design for the proposed first-in-human clinical study as well as feedback on the toxicology and specificity assessments, noted February 14, 2024.",11.0,48.72683,78.502,11.17201,11.99,12.36,0.070661426,0.101053909,-0.05001317,-0.041398925,1.35445,0.24252,1.64606,233,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
GLSI,GP2 (GLSI-100) - (FLAMINGO-01),HER2 positive breast cancerÂ ,Phase 3,2/14/2024,"DSMB recommended to continue the study as is without modification. No serious adverse events related to GLSI-100 have been reported to date, noted February 14 2024.",13.0,131.05128,59.4113,8.31,10.2,13.16,0.204928111,0.459722317,-0.05001317,-0.041398925,1.2026,0.12427,3.37672,234,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,-1
ARVN,Vepdegestrant (ARV-471) - (TACTIVE-U),Solid TumorsÂ ,Phase 1b,2/14/2024,"Phase 1b umbrella trial combination to be initiated in other arms, noted February 14, 2024.",73.0,3357.11098,78.1336,47.77,49.37,47.7,0.032945125,-0.00146643,-0.05001317,-0.041398925,9.55326,0.16656,33.33137,235,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
AZN,Ampligen (rintatolimod) with Imfinzi (durvalumab) - (DURIPANC),Pancreatic CancerÂ ,Phase 1/2,2/14/2024,"Phase 1b/2 dosing commenced on February 14, 2024.",0.0,150740.4112,23.3819,96.0,97.24,101.02,0.012833958,0.050970326,-0.05001317,-0.041398925,0.0,0.19671,610.15465,236,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
AIM,Ampligen (rintatolimod) with Imfinzi (durvalumab) - (DURIPANC),Pancreatic CancerÂ ,Phase 1/2,2/14/2024,"Phase 1b/2 dosing commenced on February 14, 2024.",2.0,59.512,58.1812,0.29,0.285,0.275,-0.017391743,-0.053109825,-0.05001317,-0.041398925,0.0,0.00779,0.00133,237,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ATRA,ATA3219,"B-cell non-Hodgkin's lymphoma (NHL), Lupus NephritisÂ ",Preclinical,2/14/2024,"IND submitted to the FDA, noted February 14, 2024.",7.0,78.50052,266.2559,19.2525,19.255,19.915,0.000129845,0.033832294,-0.05001317,-0.041398925,7.38733,0.03367,1.13953,238,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ANVS,Buntanetap (ANVS401),Alzheimerâ€™s disease (AD)Â ,Phase 2/3,2/14/2024,"Phase 2/3 last patient completed, noted February 14, 2024.",19.0,109.71391,114.2025,10.05,10.37,10.18,0.031344388,0.012852377,-0.05001317,-0.041398925,12.39142,0.01275,1.65627,239,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
SILO,SP-26,Fibromyalgia / Chornic painÂ ,Preclinical,2/14/2024,"The preclinical study demonstrated successful drug delivery, noted February 14, 2024.",9.0,4.87734,65.9588,1.6,1.69,1.56,0.0547249,-0.025317808,-0.05001317,-0.041398925,3.60416,0.16072,0.54503,240,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1
INKT,"Botensilimab plus balstilimab, agenT-797",Gastric cancerÂ ,Phase 2,2/14/2024,"Phase 2 trial initiated, noted February 14, 2024.",4.0,34.50573,82.0801,9.277,9.996,9.2001,0.074646794,-0.008323865,-0.05001317,-0.041398925,0.54872,0.09373,0.04808,241,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
AMPE,OA-201,OsteoarthritisÂ ,Preclinical,2/14/2024,Preclinical efficacy results from recently completed pre-IND enabling studies with OA-201 reported that the efficacy results of these studies do not support an Investigational New Drug (IND) submissio,1.0,1.51428,204.7306,1.72,1.82,1.94,0.05651221,0.120363682,-0.05001317,-0.041398925,6.83997,0.00877,0.02701,242,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
MESO,Revascor (Rexlemestrocel-L) - (DREAM-HF),Heart failureÂ ,Phase 3,2/14/2024,"Orphan drug designation was granted on February 14, 2024.",128.0,279.06982,65.7659,1.85,1.93,2.03,0.042334364,0.092850154,-0.05001317,-0.041398925,0.0,0.0,0.50692,243,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
RPTX,RP-1664 - (LIONS),Adult and adolescent with TRIM37-high tumor cells to treat Solid TumorsÂ ,Phase 1,2/15/2024,"Phase 1 dosing initiated, noted February 15, 2024.",42.0,292.80107,97.6163,6.81,6.95,6.26,0.020349539,-0.084211935,-0.021814311,-0.032492469,4.08919,0.05897,0.64235,244,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1
APLT,govorestat (AT-007) - (INSPIRE),Sorbitol Dehydrogenase Deficiency (SORD Deficiency)Â ,Phase 3,2/15/2024,"Phase 3 study met the interim primary endpoint, noted February 15, 2024.",144.0,289.60953,143.5374,2.68,3.75,5.6,0.335939045,0.736949803,-0.021814311,-0.032492469,4.80658,0.01459,35.20084,245,1,0,0,0,0,1,0,0,0,0,0,0,2,0,0,1
IONS,TRYNGOLZA (olezarsen),Familial Chylomicronemia Syndrome (FCS)Â ,Phase 3,2/15/2024,"Orphan Drug Designation granted by the FDA, noted February 15, 2024.",159.0,6496.41755,37.3671,49.07,45.28,43.98,-0.080382416,-0.109512865,-0.021814311,-0.032492469,5.89077,0.27415,131.94692,246,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CRDL,CardiolRx - (MAvERIC-Pilot),Recurrent PericarditisÂ ,Phase 2,2/15/2024,"FDA has granted Orphan Drug Designation (ODD), noted February 15, 2024.",83.0,8.97699,38.3426,0.045,0.045,0.0435,0.0,-0.033901552,-0.021814311,-0.032492469,0.0,0.00857,0.0021,247,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ONCY,Pelareorep and mFOLFIRINOX with and without atezolizumab - (GOBLET),Colorectal and advanced anal cancersÂ ,Phase 1,2/15/2024,"Phase 1 Stage 1 data showed a near tripling of Objective Response Rate compared to checkpoint inhibitor monotherapy, including a Complete Response, and supports expansion, additionally an enrollment e",100.0,86.33179,75.2796,1.15,1.16,1.035,0.008658063,-0.105360516,-0.021814311,-0.032492469,0.89484,0.0395,0.28364,248,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
MNKD,Afrezza (Technosphere Insulin) - (INHALE-1),Pediatric type 1/2 diabetesÂ ,Phase 3,2/15/2024,"Phase 3 enrollment goal reached, noted February 15, 2024.",306.0,1000.12197,54.6426,3.6,3.71,3.59,0.030098031,-0.002781643,-0.021814311,-0.032492469,12.97873,0.05216,10.62758,249,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
AUPH,Aritinercept (AUR200),BAFF/APRIL (B-Cell Activating Factor)Â ,Phase 1,2/15/2024,"Phase 1 was discontinued due to resource allocation, noted February 15, 2024.",135.0,870.59893,63.2772,7.97,6.02,6.0,-0.280597233,-0.283925024,-0.021814311,-0.032492469,12.81281,0.22408,118.14681,250,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
AUPH,AUR300,M2 MacrophageÂ ,IND-Enabling,2/15/2024,"The trial was discontinued due to resource allocation, noted on February 15, 2024.",135.0,870.59893,63.2772,7.97,6.02,6.0,-0.280597233,-0.283925024,-0.021814311,-0.032492469,12.81281,0.22408,118.14681,251,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ENSC,PF614-102,Severe painÂ ,Phase 3,2/15/2024,"Phase 3 additional results from the two-part PF614â€‘102 study are very significant as we believe they demonstrate a clear dose relationship between PF614 and oxycodone, which is the foundation for the",2.0,6.00555,123.8585,13.49999,13.34999,13.42498,-0.011173309,-0.005571794,-0.021814311,-0.032492469,10.05459,0.00446,0.26267,252,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
FBIO,Triplex - (COLT),Cytomegalovirus (CMV)Â ,Phase 1,2/16/2024,Phase 1 data results demonstrated the potential benefit of vaccinating donors with dose to enhance CMV protective immunity and reduce CMV events in recipients of allogeneic hematopoietic cell transpla,29.0,34.18076,151.7972,1.88,1.86,1.74,-0.010695289,-0.077386664,0.001287416,-0.015743331,8.12348,0.11164,0.65685,253,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CASI,FOLOTYN (Pralatrexate Injection) - (PROPEL),Peripheral T-cell lymphomaÂ ,Phase 1,2/16/2024,"Phase 1 dosing initiated in China, noted February 16, 2024.",15.0,77.26474,105.4952,5.97,5.8,5.55,-0.02888901,-0.072949,0.001287416,-0.015743331,0.39574,0.00237,0.08467,254,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1
IOVA,AMTAGVI (Lifileucel (LN-144)) - (TILVANCE-301),Refractory metastatic melanomaÂ ,Approved,2/16/2024,"FDA Approved on February 16, 2024.",361.0,2341.6538,94.3039,9.87,9.15,15.77,-0.075745974,0.468609548,0.001287416,-0.015743331,16.3984,0.19051,161.66011,255,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
AZN,TAGRISSO (Osimertinib) - (FLAURA2),Non-small cell lung cancer (NSCLC)Â ,Approved,2/17/2024,"Approved February 17, 2024.",0.0,156476.1118,23.5748,100.94,100.94,102.2,0.0,0.012405397,0.0,-0.017030747,0.0,0.20399,0.0,256,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1
AZN,TAGRISSO (osimertinib) - (LAURA),"Unresectable, Stage III epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC)Â ",Phase 3,2/19/2024,"Phase 3 data reported that the trial showed statistically significant and highly clinically meaningful improvement in progression-free survival (PFS), noted February 19, 2024.",0.0,161498.7252,24.008,100.94,104.18,102.54,0.031593891,0.015726685,0.008300592,-0.043998907,0.0,0.20399,195.99508,257,1,0,0,0,0,1,0,0,0,0,0,0,2,0,0,1
RAPT,Zelnecirnon (RPT193),AsthmaÂ ,Phase 2a,2/20/2024,"Phase 2a trial initiated March 29, 2023. Phase 2a trial placed on clinical hold February 20, 2024.",16.0,236.30195,199.2314,207.76,54.96,71.92,-1.329777919,-1.060829177,0.007326829,-0.099449359,11.47225,0.22387,96.01507,258,0,0,0,0,0,1,0,1,0,0,0,0,0,2,0,-1
RAPT,Zelnecirnon (RPT193),Atopic dermatitisÂ ,Phase 2a,2/20/2024,"Phase 2b trial initiated May 23, 2022. Phase 2b trial placed on hold February 20, 2024.",16.0,236.30195,199.2314,207.76,54.96,71.92,-1.329777919,-1.060829177,0.007326829,-0.099449359,11.47225,0.22387,96.01507,259,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
IMRX,Atebimetinib (IMM-1-104) + mGnP,"Solid tumors, pancreatic cancer, melanomaÂ ",Phase 1,2/20/2024,"Fast Track Designation granted by the FDA on February 20, 2024.",36.0,197.85926,97.4551,6.6,6.76,6.43,0.023953241,-0.026095111,0.007326829,-0.099449359,9.13148,0.02696,0.59628,260,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
IRON,DISC-0974,Patients with non-dialysis dependent chronic kidney disease (NDD-CKD) and anemiaÂ ,Phase 1/2,2/20/2024,"Phase 1b/2 ongoing. FDA granted Fast Track designation, noted February 20, 2024.",34.0,1603.40723,47.9417,65.92,66.42,66.25,0.00755633,0.004993579,0.007326829,-0.099449359,5.46485,0.047,9.20462,261,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
SNY,Duvakitug (TEV-'574/SAR447189) - (RELIEVE UCCD),Moderate-to-severe inflammatory bowel disease (IBD); this includes ulcerative colitis (UC) and Crohn's disease (CD)Â ,Phase 2b,2/20/2024,"PK data reported rapid and sustained suppression of free TL1A, noted February 20, 2024.",0.0,109252.5946,34.6206,46.18,46.85,48.21,0.014404205,0.043019664,0.007326829,-0.099449359,0.0,0.0,108.72283,262,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
TEVA,Duvakitug (TEV-'574/SAR447189) - (RELIEVE UCCD),Moderate-to-severe inflammatory bowel disease (IBD); this includes ulcerative colitis (UC) and Crohn's disease (CD)Â ,Phase 2b,2/20/2024,"PK data reported rapid and sustained suppression of free TL1A, noted February 20, 2024.",0.0,14651.37063,35.3922,13.02,13.07,13.3,0.003832891,0.021277398,0.007326829,-0.099449359,1.63397,0.04443,154.43069,263,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ARVN,ARV-102,Parkinson's Disease in Healthy VolunteersÂ ,Phase 1,2/20/2024,"Phase 1 dosing commenced, noted February 20, 2024.",73.0,3440.74975,78.5178,52.31,50.6,48.01,-0.033235981,-0.085778235,0.007326829,-0.099449359,9.55326,0.1657,39.89061,264,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
SPRY,Neffy (epinephrine nasal spray),Allergic reactions (type I) including anaphylaxisÂ ,Phase 3,2/20/2024,Phase 3 topline data showed that Repeated doses of neffy under nasal allergen challenge demonstrated a pharmacokinetic profile greater than or similar to injection and a pharmacodynamic profile greate,98.0,721.89934,131.4907,7.17,7.52,8.82,0.047660483,0.207116215,0.007326829,-0.099449359,5.06437,0.13708,9.60815,265,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
JNJ,TECVAYLI (teclistamab),Relapsed or refractory (R/R) multiple myeloma.Â ,Approved,2/20/2024,"Supplemental approval granted by the FDA, noted February 20, 2024.",0.0,380247.9946,13.4128,156.55,157.86,160.98,0.008333117,0.027904686,0.007326829,-0.099449359,0.51073,0.12424,1499.94499,266,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
GSK,Cabenuva (cabotegravir + rilpivirine) - (LATITUDE),HIVÂ ,Phase 3,2/21/2024,"Phase 3 interim data reported that demonstrated superior efficacy in maintaining viral load suppression compared to daily oral therapy in individuals with a history of ART adherence challenges, noted",0.0,67401.33076,18.0092,16.778,16.61,16.698,-0.010063581,-0.004779553,-0.01897875,-0.094443816,0.0,0.00379,83.18552,267,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
KZIA,Paxalisib (GDC-0084) with radiotherapy,Brain MetastasesÂ ,Phase 1,2/21/2024,"Phase 1 trial met its primary endpoint, noted February 21, 2024.",1.0,8.30651,110.1532,19.845,15.755,13.0,-0.230794311,-0.423002729,-0.01897875,-0.094443816,0.68934,0.0012,6.503,268,1,0,0,0,0,1,0,0,0,0,0,0,2,0,0,1
ENLV,Allocetra,SepsisÂ ,Phase 2,2/21/2024,"Phase 2 enrollment completed, noted February 21, 2024.",23.0,59.88735,103.9678,3.27,3.22,2.92,-0.015408625,-0.113206369,-0.01897875,-0.094443816,0.86318,0.02177,0.16829,269,0,0,0,0,0,1,0,0,0,1,0,0,2,0,0,1
NRSN,PrimeC - (PARADIGM),Amyotrophic Lateral Sclerosis (ALS)Â ,Phase 2b,2/21/2024,"Additional Phase 2b 6 month data reported a reduction of the risk of ALS disease complications or death by up to 53%, noted February 21, 2024.",23.0,17.08255,126.4737,1.37,1.25,1.8,-0.091667189,0.272975925,-0.01897875,-0.094443816,0.96673,0.05768,2.831,270,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
MNPR,MNPR-101-Zr (uPAR),Solid tumorsÂ ,Preclinical,2/22/2024,"Preclinical data to date demonstrated compelling and durable anti-tumor benefits with MNPR-101 conjugated to therapeutic radioisotopes, noted February 22, 2024.",6.0,16.65037,170.072,2.85,5.6,4.15,0.675447603,0.37578934,-0.024357576,-0.062359768,0.14477,0.0098,171.73254,271,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
TARS,TP-05 - (Carpo),Lyme diseaseÂ ,Phase 2a,2/22/2024,"Phase 2a data demonstrated a statistically significant benefit in killing ticks compared to placebo, noted February 22, 2024.",42.0,1044.11946,59.2184,30.13,31.54,38.22,0.045735228,0.237837586,-0.024357576,-0.062359768,16.40378,0.05627,26.20567,272,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1
ATXI,BAER-101,Absence epilepsyÂ ,Preclinical,2/22/2024,"Preclinical data reported full suppression of seizure activity with a minimal effective dose (MED) of 0.3 mg/kg, noted February 22, 2024.",3.0,5.30482,169.2609,11.20503,10.66503,11.37753,-0.04939262,0.015277573,-0.024357576,-0.062359768,1.81549,0.00239,0.29389,273,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
PHVS,Deucrictibant (PHVS416) - (CHAPTER-3),Hereditary angioedema - prophylactic useÂ ,Phase 2,2/22/2024,Phase 2 data reported that deucrictibant significantly reduced the monthly attack rate by 84.5% (p=0.0008) in participants dosed at 40 mg/day and 79.3% (p=0.0009) in participants dosed at 20 mg/day co,54.0,1447.57899,75.6085,27.81,27.78,22.94,-0.001079331,-0.192513557,-0.024357576,-0.062359768,0.40739,0.14889,2.28979,274,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ATNM,Iomab-B - (SIERRA),Acute myeloid leukemia (AML)Â ,Phase 3,2/22/2024,"Phase 3 data shared at ASTCT reported that a median overall survival of 5.49 months versus 1.66 months, noted February 22, 2023.",31.0,187.13093,73.9831,6.66,6.74,8.53,0.01194044,0.247469877,-0.024357576,-0.062359768,6.66452,0.08592,0.94735,275,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
VTYX,Tamuzimod (VTX002),Ulcerative Colitis (UC)Â ,Phase 2,2/22/2024,"Phase 2 open-label extension data reported that both both doses of VTX002 achieved nominal statistical significance for all key secondary endpoints, noted February 22, 2024.",71.0,340.58539,256.6821,5.04,5.77,7.08,0.135265998,0.339867826,-0.024357576,-0.062359768,8.23299,0.0149,81.75496,276,1,0,0,0,0,1,0,0,1,0,0,0,3,0,0,1
REGN,Dupixent (dupilumab) - (NOTUS),Chronic obstructive pulmonary disease (COPD)Â ,PDUFA priority review,2/23/2024,"PDUFA Priority Review date June 27, 2024.",105.0,105441.6124,16.847,964.89,981.2,982.82,0.016762207,0.018411885,-0.033320749,-0.075465066,1.16344,0.13895,431.35613,277,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
BDRX,Tolimidone,Type 2 diabetesÂ ,Preclinical,2/23/2024,"Preclinical data reported inconclusive data, noted February 23, 2024.",0.0,3.90306,167.2829,385.0,372.5,340.0,-0.033006296,-0.124297717,-0.033320749,-0.075465066,1.78874,0.0,6.15743,278,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
COGT,Bezuclastinib - (SUMMIT),Non-Advanced Systemic MastocytosisÂ ,Phase 1b,2/23/2024,"Additional Part 1b data from AAAAI reported that 51% week 12 mean change in Total Symptom Score (TSS), including 70% of patients achieving â‰¥50% reduction in TSS at week 12, noted February 23, 2024.",139.0,772.58631,147.5297,8.95,7.44,7.23,-0.184782683,-0.213414496,-0.033320749,-0.075465066,4.85228,0.01532,38.35931,279,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CMND,CMND-100,Alcohol use disorder (AUD)Â ,Phase 1/2,2/23/2024,"Phase 1/2a approval to commence dosing, noted February 23, 2024.",5.0,5.95879,195.5379,1.86,1.88,1.59,0.010695289,-0.156842471,-0.033320749,-0.075465066,4.61801,0.00047,6.65083,280,0,0,0,0,0,1,0,1,0,0,0,0,2,0,0,1
BDRX,MTX110 - (PNOC015),Diffuse Midline Glioma (DMG)Â ,Phase 1,2/23/2024,"Phase 1 results reported that the median overall survival (OS) of patients in the study was 16.5 months, noted February 23, 2024.",0.0,3.90306,167.2829,385.0,372.5,340.0,-0.033006296,-0.124297717,-0.033320749,-0.075465066,1.78874,0.0,6.15743,281,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
TEVA,SIMLANDI (adalimumab-ryvk) - (Humira biosimilar),Inflammatory diseasesÂ ,Approved,2/23/2024,"Approved February 23, 2024.",0.0,14449.592,35.2847,13.05,12.89,13.5,-0.012336317,0.033901552,-0.033320749,-0.075465066,1.63397,0.03926,161.91235,282,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1
ALVO,SIMLANDI (adalimumab-ryvk) - (Humira biosimilar),Inflammatory diseasesÂ ,Approved,2/23/2024,"Approved February 23, 2024.",301.0,4256.44144,39.7087,15.57,16.03,15.76,0.029115981,0.012129099,-0.033320749,-0.075465066,0.04062,0.02185,11.48311,283,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1
CLDX,Barzolvolimab (CDX-0159),Chronic spontaneous urticaria (CSU)Â ,Phase 2,2/24/2024,"Phase 2 data presented at AAAAI reported that treatment demonstrated strong improvement in UAS7 independent of omalizumab status at Week 12, noted February 24, 2024.",66.0,2064.51719,49.0959,37.75,37.75,51.88,0.0,0.317947884,-0.02696816,-0.069112477,12.27044,0.13569,0.0,284,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
KALV,EKTERLY (sebetralstat),Hereditary Angioedema (HAE)Â ,Phase 3,2/25/2024,"Phase 3 additional data presented at AAAAI reported that 94% of attacks required only one dose to achieve primary endpoint, noted February 25, 2024.",50.0,523.01376,61.1822,12.58,12.58,14.14,0.0,0.116899409,-0.02696816,-0.069112477,5.94943,0.12173,0.0,285,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
GSK,Blujepa (Gepotidacin) - (EAGLE 2/3),Uncomplicated urinary tract infection (uUTI)Â ,Phase 3,2/26/2024,"EAGLE-1 trial met its primary endpoint, noted February 26, 2024.",0.0,67953.20198,18.0534,16.724,16.746,16.678,0.00131461,-0.002754328,-0.082418612,-0.061201826,0.0,0.00094,118.72581,286,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1
KRYS,KB407 - (CORAL-1),Cystic FibrosisÂ ,Phase 1,2/26/2024,"Phase 1 data reported that no severe or serious adverse events were observed in patients treated in Cohort 1, noted February 26, 2024.",28.0,4441.94071,68.4981,111.33,157.0,159.95,0.343747042,0.362362503,-0.082418612,-0.061201826,7.17239,0.05104,351.24511,287,0,0,0,1,0,1,0,0,0,0,0,0,0,2,0,-1
TNYA,TN-301,Heart Failure with Preserved Ejection FractionÂ ,Preclinical,2/26/2024,"Preclinical data reported that treatment achieved comparable or superior efficacy and was shown to have a distinctive multi-modal mechanism of action versus empagliflozin, noted February 26, 2024.",162.0,438.12948,100.1762,5.22,5.69,6.61,0.086212846,0.236086252,-0.082418612,-0.061201826,3.47825,0.09021,2.83382,288,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1
ONC,BRUKINSA (zanubrutinib) + Obinutuzumab - (ROSEWOOD),Follicular Non-Hodgkin LymphomaÂ ,Approved,2/26/2024,"Approval noted February 26, 2024.",110.0,16759.66066,47.0104,155.1,160.26,167.86,0.032727426,0.079060228,-0.082418612,-0.061201826,1.98601,0.16306,92.80593,289,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
TCRX,"TSC-100, TSC-101 - (ALLOHA)",Hematologic malignanciesÂ ,Phase 1,2/26/2024,"Phase 1 presented at Tandem Meetings showed that all eight (100%) treatment-arm patients are relapse-free and have achieved and maintained complete donor chimerism following treatment, noted February",56.0,324.72958,102.1748,6.76,6.79,7.12,0.004428052,0.051884835,-0.082418612,-0.061201826,0.50935,0.00016,0.84007,290,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1
MTNB,Oral amphotericin b (MAT2203) - (EnACT),Cryptococcal meningitisÂ ,Phase 3,2/26/2024,"Phase 3 update from ongoing Compassionate/Expanded use access of the 19 patients enrolled in the program, 15 have available follow-up and 4 recently initiated or will soon commence treatment with MAT2",5.0,58.44415,267.5445,11.97,13.45,13.455,0.116575586,0.116947265,-0.082418612,-0.061201826,0.65451,0.01933,0.64075,291,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
JANX,PSMA-TRACTr (JANX007) - (ENGAGER-PSMA-01),Metastatic castration-resistant prostate cancer (mCPRC)Â ,Phase 1,2/26/2024,"Phase 1 updated clinical data at KOL illustrated a potential best-in-class profile: promising efficacy with favorable safety profile in heavily pretreated subjects with late-stage mCRPC, noted Februar",60.0,696.88655,87.6014,15.69,15.1,42.61,-0.038328823,0.999065401,-0.082418612,-0.061201826,5.30102,0.17205,11.50175,292,0,0,0,1,0,1,0,0,0,0,0,0,2,0,0,1
JANX,EGFR-TRACTr (JANX008),"Metastatic colorectal cancer (mCRC), squamous cell carcinoma of the head and neck (SCCHN) and non-small cell lung cancer (NSCLC)Â ",Phase 1,2/26/2024,"Phase 1 data at KOL display differentiated safety and encouraging signs of efficacy in heavily pretreated subjects with different solid tumor types, noted February 26, 2024.",60.0,696.88655,87.6014,15.69,15.1,42.61,-0.038328823,0.999065401,-0.082418612,-0.061201826,5.30102,0.17205,11.50175,293,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
GILD,Biktarvy,HIVÂ ,Approved,2/26/2024,"Approved for expanded indication to treat people with HIV (PWH) who have suppressed viral loads with known or suspected M184V/I resistance, noted February 26, 2024.",0.0,90879.25824,25.3457,73.55,72.95,72.25,-0.008191172,-0.01783312,-0.082418612,-0.061201826,1.25723,0.08187,377.7305,294,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1
NERV,Roluperidone (MIN-101),SchizophreniaÂ ,CRL,2/27/2024,"CRL issued by the FDA, noted February 27, 2024.",6.0,19.58154,164.8147,6.8,2.8,2.6,-0.887303195,-0.961411167,-0.042144317,-0.021545549,0.33862,0.03994,5.44997,295,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,-1
VKTX,VK2735 - (VENTURE),ObesityÂ ,Phase 2,2/27/2024,"Phase 2 study met primary and all secondary endpoints, demonstrating reductions in body weight, noted February 27, 2024.",113.0,8667.8403,133.7011,38.48,85.05,87.9,0.793100693,0.826061179,-0.042144317,-0.021545549,11.79401,0.13229,5020.81346,296,1,0,0,0,0,1,0,0,1,0,0,0,3,0,0,1
TARS,TP-04 - (Galatea),RosaceaÂ ,Phase 2a,2/27/2024,Phase 2a topline data reported statistically significant improvements (p<0.05) in inflammatory lesions and Investigator's Global Assessment (IGA) score compared to vehicle at Week 12 TP-04 was genera,42.0,1342.06471,63.9681,33.16,39.22,35.77,0.167842491,0.075765223,-0.042144317,-0.021545549,16.54856,0.05322,98.80091,297,0,1,0,0,0,1,0,0,0,0,1,0,3,0,0,1
ACXP,Ibezapolstat,C. difficile InfectionÂ ,Phase 2b,2/27/2024,"Phase 2b FDA confirmed that trial adequate information was submitted for EoP2 meeting, noted February 27, 2024.",1.0,43.09372,132.286,65.0,62.6,59.8,-0.037621992,-0.083381609,-0.042144317,-0.021545549,2.18951,0.01744,0.56528,298,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CGON,cretostimogene - (PIVOT-006) (EAP),Non-Muscle Invasive Bladder Cancer (NMIBC)Â ,Phase 3,2/27/2024,"Phase 3 dosing initiated, noted February 27, 2024.",76.0,3081.46439,0.0,46.01,46.35,41.49,0.007362528,-0.10340633,-0.042144317,-0.021545549,1.46491,0.37122,10.56289,299,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1
PPBT,NT219 in combination with cetuximab,Recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN)Â ,Phase 1,2/27/2024,"Phase 2 was well tolerated with anti-tumor activity at relevant higher dose levels observed with 29% Objective Response Rate (ORR) and 71% Disease Control Rate (DCR), noted February 27, 2024.",2.0,70.63308,74.5033,0.273,0.273,0.293,0.0,0.070700814,-0.042144317,-0.021545549,0.0,0.06711,0.0,300,1,0,0,1,0,1,0,0,0,0,0,0,3,0,0,1
GANX,"GT-02287, GT-02329",GBA1 and Idiopathic Parkinson's DiseaseÂ ,Phase 1,2/27/2024,"Phase 1 dosing initiated, noted February 27, 2024.",35.0,75.00307,75.2511,4.5,4.63,4.66,0.028479471,0.034938051,-0.042144317,-0.021545549,0.84936,0.00189,0.48479,301,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1
PTN,PL9643 - (MELODY-1),Dry eye disease (DED)Â ,Phase 3,2/28/2024,"Phase 3 final results reported met the first co-primary endpoint in the Intent-to-Treat Analysis, however did not meet the co-primary endpoint showing superiority over vehicle, noted February 28, 2024.Â read less",46.0,70.68903,69.7187,0.059,0.06,0.066,0.016807118,0.112117298,0.044416421,0.02729099,0.0,0.00236,0.04342,302,1,0,0,0,0,1,0,0,0,0,0,0,0,0,2,0
IXHL,PSX-001 (Psilocybin treatment) - (PsiGAD2),Generalized anxiety disorder (GAD)Â ,Phase 2,2/28/2024,"Phase 2 topline data reported that the trial met its primary endpoint, noted February 28, 2024.",347.0,99.52442,183.2967,4.22,6.27,4.23,0.395941227,0.002366865,0.044416421,0.02729099,0.61248,0.01455,89.15146,303,1,0,0,0,0,1,0,0,0,0,1,0,3,0,0,1
CMPX,CTX-8371,Solid TumorsÂ ,Preclinical,2/28/2024,"Preclinical data reported that CTX-8371 demonstrates enhanced anti-tumor activity relative to approved anti-PD-1 blockers and anti-PD-L1 blockers in a series of in vitro and in vivo experimental settings, noted February 28, 2024.Â read less",138.0,221.77227,73.6305,1.76,1.74,1.96,-0.011428696,0.107630664,0.044416421,0.02729099,1.54758,0.04594,0.28337,304,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1
SILO,SPC-15,Post-traumatic stress disorder (PTSD)Â ,Preclinical,2/28/2024,"Preclinical data reported rapid absorption of SPC-15 with good exposure over a 24-hour period, suggesting a once-per-day human intranasal dosing regimen would be optimal, noted February 28, 2024.",9.0,4.67532,66.2861,1.55,1.62,1.5299,0.044171218,-0.013052557,0.044416421,0.02729099,2.23434,0.13751,3.01777,305,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
HCM,Amdizalisib (HMPL-689),Follicular Lymphoma and Marginal Zone LymphomaÂ ,Phase 2,2/28/2024,"Phase 2 topline FL results reported that the trial met its primary endpoint, noted February 28, 2024.",174.0,2082.32107,51.6748,2.485,2.44,2.37,-0.01827462,-0.047382704,0.044416421,0.02729099,0.0,0.11973,0.13211,306,1,0,0,0,0,1,0,0,0,0,0,0,2,0,0,1
SNSE,Solnerstotug (formerly SNS-101) with Libtayo - (VISTA),One microsatellite stable (MSS) endometrial cancerÂ ,Phase 1,2/28/2024,"Phase 1 initial safety data reported that in the monotherapy dose escalation arm, 13/16 patients (81%) experienced at least one treatment-emergent adverse event (TEAE), with the majority of adverse events (AEs) Grade 1 or 2. In the combination dose escalation arm, 10/17 patients (59%) experienced at least one TEAE, with the majority of AEs Grade 1 or 2, noted February 28, 2024.Â read less",1.0,20.99706,92.5836,15.4,16.8,18.642,0.087011377,0.19104959,0.044416421,0.02729099,0.57242,0.15126,0.15641,307,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
REGN,Solnerstotug (formerly SNS-101) with Libtayo - (VISTA),One microsatellite stable (MSS) endometrial cancerÂ ,Phase 1,2/28/2024,"Phase 1 initial safety data reported that in the monotherapy dose escalation arm, 13/16 patients (81%) experienced at least one treatment-emergent adverse event (TEAE), with the majority of adverse events (AEs) Grade 1 or 2. In the combination dose escalation arm, 10/17 patients (59%) experienced at least one TEAE, with the majority of AEs Grade 1 or 2, noted February 28, 2024.Â read less",105.0,106130.4431,16.8107,993.35,987.61,972.1,-0.005795186,-0.021624389,0.044416421,0.02729099,1.27527,0.13895,479.97155,308,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
VANI,NPM-115 (exenatide implant) - (LIBERATE-1),Subdermal implants in development for chronic weight managementÂ ,Preclinical,2/28/2024,"Preclinical data showed that implant generated significant weight loss comparable to injectable semaglutide (Ozempic/Wegovy) from a single administration with expected twice-yearly dosing, noted February 28, 2024.Â read less",59.0,190.83372,192.7424,1.01,3.74,2.21,1.309135281,0.783042185,0.044416421,0.02729099,0.3625,0.00057,556.55458,309,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
AVIR,Bemnifosbuvir and ruzasvir (RZR) - (C-FORWARD),Hepatitis C Virus (HCV)Â ,Phase 2,2/28/2024,"Phase 2 final data from the 60-patient lead-in cohort reported that the SVR4 rate exceeded the protocol-defined efficacy criterion of â‰¥90% SVR4 for continuing the study, noted February 28, 2024.",79.0,367.79906,47.7314,4.56,4.37,4.03,-0.042559614,-0.123556248,0.044416421,0.02729099,1.92715,0.03677,3.66716,310,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
BLRX,"Motixafortide (BL-8040), gemcitabine, nab-paclitaxel and LIBTAYO (cemiplimab) - (Columbia University trial) - (CheMo4METPANC)",First-line pancreatic ductal adenocarcinoma (PDAC)Â ,Phase 2,2/28/2024,"Phase 2 trial initiated, noted February 28, 2024.",3.0,342.27559,78.981,0.299,0.315,0.318,0.052129065,0.061607809,0.044416421,0.02729099,0.0,0.00678,0.48022,311,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
IMUX,IMU-838 - (CALLIPER),Progressive Multiple SclerosisÂ ,Phase 2,2/29/2024,"Phase 2 interim data presented at ACTRIMS reported that serum NfL was decreased in the treatment group by 22.4%, noted February 29, 2024.",98.0,131.74601,78.4561,1.4,1.465,1.46,0.045383006,0.041964199,0.0,0.027357936,2.80674,0.13566,0.96432,312,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
IMUX,IMU-838 - (CALVID-1),COVID-19Â ,Phase 2,2/29/2024,"Additional Phase 2 data reported that 80% of patients who received placebo reported fatigue, compared to 50% who received 45 mg vidofludimus calcium, noted February 29, 2024.",98.0,131.74601,78.4561,1.4,1.465,1.46,0.045383006,0.041964199,0.0,0.027357936,2.80674,0.13566,0.96432,313,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
IRWD,Apraglutide - (STARS),Short Bowel Syndrome with Intestinal Failure (SBS-IF)Â ,Phase 3,2/29/2024,"Phase 3 top-line data reported that the trial met its primary endpoint, however two key secondary endpoints were specific to colon-in-continuity patients in assessing at least one day/week off PS versus baseline and reaching enteral autonomy at week 48, both of which were not achieved, noted February 29, 2024.Â read less",162.0,1476.06515,78.162,15.12,9.43,8.93,-0.472122274,-0.526601976,0.0,0.027357936,9.96442,0.04938,297.32597,314,1,0,0,0,0,1,0,0,1,0,1,0,4,0,0,1
CLNN,CNM-Au8 - (VISIONARY-MS),Multiple SclerosisÂ ,Phase 2,2/29/2024,"Phase 2 full clinical results presented at ACTRIMS Forum reported that treatment demonstrated significant improvement of vision as measured by low contrast letter acuity (LCLA) through 35 months from randomization, noted February 29, 2024.Â read less",9.0,51.67444,111.9083,8.68,8.048,8.13,-0.075597915,-0.065460605,0.0,0.027357936,0.17811,0.03295,0.70426,315,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1
IMNN,IMNN-101 - (IMUNON),SARS-CoV-2 variant XBB.1.5Â ,Preclinical,2/29/2024,"Challenge study data reported that a single dose produced IgG neutralizing antibody and T-cell responses, noted February 29, 2024.",2.0,10.71518,85.7357,12.7826,14.86956,12.7826,0.151231299,0.0,0.0,0.027357936,5.53814,0.02506,1.07745,316,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CUE,CUE-101 and KEYTRUDA (pembrolizumab) - (KEYNOTE-A78),HPV16+ head and neck cancerÂ ,Phase 1,2/29/2024,"Phase 1 data reported from the Multi-disciplinary Head and Neck Cancers Symposium that overall response rate (ORR) of 47% in first line (1L) patients treated with CUE-101 and pembrolizumab, compared to the historical ORR of 19% reported in the KEYNOTE-48 trial, noted February 29, 2024.Â read less",76.0,93.63081,77.9897,2.12,2.075,1.97,-0.021454935,-0.073382546,0.0,0.027357936,8.44038,0.19909,0.33103,317,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CRDF,"Onvansertib, FOLFIRI and AVASTIN (bevacizumab) - (ONSEMBLE)",KRAS-Mutated Colorectal CancerÂ ,Phase 2,2/29/2024,"Phase 2 data reported a 50% ORR rate in Bev Naive patients and 0% ORR in Bev Exposed patients, noted February 29, 2024.",66.0,78.8552,78.2095,1.82,1.765,3.51,-0.030685811,0.656779536,0.0,0.027357936,2.65794,0.06812,3.4809,318,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
TGTX,BRIUMVI (ublituximab-xiiy) - (ENHANCE),Relapsing forms of Multiple Sclerosis (RMS)Â ,Phase 3,2/29/2024,"Phase 3b data presented at ACTRIMS reported that 18 (86%) of participants completed the infusion without interruption or slowing, with a median infusion duration of 60 min, noted February 29, 2024.",158.0,2493.14094,85.1538,17.63,17.22,18.0,-0.023530497,0.020769761,0.0,0.027357936,24.71081,0.15503,106.8718,319,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
RYTM,Setmelanotide - (DAYBREAK),Variants in one of 31 additional genes with MC4R pathway relevanceÂ ,Phase 2,2/29/2024,"Phase 2 data showed that nearly 97% of followed patients were relapse-free at 90 days post Zeposia discontinuation; patients that did relapse showed no evidence of rebound effect, noted February 29, 2024.Â read less",66.0,2611.30029,63.2772,44.38,43.42,41.67,-0.021868753,-0.063007472,0.0,0.027357936,14.56852,0.14954,22.77058,320,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ATRA,ATA3219,"B-cell non-Hodgkin's lymphoma (NHL), Lupus NephritisÂ ",IND-Enabling,2/29/2024,"IND cleared by the FDA, noted February 29, 2024",7.0,79.29551,267.3769,19.0125,19.45,17.4075,0.022750412,-0.08819551,0.0,0.027357936,10.66789,0.03106,4.2351,321,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
CGEM,CLN-619 - (MICB),Relapsed or Refractory Multiple MyelomaÂ ,IND-Enabling,3/1/2024,"IND Clearaed by the FDA, noted March 1, 2024.",59.0,791.86972,60.4564,18.47,18.51,16.79,0.002163332,-0.095364323,-0.023199635,-0.005370637,1.83242,0.07541,8.38808,322,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
BIVI,NE3107,Parkinson's diseaseÂ ,Phase 2a,3/1/2024,"Additional Phase 2a data reported significant improvement of -2.4 points for the sleep/fatigue domain of the Non-Motor Symptom Scale (NMSS) in Parkinson's Disease, whereas placebo patients experienced a worsening of +1.0 points, noted March 1, 2024Â read less",7.0,75.41421,181.5353,124.0,189.0,71.8,0.421465449,-0.54639709,-0.023199635,-0.005370637,2.57721,0.00233,175.17597,323,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1
BIVI,NE3107,Alzheimerâ€™s diseaseÂ ,Phase 3,3/1/2024,"Additional Phase 3 data reported that due to the exclusion of data from so many sites the trial missed statistical significance but showed promising directional data on cognitive and functional measures. NE3107-treated patients saw an advantage compared to placebo of -0.95 (68% slowing of decline) on CDR-SB, -0.94 (26%) on ADAS-COG-12, -0.43 (139%) on ADAS-CGIC, -0.03 (27%) on ADCOMS, +1.02 (40%) on MMSE, and +3.08 (47%) on ADCS-ADL, noted March 1, 2024.Â read less",7.0,75.41421,181.5353,124.0,189.0,71.8,0.421465449,-0.54639709,-0.023199635,-0.005370637,2.57721,0.00233,175.17597,324,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,-1
LEXX,HYPER-H23-1 (DehydraTECH-CBD),HypertensionÂ ,IND-Enabling,3/1/2024,"IND Cleared by the FDA, noted March 1, 2024",19.0,35.03684,103.6784,3.45,2.92,5.5,-0.166790615,0.466373861,-0.023199635,-0.005370637,5.71471,0.00887,4.70875,325,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
SLS,Tambiciclib (SLS009) (GFH009) with venetoclax,"Hematologic malignancies, acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) and lymphomaÂ ",Phase 1,3/1/2024,"Phase 1 dose-escalation topline data for the heavily pretreated AML patients showed evidence of anti-tumor activity increasing with higher dose levels and no significant safety issues. Treatment with SLS009 resulted in a complete remission (CR) with no minimal residual disease (MRD) after three cycles as a monotherapy in an AML patient who had failed prior venetoclax plus azacytidine (aza/ven) therapy. The CR lasted eight months with the patient achieving one year survival at the latest assessment. This is the first time that a relapsed/refractory (r/r) AML patient achieved a CR with CDK9 inhibition monotherapy. Notably, the median survival for patients relapsed after aza/ven therapy is approximately 2.5 months. All key study objectives were met regarding pharmacokinetic (PK), pharmacodynamic (PD), safety, and clinical activity, noted March 1, 2024.Â read less",105.0,42.26289,115.3931,1.01,1.0,1.26,-0.009950331,0.22116139,-0.023199635,-0.005370637,9.19793,0.1291,1.08164,326,1,0,0,1,0,0,0,0,0,0,0,0,2,0,0,1
JNJ,RYBREVANT (amivantamab) - (PAPILLON),Non-small cell lung cancerÂ ,Approved,3/1/2024,"FDA approved on March 1, 2024.",0.0,390509.343,13.2816,161.38,162.12,159.52,0.004574969,-0.011592526,-0.023199635,-0.005370637,0.45519,0.1225,919.24229,327,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
WHWK,Nab-sirolimus - (AMPECT),Malignant PEComa (Perivascular epithelioid cell tumour)Â ,Phase 2,3/1/2024,"Phase 2 long-term efficacy and safety results demonstrated 40 months median duration of response and median survival >53 months, noted March 1, 2024.",47.0,47.08965,133.2758,1.97,1.92,2.14,-0.025708357,0.082772286,-0.023199635,-0.005370637,4.03782,0.01134,5.26143,328,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
RNA,Delpacibart etedesiran (del-desiran) - (MARINA-OLE),Myotonic dystrophy type 1 (DM1)Â ,Phase 2,3/4/2024,"Phase 2 preliminary data anticipated at the MDA conference showed reversal of disease progression in multiple functional measures, noted March 4, 2024.",128.0,1505.78227,84.5925,20.11,18.86,21.02,-0.064173927,0.044257162,0.020598768,0.047397458,9.68352,0.09712,74.10601,329,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
NVO,Efruxifermin - (HARMONY),Nonalcoholic SteatohepatitisÂ ,Phase 2b,3/4/2024,"Phase 2b 96-week results reported that the 50mg (75%, p<0.001) and 28mg (46%, p=0.07) EFX groups demonstrated â‰¥1 stage improvement in fibrosis without worsening of MASH, approximately three- and two-fold the placebo rate (24%), noted March 4, 2024.Â read less",0.0,3914623.24,27.8692,124.23,127.95,131.24,0.029504876,0.054893022,0.020598768,0.047397458,0.0,0.0,872.22863,330,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
AKRO,Efruxifermin - (HARMONY),Nonalcoholic SteatohepatitisÂ ,Phase 2b,3/4/2024,"Phase 2b 96-week results reported that the 50mg (75%, p<0.001) and 28mg (46%, p=0.07) EFX groups demonstrated â‰¥1 stage improvement in fibrosis without worsening of MASH, approximately three- and two-fold the placebo rate (24%), noted March 4, 2024.Â read less",79.0,1749.1642,158.4807,27.81,31.07,29.31,0.110847055,0.052533086,0.020598768,0.047397458,15.7995,0.10523,265.0884,331,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CLRB,CLR 131 (iopofosine) in combination with external beam radiation (EBRT),Head & neck cancerÂ ,Phase 1,3/4/2024,"Phase 1 data reported the complete remission was achieved in 64% of patients, with an ORR of 73%, noted March 4, 2024.",3.0,129.11665,88.4062,126.00013,127.20013,113.10011,0.009478734,-0.108009583,0.020598768,0.047397458,7.76741,0.05668,12.59765,332,1,0,0,0,0,1,0,0,0,0,0,0,2,0,0,1
NVS,Zolgensma (onasemnogene abeparvovec) - (SMART),Spinal muscular atrophy (SMA)Â ,Phase 3,3/4/2024,"Phase 3b data reported that nearly all patients treated maintained or improved motor milestones after 52 weeks, with most switching to the one-time gene therapy from another chronically administered disease-modifying therapy, noted March 4, 2024.Â read less",0.0,1303.17914,53.8789,4.05,4.2,4.1,0.036367644,0.012270093,0.020598768,0.047397458,0.0,0.00181,0.14593,333,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
INDP,Decoy-20 - (INDP-D101),Advanced/metastatic solid tumorsÂ ,Phase 1,3/4/2024,"Phase 1 data following completion of second cohort trial of Decoy 20 leads the independent Safety Review Committee to recommend initiating a multi-dosing cohort, noted March 4, 2024. Single dose cohort data expected to be published at a scientific conference in 2024Â read less",1.0,19.82644,76.7485,58.51998,66.07997,56.55998,0.121497441,-0.034066566,0.020598768,0.047397458,0.20422,0.05483,7.97632,334,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
BCDA,CardiAMP (BCDA-01),Ischemic Heart FailureÂ ,Phase 3,3/4/2024,"Phase 3 data reported that patients had 37% relative risk reduction in heart death equivalent and 9% relative risk reduction in non-fatal major adverse cardiac and cerebrovascular events (MACCE) at mean 20-month follow-up compared to control patients on guideline-directed heart medications alone, noted March 4, 2024.Â read less",5.0,11.79323,179.4466,8.697,6.8265,6.3225,-0.242166041,-0.318863439,0.020598768,0.047397458,1.14827,0.01903,1.63556,335,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
VTVT,Cadisegliatin (TTP399),Type 1 DiabetesÂ ,Phase 3,3/4/2024,"Phase 3 announced the submission of the study protocol to the FDA to initiate the trial, noted March 4, 2024.",3.0,35.04555,147.5029,16.55,14.01,15.02,-0.166614741,-0.097003455,0.020598768,0.047397458,1.72791,0.00051,1.0205,336,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
LNTH,DEFINITY (Perflutren Lipid Microsphere),Ultrasound enhancing agent for use in pediatric patients with suboptimal echocardiogramsÂ ,Approved,3/4/2024,"FDA approved on March 4, 2024.",67.0,4478.83034,68.0206,64.64,65.36,62.72,0.011077036,-0.030153038,0.020598768,0.047397458,7.33668,0.00631,59.11198,337,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
NRXP,NRX-101,Bipolar Depression and Suicidal IdeationÂ ,Phase 2/3,3/4/2024,"Phase 2/3 last patient dosed, noted March 4, 2024.",19.0,47.32464,107.6566,4.381,5.2,6.69,0.171381617,0.423336865,0.020598768,0.047397458,4.2504,0.03217,2.42754,338,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1
PCVX,VAX-24,Pneumococcal Disease in infantsÂ ,Phase 2,3/4/2024,"Phase 2 enrollment completed, noted March 4, 2024.",129.0,7756.57308,39.7577,71.71,71.55,70.25,-0.002233702,-0.0205699,0.020598768,0.047397458,9.82674,0.0238,44.71102,339,0,0,0,0,0,1,0,0,0,1,0,0,2,0,0,1
BCDA,Allogeneic CardiALLO,Heart failureÂ ,Phase 1/2,3/4/2024,"Data presented at the Technology and Heart Failure Therapeutics Conference (THT) reported that first patient has been enrolled and treated in the low dose group and is doing well clinically, noted March 4, 2024.Â read less",5.0,11.79323,179.4466,8.697,6.8265,6.3225,-0.242166041,-0.318863439,0.020598768,0.047397458,1.14827,0.01903,1.63556,340,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
GSK,"Cabenuva (cabotegravir, rilpivirine) - (CAB-ULA)",HIV treatment and prevention dosed at intervals of at least four monthsÂ ,Phase 1,3/4/2024,"Phase 1 data show for the first time a new ultra-long-acting cabotegravir formulation (CAB-ULA) that doubles the current dosing interval, noted March 4, 2024.",0.0,67682.93047,17.8337,16.618,16.678,16.75,0.00360404,0.007911813,0.020598768,0.047397458,0.0,0.00103,85.0566,341,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
PFE,"Cabenuva (cabotegravir, rilpivirine) - (CAB-ULA)",HIV treatment and prevention dosed at intervals of at least four monthsÂ ,Phase 1,3/4/2024,"Phase 1 data show for the first time a new ultra-long-acting cabotegravir formulation (CAB-ULA) that doubles the current dosing interval, noted March 4, 2024.",0.0,146195.0934,26.4556,26.59,25.89,28.37,-0.026678411,0.064797044,0.020598768,0.047397458,1.07461,0.07343,2246.67527,342,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
APGE,APG777 - (APEX),"Healthy volunteers, Atopic dermatitis (AD)Â ",Phase 1,3/5/2024,"Phase 1 interim data reported a half-life of approximately 75 days across doses tested and Pharmacodynamic (PD) data showed deep and sustained inhibition of key AD biomarkers pSTAT6 and TARC for ~3 months, noted March 5, 2024.Â read less",59.0,2877.19603,83.7909,41.74,59.3,69.34,0.351149404,0.507562039,0.006074203,0.046014312,6.79805,0.17131,377.03397,343,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
GSK,Cabotegravir ultra long-acting (CAB-ULA) - (4 month dosing),HIVÂ ,Phase 1,3/5/2024,"Phase 1 data reported that intramuscular dosing of CAB-ULA has a safety and pharmacokinetic (PK) profile that supports a longer dose interval, noted March 5, 2024.",0.0,68316.0122,17.8574,16.678,16.834,16.852,0.009310165,0.010378858,0.006074203,0.046014312,0.0,0.00103,85.54386,344,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
NVO,Semaglutide - (FLOW),Renal impairment in people with type 2 diabetes and chronic kidney disease (CKD)Â ,Phase 3,3/5/2024,"Phase 3 trial stopped early due to efficacy, based on a recommendation from an Independent Data Monitoring Committee. The trial achieved its primary endpoint by demonstrating a statistically significant and superior reduction in kidney disease progression, major adverse cardiovascular events (MACE) and death of 24% for people treated with semaglutide 1.0 mg compared to placebo, noted March 5, 2024.Â read less",0.0,3815552.748,28.0478,127.95,124.65,135.11,-0.026129753,0.054449699,0.006074203,0.046014312,0.0,0.0,599.29277,345,1,0,0,0,0,1,0,0,0,0,0,0,2,0,0,1
CASI,BI-1206 with rituximab - (China trial),Non-Hodgkin's Lymphoma (NHL)Â ,Phase 1,3/5/2024,"Phase 1 initial data showed promising responses including a long-lasting complete response for patients with difficult-to-treat disease, noted March 5, 2024.",15.0,75.39973,106.5545,5.085,5.66,4.1,0.107128863,-0.215308056,0.006074203,0.046014312,0.39885,0.00097,55.37822,346,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
MNPR,MNPR-101-Zr (uPAR),Solid tumorsÂ ,Preclinical,3/5/2024,"Addtional preclinical data demonstrated highly preferential uptake in the tumor. The new imaging data released today support the tumor-targeting ability of MNPR-101, noted March 5, 2024.",6.0,15.75838,177.6299,4.9505,5.3,4.13,0.068218239,-0.181211175,0.006074203,0.046014312,0.42268,0.00335,1.74942,347,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ALNY,Zilebesiran - (KARDIA-2),HypertensionÂ ,Phase 2,3/5/2024,"Phase 2 trial met the primary endpoint, noted March 5, 2024.",131.0,18851.5663,39.3577,150.04,149.68,146.65,-0.002402243,-0.02285313,0.006074203,0.046014312,3.16632,0.31728,105.3123,348,1,0,0,0,0,1,0,0,0,0,0,0,2,0,0,1
RGNX,RGX-202 - (AFFINITY DUCHENNE),Duchenne Muscular Dystrophy (DMD)Â ,Phase 1/2,3/5/2024,"Phase 1/2 new three-month assessment in first patient at dose level 2 demonstrates robust microdystrophin expression. Patient aged 12 years at dosing had expression level at 75.7% of control, noted March 5, 2024.Â read less",50.0,1093.36213,75.2986,21.36,24.61,21.98,0.14163285,0.028612935,0.006074203,0.046014312,9.39539,0.11372,69.04503,349,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CRVO,Neflamapimod - (AscenD-LB),Dementia with Lewy bodies (DLB)Â ,Phase 2a,3/5/2024,"Phase 2a data presented at AD/PD reported that there was a mean 3.7 pg/mL increase GFAP levels in placebo vs. mean 12.3 pg/mL reduction with neflamapimod, noted March 5, 2024.",9.0,80.21623,102.5337,12.7,13.0,17.57,0.023347364,0.324590909,0.006074203,0.046014312,0.65847,0.00027,0.31624,350,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
GANX,"GT-02287, GT-02329",GBA1 and Idiopathic Parkinson's DiseaseÂ ,Preclinical,3/5/2024,"Preclinical data presented at AD/PD reported that GT-02287, through its interaction with glucocerebrosidase (GCase) in the endoplasmic reticulum (ER), aids correct GCase folding, preventing ER retention, ER stress, and ER-associated degradation of mutated GCase enzyme, noted March 5, 2024.Â read less",35.0,75.48906,75.2859,4.72,4.66,4.56,-0.012793351,-0.034486176,0.006074203,0.046014312,0.84936,0.00309,3.24716,351,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
IMMP,Eftilagimod Alpha with weekly paclitaxel - (AIPAC-003),Metastatic breast cancer (MBC)Â ,Phase 2/3,3/5/2024,"Phase 2/3 90mg data reported a 50% overall response rate, including one complete response and two partial responses, and a 100% disease control rate overall, noted March 5, 2024.",145.0,451.75713,51.7776,2.35,2.61,2.55,0.104934893,0.081678031,0.006074203,0.046014312,0.0,0.0,1.37827,352,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
LLY,Rezpegaldesleukin (LY3471851) - (REZOLVE-AA),Severe to very severe alopecia areata (AA)Â ,Phase 2b,3/5/2024,https://www.biopharmcatalyst.com/company/NKTR/news/189917,946.0,699958.8762,28.7736,792.28,777.59,754.95,-0.018715472,-0.048263343,0.006074203,0.046014312,0.57244,0.0081,2463.94088,353,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
NKTR,Rezpegaldesleukin (LY3471851) - (REZOLVE-AA),Severe to very severe alopecia areata (AA)Â ,Phase 2b,3/5/2024,https://www.biopharmcatalyst.com/company/NKTR/news/189917,19.0,162.3365,88.7003,13.49999,13.26149,13.34999,-0.017824598,-0.011173309,0.006074203,0.046014312,1.33641,0.02909,5.08314,354,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ONCY,mFOLFIRINOX +/- atezolizumab and pelareorep - (PanCAN),Pancreatic Ductal Adenocarcinoma (PDAC)Â ,Phase 1/2,3/5/2024,"Company submitted an amendment to GOBLET to initiate a new Phase 1/2 cohort, noted March 5, 2024.",100.0,77.6589,81.563,0.92,1.03,1.06,0.112940411,0.141650517,0.006074203,0.046014312,1.22473,0.02796,0.44063,355,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
LIPO,LP-410,Graft-Versus-Host Disease (GVHD)Â ,IND-Enabling,3/5/2024,"IND cleared by the FDA noted, March 5, 2024.",4.0,5.04878,129.9728,8.24,6.4624,5.636,-0.242999578,-0.37982575,0.006074203,0.046014312,0.4103,0.01172,0.95773,356,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
IBRX,Anktiva (N-803),HIVÂ ,Phase 1,3/5/2024,"Phase 1 pilot study experienced a marked decrease in the burden of infection, and the procedures were found to be safe and well tolerated, noted March 5, 2024.",945.0,3230.99585,134.3936,5.07,4.82,5.05,-0.05056689,-0.003952574,0.006074203,0.046014312,7.03236,0.01625,17.65885,357,0,0,0,1,0,1,0,0,0,0,0,0,2,0,0,1
OPK,SAR441236,human immunodeficiency virus (HIV)Â ,Phase 1,3/5/2024,"Phase 1 study delivers first clinical safety and pharmacokinetic data as proof of concept for the use of multispecific antibodies in humans, noted March 5, 2024.",793.0,651.61752,86.7239,1.0,0.9349,0.9279,-0.067315707,-0.074831311,0.006074203,0.046014312,14.05216,0.07567,14.55008,358,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
GILD,Bictegravir and Lenacapavir - (ARTISTRY-1),HIVÂ ,Phase 2/3,3/5/2024,"Phase 2/3 data reported that all three treatment groups had robust virologic suppression at six months, with consistently low viral loads throughout the study, noted March 5, 2024.",0.0,90929.08922,25.069,72.25,72.99,75.08,0.010190118,0.038421885,0.006074203,0.046014312,1.59581,0.07912,458.40859,359,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
NVS,Wyost (denosumab-bddz) and Jubbonti (denosumab-bddz) interchangeable,multiple myeloma and in patients with bone metastases from solid tumorsÂ ,Approved,3/5/2024,"FDA biosimilar of Xgeva (denosumab) and Prolia (denosumab) approved on March 5, 2024.",0.0,1303.17914,53.8789,4.2,4.2,4.03,0.0,-0.041318149,0.006074203,0.046014312,0.0,0.00181,0.00995,360,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1
BTAI,BXCL501 - (SERENITY III),Agitation associated with bipolar I or II disorder or schizophreniaÂ ,Phase 3,3/6/2024,"A Type C meeting with FDA feedback resulted in an amended Phase 3 trial planned for the at-home setting, noted March 6, 2024.",14.0,89.93044,140.0889,48.32,47.36,45.92,-0.020067563,-0.050944802,0.006759168,0.024014178,24.55265,0.02276,1.40351,361,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
VNDA,HETLIOZ (tasimelteon),InsomniaÂ ,CRL,3/6/2024,"CRL issued by FDA on March 6, 2024.",59.0,224.97162,60.8849,4.14,3.91,3.84,-0.057158414,-0.075223421,0.006759168,0.024014178,5.14407,0.00941,6.03893,362,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,-1
BMEA,Icovamenib (BMF-219) - (COVALENT-111),"Healthy volunteers, type 2 diabetesÂ ",Phase 1/2,3/6/2024,"Phase 1/2 data presented at ATTD reported that across 100mg QD, 200mg QD, and 100mg BID cohorts, 38% of patients had â‰¥0.5% HbA1c reduction, and 23% of patients had â‰¥1.0% HbA1c reduction at Week 26, noted March 6, 2024.Â read less",59.0,564.15142,108.0851,17.52,15.8,17.4,-0.103333145,-0.006872879,0.006759168,0.024014178,32.999,0.03954,49.82017,363,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
XOMA,RZ358 - (sunRIZE),"Congenital hyperinsulinism (HI), non-islet cell tumors (NICTs) that have uncontrolled hypoglycemiaÂ ",Preclinical,3/6/2024,"Preclinical data reported that data demonstrated the ability of RZ358 to similarly blunt both IGF-2 and insulin-mediated insulin-receptor signaling, at levels of these ligands that are disease-relevant in humans, noted March 6, 2024.Â read less",12.0,287.1952,61.4019,24.59,25.0,25.61,0.016535969,0.040643044,0.006759168,0.024014178,2.55024,0.00058,0.40653,364,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
RZLT,RZ358 - (sunRIZE),"Congenital hyperinsulinism (HI), non-islet cell tumors (NICTs) that have uncontrolled hypoglycemiaÂ ",Preclinical,3/6/2024,"Preclinical data reported that data demonstrated the ability of RZ358 to similarly blunt both IGF-2 and insulin-mediated insulin-receptor signaling, at levels of these ligands that are disease-relevant in humans, noted March 6, 2024.Â read less",90.0,71.12736,89.0371,1.78,1.795,1.92,0.008391658,0.075711822,0.006759168,0.024014178,2.55211,0.00367,0.2199,365,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
KURA,KO-2806 and adagrasib in combination with cabozantinib - (FIT-001),Clear cell renal cell carcinoma (ccRCC)Â ,Phase 1,3/6/2024,"Phase 1 dosing initiated, noted March 6, 2024.",86.0,1728.30906,77.5201,21.04,22.7,22.83,0.075939537,0.081650073,0.006759168,0.024014178,13.80528,0.07022,35.81819,366,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1
BMY,KO-2806 and adagrasib in combination with cabozantinib - (FIT-001),Clear cell renal cell carcinoma (ccRCC)Â ,Phase 1,3/6/2024,"Phase 1 dosing initiated, noted March 6, 2024.",0.0,107944.6843,21.5146,51.82,53.38,52.65,0.029659969,0.015890063,0.006759168,0.024014178,1.55743,0.12183,1157.93626,367,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1
COYA,COYA 302,Frontotemporal dementia (FTD)Â ,Preclinical,3/6/2024,"Preclinical biomarker data shared at the AD/PD 2024 Conference clearly depicts a compromised peripheral immune environment present in patients with FTD that, we believe, contributes to the pathophysiology of the disease process, noted March 5, 2024. IND filing intended later in 2024 and Phase 2 initiation, noted March 6, 2024.Â read less",16.0,139.29949,81.6073,9.54,9.67,9.79,0.013534824,0.025867971,0.006759168,0.024014178,0.1546,0.00236,0.78757,368,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
BHC,RELISTOR (methylnaltrexone bromide: MNTX),Resectable head and neck squamous cell carcinomaÂ ,Phase 2,3/6/2024,"Phase 2 initiated sponsored by Salix Pharmaceuticals, noted March 6, 2024.",369.0,3372.75233,42.3824,9.56,9.23,9.28,-0.035128679,-0.02972618,0.006759168,0.024014178,5.89081,0.16951,24.56074,369,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
REGN,Ateganosine (THIO-101),Non-small cell lung cancer (NSCLC)Â ,Phase 2,3/6/2024,"Phase 2 third-line ombination THIO 180mg + cemiplimab achieved 38% overall response rate (ORR) in difficult-to-treat, noted March 6, 2024",105.0,104463.7091,17.2866,965.21,972.1,965.47,0.007112986,0.000269335,0.006759168,0.024014178,1.27527,0.13251,356.59933,370,1,0,0,0,0,1,0,0,0,0,0,0,2,0,0,1
MAIA,Ateganosine (THIO-101),Non-small cell lung cancer (NSCLC)Â ,Phase 2,3/6/2024,"Phase 2 third-line ombination THIO 180mg + cemiplimab achieved 38% overall response rate (ORR) in difficult-to-treat, noted March 6, 2024",32.0,24.96979,123.0616,1.48,1.47,1.3401,-0.006779687,-0.09929785,0.006759168,0.024014178,2.5578,0.00184,3.23699,371,1,0,0,0,0,1,0,0,0,0,0,0,2,0,0,1
GILD,Islatravir (MK-8591D) and Lenacapavir - (ISLEND),Human immunodeficiency virus (HIV)Â ,Phase 2,3/6/2024,"Phase 2 data reported that one participant (1.9%) treated with islatravir and lenacapavir had a viral load of more than 50 copies/mL at Week 24; the participant later suppressed on islatravir and lenacapavir at Week 30. No participants in the Biktarvy group had a viral load of more than 50 copies/mL at Week 24, noted March 6, 2024.Â read less",0.0,90480.61036,25.0199,72.99,72.63,75.94,-0.004944386,0.039621109,0.006759168,0.024014178,1.59581,0.07912,448.15092,372,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
MRK,Islatravir (MK-8591D) and Lenacapavir - (ISLEND),Human immunodeficiency virus (HIV)Â ,Phase 2,3/6/2024,"Phase 2 data reported that one participant (1.9%) treated with islatravir and lenacapavir had a viral load of more than 50 copies/mL at Week 24; the participant later suppressed on islatravir and lenacapavir at Week 30. No participants in the Biktarvy group had a viral load of more than 50 copies/mL at Week 24, noted March 6, 2024.Â read less",0.0,313414.6792,16.1292,122.83,123.75,122.16,0.007462116,-0.005469625,0.006759168,0.024014178,0.66406,0.0006,1021.10605,373,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
GSK,Cabenuva (cabotegravir + rilpivirine) - (LATITUDE),HIVÂ ,Phase 3,3/6/2024,"Phase 3 data reported that 24.1% of participants on LA-ART experienced regimen failure compared to 38.5% on SOC, noted March 6, 2024.",0.0,67902.07414,17.8764,16.834,16.732,16.952,-0.006077597,0.00698517,0.006759168,0.024014178,0.0,0.00103,101.39759,374,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ZLAB,ZEJULA (niraparib) - (NORA),Platinum-Sensitive Recurrent Ovarian Cancer (PSROC)Â ,Phase 3,3/6/2024,"Phase 3 data reported that treatment demonstrated a favorable OS trend versus placebo in this disease setting, regardless of BRCA-gene mutation status. No new safety signals were identified during the long-term follow up period subsequent to the primary analysis, noted March 6, 2024.Â read less",109.0,1954.60696,57.1708,18.91,19.8,20.16,0.045991055,0.064009561,0.006759168,0.024014178,4.74981,0.18805,8.35944,375,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
GILD,Biktarvy - (ALLIANCE),HIV/HBV CoinfectionÂ ,Phase 3,3/6/2024,"Phase 3 data reported that 97% percent (71/73) of participants treated with Biktarvy achieved viral suppression (HIV-1 RNA < 50 copies /ml) as did 97% (36/37) of participants treated with the DTG-based regimen, noted March 6, 2024.Â read less",0.0,90480.61036,25.0199,72.99,72.63,75.94,-0.004944386,0.039621109,0.006759168,0.024014178,1.59581,0.07912,448.15092,376,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1
DYN,DYNE-251 - (DELIVER),Duchenne muscular dystrophy (DMD)Â ,Phase 1/2,3/6/2024,"Phase 1/2 initial data show levels of exon skipping, dystrophin, and PDPF increased at 6 months vs. baseline, noted March 6, 2024.",142.0,2194.83706,95.7142,25.87,26.78,27.77,0.034571344,0.070872305,0.006759168,0.024014178,8.84366,0.06854,30.81853,377,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
BMY,Opdivo (nivolumab) plus Yervoy (ipilimumab),Urothelial carcinomaÂ ,Approved,3/7/2024,"Approved March 7, 2024.",0.0,107742.4649,21.4987,53.38,53.28,52.49,-0.001875118,-0.016813469,0.011754795,0.058298873,1.55743,0.12183,918.17754,378,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1
MNMD,MM-120 (LSD),Generalized Anxiety Disorder (GAD)Â ,Phase 2b,3/7/2024,"Phase 2b data 12-week data reported that the trial met its key secondary endpoint and maintained a clinically and statistically significant HAM-A reductions compared to placebo at 12 weeks with a 65% clinical response rate and 48% clinical remission rate, noted March 7, 2024.Â read less",75.0,372.00876,94.8051,5.94,9.0,8.14,0.415515444,0.315081047,0.011754795,0.058298873,8.29487,0.22287,342.94969,379,1,0,0,0,0,1,0,0,1,0,0,0,3,0,0,1
FBIO,MB-101 - (City of Hope),High-Grade GliomaÂ ,Phase 1,3/7/2024,"Phase 1 data reported well-tolerated and 50% of patients achieved stable disease or better with two partial responses and two complete responses lasting 7.5 and 66+ months, noted March 7, 2024.",29.0,38.03987,151.881,2.215,2.07,1.68,-0.067703796,-0.27645861,0.011754795,0.058298873,8.92794,0.09839,0.60512,380,0,0,0,1,0,1,0,0,0,0,0,0,2,0,0,1
MBIO,MB-101 - (City of Hope),High-Grade GliomaÂ ,Phase 1,3/7/2024,"Phase 1 data reported well-tolerated and 50% of patients achieved stable disease or better with two partial responses and two complete responses lasting 7.5 and 66+ months, noted March 7, 2024.",7.0,70.30113,59.9078,66.0,69.5,49.735,0.051672011,-0.282945831,0.011754795,0.058298873,0.08438,0.11009,5.54137,381,0,0,0,1,0,1,0,0,0,0,0,0,2,0,0,1
GSK,BLENREP (belantamab mafodotin) and POMALYST (Pomalidomide) and Dexamethasone - (DREAMM-8),Multiple MyelomaÂ ,Phase 3,3/7/2024,"Phase 3 trial met its primary endpoint, noted March 7, 2024",0.0,69444.19632,18.0914,16.732,17.112,16.878,0.022456918,0.008687945,0.011754795,0.058298873,0.0,0.00103,174.20889,382,1,0,0,0,0,1,0,0,0,0,0,0,2,0,0,1
IMRN,Travelan - (CHIM),Enterotoxigenic Escherichia coli (ETEC)Â ,Phase 2,3/7/2024,"Phase 2 interim data reported that the intended attack rate for this study was approximately 70%. The attack rate for the Placebo group of this study was only 37%, noted March 7, 2024.",6.0,28.47479,157.8071,1.6501,4.55,2.82,1.014291341,0.535900993,0.011754795,0.058298873,0.0,0.0,244.68916,383,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
TELO,Telomir-1,Age-related conditionsÂ ,Preclinical,3/7/2024,"Preclinical data reported that Telomir-1 was observed to cause cell cytotoxicity at a concentration of 500 M in both MRC-5 and HUVEC cells, noted March 7, 2024.",32.0,257.60538,0.0,8.76,8.7,6.51,-0.006872879,-0.296856449,0.011754795,0.058298873,0.01001,0.86973,0.30182,384,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
APVO,ALG.APV-527,Solid tumorsÂ ,Phase 1,3/7/2024,"Phase 1 data reported 2 stable disease responses, noted March 7, 2024.",3.0,3.51648,91.0689,4736.00474,4884.00488,3729.60373,0.030771657,-0.238891909,0.011754795,0.058298873,0.08378,0.07383,23.99023,385,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ATHA,Fosgonimeton (ATH-1017) - (SHAPE),Parkinsonâ€™s disease dementiaÂ ,Phase 2,3/8/2024,"Phase 2 data presented at AD/PD reported that changes in ADAS-Cog13 observed in the fosgonimeton 40 mg dose arm were suggestive of a pro-cognitive effect, noted March 8, 2024.",3.0,137.20941,79.4269,41.5,35.8,26.2,-0.147745534,-0.459934016,0.020039521,0.042176794,1.69681,0.03147,6.6453,386,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
AMLX,AMX0035 - (A35-004 PHOENIX),Amyotrophic Lateral Sclerosis (AML)Â ,Phase 3,3/8/2024,"Phase 3 topline results did not meet the primary endpoint, noted March 8, 2024.",89.0,227.74799,256.5398,18.97,3.36,3.24,-1.73091781,-1.767285454,0.020039521,0.042176794,7.34621,0.0378,206.52855,387,1,0,0,0,0,1,0,0,0,0,1,0,0,3,0,-1
KYTX,KYV-101,Non-relapsing and progressive forms of multiple sclerosisÂ ,Phase 1,3/8/2024,"Phase 1 trial with Stanford University commenced, noted March 8, 2024.",43.0,1221.79275,0.0,28.78,28.67,29.71,-0.003829422,0.031802988,0.020039521,0.042176794,1.36724,0.45613,7.64617,388,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
NVO,Wegovy (Semaglutide),Cardiovascular risk reduction in adults with obesityÂ ,Approved,3/8/2024,"Approved March 8, 2024.",0.0,4038684.488,30.5049,135.92,133.07,132.37,-0.021191172,-0.026465446,0.020039521,0.042176794,0.0,0.0,1698.64414,389,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1
ABOS,Sabirnetug (ACU193) - (INTERCEPT-AD),Alzheimerâ€™s disease (AD)Â ,Phase 1,3/8/2024,"Phase 1 biomarker results presented at PD/AD support sabirnetug's downstream pharmacological effects in the brain in early AD, noted March 8, 2024.",60.0,253.06872,86.2306,4.37,4.37,4.18,0.0,-0.044451763,0.020039521,0.042176794,1.17377,0.05985,1.48282,390,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
MNKD,Afrezza Combined With Insulin Degludec - (INHALE-3),Type 1 DiabetesÂ ,Phase 3,3/8/2024,"Phase 4 data presented at ATTD reported that post-meal hyperglycemia was significantly reduced by 20% with inhaled insulin compared with rapid-acting insulin delivered through MDI or insulin pumps, noted March 8, 2024.Â read less",306.0,1425.10399,57.2436,5.15,5.27,4.47,0.023033648,-0.141608306,0.020039521,0.042176794,12.81512,0.02152,27.05728,391,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
TLSA,Foralumab (Intranasal),Alzheimerâ€™s DiseaseÂ ,Phase 1,3/8/2024,"IND clearance by FDA, noted August 15, 2023. Phase 1 data presented at the AD/PD Conference on March 8, 2024.",111.0,48.84991,57.4364,0.5187,0.487,0.4997,-0.063061558,-0.037317763,0.020039521,0.042176794,0.30576,0.01965,0.03935,392,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ARQT,Roflumilast Cream (ARQ-151) - (DERMIS-1),Plaque psoriasisÂ ,Phase 3,3/9/2024,"Additional data shared at AAD reported a clinically meaningful response in >70% of patients, noted March 9, 2024.",119.0,1281.92953,109.4401,11.15,11.15,10.66,0.0,-0.044941079,0.021657808,0.043795081,14.73609,0.09407,0.0,393,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
MLTX,Nanobody sonelokimab - (IZAR),Active psoriatic arthritis (PsA)Â ,Phase 2b,3/10/2024,"Phase 2b 24-week data reported that 52% of patients achieved ACR50+PASI100 and up to 61% of patients achieved Minimal Disease Activity (MDA), noted March 10, 2024.",64.0,2867.71219,82.3884,45.61,45.61,47.25,0.0,0.035325663,0.021657808,0.043795081,10.51676,0.03112,0.0,394,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1
ARQT,ZORYVE (roflumilast) Cream 0.05%,Atopic Dermatitis - ages of 2-5 years oldÂ ,Phase 3,3/10/2024,"Phase 3 data to be shared at late-breaking presentation at AAD reported significant improvements in atopic dermatitis across multiple efficacy endpoints and all timepoints, noted March 10, 2024.",119.0,1281.92953,109.4401,11.15,11.15,10.66,0.0,-0.044941079,0.021657808,0.043795081,14.73609,0.09407,0.0,395,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
LXRX,Zynquista (sotagliflozin),Type 1 Diabetes and chronic kidney disease (CKD)Â ,NDA Filing,3/11/2024,"After public Notice of Opportunity for Hearing (NOOH) proceeding in late 2023, the FDA issued feedback for sotagliflozin resbmisssion, noted March 11, 2024.",363.0,685.70939,107.5032,2.17,2.81,2.52,0.258457316,0.149531734,0.028185314,0.062552958,8.63253,0.0361,82.8835,396,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
AMGN,Otezla - (SPROUT),Plaque psoriasis in pediatric patientsÂ ,Phase 3,3/11/2024,"Phase 3 results data presented at AAD reported that 56.3% of patients who received Otezla through week 52 achieved static Physician Global Assessment (sPGA) response, noted March 11, 2024.",538.0,147570.6286,22.751,273.75,275.36,270.9,0.005864051,-0.010465532,0.028185314,0.062552958,2.05594,0.01736,509.72551,397,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1
INCY,Ruxolitinib Cream (Opzelura),Adults with hidradenitis suppurativa (HS)Â ,Phase 2,3/11/2024,"Phase 2 additional data reported that more than three quarters (79.2%) of on-treatment patients achieved at least a 50% reduction in AN count (AN50), 54.2% achieved a 75% reduction (AN75), 20.8% achieved 90% reduction (AN90), and 20.8% achieved complete clearance (100% reduction, AN100), surpassing the 56.3%, 25.0%, 12.5% and 12.5% reductions, respectively, in the vehicle control group, noted March 11, 2024.Â read less",195.0,13648.94332,27.945,60.02,60.79,57.34,0.012747462,-0.04567938,0.028185314,0.062552958,3.46247,0.16218,133.32159,398,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1
INCY,Povorcitinib (INCB54707),Prurigo NodularisÂ ,Phase 2,3/11/2024,"Phase 2 data reported that the trial met its primary endpoint, noted March 11, 2024.",195.0,13648.94332,27.945,60.02,60.79,57.34,0.012747462,-0.04567938,0.028185314,0.062552958,3.46247,0.16218,133.32159,399,1,0,0,0,0,1,0,0,0,0,0,0,2,0,0,1
NRIX,NX-2127,"B-cell malignancies, chronic lymphocytic leukemia (CLL)Â ",Phase 1b,3/11/2024,"Phase 1a/1b clinical hold lifted by the FDA, noted March 11, 2024.",76.0,690.87341,85.7088,14.85,14.13,12.84,-0.049699669,-0.145434567,0.028185314,0.062552958,14.00249,0.1782,12.81804,400,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,-1
SONN,SON-080 - (SB211),Chemotherapy Induced Peripheral Neuropathy (CIPN)Â ,Phase 1/2,3/11/2024,"Phase 1b/2a cleared after review by the independent DSMB, noted March 11, 2024.",6.0,6.35389,97.7855,14.8,16.56,18.08,0.112362968,0.200179174,0.028185314,0.062552958,8.27734,0.04156,6.5386,401,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
APRE,APR-1051 - (ACESOT-1051),Solid tumorsÂ ,IND-Enabling,3/11/2024,"IND cleared by the FDA, noted March 11, 2024.",5.0,25.29728,96.6218,7.13,6.77,6.55,-0.051810148,-0.084846185,0.028185314,0.062552958,1.87742,0.04508,7.80276,402,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
LLY,Lebrikizumab,Moderate-to-severe atopic dermatitisÂ ,Phase 3,3/11/2024,"Phase 3 data reported that 68% of people experienced significant improvement of at least 75% in disease extent and severity (EASI-75), noted March 11, 2024.",946.0,661053.7686,29.172,762.14,734.37,762.66,-0.037117277,0.000682057,0.028185314,0.062552958,0.60249,0.00423,2914.60731,403,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1
VTYX,VTX3232,Parkinson's diseaseÂ ,Phase 1,3/11/2024,"Phase 1 clinical update presented at virtual investor event showed that treatment was well-tolerated with no dose-limiting toxicities identified. All treatment-emergent adverse events were graded mild or moderate, noted March 11, 2024.Â read less",71.0,476.28247,265.9507,9.92,8.04,7.98,-0.210123838,-0.21761451,0.028185314,0.062552958,15.51744,0.01312,62.19627,404,0,0,0,1,0,1,0,0,0,0,0,0,2,0,0,1
VTYX,VTX2735,"Healthy volunteers, cryopyrin-associated periodic syndrome (CAPS)Â ",Phase 2,3/11/2024,"Phase 2 trial ongoing, with clinical update presented at virtual investor event showed that treatment demonstrated clinically meaningful improvements in disease activity, including an 85% mean reduction in the Key Symptom Score during Treatment Period 1, noted March 11, 2024.Â read less",71.0,476.28247,265.9507,9.92,8.04,7.98,-0.210123838,-0.21761451,0.028185314,0.062552958,15.51744,0.01312,62.19627,405,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
VTYX,Tamuzimod (VTX002),Ulcerative Colitis (UC)Â ,Phase 2,3/11/2024,"Phase 2 OLE clinical update presented at the virtual investor event data continues to support the potentially differentiated profile of VTX002 in ulcerative colitis, with robust rates of clinical remission and endoscopic remission observed among participants completing 52 weeks of treatment with VTX002, noted March 11, 2024.Â read less",71.0,476.28247,265.9507,9.92,8.04,7.98,-0.210123838,-0.21761451,0.028185314,0.062552958,15.51744,0.01312,62.19627,406,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
NVCR,Tumor Treating Fields (TTFields) - (INNOVATE-3),Ovarian cancerÂ ,Phase 3,3/11/2024,"Phase 3 exploratory subgroup analysis finds that pegylated liposomal doxorubicin (PLD) -naÃ¯ve patients randomized to receive TTFields therapy and paclitaxel had a median overall survival of 16.0 months compared to 11.7 months in PLD-naÃ¯ve patients treated with paclitaxel alone, noted March 11, 2024.Â read less",111.0,1712.42398,68.1107,16.54,15.99,13.82,-0.033818163,-0.179664871,0.028185314,0.062552958,5.2674,0.05056,18.10626,407,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
TVTX,FILSPARI (sparsentan),IgA nephropathy (IgAN)Â ,sNDA Filing,3/11/2024,"sNDA submitted to the FDA, noted March 11, 2024.",89.0,608.0269,105.6802,8.66,7.99,7.18,-0.080523963,-0.18741534,0.028185314,0.062552958,13.4837,0.14398,8.94008,408,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
LGND,FILSPARI (sparsentan),IgA nephropathy (IgAN)Â ,sNDA Filing,3/11/2024,"sNDA submitted to the FDA, noted March 11, 2024.",19.0,1279.20699,42.4473,73.77,72.25,72.14,-0.020819818,-0.022343469,0.028185314,0.062552958,4.30741,0.38777,8.406,409,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
JNJ,PN-235 (JNJ-77242113) - (FRONTIER 1),Plaque psoriasisÂ ,Phase 2b,3/11/2024,"Phase 2b data presented at AAD reported that response rates were maintained from Week 16 to Week 52 with the highest PASI 75 response observed in the 100 mg twice daily group (78.6% at 16 weeks and 76.2% at 52 weeks), noted March 11, 2024Â read less",0.0,388365.5402,13.0223,159.52,161.23,156.76,0.010662611,-0.017453333,0.028185314,0.062552958,0.6165,0.11902,745.01578,410,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
PTGX,PN-235 (JNJ-77242113) - (FRONTIER 1),Plaque psoriasisÂ ,Phase 2b,3/11/2024,"Phase 2b data presented at AAD reported that response rates were maintained from Week 16 to Week 52 with the highest PASI 75 response observed in the 100 mg twice daily group (78.6% at 16 weeks and 76.2% at 52 weeks), noted March 11, 2024Â read less",62.0,1755.24294,52.3404,30.32,30.12,28.46,-0.006618158,-0.063307968,0.028185314,0.062552958,5.03761,0.09328,17.56864,411,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
JNJ,PN-235 (JNJ-77242113) - (FRONTIER 1),Plaque psoriasisÂ ,Phase 2b,3/11/2024,"Phase 2b data presented at AAD reported that response rates were maintained from Week 16 to Week 52 with the highest PASI 75 response observed in the 100 mg twice daily group (78.6% at 16 weeks and 76.2% at 52 weeks), noted March 11, 2024.Â read less",0.0,388365.5402,13.0223,159.52,161.23,156.76,0.010662611,-0.017453333,0.028185314,0.062552958,0.6165,0.11902,745.01578,412,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
PTGX,PN-235 (JNJ-77242113) - (FRONTIER 1),Plaque psoriasisÂ ,Phase 2b,3/11/2024,"Phase 2b data presented at AAD reported that response rates were maintained from Week 16 to Week 52 with the highest PASI 75 response observed in the 100 mg twice daily group (78.6% at 16 weeks and 76.2% at 52 weeks), noted March 11, 2024.Â read less",62.0,1755.24294,52.3404,30.32,30.12,28.46,-0.006618158,-0.063307968,0.028185314,0.062552958,5.03761,0.09328,17.56864,413,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
VTRS,Glatiramer (GA Depot),Primary Progressive Multiple Sclerosis (PPMS)Â ,CRL,3/11/2024,"CRL announced March 11, 2024.",0.0,14215.20271,29.1862,12.26,11.97,11.76,-0.023938411,-0.041637988,0.028185314,0.062552958,3.58073,0.05048,99.14716,414,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,-1
ACAD,NUPLAZID (pimavanserin) - (Advance-2),Adjunctive treatment in patients with negative symptoms of schizophreniaÂ ,Phase 3,3/11/2024,"Phase 3 study did not meet its primary endpoint, noted March 11, 2024.",168.0,3975.9368,63.9444,23.44,24.13,18.72,0.029011915,-0.224851494,0.028185314,0.062552958,6.55787,0.10196,50.128,415,1,0,0,0,0,1,0,0,0,0,0,0,0,2,0,-1
TERN,TERN-701 - (CARDINAL),Chronic myeloid leukemia (CML)Â ,Phase 1,3/11/2024,"Orphan drug designation grated by the FDA, noted March 11, 2024",87.0,459.1333,83.3845,8.11,7.43,6.085,-0.087572009,-0.287271142,0.028185314,0.062552958,7.09125,0.00013,6.01965,416,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
LRMR,Nomlabofusp (CTI-1601),Friedreichâ€™s ataxia (FA)Â ,Phase 2,3/11/2024,"Phase 2 OLE dosing initiated, noted March 11, 2024.",85.0,549.23689,99.5185,10.2,8.63,8.35,-0.167143215,-0.200126181,0.028185314,0.062552958,0.79634,0.01034,15.25411,417,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1
PSTV,REYOBIQ (rhenium Re186 obisbemeda) - (ReSPECT-LM),Leptomeningeal metastases (LM)Â ,Phase 1,3/11/2024,"Phase 1 Cohort 5 dosing completed, noted March 11, 2024.",99.0,6.88449,103.2547,1.69,1.61,1.72,-0.04849435,0.017595762,0.028185314,0.062552958,0.95391,0.1034,0.0804,418,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
NVS,Farabursen (RGLS8429) (MAD),Autosomal Dominant Polycystic Kidney Disease (ADPKD)Â ,Phase 1b,3/12/2024,"Phase 1b MAD data from the second cohort, reported that a mechanistic dose response was observed at a 2mg/kg dose level based on urinary biomarker analyses, noted March 12, 2024.",0.0,1250.43141,54.0149,4.1,4.03,4.02,-0.017220598,-0.019705071,-0.002784512,0.031259101,0.0,0.00203,0.14675,419,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
PFE,ADCETRIS (brentuximab vedotin) with lenalidomide and rituximab - (ECHELON-3),Relapsed/refractory diffuse large B-cell lymphoma (DLBCL)Â ,Phase 3,3/12/2024,"Phase 3 data reported a statistically significant and clinically meaningful improvement in overall survival (OS) compared to lenalidomide and rituximab plus placebo, noted March 12, 2024.",0.0,158166.2637,27.7079,28.37,28.01,27.63,-0.01277066,-0.02643011,-0.002784512,0.031259101,1.17093,0.04515,1365.71791,420,1,0,0,0,0,1,0,0,0,0,0,0,2,0,0,1
CRNX,Paltusotine,Carcinoid syndrome associated with neuroendocrine tumors (NETs)Â ,Phase 2,3/12/2024,"Phase data from treatment demonstrated rapid and sustained reductions in the frequency and severity of flushing episodes and bowel movements. Results confirm initial positive data previously reported,",94.0,3175.62859,52.9207,41.57,40.75,45.18,-0.019922914,0.083275758,-0.002784512,0.031259101,6.08553,0.00502,21.44118,421,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CYBN,CYB003 - (EXTEND and EMBRACE),Major Depressive Disorder (MDD) and Alcohol use disorder (AUD)Â ,Phase 2,3/13/2024,"Additional Phase 2 durability data reported with significant improvement in depression symptoms at four months with 75% of patients in remission from depression after two doses, noted March 13, 2024.",23.0,172.73831,100.3928,16.71999,15.95999,15.95999,-0.046520044,-0.046520044,0.018358764,0.010869672,2.27217,0.04751,19.11532,422,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1
SLN,Zerlasiran (formerly SLN360) - (ALPACAR-360),Cardiovascular diseases and Polycythemia veraÂ ,Phase 2,3/13/2024,"Phase 2 study met its primary endpoint, noted March 13, 2024.",46.0,1190.92319,71.3521,25.9,25.61,22.91,-0.011260068,-0.122669472,0.018358764,0.010869672,0.09934,0.00339,14.08222,423,1,0,0,0,0,1,0,0,0,0,0,0,2,0,0,1
PRTC,LYT-200,Relapsed/refractory AML and MDSÂ ,Phase 1b,3/13/2024,"Phase 1b orphan drug designation granted by FDA, noted March 13, 2024.",24.0,528.529,53.1547,2.015,1.956,2.19,-0.029717624,0.083282348,0.018358764,0.010869672,0.0,0.08986,0.80379,424,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
SGMO,STAC-BBB,Neurological diseasesÂ ,Preclinical,3/13/2024,"Preclinical data reported robust penetration of the BBB and widespread transgene expression throughout the brain, and the treatment was well tolerated in NHPs, with no notable treatment related pathological findings in brain, spinal cord or peripheral tissues, noted March 13, 2024.Â read less",301.0,140.45938,142.0796,0.8611,0.7851,0.8161,-0.092399543,-0.053673745,0.018358764,0.010869672,5.62389,0.00833,2.25051,425,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1
LLY,STAC-BBB,Neurological diseasesÂ ,Preclinical,3/13/2024,"Preclinical data reported robust penetration of the BBB and widespread transgene expression throughout the brain, and the treatment was well tolerated in NHPs, with no notable treatment related pathological findings in brain, spinal cord or peripheral tissues, noted March 13, 2024.Â read less",946.0,682180.6283,29.3934,754.95,757.84,772.86,0.00382076,0.023446398,0.018358764,0.010869672,0.60249,0.00423,1786.59719,426,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1
XOMA,Mezagitamab (TAK-079) - (TAK-079-1004),Primary Immune ThrombocytopeniaÂ ,Phase 2,3/13/2024,"Phase 2 topline data reported that treatment was safe and well tolerated, with all mezagitamab doses tested demonstrated a higher platelet response rate than placebo, noted March 13, 2024.",12.0,297.7374,62.036,25.65,25.61,24.62,-0.001560671,-0.040984451,0.018358764,0.010869672,2.50798,0.00055,0.22096,427,0,0,0,1,0,1,0,0,0,0,1,0,3,0,0,1
TAK,Mezagitamab (TAK-079) - (TAK-079-1004),Primary Immune ThrombocytopeniaÂ ,Phase 2,3/13/2024,"Phase 2 topline data reported that treatment was safe and well tolerated, with all mezagitamab doses tested demonstrated a higher platelet response rate than placebo, noted March 13, 2024.",0.0,6705542.501,19.8275,14.37,14.42,14.55,0.003473432,0.012448294,0.018358764,0.010869672,0.0,0.0,21.46886,428,0,0,0,1,0,1,0,0,0,0,1,0,3,0,0,1
PHIO,PH-762,Cutaneous Squamous Cell CarcinomaÂ ,Phase 1b,3/13/2024,"Phase 1b new trial sites opened, noted March 13, 2024.",5.0,2.49232,161.6794,8.82,9.18,9.63,0.040005335,0.087861356,0.018358764,0.010869672,1.88099,0.00726,0.49926,429,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
SPRB,Tildacerfont - (CAHmelia-203),Congenital Adrenal Hyperplasia (poor disease control)Â ,Phase 2b,3/13/2024,"Phase 2b top-line data reported that trial did not meet its primary endpoint, noted March 13, 2024.",0.0,212.94519,86.4598,372.00093,389.25097,55.86014,0.045327948,-1.896045287,0.018358764,0.010869672,0.08209,0.02952,18.8958,430,1,0,0,0,0,1,0,0,0,0,1,0,0,3,0,-1
SPRB,Tildacerfont - (CAHptain-205),Pediatric Classic Congenital Adrenal HyperplasiaÂ ,Phase 2,3/13/2024,"Phase 2 top-line data reported that 73% of all patients (22 of 30 patients) met the efficacy endpoint of A4 or GC reduction from baseline at 12 weeks with no treatment-related SAEs reported, noted March 13, 2024.Â read less",0.0,212.94519,86.4598,372.00093,389.25097,55.86014,0.045327948,-1.896045287,0.018358764,0.010869672,0.08209,0.02952,18.8958,431,0,0,0,1,1,1,0,0,0,0,1,0,4,0,0,1
MIRM,LIVMARLI (maralixibat),Progressive Familial Intrahepatic Cholestasis (PFIC)Â ,Approved,3/13/2024,"Approval announced March 13, 2024.",50.0,1294.47839,49.5023,27.48,27.77,26.99,0.010497834,-0.01799204,0.018358764,0.010869672,16.43598,0.03376,16.21376,432,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
CALC,Auxora - (KOURAGE),Acute kidney injury (AKI) with associated acute hypoxemic respiratory failure (AHRF)Â ,Preclinical,3/13/2024,"Preclinical data consistent with clinical observations made with Auxora, supporting the KOURAGE trial, noted March 13, 2024.",13.0,46.6121,116.6849,4.5,4.34,3.46,-0.036203049,-0.262808808,0.018358764,0.010869672,0.19387,0.03769,0.1494,433,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
IMNN,IMNN-101 - (IMUNON),SARS-CoV-2 variant XBB.1.5Â ,IND-Enabling,3/13/2024,"IND filed to FDA, noted March 13, 2024.",2.0,8.18677,89.8988,12.13043,11.36086,10.17391,-0.065543057,-0.175890571,0.018358764,0.010869672,5.22566,0.00783,0.03267,434,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
IONS,ION224,"metabolic dysfunction-associated steatohepatitis (MASH), previously referred to as nonalcoholic steatohepatitis (NASH)Â ",Phase 2,3/13/2024,"Phase 2 achieved statistically significant liver histologic improvement as measured by at least a 2-point reduction in NAFLD Activity Score (NAS), noted March 13, 2024.",159.0,6290.64756,37.5726,43.17,43.16,42.78,-0.000231669,-0.009075106,0.018358764,0.010869672,6.24815,0.16264,47.9335,435,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1
PCRX,PCRX-201 (enekinragene inzadenovec) - (ASCEND),Osteoarthritis of the kneeÂ ,Phase 1,3/13/2024,"Additional 104-week data presented at ACR reported MRI B-score change from baseline ranged from 2.3 to 5.4 in the not pretreated cohort and from 2.6 to 5.9 in the steroid pretreated cohort, noted November 17, 2024. RMAT designation granted March 13, 2024.Â read less",44.0,1408.50857,38.2209,30.56,30.29,30.02,-0.008874339,-0.017828138,0.018358764,0.010869672,8.97619,0.05502,11.20621,436,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
OCGN,OCU410 - (ArMaDa),Geographic Atrophy (GA)Â ,Phase 1/2,3/13/2024,"Phase 1/2 dosing initiated March 13, 2024.",292.0,266.76253,88.5833,0.984,1.04,1.24,0.055350095,0.231240762,0.018358764,0.010869672,14.28804,0.00067,5.77878,437,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1
IMRX,Atebimetinib (IMM-1-104) + mGnP,"Solid tumors, pancreatic cancer, melanomaÂ ",Phase 1,3/14/2024,"Phase 1 topline data reported that 100% suppression of acquired RAS alterations was observed in evaluable patients profiled for ctDNA and treated with IMM-1-104, with 53% of patients had â‰¥ 1 target lesion(s) regress when treated with IMM-1-104 at either 320mg or 240mg, noted March 14, 2024.Â read less",36.0,84.92149,139.0675,5.88,2.9,2.73,-0.706846025,-0.767255153,0.024921784,0.019761433,9.16767,0.15118,18.20639,438,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
NVCT,NXP800,Ovarian Clear Cell CarcinomaÂ ,Phase 1b,3/14/2024,"Phase 1b preliminary data reported that a 33% response rate and 100% disease control rate, defined as partial response (""PR"") plus stable disease (""SD""), in patients evaluated for efficacy, noted March 14, 2024.Â read less",25.0,162.58474,78.0102,9.64,9.15,9.05,-0.052167229,-0.063156351,0.024921784,0.019761433,4.07243,0.03497,3.99054,439,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
GERN,RYTELO (imetelstat) - (IMerge),Myelodysplastic syndromes with transfusion-dependent (TD) anemiaÂ ,NDA Filing,3/14/2024,"Advisory committee voted 12 to 2 in favor, noted March 14, 2024.",638.0,955.60379,71.9228,1.75,1.75,3.33,0.0,0.643356516,0.024921784,0.019761433,8.22365,0.01183,0.0,440,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
MDGL,Rezdiffra (resmetirom),Non-alcoholic steatohepatitis (NASH) with liver fibrosis (also known as MASH)Â ,Approved,3/14/2024,"Approved on March 14, 2024.",22.0,4846.41581,68.6183,272.98,243.57,255.27,-0.113994157,-0.067076724,0.024921784,0.019761433,17.41337,0.11609,422.1336,441,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1
ONC,TEVIMBRA,Esophageal Squamous Cell Carcinoma (ESCC)Â ,Approved,3/14/2024,"Approved March 14, 2024.",110.0,17637.8436,50.4984,176.47,168.9,163.7,-0.043844066,-0.075115406,0.024921784,0.019761433,1.84568,0.11454,66.74911,442,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1
BMY,Breyanzi (lisocabtagene maraleucel),Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)Â ,Approved,3/14/2024,"Approved March 14, 2024.",0.0,106144.9321,21.9067,52.65,52.49,51.59,-0.003043563,-0.020338383,0.024921784,0.019761433,1.61446,0.05966,757.43952,443,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1
ONC,Tislelizumab-jsgr (Tevimbra),Esophageal squamous cell carcinoma (ESCC)Â ,Approved,3/14/2024,"Approved March 14, 2024.",110.0,17637.8436,50.4984,176.47,168.9,163.7,-0.043844066,-0.075115406,0.024921784,0.019761433,1.84568,0.11454,66.74911,444,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1
AQST,Anaphylm (AQ-109)- (103),AnaphylaxisÂ ,Phase 3,3/15/2024,"Phase 3 trial met all primary and secondary pharmacokinetic endpoints, noted March 15, 2024.",99.0,446.40431,89.0039,5.25,6.09,4.38,0.148420005,-0.181179352,0.01600888,0.009467652,2.47183,0.02076,38.4921,445,0,0,0,0,0,1,0,0,1,0,0,0,2,0,0,1
JSPR,Briquilimab (JSP191),Fanconi Anemia (FA)Â ,Phase 1/2,3/15/2024,"Additional Phase 1/2 data reported that all six patients with Fanconi Anemia treated with briquilimab achieved full donor engraftment and full blood count recovery and briquilimab was well tolerated, noted March 15, 2024.Â read less",16.0,377.80251,99.5691,24.35,25.08,29.23,0.029538866,0.18266373,0.01600888,0.009467652,1.91756,0.0244,8.74658,446,0,0,0,1,0,1,0,0,0,0,0,0,2,0,0,1
JNJ,CARVYKTI (ciltacabtagene autoleucel) - (CARTITUDE-4),Multiple MyelomaÂ ,BLA Filing,3/15/2024,"Adcom resulted votes 11 to 0 supporting favorable risk-benefit assessment, noted March 15, 2024.",0.0,381179.4835,13.1235,159.21,158.18,155.23,-0.00649046,-0.025316197,0.01600888,0.009467652,0.61624,0.12001,2082.51879,447,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
LEGN,CARVYKTI (ciltacabtagene autoleucel) - (CARTITUDE-4),Multiple MyelomaÂ ,BLA Filing,3/15/2024,"Adcom resulted votes 11 to 0 supporting favorable risk-benefit assessment, noted March 15, 2024.",183.0,11638.12704,38.4628,66.11,64.02,58.14,-0.032124487,-0.128466126,0.01600888,0.009467652,5.64169,0.05095,162.69127,448,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
BMY,Abecma (idecabtagene vicleucel; ide-cel),Multiple MyelomaÂ ,BLA Filing,3/15/2024,"AdCom ODAC noted positively (8-3) that Abecma (idecabtagene vicleucel) demonstrated a favorable benefit/risk profile for patients, noted March 15, 2024.",0.0,105841.6031,21.8861,52.49,52.34,51.93,-0.002861778,-0.010726017,0.01600888,0.009467652,1.61446,0.05961,6468.45371,449,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
PHVS,Deucrictibant (PHVS416) - (CHAPTER-3),Hereditary angioedema - prophylactic useÂ ,Phase 2,3/15/2024,"Phase 2 full results presented at ITACA reported that treatment significantly reduced the monthly attack rate, noted March 15, 2024.",54.0,1256.00792,75.3128,23.68,23.35,24.35,-0.014033826,0.02790104,0.01600888,0.009467652,0.1888,0.04074,2.79005,450,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
WHWK,Nab-sirolimus - (AMPECT),Malignant PEComa (Perivascular epithelioid cell tumour)Â ,Phase 2,3/18/2024,"Phase 2 data presented at SGO reported that the overall response rate to nab-sirolimus for the subgroup was 37.5% (6/16), noted March 18, 2024.",47.0,52.05492,139.2003,2.17,2.12,2.17,-0.023311079,0.0,0.009121828,0.021774796,3.86631,2e-05,0.3894,451,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
AZN,Imfinzi (durvalumab) in combination with carboplatin and paclitaxel,Endometrial cancer (EC)Â ,Phase 3,3/18/2024,"Additional Phase 3 data reported that treatment demonstrated an improvement in multiple key secondary efficacy endpoints, particularly in patients with mismatch repair proficient (pMMR) advanced or recurrent endometrial cancer compared to chemotherapy alone, noted March 18, 2024.Â read less",0.0,159516.1478,23.6523,102.94,102.9,103.94,-0.000388651,0.009667515,0.009121828,0.021774796,0.0,0.22998,399.77093,452,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ALGS,ALG-055009 - (HERALD),Metabolic dysfunction-associated steatohepatitis (MASH)Â ,Phase 2a,3/18/2024,"Phase 2a study initiated, noted March 18, 2024.",6.0,69.61502,91.9322,23.0375,23.0,23.4675,-0.001629107,0.018493162,0.009121828,0.021774796,0.48775,0.04782,0.23324,453,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
IVA,Lanifibranor in combination with empagliflozin (Jardiance1) - (LEGEND),"Metabolic dysfunction-associated steatohepatitis (MASH), and type 2 diabetes (T2D)Â ",Phase 2a,3/18/2024,"Phase 2a achieved its primary efficacy endpoint by significantly lowering HbA1c level in both the lanifibranor arm and in the lanifibranor with empagliflozin arm compared to placebo, noted March 18, 2",95.0,197.63683,50.3545,3.71,3.8,3.425,0.02396919,-0.079930405,0.009121828,0.021774796,0.0,0.04019,0.57454,454,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1
PMVP,Rezatapopt (PC14586) - (PYNNACLE),Solid tumorsÂ ,Phase 1/2,3/18/2024,"Phase 1/2 part 1 analysis showed promising efficacy of rezatapopt (PC14586) in heavily pre-treated patients, noted March 18, 2024",52.0,85.91063,143.3366,1.76,1.67,1.7,-0.052490183,-0.034685558,0.009121828,0.021774796,3.85544,0.12093,0.64165,455,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
MRK,Rezatapopt (PC14586) - (PYNNACLE),Solid tumorsÂ ,Phase 1/2,3/18/2024,"Phase 1/2 part 1 analysis showed promising efficacy of rezatapopt (PC14586) in heavily pre-treated patients, noted March 18, 2024",0.0,307564.2718,16.0549,121.52,121.44,125.31,-0.000658545,0.030711809,0.009121828,0.021774796,0.65563,0.00037,1009.39653,456,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
PBM,Psilocybin,Adjustment Disorder due to a recent cancer diagnosisÂ ,Preclinical,3/18/2024,"Recent study published in the journal Molecular Psychiatry, suggests that nature-derived psilocybin may be demonstrably more therapeutic than its synthetic analog, noted March 18, 2024.",1.0,16.73779,273.9197,771.09952,747.18946,675.45927,-0.031498664,-0.132424585,0.009121828,0.021774796,0.60219,0.00949,1.11182,457,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
JNJ,EDURANT (rilpivirine),HIV in pediatric patients (2-12 years)Â ,Approved,3/19/2024,"Approved March 19, 2024.",0.0,376432.2109,13.1567,156.76,156.21,155.77,-0.003514717,-0.006335413,-0.023497971,0.002801122,0.61624,0.12001,1224.78388,458,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1
CRNX,PALSONIFY (paltusotine),AcromegalyÂ ,Phase 3,3/19/2024,"Phase 3 topline data reported that the trial met its primary endpoint, noted March 19, 2024.",94.0,3520.85644,57.8602,37.93,45.18,43.37,0.174912155,0.134025602,-0.023497971,0.002801122,6.08553,0.00618,139.60882,459,1,0,0,0,0,1,0,0,0,0,1,0,3,0,0,1
DTIL,PBGENE-PMM,Primary mitochondrial myopathiesÂ ,Preclinical,3/19/2024,"Preclinical data presented at Mitochondrial Medicine Therapeutic Development (MMTD) annual conference demonstrated ARCUS' ability to efficiently eliminate mutant mitochondrial DNA without nuclear off-target editing, noted March 19, 2024.Â read less",11.0,78.76747,97.4203,11.73,12.0,12.75,0.022756987,0.083381609,-0.023497971,0.002801122,0.74085,0.19921,0.64477,460,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
AXSM,Sunosi (Solriamfetol) - (PARADIGM),Major depressive disorder (MDD)Â ,Phase 3,3/19/2024,"Phase 3 initiated, noted March 19, 2024.",49.0,3641.66821,50.6771,72.54,76.87,76.72,0.05797755,0.056024297,-0.023497971,0.002801122,15.76873,0.035,94.66341,461,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CERS,INTERCEPT (ReCePI),Patients undergoing complex cardiac surgery proceduresÂ ,Phase 3,3/19/2024,"Phase 3 trial met the primary efficacy endpoint demonstrating non-inferiority of the incidence of acute kidney injury, noted March 19, 2024.",191.0,369.81676,83.9142,1.86,2.04,1.74,0.09237332,-0.066691374,-0.023497971,0.002801122,2.47988,0.3618,40.34613,462,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1
HOTH,HT-ALZ,Alzheimer's DiseaseÂ ,Preclinical,3/19/2024,"Preclinical data research presented compelling evidence of HT-ALZ's capacity to improve memory tasks related to the hippocampus and sensorimotor gating, showcasing an important step forward in Alzheim",13.0,5.86769,68.9724,1.15,1.35,1.49,0.16034265,0.259014178,-0.023497971,0.002801122,1.75675,0.03068,26.41213,463,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
JSPR,Subcutaneous briquilimab - (SPOTLIGHT),Chronic inducible urticaria (CIndU)Â ,Phase 1/2,3/19/2024,"Phase 1b/2a patient enrollment commenced, noted March 19, 2024",16.0,395.27663,99.5738,24.86,26.24,27.89,0.054024878,0.115008116,-0.023497971,0.002801122,1.91756,0.0244,2.58805,464,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
LGND,V116 - (STRIDE-6),Pneumococcal Conjugate VaccineÂ ,Phase 3,3/19/2024,"Phase 3 extensive data reaffirms confidence in the potential clinical value V116 could provide to a range of adult populations, noted March 19, 2024.",19.0,1278.49877,42.4473,72.14,72.21,68.64,0.000969865,-0.04973322,-0.023497971,0.002801122,4.30741,0.38747,7.35502,465,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
MRK,V116 - (STRIDE-6),Pneumococcal Conjugate VaccineÂ ,Phase 3,3/19/2024,"Phase 3 extensive data reaffirms confidence in the potential clinical value V116 could provide to a range of adult populations, noted March 19, 2024.",0.0,309489.0812,16.0549,121.44,122.2,125.52,0.006238733,0.033044795,-0.023497971,0.002801122,0.65563,0.00037,1429.35189,466,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CVM,CEL-4000,Rheumatoid arthritis (RA)Â ,Preclinical,3/19/2024,"Preclinical data published at the scientific journal Frontiers in Immunology showed that treatment may deliver safe and effective therapy for RA by rebalancing the inflammatory response, without weak",6.0,109.57779,114.4745,61.50615,60.90609,56.40564,-0.009804,-0.086568016,-0.023497971,0.002801122,12.92444,0.15418,0.44145,467,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
TAK,ICLUSIG (ponatinib) - (PhALLCON),Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL)Â ,Approved,3/19/2024,"FDA approved on March 19, 2024.",0.0,6868709.655,19.7231,14.56,14.41,14.39,-0.010355633,-0.011744522,-0.023497971,0.002801122,0.0,0.0,25.63821,468,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
TSHA,TSHA-102 - (REVEAL),Rett syndromeÂ ,Phase 1/2,3/19/2024,Phase 1/2 clinical data from cohort one (low dose) showed that dosing was well-tolerated with no treatment-emergent SAEs as of 35-week assessment. Data from second adult patient showed TSHA-102 (low d,272.0,420.79112,108.7634,2.13,2.25,3.06,0.054808236,0.362292936,-0.023497971,0.002801122,7.42392,0.00023,9.0731,469,0,0,0,1,0,1,0,0,0,0,0,0,2,0,0,1
AEON,ABP-450 (prabotulinumtoxinA),Chronic Migraine (prophylaxis)Â ,Phase 2,3/19/2024,"FDA and AEON align on the design and endpoints for the proposed pivotal Phase 3 trials for the preventive treatment of both episodic and chronic migraine, noted March 19, 2024.",11.0,535.09762,95.1466,1172.87991,1036.79992,821.51993,-0.123323216,-0.356061267,-0.023497971,0.002801122,0.21534,0.02224,5.11453,470,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
BMY,Opdivo (nivolumab) plus Yervoy (ipilimumab) - (CheckMate -9DW),Hepatocellular carcinoma (HCC)Â ,Phase 3,3/20/2024,"Phase 3 trial met primary endpoint, noted March 20, 2024.",0.0,105148.2421,21.9573,51.8,51.88,53.25,0.00154321,0.027607655,-0.014282179,-0.011231311,1.61083,0.05961,541.43644,471,1,0,0,0,0,1,0,0,0,0,0,0,2,0,0,1
ENTX,N-Tab (GLP-2 agonist),Short Bowel SyndromeÂ ,Preclinical,3/20/2024,"PK data reported that the trial objective were met, with oral GLP-2 tablets exhibiting significant systemic exposure, noted March 20, 2024.",45.0,53.93164,105.0588,1.4102,1.52,1.54,0.074978797,0.088050878,-0.014282179,-0.011231311,0.00372,0.01383,2.1907,472,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1
OPK,N-Tab (GLP-2 agonist),Short Bowel SyndromeÂ ,Preclinical,3/20/2024,"PK data reported that the trial objective were met, with oral GLP-2 tablets exhibiting significant systemic exposure, noted March 20, 2024.",793.0,620.32259,86.8377,0.8703,0.89,1.07,0.022383483,0.206575948,-0.014282179,-0.011231311,14.21294,0.11588,15.35336,473,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1
TFFP,TFF TAC (Tacrolimus Inhalation Powder),Lung transplant (post)Â ,Phase 2,3/20/2024,"Phase 2 data reported that eight out of eight patients have successfully transitioned from oral Tacrolimus to TFF TAC, with favorable safety results with no mortality or discontinuations due to advers",4.0,923.568,86.4614,42.65,42.65,42.55,0.0,-0.002347419,-0.014282179,-0.011231311,0.0,0.0,0.0,474,0,0,0,1,0,1,0,0,0,0,0,0,2,0,0,1
MRK,KEYTRUDA + LYNPARZA - (KEYLYNK-006),Metastatic nonsquamous non-small cell lung cancer (NSCLC)Â ,Phase 3,3/21/2024,"Phase 3 data reported that the trial did not meet its dual primary endpoints of overall survival (OS) and progression-free survival (PFS), noted March 21, 2024.",0.0,313085.4355,16.126,123.85,123.62,131.95,-0.001858812,0.063351907,0.016956744,0.002841359,0.65563,0.00037,1008.28242,475,1,0,0,0,0,1,0,0,0,0,0,0,0,2,0,-1
PHIO,INTASYL,Hematological malignanciesÂ ,Preclinical,3/21/2024,"Preclinical data presented at Immunotherapy of Cancer Conference (ITOC10) reported a consistent silencing of Cbl-b mRNA, which has been shown to limit NK cell activation, noted March 21, 2024.",5.0,2.0525,164.791,9.63,7.56,6.12,-0.242012036,-0.453321129,0.016956744,0.002841359,1.88099,0.00572,0.89428,476,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
VRTX,VX-407,"Autosomal Dominant Polycystic Kidney Disease (ADPKD), healthy volunteersÂ ",IND-Enabling,3/21/2024,"IND cleared by the FDA, noted March 21, 2024.",256.0,107381.1422,27.2335,412.11,415.71,418.01,0.008697598,0.014215052,0.016956744,0.002841359,1.56972,0.16665,372.18433,477,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
ALPN,ALPN-303 - (DENALI),Systemic lupus erythematosus (SLE)Â ,Preclinical,3/21/2024,"Preclinical data presented at SLEuro demonstrated greater reductions in disease activity in a mouse model of lupus compared to WT TACI-Ig or B cell depletion, noted March 21, 2024.",68.0,67.06623,56.5052,7.65,7.7,7.7,0.006514681,0.006514681,0.016956744,0.002841359,0.0,0.02988,0.00508,478,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
NKTX,NKX101,Acute myeloid leukemia / myelodysplastic syndromesÂ ,Phase 1,3/21/2024,"Phase 1 trial update reported that enrollment has been closed, with the aggregate CR/CRi rate (5 of 20 patients) was lower than what had been observed in the first 6 patients in the cohort, noted Marc",71.0,641.42209,174.7807,12.79,12.98,10.81,0.014746096,-0.168191984,0.016956744,0.002841359,8.58393,0.0116,8.76864,479,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ABBV,Mirvetuximab - (MIRASOL),Cancer - ovarian cancer and relapsed endometrial cancerÂ ,Approved,3/22/2024,"Approved March 22, 2024.",0.0,315971.9541,16.3268,177.5,178.45,182.1,0.005337841,0.025585378,0.026935146,0.003261616,0.80574,0.04423,728.85261,480,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1
OKYO,urcosimod (OK-101),Dry Eye Disease (DED)Â ,Phase 2,3/22/2024,"Phase 2 additional efficacy data showed a statistically significant and durable reduction in ocular pain statistically significant improvement in Tear Film Break-Up Time (TFBUT) throughout the study,",33.0,51.01734,88.3224,1.76,1.535,1.49,-0.136783428,-0.166537689,0.026935146,0.003261616,0.19447,0.0243,3.27982,481,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1
SMMT,Ivonescimab plus chemotherapy - (AK112-201),Non-small cell lung cancer (NSCLC)Â ,Phase 2,3/22/2024,Phase 2 combination data shared at the 2024 European Lung Cancer Congress (ELCC 2024) showed that patients experienced a median PFS of 11.1 months (95% CI: 9.5 â€“ 16.3 months). The frequency of treatme,744.0,2364.74033,99.5833,3.55,3.37,4.14,-0.052034859,0.153748184,0.026935146,0.003261616,2.27319,1e-05,9.48939,482,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
SMMT,ivonescimab (AK112-202),Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) and Brain MetastasesÂ ,Phase 2,3/22/2024,Phase 2 monotherapy data shared at the 2024 European Lung Cancer Congress (ELCC 2024) showed that treatment led to intracranial responses among 34% of patients with brain metastases at baseline â€“ 23%,744.0,2364.74033,99.5833,3.55,3.37,4.14,-0.052034859,0.153748184,0.026935146,0.003261616,2.27319,1e-05,9.48939,483,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ABBV,ELAHERE (mirvetuximab soravtansine-gynx),Platinum-Resistant Ovarian CancerÂ ,Approved,3/22/2024,"Full approval announced March 22, 2024.",0.0,315971.9541,16.3268,177.5,178.45,182.1,0.005337841,0.025585378,0.026935146,0.003261616,0.80574,0.04423,728.85261,484,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
IVVD,PEMGARDA (VYD222 (pemivibart)) - (CANOPY),COVID-19 PreventionÂ ,Approved,3/22/2024,"EUA approval announced March 22, 2024.",120.0,518.16999,138.3544,3.09,4.36,4.44,0.344300966,0.362483286,0.026935146,0.003261616,1.60536,0.00136,16.09801,485,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
IVVD,PEMGARDA (VYD222 (pemivibart)) - (CANOPY),COVID-19 PreventionÂ ,Phase 3,3/22/2024,"Additional Phase 3 data reported that only one patient (0.03%) was symptomatic after 90 days, noted March 22, 2024.",120.0,518.16999,138.3544,3.09,4.36,4.44,0.344300966,0.362483286,0.026935146,0.003261616,1.60536,0.00136,16.09801,486,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ESPR,NEXLETOL (bempedoic acid) - (CLEAR Outcomes),Cardiovascular DiseasesÂ ,Approved,3/22/2024,"Approved March 22, 2024.",201.0,423.77069,102.1068,2.11,2.29,2.68,0.08186387,0.239128847,0.026935146,0.003261616,9.16014,0.22077,22.16828,487,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1
TELO,Telomir-1,Age-related conditionsÂ ,Preclinical,3/22/2024,"Poster presentation delivers pre-clinical results that demonstrate that its lead development product, Telomir-1, elongates telomere caps on human normal embryonic fibroblast cells, noted March 22, 202",32.0,192.16769,0.0,6.79,6.49,5.15,-0.045188411,-0.276454227,0.026935146,0.003261616,0.01533,0.02488,0.18384,488,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
SLRX,Seclidemstat,Ewing's and other FET-rearranged sarcomasÂ ,Phase 1/2,3/22/2024,"Phase 1/2 trial enrollment resumed, noted March 22, 2024.",0.0,2.6749,68.8412,70.21208,74.39996,63.43197,0.057935028,-0.101552383,0.026935146,0.003261616,0.41744,0.00973,0.87018,489,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ZLAB,ZL-1310 (DLL3 ADC),"Solid tumors, relapsed and refractory second-line+ SCLCÂ ",Preclinical,3/22/2024,"Preclinical data presented at ELCC reported strong and specific binding to DLL3 on the cell surface, leading to internalization, cell cycle arrest and the induction of apoptosis in tumor cells, noted",109.0,1597.24952,58.7946,17.25,16.18,16.02,-0.064036232,-0.073974202,0.026935146,0.003261616,4.11671,0.10484,12.65582,490,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
AXSM,Reboxetine (AXS-12) - (SYMPHONY),NarcolepsyÂ ,Phase 3,3/25/2024,"Phase 3 trial met its primary endpoint, noted March 25, 2024.",49.0,3664.40791,50.87,80.66,77.35,76.99,-0.041902212,-0.046567246,0.00934235,-0.003094821,15.76873,0.04264,108.2002,491,1,0,0,0,0,1,0,0,0,0,0,0,2,0,0,1
AZN,ULTOMIRIS (ravulizumab-cwvz),Neuromyelitis Optica Spectrum Disorder (NMOSD)Â ,Approved,3/25/2024,"Approved March 25, 2024.",0.0,161128.3615,23.3597,104.82,103.94,106.78,-0.008430784,0.01852605,0.00934235,-0.003094821,0.0,0.22717,161.92335,492,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1
AZN,ULTOMIRIS (ravulizumab-cwvz) - (CHAMPION-NMOSD),Neuromyelitis optica spectrum disorder (NMOSD)Â ,Approved,3/25/2024,"FDA Approved on March 25, 2024.",0.0,161128.3615,23.3597,104.82,103.94,106.78,-0.008430784,0.01852605,0.00934235,-0.003094821,0.0,0.22717,161.92335,493,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
ATXS,Navenibart (STAR-0215) - (ALPHA-ORBIT),"Hereditary angioedema (HAE), healthy volunteersÂ ",Phase 1/2,3/25/2024,"Phase 1b/2 proof of concept data reported favorable safety and tolerability profile, mean monthly attack rate reduction of 90-96% for up to 6 months of follow up, noted March 25, 2024.",56.0,809.82015,78.6996,15.13,14.75,13.51,-0.025436445,-0.113249376,0.00934235,-0.003094821,3.09051,0.05098,66.50343,494,0,0,1,1,0,1,0,0,0,0,0,0,3,0,0,1
APGE,APG808,"Healthy volunteer, asthma, COPDÂ ",Phase 1,3/25/2024,"Phase 1 dosing commenced and preclinical data demonstrated the potential for improved dosing over other treatment options in development, including the potential for dosing every six- or eight- weeks",59.0,3594.07874,83.549,68.43,65.0,65.05,-0.051424055,-0.05065512,0.00934235,-0.003094821,5.66855,0.03232,46.3192,495,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
MBRX,"Annamycin (MB-106) in combination with Cytarabine - (Ara-C, MIRACLE)",Acute Myeloid Leukemia (AML)Â ,Phase 1/2,3/25/2024,"Phase 1/2 topline data reported a complete response composite (CRc) rate of 39% in all currently evaluable, intent to treat subjects (n= 18), noted March 25, 2024.",30.0,11.69446,105.8889,5.7047,5.25,5.67,-0.08306232,-0.006101279,0.00934235,-0.003094821,0.40235,0.013,4.80754,496,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
REGN,Odronextamab - (OLYMPIA),Non-Hodgkin Lymphoma (NHL)Â ,CRL,3/25/2024,CRL issued by FDA on March 25 2024.,105.0,103280.5536,16.9925,967.24,961.09,969.31,-0.006378598,0.002137823,0.00934235,-0.003094821,1.26284,0.09936,309.74777,497,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,-1
ZLAB,Odronextamab - (OLYMPIA),Non-Hodgkin Lymphoma (NHL)Â ,CRL,3/25/2024,CRL issued by FDA on March 25 2024.,109.0,1604.15975,58.7551,16.18,16.25,16.72,0.004316997,0.032829696,0.00934235,-0.003094821,4.11671,0.10484,10.30801,498,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,-1
ARWR,Plozasiran (ARO-APOC3-2001) - (SHASTA-2),HypertriglyceridemiaÂ ,Phase 2,3/25/2024,"Phase 2 expanded Access Program (EAP) initiated, noted March 25, 2024.",138.0,3455.48493,78.1288,27.21,27.89,28.24,0.024683649,0.03715486,0.00934235,-0.003094821,7.13408,0.11894,14.4307,499,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
RYTM,RM-718,Hypothalamic ObesityÂ ,Phase 1,3/25/2024,"Phase 1 trial dosing initiated, noted March 25, 2024.",66.0,2384.57063,61.6344,40.55,39.65,42.68,-0.022444832,0.051194646,0.00934235,-0.003094821,14.97223,0.16686,17.18197,500,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1
MRK,Plinabulin with Pembrolizumab plus Etoposide/Platinum (EP),1L Extensive-Stage Small-Cell Lung Cancer (ES-SCLC)Â ,Phase 2,3/25/2024,"Phase 2 investigator-initiated trial (IIT) dosing initiated, noted March 25, 2024.",0.0,317365.6036,16.1577,123.85,125.31,130.99,0.011719511,0.056049828,0.00934235,-0.003094821,0.65563,0.00099,953.07716,501,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1
BYSI,Plinabulin with Pembrolizumab plus Etoposide/Platinum (EP),1L Extensive-Stage Small-Cell Lung Cancer (ES-SCLC)Â ,Phase 2,3/25/2024,"Phase 2 investigator-initiated trial (IIT) dosing initiated, noted March 25, 2024.",40.0,135.3837,124.8625,3.12,3.47,3.6,0.106321592,0.143100844,0.00934235,-0.003094821,4.83015,0.00034,0.96628,502,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1
SYRS,Tamibarotene (SY-1425) and VIDAZA (azaciditine) - (SELECT-MDS-1),Myelodysplastic SyndromeÂ ,Phase 3,3/25/2024,"Phase 3 enrollment completed, noted March 25, 2024",26.0,166.44264,108.2511,6.27,6.4,5.04,0.020521636,-0.218370273,0.00934235,-0.003094821,5.08413,0.00744,0.99864,503,0,0,0,0,0,1,0,0,0,1,0,0,2,0,0,1
MTNB,Docetaxel,Metastatic and unresectable tumorsÂ ,Preclinical,3/25/2024,"Preclinical in vivo data reported that an oral LNC-docetaxel, at a total administered dose of more than 8x greater than IV-docetaxel, showed no evidence of weight loss, compared to an average peak wei",5.0,63.05016,267.4354,13.9,14.51,18.49,0.042949227,0.285341205,0.00934235,-0.003094821,0.67657,0.01333,0.88929,504,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
STOK,Zorevunersen (STK-001) - (EMPEROR),Dravet syndromeÂ ,Phase 1/2,3/25/2024,"Phase 1/2a end of study data of 70mg doses demonstrated substantial and sustained reductions in convulsive seizure frequency on top of the best available anti-seizure medicines, noted March 25, 2024.",54.0,300.97433,88.5564,6.3,6.5,13.49,0.031252544,0.761399037,0.00934235,-0.003094821,8.13107,0.0998,16.68324,505,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
NKGN,Troculeucel (SNK01),Alzheimer's DiseaseÂ ,Phase 1,3/25/2024,Phase 1 additional data suggested clinical activity regarding cognitive function in patients with advanced Alzheimer's disease in addition to previously disclosed positive effects on amyloid protein a,124.0,47.28019,185.5783,2.32,2.16,1.95,-0.071458964,-0.173737813,0.00934235,-0.003094821,1.53495,0.01307,3.2785,506,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
AMRX,ciprofloxacin and dexamethasone otic suspension,"Acute Otitis Externa (AOE) in pediatric (age 6 months and older), adult, and elderly patients due to staphylococcus aureus and pseudomonas aeruginosa.Â ",Approved,3/25/2024,"ANDA Approval from the FDA, noted March 25, 2024.",314.0,1823.55549,56.4704,6.07,5.91,6.05,-0.026712774,-0.003300333,0.00934235,-0.003094821,0.59166,0.02434,5.25562,507,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
REGN,Odronextamab,Relapsed/refractory (R/R) follicular lymphoma (FL) or R/R diffuse large B-cell lymphoma (DLBCL)Â ,CRL,3/25/2024,"CRL issued March 25, 2024.",105.0,103280.5536,16.9925,967.24,961.09,969.31,-0.006378598,0.002137823,0.00934235,-0.003094821,1.26284,0.09936,309.74777,508,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,-1
ZLAB,Odronextamab,Relapsed/refractory (R/R) follicular lymphoma (FL) or R/R diffuse large B-cell lymphoma (DLBCL)Â ,CRL,3/25/2024,"CRL issued March 25, 2024.",109.0,1604.15975,58.7551,16.18,16.25,16.72,0.004316997,0.032829696,0.00934235,-0.003094821,4.11671,0.10484,10.30801,509,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,-1
PRAX,PRAX-628,Photo-Paroxysmal Response (PPR)Â ,Phase 2,3/26/2024,"Phase 2 data reported a 100% complete response rate in the 45 mg cohort, and in the 15 mg cohort, 80% of patients achieved a complete response and 20% achieved a partial response, noted March 26, 2024",21.0,823.16054,107.3277,50.5,62.18,55.57,0.208060068,0.095670151,-0.023884279,0.02170797,3.09213,0.00745,51.3562,510,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1
SLS,Tambiciclib (SLS009) (GFH009) with venetoclax,"Hematologic malignancies, acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) and lymphomaÂ ",Phase 1/2,3/26/2024,"Phase 1b/2 topline data reported a 10% response rate in the 45 mg QW safety cohort , 20% response rate in the 60 mg QW cohort, and 50% response rate in the 60 mg, 2 x 30 mg BIW cohort, noted March 26,",105.0,58.45491,125.4697,1.04,1.06,1.18,0.019048195,0.126293725,-0.023884279,0.02170797,9.39311,0.08916,4.43732,511,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
VKTX,VK2735,Metabolic and endocrine disorders (GLP-1)Â ,Phase 1,3/26/2024,Phase 1 data was shown to be safe and well-tolerated in the 28-day study with low rates of GI-related adverse events. Up to 3.3% placebo-adjusted mean weight loss (5.3% from baseline) observed after 2,113.0,8839.26908,144.5414,69.19,80.83,77.35,0.15549184,0.111484234,-0.023884279,0.02170797,10.1886,0.08294,1581.46862,512,0,0,0,1,0,1,0,0,0,0,0,0,2,0,0,1
CERS,INTERCEPT,PlateletsÂ ,Approved,3/26/2024,"FDA has granted approval of 12-month shelf life for INTERCEPT Platelet Processing Sets, from the date of manufacture, effective immediately, noted March 26, 2024.",191.0,315.43194,84.7095,1.75,1.74,1.76,-0.005730675,0.005698021,-0.023884279,0.02170797,2.79544,0.35107,2.89939,513,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
LITS,Voruciclib plus Venclexta (venetoclax),B-Cell Malignancies or Acute Myeloid Leukemia (AML)Â ,Phase 1,3/26/2024,"Additional Phase 1 data observed anti-leukemic activity in multiple heavily pretreated patients in the dose escalation cohorts, including responses, anticipated decreases in myeloid leukemia cell diff",35.0,25.71863,59.6074,3.872,3.86,4.0,-0.003103986,0.032523192,-0.023884279,0.02170797,0.13652,0.03506,0.09834,514,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
STOK,Zorevunersen (STK-001),Dravet SyndromeÂ ,Phase 1/2,3/26/2024,Phase 1/2 data demonstrated durable reductions in seizures and clinically meaningful improvements in multiple measures of cognition and behavior were maintained over 12 months with continued dosing at,54.0,476.46552,109.4844,6.5,10.29,13.08,0.459370373,0.699282169,-0.023884279,0.02170797,7.67461,0.0998,200.33613,515,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ATNM,Iomab-ACT,Targeted conditioning prior to CD19 CAR T-cell therapyÂ ,Phase 1,3/26/2024,"Phase 1 trial has commenced enrollment, noted March 26, 2024.",31.0,225.44557,85.8685,8.67,8.12,8.6,-0.065538637,-0.008106588,-0.023884279,0.02170797,6.56736,0.02218,4.59985,516,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ZVRA,Serdexmethylphenidate (SDX) - (KP1077),Idiopathic hypersomnia (IH)Â ,Phase 2,3/26/2024,"Phase 2 topline data demonstrated clinically meaningful impact and encouraging outcomes on both clinical safety and efficacy, noted March 26, 2024.",56.0,237.29656,54.9098,5.64,5.72,5.115,0.01408474,-0.097706666,-0.023884279,0.02170797,5.14019,0.04863,1.07783,517,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
MRK,WINREVAIR (sotatercept-csrk),Pulmonary arterial hypertension (PAH)Â ,Approved,3/26/2024,"Approved March 26, 2024.",0.0,317897.4588,16.1371,125.31,125.52,130.35,0.001674441,0.039432473,-0.023884279,0.02170797,0.9143,0.00099,1112.65974,518,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1
ARGX,Efgartigimod - (RHO),Primary Sjogren's syndromeÂ ,Phase 2,3/27/2024,"Phase 2 trial data reported safety and tolerability profile that was consistent with other clinical trials, and a treatment effect across multiple clinical endpoints, noted March 27, 2024.",60.0,21866.12476,57.8697,366.0,368.2,366.9,0.005992935,0.002455998,-0.023457734,0.017961622,0.0,0.00092,18.54439,519,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
MRNA,mRNA-1283 - (NEXTCove),COVID-19Â ,Phase 3,3/27/2024,"Phase 3 data reported a higher immune response against both the Omicron BA.4/BA.5 and original virus strains of SARS-CoV-2 compared to mRNA-1273.222, noted March 27, 2024.",389.0,42342.65629,55.2924,107.41,110.59,101.21,0.029176381,-0.059455721,-0.023457734,0.017961622,5.80525,0.17776,505.96794,520,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
MRNA,mRNA-1283 - (NEXTCove),COVID-19Â ,Phase 3,3/27/2024,"Phase 3 data reported a higher immune response against both the Omicron BA.4/BA.5 and original virus strains of SARS-CoV-2 compared to mRNA-1273.222, noted March 27, 2024.",389.0,42342.65629,55.2924,107.41,110.59,101.21,0.029176381,-0.059455721,-0.023457734,0.017961622,5.80525,0.17776,505.96794,521,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
NVCR,Tumor Treating Fields (TTFields) - (METIS),Brain Metastases Originating from Non-Small Cell Lung CancerÂ ,Phase 3,3/27/2024,"Phase 3 final data clinical trial met its primary endpoint, demonstrating a statistically significant improvement in time to intracranial progression for adult patients treated with Tumor Treating Fie",111.0,1567.84784,70.7797,13.07,14.64,14.42,0.113437981,0.098296604,-0.023457734,0.017961622,5.17429,0.05545,174.78974,522,1,0,0,0,0,1,0,0,0,0,1,0,3,0,0,1
ZLAB,Tumor Treating Fields (TTFields) - (METIS),Brain Metastases Originating from Non-Small Cell Lung CancerÂ ,Phase 3,3/27/2024,"Phase 3 final data clinical trial met its primary endpoint, demonstrating a statistically significant improvement in time to intracranial progression for adult patients treated with Tumor Treating Fie",109.0,1598.2367,58.7915,15.95,16.19,15.9,0.014934938,-0.00313972,-0.023457734,0.017961622,3.71131,0.10484,16.79591,523,1,0,0,0,0,1,0,0,0,0,1,0,3,0,0,1
ATAI,BPL-003,Resistant DepressionÂ ,Phase 2a,3/27/2024,"Phase 2a initial results demonstrated that a single 10mg dose of BPL-003 was well-tolerated and resulted in a rapid onset and durable antidepressant effect in patients living with TRD, noted March 27,",214.0,297.15875,93.0453,1.73,1.79,2.39,0.034094211,0.323171957,-0.023457734,0.017961622,3.13558,0.17239,2.4025,524,0,0,0,1,0,1,0,0,0,0,0,0,2,0,0,1
ALT,Pemvidutide - (MOMENTUM),"Non-alcoholic steatohepatitis (NASH)/ (MASH) - Healthy, Overweight and Obese VolunteersÂ ",Phase 2,3/27/2024,"Phase 2 body composition study showed lean mass preservation, with only 25.5% of weight loss derived from lean mass, noted March 27, 2024.",88.0,630.25909,123.4174,8.65,8.89,9.29,0.027367729,0.071379232,-0.023457734,0.017961622,17.64779,0.03559,99.07734,525,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ALT,HepTCell,Hepatitis BÂ ,Phase 2,3/27/2024,"Phase 2 clinical trial evaluating the efficacy has been completed. The overall response in the trial was deemed to be insufficient to warrant further advancement. As a result, any further development",88.0,630.25909,123.4174,8.65,8.89,9.29,0.027367729,0.071379232,-0.023457734,0.017961622,17.64779,0.03559,99.07734,526,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
AVTX,AVTX-009 (anti-IL-1Î² mAb) - (LOTUS),Hidradenitis suppurativa (HS)Â ,Phase 2,3/27/2024,"Avalo acquires Phase 2-ready anti-IL-1Î² mAb, AVTX-009, through acquisition of AlmataBio, Inc, noted March 27 , 2024. Phase 2 topline results from trial planned expected in 2026.",13.0,3.8076,154.6038,4.6242,4.75,16.31,0.026841235,1.260475034,-0.023457734,0.017961622,8.38087,0.00025,14.95633,527,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
TFFP,Voriconazole Inhalation Powder - (VORI),Invasive Pulmonary Aspergillosis (IPA)Â ,Phase 2,3/27/2024,"Phase 2 data continue to demonstrate antifungal activity and a favorable safety and tolerability profile, noted March 27, 2024.",4.0,936.576,75.7081,42.55,42.55,43.2,0.0,0.01516064,-0.023457734,0.017961622,0.0,0.0,0.0,528,0,0,0,1,0,1,0,0,0,0,0,0,2,0,0,1
TFFP,TFF TAC (Tacrolimus Inhalation Powder),Lung transplant (post)Â ,Phase 2,3/27/2024,"Phase 2 8/8 patients successfully transitioned from oral tacrolimus to TFF TAC with no sign of acute rejection at reduced systemic exposures, noted March 27, 2024.",4.0,936.576,75.7081,42.55,42.55,43.2,0.0,0.01516064,-0.023457734,0.017961622,0.0,0.0,0.0,529,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
REGN,Pexa-Vec in combination with cemiplimab - (REN026),Metastatic or unresectable renal cell carcinoma (RCC).Â ,Phase 1/2,3/27/2024,"Phase 1b/2a study demonstrated an acceptable safety profile and encouraging efficacy of the combination therapy of Pexa-Vec, an engineered oncolytic vaccinia virus, and Libtayo (cemiplimab), anti-PD-1",105.0,103840.4301,16.9862,963.55,966.3,950.95,0.002849964,-0.013162896,-0.023457734,0.017961622,1.29575,0.09936,304.14776,530,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
RARE,Setrusumab (BPS-804) - (ORBIT),Osteogenesis ImperfectaÂ ,Phase 2/3,3/27/2024,Phase 3 enrollment to be completed around the end of 1Q 2024/1H 2024.,96.0,3854.95687,52.9429,45.46,46.82,47.08,0.029477644,0.035015464,-0.023457734,0.017961622,4.59209,0.12166,25.8143,531,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
MREO,Setrusumab (BPS-804) - (ORBIT),Osteogenesis ImperfectaÂ ,Phase 2/3,3/27/2024,Phase 3 enrollment to be completed around the end of 1Q 2024/1H 2024.,155.0,420.02985,72.3245,2.95,3.0,3.41,0.016807118,0.144907121,-0.023457734,0.017961622,1.56701,0.00363,1.35525,532,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
AKBA,Vafseo (vadadustat),Anemia due to Chronic Kidney Disease in Adult Patients on DialysisÂ ,Approved,3/27/2024,"Approved March 28, 2024.",265.0,468.9939,79.9819,2.0,2.24,1.49,0.113328685,-0.294371061,-0.023457734,0.017961622,4.83656,0.01774,23.70108,533,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1
RVPH,Brilaroxazine - (RECOVER),SchizophreniaÂ ,Phase 3,3/27/2024,"Phase 3 safety and efficacy shared at ASCPT reported that the 50 mg dose provided a significant decrease in primary (Total PANSS) with a discontinuation rate lower than 6%, noted March 27, 2024.",68.0,108.88238,111.4055,3.83,3.9,3.66,0.01811175,-0.045401656,-0.023457734,0.017961622,2.33054,0.02134,2.56773,534,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
MIST,CARDAMYST (etripamil) - (RAPID),Paroxysmal supraventricular tachycardia (PSVT)Â ,NDA Filing,3/28/2024,"NDA resubmitted to FDA, noted March 28, 2024.",84.0,106.91139,102.1289,1.8,1.79,1.75,-0.005571045,-0.028170877,0.000210748,0.058802187,0.80387,0.02918,0.81365,535,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
IRWD,Apraglutide - (STARGAZE),Acute Graft-Versus-Host DiseaseÂ ,Phase 2,3/28/2024,"Phase 2 initial data reported that treatment was well-tolerated with an acceptable safety profile, noted March 28, 2024.",162.0,1363.36452,78.6411,8.62,8.71,8.15,0.010386706,-0.056067157,0.000210748,0.058802187,11.99453,0.00536,23.51162,536,0,0,0,1,0,1,0,0,0,0,0,0,2,0,0,1
LPCN,LPCN 1148,"Liver cirrhosis, specifically prevention of OHE recurrence and treatment of sarcopeniaÂ ",Phase 2,3/28/2024,"Phase 2 data reported that that participants who received LPCN 1148 during Stage 1 had a significant increase in L3-SMI of 4.1 cm2/m2 (8.8%) at Week 24, noted March 28, 2024.",5.0,27.64232,72.2802,5.1288,5.2,4.61,0.013786912,-0.106643857,0.000210748,0.058802187,2.32541,0.07874,0.25498,537,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
GILD,Efarindodekin Alfa (XTX301),Solid tumorsÂ ,Phase 1,3/28/2024,"Xilio granted Gilead an exclusive global license to develop and commercialize XTX301, Xilio's tumor-activated IL-12, noted March 28, 2024.",0.0,91201.90629,25.0263,73.01,73.25,69.55,0.00328183,-0.0485505,0.000210748,0.058802187,1.54592,0.06238,613.08075,538,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
XLO,Efarindodekin Alfa (XTX301),Solid tumorsÂ ,Phase 1,3/28/2024,"Xilio granted Gilead an exclusive global license to develop and commercialize XTX301, Xilio's tumor-activated IL-12, noted March 28, 2024.",51.0,37.21725,127.9774,0.639,1.08,1.21,0.524811866,0.638471184,0.000210748,0.058802187,0.16723,0.00526,37.30241,539,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
SNDX,Revuforj (revumenib) - (AUGMENT-101),Relapsed/refractory (R/R) acute leukemiasÂ ,Phase 2,3/28/2024,"Phase 2 enrollment completed, noted March 28, 2024.",86.0,2022.17857,54.32,23.07,23.8,22.62,0.031152508,-0.019698601,0.000210748,0.058802187,9.80319,0.23862,25.1893,540,0,0,0,0,0,1,0,0,0,1,0,0,2,0,0,1
OCEA,VRON-0200,Hepatitis BÂ ,Phase 1b,3/28/2024,"Phase 1b preliminary data reported that VRON-0200 was safe and well tolerated, with no clinical or laboratory changes of concern, noted March 28, 2024.",232.0,129.02006,225.2459,4.06,3.785,2.69,-0.070137087,-0.41164178,0.000210748,0.058802187,2.56212,4e-05,2.58502,541,0,0,0,1,0,1,0,0,0,0,0,0,2,0,0,1
PPBT,NT219 in combination with cetuximab,Recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN)Â ,Phase 1/2,3/28/2024,"Phase 1/2 found to suppress cancer stem cells that promote drug resistance to KRASG12C and KRASG12D inhibitors and solid tumor recurrence, noted March 28, 2024.",2.0,65.33385,83.862,0.243,0.246,0.251,0.012270093,0.032391496,0.000210748,0.058802187,0.0,0.05014,0.05256,542,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
GRTX,Rucosopasem (GC4711) - (GRECO-1),Non-Small Cell Lung Cancer (NSCLC)Â ,Phase 1/2,3/28/2024,"Trial discontinued, noted March 28, 2024.",75.0,7.6149,170.51,0.1535,0.14,0.162,-0.092058144,0.053895768,0.000210748,0.058802187,5.15214,0.00261,0.60394,543,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
GRTX,Rucosopasem (GC4711) - (GRECO-2),Pancreatic CancerÂ ,Phase 2b,3/28/2024,"Trial discontinued, noted March 28, 2024.",75.0,7.6149,170.51,0.1535,0.14,0.162,-0.092058144,0.053895768,0.000210748,0.058802187,5.15214,0.00261,0.60394,544,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
APLT,Govorestat (AT-007) - (ACTION-Galactosemia kids),GalactosemiaÂ ,PDUFA priority review,3/28/2024,"PDUFA PR date of August 28, 2024. The FDA has set a new PDUFA target action date of November 28, 2024.",144.0,720.03045,137.4531,6.85,6.8,5.92,-0.00732604,-0.145912203,0.000210748,0.058802187,3.58148,0.02576,10.61324,545,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
NBIX,NBI-1065890,CNS IndicationsÂ ,Phase 1,3/28/2024,"Phase 1 initiated, noted March 28, 2024.",99.0,13724.07302,25.9576,137.83,137.92,137.61,0.000652765,-0.001597444,0.000210748,0.058802187,2.49601,0.10011,171.80198,546,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CADL,CAN-3110,GliomaÂ ,Phase 1b,3/28/2024,"Phase 1b showed that serial procedures were well tolerated without observed dose-limiting toxicity in first cohort, noted March 28, 2024.",54.0,46.369,109.5176,1.54,1.58,6.4,0.025642431,1.424515574,0.000210748,0.058802187,0.50183,0.00256,0.04838,547,0,0,0,1,0,1,0,0,0,0,0,0,2,0,0,1
BMY,KRAZATI (adagrasib) and Taxotere (Docetaxel) - (KRYSTAL-12),Non-small cell lung cancer (NSCLC)Â ,Phase 3,3/28/2024,"Phase 3 trial met its primary endpoints, noted March 28, 2024.",0.0,109911.1251,22.1533,53.25,54.23,51.4,0.018236456,-0.035359632,0.000210748,0.058802187,1.83812,0.05421,778.10267,548,1,0,0,0,0,1,0,0,0,0,0,0,2,0,0,1
CNTX,CTIM-76,Various cancersÂ ,IND-Enabling,3/28/2024,"IND submitted on March 28, 2024.",89.0,22.03315,91.5653,1.382,1.38,1.28,-0.001448226,-0.076671647,0.000210748,0.058802187,0.10649,0.03993,0.07734,549,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
EQ,Itolizumab (EQ001) - (EQUALISE),Systemic lupus erythematosus (SLE) and lupus nephritis (LN)Â ,Phase 1b,4/1/2024,"Phase 1b topline data continues to show clinically meaningful response in highly proteinuric subjects. More than 80% of subjects achieved >50% reduction in urine protein creatinine ratio (UPCR), noted",59.0,74.38753,126.3377,2.31,2.11,1.92,-0.090559577,-0.184922338,0.0453815,0.048474059,1.15985,0.0,0.85247,550,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1
NVCR,Tumor Treating Fields (TTFields) with pembrolizumab and temozolomide - (TIGER),Glioblastoma (GBM)Â ,Phase 2,4/1/2024,"Phase 2 long-term data presented at ASCO reported that the median OS and PFS were 19.6 months (95% CI, 17.9â€“22.4) and 10.2 months, noted April 1, 2024.",111.0,1658.87726,71.3457,15.63,15.49,14.18,-0.00899749,-0.097359623,0.0453815,0.048474059,5.17429,0.04326,25.92805,551,1,0,0,0,0,1,0,0,0,0,1,0,3,0,0,1
LQDA,YUTREPIA,Interstitial lung disease (PH-ILD)Â ,PDUFA,4/1/2024,"A District Court set aside the injunction and the FDA is no longer enjoined from issuing final approval of Liquidia's New Drug Application (NDA) for YUTREPIA (treprostinil) inhalation powder, noted Ap",86.0,1134.33442,64.3697,14.75,14.92,15.13,0.011459512,0.025436445,0.0453815,0.048474059,9.54316,0.0076,19.1627,552,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
AZN,VOYDEYA (danicopan) add-on to SoC with ULTOMIRIS (ravulizumab-cwvz) or SOLIRIS (eculizumab)- (ALPHA),Paroxysmal nocturnal hemoglobinuria (PNH) and atypical Hemolytic Uremic Syndrome (aHUS)Â ,Approved,4/1/2024,"FDA Approved on April 1, 2024.",0.0,165530.9452,23.6886,106.78,106.78,106.1,0.0,-0.006388597,0.0453815,0.048474059,0.0,0.21885,0.0,553,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
AXSM,Sunosi (Solriamfetol) - (ENGAGE),Binge eating disorderÂ ,Phase 3,4/1/2024,"Phase 3 initiated, noted April 1, 2024.",49.0,3647.35313,50.6075,79.8,76.99,72.11,-0.035847961,-0.101330774,0.0453815,0.048474059,15.40452,0.0485,45.12476,554,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
VRTX,inaxaplin (VX-147) - (AMPLITUDE),Proteinuric kidney disease with two mutations in the APOL1 gene (AMKD)Â ,Phase 2/3,4/1/2024,Phase 2/3 trial part 3 dosing initiated with expanded access to include adolescents with AMKD ages 10 to 17 years. An Independent Data Monitoring Committee (IDMC) reviewed Phase 2 safety and efficacy,256.0,108613.2705,27.1608,418.01,420.48,404.22,0.00589156,-0.033546071,0.0453815,0.048474059,1.597,0.17971,322.82436,555,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1
IRON,Bitopertin - (APOLLO),Erythropoietic Protoporphyria (EPP)Â ,Phase 2,4/1/2024,"Phase 2 study met its primary endpoint. Despite improved measures of light tolerance, including the key secondary endpoint, in both 20 mg and 60 mg dose groups, but it did not meet statistical signifi",34.0,844.33797,99.9469,62.26,34.21,31.78,-0.598801166,-0.672482004,0.0453815,0.048474059,5.12306,0.03585,212.75938,556,1,0,0,0,0,1,0,0,1,0,0,0,2,2,0,1
VTGN,PH94B - (PALISADE-3),Social Anxiety Disorder (SAD)Â ,Phase 3,4/1/2024,"PALISADE-3 initiated, noted April 1, 2024.",30.0,145.93613,84.1482,5.28,5.4,5.17,0.022472856,-0.021053409,0.0453815,0.048474059,4.9388,0.00107,5.08424,557,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
SRZN,SZN-043,Severe alcohol associated hepatitisÂ ,Phase 1a,4/1/2024,"Phase 1a demonstrated acceptable safety and tolerability with no reported serious adverse events, noted April 1, 2024.",8.0,20.5872,109.3215,15.71,10.1,11.2299,-0.441762028,-0.335717588,0.0453815,0.048474059,0.16415,0.0098,2.24533,558,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,-1
ATNM,Iomab-B - (SIERRA),Acute myeloid leukemia (AML)Â ,Phase 3,4/1/2024,"Phase 3 results demonstrated Iomab-B's ability to overcome the negative impact of a TP53 mutation in patients who otherwise would have limited treatment options and dismal prognosis, noted April 1, 20",31.0,251.63328,86.55,7.83,8.56,9.13,0.08913768,0.153603185,0.0453815,0.048474059,6.20272,0.02186,5.37038,559,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CORT,Relacorilant - (GRADIENT),Cushingâ€™s syndromeÂ ,Phase 3,4/1/2024,"Phase 3 enrollment completed, noted April 1, 2024.",105.0,2664.53757,62.3111,25.19,25.74,24.23,0.021599112,-0.038855556,0.0453815,0.048474059,19.52845,0.01082,21.57125,560,0,0,0,0,0,1,0,0,0,1,0,0,2,0,0,1
BMEA,Icovamenib (BMF-219) - (COVALENT-112),Type 1 diabetes (T1D)Â ,Phase 2,4/2/2024,"Phase 2 was initiated, noted January 8, 2024. Phase 2 data reported that in patient one, fasting C-peptide increased by 80% compared to baseline. In patient two, fasting C-peptide increased by 16% com",59.0,459.38381,112.5755,15.3,12.8,12.8,-0.178407657,-0.178407657,0.030398793,0.023829905,31.22022,0.00012,36.00533,561,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
LLY,VERVE-101 - (Heart-1),Heterozygous familial hypercholesterolemia (HeFH)Â ,Phase 1b,4/2/2024,Phase 1b clinical trial demonstrated LDL-C reduction of up to 73% at 0.45 mg/kg. Company to pause enrollment in Heart-1 clinical trial following asymptomatic Grade 3 transient ALT elevation and thromb,946.0,688149.2698,28.6376,760.55,763.96,757.24,0.004473576,-0.004361612,0.030398793,0.023829905,0.61466,0.00391,1983.84292,562,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
VTGN,PH94B - (PALISADE-3),Social Anxiety Disorder (SAD)Â ,Phase 3,4/1/2024,"PALISADE-3 initiated, noted April 1, 2024.",30.0,145.93613,84.1482,5.28,5.4,5.17,0.022472856,-0.021053409,0.0453815,0.048474059,4.9388,0.00107,5.08424,563,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
SRZN,SZN-043,Severe alcohol associated hepatitisÂ ,Phase 1a,4/1/2024,"Phase 1a demonstrated acceptable safety and tolerability with no reported serious adverse events, noted April 1, 2024.",8.0,20.5872,109.3215,15.71,10.1,11.2299,-0.441762028,-0.335717588,0.0453815,0.048474059,0.16415,0.0098,2.24533,564,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,-1
ATNM,Iomab-B - (SIERRA),Acute myeloid leukemia (AML)Â ,Phase 3,4/1/2024,"Phase 3 results demonstrated Iomab-B's ability to overcome the negative impact of a TP53 mutation in patients who otherwise would have limited treatment options and dismal prognosis, noted April 1, 20",31.0,251.63328,86.55,7.83,8.56,9.13,0.08913768,0.153603185,0.0453815,0.048474059,6.20272,0.02186,5.37038,565,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CORT,Relacorilant - (GRADIENT),Cushingâ€™s syndromeÂ ,Phase 3,4/1/2024,"Phase 3 enrollment completed, noted April 1, 2024.",105.0,2664.53757,62.3111,25.19,25.74,24.23,0.021599112,-0.038855556,0.0453815,0.048474059,19.52845,0.01082,21.57125,566,0,0,0,0,0,1,0,0,0,1,0,0,2,0,0,1
BMEA,Icovamenib (BMF-219) - (COVALENT-112),Type 1 diabetes (T1D)Â ,Phase 2,4/2/2024,"Phase 2 was initiated, noted January 8, 2024. Phase 2 data reported that in patient one, fasting C-peptide increased by 80% compared to baseline. In patient two, fasting C-peptide increased by 16% com",59.0,459.38381,112.5755,15.3,12.8,12.8,-0.178407657,-0.178407657,0.030398793,0.023829905,31.22022,0.00012,36.00533,567,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
LLY,VERVE-101 - (Heart-1),Heterozygous familial hypercholesterolemia (HeFH)Â ,Phase 1b,4/2/2024,Phase 1b clinical trial demonstrated LDL-C reduction of up to 73% at 0.45 mg/kg. Company to pause enrollment in Heart-1 clinical trial following asymptomatic Grade 3 transient ALT elevation and thromb,946.0,688149.2698,28.6376,760.55,763.96,757.24,0.004473576,-0.004361612,0.030398793,0.023829905,0.61466,0.00391,1983.84292,568,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ROIV,Brepocitinib - (NEPTUNE),Non-infectious uveitis (NIU)Â ,Phase 2,4/2/2024,"Phase 2 topline data showed the strongest efficacy data in NIU observed to date. The Treatment Failure rate from disease activity (discontinuations censored) was 18% in the brepocitinib 45 mg arm, n",682.0,8799.83839,43.3311,10.43,10.92,11.41,0.045909701,0.089803895,0.030398793,0.023829905,3.91776,0.07353,222.14696,569,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
GNPX,Oncoprex,Anti-PD1 resistant non-small cell lung cancer (NSCLC)Â ,Preclinical,4/2/2024,"Preclinical data from mouse model reported that NPRL2 treatment reduced lung metastases significantly, whereas pembrolizumab was ineffective. The antitumor effect was greater in humanized than non-hum",0.0,5.42554,125.076,148.5,142.0,153.5,-0.044757901,0.033115609,0.030398793,0.023829905,4.20195,0.16994,0.16032,570,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
KNSA,Abiprubart (KPL-404),Rheumatoid arthritisÂ ,Phase 2,4/2/2024,"Phase 2 cohort 4 data reported a a statistically significant reduction of approximately 40% in Rheumatoid Factor in the abiprubart group, noted April 2, 2024.",74.0,1322.61936,45.0308,19.7,18.73,17.73,-0.050492119,-0.105360516,0.030398793,0.023829905,4.06071,0.03907,7.97321,571,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1
CRBP,CRB-701 (SYS6002) with Pembrolizumab,"Solid tumors, Locally advanced or metastatic urothelial carcinomaÂ ",Phase 1,4/2/2024,"Phase 1 US dosing initiated, noted April 2, 2024.",12.0,393.6011,225.823,37.99,37.46,37.47,-0.01404927,-0.013782354,0.030398793,0.023829905,3.84296,0.0012,10.14754,572,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1
SGHT,TearCare - (SAHARA RCT),Dry Eye DiseaseÂ ,Phase 1,4/2/2024,"Phase 1 clinical results demonstrate long-term efficacy of the OMNI Surgical System for primary open-angle glaucoma and support use of TearCare technology as a primary treatment for dry eye disease, n",52.0,269.57034,183.0342,5.31,5.44,6.07,0.024187226,0.13376677,0.030398793,0.023829905,3.28276,0.13531,4.36926,573,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
VNDA,FANAPT (iloperidone),Bipolar DisorderÂ ,Approved,4/2/2024,"Approved April 2, 2024.",59.0,224.97162,60.1671,4.12,3.91,4.36,-0.052315789,0.056618894,0.030398793,0.023829905,5.2157,0.00824,8.30067,574,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1
FGEN,FG-3246 (FOR46) in combination with enzalutamide - (Investigator-sponsored trial),Metastatic castration-resistant prostate cancer (mCRPC)Â ,Phase 1,4/3/2024,"Phase 1 topline data reported a PSA50 response in 36% of patients, a confirmed radiographic objective response rate of 20%, with a median duration of response of 7.5 months, noted April 3, 2024.",4.0,145.1937,171.7006,54.0,36.75,35.75,-0.384845821,-0.412433777,0.013209938,0.008082865,5.59708,0.03677,15.2019,575,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
LENZ,VIZZ (aceclidine ophthalmic solution),PresbyopiaÂ ,Phase 3,4/3/2024,Phase 3 primary endpoint was met with 71% of participants dosed with LNZ100 achieving three-lines or greater improvement at 3 hours. Rapid onset and long duration shown with 71% of participants achiev,28.0,541.82157,0.0,21.01,21.22,21.03,0.009945618,0.000951475,0.013209938,0.008082865,0.49117,0.0,8.29278,576,1,0,0,0,0,1,0,0,0,0,0,0,2,0,0,1
MRK,"Raludotatug deruxtecan (DS-6000, R-DXd) - (REJOICE-Ovarian01)",Ovarian cancerÂ ,Phase 2/3,4/3/2024,"Phase 2/3 trial portion 2 initiated, noted April 3, 2024.",0.0,328990.439,17.2012,130.35,129.9,126.75,-0.003458217,-0.028006498,0.013209938,0.008082865,0.9143,0.00011,1005.61241,577,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
PRFX,PRF-110,BunionectomyÂ ,Phase 3,4/3/2024,"Phase 3 enrollment target reached 50%, noted April 2, 2024.",1.0,3.05915,86.9105,41.51999,42.47999,35.03999,0.022858144,-0.169685017,0.013209938,0.008082865,0.80285,0.09197,0.01342,578,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
NBTX,NBTXR3 - (MD Anderson Study 2020-0123),Non-small cell lung cancer (NSCLC)Â ,Phase 1,4/3/2024,"Phase 1 dose escalation study completed, noted April 2, 2024.",47.0,274.18724,80.3013,6.1,6.13,6.4,0.004905979,0.048009219,0.013209938,0.008082865,0.0,0.0,1.38696,579,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
SPRY,Neffy (epinephrine nasal spray),Allergic reactions (type I) including anaphylaxisÂ ,CRL,4/3/2024,The Company submitted its response to the U.S. Food and Drug Administration (FDA) for its New Drug Application (NDA) for neffyÂ® (epinephrine nasal spray) for the treatment of Type I allergic reactions,98.0,907.11461,55.1106,9.28,9.4,9.27,0.012848142,-0.001078167,0.013209938,0.008082865,4.40902,0.14079,5.18818,580,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
MRNA,mRNA-3927 (Paramount),Propionic AcidemiaÂ ,Phase 1/2,4/3/2024,"Phase 1/2 has been well tolerated in participants at the doses administered, with no dose-limiting toxicities observed. Fifteen participants reported treatment-emergent adverse events (TEAEs), while n",389.0,38751.24553,55.566,103.61,101.21,107.14,-0.023436284,0.03350254,0.013209938,0.008082865,5.80525,0.17896,523.03456,581,0,0,0,1,0,1,0,0,0,0,0,0,2,0,0,1
MGNX,MGC018 - (TAMARACK),Metastatic castration-resistant prostate cancer (mCRPC)Â ,Phase 2,4/3/2024,"Phase 2 preliminary safety data suggested that reducing the dose and frequency of cobra duo improves its safety and tolerability in men with mCRPC, noted April 3, 2024.",63.0,853.44562,68.8997,13.31,13.67,18.25,0.026688018,0.315649448,0.013209938,0.008082865,8.97386,0.04891,23.93714,582,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CVAC,Flu-SV-mRNA,Multivalent seasonal flu vaccineÂ ,Phase 2,4/4/2024,"Phase 2 interim data reported that the vaccine boosted antibody titers against all encoded flu strains and across all age groups and tested dose levels, including the lowest tested dose, noted April 4",224.0,662.81418,66.4663,2.91,2.96,2.96,0.017036187,0.017036187,0.009491297,-0.002632735,2.16817,0.0015,12.33373,583,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
GSK,Flu-SV-mRNA,Multivalent seasonal flu vaccineÂ ,Phase 2,4/4/2024,"Phase 2 interim data reported that the vaccine boosted antibody titers against all encoded flu strains and across all age groups and tested dose levels, including the lowest tested dose, noted April 4",0.0,66909.27752,17.9443,16.54,16.375,16.29,-0.010025908,-0.015230267,0.009491297,-0.002632735,0.0,0.00021,192.74587,584,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ADCT,ZYNLONTA (Loncastuximab Tesirine-Ipyl) - (LOTIS-7),B-cell non-Hodgkin lymphomaÂ ,Phase 1b,4/4/2024,"Phase 1b dose escalation trial completed with no dose-limiting toxicities, no or low-grade cytokine release syndrome and no immune effector cell-associated neurotoxicity syndrome across all patients a",112.0,388.71418,139.4517,4.43,4.71,4.68,0.061288324,0.054898526,0.009491297,-0.002632735,1.13868,0.03439,5.7379,585,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
AMLX,RELYVRIO (sodium phenylbutyrate and taurursodiol),Amyotrophic lateral sclerosis (ALS)Â ,Phase 3,4/4/2024,Company has started a process with the FDA and Health Canada to voluntarily discontinue the marketing authorizations for RELYVRIO/ALBRIOZA (sodium phenylbutyrate and taurursodiol [also known as ursodo,89.0,176.91138,258.4008,2.63,2.61,2.29,-0.007633625,-0.138432029,0.009491297,-0.002632735,7.51218,0.02751,7.38386,586,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
AMLX,AMX0035 - (A35-004 PHOENIX),Amyotrophic Lateral Sclerosis (AML)Â ,Phase 3,4/4/2024,"Based on Phase 3 previous results, the company has started a process with the FDA and Health Canada to voluntarily discontinue the marketing authorizations for RELYVRIO/ALBRIOZA (sodium phenylbutyrate",89.0,176.91138,258.4008,2.63,2.61,2.29,-0.007633625,-0.138432029,0.009491297,-0.002632735,7.51218,0.02751,7.38386,587,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CADL,CAN-2409 plus valacyclovir (prodrug),"Non-Metastatic Pancreatic Cancer, Pancreatic ductal adenocarcinoma (PDAC)Â ",Phase 2,4/4/2024,"Phase 2 interim data reported that at 24 months, survival rate was 71.4% in CAN-2409 treated patients versus only 16.7% in the control group after chemoradiation, noted April 4, 2024.",54.0,187.8238,217.62,1.68,6.4,7.28,1.337504197,1.466337069,0.009491297,-0.002632735,0.50183,0.00059,921.15513,588,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
EFTR,Tomivosertib (MNK1/2) - (KICKSTART),Non-small cell lung cancer (NSCLC)Â ,Phase 2b,4/4/2024,"Phase 2b study did not meet the pre-specified threshold of pâ‰¤0.2. The median PFS was 13.0 weeks in the tomivosertib plus pembrolizumab arm and 11.7 weeks in the placebo plus pembrolizumab arm, respect",4.0,10.91444,265.1333,16.47,2.96,2.235,-1.716351276,-1.997299316,0.009491297,-0.002632735,8.62597,0.0076,25.87623,589,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,-1
GOVX,GEO-CM04S1- (COH04S1),COVID-19 in immunocompromised patientsÂ ,Preclinical,4/4/2024,"Preclinical data presented at the Annual World Vaccine showed that vaccine-induced immunity protects against infections, serious disease symptoms, and death against the original Wuhan variant as well",25.0,4.36627,69.9417,1.94,2.01,1.83,0.035446749,-0.058372006,0.009491297,-0.002632735,0.76238,0.01345,0.17064,590,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
DTIL,ECUR-506 - (OTC-HOPE),Ornithine Transcarbamylase (OTC) DeficiencyÂ ,IND-Enabling,4/4/2024,"IND Cleared by the FDA, noted April 4, 2024.",11.0,99.17887,100.1952,15.44,14.34,14.45,-0.073908709,-0.06626713,0.009491297,-0.002632735,2.57417,0.20879,2.00952,591,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
CRBU,CB-010 - (GALLOP),"Lupus nephritis (LN), extrarenal lupus (ERL)Â ",IND-Enabling,4/4/2024,"IND Clearance by FDA, noted April 4, 2024. Phase 1 trial planned by year end 2024.",93.0,410.02784,92.1156,4.68,4.54,4.33,-0.030371098,-0.077730568,0.009491297,-0.002632735,11.15339,0.0415,8.62016,592,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
HCM,HMPL-295,Solid tumorsÂ ,Preclinical,4/5/2024,Preclinical data from AACR reported that HMPL-295 significantly improved the anti-tumor activity of standard-of-care chemotherapy as well as targeted agents in KRAS- or BRAF-mutant tumor models both,174.0,2227.40082,59.6042,2.67,2.61,2.9,-0.022728251,0.082632265,-0.01011738,0.015086978,0.0,0.08476,0.05729,593,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
HCM,HMPL-506,LeukemiaÂ ,Preclinical,4/5/2024,Preclinical data from AACR reported that in In vivo studies demonstrated the dose- and exposure- dependent target regulation of MEIS1 and anti-tumor efficacy following HMPL-506 treatment in multiple t,174.0,2227.40082,59.6042,2.67,2.61,2.9,-0.022728251,0.082632265,-0.01011738,0.015086978,0.0,0.08476,0.05729,594,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
HCM,HMPL-A067 (HMA800067),B-cell malignanciesÂ ,Preclinical,4/5/2024,"Preclinical data reported that an intravenous injection of HMA800067 at 10 mg/kg single dose induced complete tumor regression in all the animals within 10 days of administration, noted April 5, 2024.",174.0,2227.40082,59.6042,2.67,2.61,2.9,-0.022728251,0.082632265,-0.01011738,0.015086978,0.0,0.08476,0.05729,595,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
AZN,IMFINZI (Durvalumab) - (ADRIATIC),Small cell lung cancer (SCLC) limited diseaseÂ ,Phase 3,4/5/2024,"Phase 3 trial met the the dual primary endpoints of overall survival (OS) and progression-free survival (PFS), noted April 5, 2024.",0.0,164633.5008,23.8531,107.36,106.2,110.64,-0.010863564,0.030094014,-0.01011738,0.015086978,0.0,0.22766,277.1461,596,1,0,0,0,0,1,0,0,0,0,0,0,2,0,0,1
CYTK,Aficamten - (FOREST-HCM) (OLE),Non-obstructive hypertrophic cardiomyopathy (HCM)Â ,Phase 3,4/5/2024,Phase 3 first cohort efficacy and safety datacompleting 1-year follow-up data from ACC.24 reported that treatment with aficamten for 48 weeks resulted in substantial and sustained reductions in averag,119.0,7489.47246,109.8718,69.18,72.71,71.56,0.049767123,0.033824455,-0.01011738,0.015086978,14.36557,0.00454,73.23969,597,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
OCGN,OCU410 - (ArMaDa),Geographic Atrophy (GA)Â ,Phase 1/2,4/5/2024,"Phase 1/2 Data and Safety Monitoring Board (DSMB) convened and approved to proceed dosing with the medium dose of OCU410 in the dose-escalation phase of the study, noted April 5, 2024.",292.0,469.39945,103.0871,1.51,1.83,1.71,0.192206316,0.12438372,-0.01011738,0.015086978,13.79975,0.00937,38.06601,598,0,0,0,1,0,1,0,0,0,0,0,0,2,0,0,1
TARA,TARA-002 - (ADVANCED-1),Non-muscle invasive bladder cancer (NMIBC)Â ,Phase 1b,4/5/2024,"Phase 1b data reported a complete response rate of 43% at three months, noted April 5, 2024.",38.0,41.50483,92.9852,4.02,3.63,3.0,-0.102049254,-0.292669614,-0.01011738,0.015086978,0.53737,0.09455,31.16703,599,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
BMY,Abecma (idecabtagene vicleucel; ide-cel),Multiple MyelomaÂ ,Approved,4/5/2024,"Approved April 5, 2024.",0.0,104013.2573,22.4379,51.4,51.32,48.28,-0.001557633,-0.062620776,-0.01011738,0.015086978,1.83812,0.05109,466.78342,600,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1
CDTX,CCR5-001,Colorectal cancerÂ ,Preclinical,4/5/2024,"Preclinical data shared at the AACR conference demonstrated potent efficacy in colorectal cancer mouse model, noted April 5 2024.",25.0,105.11809,58.148,21.6,23.2,16.2,0.071458964,-0.287682072,-0.01011738,0.015086978,0.19804,0.002,2.65867,601,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CDTX,CBO421,Tumor immune evasion preventionÂ ,Preclinical,4/5/2024,"Preclinical data shared at AACR data demonstrated improved efficacy compared to oleclumab in human triple-negative breast cancer cell lines, noted April 5, 2024.",25.0,105.11809,58.148,21.6,23.2,16.2,0.071458964,-0.287682072,-0.01011738,0.015086978,0.19804,0.002,2.65867,602,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
HOWL,WTX-518,Solid tumorsÂ ,Preclinical,4/5/2024,"Preclinical data presented at AACR reported complete tumor regression in the MC38 mouse tumor model, noted April 5, 2024.",45.0,253.00417,119.2685,6.0,5.92,4.69,-0.01342302,-0.246326887,-0.01011738,0.015086978,1.01075,0.01455,0.54923,603,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1
HOWL,WTX-712,Solid tumorsÂ ,Preclinical,4/5/2024,"Preclinical data presented at AACR reported that treatment demonstrated inducibility and antitumor activity with regressions in the MC38 mouse tumor model, noted April 5, 2024.",45.0,253.00417,119.2685,6.0,5.92,4.69,-0.01342302,-0.246326887,-0.01011738,0.015086978,1.01075,0.01455,0.54923,604,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1
JNJ,CARVYKTI (ciltacabtagene autoleucel) - (CARTITUDE-4),Multiple MyelomaÂ ,Approved,4/5/2024,"FDA Approval on April 5, 2024.",0.0,367226.8396,13.4207,152.5,152.39,147.52,-0.000721572,-0.033200836,-0.01011738,0.015086978,0.65728,0.1388,1033.66442,605,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
LEGN,CARVYKTI (ciltacabtagene autoleucel) - (CARTITUDE-4),Multiple MyelomaÂ ,Approved,4/5/2024,"FDA Approval on April 5, 2024.",183.0,9992.3731,38.4153,55.14,54.93,52.92,-0.003815758,-0.041094066,-0.01011738,0.015086978,5.77745,0.03369,35.47055,606,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
AZN,Trastuzumab deruxtecan - (DESTINY-CRC02),HER2-overexpressing/amplified (HER2+) metastatic colorectal cancer (mCRC)Â ,Phase 2,4/5/2024,"Phase 2 data showed a confirmed ORR of 51.4% and a median DoR range of 19.4 months, noted April 5, 2024.",0.0,164633.5008,23.8531,107.36,106.2,110.64,-0.010863564,0.030094014,-0.01011738,0.015086978,0.0,0.22766,277.1461,607,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
AMRN,VASCEPA (icosapent ethyl) - (REDUCE-IT),Cardiovascular diseaseÂ ,Phase 1,4/6/2024,Phase 1 data presented at the American College of Cardiology's Annual Scientific Session & Expo show that findings presented on VASCEPA/VAZKEPA utility in REDUCE-IT patient subgroups by baseline High/,20.0,431.20539,88.2212,21.0,21.0,19.14,0.0,-0.092742052,-0.002436594,0.022767764,4.42949,0.08408,0.0,608,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
XLO,XTX501,Solid TumorsÂ ,Preclinical,4/7/2024,"Preclinical data shared at AACR reported superior PK profile compared to non-masked PD1/IL2 in mice, akin to PD1 antibodies, projected to achieve >95% PD-1 RO with once every 3 weeks (Q3W) dosing, no",51.0,41.36144,138.8019,1.2,1.2,1.18,0.0,-0.016807118,-0.002436594,0.022767764,0.16719,0.00871,0.0,609,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
REPL,RP1 (vusolimogene oderparepvec) - (ARTACUS),Liver and kidney transplant recipients with recurrent Cutaneous squamous cell carcinomaÂ ,Phase 1/2,4/7/2024,"Phase 1/2 open-label data presented at AACR reported an overall response rate (ORR) of 34.8 percent (8 of 23 evaluable patients, including 5 complete responses and 3 partial responses) with most respo",78.0,451.81411,109.2251,7.36,7.36,7.14,0.0,-0.030347156,-0.002436594,0.022767764,11.27959,0.02094,0.0,610,1,0,0,0,0,1,0,0,0,0,1,0,3,0,0,1
ALNY,Zilebesiran - (KARDIA-2),HypertensionÂ ,Phase 2,4/7/2024,"Phase 2 full data shared at the American College of Cardiology Scientific Sessions reported that zilebesiran demonstrated clinically significant and sustained placebo-adjusted, time-adjusted reduction",131.0,19417.98432,35.2499,153.56,153.56,148.5,0.0,-0.033506412,-0.002436594,0.022767764,2.12491,0.22756,0.0,611,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ARWR,Plozasiran (ARO-APOC3-2001) - (SHASTA-2),HypertriglyceridemiaÂ ,Phase 2,4/7/2024,"Phase 2 clinical data presented at ACC.24 reported a dose-dependent placebo-adjusted reductions in triglycerides, with Significant and durable triglyceride and APOC3 reductions to week 48, noted April",138.0,3194.06244,77.5738,25.78,25.78,24.7,0.0,-0.042795754,-0.002436594,0.022767764,7.42775,0.12943,0.0,612,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
BNTX,Cevumeran (BNT122),Resected pancreatic ductal adenocarcinoma (PDAC)Â ,Phase 1,4/7/2024,"Phase 1 data presented at AACR reported that in 8 of 16 patients, autogene cevumeran elicited high-magnitude T cells specific to the encoded neoantigens. 98% of the T cells targeting individual neoant",239.0,21518.93353,34.132,90.52,90.52,86.48,0.0,-0.045657647,-0.002436594,0.022767764,1.29653,0.10852,0.0,613,0,0,0,0,1,1,0,0,0,0,1,0,3,0,0,1
IONS,TRYNGOLZA (olezarsen),Familial Chylomicronemia Syndrome (FCS)Â ,Phase 3,4/7/2024,"Phase 3 trial met her primary endpoint, noted April 7, 2024.",159.0,6299.39267,34.54,43.22,43.22,41.74,0.0,-0.034843449,-0.002436594,0.022767764,6.6316,0.15992,0.0,614,1,0,0,0,0,1,0,0,0,0,0,0,2,0,0,1
INO,GT-30,Cancer Vaccine in advanced hepatocellular carcinomaÂ ,Phase 1/2,4/7/2024,"Phase 1/2 trial has met primary endpoints of safety and immunogenicity and secondary endpoint for efficacy based on response rate, noted April 7, 2024.",53.0,275.65346,107.4811,11.795,11.795,11.03,0.0,-0.06705688,-0.002436594,0.022767764,8.8072,0.02043,0.0,615,1,0,0,1,0,1,0,0,1,0,0,0,4,0,0,1
EWTX,EDG-7500 - (CIRRUS-HCM),Hypertrophic Cardiomyopathy (HCM)Â ,Preclinical,4/7/2024,Preclinical data presented at ACC blunted the HCM-mediated progressive slowing of LV diastolic relaxation; additionally the candidate preserved myocardial distensibility and maintained cardiac reserve,105.0,1579.15617,93.1117,16.96,16.96,16.37,0.0,-0.035407239,-0.002436594,0.022767764,4.81641,0.02114,0.0,616,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
SNDX,Revuforj (revumenib) - (AUGMENT-101),Relapsed/refractory (R/R) acute leukemiasÂ ,Phase 2,4/8/2024,"Phase 2 data reported a complete remission (CR) or CR with partial hematological recovery (CRh) rate was 23%, and the overall response rate was 46%, noted April 8, 2024.",86.0,1938.38664,51.0945,22.89,22.81,21.62,-0.003501098,-0.057081322,-0.016060185,0.043398868,9.80155,0.2702,9.73326,617,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ZYME,ZW191,"Non-small cell lung cancer, endometrial cancer, and triple-negative breast cancerÂ ",Preclinical,4/8/2024,"Preclinical data reported superior internalization, payload delivery, and spheroid penetration to other FRÎ±-targeted multi-specific antibodies, noted April 8, 2024.",75.0,678.8663,46.4301,9.65,9.62,9.09,-0.003113651,-0.059783007,-0.016060185,0.043398868,5.60663,0.03155,2.92621,618,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
BMRN,BMN 401 (INZ-701) - (adults trial),ENPP1 deficiencyÂ ,Phase 1/2,4/8/2024,"Phase 2 topline data showed avorable safety, immunogenicity and clinical outcome data were maintained through 48 weeks in Cohorts 1-3 in ENPP1 Deficiency; Data from Cohort 4 support once weekly dosing",192.0,16467.60829,29.1894,86.95,87.28,91.51,0.003788101,0.051115015,-0.016060185,0.043398868,1.5711,0.05879,117.38881,619,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
MIST,Etripamil - (NODE-303),Paroxysmal supraventricular tachycardia (PSVT)Â ,Phase 3,4/8/2024,Phase 3 data shared at ACC24 demonstrated that symptom-prompted treatment with etripamil was effective at restoring sinus rhythm as compared to placebo with a median time-to-conversion of 17.0 minutes,84.0,108.7032,102.344,1.8,1.82,1.755,0.011049836,-0.025317808,-0.016060185,0.043398868,0.80387,0.01554,0.45022,620,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
VINC,VIP236,Solid tumorsÂ ,Phase 1,4/8/2024,"Phase 1 initial data presented at AACR demonstrated positive signs of clinical activity, including tumor reduction, and an improved safety profile in heavily pretreated patients with metastatic solid",5.0,102.35596,152.4755,111.0,95.6,17.4,-0.149357381,-1.853059995,-0.016060185,0.043398868,4.03344,0.00269,10.60969,621,0,0,0,1,0,1,0,0,0,0,1,0,3,0,0,1
CRDF,"Onvansertib, FOLFIRI and AVASTIN (bevacizumab) - (ONSEMBLE)",KRAS-Mutated Colorectal CancerÂ ,Phase 1/2,4/8/2024,Phase 1/2 data presented at AACR showed enhanced clinical efficacy signal in bev naÃ¯ve patients is consistent with results of randomized ONSEMBLE trial providing two independent data sets in second-li,66.0,262.70175,115.9133,5.84,5.88,5.28,0.006825965,-0.100804699,-0.016060185,0.043398868,6.29721,0.01782,4.97709,622,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1
NUVL,Zidesamtinib - (NVL-330) - (HEROEX-1),HER2-mutant tumorsÂ ,Preclinical,4/8/2024,"Preclinical data presented at AACR continue to support NVL-330's broad activity against HER2 oncogenic alterations, selectivity over wild-type EGFR, and differentiated brain-penetrant profile , Zidesa",72.0,4384.78915,41.5223,70.2,68.44,65.28,-0.025390862,-0.0726626,-0.016060185,0.043398868,11.0059,0.11771,86.92955,623,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1
MRUS,Zenocutuzumab (Zeno) in combination with Trastuzumab and Vinorelbine,Metastatic breast cancerÂ ,Preclinical,4/8/2024,"Phase 2 data presented at AACR data show that Zeno is effective in tumor cell killing in vitro and in vivo in high NRG1 expressing cancer models representing multiple different tumor types, April 8, 2",75.0,2581.19878,52.9413,44.7,44.01,41.27,-0.015556621,-0.079837658,-0.016060185,0.043398868,6.98709,0.25394,20.02195,624,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1
GMAB,Zenocutuzumab (Zeno) in combination with Trastuzumab and Vinorelbine,Metastatic breast cancerÂ ,Preclinical,4/8/2024,"Phase 2 data presented at AACR data show that Zeno is effective in tumor cell killing in vitro and in vivo in high NRG1 expressing cancer models representing multiple different tumor types, April 8, 2",661.0,133454.9172,36.9417,2057.0,2051.0,2058.0,-0.002921132,0.000486027,-0.016060185,0.043398868,0.0,0.094,132.87609,625,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1
INKT,FAP-CAR-IL-15 iNKT (MiNK-215),Non-small cell lung cancer (NSCLC)Â ,Preclinical,4/8/2024,Preclinical data shared at AACR exhibits potent anti-tumor activity through multiple mechanisms including immune activation and eliminated MSS colorectal cancer liver metastases in human organoid mode,4.0,45.80275,84.4882,15.6,13.2,9.085,-0.167054085,-0.540646212,-0.016060185,0.043398868,0.13389,0.01656,0.60655,626,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CADL,Alpha 201-macro-1 (enLIGHTEN Discovery Platform),"Solid tumors, breast cancerÂ ",Preclinical,4/8/2024,"Preclinical data shared at AACR reported that treatment was shown to induce tertiary lymphoid structure formation, inhibit tumor growth, and improve response to immune checkpoint inhibitor therapy in",54.0,188.70422,217.8762,6.64,6.43,5.82,-0.032137425,-0.131811702,-0.016060185,0.043398868,0.50183,0.01595,99.97077,627,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
COGT,CGT4255 - (ErbB2),Solid tumorsÂ ,Preclinical,4/8/2024,Preclinical data presented at AACR showed that data further demonstrate Cogent's capability to discover and advance potential best-in-class novel therapies for rare disease populations with high unmet,139.0,623.39934,149.775,6.71,6.52,6.5,-0.028724575,-0.031796774,-0.016060185,0.043398868,10.07551,0.00215,3.29282,628,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1
AGEN,BMS-986442 (AGEN1777),Solid tumorsÂ ,Preclinical,4/8/2024,"Preclinical data presented at AACR reported that treatment demonstrated superior immune activation as monotherapy and in combination with PD-(L)1 blockade compared to conventional anti-TIGIT mAb, note",31.0,195.00729,106.8075,10.074,9.31,6.5,-0.078868756,-0.43815567,-0.016060185,0.043398868,10.9199,0.04262,12.29673,629,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1
ADCT,ADCT-601 (mipasetamab uzoptirine),"Soft tissue sarcomas, pancreatic cancer and AXL-expressing non-small cell lung cancer (NSCLC)Â ",Phase 1b,4/8/2024,"Phase 1b additional data presented at AACR reported that due to the incidence of TEAE judged related to Mipa and the preliminary activity observed, 15mg was selected as the highest dose to be tested i",112.0,420.0754,139.9339,5.0,5.09,4.37,0.017839918,-0.134674903,-0.016060185,0.043398868,1.13868,0.03134,3.20478,630,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1
ALXO,ALX148 and Vidaza (azacitidine) - (ASPEN-02),Myelodysplastic syndromes (MDS)Â ,Phase 1,4/8/2024,"Phase 1 data presented at AACR reported that the combination results in high CR rates in patients with relapsed refractory iNHL, noted April 8, 2024.",53.0,608.84628,92.7385,12.23,12.14,12.89,-0.007386164,0.052559867,-0.016060185,0.043398868,5.8098,0.10737,10.85633,631,1,0,0,0,0,1,0,0,0,0,1,0,3,0,0,1
PYXS,PYX-106,Solid TumorsÂ ,Preclinical,4/8/2024,Additional preclinical data shared at AACR reported that Siglec-15 and PD-L1 mRNA expression are not broadly mutually exclusive across cancer indications and instead expression of each gene varies bro,62.0,324.38423,108.6148,5.46,5.58,4.74,0.021739987,-0.141411654,-0.016060185,0.043398868,2.81013,0.02367,3.16234,632,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ELTX,ELI-002 (AMPLIFY-201),Solid TumorsÂ ,Phase 1,4/8/2024,Phase 1 trial data presented at AACR reported that a majority of patients who received ELI-002 booster immunizations maintained or increased mKRAS-specific T cell responses relative to baseline. Durab,16.0,88.51398,134.9312,8.85,8.66,9.23,-0.021702736,0.042041589,-0.016060185,0.043398868,0.27791,0.01395,1.19713,633,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1
RIGL,REZLIDHIA (olutasidenib) - (CONNECT),High-grade glioma (HGG) harboring an isocitrate dehydrogenase-1 (IDH1) mutationÂ ,Phase 2,4/8/2024,"Phase 2 showed induced durable composite complete remission in 43.8% of patients relapsed or refractory to prior venetoclax-based regimens, noted April 8, 2024.",17.0,220.97604,74.6803,12.9,12.6,11.5,-0.023530497,-0.114880276,-0.016060185,0.043398868,2.81941,0.11488,8.01427,634,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
PTN,PL9643 - (MELODY-1),Dry eye disease (DED)Â ,Phase 3,4/8/2024,Phase 3 results presented at the ASCRS Conference 2024 included co-Primary symptom endpoint of pain met statistical significance and 7 of 11 secondary symptom endpoints met statistical significance (p,46.0,83.64869,73.3743,0.074,0.071,0.077,-0.041385216,0.039740329,-0.016060185,0.043398868,0.0,0.00178,0.01211,635,0,0,0,0,0,1,0,0,1,0,0,0,2,0,0,1
SUPN,ONAPGO (apomorphine hydrochloride) injection (SPN-830),Motor fluctuations in Parkinsonâ€™s disease (PD)Â ,CRL,4/8/2024,"CRL announced April 8, 2024.",56.0,1720.31967,40.5167,33.55,31.43,29.99,-0.065274013,-0.112172871,-0.016060185,0.043398868,8.99609,0.09086,24.8198,636,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,-1
ORIC,ORIC-944,Metastatic castration resistant prostate cancer (mCRPC)Â ,Preclinical,4/8/2024,"Preclinical data demonstrated that EED and EZH2 inhibitors act through the same mechanism of action, making prostate cancer cells more susceptible to AR inhibition, noted April 8, 2024.",97.0,724.29036,70.7196,10.97,10.75,9.54,-0.02025852,-0.139670789,-0.016060185,0.043398868,10.2825,0.12339,5.40708,637,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
PFE,DOVATO (Dolutegravir and lamivudine) - (DANCE),HIV-1 infection in adolescents 12 years + and weighing at least 25 kg with no antiretroviral (ARV) treatment historyÂ ,Approved,4/8/2024,"FDA Approved on April 8, 2024.",0.0,150510.3475,26.873,26.66,26.58,25.91,-0.003005261,-0.02853532,-0.016060185,0.043398868,1.2654,0.03367,649.38534,638,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
ENTX,EB613,OsteoporosisÂ ,Phase 2,4/8/2024,"Phase 2 publication in the Journal of Bone Mineral Research showed that despite the superior benefits of bone building (anabolic) agents and guidelines supporting their use, these medications are used",45.0,69.18862,108.2337,1.985,1.95,2.52,-0.017789542,0.238639987,-0.016060185,0.043398868,0.02281,0.00662,0.70408,639,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CHRS,CHS-1000,Solid TumorsÂ ,Preclinical,4/8/2024,"Preclinical studies showed a high affinity for human ILT4, reverses ILT4-mediated immunosuppressive functions, leading to activation of immune cells and increased cytokine secretion, noted April 8, 20",116.0,282.91337,117.632,2.43,2.51,2.2,0.032391496,-0.099433897,-0.016060185,0.043398868,22.98948,0.05653,5.2981,640,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
NVCT,NXP900,Non-small cell lung cancer (NSCLC)Â ,Phase 1,4/8/2024,"Phase 1 data presented at AACR demonstrated that the combination reverses resistance to osimertinib versus osimertinib alone, noted April 8, 2024.",25.0,138.77452,85.5507,7.78,7.81,6.41,0.003848626,-0.193697067,-0.016060185,0.043398868,4.31145,0.00793,0.18998,641,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1
CCCC,CFT1946,Solid tumorsÂ ,Preclinical,4/8/2024,"Preclinical data reported that a CFT1946 as a single agent and in combination with cetuximab demonstrates superior activity to the standard of care combination, BRAFi with cetuximab, in all CRC models",71.0,525.48113,189.3951,7.52,7.66,6.86,0.018445846,-0.091858696,-0.016060185,0.043398868,7.70697,0.05637,7.94621,642,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CORT,Relacorilant plus ABRAXANE (nab-paclitaxel) - (ROSELLA),Ovarian cancerÂ ,Phase 3,4/8/2024,"Phase 3 enrollment completed, noted April 8, 2024.",105.0,2508.22631,62.5862,25.2,24.23,23.15,-0.03925246,-0.084849214,-0.016060185,0.043398868,19.52845,0.01165,23.08751,643,0,0,0,0,0,1,0,0,0,1,0,0,2,0,0,1
INMB,INB03,MUC4 expressing cancerÂ ,Phase 1,4/8/2024,Trial data reported that the increase in T cell infiltrate did not occur unless both anti-HER2 and INB03 immunotherapy were used in combination. Decreases in T cell and macrophage immune checkpoint p,26.0,185.97004,72.2976,10.34,10.36,9.58,0.001932368,-0.076342277,-0.016060185,0.043398868,8.04625,0.0216,2.31955,644,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
BMRN,BMN 401 (INZ-701),ABCC6 deficiencyÂ ,Phase 1/2,4/8/2024,"Phase 1/2 topline data reported a reduction or stabilization of cIMT was observed across all dose cohorts, and increased choroidal thickness was observed across all dose cohorts, noted April 8, 2024.",192.0,16467.60829,29.1894,86.95,87.28,91.51,0.003788101,0.051115015,-0.016060185,0.043398868,1.5711,0.05879,117.38881,645,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
MRKR,Neldaleucel (MT-601) - (APOLLO),Lymphoma who have failed or are ineligible to receive anti-CD19 CAR T cell treatmentÂ ,Phase 1,4/8/2024,"Phase 1 data reported that the initial dose level was well tolerated and demonstrated durable objective responses after MT-601 treatment, noted April 8, 2024.",12.0,41.93265,101.6656,4.67,4.71,4.44,0.008528836,-0.050504695,-0.016060185,0.043398868,1.68151,0.00777,0.09578,646,0,0,0,1,0,1,0,0,0,0,0,0,2,0,0,1
NVS,Leqvio - (V-INITIATE),Low-density lipoprotein cholesterol (LDL-C) in patients with atherosclerotic cardiovascular disease (ASCVD)Â ,Phase 3,4/8/2024,"Phase 3b data reported significant reductions in LDL-C compared to those receiving usual care (60% vs. 7%), noted April 8, 2024.",0.0,1306.28195,51.1609,4.21,4.21,4.3,0.0,0.021152375,-0.016060185,0.043398868,0.0,0.00056,0.0,647,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
NXTC,LNCB74,B7-H4 expressing cancersÂ ,Preclinical,4/8/2024,"Preclinical data reported durable tumor regression in multiple CDX and PDX tumor models, suggesting activity comparable or superior to competitor B7-H4 targeting ADCs, noted April 8, 2024.",2.0,57.2012,81.669,26.16001,24.60001,20.04001,-0.061485059,-0.266501134,-0.016060185,0.043398868,3.0093,0.06988,0.33645,648,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
OCS,OCS-01 - (OPTIMIZE-2),Inflammation and pain following ocular surgeryÂ ,Phase 3,4/8/2024,"Phase 3 trial data reported that 57.2% of patients treated with OCS-01 were inflammation free (i.e. absence of anterior chamber cells) at Day 15, and 75.5% had absence of ocular pain at Day 4, noted A",43.0,394.35083,43.2457,11.16,10.76,12.03,-0.036500402,0.075067573,-0.016060185,0.043398868,0.12882,0.00951,0.08709,649,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CVKD,tecarfarin - (ARIES-HM3),Thromboembolism and thrombosisÂ ,Phase 2,4/9/2024,"FDA granted orphan drug designation, noted April 9, 2024.",2.0,6.54266,123.1122,7.65,6.1305,5.8485,-0.221429335,-0.26852043,0.004990307,0.054442169,0.26246,0.02223,2.49104,650,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
ATOS,(Z)-endoxifen with abemaciclib (VERZENIO) - (EVANGELINE),Pre-menopausal women w/ early-stage estrogen receptor positive and Human Epidermal Growth Factor Receptor 2 negative breast cancerÂ ,Phase 2,4/9/2024,"Phase 2 data shared at AACR showed that a Among the six patients who were treated for a total of 24-weeks, magnetic resonance imaging (MRI) central review demonstrated target lesion decreases in all",129.0,230.55948,72.9284,1.75,1.84,1.54,0.050149784,-0.127833372,0.004990307,0.054442169,8.43033,0.03839,7.10928,651,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
LLY,(Z)-endoxifen with abemaciclib (VERZENIO) - (EVANGELINE),Pre-menopausal women w/ early-stage estrogen receptor positive and Human Epidermal Growth Factor Receptor 2 negative breast cancerÂ ,Phase 2,4/9/2024,"Phase 2 data shared at AACR showed that a Among the six patients who were treated for a total of 24-weeks, magnetic resonance imaging (MRI) central review demonstrated target lesion decreases in all",946.0,682096.1216,28.2202,777.29,757.24,746.74,-0.026133267,-0.040096445,0.004990307,0.054442169,0.60178,0.00582,1866.47317,652,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
IMRX,Atebimetinib (IMM-1-104) + mGnP,"Solid tumors, pancreatic cancer, melanomaÂ ",Preclinical,4/9/2024,Preclinical data presented at AACR demonstrated that combining IMM-1-104 with chemotherapies used in the treatment of first-line pancreatic cancer yielded deeper and more durable tumor growth inhibiti,36.0,64.13037,159.4041,2.12,2.19,1.84,0.032485455,-0.141650517,0.004990307,0.054442169,9.82096,0.16422,0.86856,653,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1
CMPX,CTX-009 in combination with paclitaxel,Biliary Tract Cancer (cholangiocarcinoma)Â ,Preclinical,4/9/2024,Preclinical data presented at AACR suggest that the combination of CTX-009 and CTX-471 could re-establish anti-tumor immunity in patients whose tumors have either downregulated or lost MHC-I expressio,138.0,229.77392,82.9639,1.7,1.67,1.57,-0.017804625,-0.079552632,0.004990307,0.054442169,1.18007,0.0208,0.40601,654,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1
NRIX,NX-5948,B-cell malignancies / graft-versus-host diseaseÂ ,Phase 1a,4/9/2024,Additional data with higher dose levels and longer treatment duration were reported at AACR; The company presented new case studies demonstrating clinical responses in two patients with B cell maligna,76.0,859.15588,91.0673,13.8,17.48,14.65,0.236388778,0.059771743,0.004990307,0.054442169,14.17901,0.21503,33.38701,655,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
IOBT,IO102-IO103 - (IOB-032),Squamous cell carcinoma of the head and neck (SCCHN)Â ,Phase 1/2,4/9/2024,"Phase 1/2 early data presented at AACR demonstrated the mechanism. Based on these results the company hopes to confirm its ongoing Phase 3 pivotal study, noted April 9, 2024.",65.0,106.06827,68.8127,1.54,1.61,1.51,0.044451763,-0.019672766,0.004990307,0.054442169,0.10352,0.06338,0.10657,656,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1
RAPT,tivumecirnon (FLX475) in combination with pembrolizumab,Advanced CancerÂ ,Phase 2,4/9/2024,"Phase 2 data shared at AACR confirmed an objective response rate (ORR) of 15.6% in all patients regardless of PD-L1 or HPV status, noted April 9, 2024.",16.0,293.70943,209.3697,66.56,67.52,65.04,0.014320054,-0.023101331,0.004990307,0.054442169,8.55399,0.07872,13.09483,657,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
FHTX,FHD-909 (LY4050784),Non-small cell lung cancer (NSCLC)Â ,Preclinical,4/9/2024,"Preclinical data presented at AACR demonstrated favorable tolerability and dose-dependent single agent activity in BRG1 mutated cancers preclinically, noted April 9, 2024.",56.0,318.39296,124.8815,7.17,7.48,6.03,0.042327137,-0.173158644,0.004990307,0.054442169,2.80103,0.04787,0.38751,658,0,0,0,1,0,0,0,0,0,0,1,0,2,0,0,1
LLY,FHD-909 (LY4050784),Non-small cell lung cancer (NSCLC)Â ,Preclinical,4/9/2024,"Preclinical data presented at AACR demonstrated favorable tolerability and dose-dependent single agent activity in BRG1 mutated cancers preclinically, noted April 9, 2024.",946.0,682096.1216,28.2202,777.29,757.24,746.74,-0.026133267,-0.040096445,0.004990307,0.054442169,0.60178,0.00582,1866.47317,659,0,0,0,1,0,0,0,0,0,0,1,0,2,0,0,1
INAB,INB-300,Solid TumorsÂ ,Preclinical,4/9/2024,"Preclinical data presented at AACR supports potential for proprietary nsCAR platform to selectively eliminate cancer cells while preserving healthy tissue, noted April 9, 2024.",4.0,47.18317,132.2812,32.70003,32.70003,29.40903,0.0,-0.106074225,0.004990307,0.054442169,0.11924,0.00307,2.50044,660,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1
TPST,TPST-1120,renal cell carcinoma (RCC)Â ,Preclinical,4/9/2024,"Preclinical data shared at AACR showed that TPST-1120 increases infiltrating cytotoxic CD8+ T cells in the tumor microenvironment, consistent with modulation of the tumor microenvironment to a more im",4.0,85.88312,560.2734,51.86998,50.30998,43.54999,-0.030536736,-0.174830729,0.004990307,0.054442169,4.3696,0.0001,2.94595,661,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
AZN,FPI-2265 - (AlphaBreak),Prostate cancerÂ ,Phase 2,4/9/2024,"Phase 2 preliminary data presented at AACR demonstrate that FPI-2265 is active in heavily pretreated patients with progressive metastatic castration-resistant prostate cancer (mCRPC), including those",0.0,165997.6955,23.8594,106.1,107.08,108.78,0.009194173,0.024945448,0.004990307,0.054442169,0.0,0.22766,183.79008,662,0,0,0,0,0,1,0,0,0,1,1,0,3,0,0,1
PRLD,PRT7732,lymphoid malignanciesÂ ,Preclinical,4/9/2024,"Preclinical data shared at AACR shows robust anti-tumor activity in vivo as monotherapy and in combination with chemotherapy, at well-tolerated doses, noted April 9, 2024.",56.0,377.87075,98.1302,4.7,4.99,4.91,0.059873401,0.043711433,0.004990307,0.054442169,0.8212,0.10664,0.32043,663,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1
PRLD,PRT2527,Solid tumors and hematological malignanciesÂ ,Preclinical,4/9/2024,"Additional preclinical data shared at the AACR provides improved depth and duration of response in combination with BTK/BCL2 inhibition, noted April 9, 2024.",56.0,377.87075,98.1302,4.7,4.99,4.91,0.059873401,0.043711433,0.004990307,0.054442169,0.8212,0.10664,0.32043,664,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
PRLD,PRT3645,CancerÂ ,Preclinical,4/9/2024,"Preclinical data at AACR showed that drug is highly effective in combination with other targeted therapies in preclinical models of breast cancer, CRC and NSCLC, noted April 9, 2024.",56.0,377.87075,98.1302,4.7,4.99,4.91,0.059873401,0.043711433,0.004990307,0.054442169,0.8212,0.10664,0.32043,665,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CRVS,Soquelitinib - (CPI-818),Peripheral T-cell lymphoma (PTCL)Â ,Phase 3,4/9/2024,"Phase 3 dosing initiated, noted April 9, 2024.",74.0,79.93289,78.8561,1.71,1.63,1.47,-0.047913356,-0.15123097,0.004990307,0.054442169,2.85005,0.00986,0.31969,666,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1
MCRB,SER-155,"Gastrointestinal infections, bacteremia and graft versus host disease (GvHD)Â ",Phase 1b,4/9/2024,"Phase 1b cohort 2 patient enrollment completed, noted April 9, 2024.",8.0,107.12611,135.3566,14.648,14.188,12.722,-0.03190727,-0.140971029,0.004990307,0.054442169,12.45171,0.00305,4.95895,667,0,0,0,0,0,1,0,0,0,1,0,0,2,0,0,1
QLGN,QN-302,"Pancreatic cancer, Prostate cancer and other solid tumorsÂ ",Phase 1,4/9/2024,"Phase 1 results demonstrated that for the first five patients (three of whom were PDAC patients), QN-302 is overall well-tolerated (no SAE) and they have reported a ""good"" quality of life during the d",1.0,2.516,64.7714,19.075,19.945,14.99,0.044599908,-0.240995265,0.004990307,0.054442169,1.26728,0.00734,0.03345,668,0,0,0,1,0,1,0,0,0,0,0,0,2,0,0,1
BCTX,SV-BR-1-GM,Metastatic breast cancerÂ ,Phase 2,4/9/2024,"Phase 2 efficacy and safety data shared at AACR shows that Bria-IMT provides prolonged progression-free survival and clinical benefits in heavily pre-treated, ADC resistant breast cancer patients comp",1.0,62.00858,87.3342,439.49978,427.51479,341.99983,-0.027648332,-0.250826977,0.004990307,0.054442169,0.0,0.0,0.09448,669,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
BCTX,Bria-IMT - (BRIA-ABC),Advanced breast cancerÂ ,Phase 2,4/9/2024,Phase 2 data shared at AACR showed that Bria-IMT's tumor reductions observed in all breast cancer subtypes in patients with intracranial disease underlines its potential clinical effectiveness in mana,1.0,62.00858,87.3342,439.49978,427.51479,341.99983,-0.027648332,-0.250826977,0.004990307,0.054442169,0.0,0.0,0.09448,670,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
IPHA,IPH45,Nectin-4 expressing tumorsÂ ,Preclinical,4/9/2024,"Preclinical data presented at AACR reported that treatment effectively inhibits Nectin-4 expressing tumor growth both in vitro and in vivo, including in Enfortumab Vedotin (EV) refractory models, note",92.0,185.93657,79.6483,2.6,2.6,2.59,0.0,-0.003853569,0.004990307,0.054442169,0.0,0.0,0.04602,671,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1
ALXO,ALX148 (evorpacept) + rituximab and lenalidomide,Non-Hodgkin lymphoma (NHL)Â ,Phase 1,4/9/2024,"Phase 1 trial data presented at AACR reported that the best ORR of 94% and a CRR of 83%, noted April 9, 2024.",53.0,618.87669,92.3812,12.14,12.34,14.49,0.016340233,0.176952971,0.004990307,0.054442169,6.22301,0.10737,5.4246,672,1,0,0,0,0,1,0,0,0,0,1,0,3,0,0,1
GNPX,REQORSA (GPX-001) with KEYTRUDA (pembrolizumab) - (Acclaim-2),Non-Small Cell Lung Cancer (NSCLC)Â ,Preclinical,4/9/2024,"Preclinical data presented at AACR reported that the NPRL2 treatment by itself led to a marked decrease in the size of lung metastases but pembrolizumab had no effect, noted April 9, 2024.",0.0,5.86493,125.5804,148.0,153.5,115.0,0.036488293,-0.252280145,0.004990307,0.054442169,3.66133,0.16201,0.38958,673,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1
CGEN,COM503,Solid tumorsÂ ,Preclinical,4/9/2024,"Preclinical data shared at AACR found that COM503's activity is localized to the tumor microenvironment with the additional advantage of a wider therapeutic window than systemic IL-18 delivery, noted",93.0,211.29126,161.6351,2.33,2.36,2.03,0.012793351,-0.137832475,0.004990307,0.054442169,2.3365,0.02795,0.35894,674,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
GILD,COM503,Solid tumorsÂ ,Preclinical,4/9/2024,"Preclinical data shared at AACR found that COM503's activity is localized to the tumor microenvironment with the additional advantage of a wider therapeutic window than systemic IL-18 delivery, noted",0.0,87080.7007,25.0705,69.42,69.94,67.31,0.007462721,-0.030866196,0.004990307,0.054442169,1.81296,0.05626,414.61859,675,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
PFE,ABRYSVO - (MONeT),Respiratory syncytial virus (RSV)-associated lower respiratory tract disease (LRTD)Â ,Phase 3,4/9/2024,"Phase 3 trial met its primary endpoint, noted April 9, 2024.",0.0,151642.8558,26.7971,26.58,26.78,25.69,0.007496287,-0.034057242,0.004990307,0.054442169,1.14785,0.03367,1210.28579,676,1,0,0,0,0,1,0,0,0,0,0,0,2,0,0,1
ONC,Tislelizumab (anti-PD1) plus ociperlimab (anti-TIGIT) - (AdvanTIG-204),Small cell lung cancer (SCLC)Â ,Phase 2,4/9/2024,"Phase 2 data presented at AACR reported that in patients with untreated limited-stage SCLC, tislelizumab + cCRT yielded a trend of improvement in PFS and ORR vs cCRT; addition of ociperlimab did not s",110.0,16093.59878,49.4643,149.75,154.02,134.05,0.028115227,-0.110754372,0.004990307,0.054442169,1.65346,0.10578,17.74326,677,1,0,0,0,0,1,0,0,0,0,1,0,3,0,0,1
ONC,BGB-10188,Solid tumorsÂ ,Phase 1a,4/9/2024,Phase 1a data presented at AACR reported that BGBâ€‘10188 + tislelizumab showed preliminary antitumor activity and was generally safe and tolerable across doses in this heavily pretreated population of,110.0,16093.59878,49.4643,149.75,154.02,134.05,0.028115227,-0.110754372,0.004990307,0.054442169,1.65346,0.10578,17.74326,678,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1
CCCC,CFT8634,Synovial sarcomaÂ ,Phase 1,4/9/2024,"Phase 1 data presented at AACR reported that selective targeting of EP300 with targeted protein degradation is a safe and effective treatment strategy for advanced tumors, noted April 9, 2024.",71.0,546.74733,188.6694,7.66,7.97,6.83,0.039672509,-0.11468731,0.004990307,0.054442169,13.33713,0.05637,9.24566,679,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1
BCYC,BT7455,EphA2-expressing cancersÂ ,Preclinical,4/9/2024,"Preclinical data shared at AACR reported that treatment engages EphA2 and CD137 with high affinity, resulting in potent EphA2-dependent activity in vitro and robust anti-tumor activity in vivo with in",69.0,982.46329,65.9098,22.96,23.07,21.93,0.004779501,-0.045898009,0.004990307,0.054442169,5.97035,0.13263,7.37649,680,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
APRE,ATRN-119,Advanced solid tumorsÂ ,Phase 1/2,4/9/2024,Phase 1/2a trial shared at AACR reported that two of 12 patients achieved stable disease (SD): one patient from Dose level 1 (50 mg) who progressed on Day 112 and one patient from Dose level 3 (200 mg,5.0,32.79524,101.1676,6.2,6.0394,5.85,-0.026244623,-0.058107631,0.004990307,0.054442169,1.94887,0.06963,0.04363,681,0,0,0,0,1,1,0,0,0,0,0,0,2,0,0,1
WHWK,Nab-sirolimus in combination with fulvestrant,Breast CancerÂ ,Preclinical,4/10/2024,"Preclinical data presented at AACR reported that nab-sirolimus enhanced the cytotoxic effects of fulvestrant in HR+ breast cancer cells and PI3Ki in both HR+ and HR- breast cancer cells, noted April 1",47.0,49.10841,137.48,2.1,2.0,1.82,-0.048790164,-0.143100844,0.003936152,0.079342749,3.84075,0.0,0.76471,682,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1
BTAI,Dexmedetomidine (BXCL501) - (TRANQUILITY III),Agitation associated with Alzheimerâ€™s DiseaseÂ ,Phase 3,4/10/2024,"Phase 3 expanded to In-Care study, trial planned to initiate soon following FDA meeting, noted April 10, 2024.",14.0,80.41661,134.8601,41.12,42.08,41.44,0.023077947,0.007751977,0.003936152,0.079342749,8.14721,0.00881,1.02688,683,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
VSTM,GFH375/VS-7375,Cancer KRAS G12DÂ ,Preclinical,4/10/2024,"Preclinical data shared at AACR shown potent efficacy and safety of orally administered GFH375 in animal models, noted April 8, 2024.",61.0,285.83909,65.5951,11.74,11.3,10.84,-0.038199089,-0.079758818,0.003936152,0.079342749,2.50825,0.01894,1.04005,684,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
GALT,GR-MD-02 (belapectin) - (NAVIGATE),Non-alcoholic steatohepatitis (NASH) with cirrhosisÂ ,Phase 2/3,4/10/2024,"5th DSMB recommends the continuation, without modifications, noted April 10, 2024.",64.0,236.47203,65.1492,3.94,3.82,3.38,-0.030930301,-0.153305014,0.003936152,0.079342749,3.62737,0.00641,2.47281,685,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ALKS,ALKS 2680 - (Vibrance-1),NarcolepsyÂ ,Phase 1,4/10/2024,Phase 1 demonstrated clinically meaningful and statistically significant improvements from baseline in mean sleep latency compared to placebo at all doses tested in both narcolepsy type 2 and idiopath,165.0,4422.47454,42.7603,26.73,26.14,24.01,-0.022319822,-0.10731612,0.003936152,0.079342749,8.47354,0.0131,53.07385,686,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1
ACRV,ACR-2316,"Dual WEE1 and PKMYT1 inhibitor, Solid tumorsÂ ",Preclinical,4/10/2024,"Preclinical data presented at AACR reported that treatment was highly potent across multiple human tumor cell lines and patient-derived ex vivo tumor models, noted April 10, 2024.",31.0,235.19792,123.5201,9.62,10.39,10.34,0.07699954,0.072175604,0.003936152,0.079342749,2.35439,0.02049,10.91246,687,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1
AIM,"Ampligen, cisplatin and KEYTRUDA (pembrolizumab)",Ovarian cancerÂ ,Phase 2,4/10/2024,"Phase 2 protocol planned interim results by leading the investigator to concluded that the combination therapy could be far more effective than pembrolizumab alone as a therapy for the disease, noted",2.0,76.21713,63.3467,0.37,0.365,0.355,-0.013605652,-0.041385216,0.003936152,0.079342749,0.0,0.0195,0.04281,688,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
BCTX,Bria-Pros+,Prostate cancerÂ ,Preclinical,4/10/2024,"Preclinical data reported that treatment engaged with multiple facets of the adaptive immune response, which may result in lasting anti-cancer effects in patients, noted April 10, 2024.",1.0,59.13189,87.4939,427.51479,409.4998,323.99984,-0.043052469,-0.277245862,0.003936152,0.079342749,0.0,0.0,0.23505,689,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
AMLX,AMX0035 - (HELIOS),Wolfram SyndromeÂ ,Phase 2,4/10/2024,"Phase 2 data demonstrated improvements in pancreatic function and glycemic control, as measured by C-peptide and other markers of glucose metabolism, rather than worsening typically expected with dise",89.0,166.74406,258.4846,2.67,2.46,2.0,-0.081917122,-0.288931292,0.003936152,0.079342749,8.86243,0.02915,7.79873,690,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
REGN,BNT116 and Libtayo - (LuCa-MERIT-1),Non-small cell lung cancer (NSCLC)Â ,Phase 1,4/10/2024,"Phase 1 trial preliminary results presented at AACR reported that BNT116 + DTX shows encouraging antitumor activity, consistent induction of immune responses, a manageable safety profile, and no signs",105.0,100605.827,16.8881,943.89,936.2,901.19,-0.008180505,-0.046293522,0.003936152,0.079342749,1.32271,0.11602,364.89799,691,0,0,0,1,0,1,0,0,0,0,1,0,3,0,0,1
BNTX,BNT116 and Libtayo - (LuCa-MERIT-1),Non-small cell lung cancer (NSCLC)Â ,Phase 1,4/10/2024,"Phase 1 trial preliminary results presented at AACR reported that BNT116 + DTX shows encouraging antitumor activity, consistent induction of immune responses, a manageable safety profile, and no signs",239.0,21363.80774,34.0293,90.05,88.65,86.4,-0.015669039,-0.041377396,0.003936152,0.079342749,1.27674,0.10852,38.06959,692,0,0,0,1,0,1,0,0,0,0,1,0,3,0,0,1
APVO,ALG.APV-527,Solid tumorsÂ ,Phase 1,4/10/2024,"Phase 1 Cohort 5 dosing imminent, trial more than 50% enrolled, noted April 10, 2024.",3.0,1.27872,118.6123,2412.40241,1776.00178,527.25053,-0.306258455,-1.520702556,0.003936152,0.079342749,6.42942,0.03701,1.75114,693,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
APVO,mipletamig (APVO711),Solid tumorsÂ ,Preclinical,4/10/2024,"Preclinical studies ongoing, in vivo studies have confirmed that APVO711 reduces the size of PD-L1-expressing tumors, noted April 10, 2024.",3.0,1.27872,118.6123,2412.40241,1776.00178,527.25053,-0.306258455,-1.520702556,0.003936152,0.079342749,6.42942,0.03701,1.75114,694,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CRBU,CB-012,Acute Myeloid Leukemia (AML)Â ,Preclinical,4/10/2024,"Preclinical data presented at AACR reported that in robust tumor control, leading to significant prolongation of survival in AML xenograft models, noted April 10, 2024.",93.0,392.86808,92.1171,4.46,4.35,3.91,-0.024972921,-0.131611392,0.003936152,0.079342749,11.29577,0.04959,9.28858,695,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1
VRTX,Povetacicept (ALPN-303) - (RAINIER),"Lupus nephritis, IgA nephropathyÂ ",Phase 2,4/10/2024,"Phase 1b/2a 240mg data presented at the World Congress of Nephrology showed that treatment continues to be well tolerated in IgA nephropathy, with UPCR reductions of greater than 60% observed at 36 we",256.0,102758.2656,27.1086,404.48,397.58,393.1,-0.01720612,-0.028538259,0.003936152,0.079342749,1.53816,0.19209,408.18743,696,0,0,0,1,0,1,0,0,0,0,0,0,2,0,0,1
ALPN,Povetacicept (ALPN-303) - (RAINIER),"Lupus nephritis, IgA nephropathyÂ ",Phase 2,4/10/2024,"Phase 1b/2a 240mg data presented at the World Congress of Nephrology showed that treatment continues to be well tolerated in IgA nephropathy, with UPCR reductions of greater than 60% observed at 36 we",68.0,67.50173,23.0024,7.7,7.75,7.5,0.006472515,-0.026317308,0.003936152,0.079342749,0.0,0.02553,0.03972,697,0,0,0,1,0,1,0,0,0,0,0,0,2,0,0,1
KRYS,KB707 - (KYANITE-1),Solid TumorsÂ ,Preclinical,4/10/2024,"Preclinical data shared at AACR reported that KB703/KB704 treatment enhanced the frequency of IFNÎ³-expressing T cells both in the tumor and tumor-draining lymph node, leading to higher levels of circu",28.0,5010.00591,70.3148,179.77,175.7,169.64,-0.022900261,-0.057999711,0.003936152,0.079342749,7.62476,0.01445,43.04632,698,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
LPCN,LPCN 2401,"Obesity, Chronic Weight ManagementÂ ",Phase 2,4/11/2024,Phase 2 treatment resulted in statistically significant body composition improvement in men Increased lean mass (LM) by 4.4% and decreased fat mass (FM) by 6.7%. Reduced android fat (AF) by 4.1% and i,5.0,34.07447,75.8804,6.51,6.41,5.44,-0.015480185,-0.179560395,0.020214052,0.074646878,2.04839,0.06649,14.13277,699,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1
PRTC,LYT-200,"Solid tumors, urothelial and head and neck cancers, acute myeloid leukemia (AML)Â ",Phase 1/2,4/11/2024,"Fast track designation granted by the FDA, noted April 11, 2024.",24.0,586.35375,50.3245,2.175,2.17,2.075,-0.002301497,-0.047067511,0.020214052,0.074646878,0.0,0.09069,1.33893,700,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
CLYM,Budoprutug (TNT119),Systemic lupus erythematosusÂ ,Phase 2,4/11/2024,"Phase 2 ongoing, acquired by Eliem from Tenet Medicines, noted April 11, 2024.",67.0,128.43817,89.6996,2.67,4.58,4.18,0.539620526,0.448232774,0.020214052,0.074646878,0.04713,2e-05,179.10551,701,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CLYM,Budoprutug (TNT119),Immune thrombocytopeniaÂ ,Phase 2,4/11/2024,"Phase 2 ongoing, acquired by Eliem from Tenet Medicines, noted April 11, 2024.",67.0,128.43817,89.6996,2.67,4.58,4.18,0.539620526,0.448232774,0.020214052,0.074646878,0.04713,2e-05,179.10551,702,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CLYM,Budoprutug (TNT119),Membranous nephropathyÂ ,Phase 1,4/11/2024,"Phase 1 ongoing, acquired by Eliem from Tenet Medicines, noted April 11, 2024.",67.0,128.43817,89.6996,2.67,4.58,4.18,0.539620526,0.448232774,0.020214052,0.074646878,0.04713,2e-05,179.10551,703,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
BOLD,BBI-355/BBI-825 - (POTENTIATE),Resistance gene amplificationsÂ ,Phase 1/2,4/11/2024,"Phase 1/2 dosing commenced, noted April 11, 2024.",22.0,258.60976,0.0,11.87,11.63,11.3,-0.020426242,-0.049211483,0.020214052,0.074646878,0.0,0.0,1.81944,704,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
AZN,FASENRA (benralizumab) - (TATE),Eosinophilic asthma aged 6 to 11 with an eosinophilic phenotypeÂ ,Approved,4/11/2024,"FDA approved on April 11, 2024.",0.0,169936.3314,23.9938,107.32,109.62,109.14,0.021204814,0.016816436,0.020214052,0.074646878,0.0,0.22766,295.81242,705,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
RARE,GTX-102 - (Aspire),Angelman SyndromeÂ ,Phase 1/2,4/15/2024,"Phase 1/2 data from expansion cohorts showed rapid, clinically meaningful improvement across multiple domains; improvements consistent or exceeding Dose-escalation Cohorts data at Day 170, noted April",96.0,3529.7309,51.6463,47.0,42.87,43.69,-0.091975321,-0.073028359,0.02923781,0.051203738,4.75909,0.10488,74.04914,706,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
LGND,ZTALMY (ganaxolone) - (RAISE),Refractory status epilepticus (RSE)Â ,Phase 3,4/15/2024,Phase 3 did not meet pre-defined stopping criteria at the interim analysis; Marinus has completed RAISE enrollment at approximately 100 patients with topline results expected summer 2024.,19.0,1412.35074,41.7769,81.36,79.77,68.53,-0.019736258,-0.171612146,0.02923781,0.051203738,3.79595,0.26731,14.0108,707,0,0,0,0,1,1,0,0,0,0,1,0,0,3,0,-1
MRNS,ZTALMY (ganaxolone) - (RAISE),Refractory status epilepticus (RSE)Â ,Phase 3,4/15/2024,Phase 3 did not meet pre-defined stopping criteria at the interim analysis; Marinus has completed RAISE enrollment at approximately 100 patients with topline results expected summer 2024.,55.0,3971.16328,41.6345,53.5,53.0,52.51,-0.00938974,-0.018678026,0.02923781,0.051203738,0.0,0.00299,1.8815,708,0,0,0,0,1,1,0,0,0,0,1,0,0,3,0,-1
TFFP,TFF TAC (Tacrolimus Inhalation Powder),Lung transplant (post)Â ,Phase 2,4/15/2024,Phase 2 updates data to be presented at the upcoming ISHLT 2024 meeting provided strong biomarker evidence that treatment with TFF TAC results in normalization of rejection-related genes; the treatmen,4.0,979.936,70.4002,43.2,43.2,45.0,0.0,0.040821995,0.02923781,0.051203738,0.0,0.0,0.0,709,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
RNAZ,TTX-MC138,Metastatic solid tumorsÂ ,Phase 1/2,4/15/2024,"IND clearance by the FDA, noted April 15, 2024.",0.0,3.11448,172.2113,574.08156,495.54151,424.11627,-0.147120353,-0.302763837,0.02923781,0.051203738,0.68803,0.00522,1.91874,710,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CORT,Dazucorilant (DAZALS),Amyotrophic Lateral Sclerosis (ALS)Â ,Phase 2,4/15/2024,"Phase 2 enrollment completed, noted April 15, 2024.",105.0,2403.83039,63.5507,23.51,23.15,22.3,-0.015431082,-0.052839184,0.02923781,0.051203738,20.54224,0.01707,16.77039,711,0,0,0,0,0,1,0,0,0,1,0,0,2,0,0,1
EWTX,sevasemten (EDG-5506) - (ARCH),Becker muscular dystrophy (BMD)Â ,Phase 1b,4/15/2024,"Phase 1b 24-months topline data showed that significant decreases were observed in circulating levels of creatine kinase (CK) and fast skeletal muscle troponin I (TNNI2), biomarkers associated with sk",105.0,1539.40464,92.4571,16.37,16.48,15.08,0.006697133,-0.082081029,0.02923781,0.051203738,6.12809,0.02428,6.65024,712,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ORIC,ORIC-114,"Tumors - EGFR/HER2 Exon 20 Inhibitor, 1L NSCLCÂ ",Phase 1b,4/15/2024,"Phase 1b expansion cohorts initiated, noted April 15, 2024.",97.0,642.76558,69.8516,9.8,9.54,8.72,-0.0268889,-0.116763148,0.02923781,0.051203738,12.07832,0.13655,3.16931,713,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
TELO,Telomir-1,Age-related conditionsÂ ,Preclinical,4/15/2024,"Preclinical data confirmed our hypothesis that TELOMIR-1 affects telomere length, promoting its extension in primary cell strains including MRC-5, HUVEC, and MSCs (~40% increase), noted April 15, 2024",32.0,261.75076,0.0,9.0,8.84,5.605,-0.017937701,-0.473565521,0.02923781,0.051203738,0.05305,0.09532,0.5129,714,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
NVS,Fabhalta (iptacopan),IgA nephropathy (IgAN)Â ,Phase 3,4/15/2024,"Phase 3 data show clinically meaningful and statistically significant proteinuria reduction of 38.3% versus placebo, noted April 15, 2024.",0.0,1334.20722,51.7048,4.3,4.3,4.88,0.0,0.126530197,0.02923781,0.051203738,0.0,0.00104,0.20961,715,0,0,1,0,0,1,0,0,0,0,0,0,2,0,0,1
HALO,Efgartigimod - (ADHERE),Chronic inflammatory demyelinating polyneuropathy (CIDP)Â ,Phase 3,4/16/2024,"Phase 3 data presented at AAN reported that 67% of patients treated with VYVGART Hytrulo demonstrated evidence of clinical improvement (ECI), including 40% who had achieved ECI by the earliest possibl",116.0,4876.34864,38.5893,38.72,38.38,38.97,-0.008819772,0.006435857,0.019883696,0.019411274,6.20677,0.21406,24.65124,716,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1
ARGX,Efgartigimod - (ADHERE),Chronic inflammatory demyelinating polyneuropathy (CIDP)Â ,Phase 3,4/16/2024,"Phase 3 data presented at AAN reported that 67% of patients treated with VYVGART Hytrulo demonstrated evidence of clinical improvement (ECI), including 40% who had achieved ECI by the earliest possibl",60.0,20749.65778,57.74,358.0,349.4,349.2,-0.024315589,-0.024888162,0.019883696,0.019411274,0.0,0.0014,23.5562,717,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1
ZLAB,Efgartigimod - (ADHERE),Chronic inflammatory demyelinating polyneuropathy (CIDP)Â ,Phase 3,4/16/2024,"Phase 3 data presented at AAN reported that 67% of patients treated with VYVGART Hytrulo demonstrated evidence of clinical improvement (ECI), including 40% who had achieved ECI by the earliest possibl",109.0,1423.50668,57.9772,14.2,14.42,15.12,0.015374167,0.062776406,0.019883696,0.019411274,3.91761,0.10967,5.78216,718,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1
JNJ,CAPLYTA (lumateperone) - (Study 501),Major depressive disorder (MDD)Â ,Phase 3,4/16/2024,"Phase 3 topline results for the 42 mg Cohort achieved statistically significant and clinically meaningful results in both the primary and the key secondary endpoints, noted April 16, 2024.",0.0,348093.1622,13.8239,147.59,144.45,149.56,-0.021504732,0.013259491,0.019883696,0.019411274,0.6616,0.15359,1845.32838,719,1,0,0,0,0,1,0,0,1,0,1,0,4,0,0,1
PRTC,Deupirfenidone (LYT-100) - (ELEVATE IPF),Idiopathic pulmonary fibrosis (IPF)Â ,Phase 2,4/16/2024,"Phase 2 enrollment completed, noted April 16, 2024.",24.0,568.79016,49.496,2.135,2.105,2.13,-0.01415118,-0.002344667,0.019883696,0.019411274,0.0,0.09548,0.75435,720,0,0,0,0,0,1,0,0,0,1,0,0,2,0,0,1
CGEM,CLN-978,Relapsed/refractory B-cell non-Hodgkin lymphomaÂ ,Phase 1,4/16/2024,"The company has discontinued enrollment in its B-NHL study to focus ongoing development on autoimmune indications, noted April 16, 2024.",59.0,745.89697,59.6374,16.55,17.32,16.67,0.045475801,0.007224595,0.019883696,0.019411274,3.33446,0.09648,58.0983,721,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
PALI,PALI-2108,Moderate-to-severe ulcerative colitis (UC)Â ,Preclinical,4/16/2024,"Preclinical data completion of exvivo analysis, noted April 16, 2024.",9.0,5.04881,138.6343,4.16,5.93,5.92,0.354509139,0.352821375,0.019883696,0.019411274,3.22069,0.05738,171.82315,722,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CMPX,CTX-8371,Solid TumorsÂ ,Phase 1,4/16/2024,"Phase 1 dosing initiated, noted April 16, 2024.",138.0,216.015,81.9536,1.58,1.57,1.52,-0.006349228,-0.038714512,0.019883696,0.019411274,1.18007,0.02318,1.12837,723,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1
ABOS,Sabirnetug (ACU193) - (INTERCEPT-AD),Alzheimerâ€™s disease (AD)Â ,Phase 1,4/16/2024,"Phase 1 additional data presented at AAN demonstrated a favorable safety and tolerability profile in participants with early AD with a relatively low incidence of ARIA-E, noted April 16, 2024.",60.0,210.27922,88.1311,3.53,3.5,3.16,-0.008534902,-0.110725843,0.019883696,0.019411274,2.06279,0.07411,0.7796,724,0,0,0,1,0,1,0,0,0,0,0,0,2,0,0,1
LEXX,DehydraTECH-GLP-1 - (GLP-1-H24-2),"Healthy volunteers, Diabetes-related control, weight lossÂ ",Preclinical,4/16/2024,"Preclinical approval has been received from an independent third-party ethics review board, for human pilot study #2, noted April 16, 2024.",19.0,29.76591,138.7244,1.99,2.31,2.24,0.149112886,0.118341227,0.019883696,0.019411274,3.80611,0.00332,0.70809,725,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
CLNN,CNM-Au8 - (VISIONARY-MS),Multiple SclerosisÂ ,Phase 2,4/16/2024,"Phase 2 LTE emonstrated significant evidence of repair and remyelination across multiple paraclinical endpoints, noted April 16, 2024.",9.0,39.81445,113.0767,6.628,6.2,6.702,-0.066753808,0.01110289,0.019883696,0.019411274,0.12683,0.06053,2.89327,726,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
PXMD,PAX-HAT-301,Stage 1 Trypanosoma Brucei Rhodesiense Human African Trypanosomiasis (Stage 1 TBR HAT)Â ,NDA Filing,4/16/2024,"NDA Company received an urgent request from the Ministry of Health (MOH) of Malawi, asking for emergency access to IV suramin to avert a potential humanitarian crisis brought on by dwindling supplies",10.0,4.92732,213.8016,0.74,0.66,0.716,-0.114410351,-0.032970019,0.019883696,0.019411274,1.79114,0.05293,2.56833,727,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
TEVA,SELARSDI (ustekinumab-aekn) - (STELARA biosimilar),moderate to severe plaque psoriasis and for active psoriatic arthritis in adults and pediatric patients 6 years and older.Â ,Approved,4/16/2024,"FDA approved on April 16, 2024.",0.0,14826.26542,30.9571,13.23,13.09,13.01,-0.010638398,-0.016768686,0.019883696,0.019411274,1.0202,0.03118,105.87137,728,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
ALVO,SELARSDI (ustekinumab-aekn) - (STELARA biosimilar),moderate to severe plaque psoriasis and for active psoriatic arthritis in adults and pediatric patients 6 years and older.Â ,Approved,4/16/2024,"FDA approved on April 16, 2024.",301.0,3558.8862,47.4421,12.5,12.73,13.4,0.018232768,0.069526063,0.019883696,0.019411274,0.06832,0.02187,4.80792,729,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
SAGE,Dalzanemdor (SAGE-718) - (PRECEDENT),Mild cognitive impairment (MCI)Â ,Phase 2,4/17/2024,"Phase 2 data did not show statistically significant differences versus placebo on the primary endpoint , noted April 17, 2024.",62.0,401663.162,9.871,50.0,50.0,50.0,0.0,0.0,0.025195017,0.019699841,0.0,0.0162,0.335,730,1,0,0,0,0,1,0,0,0,0,0,0,2,0,0,1
SUPN,Dalzanemdor (SAGE-718) - (PRECEDENT),Mild cognitive impairment (MCI)Â ,Phase 2,4/17/2024,"Phase 2 data did not show statistically significant differences versus placebo on the primary endpoint , noted April 17, 2024.",56.0,1587.31372,40.0297,29.43,29.0,30.26,-0.014718732,0.027812146,0.025195017,0.019699841,8.8111,0.11292,11.42107,731,1,0,0,0,0,1,0,0,0,0,0,0,2,0,0,1
LLY,Zepbound (Tirzepatide) - (SURMOUNT-OSA),Obstructive Sleep Apnea (OSA)Â ,Phase 3,4/17/2024,"Phase 3 trial data showed tirzepatide injection (10 mg or 15 mg) significantly reduced the apnea-hypopnea index (AHI) compared to placebo, achieving the primary endpoints, noted April 17, 2024.",946.0,676268.1649,27.4928,746.74,750.77,732.2,0.005382281,-0.019663365,0.025195017,0.019699841,0.60178,0.01132,2304.38866,732,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
GSK,Blujepa (Gepotidacin) - (EAGLE 2/3),Uncomplicated urinary tract infection (uUTI)Â ,Phase 3,4/17/2024,"Phase 3 EAGLE-1 data from ESCMID reported that gepotidacin (oral, two doses of 3,000mg) was non-inferior with 92.6% success rates when compared to 91.2% success rates for intramuscular (IM) ceftriaxon",0.0,64968.39771,18.1341,16.105,15.9,16.36,-0.012810674,0.015709548,0.025195017,0.019699841,0.0,0.00195,117.46287,733,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
HALO,Ocrevus Zunovo,Multiple sclerosis (MS) or primary progressive MSÂ ,Phase 3,4/17/2024,Phase 3 data reported near-complete suppression of clinical relapses and brain lesions in people with relapsing or primary progressive multiple sclerosis (RMS or PPMS) which reinforce the potential be,116.0,4830.60905,38.5577,38.38,38.02,39.12,-0.009424154,0.019097355,0.025195017,0.019699841,6.20677,0.21406,27.90124,734,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
NVS,Kesimpta (ofatumumab) - (ALITHIOS),Relapsing Multiple SclerosisÂ ,Phase 3,4/17/2024,"Additional Phase 3 data reported that significant reductions in ARR (71.3%) and in MRI lesion activity (Gd+ T1: 98.5% reduction; neT2: 93% reduction), and rapid increase in rates of NEDA-3, noted Apri",0.0,1334.20722,51.4945,4.3,4.3,4.35,0.0,0.011560822,0.025195017,0.019699841,0.0,0.00104,0.1763,735,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
MTVA,DA-1726,NASH and obesityÂ ,Phase 1a,4/17/2024,"Phase 1a dosing initiated, noted April 17, 2024.",24.0,16.97487,113.5985,3.4,3.46,3.1,0.017493157,-0.09237332,0.025195017,0.019699841,1.26157,0.00645,0.03974,736,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1
SNY,iluzanebart (VGL101) - (IGNITE),Adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP)Â ,Phase 2,4/17/2024,"Phase 2 interim results shared at the 2024 American Academy of Neurology (AAN) Annual Meeting demonstrated iluzanebart (VGL101) as potential disease-modifying therapy for ALSP, noted April 17, 2024.",0.0,107608.2844,34.9606,45.8,46.11,46.61,0.006745755,0.017531019,0.025195017,0.019699841,0.0,0.0,171.29293,737,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
SNY,VGL101 - (ILLUMINATE),Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP)Â ,Phase 2,4/17/2024,"Phase 2 Natural History Study show that MRI and fluid biomarkers are emerging as key measures of ALSP pathophysiology, noted April 17, 2024.",0.0,107608.2844,34.9606,45.8,46.11,46.61,0.006745755,0.017531019,0.025195017,0.019699841,0.0,0.0,171.29293,738,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
DMAC,Rinvecalinase Alfa (DM199) - (ReMEDy2),Acute ischaemic stroke (AIS)Â ,Phase 2/3,4/17/2024,"Phase 2/3 resumed with dosing of first patient, noted April 17, 2024.",51.0,98.6908,60.0722,2.37,2.6,2.45,0.09262149,0.033198069,0.025195017,0.019699841,0.53261,0.06571,0.1061,739,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
GLPG,GLPG5101 - (ATALANTA-1),Relapsed/refractory Non-Hodgkin Lymphoma (rrNHL)Â ,Phase 1/2,4/17/2024,"Phase 1/2 preliminary data reported that six patients responded to treatment (ORR 86%), including four CRs (CRR 57%), noted April 17, 2024.",65.0,1804.2618,27.1339,27.7,27.38,27.12,-0.011619593,-0.02116095,0.025195017,0.019699841,0.0,0.03344,2.86274,740,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ATHA,ATH-1020,"Healthy volunteers, Neuropsychiatric conditionsÂ ",Preclinical,4/17/2024,"Preclinical data presented at AAN reported that significantly enhanced neurite outgrowth, increased synaptic count, and promoted survival in primary neuron cultures, noted April 17, 2024.",3.0,80.86923,93.05,21.1,21.1,20.1,0.0,-0.048553225,0.025195017,0.019699841,2.63379,0.03941,0.23531,741,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
GLPG,GLPG5201 - (EUPLAGIA-1),"B-cell malignancies, Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)Â ",Phase 1/2,4/17/2024,"Phase 1/2 data reported an ORR of 93% , noted April 17, 2024.",65.0,1804.2618,27.1339,27.7,27.38,27.12,-0.011619593,-0.02116095,0.025195017,0.019699841,0.0,0.03344,2.86274,742,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ABBV,Tavapadon - (TEMPO-3),Late Parkinsonâ€™s diseaseÂ ,Phase 3,4/18/2024,"Phase 3 trial met its primary endpoint, noted April 18, 2024.",0.0,291554.7322,18.6511,164.25,164.66,167.29,0.002493085,0.018339176,0.021734794,0.029126527,0.74102,0.07372,737.71368,743,1,0,0,0,0,1,0,0,0,0,0,0,2,0,0,1
OCUL,AXPAXLI (OTX-TKI) - (HELIOS),Non-proliferative diabetic retinopathy (NPDR)Â ,Phase 1,4/18/2024,"Phase 1 interim data showed that demonstrated a 1- or 2-step improvement in the Diabetic Retinopathy Severity Scale (DRSS) at 40 weeks in the AXPAXLI arm, compared to 0% in the control arm. No patient",174.0,870.95679,102.3882,7.58,5.86,4.2,-0.257363596,-0.590428674,0.021734794,0.029126527,7.94491,0.04768,35.59393,744,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
BPTH,BP1002,Acute Myeloid Leukemia (AML)Â ,Phase 1b,4/18/2024,"Phase 1/1b second dose cohort completed, noted April 18, 2024.",8.0,3.16594,116.8904,3.24,4.2,2.635,0.259511195,-0.206690148,0.021734794,0.029126527,8.94222,0.00265,350.85696,745,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
BNTC,BB-301,Oculopharyngeal muscular dystrophy (OPMD)Â ,Phase 1/2,4/18/2024,"Phase 1b/2a interim safety and efficacy data reported that facilitated improvements across multiple measures of swallowing function in the first subject, as compared to pretreatment assessments conduc",26.0,17.6804,98.1887,4.8,6.82,6.94,0.351243554,0.368685857,0.021734794,0.029126527,0.42285,0.03629,23.99093,746,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
PBLA,Lvospemin (SBP-101),Ovarian cancerÂ ,Phase 1,4/18/2024,"Phase 1 data presented at AACR results suggest that SBP-101 in combination with doxorubicin may have a role in the clinical management of ovarian cancer, in particular the difficult to treat platinum-",4.0,2.37645,269.4529,0.516,0.4895,0.44,-0.052722304,-0.159332039,0.021734794,0.029126527,0.28641,0.00031,0.03245,747,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1
ATNM,Iomab-B - (SIERRA),Acute myeloid leukemia (AML)Â ,Phase 3,4/18/2024,Phase 3 data presented at the Annual European Bone Marrow Transplant Society Meeting (EBMT) demonstrated that Iomab-B led bone marrow transplant produced high rates of complete remission and durable c,31.0,196.07406,89.0766,7.25,6.67,6.56,-0.083381609,-0.100010866,0.021734794,0.029126527,7.43877,0.0117,2.80721,748,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
IMNN,IMNN-101 - (IMUNON),SARS-CoV-2 variant XBB.1.5Â ,IND-Enabling,4/18/2024,"IND Cleared by the FDA, noted April 18, 2024.",2.0,10.57475,119.2511,14.86956,14.67391,18.7826,-0.013245083,0.233614739,0.021734794,0.029126527,4.7157,0.00729,0.23045,749,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
ABBV,Upadacitinib (RINVOQ) - (SELECT-GCA),Giant cell arteritis (GCA)Â ,Phase 3,4/18/2024,"Phase 3 showed that upadacitinib (RINVOQ; 15 mg, once daily) in combination with a 26-week steroid taper regimen achieved its primary endpoint of sustained remissiona from week 12 through week 52, not",0.0,291554.7322,18.6511,164.25,164.66,167.29,0.002493085,0.018339176,0.021734794,0.029126527,0.74102,0.07372,737.71368,750,1,0,0,0,0,1,0,0,0,0,0,0,2,0,0,1
NRSN,PrimeC - (PARADIGM),Amyotrophic Lateral Sclerosis (ALS)Â ,Phase 2b,4/18/2024,Phase 2b data presented at AAN reported that PrimeC met safety and tolerability measures as well as statistically significant slowing of disease progression as demonstrated by the ALSFRS-R by 37% (p=0,23.0,26.34774,138.3702,1.6,1.52,1.26,-0.051293294,-0.238891908,0.021734794,0.029126527,0.36758,0.10794,0.40763,751,0,1,0,1,0,1,0,0,0,0,0,0,3,0,0,1
MGTX,AAV2-hAQP1 - (AQUAx2),XerostomiaÂ ,Phase 1,4/18/2024,"Phase 1 data presented at AAOM resulted in no treatment-related serious adverse events or dose-limiting toxicities were reported, and all participants completed the study, noted April 18, 2024.",80.0,321.728,78.6553,5.25,5.01,4.71,-0.046792162,-0.108540169,0.021734794,0.029126527,1.78449,0.15064,1.17857,752,0,0,0,1,0,1,0,0,0,0,0,0,0,2,0,-1
BRNS,VTP-200 - (APOLLO),Human papillomavirus (HPV)Â ,Phase 1/2,4/18/2024,"Additional Phase 1/2a met its primary endpoint, noted April 18, 2024.",40.0,105.47649,103.5361,2.6,2.71,2.4289,0.04143719,-0.068072965,0.021734794,0.029126527,0.02603,0.00011,0.02527,753,1,0,0,0,0,1,0,0,0,0,0,0,2,0,0,1
CLYD,VTP-200 - (APOLLO),Human papillomavirus (HPV)Â ,Phase 1/2,4/18/2024,"Additional Phase 1/2a met its primary endpoint, noted April 18, 2024.",0.0,1.02,370.1367,0.03,0.03,0.03,0.0,0.0,0.021734794,0.029126527,0.0,,0.0,754,1,0,0,0,0,1,0,0,0,0,0,0,2,0,0,1
TAK,ENTYVIO (vedolizumab),Crohn's DiseaseÂ ,Approved,4/18/2024,"FDA Approved by the FDA, noted April 18, 2024.",0.0,6415330.036,19.1128,13.15,13.16,13.07,0.000760167,-0.006102231,0.021734794,0.029126527,0.0,0.0,16.94672,755,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
TVGN,TVGN 489 - (TCTL Study),Cytotoxic T Lymphocytes for the Treatment of Elderly and High-Risk Patients with Covid-19Â ,Phase 1,4/19/2024,"Phase 1 study proof-of-concept clinical trial suggested the ability to target and eliminate a virus in high-risk population with multiple comorbidities, noted April 11, 2024.",196.0,304.53667,185.8154,2.12,1.85,1.0,-0.13623045,-0.751416089,-0.003229088,-0.000119782,0.00695,0.00204,0.38824,756,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
OCGN,OCU410 - (ArMaDa),Geographic Atrophy (GA)Â ,Phase 1/2,4/19/2024,"Phase 1/2 Cohort 2 dosing completed, noted April 19, 2024.",292.0,339.66935,105.9363,1.32,1.32,1.28,0.0,-0.030771659,-0.003229088,-0.000119782,16.89809,0.02626,8.77352,757,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CNTA,ORX750 - (CRYSTAL-1),Narcolepsy and other sleep-wake disordersÂ ,IND-Enabling,4/22/2024,"IND cleared by the FDA, noted April 22, 2024",134.0,1003.0585,80.2238,10.57,10.0,9.29,-0.055434707,-0.129081247,-0.022207216,-0.031959952,1.73293,0.18078,2.1081,758,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
KRYS,KB707 - (KYANITE-1),Solid TumorsÂ ,Phase 1,4/22/2024,"Phase 1 dosing initiated, noted April 22, 2024.",28.0,4483.91252,70.5204,158.53,157.25,157.99,-0.008106954,-0.00341211,-0.022207216,-0.031959952,7.62476,0.02848,53.75009,759,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1
ENLV,Allocetra - (ENX-CL-05-001),Knee osteoarthritis (OA)Â ,Phase 2,4/22/2024,"Phase 2 trial initiated, noted April 22, 2024.",23.0,23.89096,159.9022,1.32,1.27,1.66,-0.038614836,0.229185866,-0.022207216,-0.031959952,1.25656,0.02864,0.06544,760,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CORT,Relacorilant - (GRACE),Hypercortisolism (Cushing's Syndrome)Â ,Phase 3,4/22/2024,"Phase 3 additional results exhibited clinically meaningful and statistically significant improvements in hypertension, hyperglycemia and other key secondary and exploratory endpoints, noted April 22,",105.0,2315.5688,63.6788,22.95,22.3,23.37,-0.028731258,0.018135212,-0.022207216,-0.031959952,20.54224,0.02016,86.92498,761,0,0,0,0,0,1,0,0,1,0,0,0,2,0,0,1
PHIO,PH-762,Cutaneous Squamous Cell CarcinomaÂ ,Preclinical,4/22/2024,Preclinical studies demonstrated PH-762 is rapidly taken up by cells and robustly silences PD-1 mRNA and protein in lymphocytes within the tumor microenvironment (TME) Intratumoral injection of murine,5.0,3.81065,131.7579,5.7591,7.4691,6.075,0.259993297,0.053400777,-0.022207216,-0.031959952,0.46584,0.00048,6.0937,762,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ABEO,ZEVASKYN (prademagene zamikeracel),Recessive dystrophic epidermolysis bullosa (RDEB)Â ,CRL,4/22/2024,"CRL issued by the FDA, noted April 22, 2024.",51.0,201.33307,76.2204,7.57,7.36,3.44,-0.028133135,-0.788721596,-0.022207216,-0.031959952,7.29028,0.00265,7.56636,763,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,-1
AZTR,ATR12-351,Netherton SyndromeÂ ,Preclinical,4/22/2024,"Preclinical data suggests ATR-12 can significantly reduce IL-36g, a pro-inflammatory cytokine that drives Netherton syndrome, noted April 22, 2024.",3.0,5.6169,228.6311,38.96104,38.96104,43.95604,0.0,0.120627871,-0.022207216,-0.031959952,0.69588,0.00839,0.25979,764,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
TOVX,VCN-01 (VIRAGE),Metastatic PDACÂ ,Preclinical,4/22/2024,"Preclinical data demonstrated enhanced anti-tumor effects in a human pancreatic mouse xenograft, noted April 22, 2024.",9.0,7.04784,93.5829,10.38,10.275,10.5,-0.010167117,0.011494379,-0.022207216,-0.031959952,2.39682,0.05056,0.47476,765,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ACET,ADI-270,"Solid tumors CAR T, relapsed/refractory renal cell carcinoma (RCC)Â ",Preclinical,4/22/2024,"Preclinical findings showed robust anti-tumor activity of ADI-270 in multiple CD70-positive solid and hematological cancer models, noted April 22, 2024",83.0,181.22987,105.0366,1.95,2.0,1.59,0.025317808,-0.204095356,-0.022207216,-0.031959952,8.48325,0.02528,0.6507,766,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
IBRX,ANKTIVA,BCG-Unresponsive Non-Muscle Invasive Bladder CancerÂ ,Approved,4/22/2024,"Approved April 22, 2024.",945.0,3344.39685,132.5152,5.27,4.94,8.99,-0.064665031,0.534082486,-0.022207216,-0.031959952,8.08936,0.00683,27.01443,767,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1
TOVX,VCN-01 (zabilugene almadenorepvec),RetinoblastomaÂ ,Phase 1,4/23/2024,"Phase 1 topline data in collaboration with Sant Joan de DÃ©u-Barcelona Children's Hospital (SJD) determined to have a positive outcome by the study Monitoring Committee, safety and clinical outcomes su",9.0,6.46309,94.3608,10.275,9.4225,10.0625,-0.086613314,-0.020898118,-0.002266087,-0.010334475,2.39682,0.05056,0.44982,768,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
TLSA,Foralumab (Intranasal),Secondary Progressive Multiple Sclerosis (SPMS)Â ,Phase 2a,4/23/2024,"Phase 2a FDA allowed its intranasal foralumab na-SPMS Expanded Access (EA) Program to expand from 10 patients to a total of 30 patients, noted April 23, 2024.",111.0,77.73856,66.4584,0.7536,0.775,0.65675,0.028001306,-0.137558295,-0.002266087,-0.010334475,0.32117,0.02904,1.94762,769,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
SILO,SPC-15,Post-traumatic stress disorder (PTSD)Â ,Preclinical,4/23/2024,"Preclinical study of intranasal delivery showed rapid and effective drug exposure for PTSD Therapy, noted April 23, 2024.",9.0,5.06167,67.532,1.99,1.78,1.8377,-0.111521274,-0.079619849,-0.002266087,-0.010334475,2.15896,0.10808,9.36999,770,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
NBIX,Osavampator (NBI-1065845) - (SAVITRI),Major depressive disorderÂ ,Phase 2,4/23/2024,"Phase 2 study met its primary and key secondary endpoints, demonstrating that once-daily, oral administration of NBI-1065845 produced a statistically significant change from baseline in Montgomery Ã…sb",99.0,14090.32183,25.9813,133.66,140.09,137.54,0.046985811,0.028615522,-0.002266087,-0.010334475,2.41211,0.11564,225.23922,771,1,0,0,0,0,1,0,0,1,0,0,0,3,0,0,1
TAK,Osavampator (NBI-1065845) - (SAVITRI),Major depressive disorderÂ ,Phase 2,4/23/2024,"Phase 2 study met its primary and key secondary endpoints, demonstrating that once-daily, oral administration of NBI-1065845 produced a statistically significant change from baseline in Montgomery Ã…sb",0.0,6467145.334,19.1697,13.36,13.38,13.08,0.001495887,-0.021180822,-0.002266087,-0.010334475,0.0,0.0,22.77858,772,1,0,0,0,0,1,0,0,1,0,0,0,3,0,0,1
ANRO,ALTO-101,SchizophreniaÂ ,Phase 1,4/23/2024,Phase 1 study in healthy volunteers demonstrated favorable tolerability and improved pharmacokinetics of ALTO-101 when administered via a transdermal delivery system (TDS) compared to oral administrat,27.0,372.85723,0.0,13.64,13.88,15.51,0.017442303,0.128478325,-0.002266087,-0.010334475,8.9213,0.00026,1.18509,773,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
HOWL,IL-10 Indukine (PREDATOR Platform),Ulcerative Colitis (UC)Â ,Preclinical,4/23/2024,"Preclinical data in animal models supported unique conditionally active cytokine immunotherapy approach for the potential treatment, noted April 23, 2024.",45.0,279.15702,116.7671,6.09,6.44,6.24,0.055880458,0.024332101,-0.002266087,-0.010334475,1.0889,0.00604,2.53729,774,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
INMB,XPro1595 (pegipanermin) - (XPro),Neuroinflammation caused by Alzheimerâ€™s diseaseÂ ,Phase 2,4/23/2024,"Phase 3 preparation ongoing after 24-month validation data completed, noted April 23, 2024.",26.0,190.37835,80.8152,10.625,10.14,11.84,-0.046721717,0.108273915,-0.002266087,-0.010334475,8.1276,0.04747,1.81114,775,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
NVS,LUTATHERA (lutetium Lu 177) - (NETTER-P),Gastroenteropancreatic neuroendocrine tumors (GEP-NETs)Â ,Approved,4/23/2024,"FDA approved on April 23, 2024.",0.0,1427.29144,54.9715,4.88,4.6,4.36,-0.059088916,-0.112673163,-0.002266087,-0.010334475,0.0,0.00057,0.09887,776,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
DAWN,OJEMDA (tovorafenib),Low-grade GliomaÂ ,Approved,4/23/2024,"FDA Approved on April 23, 2024.",102.0,1453.95599,60.4801,15.38,16.64,17.1,0.078741471,0.106010499,-0.002266087,-0.010334475,10.28268,0.17464,111.5693,777,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
HOOK,HB-700,KRAS-mutated cancersÂ ,IND-Enabling,4/24/2024,"IND cleared by the FDA, noted April 24, 2024.",12.0,106.57989,100.3754,7.65,8.5,8.99,0.105360516,0.161407201,0.029598949,-0.030696515,0.25259,0.02106,8.87726,778,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
ALVO,AVT05 (biosimilar to golimumab),Rheumatoid ArthritisÂ ,Phase 3,4/24/2024,"Phase 3 trial met its primary endpoint, with results demonstrating therapeutic equivalence between AVT05 and Simponi. Additionally, no clinically meaningful differences in safety were observed through",301.0,3785.33537,47.1227,13.4,13.54,14.48,0.010393561,0.07751368,0.029598949,-0.030696515,0.05711,0.00774,2.58735,779,1,0,0,0,0,1,0,0,0,0,0,0,2,0,0,1
IMMP,Eftilagimod alpha (IMP321) and KEYTRUDA (pembrolizumab) - (TACTI-003),Head and neck squamous cell carcinoma (HNSCC)Â ,Phase 2b,4/24/2024,"Phase 2b enrollment completed, noted November 9, 2023. Phase 2b data from efti in combination in patients who do not express PD-L1 (TACTI-003, Cohort B) showed a preliminary 26.9% response rate, the p",145.0,534.97555,55.9075,2.51,2.59,2.6,0.031375123,0.035228692,0.029598949,-0.030696515,0.0,0.0,3.6384,780,0,0,0,0,0,1,0,0,0,1,0,0,2,0,0,1
ALKS,ALKS 2680 - (Vibrance-1),NarcolepsyÂ ,Phase 2,4/24/2024,"Phase 2 initiated, noted April 24, 2024.",165.0,4170.39011,40.3317,24.26,24.65,24.01,0.015947997,-0.010358493,0.029598949,-0.030696515,7.98986,0.02329,42.81752,781,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ATAI,BPL-003,Resistant DepressionÂ ,Phase 2a,4/24/2024,"Phase 2a OLE study initiated, noted April 24, 2024.",214.0,313.06167,98.924,1.97,1.87,2.05,-0.052095112,0.03980625,0.029598949,-0.030696515,3.52501,0.11802,1.57589,782,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
RDHL,RHB-107 (upamostat) - (ACESO PROTECT),Early COVID-19 outpatient treatmentÂ ,Phase 2,4/24/2024,"Phase 2 dosing commenced, noted April 24, 2024.",3.0,13.38094,243.0954,10.69465,10.4975,11.275,-0.018606483,0.052844269,0.029598949,-0.030696515,2.32669,3e-05,0.08109,783,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
AMRX,Naloxone hydrochloride nasal spray - (generic Narcan),Opioid overdoseÂ ,Approved,4/24/2024,"FDA Approved, noted April 24, 2024.",314.0,1866.75308,48.2579,5.4,6.05,6.12,0.113659318,0.125163143,0.029598949,-0.030696515,0.90884,0.05161,18.55227,784,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
CALC,Auxora - (CARPO),Acute PancreatitisÂ ,Phase 2b,4/24/2024,"Phase 2b enrolment completed, noted April 24, 2024.",13.0,58.96323,114.4365,4.59,5.49,5.96,0.179048231,0.261190457,0.029598949,-0.030696515,0.31291,0.11831,0.42117,785,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
NVS,Coartem (artemether-lumefantrine) - (CALINA),Malaria in babies <5 kgÂ ,Phase 2/3,4/24/2024,"Phase 2/3 data reported that the new formulation has good efficacy and safety, and the data have been submitted for regulatory review, noted April 24, 2024.",0.0,1349.72125,55.5675,4.6,4.35,4.36,-0.055880458,-0.053584246,0.029598949,-0.030696515,0.0,0.00057,0.03342,786,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
GANX,"GT-02287, GT-02329",GBA1 and Idiopathic Parkinson's DiseaseÂ ,Phase 1,4/24/2024,"Phase 1 data reported that treatment was generally well tolerated up to and including the highest planned dose level, and there were no serious adverse events, noted April 24, 2024.",35.0,51.74087,77.1706,3.39,3.19,2.97,-0.060809005,-0.132267969,0.029598949,-0.030696515,0.92231,0.00054,0.46833,787,0,0,0,1,0,1,0,0,0,0,0,0,0,0,2,0
ACRV,ACR-368,"Platinum-resistant ovarian,(PROC) endometrial, and urothelial cancersÂ ",Phase 2b,4/24/2024,"Phase 2b initial data demonstrated a 50% confirmed overall response rate observed with ACR-368 in OncoSignature-positive gynecological (ovarian and endometrial) cancers, noted April 24, 2024.",31.0,293.30407,125.8634,9.82,9.5,8.23,-0.033129324,-0.176635108,0.029598949,-0.030696515,3.32162,0.00541,3.04218,788,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
IBRX,Anktiva (N-803) + various Checkpoint Inhibitors (QUILT-3.055),"NSCLC, Various tumorsÂ ",Phase 2,4/25/2024,"Phase 2 results reported significant prolongation of overall survival, noted April 25, 2024.",945.0,3459.48743,129.1174,4.82,5.11,8.97,0.058425476,0.621111748,0.005375394,-0.051090748,8.10017,0.00683,43.72129,789,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
VTGN,PH15,Psychomotor impairment caused by mental fatigueÂ ,Phase 2a,4/25/2024,"Phase 2a data reported that treatment demonstrated a statistically significant improvement in reaction time compared to placebo and caffeine in sleep-deprived study participants, noted April 25, 2024.",30.0,127.01848,74.976,4.72,4.7,4.41,-0.004246291,-0.06793411,0.005375394,-0.051090748,4.78306,0.00209,0.91558,790,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1
BLCO,LCD supplement capsule,Dry eyesÂ ,Phase 1,4/25/2024,"Trial met both primary endpoints, noted April 25, 2024.",353.0,5180.70344,37.9347,14.9,14.76,13.86,-0.009440394,-0.072354219,0.005375394,-0.051090748,0.46399,0.087,3.70883,791,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1
TLSA,Foralumab,"Non-active, secondary-progressive multiple sclerosis (na-SPMS)Â ",Phase 2,4/25/2024,"Phase 2 data quantitative data showing improvement in White Matter Z-scores measured from PET images taken at 3 months in nasal foralumab, noted April 25, 2024.",111.0,84.36891,66.8253,0.7901,0.8411,0.7051,0.062551039,-0.113819883,0.005375394,-0.051090748,0.25699,0.02904,0.74832,792,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
BIVI,Bezisterim (NE3107) - (Biomarker Trial),Alzheimer's diseaseÂ ,Phase 2,4/25/2024,"Phase 2 data shared at the Annual Alzheimer's & Parkinson's Drug Development Summit shows how bezisterim may be restoring homeostasis via specific genes associated with dementia, metabolism, and infla",7.0,26.84144,196.7348,50.54,48.89,49.99,-0.033192225,-0.010942117,0.005375394,-0.051090748,2.02737,0.0114,0.38388,793,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ROIV,Namilumab - (RESOLVE-Lung),SarcoidosisÂ ,Phase 2,4/25/2024,"Phase 2 enrollment completed, noted April 25, 2024.",682.0,8767.60455,38.4991,10.9,10.88,11.24,-0.001836548,0.030716055,0.005375394,-0.051090748,5.60026,0.11755,40.47067,794,0,0,0,0,0,1,0,0,0,1,0,0,2,0,0,1
ALGS,ALG-097558,COVID-19Â ,Phase 1,4/25/2024,"Phase 1 data presented at ECCMID showed that single (up to 2000 mg) and multiple (up to 800 mg Q12 for 7 days) doses of this potent, pan-coronavirus protease inhibitor were well tolerated in healthy v",6.0,61.89683,89.3154,20.725,20.45,21.15,-0.013357819,0.020299204,0.005375394,-0.051090748,0.86853,0.1542,0.10918,795,0,0,0,1,0,1,0,0,0,0,0,0,2,0,0,1
NKGN,Troculeucel (SNK01),Alzheimer's DiseaseÂ ,Phase 1,4/25/2024,Preclinical data to be presented at the Alzheimer's & Parkinson's Drug Development Summit shows a direct ability to phagocytose and digest amyloid and alpha-synuclein proteins while also secreting imm,124.0,45.15517,182.8366,1.71,1.98,1.32,0.146603474,-0.258861634,0.005375394,-0.051090748,1.85819,0.00513,4.09522,796,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
PFE,BEQVEZ (fidanacogene elaparvovec-dzkt),Hemophilia BÂ ,Approved,4/26/2024,"Approval announced April 26, 2024.",0.0,143828.5488,26.1615,25.26,25.4,27.81,0.005527057,0.096173551,-0.039351685,-0.090188842,1.20198,0.02483,1181.77201,797,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
GILD,Biktarvy,HIVÂ ,Approved,4/26/2024,"Approved for updated label on (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, B/F/TAF) to treat pregnant people with HIV-1 (PWH) with suppressed viral loads, noted April 2",0.0,81452.95167,25.1053,65.27,65.42,64.78,0.002295509,-0.007535599,-0.039351685,-0.090188842,1.70127,0.07102,810.05824,798,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1
CDTX,JNJ-0953 (CD388) - (ANCHOR),Seasonal InfluenzaÂ ,Phase 2a,4/26/2024,Phase 2a data presented at ESCMID reported that well tolerated and demonstrated statistically significant antiviral effects when administered as a single subcutaneous dose in healthy volunteers challe,25.0,57.61492,83.9854,13.0,12.63,12.51,-0.028874421,-0.038421033,-0.039351685,-0.090188842,0.17906,0.02553,2.52736,799,0,0,0,1,0,1,0,0,0,0,0,0,2,0,0,1
JNJ,JNJ-0953 (CD388) - (ANCHOR),Seasonal InfluenzaÂ ,Phase 2a,4/26/2024,Phase 2a data presented at ESCMID reported that well tolerated and demonstrated statistically significant antiviral effects when administered as a single subcutaneous dose in healthy volunteers challe,0.0,352165.6955,13.5345,146.82,146.14,149.27,-0.00464228,0.0165494,-0.039351685,-0.090188842,0.68735,0.12025,903.58099,800,0,0,0,1,0,1,0,0,0,0,0,0,2,0,0,1
ENTA,EDP-235 - (SPRINT),COVID-19Â ,Phase 2,4/27/2024,"Phase 2 data presented at ESCMID reported that the EDP-235 400 mg arm achieved greater mean change in TSS compared with the placebo arm at all time points, noted April 27, 2024.",21.0,261.69951,64.58,12.37,12.37,15.17,0.0,0.204045607,-0.024023403,-0.074860559,12.97295,0.05986,0.0,801,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1
AZN,Enhertu - (DESTINY-Breast06),"HR-positive, HER2-low (IHC 1+ or 2+/ISH-) metastatic breast cancerÂ ",Phase 3,4/29/2024,"Phase 3 data reported statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to standard-of-care chemotherapy, noted April 29, 2024",0.0,186399.7855,22.4032,119.88,120.24,120.5,0.002998503,0.00515851,-0.013443781,-0.081506574,0.0,0.19694,445.38615,802,1,0,0,0,0,1,0,0,0,0,0,0,2,0,0,1
AQST,Libervant (diazepam) - (pediatric),Acute treatment seizure activityÂ ,Approved,4/29/2024,"FDA Approved on April 29, 2024.",99.0,340.02892,93.2461,4.07,3.735,3.5,-0.085895181,-0.150880031,-0.013443781,-0.081506574,4.40314,0.00101,28.56347,803,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
XFOR,XOLREMDI (mavorixafor),WHIM syndromeÂ ,Approved,4/29/2024,"Approved April 29, 2024.",11.0,183.05216,108.8899,34.95003,32.70003,36.00004,-0.066543332,0.029600723,-0.013443781,-0.081506574,7.30319,0.15033,23.86821,804,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1
PRME,PM359,Chronic Granulomatous Disease (CGD)Â ,IND-Enabling,4/29/2024,"IND cleared by the FDA, noted April 29, 2024.",134.0,560.32309,88.6465,4.425,4.86,5.4,0.093768159,0.199128675,-0.013443781,-0.081506574,8.85887,0.22345,6.16477,805,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
ADXN,ADX71149 (mGlu2 PAM) - (JNJ-40411813),EpilepsyÂ ,Phase 2,4/29/2024,"Phase 2 trial did not meet its primary endpoint, noted April 29, 2024.",1.0,8.0802,146.5067,0.1155,0.063,0.075,-0.606135804,-0.431782416,-0.013443781,-0.081506574,0.0,0.00142,0.73788,806,1,0,0,0,0,1,0,0,0,0,0,0,0,2,0,-1
JNJ,ADX71149 (mGlu2 PAM) - (JNJ-40411813),EpilepsyÂ ,Phase 2,4/29/2024,"Phase 2 trial did not meet its primary endpoint, noted April 29, 2024.",0.0,353804.348,13.1314,146.14,146.82,148.58,0.00464228,0.016558467,-0.013443781,-0.081506574,0.68735,0.12025,948.69035,807,1,0,0,0,0,1,0,0,0,0,0,0,0,2,0,-1
ATHE,ATH434,Parkinson's DiseaseÂ ,Preclinical,4/29/2024,"Preclinical data presented at the World Orphan Drug Congress USA 2024 Indicated that ATH434 can function as an iron chaperone to redistribute iron, noted April 29, 2024.",15.0,31.47069,180.6609,2.51,2.195,2.01,-0.134100707,-0.222148031,-0.013443781,-0.081506574,0.0,0.0,0.3751,808,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ITRM,ORLYNVAH (Oral Sulopenem),Uncomplicated urinary tract infections (uUTI)Â ,NDA Filing,4/29/2024,"NDA resubmitted to the FDA, noted April 29, 2024.",44.0,25.49452,128.5134,1.67,1.54,1.59,-0.08104121,-0.04908961,-0.013443781,-0.081506574,7.23115,0.07299,0.78766,809,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
SLS,Galinpepimut-S - (REGAL),Acute Myeloid Leukemia (AML)Â ,Phase 3,4/29/2024,"IDMC recommended the continuation of the trial, noted April 29, 2024.",105.0,69.88346,118.6534,1.46,1.21,1.29,-0.187816076,-0.123794217,-0.013443781,-0.081506574,9.8107,0.01803,4.03264,810,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
AZN,Ampligen (rintatolimod) with Imfinzi (durvalumab) - (DURIPANC),Pancreatic CancerÂ ,Phase 1/2,4/29/2024,"Phase 1b/2 first dose level is generally well tolerated, noted April 29, 2024.",0.0,186399.7855,22.4032,119.88,120.24,120.5,0.002998503,0.00515851,-0.013443781,-0.081506574,0.0,0.19694,445.38615,811,0,0,0,1,0,1,0,0,0,0,0,0,2,0,0,1
AIM,Ampligen (rintatolimod) with Imfinzi (durvalumab) - (DURIPANC),Pancreatic CancerÂ ,Phase 1/2,4/29/2024,"Phase 1b/2 first dose level is generally well tolerated, noted April 29, 2024.",2.0,73.08492,60.5892,0.34,0.35,0.345,0.028987537,0.014598799,-0.013443781,-0.081506574,0.0,0.02082,0.00044,812,0,0,0,1,0,1,0,0,0,0,0,0,2,0,0,1
LGND,V116 - (STRIDE-10),Pneumococcal vaccineÂ ,Phase 3,4/29/2024,"Phase 3 data presented at ESCMID Global showed that results build on the data supporting the clinical profile of V116 for adults, noted April 29, 2024.",19.0,1265.34562,43.1683,70.57,70.46,72.83,-0.001559952,0.031522833,-0.013443781,-0.081506574,4.60292,0.30034,13.92712,813,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
MRK,V116 - (STRIDE-10),Pneumococcal vaccineÂ ,Phase 3,4/29/2024,"Phase 3 data presented at ESCMID Global showed that results build on the data supporting the clinical profile of V116 for adults, noted April 29, 2024.",0.0,329597.628,16.6636,131.2,130.12,127.57,-0.008265775,-0.028057643,-0.013443781,-0.081506574,0.80654,0.01085,888.63802,814,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ANVS,Buntanetap (ANVS401),Alzheimerâ€™s disease (AD)Â ,Phase 2/3,4/29/2024,"Phase 2/3 AD study data reported a significantly higher improvement in ADAS-Cog 11 scores in each treatment dose relative to placebo for patients with mild AD (n=90), after unblinding the data to scre",19.0,80.16226,182.5694,18.01,7.28,5.39,-0.905796297,-1.206381774,-0.013443781,-0.081506574,13.19292,0.04736,69.85489,815,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
TERN,TERN-701 - (CARDINAL),Chronic myeloid leukemia (CML)Â ,Phase 1,4/29/2024,"Phase 1 interim data showed no clinically significant difference in exposure between fed and fasted dosing, noted April 29, 2024.",87.0,329.84138,90.3146,4.91,5.1,5.79,0.037966598,0.16485835,-0.013443781,-0.081506574,6.79779,1e-05,2.51141,816,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
TFFP,TFF TAC (Tacrolimus Inhalation Powder),Lung transplant (post)Â ,Phase 2,4/29/2024,"Phase 2 demonstrated that treatment with TFF TAC prevents Lung Transplant Rejection at only one-sixth of the dose of oral Tacrolimus and at Two-thirds of the oral Tacrolimus Systemic Trough Exposures,",4.0,923.568,69.8436,45.0,45.0,45.0,0.0,0.0,-0.013443781,-0.081506574,0.0,0.0,0.0,817,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
PFE,TIVDAK (tisotumab vedotin-tftv),Cervical Cancer with disease progression on or after first-line therapyÂ ,Approved,4/29/2024,"Approved April 29, 2024.",0.0,145187.5587,25.7947,25.4,25.64,28.16,0.009404458,0.103153357,-0.013443781,-0.081506574,1.20198,0.02483,1068.53174,818,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1
GMAB,TIVDAK (tisotumab vedotin-tftv),Cervical Cancer with disease progression on or after first-line therapyÂ ,Approved,4/29/2024,"Approved April 29, 2024.",661.0,127379.8139,32.5572,1954.5,1970.0,2004.0,0.007899136,0.025010777,-0.013443781,-0.081506574,0.0,0.07436,245.88555,819,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1
MOLN,MP0533,Acute myeloid leukemia (AML)Â ,Preclinical,4/29/2024,"Preclinical data of tetra-specific T cell engager MP0533 demonstrated preferential T cell mediated killing of AML cells, while sparing healthy cells, noted April 29 2024.",40.0,104.68745,56.5668,3.36,3.185,3.35,-0.053488685,-0.002980628,-0.013443781,-0.081506574,0.0,0.05956,0.02266,820,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
VERU,Enobosarm with semaglutide (Wegovy) - (PLATEAU),ObesityÂ ,Phase 2b,4/30/2024,"IND cleared February 6, 2024. Phase 2b first patient dosed April 30, 2024.",14.0,197.61459,127.22,12.5,13.5,16.3,0.076961041,0.265436464,-0.02094378,-0.055825804,7.5501,0.00012,5.01321,821,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
NBIX,TAK-653 / NBI-1065845,Major Depressive Disorder (MDD)Â ,Phase 2,4/30/2024,"Phase 2 study met its primary and key secondary endpoints, noted April 2024.",99.0,13833.84156,26.0777,138.89,137.54,143.19,-0.009767469,0.030490167,-0.02094378,-0.055825804,2.00974,0.13381,132.93709,822,1,0,0,0,0,1,0,0,1,0,0,0,3,0,0,1
TAK,TAK-653 / NBI-1065845,Major Depressive Disorder (MDD)Â ,Phase 2,4/30/2024,"Phase 2 study met its primary and key secondary endpoints, noted April 2024.",0.0,6515782.283,15.6201,13.17,13.08,13.28,-0.00685717,0.008317628,-0.02094378,-0.055825804,0.0,0.0,11.89756,823,1,0,0,0,0,1,0,0,1,0,0,0,3,0,0,1
AUPH,LUPKYNIS (Voclosporin) - (updated label),Lupus NephritisÂ ,Approved,4/30/2024,"Updated label approved April 30, 2024.",135.0,736.10441,62.8945,5.01,5.09,5.12,0.015841915,0.021718524,-0.02094378,-0.055825804,7.87767,0.15708,8.04763,824,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1
VRPX,Probudur,Pain ReliefÂ ,Preclinical,4/30/2024,"MTD data reported that all doses were well-tolerated, noted April 30, 2024.",1.0,3.10375,147.4997,69.25,66.25,54.0,-0.04428768,-0.248739099,-0.02094378,-0.055825804,1.26696,0.00175,0.0479,825,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1
SNTI,SENTI-202,Acute Myeloid Leukemia (AML)Â ,Preclinical,4/30/2024,"Preclinical data reported that the engineered NK cells killed multiple AML subtypes while protecting primary hematopoietic stem cells (HSCs), noted April 30, 2024.",26.0,16.45206,138.9015,3.097,3.6,4.018,0.150499944,0.260350365,-0.02094378,-0.055825804,0.36157,0.0115,0.86334,826,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
NRXP,NRX-101,Bipolar Depression and Suicidal IdeationÂ ,Phase 2/3,4/30/2024,"Phase 2/3 top line data reported that NRX-101 vs lurasidone demonstrated a promising, though not yet statistically significant 33% reduction in suicidality together with a 70% reduction (P=.076) reduc",19.0,26.88722,145.5802,3.55,2.58,2.81,-0.319158205,-0.23376312,-0.02094378,-0.055825804,4.90173,0.0582,2.41909,827,0,1,0,0,0,1,0,0,0,0,1,0,3,0,0,1
VXRT,Norovirus vaccine - (lactating mothers trial),NorovirusÂ ,Phase 1,4/30/2024,"Phase 1 topline data reported no vaccine-related serious adverse events (SAEs) and no dose-limiting pharmacotoxicity, noted April 30, 2024.",228.0,126.38613,80.7235,0.7133,0.7147,0.7384,0.001960785,0.034583594,-0.02094378,-0.055825804,10.37269,0.07211,1.41053,828,0,0,0,1,0,1,0,0,0,0,1,0,0,3,0,-1
INMB,XPro1595 (pegipanermin) - (XPro),Neuroinflammation caused by Alzheimerâ€™s diseaseÂ ,Phase 1b,4/30/2024,"Phase 1b compassionate use data reported that treatment has been well-tolerated throughout the treatment period, with stable cognitive function observed in the patients. Furthermore, the patients expr",26.0,233.97006,81.1599,11.77,11.84,11.18,0.005929708,-0.051427454,-0.02094378,-0.055825804,7.5953,0.07743,5.22798,829,0,0,0,1,0,1,0,0,0,0,0,0,2,0,0,1
SCYX,SCY-247,Pulmonary mucormycosisÂ ,Preclinical,4/30/2024,"Preclinical data shared at the ECCMID reported that SCY-247 showed in vitro activity against a broad range of pathogenic fungi, including azole-resistant strains of Candida and Aspergillus species, no",41.0,63.84786,70.0318,1.82,1.69,1.845,-0.074107972,0.013642776,-0.02094378,-0.055825804,2.75213,0.08018,0.40047,830,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
NBIX,INGREZZA SPRINKLE (valbenazine) Capsules,Tardive dyskinesia (TD)Â ,Approved,4/30/2024,"Approved April 30, 2024.",99.0,13833.84156,26.0777,138.89,137.54,143.19,-0.009767469,0.030490167,-0.02094378,-0.055825804,2.00974,0.13381,132.93709,831,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1
ACXP,Ibezapolstat,C. difficile InfectionÂ ,Phase 2b,4/30/2024,"Phase 2b data results shared at ESCMID einforced earlier findings related to the anti-recurrence properties, noted April 30, 2024.",1.0,34.81082,96.7135,43.8,44.0,39.4,0.004555817,-0.105868001,-0.02094378,-0.055825804,3.65997,0.02867,0.07951,832,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
MRK,KEYTRUDA (pembrolizumab) in combination with trastuzumab - (KEYNOTE-811),HER2-positive gastric or Gastroesophageal junction (GEJ) adenocarcinomaÂ ,Phase 3,5/1/2024,"Phase 3 trial met its dual primary endpoint of overall survival (OS), noted May 1, 2024.",0.0,326254.0307,16.7253,129.22,128.8,129.55,-0.003255564,0.002550529,-0.043022361,-0.051700916,0.80654,0.01085,759.37994,833,1,0,0,0,0,1,0,0,0,0,0,0,2,0,0,1
PALI,PALI-2108,Moderate-to-severe ulcerative colitis (UC)Â ,Preclinical,5/1/2024,"Preclinical successful completion of its analysis to determine the effects of bioactivated PALI-2108 on TNF-Î± production in a whole blood (WB) assay, noted May 1, 2024.",9.0,6.02792,149.0113,6.03,7.08,7.06,0.160526897,0.157698041,-0.043022361,-0.051700916,4.05402,0.04972,86.8387,834,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1
SLS,Tambiciclib (SLS009) (GFH009) with venetoclax,"Hematologic malignancies, acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) and lymphomaÂ ",Phase 2,5/1/2024,"Phase 2 30 mg cohort showed a 100% overall response rate in patients with ASXL1 mutation, treatment exhibited strong anti-leukemic activity in 62% of patients with a favorable safety profile across al",105.0,73.92631,115.9323,1.24,1.28,1.28,0.031748698,0.031748698,-0.043022361,-0.051700916,9.8107,0.01803,12.18197,835,0,0,0,1,0,1,0,0,0,0,0,0,2,0,0,1
COCP,CC-42344,Influenza AÂ ,Phase 2a,5/1/2024,"Phase 2a enrollment completed, noted May 1, 2024.",10.0,15.5659,59.2579,1.55,1.53,1.605,-0.012987196,0.034868826,-0.043022361,-0.051700916,0.01466,0.00898,0.03566,836,0,0,0,0,0,1,0,0,0,1,0,0,2,0,0,1
DNLI,DNL343 - (HEALEY),Amyotrophic lateral sclerosis (ALS)Â ,Phase 2/3,5/1/2024,"Phase 2/3 trial enrollment completed noted May 1, 2024.",146.0,2303.43879,82.1006,15.44,16.16,18.9,0.045577508,0.202200377,-0.043022361,-0.051700916,6.71793,0.22361,21.99846,837,0,0,0,0,0,1,0,0,0,1,0,0,2,0,0,1
BCDA,CardiAMP (BCDA-02),Chronic Myocardial IschemiaÂ ,Phase 3,5/1/2024,"Phase 3 data reported that 100% of patients responded for the change in Angina Episodes per week, noted May 1, 2024.",5.0,10.10756,169.4965,5.8065,5.643,5.91,-0.028562141,0.017667852,-0.043022361,-0.051700916,1.00929,0.02775,0.46309,838,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
KZIA,EVT801,Renal cell carcinoma and soft-tissue sarcomaÂ ,Phase 1,5/1/2024,"Phase 1 trial successful and complete, noted May 1, 2024.",1.0,7.87418,119.1072,16.74,14.935,14.46,-0.114093613,-0.146414848,-0.043022361,-0.051700916,0.06959,0.00567,0.20678,839,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1
GLTO,GB1211 in combination with KEYTRUDA (pembrolizumab),Melanoma and head and neck squamous cell carcinoma (HNSCC)Â ,Phase 2,5/1/2024,"Phase 2 trial initiated, noted May 1, 2024.",1.0,18.43933,68.9614,16.8875,17.0025,17.625,0.006786689,0.042744645,-0.043022361,-0.051700916,0.06624,0.08647,0.03217,840,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
AZN,"Calquence (acalabrutinib) with chemoimmunotherapy, bendamustine and rituximab - (ECHO)",Mantle cell lymphoma (MCL)Â ,Phase 3,5/2/2024,"Phase 3 data reported a statistically significant and clinically meaningful improvement in progression-free survival (PFS) versus standard of care, noted May 2, 2024.",0.0,188446.5696,22.4079,121.7,121.56,123.32,-0.001151032,0.013223603,-0.029893377,-0.018717579,0.0,0.19694,243.90747,841,1,0,0,0,0,1,0,0,0,0,0,0,2,0,0,1
CNTX,CTIM-76,Various cancersÂ ,IND-Enabling,5/2/2024,"IND Cleared by the FDA, noted May 2, 2024.",89.0,27.94059,86.0993,1.36,1.75,1.83,0.252131088,0.296831267,-0.029893377,-0.018717579,0.25309,0.06172,46.43829,842,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
PTN,Bremelanotide with Tirzepatide (GLP-1),ObesityÂ ,IND-Enabling,5/2/2024,"IND clearance by the FDA, noted May 2, 2024.",46.0,78.93609,69.1163,0.066,0.067,0.061,0.015037877,-0.078780878,-0.029893377,-0.018717579,0.0,2e-05,0.10254,843,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ALLR,Stenoparib,Advanced ovarian cancer (AOC)Â ,Phase 2,5/2/2024,"Phase 2 trial discontinued early due to clear clinical benefit, including tumor shrinkage and long-term disease stability, noted May 2, 2024.",14.0,0.38,96.5127,41.10004,36.90004,22.62002,-0.10779646,-0.59717374,-0.029893377,-0.018717579,34.00495,0.21126,116.08748,844,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ELAB,EL-22 (BLS-M22),GLP-1 Weight Loss Drugs and Age-Related SarcopeniaÂ ,Preclinical,5/2/2024,"Preclinical data reported statistically significant increase in anti-myostatin IgG antibody concentration, where myostatin is a key negative regulator of muscle growth, noted May 2, 2024.",0.0,12.21511,0.0,3194.80051,3454.50055,3346.21054,0.07815324,0.046303876,-0.029893377,-0.018717579,0.31627,0.00972,1.11235,845,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1
IMMP,Eftilagimod alpha with pembrolizumab and radiotherapy - (EFTISARC-NEO),Soft tissue sarcomaÂ ,Phase 2,5/2/2024,"Phase 2 trial is well tolerated and has led to encouraging initial efficacy data. Four of six patients treated have very good, near-complete pathologic responses (primary endpoint of study) that are r",145.0,499.31052,55.9186,2.6,2.69,3.01,0.034029749,0.146428634,-0.029893377,-0.018717579,0.0,0.0,0.45351,846,0,0,0,1,0,1,0,0,0,0,0,0,2,0,0,1
AEON,ABP-450 (prabotulinumtoxinA),Chronic Migraine (prophylaxis)Â ,Phase 2,5/3/2024,"Phase 2 trial did not meet its primary endpoint, noted May 3, 2024.",11.0,65.93051,166.1129,241.91998,122.39999,124.55999,-0.681312722,-0.663819563,-0.025040432,0.002266547,1.11607,0.0421,1.58373,847,1,0,0,0,0,1,0,0,0,0,0,0,0,2,0,-1
XOMA,Seralutinib (GB002) - (TORREY/PROSERA),Pulmonary arterial hypertension (PAH)Â ,Phase 2,5/3/2024,Phase 2 data from TPRREY trail published at the Lancet Respiratory Medicine journal confirmed results demonstrating a statistically significant improvement for seralutinib compared to placebo in the p,12.0,288.31567,57.6104,25.44,24.78,25.44,-0.026285862,0.0,-0.025040432,0.002266547,2.42188,0.00305,0.20352,848,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1
GOSS,Seralutinib (GB002) - (TORREY/PROSERA),Pulmonary arterial hypertension (PAH)Â ,Phase 2,5/3/2024,Phase 2 data from TPRREY trail published at the Lancet Respiratory Medicine journal confirmed results demonstrating a statistically significant improvement for seralutinib compared to placebo in the p,227.0,167.4018,93.9671,0.7713,0.74,0.7423,-0.041427217,-0.038323929,-0.025040432,0.002266547,4.91226,0.14032,3.20387,849,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1
CGON,Cretostimogene - (BOND-003),BCG-unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) with Carcinoma in SituÂ ,Phase 3,5/3/2024,"Phase 3 data presented at AUA showed sustained, durable complete responses over 12 months with novel investigational oncolytic immunotherapy. Although the median duration of response (DOR) was not rea",76.0,2416.89686,0.0,39.5,36.27,28.5,-0.085309719,-0.326396585,-0.025040432,0.002266547,4.20452,0.1641,88.61363,850,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
URGN,UGN-102 - (ATLAS),Non-Muscle-Invasive Bladder CancerÂ ,Phase 3,5/4/2024,"Data from AUA 2024 reported that DOR at 12 months after achieving CR at 3 months was 87.5% and 69.1% in new and recurrent patients, respectively. Also, patients achieved similar probabilities of DFS r",46.0,487.94584,61.9111,14.3,14.3,12.74,0.0,-0.115512887,-0.006646015,0.020660964,12.30565,0.02043,0.0,851,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1
MNMD,MM120 ODT (Lysergide (LSD)) - (Emerge),Major Depressive Disorder (MDD)Â ,Phase 2,5/4/2024,"Phase 2 data at APA reported clinically and statistically significant efficacy compared to placebo at its primary week 4 and secondary week 12 timepoints, noted May 4, 2024.",75.0,718.72422,102.3772,10.0,10.0,9.26,0.0,-0.076881044,-0.006646015,0.020660964,9.63392,0.10019,0.0,852,0,0,0,0,0,1,0,0,1,0,0,0,2,0,0,1
IRD,APX3330 Oral Pill - (ZETA-1),Diabetic Retinopathy (DR) / Macular Edema (DME)Â ,Phase 2,5/5/2024,"Additional data shared at ARVO on May 5, 2024 reported that no participants in the APX3330 group had a â‰¥ 4-step worsening at week 24 compared to 15.2% in the placebo group, representing a 100% reducti",59.0,50.96093,67.2031,1.99,1.99,1.72,0.0,-0.145810348,-0.006646015,0.020660964,6.17083,0.04518,0.0,853,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
VTRS,APX3330 Oral Pill - (ZETA-1),Diabetic Retinopathy (DR) / Macular Edema (DME)Â ,Phase 2,5/5/2024,"Additional data shared at ARVO on May 5, 2024 reported that no participants in the APX3330 group had a â‰¥ 4-step worsening at week 24 compared to 15.2% in the placebo group, representing a 100% reducti",0.0,13989.56458,27.6857,11.78,11.78,11.16,0.0,-0.054067221,-0.006646015,0.020660964,3.46463,0.07658,0.0,854,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
NNVC,NV-387,"Influenza A viruses, Bird Flu H5N1Â ",Preclinical,5/6/2024,"Preclinical data reported that in a lethal animal model of lung infection by Influenza A /H3N2 virus, NV-387 was found to have substantially superior antiviral effects compared to three approved anti-",17.0,16.4906,67.2,1.13,1.4,1.82,0.214254604,0.476618868,-0.004988647,0.001111976,0.95189,0.0137,1.49503,855,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1
EYPT,DURAVYU ( EYP-1901 vorolanib intravitreal) - (PAVIA),Non-proliferative diabetic retinopathy (NPDR)Â ,Phase 2,5/6/2024,"Phase 2 trial did not meet the pre-specified primary endpoint, noted May 6, 2024.",68.0,583.34246,182.3796,19.74,11.2,12.22,-0.566733256,-0.47957308,-0.004988647,0.001111976,12.549,0.04381,108.1063,856,1,0,0,0,0,1,0,0,0,0,0,0,0,2,0,-1
APLM,Uproleselan,Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)Â ,Phase 3,5/6/2024,"Phase 3 data reported that median overall survival of 13 months, compared to 12.3 months in the placebo arm. Adverse events were consistent with known side effect profiles of chemotherapy used in the",1.0,37.57924,94.3481,39.65,41.99,34.98,0.057340547,-0.125314478,-0.004988647,0.001111976,0.23383,0.09373,0.08339,857,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ADCT,ZYNLONTA (loncastuximab tesirine-lpyl),Relapsed/refractory (r/r) marginal zone lymphoma (MZL)Â ,Phase 2,5/6/2024,"Phase 2 data reported that treatment was generally well-tolerated and safety was consistent with the known profile, with two patient discontinuations, with both of these patients remain in CR at 10 an",112.0,368.5223,137.7915,4.9,4.45,4.19,-0.096331109,-0.156534471,-0.004988647,0.001111976,1.07244,0.02701,14.9719,858,1,0,0,1,0,1,0,0,0,0,0,0,3,0,0,1
VYNE,VYN202,Moderate-to-severe plaque psoriasisÂ ,IND-Enabling,5/6/2024,"IND Cleared by the FDA, noted April 6, 2024.",25.0,38.20799,78.9668,2.62,2.71,2.83,0.033774317,0.077102394,-0.004988647,0.001111976,0.68676,0.12469,0.09688,859,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
LYRA,LYR-210 - (ENLIGHTEN I),Chronic rhinosinusitisÂ ,Phase 3,5/6/2024,Phase 3 data reported that the trial did not meet its primary endpoint of demonstrating statistically significant improvement compared to sham control in the composite score of the three cardinal symp,1.0,31.79317,299.795,201.5,26.075,18.13,-2.04481238,-2.408221357,-0.004988647,0.001111976,0.54713,0.00963,56.65847,860,1,0,0,0,0,1,0,0,0,0,1,0,0,0,3,0
BCAB,BA3361 (CAB-Nectin-4),Multiple tumor typesÂ ,IND-Enabling,5/6/2024,"IND cleared by the FDA, noted May 6 2024.",58.0,152.49703,136.4554,3.25,3.17,2.64,-0.024923408,-0.207876079,-0.004988647,0.001111976,11.25706,0.3139,1.77734,861,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
DRTS,Alpha DaRT,Pancreatic CancerÂ ,Preclinical,5/6/2024,"Preclinical data reported that a statistically significant (FDR adjusted p-value < 0.05) decline in secondary tumor growth rate was found at days 21, 25 and 29 in those mice that received Alpha DaRT",70.0,171.38971,44.6909,2.49,2.46,2.65,-0.012121361,0.06227693,-0.004988647,0.001111976,0.06251,0.01584,0.10786,862,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1
CALT,Setanaxib with pembrolizumab,Squamous Cell Carcinoma of the Head and Neck (SCCHN)Â ,Phase 2,5/6/2024,"Phase 2 final data reported statistically significant improvements in key secondary endpoints, such as progression-free survival, (PFS median 5 months versus 2.9 months; Hazard ratio= 0.58) and statis",26.0,641.4408,24.8776,5.3,5.34,5.3,0.007518832,0.0,-0.004988647,0.001111976,0.0,0.00835,0.04139,863,1,0,0,0,0,1,0,0,1,0,0,0,3,0,0,1
BLTE,Tinlarebant (LBS-008) - (DRAGON),Adolescent Stargardt disease (STGD1)Â ,Phase 2/3,5/6/2024,"Phase 2/3 24-month data shared at ARVO 2024 provided further support for the potential of Tinlarebant to slow and potentially halt lesion growth, May 6, 2024.",32.0,1262.17093,51.3364,43.2,43.3,41.685,0.00231214,-0.035699143,-0.004988647,0.001111976,0.11666,0.01319,1.54274,864,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
NVS,RGSL8429,ADPKDÂ ,Phase 1b,5/6/2024,"Phase 1b Cohort 4 advanced, noted May 6, 2024.",0.0,1424.18863,54.1777,4.4,4.59,4.5,0.042275483,0.022472856,-0.004988647,0.001111976,0.0,0.00374,0.08381,865,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
LCTX,RG6501 - (OpRegen),Geographic atrophy (GA)Â ,Phase 1/2,5/6/2024,"Additional Phase 1/2a data suggested that OpRegen may counteract RPE cell dysfunction and cell loss in GA by providing support to remaining retinal cells, with effects observed through at least 2 year",228.0,245.43759,86.9611,1.06,1.3,1.09,0.204095356,0.027908788,-0.004988647,0.001111976,5.60533,0.01288,5.33418,866,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
EWTX,EDG-7500 - (CIRRUS-HCM),Hypertrophic Cardiomyopathy (HCM)Â ,Phase 2,5/6/2024,"Phase 2 initiated, noted May 6, 2024.",105.0,1899.96908,90.7827,19.52,20.34,17.48,0.04114981,-0.110382211,-0.004988647,0.001111976,6.16896,0.04917,11.94772,867,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
RYTM,IMCIVREE (setmelanotide),"Obesity due to biallelic POMC, PCSK1, LEPR deficiency, or BBS (ages 2-6 years old)Â ",Phase 3,5/6/2024,"Phase 3 data showcased previously disclosed data that demonstrated that setmelanotide achieved 3.04 mean reduction in BMI-Z score and 18.4 percent mean reduction in BMI in 12 patients, noted May 6, 20",66.0,2675.49125,60.5892,43.76,43.88,40.2,0.002738477,-0.084853162,-0.004988647,0.001111976,16.72863,0.16876,43.11052,868,0,0,0,0,1,1,0,0,0,0,0,0,2,0,0,1
MRUS,BIZENGRI (zenocutuzumab-zbco),Solid tumors - NRG1+ NSCLC and PDAC cancerÂ ,BLA Filing,5/6/2024,"BLA accepted for priority review by the FDA, noted May 6, 2024.",75.0,2778.26866,49.8375,48.36,47.34,45.85,-0.021317422,-0.053297827,-0.004988647,0.001111976,5.60655,0.35683,24.53916,869,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
GMAB,BIZENGRI (zenocutuzumab-zbco),Solid tumors - NRG1+ NSCLC and PDAC cancerÂ ,BLA Filing,5/6/2024,"BLA accepted for priority review by the FDA, noted May 6, 2024.",661.0,129426.9693,33.011,2061.0,2004.0,1990.0,-0.028046119,-0.035056663,-0.004988647,0.001111976,0.0,0.08219,207.93704,870,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
DTIL,ECUR-506 - (OTC-HOPE),Ornithine Transcarbamylase (OTC) DeficiencyÂ ,Phase 1/2,5/7/2024,"Fast track designation granted by the FDA, noted May 7, 2024.",11.0,73.10465,96.5744,10.66,10.57,11.62,-0.008478619,0.086229333,0.016361877,-0.002205559,5.05574,0.24688,0.35133,871,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
ANNX,ANX007 - (ARCHER-II),Geographic atrophyÂ ,Phase 2,5/7/2024,"Phase 2 data presented at ARVO demonstrated significant, broad-based protection from vision loss in foveal and non-foveal patients, and in low light settings, noted May 7, 2024.",109.0,431.0987,97.6733,4.81,4.73,4.82,-0.016771882,0.002076844,0.016361877,-0.002205559,4.5447,0.05272,11.04964,872,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1
DNLI,DNL788 (SAR443820) - (HIMALAYA),Amyotrophic lateral sclerosis (ALS)Â ,Phase 2,5/7/2024,"Phase 2 trial did not meet the primary endpoint, noted May 7, 2024.",146.0,2402.96226,80.393,17.14,16.85,19.75,-0.017064256,0.141738578,0.016361877,-0.002205559,6.71466,0.23383,18.52346,873,1,0,0,0,0,1,0,0,0,0,0,0,0,2,0,-1
ELDN,Tegoprubart (AT-1501) - (BESTOW),Kidney transplant rejectionÂ ,Phase 1b,5/7/2024,"Phase 1b data reported that two subjects completed 12 months on therapy post-transplant and both demonstrated mean eGFRs above 90 mL/min/1.73m2 at one year, noted May 7, 2024.",59.0,56.07767,76.8291,2.44,2.26,2.34,-0.076633226,-0.04184711,0.016361877,-0.002205559,0.12547,0.01205,5.72421,874,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
MBRX,"Annamycin (MB-106) in combination with Cytarabine - (Ara-C, MIRACLE)",Acute Myeloid Leukemia (AML)Â ,Phase 1/2,5/7/2024,"Phase 1/2 topline data reported a CRc rate of 45% and an overall remission rate (ORR) of 55% for all subjects, noted May 7, 2024.",30.0,11.33806,97.5563,5.04,5.09,4.85,0.009871748,-0.038427377,0.016361877,-0.002205559,1.19748,0.02328,0.51504,875,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
NRSN,PrimeC - (PARADIGM),Amyotrophic Lateral Sclerosis (ALS)Â ,Phase 2b,5/7/2024,"Additional Phase 2b data analysis reported a statistically significant slowing of disease progression in high-risk ALS patients treated with PrimeC by 43% (p=0.02), noted May 7, 2024.",23.0,22.36091,137.88,1.27,1.29,1.12,0.015625318,-0.125688215,0.016361877,-0.002205559,0.51005,0.09678,0.52436,876,0,1,0,0,0,1,0,0,0,0,0,0,2,0,0,1
REGN,Otoferlin gene therapy (DB-OTO) - (CHORD),Genetic hearing lossÂ ,Phase 1/2,5/8/2024,"Phase 1/2 data presented at ASGCT reported an average 84 dB improvement from baseline and one frequency measure reaching 10 dB in hearing level per PTA. Across all tested frequencies, an average 80 dB",105.0,103112.6484,17.021,969.97,955.76,978.21,-0.014758308,0.008459228,0.016164445,-0.023821056,1.28576,0.09316,406.12632,877,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
VYGR,TRACER (GBA1),Parkinson's DiseaseÂ ,Preclinical,5/8/2024,"Preclinical data reported that showed further enhanced blood-brain barrier (BBB) penetrance, greater liver detargeting, and transduction of 50-75% of cells across diverse brain regions, with upwards o",55.0,466.10804,69.7361,8.77,8.57,8.57,-0.023069074,-0.023069074,0.016164445,-0.023821056,6.3664,0.06605,3.33586,878,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ALDX,Reproxalap (ADX-102) - (TRANQUILITY),Dry eye diseaseÂ ,Phase 3,5/8/2024,"Phase 3 first patient enrollment, noted May 8, 2024.",59.0,241.81697,79.8807,4.17,4.07,4.17,-0.024273036,0.0,0.016164445,-0.023821056,3.97412,0.24598,0.83036,879,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CYTK,CK-4021586 (CK-586) - (AMBER-HFpEF),Heart failure with preserved ejection fraction (HFpEF)Â ,Phase 1,5/8/2024,"Phase 1 trial met its primary and secondary objectives, noted May 8, 2024.",119.0,6838.5963,107.0368,65.28,65.27,60.5,-0.000153198,-0.076042346,0.016164445,-0.023821056,13.40261,0.00807,76.66693,880,0,0,0,0,0,1,0,0,1,0,0,0,2,0,0,1
TEVA,Olanzapine LAI (44749) - (SOLARIS),SchizophreniaÂ ,Phase 3,5/8/2024,"Phase 3 trial data reported that the trial met its primary endpoint as measured by a change in the PANSS total score from baseline after 8 weeks compared to placebo, noted May 8, 2024.",0.0,17827.763,34.5178,13.95,15.74,16.78,0.120725735,0.184708193,0.016164445,-0.023821056,1.02911,0.05207,605.95613,881,1,0,0,0,0,1,0,0,0,0,0,0,2,0,0,1
CYTK,Aficamten - (CEDAR-HCM),obstructive HCMÂ ,Phase 3,5/8/2024,"Phase 3 initiated, noted May 8, 2024.",119.0,6838.5963,107.0368,65.28,65.27,60.5,-0.000153198,-0.076042346,0.016164445,-0.023821056,13.40261,0.00807,76.66693,882,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
PRME,PM359,Chronic Granulomatous Disease (CGD)Â ,Preclinical,5/8/2024,"Preclinical data presented at ASGCT demonstrated the ability of PM359 to correct disease-causing mutation in CGD patient blood stem cells, leading to restored immune function in vivo with no off-targe",134.0,617.9695,83.5837,5.57,5.36,6.76,-0.038431079,0.193627836,0.016164445,-0.023821056,8.85887,0.2113,3.45228,883,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
LLY,VERVE-102 - (Heart-2),PCSK9Â ,Phase 1b,5/8/2024,"Phase 1b dosing initiated, noted May 8, 2024.",946.0,697814.1742,27.3015,777.77,775.0,787.02,-0.003567821,0.01182281,0.016164445,-0.023821056,0.61482,0.02855,1619.69885,884,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1
CVM,Multikine - (IT-MATTERS),Head and Neck cancerÂ ,Phase 3,5/8/2024,"Phase 3 Go-Ahead received by the FDA for its study, noted May 8, 2024.",6.0,75.0311,95.0992,50.10501,41.70417,43.20432,-0.183519879,-0.148180513,0.016164445,-0.023821056,12.62154,0.15651,5.88041,885,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
LEXX,DehydraTECH-GLP-1 - (GLP-1-H24-2),"Healthy volunteers, Diabetes-related control, weight lossÂ ",Phase 1,5/8/2024,"Phase 1 dosing initiated, noted May 8, 2024.",19.0,45.61528,141.251,3.43,3.54,3.08,0.031566466,-0.107630664,0.016164445,-0.023821056,3.38035,0.00124,0.37812,886,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1
PRQR,AX-0810,"Healthy volunteers, deficiency of sodium taurocholate cotransporting polypeptide (NTCP), cholestatic diseasesÂ ",Preclinical,5/8/2024,"Preclinical data shared at the American Society of Gene & Cell Therapy (ASGCT) confirmed findings in in vitro models and showed translatability across models, noted May 8, 2024",105.0,162.70918,82.6366,1.99,2.0,1.91,0.005012542,-0.041031397,0.016164445,-0.023821056,0.29688,0.06308,0.23441,887,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CTMX,CX-904,Advanced solid tumorsÂ ,Phase 1,5/8/2024,"Phase 1 data demonstrated a favorable safety profile with no cytokine release syndrome (CRS) of any grade observed in step-dosing cohorts and no grade >1 CRS observed overall, noted May 8, 2024.",164.0,326.48216,180.098,4.07,4.19,1.96,0.029057734,-0.730698526,0.016164445,-0.023821056,4.61241,0.02665,169.7928,888,0,0,0,1,0,1,0,0,0,0,0,0,2,0,0,1
OCS,OCS-05 - (ACUITY),Acute optic neuritisÂ ,Phase 2,5/8/2024,"Phase 2 enrollment completed, noted May 8, 2024.",43.0,516.32745,39.4763,12.64,12.37,12.01,-0.021592202,-0.051126753,0.016164445,-0.023821056,0.06127,0.01789,0.53248,889,0,0,0,0,0,1,0,0,0,1,0,0,2,0,0,1
MRK,KEYTRUDA versus chemotherapy - (KEYNOTE-B21),High-Risk Endometrial CancerÂ ,Phase 3,5/9/2024,"Phase 3 study did not meet the study's pre-specified statistical criteria for DFS compared to placebo plus adjuvant chemotherapy, with or without radiotherapy, noted May 9, 2024.",0.0,329847.3654,16.7348,129.55,130.23,130.88,0.005235211,0.010213966,0.010945102,-0.038309583,0.74044,0.01233,1200.29605,890,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,-1
PRTC,SPT-300 (Glyph allopregnanolone; formerly LYT-300),"Healthy volunteers, neurological and neuropsychological conditionsÂ ",Phase 2a,5/9/2024,"Phase 2a demonstrated nine times greater allopregnanolone exposure in humans dosed orally than published data for oral allopregnanolone, validating Glyph platform's ability to enhance oral bioavailabi",24.0,603.02042,48.3971,2.215,2.23,2.22,0.006749182,0.002254792,0.010945102,-0.038309583,0.0,0.10713,0.52339,891,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
TCRX,TSC-203-A0201 - (PRAME),Targeting PRAME Solid tumorsÂ ,Phase 1,5/9/2024,"Phase 1 dosing initiated, noted May 9, 2024.",56.0,392.94308,91.423,8.01,7.8,8.9,-0.026567027,0.105360516,0.010945102,-0.038309583,0.78998,0.008,1.86279,892,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1
ANVS,Buntanetap,Parkinson's Disease (PD)Â ,Phase 3,5/9/2024,"The phase 3 study was completed, noted May 9, 2024.",19.0,66.39813,188.0369,4.82,6.03,8.03,0.223973083,0.5104106,0.010945102,-0.038309583,14.59964,0.03173,12.79998,893,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
IKT,IkT-001Pro,Pulmonary Arterial Hypertension (PAH)Â ,Preclinical,5/9/2024,Pre-IND meeting with FDA indicated IkT-001Pro can be considered a New Molecular Entity and is eligible for exclusivity designations in Pulmonary Arterial Hypertension. FDA agreed that the 505(b)(2) pa,74.0,8.80851,120.8211,1.4,1.36,1.76,-0.028987537,0.228841572,0.010945102,-0.038309583,2.08829,0.03318,0.04714,894,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
FATE,FT819,B-cell Leukemias and LymphomasÂ ,Phase 1b,5/9/2024,"Phase 1b translational data presented at ASGCT highlighted the scientific rationale and demonstrate key therapeutic mechanisms of activity for the treatment of B cell-mediated autoimmune disease, note",115.0,443.94468,92.31,3.7,3.9,4.14,0.052643733,0.112362968,0.010945102,-0.038309583,19.44892,0.20862,15.2216,895,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
FATE,FT819,B-cell Leukemias and LymphomasÂ ,Phase 1b,5/9/2024,"Phase 1b translational data presented at ASGCT highlighted the scientific rationale and demonstrate key therapeutic mechanisms of activity for the treatment of B cell-mediated autoimmune disease, note",115.0,443.94468,92.31,3.7,3.9,4.14,0.052643733,0.112362968,0.010945102,-0.038309583,19.44892,0.20862,15.2216,896,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
FATE,FT522,LupusÂ ,Preclinical,5/9/2024,"Preclinical data to be presented at ASGCT showed dose-dependent trafficking, infiltration, and residency in secondary and tertiary tissues without cytokine support at human dose equivalency levels of",115.0,443.94468,92.31,3.7,3.9,4.14,0.052643733,0.112362968,0.010945102,-0.038309583,19.44892,0.20862,15.2216,897,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
RAPT,Zelnecirnon (RPT193),AsthmaÂ ,Phase 2a,5/9/2024,"Trial closed due to clinical hold, noted May 9, 2024.",16.0,162.65018,220.1641,63.84,37.28,33.12,-0.537922963,-0.656242624,0.010945102,-0.038309583,9.22853,0.08535,22.71497,898,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,-1
RAPT,Zelnecirnon (RPT193),Atopic dermatitisÂ ,Phase 2a,5/9/2024,"Trial closed due to clinical hold, noted May 9, 2024.",16.0,162.65018,220.1641,63.84,37.28,33.12,-0.537922963,-0.656242624,0.010945102,-0.038309583,9.22853,0.08535,22.71497,899,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,-1
AZN,FPI-2265 - (AlphaBreak),Prostate cancerÂ ,Phase 2/3,5/9/2024,"Phase 2/3 trial AlphaBreak initiated, noted May 9, 2024.",0.0,191174.9833,22.2545,122.64,123.32,121.66,0.005529368,-0.008022966,0.010945102,-0.038309583,0.0,0.19837,164.01042,900,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ANAB,Imsidolimab (ANB019) - (GEMINI-1),Generalized pustular psoriasisÂ ,Phase 3,5/9/2024,Phase 3 data showed that All 8 patients who responded to IV imsidolimab in GEMINI-1 and received monthly SC maintenance dosing in GEMINI-2 maintained clear/almost clear skin through 24 weeks with no f,28.0,716.56803,59.0176,25.75,26.23,25.47,0.018469167,-0.010933338,0.010945102,-0.038309583,16.01451,0.04242,5.93685,901,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
PDSB,PDS0101 + KEYTRUDA (pembrolizumab) - (VERSATILE-002),HPV16-positive first-line recurrent and/or metastatic head and neck squamous cell cancer with low PD-L1 expression (CPS 1-19)Â ,Phase 2,5/9/2024,"Phase 2 data presented at a KOL showed a 30-month median overall survival (OS); median OS independent of patient CPS score; ORR 34% (CPSâ‰¥1); 48% (CPSâ‰¥20, noted May 9, 2024.",46.0,140.48162,83.1742,4.02,3.83,3.53,-0.048417099,-0.129984032,0.010945102,-0.038309583,18.71362,0.11043,4.78176,902,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
PHIO,PH-762,Cutaneous Squamous Cell CarcinomaÂ ,Preclinical,5/9/2024,"Preclinical data presented at ASCGT data demonstrates that intratumoral injection of PH-762 significantly inhibits tumor growth in murine cells and may generate memory-specific T cells, noted May 9, 2",5.0,3.5356,133.728,7.2,6.93,6.5916,-0.038221213,-0.088284915,0.010945102,-0.038309583,4.0222,0.00563,0.0678,903,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
FDMT,4D-175 - (GAZE),Geographic AtrophyÂ ,Preclinical,5/9/2024,Preclinical data presented at ARVO showed that intravitreal administration of 4D-175 to non-human primates (NHP) was safe and well tolerated and resulted in robust transgene expression in the retina a,46.0,1325.67548,109.8702,26.33,25.64,25.64,-0.026555341,-0.026555341,0.010945102,-0.038309583,18.61105,0.08633,8.28182,904,0,0,0,1,0,0,0,0,0,0,1,0,2,0,0,1
FDMT,4D-150 - (PRISM),Wet age-related macular degeneration (AMD)Â ,Phase 2,5/9/2024,"Phase 2 interim 24-week landmark data presented at ARVO demonstrated that a high dose of 4D-150 (3E10 vg/eye) resulted in robust reductions in overall treatment burden of 89%, percent of patients with",46.0,1325.67548,109.8702,26.33,25.64,25.64,-0.026555341,-0.026555341,0.010945102,-0.038309583,18.61105,0.08633,8.28182,905,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1
CELU,CYNK-201,Solid TumorsÂ ,Preclinical,5/9/2024,Preclinical data presented on at ASGCT reported that PT-CD16VS can be combined with various monoclonal antibodies to engage in anti-tumor antibody-dependent cellular cytotoxicity against diverse cance,26.0,66.43773,132.1547,2.99,3.05,3.05,0.019868203,0.019868203,0.010945102,-0.038309583,2.73145,0.09107,0.11389,906,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
INSM,Treprostinil Palmitil Inhalation Powder (TPIP),Pulmonary hypertension associated with interstitial lung disease (PH-ILD)Â ,Phase 2,5/9/2024,"Phase 2 topline results reported that serious adverse events occurred in 20.7% of TPIP-treated patients and 40.0% of placebo-treated patients, noted May 9, 2024.",211.0,3920.18798,37.6896,26.0,26.38,25.1,0.014509609,-0.035228692,0.010945102,-0.038309583,5.74059,0.09221,63.85057,907,0,0,0,1,0,1,0,0,0,0,1,0,0,3,0,-1
EWTX,EDG-5506 - (DUNE),Becker muscular dystrophy (BMD)Â ,Phase 2,5/9/2024,Phase 2 data reported that sevasemten was well tolerated across all 21 participants and significantly reduced biomarkers of muscle damage associated with exercise with a mean post-exercise reduction o,105.0,1867.97534,90.0411,20.89,20.0,18.18,-0.043538302,-0.138948487,0.010945102,-0.038309583,6.98411,0.04917,20.5297,908,0,0,0,1,1,1,0,0,0,0,0,0,3,0,0,1
CANF,Namodenoson (CF102),Metabolic dysfunction-associated steatohepatitis (MASH)Â ,IND-Enabling,5/9/2024,"IND cleared by the FDA, noted May 9, 2024.",10.0,40.42247,38.5545,0.027,0.027,0.026,0.0,-0.037740328,0.010945102,-0.038309583,0.0,0.04767,1.22032,909,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
MRNA,mRESVIA (mRNA-1345) - (ConquerRSV),Respiratory syncytial virus (RSV) vaccineÂ ,PDUFA,5/10/2024,"PDUFA decision due on May 12, 2024. FDA has informed Moderna that due to administrative constraints, the agency will not complete its review of mRNA-1345 by the PDUFA date of May 12, 2024, The FDA has",389.0,44957.85226,53.18,122.69,117.31,132.9,-0.044840845,0.079936117,-0.010063822,-0.024423949,5.49839,0.16404,497.21937,910,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
IPSC,CNTY-101 - (CALiPSO-1),Systemic Lupus ErythematosusÂ ,Preclinical,5/10/2024,"Preclinical data demonstrates the potential utility of using a synthetic ligand targeting CD300a as a universal strategy for preventing NK-mediated rejection in allogeneic cell therapies, as noted on",86.0,259.31228,102.7914,3.04,3.13,3.01,0.029175489,-0.009917437,-0.010063822,-0.024423949,1.87728,0.03834,0.21839,911,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
RCKT,RP-L301,Pyruvate Kinase Deficiency (PKD)Â ,Phase 1,5/10/2024,"Phase 1 data reported robust and sustained efficacy in adults and the first pediatric patient infusion of RP-L301 was well tolerated, with engraftment achieved at day +15, noted May 19, 2023. Phase 1",107.0,2062.57183,46.019,23.33,22.72,22.62,-0.026494492,-0.030905615,-0.010063822,-0.024423949,10.83579,0.09814,9.13203,912,0,0,0,1,0,1,0,0,0,0,0,0,2,0,0,1
AZTR,ATR12-351,Netherton SyndromeÂ ,Preclinical,5/10/2024,Preclinical data presented at ASGCT from In vitro data showed that LEKTI (lympho-epithelial Kazal-type-related inhibitor) protein secreted by ATR-12 has nanomolar inhibition of a key protease that dr,3.0,6.22179,230.7498,49.65035,43.15684,36.36364,-0.140164518,-0.311436066,-0.010063822,-0.024423949,1.02826,0.01343,0.48685,913,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
IMMX,NXC-201 (HBI10101) - (NEXICART-1),relapsed/refractory multiple myeloma and relapsed/refractory AL amyloidosisÂ ,Phase 1/2,5/10/2024,"Phase 1/2 data presented at ASGCT showed a 92% (12/13) overall response rate (ORR) for relapsed/refractory AL Amyloidosis. Best responder duration of response was 28.0 months with response ongoing, no",28.0,57.58317,105.4319,2.18,2.18,2.47,0.0,0.124893274,-0.010063822,-0.024423949,1.46702,0.02293,0.87973,914,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
PLX,PRX-115,Severe GoutÂ ,Phase 1,5/10/2024,"Phase 1 initial data from the seven cohorts, and following the review and acceptance of the safety data from cohort 7 by the safety and monitoring committee for dose escalation for the FIH Study, the",79.0,80.64769,56.2253,1.25,1.1,1.14,-0.127833372,-0.092115289,-0.010063822,-0.024423949,9.52807,0.06223,2.39603,915,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
MGNX,MGC018 - (TAMARACK),Metastatic castration-resistant prostate cancer (mCRPC)Â ,Phase 2,5/10/2024,"Phase 2 interim data showed PSA50 responses 43.9%/36.6%, ORR 17.8%/25% confirmed. Unfortunately, 5 deaths were found: 1 unrelated, 2 pneumonitis under investigation., noted May 10, 2024",63.0,207.31675,225.2949,14.67,3.31,4.365,-1.488856403,-1.212186403,-0.010063822,-0.024423949,15.909,0.00186,116.34107,916,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
BMY,Opdivo (nivolumab) + Yervoy (ipilimumab) versus CCRT - (CheckMate-73L),Stage III non-small cell lung cancer (NSCLC)Â ,Phase 3,5/10/2024,"Phase 3 CheckMate -73L trial did not meet its primary endpoint of progression-free survival (PFS), noted May 10, 2024.",0.0,91097.87831,23.3945,44.74,44.94,44.03,0.004460311,-0.015996736,-0.010063822,-0.024423949,1.3825,0.03278,390.9598,917,1,0,0,0,0,1,0,0,0,0,0,0,0,2,0,-1
ACET,ADI-270,"Solid tumors CAR T, relapsed/refractory renal cell carcinoma (RCC)Â ",Preclinical,5/10/2024,"Preclinical data featured at ASGCT data reported robust efficacy maintained across multiple relevant tumor models of varying stringency, noted May 10, 2024.",83.0,133.20396,105.0398,1.63,1.47,1.6,-0.103317614,-0.018576386,-0.010063822,-0.024423949,8.47008,0.02186,1.38139,918,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
MRK,KEYTRUDA (KeyVibe-010),Resected high-risk melanoma (Stage IIB-IV)Â ,Phase 3,5/13/2024,Phase 3 pre-planned analysis data showed that the primary endpoint of recurrence-free survival (RFS) met the pre-specified futility criteria. A higher rate of discontinuation of all adjuvant therapy b,0.0,327466.5274,16.651,130.06,129.29,130.99,-0.005937939,0.007125102,-0.029512538,-0.045792602,0.74044,0.01416,919.24052,919,1,0,0,0,0,1,0,0,0,0,0,0,0,0,2,0
VALN,VLA1553-321 - (Adolescents trial),Chikungunya Vaccine for adolecentsÂ ,Phase 3,5/13/2024,"Phase 3 day 180 results confirm the initial positive immunogenicity and safety data Valneva reported previously, noted May 13, 2024.",81.0,479.09556,53.7255,7.4198,7.61,8.84,0.025311069,0.175134774,-0.029512538,-0.045792602,0.0,0.0,0.02173,920,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
MRUS,Petosemtamab (MCLA-158),"Recurrent/metastatic (r/m) head and neck squamous cell carcinoma (HNSCC), Solid TumorsÂ ",Phase 2,5/13/2024,"FDA Granted Breakthrough Therapy Designation (BTD) on May 13, 2024.",75.0,2690.82421,50.2344,44.52,45.85,43.63,0.029436672,-0.020193539,-0.029512538,-0.045792602,5.7613,0.31259,38.20029,921,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
GMAB,Petosemtamab (MCLA-158),"Recurrent/metastatic (r/m) head and neck squamous cell carcinoma (HNSCC), Solid TumorsÂ ",Phase 2,5/13/2024,"FDA Granted Breakthrough Therapy Designation (BTD) on May 13, 2024.",661.0,128536.3288,30.7879,2003.0,1990.0,2041.0,-0.006511418,0.018793827,-0.029512538,-0.045792602,0.0,0.08977,231.41113,922,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
INAB,INB-200,GlioblastomaÂ ,Phase 1,5/13/2024,"Phase 1 data presented at ASGCT data provide additional insight into the complex gene-expression changes that occur throughout the manufacturing of our gamma-delta T cell products, which demonstrate a",4.0,45.0064,131.6757,30.30003,30.60003,30.60003,0.009852287,0.009852287,-0.029512538,-0.045792602,0.40778,0.01113,0.04587,923,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CYTK,Aficamten (CK-274) - (SEQUOIA-HCM),Hypertrophic cardiomyopathy (HCM)Â ,Phase 3,5/13/2024,"Phase 3 full results due presented at Heart Failure showed that treatment with aficamten for 24 weeks significantly improved exercise capacity compared to placebo, noted May 13, 2024.",119.0,6069.99331,107.383,62.1,57.89,60.6,-0.070201331,-0.024451096,-0.029512538,-0.045792602,13.03782,0.00609,205.63645,924,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
EWTX,Sevasemten (EDG-5506) - (CANYON),Becker Muscular Dystrophy (BMD)Â ,Phase 2,5/13/2024,"Phase 2 trial met primary endpoint, noted May 13, 2024.",105.0,1632.61045,90.1391,18.33,17.48,18.77,-0.047481692,0.023720789,-0.029512538,-0.045792602,6.98411,0.04146,11.14219,925,1,0,0,0,0,1,0,0,0,0,0,0,2,0,0,1
PLRX,Bexotegrast (PLN-74809) - (INTEGRIS-IPF),Idiopathic pulmonary fibrosis (IFP)Â ,Phase 2a,5/14/2024,"Phase 2a 12-week post-hoc analysis reported that bexotegrast-treated patients showed a reduction in SUV in the lung compared to an increase seen in placebo, noted May 14, 2024.",61.0,853.00726,56.8182,13.67,14.14,14.59,0.03380401,0.065132712,-0.02992168,-0.01862826,12.50717,0.07149,13.77512,926,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
HCM,SULANDA (surufatinib),Metastatic pancreatic ductal adenocarcinoma (PDAC) in ChinaÂ ,Phase 2/3,5/14/2024,"Phase 2/3 study initiated in China, noted May 14, 2024.",174.0,2936.56334,58.9812,3.5,3.44,3.15,-0.017291497,-0.105360516,-0.02992168,-0.01862826,0.0,0.07558,0.19084,927,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
KOD,Tarcocimab tedromer (KSI-301) - (GLOW2),Non-proliferative diabetic retinopathyÂ ,Phase 3,5/14/2024,"Phase GLOW2 dosing initiated, noted May 14, 2024.",52.0,201.1013,118.0289,3.83,3.84,3.21,0.002607563,-0.176593866,-0.02992168,-0.01862826,4.96722,0.18154,1.0907,928,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1
HCM,HMPL-306 - (RAPHAEL),Relapsed / refractory acute myeloid leukemia (AML)Â ,Phase 3,5/14/2024,"Phase 3 initiated, noted May 14, 2024.",174.0,2936.56334,58.9812,3.5,3.44,3.15,-0.017291497,-0.105360516,-0.02992168,-0.01862826,0.0,0.07558,0.19084,929,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
DVAX,HEPLISAV-B,End Stage Renal Disease on Dialysis undergoing hemodialysisÂ ,CRL,5/14/2024,"CRL announced May 14, 2024.",117.0,1439.80881,27.2035,11.03,11.0,11.46,-0.00272356,0.038243878,-0.02992168,-0.01862826,14.99154,0.00753,37.45375,930,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,-1
NNVC,NV-CoV-2 (NV-387),"RSV (Respiratory Syncytial Virus), Coronavirus, Smallpox/Mpox related Ectromelia virus infectionÂ ",Preclinical,5/14/2024,"Preclinical antiviral activity study resulted in full survival of lethally infected animals was achieved, noted May 14, 2024.",17.0,26.62054,80.6808,1.82,2.26,2.18,0.216528312,0.180488376,-0.02992168,-0.01862826,0.8508,0.0254,1.51749,931,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1
NMRA,Navacaprant (NMRA-140),Bipolar DepressionÂ ,Phase 2,5/14/2024,"Phase 2 initiated, noted May 14, 2024.",161.0,1528.23989,73.2447,8.96,9.58,9.45,0.066907365,0.053244515,-0.02992168,-0.01862826,4.12565,0.03723,5.63684,932,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
EQ,Itolizumab - (EQUATOR),1st line Acute graft-versus-host disease (aGVHD)Â ,Phase 3,5/14/2024,"Phase 3 enrollment target surpassed, noted May 14, 2024.",59.0,54.29232,130.6274,1.54,1.54,1.51,0.0,-0.019672766,-0.02992168,-0.01862826,1.07335,0.00213,0.22114,933,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ATYR,Efzofitimod - (EFZO-FIT),Pulmonary sarcoidosisÂ ,Phase 3,5/14/2024,"Second DSMB recommended that the ongoing Phase 3 study could continue without any modifications after a second pre-planned, interim analysis, noted May 14, 2024.",97.0,125.59991,62.1767,1.7,1.82,1.95,0.06820825,0.137201122,-0.02992168,-0.01862826,0.92191,0.1034,0.75622,934,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
GNPX,REQORSA Immunogene Therapy (quratusugene ozeplasmid) - (Acclaim-3),Extensive-stage small cell lung cancer (ES-SCLC)Â ,Phase 1/2,5/14/2024,"Phase 1/2 trial dosing initiated, noted May 14, 2024.",0.0,5.39353,113.7772,119.5,128.5,117.5,0.072612533,-0.016878038,-0.02992168,-0.01862826,2.38067,0.22629,0.44551,935,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1
CRIS,CA-4948 - (TakeAim Lymphoma),Relapsed or Refractory Non-Hodgkin LymphomaÂ ,Phase 2,5/14/2024,"Phase 2 data reported that 3 of 3 patients who were naÃ¯ve to FLT3i treatment achieved objective response (2 CR, 1 MLFS), noted May 14, 2024.",12.0,92.47819,112.6435,15.66,15.69,10.795,0.001913876,-0.372026627,-0.02992168,-0.01862826,1.14199,0.08505,0.44114,936,1,0,0,0,0,1,0,0,0,0,0,0,2,0,0,1
KYMR,KT-333,Cutaneous T-cell lymphoma (CTCL)Â ,Phase 1a,5/14/2024,"Phase 1a data reported two complete responses in two cHL patients at DL4, three partial responses in CTCL patients at DL2, 4 and 5, and stable disease in four solid tumor patients at DL3-4, noted May",71.0,2153.06141,63.1839,38.36,35.09,35.32,-0.08909906,-0.082565874,-0.02992168,-0.01862826,16.14831,0.28987,36.1434,937,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
TFFP,TFF TAC (Tacrolimus Inhalation Powder),Lung transplant (post)Â ,Phase 2,5/15/2024,"Phase 2 additional data showed that patient enrollment has accelerated to now 10 patients, 6/6 who completed 12-week tratemetn chosen to remain on TFF TAC, 1 patient has been treated for over a year a",4.0,899.72,76.7722,45.0,41.75,44.1,-0.074963038,-0.020202707,-0.019742147,-0.015195701,0.0,0.0,0.0,938,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
VNDA,Tradipitant - (Motion Serifos),Motion sicknessÂ ,Phase 3,5/15/2024,"Phase 3 trial conducted in real-world conditions on boats in U.S. coastal waters, both the 170 mg and 85 mg doses of tradipitant demonstrated superiority over placebo in preventing vomiting, noted May",59.0,311.94274,74.7768,5.13,5.36,5.14,0.043858316,0.00194742,-0.019742147,-0.015195701,3.9601,0.00212,4.86883,939,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
SGMT,Denifanstat (PK Study),Metabolic dysfunction-associated steatohepatitis (MASH)Â ,Phase 1,5/15/2024,"Phase 1 data reported that denifanstat was well-tolerated and no safety signals were reported, noted May 15, 2024.",32.0,147.44216,200.6955,4.38,4.62,5.08,0.053345981,0.148262537,-0.019742147,-0.015195701,6.89939,0.13131,1.89366,940,0,0,0,1,0,1,0,0,0,0,0,0,2,0,0,1
IMMP,Eftilagimod Alpha with weekly paclitaxel - (AIPAC-003),Metastatic breast cancer (MBC)Â ,Phase 2/3,5/15/2024,"Phase 2/3 data reported an 50% overall response rate, including one complete response and two partial responses, and a 100% disease control rate, with three patients having stable disease as best over",145.0,529.03138,57.1376,2.93,2.82,3.12,-0.038265538,0.062830579,-0.019742147,-0.015195701,0.0,0.0,0.73628,941,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
OLMA,Palazestrant (OP-1250) and ribociclib - (OPERA-02),Breast CancerÂ ,Phase 1/2,5/15/2024,Phase 1b/2 data to be shared at ESMO Breast Cancer showed that treatment was well tolerated with no new safety signals or increased toxicity and no clinically meaningful impact on drug exposure of eit,68.0,550.55073,75.8931,10.17,9.85,9.21,-0.031970755,-0.09915236,-0.019742147,-0.015195701,15.03284,0.05742,16.09688,942,0,0,0,1,0,1,0,0,0,0,0,0,2,0,0,1
ACXP,Ibezapolstat,C. difficile InfectionÂ ,Phase 2b,5/15/2024,"Phase 3 agreement with the FDA after EoP2 meeting, noted May 15, 2024.",1.0,35.64698,83.481,41.8,45.0,51.0,0.07376615,0.198929293,-0.019742147,-0.015195701,3.88466,0.03056,0.38358,943,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
BCAB,Ozuriftamab Vedotin (BA3021),"Solid Tumors, Non-small cell lung cancer (NSCLC), recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN)Â ",Phase 2,5/15/2024,"Phase 2 data reported 11 responses at the combined 2Q3W and Q2W dose regimens (5 confirmed, including 1 complete response), noted May 15, 2024.",58.0,144.34775,136.2625,2.61,3.0,2.28,0.139262067,-0.135174778,-0.019742147,-0.015195701,11.07718,0.28555,3.9458,944,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
BCDA,BCDA-03,Ischemic heart failureÂ ,Phase 1/2,5/15/2024,"Phase 1/2 data reported that treatment-emergent adverse events, arrhythmias, rejection, or allergic response have been observed, noted May 15, 2024.",5.0,10.91891,90.8696,5.94,5.9985,4.6395,0.009800305,-0.247102532,-0.019742147,-0.015195701,0.96255,0.02884,0.03647,945,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
PHIO,PH-762 (direct drug therapy),MelanomaÂ ,Phase 1b,5/15/2024,"Phase 1b dosing of the first cohort of patients was completed and screening for the next dose cohort is on-going, noted May 15, 2024",5.0,3.67335,134.6893,6.6042,7.2,7.02,0.086375216,0.061057408,-0.019742147,-0.015195701,4.0222,0.00258,0.08387,946,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
AXGN,Avance Nerve Graf - (RECON),Severed peripheral nervesÂ ,BLA Filing,5/15/2024,"BLA submitted on May 15, 2024.",46.0,260.04222,59.5963,5.77,5.95,6.2,0.030719139,0.071877212,-0.019742147,-0.015195701,4.15643,0.08974,0.81598,947,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
LLY,Insulin efsitora alfa (efsitora) - (QWINT-2 and QWINT-4),Type 2 diabetesÂ ,Phase 3,5/16/2024,"Phase 3 data reported that trials met their primary endpoints, noted May 16, 2024.",946.0,694320.6013,26.2437,787.02,771.12,808.45,-0.020409658,0.026865173,0.015561552,0.0361717,0.5674,0.03144,1773.30842,948,1,0,0,0,0,1,0,0,0,0,0,0,2,0,0,1
PFE,ARV-471 with IBRANCE (palbociclib) - (TACTIVE-N),ER+ positive / HER2- negative breast cancerÂ ,Phase 1b,5/16/2024,"Phase 1b data reported a clinical benefit rate (63%), overall response rate (41.9%), median progression-free survival (11.2 months), noted May 16, 2024.",0.0,163877.8666,26.3687,28.82,28.92,28.69,0.003463807,-0.004520961,0.015561552,0.0361717,1.10312,0.0212,1159.04946,949,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ARVN,ARV-471 with IBRANCE (palbociclib) - (TACTIVE-N),ER+ positive / HER2- negative breast cancerÂ ,Phase 1b,5/16/2024,"Phase 1b data reported a clinical benefit rate (63%), overall response rate (41.9%), median progression-free survival (11.2 months), noted May 16, 2024.",73.0,2197.34802,66.8885,32.33,32.11,35.23,-0.006828084,0.085902401,0.015561552,0.0361717,12.65675,0.10887,43.0292,950,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
AZN,Sipavibart (AZD3152) - (SUPERNOVA),COVIDâ€‘19Â ,Phase 3,5/16/2024,"Phase 3 data reported that the trial met both dual primary endpoints, noted May 16, 2024.",0.0,188601.5931,21.5588,121.72,121.66,124.04,-0.000493056,0.018880769,0.015561552,0.0361717,0.0,0.20815,200.648,951,1,0,0,0,0,1,0,0,0,0,0,0,2,0,0,1
BIIB,ION582 (BIIB121) - (HALOS),Angelman SyndromeÂ ,Phase 1/2,5/16/2024,"Phase 1b/2 enrollment completed, noted November 2, 2023. Phase 1b datademonstrated consistent improvements across multiple functional domains, noted May 16, 2024.",146.0,33493.10973,26.2675,235.32,230.04,218.06,-0.022693083,-0.076176036,0.015561552,0.0361717,2.1621,0.18633,215.47341,952,0,0,0,0,0,1,0,0,0,1,0,0,2,0,0,1
IONS,ION582 (BIIB121) - (HALOS),Angelman SyndromeÂ ,Phase 1/2,5/16/2024,"Phase 1b/2 enrollment completed, noted November 2, 2023. Phase 1b datademonstrated consistent improvements across multiple functional domains, noted May 16, 2024.",159.0,5491.21737,30.8211,39.21,37.62,38.0,-0.041395992,-0.031345657,0.015561552,0.0361717,5.99709,0.16096,124.67035,953,0,0,0,0,0,1,0,0,0,1,0,0,2,0,0,1
TRML,TOUR006 - (TRANQUILITY),Atherosclerotic cardiovascular disease (ASCVD)Â ,Phase 2,5/16/2024,"Phase 2 dosing initiated, noted May 16, 2024.",25.0,1.17391,130.2937,0.5,0.5,0.5,0.0,0.0,0.015561552,0.0361717,0.0,0.03688,8e-05,954,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1
BIIB,BIIB105 (ATXN2 ASO) - (ALSpire),Amyotrophic Lateral Sclerosis (ALS)Â ,Phase 1/2,5/16/2024,"Phase 1/2 topline data reported that treatment did not result in a reduction in levels of plasma neurofilament light chain (NfL), a marker of neurodegeneration and neuronal damage, noted May 16, 2024.",146.0,33493.10973,26.2675,235.32,230.04,218.06,-0.022693083,-0.076176036,0.015561552,0.0361717,2.1621,0.18633,215.47341,955,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
IONS,BIIB105 (ATXN2 ASO) - (ALSpire),Amyotrophic Lateral Sclerosis (ALS)Â ,Phase 1/2,5/16/2024,"Phase 1/2 topline data reported that treatment did not result in a reduction in levels of plasma neurofilament light chain (NfL), a marker of neurodegeneration and neuronal damage, noted May 16, 2024.",159.0,5491.21737,30.8211,39.21,37.62,38.0,-0.041395992,-0.031345657,0.015561552,0.0361717,5.99709,0.16096,124.67035,956,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ASND,Breyanzi (lisocabtagene maraleucel) - (TRANSCEND FL),Follicular lymphomaÂ ,Approved,5/16/2024,"Approved May 16, 2024.",60.0,7041.98921,36.801,124.04,122.8,129.44,-0.010047079,0.042613359,0.015561552,0.0361717,6.44529,0.0983,61.86099,957,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1
BMY,Breyanzi (lisocabtagene maraleucel) - (TRANSCEND FL),Follicular lymphomaÂ ,Approved,5/16/2024,"Approved May 16, 2024.",0.0,89415.38524,23.1178,44.55,44.11,41.54,-0.00992564,-0.069955335,0.015561552,0.0361717,1.3825,0.03278,695.42551,958,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1
PHIO,PH-762,Cutaneous Squamous Cell CarcinomaÂ ,Phase 1b,5/16/2024,"Phase 1b data reported that treatment was well tolerated at the maximum administered dose and treatment with mPH-762 provided robust inhibition of tumor growth, noted May 16, 2024.",5.0,3.36296,135.0024,7.2,6.5916,6.9102,-0.088284915,-0.041082445,0.015561552,0.0361717,4.0222,0.00258,0.06625,959,0,0,0,1,0,1,0,0,0,0,0,0,2,0,0,1
MLTX,Nanobody (sonelokimab) - (VELA),Hidradenitis suppurativaÂ ,Phase 3,5/16/2024,"Phase 3 trial VELA initiated, noted May 16, 2024.",64.0,2569.05767,54.3327,40.69,40.86,39.96,0.004169227,-0.018103408,0.015561552,0.0361717,11.02638,0.05724,9.64807,960,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ATXI,AJ201,Spinal and bulbar muscular atrophy (SBMA)Â ,Phase 1/2,5/16/2024,"Phase 1b/2 last patient dosed completed, noted May 16, 2024.",3.0,3.41578,176.0946,3.65,3.63,3.62,-0.005494519,-0.008253142,0.015561552,0.0361717,1.82064,0.01324,0.1657,961,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1
IVA,Lanifibranor - (NATiV3),Nonalcoholic steatohepatitis (NASH)Â ,Phase 3,5/16/2024,"Positive recommendation from DMC on May 16, 2024.",95.0,178.58536,52.8749,3.52,3.41,3.325,-0.031748698,-0.056991316,0.015561552,0.0361717,0.0,0.09918,0.1428,962,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
AMGN,IMDELLTRA (tarlatamab-dlle),Extensive-stage small cell lung cancer (ES-SCLC)Â ,Approved,5/17/2024,"Approved May 17, 2024.",538.0,167619.7482,26.7228,314.72,312.47,305.84,-0.00717489,-0.028621265,0.003462083,0.041456714,1.81116,0.02106,616.88515,963,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1
MRNS,Ganaxolone - (TrustTSC),Tuberous Sclerosis ComplexÂ ,Phase 3,5/17/2024,"Phase 3 enrollment completed, noted May 17, 2024.",55.0,4494.90726,40.2005,59.65,59.99,53.57,0.005683733,-0.107504939,0.003462083,0.041456714,0.0,0.00845,0.53991,964,0,0,0,0,0,1,0,0,0,1,0,0,2,0,0,1
AZTR,ATR04-484,EGFRi-associated rashÂ ,Preclinical,5/17/2024,"Preclinical data reported that treatment reduced IL-36g, a pro-inflammatory cytokine that drives inflammation in EGFRi-induced toxicity, in human skin model by 75% compared to erlotinib-treated skin,",3.0,5.24244,230.6059,39.62038,36.36364,38.002,-0.085774258,-0.041704842,0.003462083,0.041456714,1.02826,0.01114,2.1416,965,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
LEXX,DehydraTECH-powered GLP-1 drugs (semaglutide) - (WEIGHT-A24-1),DiabetesÂ ,Preclinical,5/17/2024,"Preclinical trial initiated, noted May 17, 2024.",19.0,40.58987,140.6186,3.14,3.15,3.12,0.003179653,-0.006389798,0.003462083,0.041456714,1.99575,0.00028,0.88715,966,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ARWR,Plozasiran (ARO-APOC3) - (CAPITAN),Mixed hyperlipidemiaÂ ,Phase 2b,5/18/2024,"Phase 2b data reported that treatment significantly reduced triglycerides and atherogenic triglyceride rich lipoproteins and increased HDL, across all dose levels at Week 24 in patients with mixed dys",138.0,3076.4397,79.0301,24.77,24.77,24.88,0.0,0.004431024,-0.011883487,0.026111144,7.74045,0.18258,0.0,967,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
NNVC,NV-CoV-2 (NV-387),"RSV (Respiratory Syncytial Virus), Coronavirus, Smallpox/Mpox related Ectromelia virus infectionÂ ",Preclinical,5/20/2024,"Preclinical data reported that NV-387 against RSV/A2 is clearly demonstrated by lungs remaining normal and showing no infection-related damage, when treated orally with NV-387, in a lethal lung RSV in",17.0,24.98661,90.8918,2.07,2.115,2.23,0.021506205,0.074452978,-0.004268132,0.026111144,0.84828,0.02801,0.39121,968,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
DYN,DYNE-101 - (ACHIEVE),Myotonic Dystrophy Type 1 (DM1)Â ,Phase 1/2,5/20/2024,"Phase 1/2 data reported that patients in the 5.4 mg/kg Q8W cohort had a 27% mean splicing correction from baseline across a broad, 22-gene panel at 3 months, with all participants demonstrating splici",142.0,3081.23178,83.2802,27.68,35.38,31.22,0.245436558,0.120348784,-0.004268132,0.026111144,11.06178,0.125,162.67452,969,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
DYN,DYNE-251 - (DELIVER),Duchenne muscular dystrophy (DMD)Â ,Phase 1/2,5/20/2024,"Phase 1/2 data reported that patients treated with 10 mg/kg of DYNE-251 Q4W had a mean absolute dystrophin level of 3.22% of normal and a 2.97% change, noted May 20, 2024.",142.0,3081.23178,83.2802,27.68,35.38,31.22,0.245436558,0.120348784,-0.004268132,0.026111144,11.06178,0.125,162.67452,970,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
BCLI,NurOwn,Amytrophic lateral sclerosis (ALS)Â ,Phase 3,5/20/2024,"Phase 3 data reported a 4% decrease from baseline in NfL in Phase 3 and a 27% and 36% decrease from baseline, at the ends of Period 1 and Period 2 of the EAP, respectively, noted May 20, 2024.",10.0,39.73565,169.2925,7.8015,8.505,8.0595,0.086338203,0.032535497,-0.004268132,0.026111144,2.99414,0.10377,0.34736,971,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
PLUR,NurOwn,Amytrophic lateral sclerosis (ALS)Â ,Phase 3,5/20/2024,"Phase 3 data reported a 4% decrease from baseline in NfL in Phase 3 and a 27% and 36% decrease from baseline, at the ends of Period 1 and Period 2 of the EAP, respectively, noted May 20, 2024.",8.0,32.60219,86.648,6.1,6.05,6.0199,-0.008230499,-0.013218123,-0.004268132,0.026111144,0.7302,0.05488,0.02354,972,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ESPR,Bempedoic acid - (Japan trial),HypercholesterolemiaÂ ,Phase 3,5/20/2024,"Phase 3 data reported that the percentage change from baseline in LDL-C at Week 12, the primary endpoint, was -25.25%% in the group receiving bempedoic acid placebo group and -3.46% in the placebo gro",201.0,469.86153,100.8292,2.36,2.48,2.13,0.049596941,-0.102539639,-0.004268132,0.026111144,10.48621,0.23432,14.55998,973,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ARWR,ARO-RAGE-1001,AsthmaÂ ,Phase 1/2,5/20/2024,"Phase 1/2a trial data presented at ATS reported that after two doses of ARO-RAGE in patients with mild to moderate asthma, serum sRAGE was reduced up to 88% with a mean maximum reduction up to 77%, no",138.0,3082.64971,78.9099,24.77,24.82,24.88,0.002016536,0.004431024,-0.004268132,0.026111144,7.74045,0.18258,11.02909,974,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
AMGN,TEZSPIRE (tezepelumab-ekko) - (COURSE),Chronic obstructive pulmonary disease (COPD)Â ,Phase 2,5/20/2024,"Phase 2 data presented at ATS reported that a 17% numerical reduction in the annual rate of moderate or severe COPD exacerbations compared to placebo at week 52, which was not statistically significan",538.0,168730.168,26.7323,312.47,314.54,305.84,0.006602789,-0.021446375,-0.004268132,0.026111144,1.81116,0.02106,438.71505,975,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
GILD,Livdelzi (Seladelpar) - (ASSURE),Pruritus (itch) in people living with primary biliary cholangitis (PBC)Â ,Phase 3,5/20/2024,"Phase 3 data reported that 70% of patients achieved the composite response endpoint and 25% experienced ALP normalization, noted May 20, 2024.",0.0,84593.43289,24.0191,67.72,67.9,65.68,0.002654477,-0.030587092,-0.004268132,0.026111144,1.69843,0.07141,320.47809,976,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1
SONN,SON-1010 with Trabectedin - (SB101),Solid tumorsÂ ,Phase 1,5/20/2024,"Additional safety data reported a 10-fold extended half-life for SON-1010 compared with rhIL-12 that induces prolonged and controlled IFNÎ³ responses, with no evidence of cytokine release syndrome at a",6.0,5.41558,86.0203,14.72,13.92,13.2,-0.055880458,-0.108990284,-0.004268132,0.026111144,12.8577,0.06649,0.07184,977,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
SONN,SON-1010 in combination with atezolizumab - (SB221),Platinum-resistant ovarian cancerÂ ,Phase 1/2,5/20/2024,Phase 1b/2 data reported that one patient in Part 1 of SB221 with uterine sarcomas received 8 cycles of the SON-1010/atezolizumab combination therapy every 3 weeks before progressing; another two have,6.0,5.41558,86.0203,14.72,13.92,13.2,-0.055880458,-0.108990284,-0.004268132,0.026111144,12.8577,0.06649,0.07184,978,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
GRI,GRI-0621,Idiopathic pulmonary fibrosis (IPF)Â ,Preclinical,5/20/2024,"Preclinical data reported that GRI-0621 was shown to reduce the fibrotic score, inhibit the production of TGFÎ² and VCAM-1 and reduce the immune cell, noted May 20, 2024.",2.0,1.62302,150.5529,92.82002,95.03002,70.27801,0.023530492,-0.278203402,-0.004268132,0.026111144,0.43047,0.00229,1.09731,979,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
KRRO,KRRO-110 - (REWRITE),Alpha-1 Antitrypsin Deficiency (AATD)Â ,Preclinical,5/20/2024,Preclinical data presented at ATS showed sustained editing efficiency of approximately 60% and increased total alpha-1 antitrypsin (AAT) protein levels to greater than 60uM at week 13 in an in vivo ge,9.0,506.30509,95.4233,54.66,54.6,48.85,-0.001098298,-0.112377802,-0.004268132,0.026111144,1.33702,0.00011,2.03587,980,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
LRMR,Nomlabofusp (CTI-1601),Friedreichâ€™s ataxia (FA)Â ,Phase 2,5/20/2024,"Phase 2 clinical hold removed, noted May 20, 2024.",85.0,463.84066,91.0578,7.38,7.27,7.08,-0.015017347,-0.041499731,-0.004268132,0.026111144,6.12048,0.02682,5.62276,981,0,0,0,0,0,1,0,1,0,0,0,0,0,2,0,-1
VTVT,Azeliragon,Refractory to first-line treatment of metastatic pancreatic cancerÂ ,Phase 1/2,5/20/2024,"Phase 1/2 Orphan Drug Designation granted by the FDA on May 20, 2024.",3.0,180.64116,159.8436,27.9,28.21,27.72,0.011049836,-0.006472515,-0.004268132,0.026111144,0.41543,0.00052,0.26867,982,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ARCT,Kostaive (ARCT-154),COVID-19 variant vaccineÂ ,Phase 1/2,5/20/2024,"Phase 1/2 additional results demonstrate that two 5 Î¼g doses of ARCT-154, sa-mRNA vaccine, were well-tolerated, immunogenic and provided significant protection against multiple strains of COVID-19, no",27.0,821.42069,64.6101,29.78,30.5,30.41,0.023889656,0.020934474,-0.004268132,0.026111144,18.25466,0.29851,9.51335,983,0,0,0,1,0,1,0,0,0,0,0,0,2,0,0,1
GLUE,MRT-6160,Autoimmune conditionsÂ ,Preclinical,5/21/2024,"Preclinical data reported that MRT-6160-mediated murine (m)VAV1 degradation prevented disease progression by 85% compared to vehicle (P<0.0001), and also reduced the disease activity index (DAI) score",61.0,262.59841,109.9002,4.95,4.295,4.18,-0.141936021,-0.16907633,0.001084364,0.034623083,3.13201,0.18288,2.21366,984,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
IRWD,Apraglutide - (STARS),Short Bowel Syndrome with Intestinal Failure (SBS-IF)Â ,Phase 3,5/21/2024,"Additional Phase 3 data to be presented at the Digestive Disease Week reported that significantly more apraglutide-patients gained additional days off from PS per week at week 24 versus placebo, noted",162.0,1077.72929,82.6746,6.42,6.78,5.88,0.054558984,-0.087861356,0.001084364,0.034623083,12.63204,0.00201,15.70096,985,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
GILD,Depemokimab - (SWIFT-1 and SWIFT-2),Severe asthma with type 2 inflammation characterised by blood eosinophil countÂ ,Phase 3,5/21/2024,"Phase 3 data reported that both trials met its primary endpoints, noted May 21, 2024.",0.0,83833.46243,23.9321,67.9,67.29,63.94,-0.009024397,-0.060090891,0.001084364,0.034623083,1.69843,0.07141,383.63563,986,1,0,0,0,0,1,0,0,0,0,0,0,2,0,0,1
CTXR,Mino-Lok,Catheter related blood stream infection (CRBSI)Â ,Phase 3,5/21/2024,"Phase 3 topline data study met its primary endpoint with a statistically significant improvement in the time to failure event, noted May 21, 2024.",17.0,131.89155,68.3558,16.495,18.25,15.7975,0.101107775,-0.043205605,0.001084364,0.034623083,7.98581,0.01613,15.84007,987,1,0,0,0,0,1,0,0,0,0,1,0,3,0,0,1
PRTC,VE303 - (RESTORATiVE303),Clostridioides difficile infection (CDI)Â ,Phase 3,5/21/2024,"Phase 3 dosing initiated, noted May 21, 2024.",24.0,611.92003,46.9567,2.285,2.26,2.26,-0.011001211,-0.011001211,0.001084364,0.034623083,0.0,0.10067,0.64292,988,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1
PALI,PALI-2108,Moderate-to-severe ulcerative colitis (UC)Â ,Preclinical,5/21/2024,"Preclinical data presented at DDW exhibited a dose-dependent efficacy response in two DSS colitis mouse models, achieving efficacy comparable to doses of apremilast considered intolerable for human us",9.0,5.07221,150.3663,5.85,5.41,4.76,-0.078192568,-0.206193993,0.001084364,0.034623083,19.03703,0.04173,0.1657,989,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
GRI,GRI-0124,Systemic Lupus Erythematosus (SLE)Â ,Preclinical,5/21/2024,"Preclinical data reported that it inhibited pro-inflammatory cytokines and signaling pathways in NZBWF1 mice, noted May 21, 2024.",2.0,1.56451,150.5624,95.03002,91.60452,69.61501,-0.036712226,-0.311212637,0.001084364,0.034623083,0.43047,0.00229,1.32085,990,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
GRI,GRI-0803,Systemic lupus erythematosus (SLE)Â ,Preclinical,5/21/2024,"Preclinical data reported favorable solubility profile, and an excellent bioavailability, noted May 21, 2024.",2.0,1.56451,150.5624,95.03002,91.60452,69.61501,-0.036712226,-0.311212637,0.001084364,0.034623083,0.43047,0.00229,1.32085,991,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
BDRX,"eRapa (rapamycin, sirolimus) - (Serenta)",Familial Adenomatous Polyposis (FAP)Â ,Phase 2,5/21/2024,"Phase 2 results presented at DDW showed an 83% non-progression rate at 6 months and a statistically significant decrease in overall mean polyp burden at 6 months, noted May 21, 2024.",0.0,13.03752,207.6051,317.5,582.5,270.0,0.606851367,-0.162055859,0.001084364,0.034623083,36.7441,0.05173,292.77557,992,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1
BHC,larsucosterol (DUR-928) - (AHFIRM),Alcoholic hepatitis (AH)Â ,Phase 2b,5/21/2024,"Breakthrough Therapy designation (BTD) granted by the FDA, noted May 21, 2024.",369.0,2402.51852,39.0905,6.5,6.55,6.2,0.007662873,-0.047252885,0.001084364,0.034623083,5.59087,0.12826,18.85395,993,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
LLY,Mirikizumab - (VIVID-1),Crohn's diseaseÂ ,Phase 3,5/21/2024,"Phase 3 data showed that nearly one-half of patients on mirikizumab achieved endoscopic response at 52 weeks; most of these patients were also in clinical remission, noted May 21, 2024.",946.0,723178.5939,26.4651,783.18,803.17,807.86,0.025203843,0.031026222,0.001084364,0.034623083,0.5674,0.03089,3481.33956,994,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1
XOMA,RZ402,Diabetic macular edema (DME)Â ,Phase 2,5/21/2024,"Phase 2 study met its primary endpoint, noted May 21, 2024.",12.0,301.43852,54.1587,25.03,25.9,25.5,0.034167863,0.018603347,0.001084364,0.034623083,2.33185,0.00232,0.22233,995,1,0,0,0,0,1,0,0,0,0,0,0,2,0,0,1
RZLT,RZ402,Diabetic macular edema (DME)Â ,Phase 2,5/21/2024,"Phase 2 study met its primary endpoint, noted May 21, 2024.",90.0,120.40544,90.4443,2.81,3.0,3.69,0.065427805,0.272441975,0.001084364,0.034623083,0.7845,0.02002,11.56727,996,1,0,0,0,0,1,0,0,0,0,0,0,2,0,0,1
LIPO,LP-10 (liposomal tacrolimus),Hemorrhagic cystitisÂ ,Phase 2b,5/21/2024,"Phase 2b type C meeting with the FDA resulted in a preliminary agreement to proceed to Phase 2b expected to initiated in 2H 2024, noted May 21, 2024.",4.0,5.53842,68.7969,6.04,5.8256,4.96679,-0.036142014,-0.195630256,0.001084364,0.034623083,0.42141,0.01103,0.15897,997,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ALGS,ALG-055009 - (HERALD),Metabolic dysfunction-associated steatohepatitis (MASH)Â ,Phase 2a,5/21/2024,"Phase 2a enrollment completed, noted May 21, 2024",6.0,49.87317,79.3178,16.7775,15.9625,15.325,-0.049796482,-0.090553221,0.001084364,0.034623083,1.07344,0.14747,0.23945,998,0,0,0,0,0,1,0,0,0,1,0,0,2,0,0,1
SANA,SC379,Secondary progressive multiple sclerosisÂ ,Preclinical,5/21/2024,"Preclinical data published in a paper showed that when healthy wild-type (WT), pluripotent stem cell-derived glial progenitor cells (hGPCs) â€“ the cells that give rise to the glial support cells of the",237.0,1838.47414,104.9544,8.63,8.3,7.8,-0.03898899,-0.101120771,0.001084364,0.034623083,11.58027,0.11894,10.65727,999,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
IFRX,Gohibic (vilobelimab) - (PANAMO),COVID-19Â ,Phase 3,5/21/2024,"Phase 3 data shared at ATS 2024 showed that co-administration of vilobelimab with baricitinib or tocilizumab was not associated with safety concerns, noted May 21, 2024.",59.0,89.50257,78.2632,1.54,1.52,1.46,-0.013072082,-0.053345981,0.001084364,0.034623083,0.22326,0.04854,0.38046,1000,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
RVPH,Brilaroxazine,Idiopathic pulmonary fibrosis (IPF)Â ,Preclinical,5/21/2024,"Preclinical data shared at ATS reported that interactions with multiple 5-HT targets, particularly 5-HT2B/7 receptors, within the pulmonary tissue, provide an underlying basis for this agent's effecti",68.0,36.43372,94.2628,1.54,1.305,1.38,-0.165579376,-0.109698917,0.001084364,0.034623083,4.47701,0.01735,1.2585,1001,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
LYRA,LYR-220 - (BEACON),Chronic rhinosinusitisÂ ,Phase 2,5/21/2024,"Development paused, noted May 21, 2024.",1.0,21.66691,301.15,18.65,17.77,16.675,-0.048334504,-0.111935554,0.001084364,0.034623083,0.67874,0.0005,1.71719,1002,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
AMPH,Albuterol Sulfate Inhalation Aerosol (AMP-008),BronchospasmÂ ,Approved,5/22/2024,"Approved May 22, 2024.",46.0,2125.2794,40.7428,41.91,43.46,41.64,0.036316513,-0.006463218,0.02487828,0.045693511,8.1531,0.08162,14.12846,1003,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1
PLRX,Bexotegrast (PLN-74809) - (INTEGRIS-IPF),Idiopathic pulmonary fibrosis (IFP)Â ,Phase 2a,5/22/2024,Phase 2a data reported that seven previously identified plasma biomarkers of interstitial lung disease (ILD) progression were significantly modulated in participants with IPF receiving bexotegrast ove,61.0,855.4203,57.8286,14.59,14.18,12.62,-0.028503841,-0.145053505,0.02487828,0.045693511,12.50717,0.07887,3.83315,1004,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
RNAC,Descartes-08 - (AURORA),"Generalized myasthenia gravis (MG), Multiple Myeloma and Autoimmune DiseasesÂ ",Phase 2b,5/22/2024,"Regenerative Medicine Advanced Therapy (RMAT) granted by the FDA, noted May 22, 2024.",26.0,453.08751,126.2033,24.6,25.46,29.0,0.03436215,0.164549387,0.02487828,0.045693511,4.40676,0.03004,1.48376,1005,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
INKT,AGENT-797,Acute respiratory distress (ARDS) secondary to COVID-19Â ,Phase 1/2,5/22/2024,"Phase 1/2 data reported that allogeneic iNKT therapy was safely administered with rapid decrease in IL-18 and other inflammatory cytokines, noted May 22, 2024.",4.0,39.36763,89.9178,9.9,10.0,9.688,0.010050336,-0.021646751,0.02487828,0.045693511,0.22215,0.04247,0.0879,1006,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
SRRK,SRK-439 with apitegromab - (EMBRAZE),ObesityÂ ,Phase 2,5/22/2024,"Phase 2 trial initiated, noted May 22, 2024.",96.0,933.9201,73.115,12.27,11.71,9.21,-0.046714081,-0.286867408,0.02487828,0.045693511,16.77973,0.01424,11.40688,1007,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ABUS,Imdusiran (AB-729 and VTP-300 with nivolumab) - (IM-PROVE I),Hepatitis B (HBV)Â ,Phase 2a,5/22/2024,"Phase 2a key findings noting that VTP-300 in combination with nivolumab has been generally well tolerated, with no observed treatment-related serious adverse events, and contributed to declines in hep",191.0,643.52637,43.1936,3.21,3.41,3.36,0.060441354,0.045670037,0.02487828,0.045693511,3.07634,0.07562,7.42613,1008,0,0,0,1,0,1,0,0,0,0,0,0,0,0,2,0
BRNS,Imdusiran (AB-729 and VTP-300 with nivolumab) - (IM-PROVE I),Hepatitis B (HBV)Â ,Phase 2a,5/22/2024,"Phase 2a key findings noting that VTP-300 in combination with nivolumab has been generally well tolerated, with no observed treatment-related serious adverse events, and contributed to declines in hep",40.0,89.77626,85.5807,2.1513,2.3,2.09,0.066836812,-0.028908245,0.02487828,0.045693511,0.04873,0.00122,0.02489,1009,0,0,0,1,0,1,0,0,0,0,0,0,0,0,2,0
CLYD,Imdusiran (AB-729 and VTP-300 with nivolumab) - (IM-PROVE I),Hepatitis B (HBV)Â ,Phase 2a,5/22/2024,"Phase 2a key findings noting that VTP-300 in combination with nivolumab has been generally well tolerated, with no observed treatment-related serious adverse events, and contributed to declines in hep",0.0,1.02,370.1367,0.03,0.03,0.03,0.0,0.0,0.02487828,0.045693511,0.0,,0.0,1010,0,0,0,1,0,1,0,0,0,0,0,0,0,0,2,0
INDP,Decoy 20,Solid tumorsÂ ,Phase 1a,5/22/2024,"Phase 1a first-in-human trial confirms ""Pulse-Prime"" hypothesis targeting stimulation of innate and adaptive immune systems, this data to be presented at ASCO 24, noted May 22, 2024.",1.0,21.17641,74.3768,65.79997,69.43997,77.27997,0.053843256,0.160815419,0.02487828,0.045693511,0.30224,0.0995,0.24026,1011,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1
BIVI,Bezisterim (NE3107) - (Biomarker Trial),Alzheimer's diseaseÂ ,Phase 2a,5/22/2024,Phase 2a full dataset presented at IAPRD suggest patients treated with bezisterim experienced significant improvements in both non-motor symptoms and motor control while placebo-treated patients worse,7.0,29.52163,182.7196,48.37,48.42,43.74,0.001033165,-0.100616772,0.02487828,0.045693511,2.0868,0.01306,0.36422,1012,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ANL,Palupiprant (AN0025) + Keytruda - (ARTEMIS),"TNBC, NSCLC, bladder cancer, microsatellite stable CRC and cervical cancerÂ ",Phase 2,5/22/2024,"Phase 2 trial initiated, noted May 22, 2024.",36.0,470.47842,104.2793,12.75,12.75,8.26,0.0,-0.434106684,0.02487828,0.045693511,0.03114,0.00053,0.00296,1013,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
KYMR,KT-621 (STAT6),Type 2 inflammation in allergic diseasesÂ ,Preclinical,5/22/2024,"Preclinical data reported that KT-621 was comparable to a saturating dose of the IL-4RÎ± antibody, dupilumab, in an asthma efficacy model which demonstrated that KT-621 robustly inhibited all the teste",71.0,2190.48995,59.8255,35.32,35.7,32.49,0.010701313,-0.083517026,0.02487828,0.045693511,16.14831,0.27002,18.39485,1014,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CNTB,Rademikibart - (Seabreeze STAT Asthma),AsthmaÂ ,Phase 2b,5/22/2024,"Phase 2b data presented at ATS showed that treatment significantly improved lung function at Week 12; improvements were observed as early as Week 1 and sustained through Week 24, noted May 22, 2024.",55.0,92.57044,129.6297,1.77,1.68,1.5999,-0.052185753,-0.101038419,0.02487828,0.045693511,0.05668,0.00037,0.04415,1015,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
TNGX,TNG348,"BRCA1/2-Mutant and Other HRD+ Cancers, Solid TumorsÂ ",Phase 1/2,5/23/2024,"Phase 1/2 first patient dosed January 3, 2024. Phase 1/2 discontinued due to toxicity observed in the initial study cohorts. No patient had yet received a combination of TNG348 and olaparib., noted Ma",111.0,757.54,56.8593,7.39,7.09,6.66,-0.041442394,-0.10400825,0.036910267,0.035447868,10.19008,0.00461,8.68088,1016,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CYTO,Bentrio (AM-301) - (NASAR),Seasonal allergic rhinitis (SAR)Â ,Phase 1,5/23/2024,"Phase 1 data published at in video format showed that the study met its primary efficacy endpoint, showing a statistically significant reduction in the mean daily reflective Total Nasal Symptom Score",4.0,27.41421,121.4821,0.51,0.51,0.46,0.0,-0.103184236,0.036910267,0.035447868,0.0,0.00474,0.01193,1017,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1
NNVC,NV-CoV-2 (NV-387),"RSV (Respiratory Syncytial Virus), Coronavirus, Smallpox/Mpox related Ectromelia virus infectionÂ ",Phase 1b,5/23/2024,"Phase 1b trial completed, the company also engaged with Aagami, Inc for partnership developments and licensing opportunities, noted May 23, 2024.",17.0,26.34522,90.4996,2.27,2.23,2.43,-0.017778246,0.068111426,0.036910267,0.035447868,0.84828,0.02801,0.79282,1018,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
EVGN,BMC128 with Opdivo,"Non-small cell lung cancer (NSCLC), melanoma or renal cell carcinomaÂ ",Phase 1,5/23/2024,"Phase 1 data from ASCO abstract reported that one patient demonstrated partial response (PR) upon imaging and RECIST v1.1 assessment and remains actively responding to treatment. Additionally, 64% of",6.0,27.86026,52.4132,1.99,2.0,1.96,0.005012542,-0.015190165,0.036910267,0.035447868,0.0,0.11493,0.004,1019,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
BMY,BMC128 with Opdivo,"Non-small cell lung cancer (NSCLC), melanoma or renal cell carcinomaÂ ",Phase 1,5/23/2024,"Phase 1 data from ASCO abstract reported that one patient demonstrated partial response (PR) upon imaging and RECIST v1.1 assessment and remains actively responding to treatment. Additionally, 64% of",0.0,84205.73799,22.6783,42.34,41.54,40.25,-0.019075447,-0.050622262,0.036910267,0.035447868,1.3825,0.03537,516.67282,1020,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
SUPN,SPN-817,Treatment-resisted seizuresÂ ,Phase 2,5/23/2024,"Phase 2 interim data reported that 81% of subjects with focal seizures had 30% or more seizure reduction, noted May 23, 2024.",56.0,1526.63503,36.3314,27.87,27.77,26.57,-0.00359454,-0.047768082,0.036910267,0.035447868,8.76868,0.11794,17.31576,1021,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
MRUS,MCLA-145 with Keytruda (pembrolizumab),Solid tumorsÂ ,Phase 1,5/23/2024,"Phase 1 data from abstract reported that 5 partial responses (PRs) were observed with 1 complete response was observed in PD-L1+ NSCLC (treated 6+ mo) and 1 PR in Merkel cell carcinoma, noted May 23,",75.0,2586.36037,49.2683,43.4,44.07,57.3,0.015319838,0.277841183,0.036910267,0.035447868,5.7613,0.29835,71.09584,1022,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
GMAB,MCLA-145 with Keytruda (pembrolizumab),Solid tumorsÂ ,Phase 1,5/23/2024,"Phase 1 data from abstract reported that 5 partial responses (PRs) were observed with 1 complete response was observed in PD-L1+ NSCLC (treated 6+ mo) and 1 PR in Merkel cell carcinoma, noted May 23,",661.0,130727.4937,31.2085,2055.0,2025.0,1931.0,-0.014706147,-0.062237845,0.036910267,0.035447868,0.0,0.09384,216.03105,1023,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
BCYC,BT5528 and OPDIVO (nivolumab),Solid tumorsÂ ,Phase 1/2,5/23/2024,"Phase 1/2 data from ASCO abstract reported that BT5528-related AEs occurred in 91% of patients, of which 22% were Grade â‰¥3, noted May 23, 2024.",69.0,1004.81188,61.345,21.42,23.48,21.92,0.09182393,0.023074397,0.036910267,0.035447868,6.51743,0.10273,48.69421,1024,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
BCAB,Evalstotug (BA3071),Oncology (various)Â ,Phase 2,5/23/2024,"Phase 2 data from abstract reported two treatment related discontinuations with responses in three of eight patients who received evalstotug 350mg(1 CR, 1 PR, 1 unPR), noted May 23, 2024.",58.0,101.04343,137.7567,2.28,2.1,1.515,-0.082238098,-0.408760004,0.036910267,0.035447868,11.07718,0.29957,1.23228,1025,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
NKGN,SNK02,Solid TumorsÂ ,Phase 1,5/23/2024,"Phase 1 data from ASCO abstract reported that the best objective response of stable disease was demonstrated in 100% of patients that completed 8 treatment cycles of SNK02, noted May 23, 2024.",124.0,46.29131,194.2951,1.78,1.86,1.57,0.043963123,-0.125537745,0.036910267,0.035447868,2.21258,0.00116,3.53924,1026,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
FGEN,FG-3246 (FOR46) in combination with enzalutamide - (Investigator-sponsored trial),Metastatic castration-resistant prostate cancer (mCRPC)Â ,Phase 1/2,5/23/2024,"Phase 1b/2 data from abstract reported a preliminary estimate of median radiographic progression free survival (rPFS) of 10.2 months, noted May 23, 2024.",4.0,127.32848,163.6463,30.75,32.0,28.75,0.039845909,-0.067252227,0.036910267,0.035447868,6.95632,0.05229,2.05146,1027,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
VSTM,VS-6766 and defactinib - (RAMP 205),Metastatic pancreatic cancerÂ ,Phase 1/2,5/23/2024,"Phase 1/2 study as of May 14, 2024, patients receiving the combination of avutometinib and defactinib with gemcitabine and Nab-paclitaxel in dose level 1 cohort achieved a confirmed overall response r",61.0,308.46521,64.5026,11.88,12.18,3.99,0.024938948,-1.091065083,0.036910267,0.035447868,3.25902,0.02172,3.76073,1028,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1
IMAB,Ragistomig (ABL503),Solid tumorsÂ ,Phase 1,5/23/2024,"Phase 1 data from ASCO abstract reported an overall response rate of 25% at 5 mg/kg, based on 3 partial responses (PR) out of 12 patients with median progression free survival (PFS) of 15.6 weeks, not",81.0,141.22779,72.1521,1.76,1.75,1.74,-0.005698021,-0.011428696,0.036910267,0.035447868,1.43217,0.15627,0.19121,1029,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CGEM,CLN-619 - (MICA) monotherapy and in combination with pembrolizumab,Solid tumorsÂ ,Phase 1,5/23/2024,"Phase 1 data from ASCO abstract reported that confirmed partial responses (PR) were observed in 3 patients, noted May 23, 2024.",59.0,1305.4154,76.0291,23.14,22.65,22.79,-0.02140287,-0.015240879,0.036910267,0.035447868,4.08873,0.12008,13.48887,1030,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
REGN,REGN7075 in combination with cemiplimab,Solid TumorsÂ ,Phase 1/2,5/23/2024,"Phase 1/2 updated data to be presented at ASCO on June 3, 2024. Phase 1/2 data from ASCO abstract reported a 6% (n=3) overall response rate (ORR) and 29% (n=15) disease control rate (DCR), noted May 2",105.0,105789.2877,16.8217,983.8,980.57,969.91,-0.003288589,-0.014219341,0.036910267,0.035447868,1.4588,0.09017,309.59929,1031,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1
MURA,Nemvaleukin (ALKS 4230) - (ARTISTRY-3),Solid TumorsÂ ,Phase 2,5/23/2024,"Phase 2 data from ASCO abstract reported that all dosing schedules tested in ARTISTRY-3 demonstrated the desired pharmacodynamic effects, including expansion of immune-stimulating NK and CD8+ cells, n",17.0,60.75672,67.8356,3.77,3.59,3.35,-0.048922799,-0.118114656,0.036910267,0.035447868,10.16275,0.0,0.38631,1032,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ALKS,Nemvaleukin (ALKS 4230) - (ARTISTRY-3),Solid TumorsÂ ,Phase 2,5/23/2024,"Phase 2 data from ASCO abstract reported that all dosing schedules tested in ARTISTRY-3 demonstrated the desired pharmacodynamic effects, including expansion of immune-stimulating NK and CD8+ cells, n",165.0,4061.31146,37.386,24.21,24.0,23.21,-0.008711941,-0.042182551,0.036910267,0.035447868,7.61973,0.04095,36.8357,1033,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
IOVA,LN-145 - (IOV-COM-202),Non-small cell lung cancer (NSCLC)Â ,Phase 2,5/23/2024,"Phase 2 data from ASCO abstract reported a confirmed ORR was 65.2%, including 7 (30.4%) complete responses and 8 (34.8%) partial responses, noted May 23, 2024.",361.0,2871.08373,98.7374,10.33,10.26,9.0,-0.006799443,-0.137827706,0.036910267,0.035447868,17.88762,0.14133,59.13376,1034,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
HOWL,WTX-124,Solid TumorsÂ ,Phase 1b,5/23/2024,"Phase 1/1b data from ASCO abstract reported that treatment was well tolerated and clinically active in patients with checkpoint inhibitor therapy relapsed/refractory cancers, noted May 23, 2024.",45.0,224.22969,93.9386,4.89,5.16,5.36,0.053744276,0.091771672,0.036910267,0.035447868,0.95383,0.00968,0.67445,1035,0,0,0,1,0,1,0,0,0,0,0,0,2,0,0,1
CMPX,CTX-471 (CD137 agonist),Solid tumorsÂ ,Phase 1,5/23/2024,"Phase 1 Dose Escalation and Dose Expansion, first-in-human monotherapy study in patients with metastatic or locally advanced malignancies who had progressed on approved PD-1 or PD-L1 inhibitors, noted",138.0,205.69581,78.8482,1.56,1.495,1.36,-0.042559614,-0.137201122,0.036910267,0.035447868,1.19404,0.03297,0.25523,1036,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1
INAB,INB-200,GlioblastomaÂ ,Phase 1,5/23/2024,"Phase 1 data from ASCO reported no dose-limiting toxicities, cytokine release syndrome, or neurotoxicity, noted May 23, 2024.",4.0,45.88447,129.8115,31.50003,31.19703,30.90003,-0.0096656,-0.019231343,0.036910267,0.035447868,0.40778,0.00698,0.0253,1037,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
EVAX,EVX-01 + KEYTRUDA (pembrolizumab) / OPDIVO (nivolumab),Metastatic MelanomaÂ ,Phase 2b,5/23/2024,"Phase 2 data from ASCO abstract reported that EVX-01 vaccine-induced specific and robust immune responses, mediated by both CD4+ and CD8+ T-cells, noted May 23, 2024.",6.0,20.99487,179.5699,19.05,19.4,17.997,0.018205964,-0.056862024,0.036910267,0.035447868,0.98328,0.01641,0.07265,1038,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
MRK,EVX-01 + KEYTRUDA (pembrolizumab) / OPDIVO (nivolumab),Metastatic MelanomaÂ ,Phase 2b,5/23/2024,"Phase 2 data from ASCO abstract reported that EVX-01 vaccine-induced specific and robust immune responses, mediated by both CD4+ and CD8+ T-cells, noted May 23, 2024.",0.0,332025.5788,16.7711,131.1,131.09,124.53,-7.62806e-05,-0.05141374,0.036910267,0.035447868,0.74044,0.01723,895.47409,1039,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
AGEN,Botensilimab plus balstilimab,Relapsed/refractory microsatellite stable colorectal cancer with no active liver metastases (r/r MSS CRC NLM)Â ,Phase 1b,5/23/2024,"Phase 1b data to be presented at ASCO 2024, ASCO abstract released across different NLM sites, overall response rates (ORR) ranged from 18-33%, and disease control rates (DCR) ranged from 67-82%. Over",31.0,259.34087,123.6229,11.91,12.35,15.11,0.03627768,0.237978393,0.036910267,0.035447868,15.4211,0.11062,7.41058,1040,1,0,0,0,0,1,0,0,0,0,1,0,3,0,0,1
MRUS,Petosemtamab (MCLA-158),"Recurrent/metastatic (r/m) head and neck squamous cell carcinoma (HNSCC), Solid TumorsÂ ",Phase 2,5/23/2024,"Phase 2 data from abstract reported a 60% response rate observed among 10 evaluable patients, noted May 23, 2024.",75.0,2586.36037,49.2683,43.4,44.07,57.3,0.015319838,0.277841183,0.036910267,0.035447868,5.7613,0.29835,71.09584,1041,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
GMAB,Petosemtamab (MCLA-158),"Recurrent/metastatic (r/m) head and neck squamous cell carcinoma (HNSCC), Solid TumorsÂ ",Phase 2,5/23/2024,"Phase 2 data from abstract reported a 60% response rate observed among 10 evaluable patients, noted May 23, 2024.",661.0,130727.4937,31.2085,2055.0,2025.0,1931.0,-0.014706147,-0.062237845,0.036910267,0.035447868,0.0,0.09384,216.03105,1042,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ZNTL,Azenosertib and gemcitabine,Relapsed or refractory (R/R) osteosarcomaÂ ,Phase 1,5/23/2024,Phase 1 data from ASCO abstract support further investigation of azenosertib administered in combination with gemcitabine in patients with R/R osteosarcoma in an upcoming investigator-initiated Phase,72.0,801.02927,70.3117,11.98,11.28,11.97,-0.060207347,-0.000835073,0.036910267,0.035447868,24.64759,0.04105,5.79658,1043,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
SNSE,Solnerstotug (formerly SNS-101) with Libtayo - (VISTA),One microsatellite stable (MSS) endometrial cancerÂ ,Phase 1/2,5/23/2024,"Phase 1/2 data demonstrated initial signs of promising clinical activity, noted May 23, 2024.",1.0,36.36736,84.983,27.2,29.0,15.1,0.064078857,-0.588522229,0.036910267,0.035447868,0.23975,0.04288,1.26901,1044,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
REGN,Solnerstotug (formerly SNS-101) with Libtayo - (VISTA),One microsatellite stable (MSS) endometrial cancerÂ ,Phase 1/2,5/23/2024,"Phase 1/2 data demonstrated initial signs of promising clinical activity, noted May 23, 2024.",105.0,105789.2877,16.8217,983.8,980.57,969.91,-0.003288589,-0.014219341,0.036910267,0.035447868,1.4588,0.09017,309.59929,1045,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
COGT,Bezuclastinib and SUTENT (sunitinib) - (PEAK),Gastrointestinal Stromal Tumors (GIST)Â ,Phase 3,5/23/2024,Phase 3 updated data presented at an ASCO abstract showed d that study reached median progression free survival (mPFS) of 19.4-months and 33% ORR in subset of advanced GIST patients with one prior tre,139.0,716.14434,148.6761,8.03,7.49,7.29,-0.06961573,-0.096680982,0.036910267,0.035447868,12.59651,0.00118,8.49571,1046,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
HOOK,Eseba-vec (formerly HB-200) in combination with KEYTRUDA (pembrolizumab),Head and neck squamous cell carcinoma (HNSCC)Â ,Phase 1/2,5/23/2024,"Phase 2 data due to be presented at ASCO 2024, abstract from updated data showed confirmed objective response rate (ORR) of 53%, complete response (CR) rate of 18%, and disease control rate (DCR) of 8",12.0,130.40363,100.3438,9.8,10.4,7.517,0.05942342,-0.265215263,0.036910267,0.035447868,0.51337,0.16829,1.71901,1047,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CADL,CAN-2409 + valacyclovir,Non-small cell lung cancer (NSCLC)Â ,Phase 2,5/23/2024,"Phase 2 data from ASCO abstract showed that treatment resulted in activation of the systemic immune response after two administrations of CAN-2409, including increased numbers of circulating cytotoxic",54.0,317.97117,225.1874,10.58,10.69,8.62,0.010343299,-0.204880342,0.036910267,0.035447868,3.54595,0.00483,10.79297,1048,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ELTX,ELI-002 - (AMPLIFY-7P),mKRAS-driven cancersÂ ,Phase 2,5/23/2024,"Phase 2 ASCO abstract showed that treatment administered as a monotherapy was well tolerated and able to generate a ~100x mKRAS-specific expanded T cell response relative to baseline levels, noted May",16.0,90.7641,129.236,8.86,8.85,7.51,-0.001129306,-0.165311299,0.036910267,0.035447868,0.83233,0.00223,0.15996,1049,0,0,0,1,0,1,0,0,0,0,0,0,2,0,0,1
PBYI,Alisertib - (PUMA-ALI-4201) - (ALISCA-Lung1),Small Cell Lung Cancer (SCLC)Â ,Phase 1b,5/23/2024,Phase 1/1b data shared at ASCO abstract showed that intermittent dosing of alisertib 30 mg BID in combination with osimertinib 80 mg daily demonstrated no dose-limiting toxicities and was identified a,50.0,192.47301,77.9612,4.23,3.99,3.81,-0.058410762,-0.104572804,0.036910267,0.035447868,6.45295,0.07724,1.62452,1050,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
IPHA,IPH6501,Relapsed and/or Refractory CD20-expressing B-cell Non-Hodgkin's Lymphoma (NHL)Â ,Preclinical,5/23/2024,"Preclinical data from ASCO abstract reported that IPH6501, at well-tolerated doses, significantly boosted peripheral NK cell proliferation, drove their accumulation at tumor locations, and effectively",92.0,215.84811,71.6335,2.9998,2.96,2.75,-0.013356351,-0.086944708,0.036910267,0.035447868,0.0,0.0,0.06977,1051,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1
ALXO,Evorpacept w/ cetuximab and pembrolizumab,Colorectal cancerÂ ,Phase 2,5/23/2024,"Phase 2 data from the abstract has ORR was 6.3% (1 ongoing partial response, 95% confidence interval [CI] 0.2-30.2%), disease control rate was 12.5% (95% CI 1.6-38.4%), median progression-free surviva",53.0,765.35057,90.2735,15.0,14.69,10.65,-0.020883211,-0.342490309,0.036910267,0.035447868,6.07009,0.0751,20.00262,1052,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
BNTX,BNT327/PM8002,Non-small cell lung cancer (NSCLC)Â ,Phase 1/2,5/23/2024,"Phase 1b/2 data from ASCO abstract reported a 47% ORR in cohort 6, 19.4% ORR in cohort 7, noted May 23, 2024.",239.0,23890.54457,33.3241,102.3,99.0,98.75,-0.032789823,-0.035318269,0.036910267,0.035447868,1.5296,0.08657,153.81729,1053,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CUE,CUE-102,Wilms' Tumor (WT1)-expressing cancersÂ ,Phase 1,5/23/2024,"Phase 1 data from abstract reported that stable disease of â‰¥ 6 weeks (range 6-36 weeks), as determined by RECIST 1.1, has been observed in 10 of 23 patients (DCR 43.5%), noted May 23, 2024.",76.0,84.63937,95.9008,1.91,1.74,1.59,-0.093218129,-0.183369226,0.036910267,0.035447868,10.19414,0.067,0.279,1054,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CUE,CUE-101 and KEYTRUDA (pembrolizumab) - (KEYNOTE-A78),HPV16+ head and neck cancerÂ ,Phase 1,5/23/2024,"Phase 1 data from ASCO abstract reported that of CUE-101 plus pembrolizumab, an ORR of 47% (1 CR, 8 PRs), a Disease Control Rate (ORR + durable SDs) of 74%, and mPFS of 5.8 months, noted May 23, 2024.",76.0,84.63937,95.9008,1.91,1.74,1.59,-0.093218129,-0.183369226,0.036910267,0.035447868,10.19414,0.067,0.279,1055,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
MRK,Sacituzumab tirumotecan (SKB264/MK-2870) - (OptiTROP-Breast01),Locally recurrent or metastatic triple-negative breast cancer (TNBC)Â ,Phase 3,5/23/2024,"Phase 3 data from ASCO abstract reported an objective response rate assessed by BICR was 43.8% with SKB264 and 12.8% with chemotherapy, noted May 23, 2024.",0.0,332025.5788,16.7711,131.1,131.09,124.53,-7.62806e-05,-0.05141374,0.036910267,0.035447868,0.74044,0.01723,895.47409,1056,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
PFE,PF-07248144,ER+ HER2âˆ’ breast cancerÂ ,Phase 1,5/23/2024,"Phase 1 data from ASCO abstract reported that for the fulvestrant combination (n=43), with median duration of follow-up of 9.2 mos, the ORR was 30.2% (17.2, 46.1), median DOR was 9.2 mos (7.2, NE), CB",0.0,162574.5502,27.096,29.6,28.69,28.2,-0.031225731,-0.048452383,0.036910267,0.035447868,1.10312,0.0254,1205.87871,1057,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
PFE,Mevrometostat (PF-06821497),Castration-resistant prostate cancer (CRPC)Â ,Phase 1,5/23/2024,"Phase 1 data from ASCO abstract reported that the OR rate (95% CI) was 27.3% (10.7, 50.2), including 1 complete and 5 partial responses, noted May 23, 2024.",0.0,162574.5502,27.096,29.6,28.69,28.2,-0.031225731,-0.048452383,0.036910267,0.035447868,1.10312,0.0254,1205.87871,1058,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
PFE,Elranatamab - (MagnetisMM-9),Multiple MyelomaÂ ,Phase 1/2,5/23/2024,"Phase 1/2 data from ASCO abstract reported that after a median follow-up of 7.4 mo, the most common (>50%) AEs were CRS (63.5%; grade â‰¥2, 15.3%) and neutropenia (54.1%; all grade â‰¥2), noted May 23, 20",0.0,162574.5502,27.096,29.6,28.69,28.2,-0.031225731,-0.048452383,0.036910267,0.035447868,1.10312,0.0254,1205.87871,1059,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
PFE,Sigvotatug vedotin (SGNB6A-001),Non-small cell lung cancer (NSCLC)Â ,Phase 1,5/23/2024,"Phase 1 data reported in ASCO abstract reported that the cORR was 19.5% (95% CI, 12.6-28.0) in all pts with NSCLC and 32.5% (95% CI, 18.6-49.1) in pts with non-squamous (non-Sq)/taxane-naive NSCLC. Ad",0.0,162574.5502,27.096,29.6,28.69,28.2,-0.031225731,-0.048452383,0.036910267,0.035447868,1.10312,0.0254,1205.87871,1060,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
MOLN,MP0317,Solid TumorsÂ ,Phase 1,5/23/2024,"Phase 1 data from ASCO abstract reported that one patient achieved unconfirmed partial response, and stable disease was observed in 11 patients (24%), noted May 23, 2024.",40.0,112.32136,51.8882,3.365,3.385,3.5,0.005925943,0.039335005,0.036910267,0.035447868,0.0,0.05974,0.05838,1061,0,0,0,0,1,1,0,0,0,0,0,0,2,0,0,1
XLO,XTX202,Solid TumorsÂ ,Phase 1/2,5/23/2024,"Phase 1/2 data from ASCO abstract reported that the DCR was 62% at the 1.4 mg/kg dose-level and 80% at the 4 mg/kg dose-level, with 19 pts ongoing and awaiting first response assessment, noted May 23,",51.0,39.49534,142.3294,1.15,1.07,0.9301,-0.072103294,-0.212225114,0.036910267,0.035447868,1.23676,0.00899,0.05665,1062,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
VSTM,AVMAPKI FAKZYNJA CO-PACK,Recurrent low-grade serous ovarian cancer (LGSOC)Â ,NDA Filing,5/24/2024,"NDA and accelerated approval application submitted May 24, 2024.",61.0,104.34127,166.7975,12.18,4.12,3.96,-1.083942099,-1.123551237,0.005500996,0.002129449,3.19708,0.07256,81.22537,1063,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
IDYA,Darovasertib - (neo-adjuvant and adjuvant settings) - (NADOM),Ocular MelanomaÂ ,Phase 2,5/24/2024,Phase 2 clinical efficacy update presented at ASCO abstract showed that monotherapy neoadjuvant treatment was generally well tolerated. Drug-related adverse events (AEs) were predominantly Grade 1 or,87.0,2854.14274,39.8969,38.45,37.71,36.55,-0.019433385,-0.05067751,0.005500996,0.002129449,14.64747,0.17227,80.20434,1064,0,0,0,1,0,1,0,0,0,0,0,0,2,0,0,1
BLRX,"Motixafortide (BL-8040), gemcitabine, nab-paclitaxel and LIBTAYO (cemiplimab) - (Columbia University trial) - (CheMo4METPANC)",First-line pancreatic ductal adenocarcinoma (PDAC)Â ,Phase 2,5/24/2024,"Phase 2 data from ASCO reported that 7 of 11 patients in the pilot phase experienced a partial response, with 6 confirmed; 10 of 11 patients experienced disease control , noted May 24, 2024.",3.0,193.05336,62.036,0.161,0.161,0.18,0.0,0.111552486,0.005500996,0.002129449,0.0,0.00464,0.0,1065,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CHRS,CHS-114 - (SRF114),Solid tumorsÂ ,Phase 1,5/24/2024,Phase 1 preliminary results from dose escalation in an ASCO abstract shown to have an acceptable safety profile with no dose-limiting toxicities (DLTs) in heavily pretreated patients with solid tumors,116.0,219.12616,88.343,2.01,1.91,1.82,-0.05103148,-0.099298221,0.005500996,0.002129449,18.98862,0.05922,2.75926,1066,0,0,0,1,0,1,0,0,0,0,0,0,0,2,0,-1
BCTX,Bria-IMT - (BRIA-ABC),Advanced breast cancerÂ ,Phase 2,5/24/2024,"Phase 2 data in an ASCO abstract resulted in an 83% intracranial objective response rate, median progression-free survival of 4.1 months in antibody-drug conjugate (ADC) resistant patients (double his",1.0,36.02055,89.9779,214.49989,215.99989,253.49987,0.006968673,0.167054085,0.005500996,0.002129449,0.0,0.0,2.85012,1067,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CGON,Cretostimogene in combination with pembrolizumab - (CORE-001),Intermediate-risk NMIBCÂ ,Phase 2,5/24/2024,"Phase 2 final results to be presented at ASCO 2024, abstract released resulted in a ITT CR rate 57% at 12mo, 83% any time. 95% of 12mo CRs maintained CR for 24mo. Median DoR >21mo. 24mo CR rate 69.6%.",76.0,2179.79931,0.0,29.99,32.71,32.58,0.086816849,0.08283461,0.005500996,0.002129449,4.2295,0.05336,29.0751,1068,1,0,0,0,0,1,0,0,0,0,1,0,3,0,0,1
MRK,Cretostimogene in combination with pembrolizumab - (CORE-001),Intermediate-risk NMIBCÂ ,Phase 2,5/24/2024,"Phase 2 final results to be presented at ASCO 2024, abstract released resulted in a ITT CR rate 57% at 12mo, 83% any time. 95% of 12mo CRs maintained CR for 24mo. Median DoR >21mo. 24mo CR rate 69.6%.",0.0,327973.0887,16.8929,131.09,129.49,125.54,-0.012280452,-0.043259677,0.005500996,0.002129449,0.80013,0.01813,774.84822,1069,1,0,0,0,0,1,0,0,0,0,1,0,3,0,0,1
IPHA,Lacutamab (IPH4102) - (TELLOMAK),"Mycosis Fungoides, SÃ©zary SyndromeÂ ",Phase 2,5/24/2024,"Phase 2 topline results reported that the ORR was 16.8%, with the median time to response was 1.0 months and median PFS 10.2m, noted May 24, 2024.",92.0,215.84811,71.6667,2.96,2.9013,2.74,-0.020030356,-0.077231348,0.005500996,0.002129449,0.0,0.0,0.05026,1070,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
AZN,"Imfinzi (durvalumab), Monalizumab, and Oleclumab - (COAST)",Non-small cell lung cancer (NSCLC)Â ,Phase 2,5/24/2024,"Phase 2 data reported that D+O and D+M increased ORR and prolonged PFS and OS vs D alone, noted May 24, 2024.",0.0,190616.8987,21.5572,124.04,122.96,121.9,-0.008744995,-0.017403058,0.005500996,0.002129449,0.0,0.18044,113.05779,1071,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
IPHA,"Imfinzi (durvalumab), Monalizumab, and Oleclumab - (COAST)",Non-small cell lung cancer (NSCLC)Â ,Phase 2,5/24/2024,"Phase 2 data reported that D+O and D+M increased ORR and prolonged PFS and OS vs D alone, noted May 24, 2024.",92.0,215.84811,71.6667,2.96,2.9013,2.74,-0.020030356,-0.077231348,0.005500996,0.002129449,0.0,0.0,0.05026,1072,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ANL,AN0025 + Keytruda,Solid tumorsÂ ,Phase 1b,5/24/2024,"Phase 1b data reported that the disease control rate (DCR) was 92% (11/12). The median progression-free survival (PFS) was not reached, with 6-month and 1-year PFS rates of 91% and 73%, respectively,",36.0,387.45281,106.3347,12.03,10.5,7.26,-0.136028273,-0.505023701,0.005500996,0.002129449,0.03261,0.0,0.18588,1073,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
HCM,Fruquintinib - (FRESCO),Metastatic colorectal cancer (CRC)Â ,Phase 3,5/24/2024,"Phase 3 data reported improvements in OS and PFS were seen with F vs P regardless of prior tx sequence (Table), with similar magnitudes of benefit for OS and PFS, noted May 24, 2024.",174.0,2526.81032,57.7116,3.04,2.96,2.95,-0.026668247,-0.030052345,0.005500996,0.002129449,0.0,0.07989,0.04093,1074,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
HCM,Fruquintinib (HMPL-013) - (FRESCO-2),Metastatic Colorectal CancerÂ ,Phase 3,5/24/2024,"Phase 3 data reported at ASCO reported improvements in OS and PFS were seen with F vs P regardless of prior tx sequence, with similar magnitudes of benefit for OS (HRs 0.53â€“0.77) and PFS (HRs 0.25â€“0.3",174.0,2526.81032,57.7116,3.04,2.96,2.95,-0.026668247,-0.030052345,0.005500996,0.002129449,0.0,0.07989,0.04093,1075,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
HCM,HMPL-295,Solid tumorsÂ ,Preclinical,5/24/2024,"Preclinical data from ASCO reported that stable disease with tumor shrinkage was also observed in 2 pts with NSCLC on 50 mg QD and 75 mg QD 2w on/1w off cohort respectively, and 1 pt with pancreatic d",174.0,2526.81032,57.7116,3.04,2.96,2.95,-0.026668247,-0.030052345,0.005500996,0.002129449,0.0,0.07989,0.04093,1076,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
HCM,Stereotactic ablative radiotherapy (SABR) + fruquintinib and tislelizumab - (RIFLE),Metastatic colorectal cancerÂ ,Phase 2,5/24/2024,"Phase 2 data from ASCO reported 1 CR, 8 PR, 14 SD and 8 PD, noted May 24, 2024.",174.0,2526.81032,57.7116,3.04,2.96,2.95,-0.026668247,-0.030052345,0.005500996,0.002129449,0.0,0.07989,0.04093,1077,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
INCY,INCB099280,Solid TumorsÂ ,Phase 1,5/24/2024,"Phase 1 data to be presented at ASCO on June 1, 2024, with abstract data reporting that 96.6% of pts had â‰¥1 tx-emergent adverse events, and decreased ctCNA was seen in all complete responders (n=2) an",195.0,12886.41443,27.5766,57.45,57.31,57.79,-0.002439876,0.005900746,0.005500996,0.002129449,3.35364,0.17017,112.72052,1078,0,0,0,1,0,1,0,0,0,0,1,0,3,0,0,1
INCY,INCB057643,Myelofibrosis (MF) and Other Advanced Myeloid NeoplasmsÂ ,Phase 1,5/24/2024,"Phase 1 data from ASCO abstract reported that SVR35 was achieved by all 3 evaluable pts receiving â‰¥10 mg monotherapy, and 3/12 achieved a best response of SVR35, noted May 24, 2024.",195.0,12886.41443,27.5766,57.45,57.31,57.79,-0.002439876,0.005900746,0.005500996,0.002129449,3.35364,0.17017,112.72052,1079,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1
ALXO,Evorpacept with PADCEV (enfortumab vedotin-ejfv) - (ASPEN-07),Urothelial Carcinoma (UC)Â ,Phase 1a,5/24/2024,"Phase 1a data from abstract reported an overall response rate (ORR) was 63% (1CR, 9PR), noted May 24, 2024.",53.0,686.15841,91.4641,14.69,13.17,10.63,-0.109225474,-0.323486798,0.005500996,0.002129449,6.44991,0.0764,6.93825,1080,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
BNTX,YL202/BNT326,Locally advanced or metastatic non-small cell lung cancer and breast cancerÂ ,Phase 1,5/24/2024,"Phase 1 data from ASCO abstract reported an ORR of 42.2% (19/45) and disease control rate (DCR) of 93.3% (42/45), noted May 24, 2024.",239.0,23395.84137,33.4316,99.0,96.95,100.6,-0.020924468,0.016032408,0.005500996,0.002129449,1.41897,0.07533,120.72718,1081,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
GMAB,Acasunlimab (GEN1046/BNT311),Non-small cell lung cancer (NSCLC)Â ,Phase 2,5/24/2024,"Phase 2 data from ASCO abstract reported confirmed ORRs (and mDoR) were 13% (2 mo), 21% (6 mo), and 22% (NR), with 6-mo PFS rates of 0%, 18%, and 33% for arms A, B, and C, respectively, noted May 24,",661.0,124368.6502,31.9785,2025.0,1926.5,1937.0,-0.049864815,-0.044429316,0.005500996,0.002129449,0.0,0.10611,827.3701,1082,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CGEN,"COM701, COM902 and Pembrolizumab","Advanced malignancies, Ovarian cancerÂ ",Phase 1,5/24/2024,"Data from abstract reported an ORR 2/17 (12%); disease control rate [DCR] 5/17 (29%) noted May 24, 2024,",93.0,218.45367,165.2338,2.27,2.44,2.17,0.072218208,-0.045052664,0.005500996,0.002129449,1.93067,0.04252,1.6432,1083,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
NUVB,Taletrectinib - (TRUST-I) (China),ROS1-positive non-small cell lung cancer (NSCLC)Â ,Phase 2,5/24/2024,"Phase 2 data from ASCO abstract reported that in TKI-pretreated patients, the ORR was 52% (95% CI: 40, 65) and IC-ORR was 75% , noted May 24, 2024.",342.0,761.2856,89.9542,3.08,3.08,3.1,0.0,0.006472515,0.005500996,0.002129449,1.34096,0.14163,2.40615,1084,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
APLS,EMPAVELI (pegcetacoplan) - (VALIANT),C3G and IC-MPGNÂ ,Phase 2,5/24/2024,"Phase 2 data from NOBLE study demonstrated a rreduction in disease activity seen at 12 weeks was sustained at one year, 55% of patients showed zero C3c staining intensity, indicating that C3c deposit",126.0,4928.65519,67.034,39.68,40.61,39.25,0.023167059,-0.010895838,0.005500996,0.002129449,10.37072,0.01872,52.03587,1085,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
MRK,KEYTRUDA (pembrolizumab) - (KEYNOTE-522),Triple negative breast cancer (TNBC)Â ,Phase 3,5/28/2024,"Phase 3 data reported that trial met its primary endpoint, noted May 28, 2024.",0.0,319361.5473,17.2992,129.49,126.09,128.71,-0.02660772,-0.006041846,0.015314235,-0.026001465,0.80013,0.01813,1294.10996,1086,1,0,0,0,0,1,0,0,0,0,0,0,2,0,0,1
INSM,BRINSUPRI (Brensocatib) - (ASPEN),Non-Cystic Fibrosis Bronchiectasis (NCFBE)Â ,Phase 3,5/28/2024,"Phase 3 topline data reported that the trial met its primary endpoint, noted May 28, 2024.",211.0,7141.93458,117.8407,22.0,48.06,57.0,0.781407777,0.952008814,0.015314235,-0.026001465,6.68184,0.07315,1605.69075,1087,1,0,0,0,0,1,0,0,0,0,1,0,3,0,0,1
ARCT,ARCT-032 - (LUNAR-CF),Cystic FibrosisÂ ,Phase 1b,5/28/2024,"Phase 1b data reported that the first four patients had an average improvement of 4% FEV1 after two administrations, noted May 28, 2024.",27.0,1034.45144,72.3561,30.41,38.41,41.42,0.233546341,0.308992354,0.015314235,-0.026001465,15.33095,0.29737,41.19415,1088,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
UNCY,UNI-494,Acute kidney injury (AKI)Â ,Preclinical,5/28/2024,"Preclinical model results of hyperphosphatemia demonstrated the relative potency of OLC Compared to tenapanor, noted May 28, 2024.",17.0,31.42782,95.6099,9.459,8.35699,8.056,-0.123868355,-0.160549514,0.015314235,-0.026001465,2.28622,0.00439,1.07219,1089,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
MRUS,Petosemtamab (MCLA-158),"Recurrent/metastatic (r/m) head and neck squamous cell carcinoma (HNSCC), Solid TumorsÂ ",Phase 1/2,5/28/2024,"Phase 2 data to be presented at ASCO 2024, abstract released on May 23 showed that as of the March 6, 2024 data cutoff, the combination demonstrated a 67% overall response rate across PD-L1 expression",75.0,3220.18592,66.9549,59.99,54.87,50.36,-0.089211131,-0.174980672,0.015314235,-0.026001465,5.93469,0.18762,211.7205,1090,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1
GMAB,Petosemtamab (MCLA-158),"Recurrent/metastatic (r/m) head and neck squamous cell carcinoma (HNSCC), Solid TumorsÂ ",Phase 1/2,5/28/2024,"Phase 2 data to be presented at ASCO 2024, abstract released on May 23 showed that as of the March 6, 2024 data cutoff, the combination demonstrated a 67% overall response rate across PD-L1 expression",661.0,124739.8216,31.7145,1955.0,1934.5,1937.5,-0.010541298,-0.008991711,0.015314235,-0.026001465,0.0,0.10611,229.69479,1091,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1
VERA,Atacicept - (ORIGIN 3),IgA NephropathyÂ ,Phase 2b,5/28/2024,"Phase 2b 72-week data reported that participants who switched from placebo to atacicept also demonstrated stable eGFR, as well as similar reductions in Gd-IgA1, hematuria, and UPCR, noted May 28, 2024",63.0,2031.05619,93.7188,37.11,37.13,39.47,0.000538793,0.061654415,0.015314235,-0.026001465,11.81125,0.06407,39.32112,1092,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CORT,Relacorilant - (GRACE),Hypercortisolism (Cushing's Syndrome)Â ,Phase 3,5/28/2024,"Phase 3 trial met its primary endpoint, noted May 28, 2024.",105.0,3290.9831,66.1659,27.52,31.61,32.87,0.138560513,0.177647375,0.015314235,-0.026001465,19.01861,0.02973,113.93268,1093,1,0,0,0,0,1,0,0,0,0,0,0,2,0,0,1
ABBV,ABBV-400,Colorectal cancer (CRC)Â ,Phase 1,5/28/2024,"Phase 1 preliminary data derived from ASCO abstract showed that among 122 heavily pre-treated advanced CRC patients, promising antitumor activity was observed at 2.4 and 3.0 mg/kg doses administered o",0.0,274309.9011,18.7191,157.06,155.34,162.14,-0.011011635,0.031832262,0.015314235,-0.026001465,0.90198,0.04121,859.56876,1094,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ABBV,ABBV-706,Solid TumorsÂ ,Phase 1,5/28/2024,"Phase 1 data at ASCO abstract demonstrated that among a total of 48 efficacy-evaluable patients (23 SCLC and 25 NEN), the overall confirmed objective response rate was 43.8%. Within the SCLC group, th",0.0,274309.9011,18.7191,157.06,155.34,162.14,-0.011011635,0.031832262,0.015314235,-0.026001465,0.90198,0.04121,859.56876,1095,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
AZN,DATROWAY (datopotamab deruxtecan-dlnk)- (TROPION-Lung01),Non-small cell lung cancer (NSCLC)Â ,Phase 3,5/28/2024,Phase 3 trial data reported numerically favored datopotamab deruxtecan (Dato-DXd) compared to docetaxel in the overall trial population of adult patients with locally advanced or metastatic non-small,0.0,186462.2688,21.6426,122.96,120.28,124.04,-0.022036741,0.008744995,0.015314235,-0.026001465,0.0,0.18044,264.24277,1096,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
NVS,Vanrafia (atrasentan),Proteinuria reduction in primary IgA nephropathy (IgAN)Â ,Phase 3,5/28/2024,"Phase 3 data reported a statistically significant 36.1% proteinuria (protein in urine) reduction vs. placebo + supportive care at 36 weeks, noted May 28, 2024.",0.0,1489.34759,56.9763,4.5,4.8,5.24,0.064538521,0.152244102,0.015314235,-0.026001465,0.0,0.00131,0.04877,1097,0,0,1,0,0,1,0,0,0,0,0,0,2,0,0,1
NVS,Fabhalta (iptacopan),C3 glomerulopathy (C3G)Â ,Phase 3,5/28/2024,"Phase 3 data reported that patients treated with Fabhalta in addition to supportive care achieved a 35.1% reduction in proteinuria at 6 months when compared to placebo on top of supportive care, noted",0.0,1489.34759,56.9763,4.5,4.8,5.24,0.064538521,0.152244102,0.015314235,-0.026001465,0.0,0.00131,0.04877,1098,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1
PROK,RMCL-002 - (REACT),"Type 2 diabetes, prevent/delay CKDÂ ",Phase 2,5/28/2024,"Phase 2 full results reported that patients s randomized to the deferred treatment arm experienced less decline in kidney function after rilparencel treatment versus standard of care , noted May 28, 2",294.0,237.15518,127.4935,3.37,3.71,3.21,0.096119132,-0.048641807,0.015314235,-0.026001465,15.47241,0.05632,2.20729,1099,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
VANI,OKV-119,ObesityÂ ,Preclinical,5/28/2024,"Preclinical data of proof-of-concept study in felines showed that a single OKV-119 implant effectively delivered therapeutic exenatide levels for the intended 3-month duration, achieving weight loss i",59.0,91.26425,204.7053,1.67,1.66,1.64,-0.006006024,-0.018127385,0.015314235,-0.026001465,1.23833,0.00329,0.96203,1100,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
SRRK,SRK-181 - (DRAGON),Solid TumorsÂ ,Phase 1,5/28/2024,"Phase 1 data from abstract continued to showed that study continues to be well tolerated in the dose expansion portion of the DRAGON trial (Part B), noted May 28, 2024.",96.0,823.85949,73.8471,10.67,10.33,9.8,-0.032383782,-0.08505368,0.015314235,-0.026001465,16.7081,0.01576,9.82309,1101,0,0,0,1,0,1,0,0,0,0,0,0,2,0,0,1
XENE,azetukalner (XEN1101) - (X-NOVA),Major depressive disorder (MDD)Â ,Phase 2,5/28/2024,"Phase 2 data presented at American Epilepsy Society showed azetukalner 20mg achieved clinically meaningful reductions in depression scores on MADRS and HAM-D17 scales, with a 3.04 point difference vs",77.0,2913.85357,36.2397,38.37,38.61,38.1,0.006235406,-0.007061622,0.015314235,-0.026001465,3.73431,0.07207,12.78844,1102,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1
NRXP,NRX-101,Bipolar Depression and Suicidal IdeationÂ ,Phase 2/3,5/28/2024,Phase 2b/3 trial results evaluating NRX-101 versus lurasidone in bipolar depression with suicidal ideation/behavior at ASCP 2024. The data showed NRX-101 achieved similar efficacy to lurasidone on dep,19.0,41.07672,158.3099,3.95,3.83,3.54,-0.030850776,-0.109588852,0.015314235,-0.026001465,4.54899,0.0629,0.51177,1103,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1
JAGX,Mytesi (crofelemer),Moderate-to-severe diarrhea including Vibrio choleraeÂ ,Phase 1,5/28/2024,Phase 1 nnounced results from an investigator-initiated study showing that crofelemer led to statistically meaningful reductions in abdominal pain/discomfort and improved stool consistency compared to,2.0,19.70358,203.8104,115.75,100.75,98.5,-0.138790492,-0.161376145,0.015314235,-0.026001465,4.33199,0.00364,5.4802,1104,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
APRE,ATRN-119 - (ABOYA-119),Solid tumorsÂ ,Phase 1/2,5/28/2024,Phase 1/2a Safety Review Committee has approved opening enrollment for the 800mg once daily dosing cohort after reviewing favorable safety and pharmacokinetic data from the 550mg cohort. Initial signs,5.0,28.18282,95.7617,5.299,5.19,4.78,-0.020784426,-0.103077577,0.015314235,-0.026001465,0.59581,0.08002,0.1019,1105,0,0,0,1,0,1,0,0,0,0,0,0,2,0,0,1
NLSP,KO-874,Sleep and wakefulness disordersÂ ,Preclinical,5/28/2024,"Preclinical results results suggested that mazindol may modulate the orexin system through direct or indirect mechanisms. While lower 1 mg/kg doses were not effective, the dose-dependent response and",3.0,7.00484,124.7266,6.96,6.98,5.428,0.002869442,-0.248608732,0.015314235,-0.026001465,0.11307,0.00759,0.8827,1106,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
AZN,IK-930,"Solid tumors, non-small cell lung cancerÂ ",Phase 1,5/28/2024,"Phase 1 trial discontinued based on a clinical data review, noted May 28, 2024",0.0,186462.2688,21.6426,122.96,120.28,124.04,-0.022036741,0.008744995,0.015314235,-0.026001465,0.0,0.18044,264.24277,1107,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
TELO,Telomir-1,Age-related conditionsÂ ,Preclinical,5/28/2024,"Preclinical canine study dosing initiated, noted May 28, 2024.",32.0,184.46914,0.0,6.74,6.23,5.28,-0.078683592,-0.244133827,0.015314235,-0.026001465,0.13454,0.03581,0.48273,1108,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1
VTGN,Fasedienol (PH94B) - (PALISADE-2),Social Anxiety Disorder (SAD)Â ,Phase 3,5/29/2024,Phase 3 results presented at the American Society of Clinical Psychopharmacology Conference reported that a single dose of fasedienol prior to a stressful PSC reduced anxiety levels as measured by SUD,30.0,107.01983,64.8884,4.06,3.96,3.9,-0.024938948,-0.04020642,0.001909148,-0.054474586,3.91512,0.00162,0.44107,1109,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
KYMR,KT-253,"AML, Lymphomas, and Uveal melanomaÂ ",Phase 1,6/1/2024,"Phase 1 update from ASCO reported that treatment was was generally well tolerated without hematologic adverse events seen with traditional MDM2 small molecule inhibitors, noted June 1, 2024.",71.0,1970.21379,59.6374,32.11,32.11,32.96,0.0,0.026127197,-0.025368295,-0.025040085,16.08131,0.29743,0.0,1110,0,0,0,1,0,1,0,0,0,0,0,0,2,0,0,1
MOLN,MP0317,Solid TumorsÂ ,Phase 1,6/1/2024,"Phase 1 full data presented at ASCO reported that one patient achieved an unconfirmed partial response and stable disease was observed in 14 additional patients, noted June 1, 2024.",40.0,112.81909,50.7403,3.4,3.4,3.745,0.0,0.096646185,-0.025368295,-0.025040085,0.0,0.0528,0.0,1111,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1
CRBP,CRB-701 (SYS6002) with Pembrolizumab,"Solid tumors, Locally advanced or metastatic urothelial carcinomaÂ ",Phase 1,6/1/2024,"Additional data due presented at ASCO demonstrated 44% ORR and 78% DCR in mUC and 43% ORR and 86% DCR in cervical cancer to date at doses â‰¥ 1.2mg/Kg, noted June 1, 2024.",12.0,457.39046,215.1614,42.8,42.8,44.13,0.0,0.030601721,-0.025368295,-0.025040085,4.80199,0.00158,0.0,1112,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
EVAX,EVX-01 + KEYTRUDA (pembrolizumab) / OPDIVO (nivolumab),Metastatic MelanomaÂ ,Phase 2,6/1/2024,"Phase 2 ASCO presentation reported a statistically significant positive correlation between neoantigen quality, as predicted by AI-Immunologyâ„¢, and vaccine-induced immune response was demonstrated, no",6.0,19.85855,179.4751,18.35,18.35,16.95,0.0,-0.079361741,-0.025368295,-0.025040085,0.88434,0.0175,0.0,1113,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1
MRK,EVX-01 + KEYTRUDA (pembrolizumab) / OPDIVO (nivolumab),Metastatic MelanomaÂ ,Phase 2,6/1/2024,"Phase 2 ASCO presentation reported a statistically significant positive correlation between neoantigen quality, as predicted by AI-Immunologyâ„¢, and vaccine-induced immune response was demonstrated, no",0.0,317968.5038,17.2407,125.54,125.54,130.67,0.0,0.040050628,-0.025368295,-0.025040085,0.80013,0.01986,0.0,1114,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1
INAB,INB-200,GlioblastomaÂ ,Phase 1,6/1/2024,"Phase 1 data presented at ASCO reported 92% of evaluable patients treated with INB-200 for GBM exceeded a median PFS of 7 months achieved with the standard-of-care regimen, noted June 1, 2024.",4.0,52.50747,129.9427,35.70004,35.70004,40.20004,0.0,0.118716181,-0.025368295,-0.025040085,0.23917,0.00372,0.0,1115,1,0,0,0,0,1,0,0,0,0,1,0,3,0,0,1
NUVB,Taletrectinib - (TRUST-I) (China),ROS1-positive non-small cell lung cancer (NSCLC)Â ,Phase 2,6/1/2024,"Phase 2 data presented at ASCO 2024 reported that results showed taletrectinib shrank tumors (confirmed objective response rate, cORR, as assessed by an independent review committee, IRC) in 91% of pa",342.0,766.22901,89.6095,3.1,3.1,2.77,0.0,-0.112554791,-0.025368295,-0.025040085,1.34096,0.13947,0.0,1116,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1
KPTI,XPOVIO (selinexor) - (SIENDO),Endometrial cancerÂ ,Phase 3,6/1/2024,"Phase 3 data presented at ASCO reported that median duration of follow-up of 36.9 months, selinexor-treated patients had a median PFS of 28.4 months compared to 5.2 months for patients receiving place",8.0,120.76509,110.4805,14.53649,14.53649,14.40299,0.0,-0.009226216,-0.025368295,-0.025040085,14.09122,0.03725,0.0,1117,1,0,0,0,0,1,0,0,0,0,1,0,3,0,0,1
BDTX,BDTX-1535,Glioblastoma multiforme (GBM) and NSCLCÂ ,Phase 1,6/1/2024,"Phase 1 initial results presented at ASCO reported one confirmed partial response was observed and eight patients experienced stable disease, noted June 1, 2024.",56.0,268.88836,90.5376,4.78,4.78,5.19,0.0,0.082293151,-0.025368295,-0.025040085,3.80191,0.06742,0.0,1118,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1
HOWL,WTX-124,Solid TumorsÂ ,Phase 1b,6/1/2024,"Phase1/1b updated data from ASCO reported that 100% regression of target lesions with responses occurring within the first two cycles of therapy and showing durability at RDE, noted June 1, 2024.",45.0,224.66425,94.2691,5.17,5.17,3.49,0.0,-0.392970952,-0.025368295,-0.025040085,0.85611,0.00506,0.0,1119,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
RCUS,"Quemliclustat, domvanalimab, zimberelimab, and chemotherapy (ARC-21) - (STAR-221)","Locally advanced unresectable or metastatic gastric, gastroesophageal junction or esophageal adenocarcinomaÂ ",Phase 2,6/1/2024,"Phase 2 data shared at ASCO reported that 60% of patients in the EDGE-Gastric study achieved progression-free survival at 12 months, noted June 1, 2024.",107.0,1370.66188,59.2579,15.07,15.07,15.5,0.0,0.028134011,-0.025368295,-0.025040085,8.29533,0.13724,0.0,1120,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1
GILD,"Quemliclustat, domvanalimab, zimberelimab, and chemotherapy (ARC-21) - (STAR-221)","Locally advanced unresectable or metastatic gastric, gastroesophageal junction or esophageal adenocarcinomaÂ ",Phase 2,6/1/2024,"Phase 2 data shared at ASCO reported that 60% of patients in the EDGE-Gastric study achieved progression-free survival at 12 months, noted June 1, 2024.",0.0,80070.98574,24.1392,64.27,64.27,64.7,0.0,0.006668242,-0.025368295,-0.025040085,1.74183,0.07268,0.0,1121,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1
ONC,BGBâ€‘15025 monotherapy and in combination with tislelizumab (TIS; antiâ€‘PDâ€‘1 antibody),Solid TumorsÂ ,Phase 1a,6/1/2024,"Phase 1a presented at ASCO reported that 5 DLTs were observed with combo tx, no responders and disease control rate (DCR) was 35.0%, noted June 1 2024.",110.0,15579.38495,48.1425,148.85,148.85,156.36,0.0,0.049221953,-0.025368295,-0.025040085,1.59457,0.17898,0.0,1122,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,-1
CGEN,"COM701, COM902 and Pembrolizumab","Advanced malignancies, Ovarian cancerÂ ",Phase 1,6/1/2024,"Trial data presented at ASCO reported that the objective response rate [ORR] 1/20 [5%] pts; 7 pts with SD, noted June 1, 2024.",93.0,194.28052,166.018,2.17,2.17,2.11,0.0,-0.02803922,-0.025368295,-0.025040085,1.93067,0.04692,0.0,1123,1,0,0,0,0,0,0,0,0,0,1,0,2,0,0,1
LLY,ERAS-601 - (FLAGSHP-1),Advanced solid tumorsÂ ,Phase 1,6/1/2024,"Phase 1 data presented at ASCO reported to be 1 PR and 8 pts with a best response of SD, noted June 1, 2024.",946.0,738638.5544,26.2184,820.34,820.34,849.99,0.0,0.035505696,-0.025368295,-0.025040085,0.59978,0.02585,0.0,1124,1,0,0,0,0,1,0,0,0,0,1,0,3,0,0,1
ERAS,ERAS-601 - (FLAGSHP-1),Advanced solid tumorsÂ ,Phase 1,6/1/2024,"Phase 1 data presented at ASCO reported to be 1 PR and 8 pts with a best response of SD, noted June 1, 2024.",283.0,686.87767,69.5353,2.52,2.52,2.375,0.0,-0.059261464,-0.025368295,-0.025040085,3.93789,0.11601,0.0,1125,1,0,0,0,0,1,0,0,0,0,1,0,3,0,0,1
MRK,WTX-124 and KEYTRUDA (pembrolizumab),Solid tumorsÂ ,Phase 1b,6/1/2024,"Phase 1/1b initial combination dose escalation data reported that treatment was generally well-tolerated with enhanced immune activation in tumors, noted June 1, 2024.",0.0,317968.5038,17.2407,125.54,125.54,130.67,0.0,0.040050628,-0.025368295,-0.025040085,0.80013,0.01986,0.0,1126,0,0,0,1,0,1,0,0,0,0,0,0,2,0,0,1
HOWL,WTX-124 and KEYTRUDA (pembrolizumab),Solid tumorsÂ ,Phase 1b,6/1/2024,"Phase 1/1b initial combination dose escalation data reported that treatment was generally well-tolerated with enhanced immune activation in tumors, noted June 1, 2024.",45.0,224.66425,94.2691,5.17,5.17,3.49,0.0,-0.392970952,-0.025368295,-0.025040085,0.85611,0.00506,0.0,1127,0,0,0,1,0,1,0,0,0,0,0,0,2,0,0,1
NTLA,"Lonvoguran ziclumeran (lonvo-z, formerly NTLA-2002) - (HAELO)",Hereditary angioedema (HAE)Â ,Phase 1,6/2/2024,"Phase 1 results presented at EAACI reported that 8 of 10 patients remain completely attack-free following the 16-week primary observation period through the latest follow-up, including patients with t",107.0,2062.6445,58.7915,21.38,21.38,22.73,0.0,0.061229732,-0.025368295,-0.025040085,15.72158,0.34807,0.0,1128,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CRBU,CB-010 - (ANTLER),B-Cell Non-Hodgkin LymphomaÂ ,Phase 1,6/2/2024,"Phase 1 initial dose expansion data presented at ASCO reported a median PFS of 14.4 months, noted June 2, 2024.",93.0,260.11518,81.5741,2.88,2.88,1.95,0.0,-0.389960922,-0.025368295,-0.025040085,11.60993,0.04725,0.0,1129,1,0,0,0,0,1,0,0,0,0,1,0,3,0,0,1
FLGT,FID-007,Various cancersÂ ,Phase 1,6/2/2024,"Phase 1 efficacy data presented ASCO reported five (45%) had a partial response and three (27%) had stable disease, noted June 2, 2024.",30.0,617.93655,37.1125,20.65,20.65,20.3,0.0,-0.017094433,-0.025368295,-0.025040085,2.35263,0.14795,0.0,1130,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
FLGT,FID-007,Various cancersÂ ,Phase 1,6/2/2024,"Phase 1 efficacy data presented ASCO reported five (45%) had a partial response and three (27%) had stable disease, noted June 2, 2024.",30.0,617.93655,37.1125,20.65,20.65,20.3,0.0,-0.017094433,-0.025368295,-0.025040085,2.35263,0.14795,0.0,1131,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
AZN,TAGRISSO (osimertinib) - (LAURA),"Unresectable, Stage III epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC)Â ",Phase 3,6/2/2024,Phase 3 data presented at ASCO showed TAGRISSO reduced the risk of disease progression or death by 84% compared to placebo (hazard ratio [HR] 0.16; 95% confidence interval [CI] 0.10-0.24; p<0.001) as,0.0,188973.6496,21.5936,121.9,121.9,125.56,0.0,0.029582695,-0.025368295,-0.025040085,0.0,0.18211,0.0,1132,0,1,0,0,0,1,0,0,0,0,1,0,3,0,0,1
MRUS,MCLA-145 with Keytruda (pembrolizumab),Solid tumorsÂ ,Phase 1,6/2/2024,"Phase 1 trial data presented at ASCO reported 1 PR in Merkel cell carcinoma was observed at 25 mg Q3W, 1 complete response was observed in PD-L1+ NSCLC at the RDE 40 mg Q3W, and 3 pts were continuing",75.0,3526.48722,67.7834,53.24,53.24,52.9,0.0,-0.006406655,-0.025368295,-0.025040085,5.25823,0.18945,0.0,1133,1,0,0,0,0,1,0,0,0,0,1,0,3,0,0,1
GMAB,MCLA-145 with Keytruda (pembrolizumab),Solid tumorsÂ ,Phase 1,6/2/2024,"Phase 1 trial data presented at ASCO reported 1 PR in Merkel cell carcinoma was observed at 25 mg Q3W, 1 complete response was observed in PD-L1+ NSCLC at the RDE 40 mg Q3W, and 3 pts were continuing",661.0,124901.0258,31.0773,1937.0,1937.0,1930.0,0.0,-0.003620382,-0.025368295,-0.025040085,0.0,0.10942,0.0,1134,1,0,0,0,0,1,0,0,0,0,1,0,3,0,0,1
MRUS,MCLA-145 with Keytruda (pembrolizumab),Solid tumorsÂ ,Phase 1,6/2/2024,"Phase 1 trial data presented at ASCO reported 1 PR in Merkel cell carcinoma was observed at 25 mg Q3W, 1 complete response was observed in PD-L1+ NSCLC at the RDE 40 mg Q3W, and 3 pts were continuing",75.0,3526.48722,67.7834,53.24,53.24,52.9,0.0,-0.006406655,-0.025368295,-0.025040085,5.25823,0.18945,0.0,1135,1,0,0,0,0,1,0,0,0,0,1,0,3,0,0,1
GMAB,MCLA-145 with Keytruda (pembrolizumab),Solid tumorsÂ ,Phase 1,6/2/2024,"Phase 1 trial data presented at ASCO reported 1 PR in Merkel cell carcinoma was observed at 25 mg Q3W, 1 complete response was observed in PD-L1+ NSCLC at the RDE 40 mg Q3W, and 3 pts were continuing",661.0,124901.0258,31.0773,1937.0,1937.0,1930.0,0.0,-0.003620382,-0.025368295,-0.025040085,0.0,0.10942,0.0,1136,1,0,0,0,0,1,0,0,0,0,1,0,3,0,0,1
NBTX,NBTXR3 - (Study 1100),Advanced CancersÂ ,Phase 1,6/2/2024,"Phase 1 safety and efficacy data presented at ASCO reported that anti-PD-1 naive patients reported a 48.0% (12/25) overall response rate (""ORR"") as per RECIST 1.1(3 CR; 9 PR), noted June 2, 2024.",47.0,305.75175,71.3837,7.04,7.04,5.7,0.0,-0.211141995,-0.025368295,-0.025040085,0.0,0.0,0.0,1137,1,0,0,1,0,1,0,0,0,0,1,0,4,0,0,1
AZN,IMFINZI (Durvalumab) - (ADRIATIC),Small cell lung cancer (SCLC) limited diseaseÂ ,Phase 3,6/2/2024,"Phase 3 data presented at ASCO reported statistically significant and clinically meaningful improvements in the dual primary endpoints of overall survival (OS) and progression-free survival (PFS), not",0.0,188973.6496,21.5936,121.9,121.9,125.56,0.0,0.029582695,-0.025368295,-0.025040085,0.0,0.18211,0.0,1138,1,0,0,0,0,1,0,0,0,0,1,0,3,0,0,1
AZN,Enhertu - (DESTINY-Breast06),"HR-positive, HER2-low (IHC 1+ or 2+/ISH-) metastatic breast cancerÂ ",Phase 3,6/2/2024,"Phase 3 data presented at ASCO reported a reduced the risk of disease progression or death by 38% by blinded independent central review (BICR) versus chemotherapy in patients with HER2-low expression,",0.0,188973.6496,21.5936,121.9,121.9,125.56,0.0,0.029582695,-0.025368295,-0.025040085,0.0,0.18211,0.0,1139,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1
RCUS,Etrumadenant (AB928) and zimberelimab - (ARC-9),Colorectal CancerÂ ,Phase 1/2,6/2/2024,"Phase 1b/2 data presented at ASCO reported that treatment significantly reduced the risk of death by 63% and risk of disease progression by 73% compared to regorafenib, noted June 2, 2024.",107.0,1370.66188,59.2579,15.07,15.07,15.5,0.0,0.028134011,-0.025368295,-0.025040085,8.29533,0.13724,0.0,1140,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1
AMGN,LUMAKRAS (Sotorasib) + Vectibix (panitumumab) - (CodeBreak 101),Colorectal Cancer (CRC)Â ,Phase 1b,6/2/2024,"Phase 1b data from ASCO reported that in 1L, ORR was 65%, DCR was 100%, median DOR was 9.1 mo, and median PFS was 10.8 mo, noted June 2, 2024.",538.0,164068.5506,27.0659,305.85,305.85,305.02,0.0,-0.002717437,-0.025368295,-0.025040085,1.9104,0.02287,0.0,1141,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
AMGN,Tarlatamab (AMG 757) - (DeLLpro-300),Treatment-emergent neuroendocrine prostate cancerÂ ,Phase 1b,6/2/2024,"Phase 1b data presented at ASCO reported that the ORR per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) was 10.5% (95% CI, 2.9, 24.8); median progression free survival (mPFS)",538.0,164068.5506,27.0659,305.85,305.85,305.02,0.0,-0.002717437,-0.025368295,-0.025040085,1.9104,0.02287,0.0,1142,1,0,0,0,0,1,0,0,0,0,1,0,3,0,0,1
AMGN,Tarlatamab (AMG 757) - (DeLLphi-301),Brain metastasisÂ ,Phase 2,6/2/2024,"Phase 2 trial data presented at ASCO reported that ORR was 45.3% in patients with brain metastases and 32.6% in patients without brain metastases June 2, 2024.",538.0,164068.5506,27.0659,305.85,305.85,305.02,0.0,-0.002717437,-0.025368295,-0.025040085,1.9104,0.02287,0.0,1143,1,0,0,0,0,1,0,0,0,0,1,0,3,0,0,1
CGEM,Zipalertinib (CLN-081/TAS6417) - (REZILIENT1),Non-small cell lung cancerÂ ,Phase 2b,6/3/2024,"Phase 2b data reported a 39% ORR in Modeule C, noted June 3, 2024.",59.0,1299.07563,76.554,23.5,22.54,22.97,-0.041708913,-0.022811404,-0.022629917,-0.031583897,6.49323,0.12214,14.48587,1144,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
KALV,EKTERLY (sebetralstat),Hereditary Angioedema (HAE)Â ,Phase 3,6/3/2024,"Phase 3 data reported that the time to beginning of symptom relief was significantly faster than placebo, with a significantly faster time to a reduction in attack severity from baseline compared to p",50.0,510.90027,61.2312,11.67,12.11,12.04,0.037010111,0.031212994,-0.022629917,-0.031583897,13.64784,0.03832,6.64743,1145,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
GPCR,GSBR-1290 -(ACCESS and ACCESS II ),"Type 2 Diabetes, obesityÂ ",Phase 2a,6/3/2024,"Phase 2a 12-week data from obesity cohort achieved a statistically significant placebo-adjusted mean weight loss of 6.2%, with 67% of patients achieving â‰¥6% weight loss. The tablet formulation demonst",57.0,2458.79803,119.1088,34.2,52.74,52.91,0.433148537,0.436366713,-0.022629917,-0.031583897,8.82045,0.01524,622.35452,1146,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1
CLDI,CLD-400 - (RTNova),Metastatic Solid Tumors & Lung cancerÂ ,Phase 1,6/3/2024,"Phase 1 update highlights enrollment progress, safety and feasibility in delivering up to four weekly doses, noted June 3, 2024.",3.0,11.20374,232.5017,22.80091,26.40106,24.60098,0.146603713,0.075985832,-0.022629917,-0.031583897,0.57936,0.01582,0.8644,1147,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CLDI,CLD-400 - (RTNova),Metastatic Solid Tumors & Lung cancerÂ ,Preclinical,6/3/2024,"Preclinical data on platform's showcased ability to survive bloodstream and reach all tumors systemically, noted June 03, 2024.",3.0,11.20374,232.5017,22.80091,26.40106,24.60098,0.146603713,0.075985832,-0.022629917,-0.031583897,0.57936,0.01582,0.8644,1148,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CLDI,CLD-201 - (SuperNova),"Advanced Solid Tumors (TNBC, Melanoma, Head and Neck)Â ",Preclinical,6/3/2024,"Preclinical trials ongoing. Non-clinical data supporting the upcoming SuperNova (CLD-201) clinical trial presented at ASCO, noted June 3, 2024.",3.0,11.20374,232.5017,22.80091,26.40106,24.60098,0.146603713,0.075985832,-0.022629917,-0.031583897,0.57936,0.01582,0.8644,1149,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
BPTH,Prexigebersen (BP1001),Acute Myeloid Leukemia (AML)Â ,Phase 2,6/3/2024,"Phase 2 data presneted at ASCO In the newly diagnosed AML cohort, 75% of evaluable patients achieved complete remission or related responses. In the relapsed/refractory AML cohort, 55% of evaluable pa",8.0,5.34964,134.4395,2.06,3.23,2.31,0.449776154,0.114541542,-0.022629917,-0.031583897,1.44859,0.00583,184.01202,1150,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1
NVCR,Tumor Treating Fields (TTFields) - (METIS),Brain Metastases Originating from Non-Small Cell Lung CancerÂ ,Phase 3,6/3/2024,Phase 3 data shared at ASCO 2024 demonstrated 21.9 months median time to intracranial progression for patients treated with TTFields therapy and supportive care compared to 11.3 months for patients tr,111.0,2570.82863,73.6795,22.01,23.89,21.46,0.081963066,-0.025306158,-0.022629917,-0.031583897,5.23982,0.0761,36.01855,1151,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ZLAB,Tumor Treating Fields (TTFields) - (METIS),Brain Metastases Originating from Non-Small Cell Lung CancerÂ ,Phase 3,6/3/2024,Phase 3 data shared at ASCO 2024 demonstrated 21.9 months median time to intracranial progression for patients treated with TTFields therapy and supportive care compared to 11.3 months for patients tr,109.0,1776.91541,67.2648,17.78,18.0,20.0,0.012297528,0.117658043,-0.022629917,-0.031583897,3.31963,0.13863,11.61524,1152,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CLDX,Barzolvolimab (CDX-0159),Chronic spontaneous urticaria (CSU)Â ,Phase 2,6/3/2024,"Additional Phase 2 data reported that patients on barzolvolimab experienced a > 8 point improvement in AAS7 (considered a clinically meaningful result) across all doses compared to placebo (p<0.05), n",66.0,2206.02604,55.8063,33.3,33.47,34.64,0.005092118,0.039451687,-0.022629917,-0.031583897,10.03701,0.12039,29.2727,1153,0,1,0,0,0,1,0,0,0,0,0,0,2,0,0,1
ENTX,PTH(1-34) Peptide Tablets (EB612),HypoparathyroidismÂ ,Phase 1,6/3/2024,"Phase 1 study results from PK/PD study presented at the ENDO showed that significant systemic exposure was reported following both administrations of EB612 tablets, noted June 3, 2024",45.0,82.3799,116.2596,2.25,2.3,2.04,0.021978907,-0.097980408,-0.022629917,-0.031583897,0.3546,0.01016,0.10121,1154,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
GSK,BLENREP (belantamab mafodotin) and POMALYST (Pomalidomide) and Dexamethasone - (DREAMM-8),Multiple MyelomaÂ ,Phase 3,6/3/2024,"Additional data presented at ASCO reported that at the end of one year, 71% (95% CI: 63-78) of patients in the belantamab mafodotin combination group compared to 51% (95% CI: 42-60) in the bortezomib",0.0,65167.45924,22.6972,17.665,15.98,16.21,-0.10024734,-0.085956945,-0.022629917,-0.031583897,0.0,0.011,385.24105,1155,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1
BCTX,Bria-IMT - (BRIA-ABC),Advanced breast cancerÂ ,Phase 2,6/3/2024,"Phase 2 data presented at ASCO resulted in an 83% intracranial objective response rate, median progression-free survival of 4.1 months in antibody-drug conjugate (ADC) resistant patients (double histo",1.0,38.21469,93.0769,253.49987,229.49989,208.4999,-0.09946076,-0.195424749,-0.022629917,-0.031583897,0.0,0.0,0.16363,1156,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1
BMY,Neoadjuvant Opdivo (nivolumab) and Chemotherapy,Stage IIA to IIIB non-small cell lung cancer (NSCLC)Â ,Phase 3,6/3/2024,"Phase 3 improved median event-free survival (EFS) regardless of nodal status, including in the N2 subgroup (30.2 vs. 10.0 months; HR, 0.46; 95% CI, 0.30â€“0.70) and non-N2 subgroup (NR vs. 17.0 months;",0.0,84671.97101,22.955,41.09,41.77,42.57,0.016413596,0.035384997,-0.022629917,-0.031583897,1.39438,0.03003,571.35721,1157,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
BMY,Neoadjuvant nivolumab (N) + chemotherapy - (CheckMate-816),Non-small cell lung cancer (NSCLC)Â ,Phase 3,6/3/2024,"Phase 3 overall survival (OS) did not meet statistical significance at this analysis, neoadjuvant Opdivo with chemotherapy continued to show a clinically important OS improvement trend over chemothera",0.0,84671.97101,22.955,41.09,41.77,42.57,0.016413596,0.035384997,-0.022629917,-0.031583897,1.39438,0.03003,571.35721,1158,1,0,0,0,0,1,0,0,0,0,0,0,0,2,0,-1
BMY,Opdivo (nivolumab) plus Yervoy (ipilimumab) - (CheckMate -9LA),Metastatic non-small cell lung cancer (NSCLC)Â ,Phase 3,6/3/2024,"Phase 3 follow-up of 57.3 months, the dual immunotherapy-based combination continued to improve OS, with 18% of patients treated with Opdivo plus Yervoy with two cycles of chemotherapy alive at five y",0.0,84671.97101,22.955,41.09,41.77,42.57,0.016413596,0.035384997,-0.022629917,-0.031583897,1.39438,0.03003,571.35721,1159,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CVKD,tecarfarin - (ARIES-HM3),Thromboembolism and thrombosisÂ ,Phase 2/3,6/3/2024,"Phase 2/3 data demonstrated that lower time in therapeutic range, or TTR, translated directly to excessive bleeding events, noted June 3, 2024.",2.0,7.9562,118.938,7.0695,7.455,6.6225,0.053095192,-0.065316814,-0.022629917,-0.031583897,0.06251,0.03451,0.06438,1160,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
TAK,Oveporexton (TAK-861-2001),Narcolepsy type 1 (NT1)Â ,Phase 2b,6/3/2024,Phase 2b data presented at SLEEP reported statistically significant and clinically meaningful increased sleep latency on the Maintenance of Wakefulness Test (MWT) versus placebo across all doses (LS m,0.0,6592660.042,16.2478,13.35,13.36,13.51,0.000748783,0.011913767,-0.022629917,-0.031583897,0.0,0.0,26.77658,1161,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1
PGEN,PAPZIMEOS (zopapogene imadenovec-drba),Recurrent Respiratory Papillomatosis (RRP)Â ,Phase 1/2,6/3/2024,"Phase 1/2 presented art ASCO showed that study met the primary safety and efficacy endpoints, noted June 3, 2024.",297.0,393.77472,64.6765,1.4,1.56,1.7,0.108213585,0.194156014,-0.022629917,-0.031583897,5.4524,0.17038,7.34151,1162,0,0,0,1,0,1,0,0,0,0,0,0,2,0,0,1
AGIO,Mitapivat - (ENERGIZE-T),Transfusion-dependent thalassemiaÂ ,Phase 3,6/3/2024,"Phase 3 topline data reported that the trial met its primary endpoint, note June 3, 2024.",58.0,2488.3591,59.0713,36.34,43.83,47.22,0.187399451,0.261898469,-0.022629917,-0.031583897,10.7141,0.15542,88.79783,1163,1,0,0,0,0,1,0,0,0,0,1,0,3,0,0,1
IDYA,Darovasertib - (neo-adjuvant and adjuvant settings) - (NADOM),Ocular MelanomaÂ ,Phase 2,6/3/2024,Additional data shared at ASCO reported 75% (9 out of 12 enucleation patients) had confirmed Eye Saved and approximately 67% (8 out of 12 enucleation patients) observed greater than 30% tumor shrinkag,87.0,2943.45296,41.2235,36.55,38.89,38.33,0.062055962,0.047551693,-0.022629917,-0.031583897,14.64747,0.16541,44.8747,1164,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
MNOV,Ibudilast (MN-166),GlioblastomaÂ ,Phase 1/2,6/3/2024,Phase 1b/2a data presented at ASCO reported that treatment was safe and well tolerated. No unexpected adverse effects were observed in both new GBM and recurrent GBM patients. Most reported adverse ev,49.0,72.09798,46.8333,1.36,1.47,1.33,0.077777701,-0.022305758,-0.022629917,-0.031583897,0.32331,0.01081,0.06917,1165,0,0,0,1,0,1,0,0,0,0,1,0,3,0,0,1
GSK,BLENREP (belantamab mafodotin) and POMALYST (Pomalidomide) and Dexamethasone - (DREAMM-8),Multiple MyelomaÂ ,Phase 3,6/3/2024,"Phase 3 data reported was observed but not statistically significant, noted June 3, 2024.",0.0,65167.45924,22.6972,17.665,15.98,16.21,-0.10024734,-0.085956945,-0.022629917,-0.031583897,0.0,0.011,385.24105,1166,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0
GMAB,EPCORE (Epcoritamab) - (EPCORE NHL-2),Non-Hodgkin lymphoma (NHL)Â ,Phase 1/2,6/3/2024,"Phase 1b/2 data with a median follow-up of 21.1 months, additional findings from this arm showed durable responses, with an estimated 89 percent of patients remaining progression free and 93 percent o",661.0,125509.1791,31.1231,1937.0,1953.5,1922.5,0.008482251,-0.007513962,-0.022629917,-0.031583897,0.0,0.10942,382.9993,1167,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
PBYI,Alisertib (PUMA-ALI-4201) in combination with endocrine treatment - (ALISCA-Breast1),"HER2-negative, hormone receptor-positive metastatic breast cancerÂ ",Phase 3,6/3/2024,"Phase 2 data reported an overall response rate 19.6% vs. 20.0% and median progression-free survival 5.6 months vs. 5.4 months for alisertib vs. alisertib + fulvestrant, respectively, noted June 3, 202",50.0,182.82524,76.3801,3.85,3.79,3.49,-0.015707129,-0.098171412,-0.022629917,-0.031583897,6.30746,0.07542,1.52298,1168,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ALXO,Evorpacept with PADCEV (enfortumab vedotin-ejfv) - (ASPEN-07),Urothelial Carcinoma (UC)Â ,Phase 1a,6/3/2024,"Phase 1a dose escalation results due presented at ASCO unconfirmed overall response rate (""ORR"") of 59% (n=22) with evorpacept plus EV, noted June 3, 2024.",53.0,466.81696,95.8471,10.63,8.96,8.67,-0.170909965,-0.203811402,-0.022629917,-0.031583897,6.44991,0.07386,38.19829,1169,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
XAIR,Beyond Cancer (UNO),Solid tumorsÂ ,Phase 1a,6/3/2024,"Additional Phase 1a data continues to demonstrate proof of concept for the UNO solid tumor platform with observed early tumor responses and clinical resolution of radiation dermatitis, noted June 3, 2",5.0,53.70103,91.0989,25.6,23.4,24.6,-0.089856329,-0.039845909,-0.022629917,-0.031583897,8.22724,0.07253,0.56406,1170,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
IPSC,CNTY-101 - (ELiPSE-1),Lymphoma or Indolent LymphomaÂ ,Phase 1,6/3/2024,"Phase 1 additional data shared at ASCO demonstrated a manageable safety profile with no observed DLTs or GvHD and with majority of patients treated in outpatient setting, noted June 3, 2024.",86.0,247.86671,102.5179,2.97,2.98,3.35,0.003361348,0.120398393,-0.022629917,-0.031583897,1.87984,0.03588,0.31348,1171,0,0,0,1,0,1,0,0,0,0,0,0,0,0,2,0
ARWR,Plozasiran (ARO-APOC3-3001) - (PALISADE),"Familial chylomicronemia syndrome (FCS), HypertriglyceridemiaÂ ",Phase 3,6/3/2024,"Phase 3 trial enrollment completed on May 16, 2023 Phase study achieved statistically significant median reductions in triglycerides up to 80% and mean reductions in APOC3 up to 94% at month 10, noted",138.0,3057.80966,64.3286,22.95,24.62,24.51,0.070241184,0.065763261,-0.022629917,-0.031583897,7.52332,0.18052,38.01392,1172,0,0,0,0,0,1,0,0,0,1,0,0,2,0,0,1
BDRX,"eRapa (rapamycin, sirolimus) - (Serenta)",Familial Adenomatous Polyposis (FAP)Â ,Phase 2,6/3/2024,"Phase 2 results demonstrated a 24% reduction in polyp burden at 6 months and an 83% non-progression rate, showing potential to stall disease progression before polyps turn cancerous, noted June 3, 202",0.0,10.30571,204.6025,241.1,267.5,245.05,0.103907781,0.016250486,-0.022629917,-0.031583897,3.34352,0.07011,1.34044,1173,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
GMAB,Acasunlimab (GEN1046/BNT311),Non-small cell lung cancer (NSCLC)Â ,Phase 2,6/3/2024,"Phase 2 trial data presented at ASCO reported that 12-month overall survival (""OS"") rate of 69%, a median overall survival (mOS) of 17.5 months, and a 30% overall response rate (ORR) at the time of da",661.0,125509.1791,31.1231,1937.0,1953.5,1922.5,0.008482251,-0.007513962,-0.022629917,-0.031583897,0.0,0.10942,382.9993,1174,1,0,0,0,0,1,0,0,0,0,1,0,3,0,0,1
ALKS,ALKS 2680 - (Vibrance-1),NarcolepsyÂ ,Phase 1,6/3/2024,"Phase 1 data presented at SLEEP 2024 demonstrated clinically meaningful and statistically significant improvements from baseline in mean sleep latency compared to placebo at all doses tested, noted Ju",165.0,4070.61864,35.7606,23.4,24.055,24.19,0.027606853,0.033203302,-0.022629917,-0.031583897,7.64854,0.04189,48.3206,1175,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1
SPRB,Tildacerfont - (POWER),Polycystic Ovary SyndromeÂ ,Phase 2,6/3/2024,"Phase 2 data presented at ENDO showed a significant reduction in dehydroepiandrosterone sulfate (DHEAS) versus placebo observed in women with elevated DHEAS levels at baseline, noted June 3, 2024.",0.0,29.4216,274.6248,55.58264,53.61763,51.68263,-0.03599299,-0.072749174,-0.022629917,-0.031583897,0.2996,0.03675,0.14911,1176,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ONC,Ziihera (zanidatamab-hrii),HER2-amplified biliary tract cancersÂ ,Phase 2b,6/3/2024,"Phase 2b data reported a confirmed objective response rate (cORR) by independent central review (ICR) was maintained at 41.3%, noted June 3, 2024.",110.0,15306.20931,48.1631,148.85,146.24,156.07,-0.01768998,0.047365537,-0.022629917,-0.031583897,1.59457,0.17898,39.68851,1177,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
JAZZ,Ziihera (zanidatamab-hrii),HER2-amplified biliary tract cancersÂ ,Phase 2b,6/3/2024,"Phase 2b data reported a confirmed objective response rate (cORR) by independent central review (ICR) was maintained at 41.3%, noted June 3, 2024.",60.0,6665.80921,26.1821,105.25,105.74,108.99,0.004644778,0.034917662,-0.022629917,-0.031583897,5.19618,0.04388,78.92497,1178,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ZYME,Ziihera (zanidatamab-hrii),HER2-amplified biliary tract cancersÂ ,Phase 2b,6/3/2024,"Phase 2b data reported a confirmed objective response rate (cORR) by independent central review (ICR) was maintained at 41.3%, noted June 3, 2024.",75.0,600.85269,44.2213,8.48,8.43,8.97,-0.005913678,0.056175226,-0.022629917,-0.031583897,5.65931,0.05418,19.06255,1179,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
NGNE,NGN-401 - (Embolden),Rett SyndromeÂ ,Phase 1/2,6/3/2024,"Study selected by the FDA for the START program, noted June 3, 2024.",14.0,483.25616,0.0,37.6,37.23,37.35,-0.009889163,-0.006671139,-0.022629917,-0.031583897,7.68695,0.11018,2.34315,1180,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
BMY,KRAZATI (adagrasib) and Taxotere (Docetaxel) - (KRYSTAL-12),Non-small cell lung cancer (NSCLC)Â ,Phase 3,6/3/2024,"Phase 3 data reported that the ORR as assessed by BICR was also significantly higher with KRAZATI compared to docetaxel (32% vs 9%; odds ratio, 4.68; P < 0.0001), noted June 3, 2024.",0.0,84671.97101,22.955,41.09,41.77,42.57,0.016413596,0.035384997,-0.022629917,-0.031583897,1.39438,0.03003,571.35721,1181,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
MRNA,V940-001 (mRNA-4157) with KEYTRUDA (pembrolizumab) - (INTerpath-002),"Personalized cancer vaccine, high-risk melanoma, lung cancerÂ ",Phase 3,6/3/2024,Phase 3 data presented at ASCO showed that at 34.9 months it reduced the risk of recurrence or death by 49% and the risk of distant metastasis or death by 62% compared to KEYTRUDA alone in these patie,389.0,56650.4963,59.0808,142.55,147.82,148.59,0.036302502,0.04149802,-0.022629917,-0.031583897,5.59185,0.13319,730.44588,1182,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1
MRK,V940-001 (mRNA-4157) with KEYTRUDA (pembrolizumab) - (INTerpath-002),"Personalized cancer vaccine, high-risk melanoma, lung cancerÂ ",Phase 3,6/3/2024,Phase 3 data presented at ASCO showed that at 34.9 months it reduced the risk of recurrence or death by 49% and the risk of distant metastasis or death by 62% compared to KEYTRUDA alone in these patie,0.0,325262.986,17.4226,125.54,128.42,131.49,0.022681709,0.04630637,-0.022629917,-0.031583897,0.80013,0.01986,989.17765,1183,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1
REPL,RP1 (vusolimogene oderparepvec) and OPDIVO (nivolumab) - (IGNYTE-3),Non-melanoma (NMSC) / Non-small cell lung cancer (NSCLC)Â ,Phase 2,6/3/2024,"Phase 2 data presented at ASCO from its 12-month study results demonstrated an overall response rate of 32.7% and duration of response consistent with the previously reported 6-month data, noted June",78.0,334.09817,105.4794,5.27,5.44,9.0,0.031748698,0.535194215,-0.022629917,-0.031583897,14.15526,0.03986,5.18272,1184,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1
LLY,Olomorasib,KRAS G12C-mutant advanced solid tumorsÂ ,Phase 1/2,6/3/2024,Phase 1/2 data reported that the median progression free survival (PFS) in all patients with KRAS G12C inhibitor-naive non-CRC solid tumors was 7.1 months and 7.9 months (95% CI: 4.1-NE) in patients w,946.0,748470.9812,26.2849,820.34,831.26,865.0,0.013223734,0.053010618,-0.022629917,-0.031583897,0.59978,0.02585,2109.10529,1185,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
SMMT,Ivonescimab - (HARMONi-A),Non-squamous non-small cell lung cancer (NSCLC)Â ,Phase 3,6/3/2024,"Phase 3 data reported that the PFS was significantly improved in the ivonescimab plus chemotherapy arm representing a 54% reduction in the risk of disease progression compared to chemotherapy, noted J",744.0,6205.49963,227.48,8.685,8.84,7.98,0.017689477,-0.084658988,-0.022629917,-0.031583897,3.21455,0.0,200.27008,1186,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
PFE,ADCETRIS (brentuximab vedotin) with lenalidomide and rituximab - (ECHELON-3),Relapsed/refractory diffuse large B-cell lymphoma (DLBCL)Â ,Phase 3,6/3/2024,"Phase 3 full data presented at ASCO reported that the treatment improved the risk-to-benefit profile of the combination treatment, maintaining efficacy with significantly fewer acute and long-lasting",0.0,166087.8378,26.4698,28.66,29.31,28.07,0.022426332,-0.020801032,-0.022629917,-0.031583897,1.23926,0.02242,1118.9747,1187,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1
PPBT,CM24 and OPDIVO (nivolumab),2L metastatic pancreatic cancer (PDAC)Â ,Phase 2,6/3/2024,"Phase 2 interim analysis presented at ASCO reported that an ORR (25% vs 7%), disease control rate (DCR) (63% vs 40%), and decrease in CA19-9 level (61% decrease vs. 34% increase), noted June 3, 2024.",2.0,86.26048,90.8886,0.276,0.314,0.206,0.12899212,-0.292524697,-0.022629917,-0.031583897,0.0,0.01391,0.58781,1188,1,0,0,0,0,1,0,0,0,0,1,0,3,0,0,1
DNLI,DNL126,MPS IIIA (Sanfilippo syndrome Type A)Â ,Phase 1/2,6/3/2024,"Study selected by the FDA for START Program, noted June 3, 2024.",146.0,2906.37215,76.0828,18.56,20.38,21.02,0.0935453,0.124465638,-0.022629917,-0.031583897,6.6569,0.24537,29.5046,1189,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
AZN,ENHERTU,Multiple HER2-expressing advanced solid tumorsÂ ,Approved,6/3/2024,"Approved April 6, 2024.",0.0,191394.6431,21.7138,121.9,123.46,126.0,0.01271618,0.03308087,-0.022629917,-0.031583897,0.0,0.18211,265.18825,1190,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1
CELU,PT-CD16VS,HER2-positive cancersÂ ,Preclinical,6/3/2024,Preclinical data presented at ASCO demonstrated the potential of combining Celularity's placental-derived cell therapy platform with currently available antibody therapies to address difficult-to-trea,26.0,68.61601,138.4113,3.11,3.15,3.25,0.012779727,0.04403227,-0.022629917,-0.031583897,2.8789,0.0711,0.01541,1191,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1
GMAB,Acasunlimab (DuoBody-PD-L1x4-1BB) with pembrolizumab,Metastatic non-small cell lung cancer (mNSCLC)Â ,Phase 2,6/3/2024,"Phase 2 data presented at ASCO reported that confirmed ORRs (and mDoR) were 13% (2 mo), 21% (6 mo), and 22% (NR), with 6-mo PFS rates of 0%, 18%, and 33% for arms A, B, and C, respectively, noted June",661.0,125509.1791,31.1231,1937.0,1953.5,1922.5,0.008482251,-0.007513962,-0.022629917,-0.031583897,0.0,0.10942,382.9993,1192,1,0,0,0,0,1,0,0,0,0,1,0,3,0,0,1
BTAI,BXCL701 and KEYTRUDA (pembrolizumab),Metastatic pancreatic ductal adenocarcinoma (PDAC)Â ,Phase 2,6/3/2024,"Phase 2 initial data from ASCO reported an objective response rate is 16% and disease control rate is 50%, noted June 3, 2024.",14.0,63.42708,118.421,28.96,27.04,23.04,-0.068598316,-0.228683732,-0.022629917,-0.031583897,4.3463,0.00944,1.32358,1193,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
PFE,Tisotumab vedotin - (innovaTV 207),Squamous cell carcinoma of the head and neck (SCCHN)Â ,Phase 2,6/3/2024,"Phase 2 results from innovaTV207 evaluating tisotumab vedotin, showing 32.5% confirmed objective response rate, noted June 3, 2024.",0.0,166087.8378,26.4698,28.66,29.31,28.07,0.022426332,-0.020801032,-0.022629917,-0.031583897,1.23926,0.02242,1118.9747,1194,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
GMAB,Tisotumab vedotin - (innovaTV 207),Squamous cell carcinoma of the head and neck (SCCHN)Â ,Phase 2,6/3/2024,"Phase 2 results from innovaTV207 evaluating tisotumab vedotin, showing 32.5% confirmed objective response rate, noted June 3, 2024.",661.0,125509.1791,31.1231,1937.0,1953.5,1922.5,0.008482251,-0.007513962,-0.022629917,-0.031583897,0.0,0.10942,382.9993,1195,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
GILD,Brexucabtagene Autoleucel (KTE-X19) - (ZUMA-3),Relapsed/Refractory B-precursor Acute Lymphoblastic LeukemiaÂ ,Phase 1/2,6/3/2024,"Phase 1/2 study presented at ASCO showed that after more than 4 years of follow-up median overall survival (OS) was 26 months and the OS rate was 40% at 48 months, noted June 3, 2024.",0.0,79024.46905,24.1519,64.27,63.43,65.25,-0.013156024,0.015133087,-0.022629917,-0.031583897,1.74183,0.07268,543.01763,1196,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ZVRA,Serdexmethylphenidate (SDX) - (KP1077),Idiopathic hypersomnia (IH)Â ,Phase 2,6/3/2024,"Phase 2 full data presented at SLEEP 2024 showed that study was well tolerated and showed meaningful clinical improvements in patient-reported assessments of daytime sleepiness, sleep inertia, and bra",56.0,204.24505,55.8411,4.65,4.88,4.64,0.048278,-0.002152853,-0.022629917,-0.031583897,6.39699,0.05011,1.54665,1197,0,0,0,1,0,1,0,0,0,0,0,0,2,0,0,1
MRUS,MCLA-129 - (ZENO),"Solid Tumors, MET ex14 NSCLCÂ ",Phase 3,6/3/2024,"Phase 3 results published at ASCO showed that as of the cutoff, in 15 evaluable patients, the confirmed partial response rate was 53% (8/15), including 6/8 responses in TKI-naÃ¯ve and 3/7 in prior MET",75.0,3506.61595,67.3407,53.24,52.94,53.33,-0.005650797,0.001689031,-0.022629917,-0.031583897,5.25823,0.18945,126.43708,1198,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1
GMAB,MCLA-129 - (ZENO),"Solid Tumors, MET ex14 NSCLCÂ ",Phase 3,6/3/2024,"Phase 3 results published at ASCO showed that as of the cutoff, in 15 evaluable patients, the confirmed partial response rate was 53% (8/15), including 6/8 responses in TKI-naÃ¯ve and 3/7 in prior MET",661.0,125509.1791,31.1231,1937.0,1953.5,1922.5,0.008482251,-0.007513962,-0.022629917,-0.031583897,0.0,0.10942,382.9993,1199,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1
FGEN,FG-3165,Solid TumorsÂ ,IND-Enabling,6/3/2024,"IND cleared by the FDA, noted June 3, 2024.",4.0,122.35471,161.847,30.0,30.75,28.25,0.024692613,-0.060103924,-0.022629917,-0.031583897,7.42235,0.05056,8.33879,1200,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
CRNX,Atumelnant (CRN04894) - (TouCAHn),Congenital adrenal hyperplasia (CAH) and Cushingâ€™s diseaseÂ ,Phase 2,6/3/2024,"Phase 2 trial results presented at ENDO showed that 100% of patients on the 80mg dose maintained normal androstenedione levels through 12 weeks, with >90% reductions in androstenedione and 17-OHP seen",94.0,3649.61812,53.4868,44.41,46.28,45.01,0.041245233,0.013420018,-0.022629917,-0.031583897,6.22481,0.0234,71.58521,1201,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CRNX,PALSONIFY (paltusotine),AcromegalyÂ ,Phase 3,6/3/2024,"Phase 3 data presented at ENDO showed rapid and sustained IGF-1 responded in patients treated, noted June 3, 2024.",94.0,3649.61812,53.4868,44.41,46.28,45.01,0.041245233,0.013420018,-0.022629917,-0.031583897,6.22481,0.0234,71.58521,1202,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
GSK,Lete-cel - (IGNYTE-ESO),SarcomaÂ ,Phase 2,6/3/2024,Phase 2 interim results presented at ASCO showed an verall response rate of 40% consistent across sarcoma indications; median duration of response ~11 months with patients still in response at time of,0.0,65167.45924,22.6972,17.665,15.98,16.21,-0.10024734,-0.085956945,-0.022629917,-0.031583897,0.0,0.011,385.24105,1203,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1
PBYI,Alisertib - (PUMA-ALI-4201) - (ALISCA-Lung1),Small Cell Lung Cancer (SCLC)Â ,Phase 2,6/3/2024,"Phase 2 data shared at ASCO study identified alisertib 30mg twice daily as the recommended dose, with a 9.5% overall response rate and 81% disease control rate across 21 evaluable patients, the respon",50.0,182.82524,76.3801,3.85,3.79,3.49,-0.015707129,-0.098171412,-0.022629917,-0.031583897,6.30746,0.07542,1.52298,1204,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
RYTM,Setmelanotide - (DAYBREAK),Variants in one of 31 additional genes with MC4R pathway relevanceÂ ,Phase 2,6/3/2024,"Phase 2 data presented at ENDO showed potential setmelanotide efficacy in multiple MC4R pathway variants; stage two data expected in 3Q 2024, noted June 3, 2024.",66.0,2307.82461,59.0128,35.68,37.85,41.01,0.059040672,0.139225632,-0.022629917,-0.031583897,16.92955,0.13628,24.28358,1205,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
SRRK,SRK-181 - (DRAGON),Solid TumorsÂ ,Phase 1,6/3/2024,"Phase 1 updated safety and efficacy results shared at ASCO showed promising objective response rates (ORR) were observed in multiple tumor types in anti-PD-(L)1 resistant patients, noted June 3, 2024.",96.0,756.06854,73.7269,9.39,9.48,9.63,0.009539023,0.025237933,-0.022629917,-0.031583897,16.7081,0.01979,7.26021,1206,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ASND,TLR7/8 with pembrolizumab - (transcendIT-101),Solid tumorsÂ ,Phase 1/2,6/3/2024,"Phase 1/2 showed that 40% of efficacy-evaluable patients (2 out of 5) in the initial cohort of melanoma treated exhibited confirmed clinical responses with no new safety signals, noted June 3, 2024.",60.0,7759.37752,37.0413,135.1,135.31,131.48,0.001553197,-0.027160496,-0.022629917,-0.031583897,6.03487,0.07401,51.20658,1207,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ELDN,Tegoprubart (AT-1501) - (BESTOW),Kidney transplant rejectionÂ ,Phase 1b,6/3/2024,"Phase 1b data shared at ATC showed that data from 13 participants continue to support the safety and tolerability profile, noted June 3, 2024.",59.0,107.81852,79.993,2.75,2.8,2.87,0.018018506,0.042711118,-0.022629917,-0.031583897,0.49722,0.0068,0.40017,1208,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
PHVS,Deucrictibant (PHVS416) - (CHAPTER-3),Hereditary angioedema - prophylactic useÂ ,Phase 2,6/3/2024,"Phase 2 results presented at EAACI showed satisfaction with the effectiveness of deucrictibant is higher to placebo and is in-line with separate observations of high-efficacy injectables, while numeri",54.0,953.09388,70.9315,18.96,17.71,16.0,-0.068202045,-0.169742775,-0.022629917,-0.031583897,0.23184,0.06526,0.98948,1209,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
PFE,ERAS-007 - (HERKULES-3),Colorectal cancer and gastrointestinal (GI) cancerÂ ,Phase 1b,6/3/2024,"Phase 1b combination expansion data presented at ASCO reported that the ORR was 40% with 3 of the 4 responses confirmed, noted June 3, 2024.",0.0,166087.8378,26.4698,28.66,29.31,28.07,0.022426332,-0.020801032,-0.022629917,-0.031583897,1.23926,0.02242,1118.9747,1210,1,0,0,0,0,1,0,0,0,0,1,0,3,0,0,1
ERAS,ERAS-007 - (HERKULES-3),Colorectal cancer and gastrointestinal (GI) cancerÂ ,Phase 1b,6/3/2024,"Phase 1b combination expansion data presented at ASCO reported that the ORR was 40% with 3 of the 4 responses confirmed, noted June 3, 2024.",283.0,703.2319,69.8104,2.52,2.58,2.28,0.023530497,-0.100083459,-0.022629917,-0.031583897,3.93789,0.11601,4.46186,1211,1,0,0,0,0,1,0,0,0,0,1,0,3,0,0,1
NVS,ARV-766,Metastatic castration-resistant prostate cancer (mCRPC)Â ,Phase 1/2,6/3/2024,"Phase 1/2 initial results from ASCO reported that pharmacokinetics indicated dose-dependent increases in ARV-766 exposure up to 320 mg QD, with exposure accumulation ranging from â‰ˆ5- to 8-fold at stea",0.0,1554.50655,58.1385,4.7,5.01,5.6,0.063873406,0.175204089,-0.022629917,-0.031583897,0.0,0.00019,0.39914,1212,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ARVN,ARV-766,Metastatic castration-resistant prostate cancer (mCRPC)Â ,Phase 1/2,6/3/2024,"Phase 1/2 initial results from ASCO reported that pharmacokinetics indicated dose-dependent increases in ARV-766 exposure up to 320 mg QD, with exposure accumulation ranging from â‰ˆ5- to 8-fold at stea",73.0,1908.56544,67.2854,33.14,27.89,26.99,-0.17247281,-0.205274585,-0.022629917,-0.031583897,13.04357,0.11692,47.86599,1213,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
REGN,Ateganosine (THIO-101),Non-small cell lung cancer (NSCLC)Â ,Phase 2,6/3/2024,"Phase 2 data from ASCO reported that most AEs were G1/2. The most frequent related AEs were AST increase (23%), ALT increase (20%), and nausea (11%), noted June 3, 2024",105.0,106750.5475,16.7743,980.16,989.48,1001.73,0.009463729,0.021767961,-0.022629917,-0.031583897,1.50921,0.09292,527.3869,1214,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
MAIA,Ateganosine (THIO-101),Non-small cell lung cancer (NSCLC)Â ,Phase 2,6/3/2024,"Phase 2 data from ASCO reported that most AEs were G1/2. The most frequent related AEs were AST increase (23%), ALT increase (20%), and nausea (11%), noted June 3, 2024",32.0,111.36946,108.1341,4.75,5.1,3.96,0.071095922,-0.181900593,-0.022629917,-0.031583897,5.60851,0.0151,4.93476,1215,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ATRA,Tabelecleucel (tab-cel),Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative DiseaseÂ ,Phase 2,6/4/2024,"Phase 2 data presented at ASCO showed an Overall Response Rate (ORR) of 60%, noted June 4, 2022.",7.0,68.39636,122.0955,14.4525,14.2,14.0525,-0.017625445,-0.028067094,-0.029106291,-0.011311846,9.64581,0.03322,0.68884,1216,1,0,0,0,0,1,0,0,0,0,1,0,3,0,0,1
ANNX,Tanruprubart (ANX005),Guillain-BarrÃ© Syndrome (GBS)Â ,Phase 3,6/4/2024,"Phase 3 topline data of its single infusion 30 mg/kg dose met the primary endpoint with a highly statistically significant 2.4-fold improvement in GBS disability score versus placebo at week 8, noted",109.0,553.55307,103.982,4.58,5.99,5.46,0.268392414,0.175749792,-0.029106291,-0.011311846,8.19083,0.05227,289.0471,1217,1,0,0,0,0,1,0,0,0,0,1,0,3,0,0,1
VKTX,VK2809 - (VOYAGE),Non-alcoholic steatohepatitis (NASH) and fibrosisÂ ,Phase 2b,6/4/2024,"Phase 2b 52-week biopsy data showed that up to 75% of VK2809-treated patients achieved NASH resolution with no worsening of fibrosis, compared to 29% for placebo. Additionally, up to 57% achieved â‰¥1-",113.0,6200.38145,143.7824,62.27,56.23,52.73,-0.102029347,-0.166295215,-0.029106291,-0.011311846,11.04118,0.05301,639.98051,1218,0,0,0,0,0,1,0,0,0,0,0,1,2,0,0,1
LGND,VK2809 - (VOYAGE),Non-alcoholic steatohepatitis (NASH) and fibrosisÂ ,Phase 2b,6/4/2024,"Phase 2b 52-week biopsy data showed that up to 75% of VK2809-treated patients achieved NASH resolution with no worsening of fibrosis, compared to 29% for placebo. Additionally, up to 57% achieved â‰¥1-",19.0,1452.00207,47.0104,87.91,80.83,80.1,-0.08396538,-0.09303771,-0.029106291,-0.011311846,4.78027,0.28782,16.43654,1219,0,0,0,0,0,1,0,0,0,0,0,1,2,0,0,1
BBIO,Low-dose infigratinib - (PROPEL3),AchondroplasiaÂ ,Phase 2,6/4/2024,"Phase 2 data cohort 5 from PROPEL 2 reported a statistically significant and sustained increase in annualized height velocity (AHV), with a mean change from baseline of +2.51cm/yr at Month 12, and +2.",191.0,5076.81682,54.2852,28.98,27.13,27.48,-0.06596581,-0.05314747,-0.029106291,-0.011311846,8.43398,0.09655,113.30058,1220,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1
AZN,C-CAR301,Solid tumorsÂ ,Phase 1,6/4/2024,Phase 1 data presented at ASCO showed that at 9.03-mo median follow up achieves disease control rate (DCR) of 91.3% and objective response rate (ORR) of 56.5% for patients across all dose levels (DLs),0.0,192293.7917,21.63,123.46,124.04,123.76,0.004686877,0.002426989,-0.029106291,-0.011311846,0.0,0.18211,204.20284,1221,1,0,0,0,0,1,0,0,0,0,1,0,3,0,0,1
EQ,EQ101,Alopecia areataÂ ,Phase 2,6/4/2024,Phase 2 top-line data showed that 20% of all patients and 29% of those with moderate to severe disease who completed 24 weeks of treatment achieved a SALT score â‰¤20 (reduction in hair loss). The mean,59.0,37.37004,137.9686,1.47,1.06,0.7273,-0.326993493,-0.703678633,-0.029106291,-0.011311846,0.86778,0.00227,11.48117,1222,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1
CUE,CUE-101 and KEYTRUDA (pembrolizumab) - (KEYNOTE-A78),HPV16+ head and neck cancerÂ ,Phase 1,6/4/2024,"Phase 1 dose escalation data presented at ASCO 2024 showed an overall response rate (ORR) of 46% and 12-month overall survival (OS) of 96%, noted June 4, 2024.",76.0,75.88357,94.1031,1.65,1.56,1.47,-0.056089467,-0.115512887,-0.029106291,-0.011311846,9.4368,0.06367,0.46921,1223,1,0,0,0,0,1,0,0,0,0,1,0,3,0,0,1
CAPR,Deramiocel (CAP-1002) - (HOPE-2),Duchenne Muscular Dystrophy (DMD)Â ,Phase 2,6/4/2024,"Phase 2 OLE 3-year safety and efficacy data reported a -4.1 points change from baseline, noted June 4, 2024.",45.0,184.50653,62.5356,5.64,5.8,5.55,0.027973852,-0.016086138,-0.029106291,-0.011311846,13.23988,0.02308,4.70166,1224,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ARTL,ART26.12,Chemotherapy-Induced PainÂ ,Preclinical,6/4/2024,Preclinical data reported that there was no impact of ART26.12 on body weight or bone density. All CIBP rats had swelling below the knee and above the ankle but no other clinical observations througho,1.0,4.50264,49.8565,8.34,8.37,8.25,0.003590668,-0.010850016,-0.029106291,-0.011311846,0.19203,0.00291,0.03013,1225,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
BMY,Opdivo (nivolumab) plus Yervoy (ipilimumab) - (CheckMate -9DW),Hepatocellular carcinoma (HCC)Â ,Phase 3,6/4/2024,Phase 3 late-breaking data presented at ASCO demonstrated improved survival benefit compared to lenvatinib or sorafenib in this patient population. ORR was more than double that for lenvatinib or sora,0.0,84631.42901,22.8617,41.77,41.75,43.02,-0.000478927,0.029486745,-0.029106291,-0.011311846,1.39438,0.03003,510.60233,1226,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1
SILO,SPC-15,Post-traumatic stress disorder (PTSD)Â ,IND-Enabling,6/4/2024,"Pre -IND submitted, noted June 4, 2024.",9.0,6.30762,64.2069,2.03,2.25,1.13,0.102894423,-0.58581816,-0.029106291,-0.011311846,3.82459,0.06913,3.38712,1227,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
RPTX,Lunresertib (RP-6306) + Debio 0123 - (MYTHIC),Solid TumorsÂ ,Phase 1,6/4/2024,"Fast Track designation granted by the FDA, noted June 4, 2024.",42.0,149.83228,71.409,3.52,3.53,3.8,0.002836881,0.076540077,-0.029106291,-0.011311846,1.23517,0.07934,1.06296,1228,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
ALT,Pemvidutide - (MOMENTUM),"Non-alcoholic steatohepatitis (NASH)/ (MASH) - Healthy, Overweight and Obese VolunteersÂ ",Phase 2,6/5/2024,"Phase 2 data presented at EASL International Liver Congress suggests that glucagon receptor agonism could potently affect MASH fibrosis, over and above GLP-1 monotherapy, noted June 5, 2024.",88.0,517.58599,120.2519,7.38,7.3,6.38,-0.01089929,-0.145605541,-0.017936238,-0.028652157,32.53004,0.08139,13.16079,1229,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ALNY,Elebsiran (VIR-2218) and tobevibart (VIR-3434) - (SOLSTICE),Hepatitis Delta Virus (HDV)Â ,Phase 2,6/5/2024,"Additional Phase 2 data presented at EASL reported that 50% (3 of 6) achieved the combined endpoint, noted June 5, 2024.",131.0,19234.33976,33.196,149.76,152.06,159.04,0.015241167,0.06012173,-0.017936238,-0.028652157,2.00828,0.27987,119.51734,1230,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1
VIR,Elebsiran (VIR-2218) and tobevibart (VIR-3434) - (SOLSTICE),Hepatitis Delta Virus (HDV)Â ,Phase 2,6/5/2024,"Additional Phase 2 data presented at EASL reported that 50% (3 of 6) achieved the combined endpoint, noted June 5, 2024.",138.0,1722.50289,61.5933,10.58,12.66,10.48,0.17948199,-0.009496748,-0.017936238,-0.028652157,4.56633,0.10072,44.13796,1231,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1
ABUS,Imdusiran (AB-729 and VTP-300 with nivolumab) - (IM-PROVE I),Hepatitis B (HBV)Â ,Phase 2a,6/5/2024,"Phase 2a data presented at EASL reported that all six patients with sustained HBsAg loss have seroconverted with high anti-HBsAg antibody levels, noted June 5, 2024.",191.0,685.0442,43.66,3.34,3.63,3.25,0.083261841,-0.027315811,-0.017936238,-0.028652157,2.82802,0.06262,7.57618,1232,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
BRNS,Imdusiran (AB-729 and VTP-300 with nivolumab) - (IM-PROVE I),Hepatitis B (HBV)Â ,Phase 2a,6/5/2024,"Phase 2a data presented at EASL reported that all six patients with sustained HBsAg loss have seroconverted with high anti-HBsAg antibody levels, noted June 5, 2024.",40.0,76.70016,83.8984,1.89,1.965,1.9,0.038915416,0.005277057,-0.017936238,-0.028652157,0.02319,0.00231,0.09243,1233,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CLYD,Imdusiran (AB-729 and VTP-300 with nivolumab) - (IM-PROVE I),Hepatitis B (HBV)Â ,Phase 2a,6/5/2024,"Phase 2a data presented at EASL reported that all six patients with sustained HBsAg loss have seroconverted with high anti-HBsAg antibody levels, noted June 5, 2024.",0.0,1.02,370.1367,0.03,0.03,0.03,0.0,0.0,-0.017936238,-0.028652157,0.0,,0.0,1234,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
DTIL,PBGENE-HBV - (ELIMINATE-B),Chronic Hepatitis B Virus (HBV)Â ,Preclinical,6/5/2024,"Preclinical safety data shared at EASL supports the advancement of PBGENE-HBV to clinical trials as a potentially curative, finite treatment, noted June 8, 2024.",11.0,90.10203,90.9851,13.23,13.01,11.75,-0.016768686,-0.118633738,-0.017936238,-0.028652157,4.96886,0.24236,0.29369,1235,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
GNFT,Iqirvo (elafibranor) - (ELATIVE),Primary biliary cholangitis (PBC)Â ,Phase 3,6/5/2024,"Phase 3 data reported that 70% of patients treated with elafibranor achieved composite endpoint of slowing disease progression measured by biochemical response after 78-weeks, noted June 5, 2024.",50.0,239.87329,51.3396,5.1,4.825,4.66,-0.055429805,-0.090225092,-0.017936238,-0.028652157,0.0,0.0672,4.26289,1236,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1
ACET,ADI-001,Lupus nephritis and Systemic Lupus Erythematosus (SLE)Â ,Phase 1,6/5/2024,"Fast track designation granted by the FDA, noted June 5, 2024.",83.0,130.49112,107.4384,1.36,1.44,1.4,0.057158414,0.028987537,-0.017936238,-0.028652157,7.65755,0.02604,2.07888,1237,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
GILD,Livdelzi (Seladelpar) - (ASSURE),Pruritus (itch) in people living with primary biliary cholangitis (PBC)Â ,Phase 3,6/5/2024,"Phase 3 interim results presented at EASL reported that 73% achieved the clinically meaningful composite response endpoint, with 42% experiencing ALP normalization, noted June 5, 2024.",0.0,79585.10299,24.0839,64.16,63.88,64.34,-0.00437364,0.002801558,-0.017936238,-0.028652157,1.74183,0.07268,392.59422,1238,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1
AVIR,SVR12 in combination of bemnifosbuvir and ruzasvir,Hepatitis C virus (HCV)Â ,Phase 2,6/5/2024,"Phase 2 data from the lead-in cohort, presented at EASL, exhibited a 97% SVR12 rate observed with 8 weeks of treatment in the lead-in cohort of HCV-infected patients, noted June 6, 2024.",79.0,333.52348,49.1876,3.77,3.96,3.78,0.049169024,0.002649008,-0.017936238,-0.028652157,2.22354,0.04245,1.19849,1239,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ASMB,ABI-6250,Chronic hepatitis D virus (HDV)Â ,Preclinical,6/5/2024,Preclinical data presented at EASL reported that ABI-6250 also effectively inhibited NTCP-mediated bile acid uptake and demonstrated selectivity for the NTCP bile transporter versus other transporters,7.0,84.35361,49.6066,15.1,15.3,15.51,0.013158085,0.026790233,-0.017936238,-0.028652157,0.3861,0.02182,0.14114,1240,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
VYNE,Repibresib Gel (VYN201),VitiligoÂ ,Phase 2b,6/5/2024,"Phase 2b initiated, noted June 5, 2024.",25.0,34.57723,69.3487,2.41,2.38,2.15,-0.01252626,-0.114158905,-0.017936238,-0.028652157,0.39479,0.13994,0.05425,1241,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
HRMY,WAKIX (pitolisant),Type 1 myotonic dystrophy (DM1)Â ,Phase 2,6/5/2024,"Phase 2 data reported that the mean improvement on the Daytime Sleepiness Scale (primary endpoint) was greater for pitolisant. Compared with placebo, a dose-response relationship was observed from bas",57.0,1696.94081,39.0178,29.71,29.88,29.45,0.005705671,-0.008789779,-0.017936238,-0.028652157,12.48966,0.21872,5.7833,1242,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
GOVX,COVID-19 booster with GEO-CM04S1 or Pfizer-BioNTech Bivalent vaccine,"COVID-19 Infection, Chronic Lymphocytic LeukemiaÂ ",Phase 2,6/5/2024,"Phase 2 interim data reported that statistically significant increases in neutralizing antibody responses against multiple SARS-CoV-2 variants, ranging from the original Wuhan strain through Delta and",25.0,4.55096,78.6664,1.76,1.8,1.4834,0.022472856,-0.170977059,-0.017936238,-0.028652157,0.84432,0.02748,0.2467,1243,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1
VTYX,VTX3232,Obesity and cardiometabolic risk factorsÂ ,Preclinical,6/5/2024,"Preclinical data reported that treatment decreased body weight and food intake compared to DIO control. Reductions in liver steatosis and triglycerides were also observed, noted June 5, 2025.",71.0,372.20852,130.3412,4.945,5.28,2.98,0.065549133,-0.506453665,-0.017936238,-0.028652157,11.78327,0.01364,16.20199,1244,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
IMNN,IMNN-101 - (IMUNON),SARS-CoV-2 variant XBB.1.5Â ,Phase 1,6/5/2024,"Phase 1 initiated, noted June 5, 2024.",2.0,12.55018,122.6758,17.34782,17.41303,15.91304,0.003751926,-0.086327951,-0.017936238,-0.028652157,3.75406,0.03131,0.03166,1245,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
AMGN,UPLIZNA (INEBILIZUMAB-CDON),Immunoglobulin G4-related disease (IgG4-RD)Â ,Phase 3,6/5/2024,"Phase 3 trial met its primary endpoint, showing a statistically significant 87% reduction in the risk of IgG4-RD flare compared to placebo during the 52-week placebo-controlled period. All key seconda",538.0,164889.2956,27.0217,307.37,307.38,301.08,3.25336e-05,-0.020676223,-0.017936238,-0.028652157,1.9104,0.02287,537.4736,1246,1,0,0,0,0,1,0,0,0,0,0,0,2,0,0,1
KALV,EKTERLY (sebetralstat),Hereditary Angioedema (HAE)Â ,Phase 3,6/6/2024,"Phase 3 data from US subgroup demonstrated a median time to treatment of 38 minutes and time to beginning of symptom relief 1.3 hours, noted June 6, 2024.",50.0,499.93131,61.1806,12.07,11.85,12.26,-0.018395168,0.015618895,0.029434501,0.003192511,13.64784,0.03832,1.23513,1247,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
SGMT,Denifanstat - (FASCINATE-3),Nonalcoholic steatohepatitis (NASH)Â ,Phase 2b,6/6/2024,"Phase 2b data reported that treatment statistically significant results on primary and secondary liver biopsy endpoints in the ITT population, noted June 6, 2024.",32.0,148.39958,196.0391,4.64,4.65,4.79,0.002152853,0.031816045,0.029434501,0.003192511,6.70324,0.12578,3.10871,1248,0,0,0,0,0,1,0,0,1,0,0,0,2,0,0,1
GILD,Hepcludex (Bulevirtide) - (MYR204),Hepatitis delta virus (HDV)Â ,Phase 2b,6/6/2024,"Phase 2b final results reported that treatment with bulevirtide 10 mg in combination with PegIFN maintained a 46% rate of undetectable HDV RNA at Week 48 after EOT, noted June 6, 2024.",0.0,79547.7274,24.0697,63.88,63.85,63.56,-0.000469741,-0.005021982,0.029434501,0.003192511,1.74183,0.07268,388.68113,1249,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
FDMT,4D-710 - (AEROW),Cystic fibrosisÂ ,Phase 1/2,6/6/2024,Phase 1/2 data reported meaningful improvements in ppFEV1 at 12 months observed in 2 of 3 participants with mild to moderate baseline lung function impairment (ppFEV1 50-80%) and >6 months follow up A,46.0,1166.94601,112.4727,27.28,22.57,24.41,-0.189532242,-0.111160949,0.029434501,0.003192511,18.65643,0.08428,25.79968,1250,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ABBV,ABBV-383 - (CERVINO),Multiple myelomaÂ ,Phase 3,6/6/2024,"Phase 3 trial commenced, noted June 6, 2024.",0.0,297672.3318,19.1523,165.44,168.57,166.56,0.018742502,0.006747014,0.029434501,0.003192511,0.90198,0.03907,874.32421,1251,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CMMB,nebokitug (CM-101) - (SPRING),Primary Sclerosing CholangitisÂ ,Phase 2,6/6/2024,"Phase 2 new translational data futher confirmsmodifying activity based on exvivo studies presented at EASL, noted June 6, 2024.",5.0,16.20823,81.7101,5.16,4.5596,4.6,-0.123701679,-0.114880276,0.029434501,0.003192511,0.73298,0.08652,0.16432,1252,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ABBV,Mirvetuximab - (PICCOLO),Ovarian cancerÂ ,Phase 2,6/6/2024,"Phase 2 full data reported ORR of 51.9%, noted June 6, 2024.",0.0,297672.3318,19.1523,165.44,168.57,166.56,0.018742502,0.006747014,0.029434501,0.003192511,0.90198,0.03907,874.32421,1253,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
PLRX,Bexotegrast (PLN-74809) - (INTEGRIS-PSC),Primary sclerosing cholangitis (PSC)Â ,Phase 2a,6/6/2024,"Phase 2a data reported that across all doses tested, bexotegrast attenuated increases in enhanced liver fibrosis (ELF) scores and pro-peptide of type III collagen formation (PRO-C3) when compared to p",61.0,696.1601,58.9464,12.1,11.54,11.97,-0.047386192,-0.010801933,0.029434501,0.003192511,11.52617,0.07689,5.90316,1254,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
MDGL,Resmetirom - (MAESTRO-NASH Outcomes),Nonalcoholic Steatohepatitis (NASH)Â ,Phase 3,6/6/2024,"Phase 3 MAESTRO-NASH data from EASL reported that patients treated with Rezdiffra showed reduction from baseline in these key features compared to placebo, noted June 6, 2024.",22.0,5143.5368,67.23,235.97,241.35,277.02,0.022543484,0.160385027,0.029434501,0.003192511,19.558,0.12957,153.60841,1255,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
TVGN,TVGN 489 - (TCTL Study),Cytotoxic T Lymphocytes for the Treatment of Elderly and High-Risk Patients with Covid-19Â ,Phase 1,6/6/2024,"Phase 1 data reported that all patients, regardless of variant, experienced prompt clinical improvement and a reduced amount of virus in their nasal swabs (>99 to 100% in all patients) within 14 days,",196.0,148.26526,198.3634,0.7768,0.89255,0.8781,0.138899618,0.122577565,0.029434501,0.003192511,0.54556,0.0123,1.10039,1256,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
BMEA,Icovamenib (BMF-219) - (COVALENT-111),"Healthy volunteers, type 2 diabetesÂ ",Phase 1/2,6/6/2024,"Full clinical hold place June 6, 2024.",59.0,405.09546,102.9495,11.84,11.27,5.81,-0.049339301,-0.711903059,0.029434501,0.003192511,36.55102,0.00445,13.48144,1257,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,-1
BMEA,Icovamenib (BMF-219) - (COVALENT-112),Type 1 diabetes (T1D)Â ,Phase 2,6/6/2024,"Full clinical hold announced June 6, 2024.",59.0,405.09546,102.9495,11.84,11.27,5.81,-0.049339301,-0.711903059,0.029434501,0.003192511,36.55102,0.00445,13.48144,1258,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,-1
GERN,RYTELO (imetelstat) - (IMerge),Myelodysplastic syndromes with transfusion-dependent (TD) anemiaÂ ,Approved,6/6/2024,"Approved June 6, 2024.",638.0,2307.28558,116.7402,4.0,3.89,4.88,-0.027885203,0.198850859,0.029434501,0.003192511,9.08538,0.0118,22.66846,1259,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1
SNDX,SNDX-5613,Unresectable metastatic microsatellite stable colorectal cancer.Â ,Phase 1a,6/6/2024,"Phase 1a received IDMC recommendation to advance based on favorable safety profile observed in Phase 1a portion of trial, noted June 6, 2024.",86.0,1648.74896,46.8318,19.21,19.4,20.7,0.009842089,0.074702723,0.029434501,0.003192511,11.80076,0.27785,22.69007,1260,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1
JNJ,Amivantamab - (PALOMA-3),Non-small cell lung cancer (NSCLC)Â ,BLA Filing,6/7/2024,"BLA submitted June 17, 2024.",0.0,353974.3742,15.0809,146.42,147.08,145.54,0.004497452,-0.006028241,0.008982258,0.011594647,0.72416,0.12546,751.81795,1261,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
MRNA,SPIKEVAX (mRNA-1273),COVID-19 vaccineÂ ,Approved,6/7/2024,"Approved vaccine submitted to the FDA for review of its Spikevax 2024-2025 formula, targeting the SARS-CoV-2 variant JN.1., noted June 7, 2024.",389.0,57873.03102,59.416,154.69,151.01,140.03,-0.024077054,-0.099566429,0.008982258,0.011594647,5.59185,0.13748,380.78667,1262,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1
ARCT,ARCT-032 - (LUNAR-CF),Cystic FibrosisÂ ,Phase 1b,6/7/2024,"Phase 1b showed improvements in FEV1 (Forced Expiratory Volume in 1 second) in the four adults with CF after two inhaled administrations, noted June 7, 2024.",27.0,856.9707,83.7861,42.6,31.82,31.0,-0.29175923,-0.317867049,0.008982258,0.011594647,15.33095,0.19561,73.40435,1263,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
GSK,Arexvy (50-59 at increased risk),"Respiratory syncytial virus (RSV) disease, VaccineÂ ",Approved,6/7/2024,"Approved June 7, 2024.",0.0,66431.65901,22.8111,16.4,16.29,16.045,-0.006729912,-0.02188406,0.008982258,0.011594647,0.0,0.0073,113.66457,1264,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1
ETNB,Pegozafermin - (ENLIVEN),Nonalcoholic Steatohepatitis (NASH)Â ,Phase 2b,6/8/2024,Phase 2b 48-week data presented at EASL reported statistically significant improvements across key markers of liver health. The benefits observed at week 48 were consistent with the results observed a,148.0,796.91038,67.1589,8.1,8.1,8.77,0.0,0.079472745,-0.006543812,-0.003931424,10.28216,0.05363,0.0,1265,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1
MRNA,mRNA-1083,COVID-19Â ,Phase 3,6/10/2024,"Phase 3 data reported that the trial met its primary endpoints, noted June 10, 2024.",389.0,56945.59089,59.6912,151.01,148.59,137.9,-0.016155225,-0.090817275,-0.011640055,0.008792232,5.59185,0.13748,887.01737,1266,1,0,0,0,0,1,0,0,0,0,0,0,2,0,0,1
PROK,Rilparencel - (REGEN-007),Diabetic CKD Stage 3/4Â ,Phase 2,6/10/2024,"Phase 2 data reported a sustained eGFR decline of â‰¥ 20%, and/or an increase in the urine albumin to creatinine ratio (UACR) from baseline of â‰¥ 30% and â‰¥ 30 mg/g, noted June 10, 2024.",294.0,193.04816,131.5112,3.19,3.02,2.92,-0.054764085,-0.088437301,-0.011640055,0.008792232,15.47241,0.05072,9.41818,1267,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
OCS,Licaminlimab (OCS-02) - (PREDICT-1),Dry eye diseaseÂ ,Phase 2b,6/10/2024,"Phase 2b data reported a treatment effect favoring licaminlimab was observed in multiple sign endpoints including fluorescein staining in the total cornea, inferior corneal, central corneal and nasal",43.0,500.88354,37.4841,11.85,12.0,11.75,0.012578782,-0.008474627,-0.011640055,0.008792232,0.1103,0.01162,0.22154,1268,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
SKYE,SBI-100,Primary open-angle glaucoma (POAG) or Ocular hypertension (OHT)Â ,Phase 2a,6/10/2024,"Phase 2a study did not meet the primary endpoint for lowering intraocular pressure, leading the company to discontinue the program and associated ophthalmology pipeline, noted June 10, 2024.",30.0,280.11771,159.4911,10.94,9.98,10.86,-0.091842707,-0.007339482,-0.011640055,0.008792232,0.82798,0.00041,12.69659,1269,1,0,0,0,0,1,0,0,0,0,0,0,0,2,0,-1
CANF,Namodenoson - (CF102-222PC),Pancreatic CancerÂ ,Phase 2a,6/10/2024,"Phase 2a received approval from an Israeli review board to initiate open-label study, noted June 10, 2024.",10.0,44.91386,38.8786,0.029,0.03,0.04,0.033901552,0.321583624,-0.011640055,0.008792232,0.0,0.04204,0.44405,1270,0,0,0,0,0,1,0,1,0,0,0,0,2,0,0,1
FDMT,4D-150 - (PRISM),Wet age-related macular degeneration (AMD)Â ,Phase 2,6/10/2024,Additional subgroup results demonstrated that a single intravitreal dose of 4D-150 without any supplemental anti-VEGF injections resulted in stable mean visual acuity that was equal to or higher than,46.0,1166.94601,112.7289,22.72,22.57,23.8,-0.006624003,0.046439987,-0.011640055,0.008792232,18.65643,0.08511,15.35837,1271,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
RPTX,RP-3500 - (TRESR),Solid tumorsÂ ,Phase 2,6/10/2024,"Phase 2 dosing initiated, noted June 10, 2024.",42.0,169.78162,72.2486,3.88,4.0,3.8,0.030459207,-0.020834087,-0.011640055,0.008792232,1.23517,0.08377,0.81444,1272,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1
LLY,Tirzepatide - (SYNERGY-NASH),"Nonalcoholic steatohepatitis (NASH), Metabolic dysfunction-associated steatohepatitis (MASH)Â ",Phase 2,6/10/2024,"Phase 2 data reported that the efficacy estimandi showed 51.8%, 62.8% and 73.3% of participants taking 5 mg, 10 mg and 15 mg, respectively, achieved an absence of MASH with no worsening of fibrosis on",946.0,778850.6589,26.0777,849.99,865.0,885.01,0.017504922,0.04037436,-0.011640055,0.008792232,0.59978,0.02742,2979.49077,1273,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1
NVO,Efruxifermin - (HARMONY),Nonalcoholic SteatohepatitisÂ ,Phase 2b,6/10/2024,"Phase 2b data presented at EASL reported that â‰¥1-stage improvement in fibrosis with no worsening of MASH after 24 weeks of treatment for both the 50 mg EFX (41%, p<0.05) and 28 mg EFX (39%, p<0.05) do",0.0,4384160.523,26.8794,142.88,143.63,140.37,0.005235431,-0.017723324,-0.011640055,0.008792232,0.0,0.0,524.97038,1274,0,1,0,0,0,1,0,0,0,0,0,0,2,0,0,1
AKRO,Efruxifermin - (HARMONY),Nonalcoholic SteatohepatitisÂ ,Phase 2b,6/10/2024,"Phase 2b data presented at EASL reported that â‰¥1-stage improvement in fibrosis with no worsening of MASH after 24 weeks of treatment for both the 50 mg EFX (41%, p<0.05) and 28 mg EFX (39%, p<0.05) do",79.0,1589.78165,67.5273,23.02,22.99,22.91,-0.001304065,-0.004789907,-0.011640055,0.008792232,12.04213,0.10069,21.90986,1275,0,1,0,0,0,1,0,0,0,0,0,0,2,0,0,1
SRZN,SZN-043,Severe alcohol associated hepatitisÂ ,Phase 1a,6/10/2024,"Phase 1a data reported that target engagement was confirmed via transient increases in alkaline phosphatase (ALP), noted June 10, 2024.",8.0,35.8264,99.8631,11.09,11.2,10.9999,0.009869977,-0.00815762,-0.011640055,0.008792232,1.23863,0.0207,0.13222,1276,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
BDRX,"eRapa (rapamycin, sirolimus) - (Serenta)",Familial Adenomatous Polyposis (FAP)Â ,Phase 2,6/10/2024,"Phase 2 data reported that 14/18 (78%) patients were non-progressors with 11/18 (61%) of these patients with PR. In the colorectum, 25/29 (86%) patients were non progressors including all with an inta",0.0,9.4408,203.4752,234.775,245.05,249.875,0.042834663,0.062333184,-0.011640055,0.008792232,3.34352,0.06969,0.161,1277,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
MNPR,MNPR-101-Zr (uPAR),Solid tumorsÂ ,Phase 1,6/10/2024,"Phase 1 data shared at SNMMI reported durable tumor uptake across multiple cancers with optimization improved biodistribution and stability, noted June 10, 2024.",6.0,13.54324,176.9785,4.055,3.873,4.3,-0.045921287,0.058664335,-0.011640055,0.008792232,0.45621,0.01149,0.10084,1278,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
MIRA,Ketamir-2,"Treatment-resistant depression (TRD), major depressive disorder with suicidal ideation (MDSI) and post-traumatic stress disorder (PTSD)Â ",Preclinical,6/10/2024,Preclinical study results highlight the potential as a superior alternative to intravenous ketamine for treating depression and treatment-resistant depression (TRD). The encouraging data support MIRA',19.0,11.18869,145.2434,0.76,0.75697,0.72,-0.003994811,-0.054067221,-0.011640055,0.008792232,0.09921,0.00011,0.03494,1279,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
SLS,Tambiciclib (SLS009) (GFH009) with venetoclax,"Hematologic malignancies, acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) and lymphomaÂ ",Phase 2a,6/10/2024,"Phase 2a enrollment was completed with initial data showing an overall response rate (ORR) of 33% and 50% achieved to date in 60 mg QW and 30 mg BIW cohorts, noted June 10, 2024.",105.0,81.43445,115.1543,1.45,1.41,1.25,-0.027973852,-0.148420005,-0.011640055,0.008792232,12.56056,0.02129,1.29254,1280,1,0,0,0,0,1,0,0,0,1,0,0,3,0,0,1
ATNM,Iomab-B - (SIERRA),Acute myeloid leukemia (AML)Â ,Phase 3,6/10/2024,"Phase 3 data presented at SNMMI showed the CD45-targeting antibody radiation conjugate (ARC) improved survival in high-risk relapsed/refractory acute myeloid leukemia (AML) patients, including those w",31.0,237.96977,84.923,7.96,7.99,7.93,0.00376176,-0.003775964,-0.011640055,0.008792232,7.01972,0.03419,1.50658,1281,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
NRXP,HTX-100 (NRX-100) (Ketamine Hydrochloride),Acute Suicidal Ideation and Behavior in Bipolar DepressionÂ ,Phase 3,6/10/2024,"Phase 3 trial discussed at ASCP meeting suggested intravenous ketamine may have advantages over the intranasal form, noted June 10, 2024.",19.0,34.10548,158.7938,3.21,3.18,3.07,-0.00938974,-0.044593376,-0.011640055,0.008792232,4.54899,0.05597,0.27871,1282,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
GNFT,Iqirvo (elafibranor) - (ELATIVE),Primary biliary cholangitis (PBC)Â ,Approved,6/10/2024,"FDA approved on June 10, 2024.",50.0,243.60189,50.7182,4.85,4.9,3.915,0.0102565,-0.214163376,-0.011640055,0.008792232,0.0,0.06802,3.14188,1283,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
LLY,Kisunla (donanemab) - (TRAILBLAZER-ALZ 2),Alzheimerâ€™s diseaseÂ ,BLA Filing,6/10/2024,"Advisory committee voted 11-0 (11 Yes; 0 No; 0 Abstain) that the evidence presented showed that donanemab is effective for the treatment of AD, noted June 10, 2024.",946.0,778850.6589,26.0777,849.99,865.0,885.01,0.017504922,0.04037436,-0.011640055,0.008792232,0.59978,0.02742,2979.49077,1284,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
NNVC,NV-387,"Influenza A viruses, Bird Flu H5N1Â ",Preclinical,6/11/2024,"Preclinical data reported an ideal flat blood concentration profile for an extended time period upon oral administration in two different animal models, noted June 11, 2024.",17.0,39.10434,92.1962,3.03,3.31,1.64,0.08838557,-0.613866378,-0.019698177,0.025209106,1.26998,0.02364,2.14601,1285,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
SAGE,SAGE-718 - (SURVEYOR),Huntington's diseaseÂ ,Phase 2,6/11/2024,"Phase 2 topline data reported that the study met its primary endpoint, noted June 11, 2024.",62.0,192798.3333,37.9568,26.0,24.0,18.0,-0.080042708,-0.36772478,-0.019698177,0.025209106,0.0,0.02366,1.8552,1286,1,0,0,0,0,1,0,0,0,0,1,0,3,0,0,1
SUPN,SAGE-718 - (SURVEYOR),Huntington's diseaseÂ ,Phase 2,6/11/2024,"Phase 2 topline data reported that the study met its primary endpoint, noted June 11, 2024.",56.0,1440.32546,36.1164,26.19,26.2,26.66,0.000381752,0.017786656,-0.019698177,0.025209106,9.49349,0.11885,10.36231,1287,1,0,0,0,0,1,0,0,0,0,1,0,3,0,0,1
MOLN,MP0712,Small-cell lung cancer (SCLC) and other DLL3+ neuroendocrine tumorsÂ ,Preclinical,6/11/2024,"Preclinical data reported that treatment showed significant and durable inhibition of tumor growth at clinically-relevant doses, noted June 11, 2024.",40.0,148.48984,54.4908,3.98,4.475,7.12,0.117224532,0.581625906,-0.019698177,0.025209106,0.0,0.05201,0.52967,1288,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
THAR,TH104 (AV104),Primary biliary cholangitis (PBC)Â ,Phase 1,6/11/2024,Phase 1 data reported consistent pharmacokinetic (PK) profiles across buccal and intravenous routes of administration with a comparable safety and tolerability profile between routes of administration,4.0,2.69609,91.091,3.47,3.43,2.965,-0.011594333,-0.157277562,-0.019698177,0.025209106,1.95603,0.00172,0.28168,1289,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
REGN,Kevzara (sarilumab),Polyarticular juvenile idiopathic arthritisÂ ,Approved,6/11/2024,"FDA Approved on June 11, 2024.",105.0,109022.6162,16.4106,1001.73,1010.54,1039.11,0.008756336,0.036636072,-0.019698177,0.025209106,1.61887,0.09567,452.95536,1290,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
SNY,Kevzara (sarilumab),Polyarticular juvenile idiopathic arthritisÂ ,Approved,6/11/2024,"FDA Approved on June 11, 2024.",0.0,112373.0089,20.1042,48.86,48.51,47.22,-0.007189104,-0.034141534,-0.019698177,0.025209106,0.0,0.0,261.90908,1291,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
ANVS,Buntanetap (ANVS401),Alzheimerâ€™s disease (AD)Â ,Phase 2/3,6/11/2024,"Additional Phase 2/3 data reported that buntanetap was found to be equally safe in both APOE4 carriers and non-carriers, with no instances of ARIA, noted June 11, 2024.",19.0,75.63092,190.1825,6.5,6.77,5.31,0.04069891,-0.202210342,-0.019698177,0.025209106,10.85419,0.04566,2.49403,1292,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
PCSA,NGC-Capecitabine (PCS6422),Gastrointestinal CancerÂ ,Phase 1b,6/11/2024,"Phase 1b data showed that 8/12 patients had progression-free survival (PFS) ranging from 5 to 11 months, noted June 11, 2024.",50.0,5.14441,223.7659,1.58,1.8,1.83,0.130361818,0.14689112,-0.019698177,0.025209106,0.78614,0.02218,3.93796,1293,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CAPR,Deramiocel (CAP-1002) - (HOPE-2),Duchenne Muscular Dystrophy (DMD)Â ,BLA Filing,6/11/2024,"Type-B meeting with the FDA completed, noted June 11, 2024",45.0,176.55366,62.2399,5.41,5.55,4.84,0.025548835,-0.111334372,-0.019698177,0.025209106,14.35271,0.02061,1.87242,1294,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ATNM,Actimab-A in combination with CLAG-M,Relapsed or refractory acute myeloid leukemia (AML)Â ,Phase 1b,6/11/2024,"Phase 1b SNMMI oral presentation highlighted dosimetry results and safety data supporting this novel radiotherapy combination, noted June 11, 2024.",31.0,240.65028,84.5862,7.99,8.08,7.87,0.011201113,-0.015132697,-0.019698177,0.025209106,6.07733,0.03419,1.12185,1295,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
NVO,Efruxifermin - (SYMMETRY),Metabolic-associated steatohepatitis (MASH)Â ,Phase 3,6/11/2024,"Phase 3 initiated, noted June 11, 2024.",0.0,4355772.595,26.8667,143.63,141.79,140.8,-0.012893459,-0.019900105,-0.019698177,0.025209106,0.0,0.0,628.60214,1296,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
AKRO,Efruxifermin - (SYMMETRY),Metabolic-associated steatohepatitis (MASH)Â ,Phase 3,6/11/2024,"Phase 3 initiated, noted June 11, 2024.",79.0,1620.20809,67.2996,22.99,23.43,22.16,0.018957914,-0.036770477,-0.019698177,0.025209106,10.78416,0.10069,20.62719,1297,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ATHA,ATH-1105,Amyotrophic Lateral Sclerosis (ALS)Â ,Phase 1,6/11/2024,"Phase 1 first cohort completed, noted June 11, 2024.",3.0,97.73806,92.914,25.5,25.5,26.0,0.0,0.019418086,-0.019698177,0.025209106,2.32069,0.05401,0.17904,1298,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1
INDV,INDV-2000,Opioid Use Disorder (OUD)Â ,Phase 2,6/11/2024,"Phase 2 POC trial initiated, June 11, 2024",124.0,2267.81755,55.4031,16.97,16.87,15.86,-0.005910183,-0.067646863,-0.019698177,0.025209106,0.08554,0.01427,0.69518,1299,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
RARE,Setrusumab (BPS-804) - (ORBIT),Osteogenesis ImperfectaÂ ,Phase 2/3,6/12/2024,"Phase 2 data reported that continued, substantial improvements in bone mineral density (BMD) with a mean increase from baseline of 22% (p<0.0001) and a mean improvement in Z-score of +1.25, noted June",96.0,3708.23435,42.6496,41.4,44.64,37.42,0.075349437,-0.10107556,-0.014601934,0.030305349,5.37554,0.1578,67.76048,1300,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
MREO,Setrusumab (BPS-804) - (ORBIT),Osteogenesis ImperfectaÂ ,Phase 2/3,6/12/2024,"Phase 2 data reported that continued, substantial improvements in bone mineral density (BMD) with a mean increase from baseline of 22% (p<0.0001) and a mean improvement in Z-score of +1.25, noted June",155.0,536.29668,64.4472,3.52,3.83,3.98,0.084403814,0.12282083,-0.014601934,0.030305349,1.71438,0.01286,16.51177,1301,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
RNA,Delpacibart braxlosiran (del-brax) - (FORTITUDE),Facioscapulohumeral Muscular Dystrophy (FSHD)Â ,Phase 1/2,6/12/2024,"Phase 1/2 preliminary data demonstrated greater than 50% mean reduction in DUX4 regulated genes, trends of functional improvement including increased muscle strength and reachable workspace, and posit",128.0,3668.62565,82.537,28.92,38.36,38.33,0.282481853,0.281699482,-0.014601934,0.030305349,11.31761,0.15024,390.10939,1302,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
PDSB,PDS0101 + KEYTRUDA (pembrolizumab) - (VERSATILE-002),HPV16-positive first-line recurrent and/or metastatic head and neck squamous cell cancer with low PD-L1 expression (CPS 1-19)Â ,Phase 2,6/12/2024,"Phase 2 data reported that the mOS is 30 months, noted June 12, 2024.",46.0,107.47028,78.8055,2.76,2.93,2.74,0.059771743,-0.007272759,-0.014601934,0.030305349,18.28992,0.11415,2.57899,1303,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
DNTH,DNTH103 - (MoMeNtum),Multifocal Motor Neuropathy (MMN)Â ,IND-Enabling,6/12/2024,"Phase 2 trial initiated and IND cleared by the FDA, noted June 12, 2024.",32.0,738.43264,103.3859,23.96,25.16,24.88,0.048869659,0.037678495,-0.014601934,0.030305349,7.07931,0.00127,5.13475,1304,0,0,0,0,0,1,0,1,0,0,0,0,2,0,0,1
NKTR,NKTR-0165,Autoimmune diseasesÂ ,Preclinical,6/12/2024,"Preclinical data presented at EULAR demonstrated selective enhancement of Treg Cell function through novel agonistic mechanism, noted June 12, 2024.",19.0,237.38517,100.8514,18.89999,19.34999,17.09999,0.02353051,-0.100083514,-0.014601934,0.030305349,1.48798,0.02215,1.66694,1305,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1
AZN,Farxiga,Paediatric type-2 diabetesÂ ,Approved,6/12/2024,"Approved June 12, 2024.",0.0,193254.9506,21.7438,123.76,124.66,123.4,0.007245825,-0.002913095,-0.014601934,0.030305349,0.0,0.182,409.89255,1306,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1
NKGN,SNK02,Solid TumorsÂ ,Phase 1,6/12/2024,"Additional Phase 1 data reported that there were 17 Grade 1, 3 Grade 2, and 1 Grade 3 adverse events (""AEs"") related to investigational product, noted June 12, 2024.",124.0,32.10526,197.7088,1.41,1.29,1.19,-0.088947486,-0.169636397,-0.014601934,0.030305349,2.41319,0.00267,1.14871,1307,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
PFE,Fordadistrogene movaparvovec,Duchenne muscular dystrophy (DMD)Â ,Phase 3,6/12/2024,"Phase 3 trial did met its primary endpoint, noted June 12, 2024.",0.0,156737.9596,26.7497,28.03,27.66,27.41,-0.013288039,-0.022367455,-0.014601934,0.030305349,1.34074,0.02281,899.16968,1308,1,0,0,0,0,1,0,0,0,0,0,0,2,0,0,1
PFE,PF-06939926 (CIFFREO),Duchenne muscular dystrophy (DMD)Â ,Phase 3,6/12/2024,"Phase 3 trial did not meet its primary endpoint, noted June 12, 2024.",0.0,156737.9596,26.7497,28.03,27.66,27.41,-0.013288039,-0.022367455,-0.014601934,0.030305349,1.34074,0.02281,899.16968,1309,1,0,0,0,0,1,0,0,0,0,0,0,0,2,0,-1
CRDL,CardiolRx - (MAvERIC-Pilot),Recurrent PericarditisÂ ,Phase 2,6/12/2024,"Phase 2 topline data reported a mean reduction of 3.7, from 5.8 at baseline for patient-reported pericardial pain, noted June 12, 2024.",83.0,9.37597,56.7803,0.047,0.047,0.0455,0.0,-0.032435276,-0.014601934,0.030305349,0.0,0.05587,0.01323,1310,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
MRNA,mRNA-1283 - (NEXTCove),COVID-19Â ,Phase 3,6/13/2024,"Phase 3 met its primary vaccine efficacy endpoint demonstrating non-inferior vaccine efficacy against COVID-19 compared to Spikevax in participants 12 years of age and older, noted June 13, 2024.",389.0,55657.90541,59.0492,147.72,145.23,134.4,-0.016999897,-0.094498162,0.022310566,0.042791352,5.2662,0.13748,263.62135,1311,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1
URGN,ZUSDURI (VesiGel UGN-102 (mitomycin)) - (ENVISION),Low grade non-muscle invasive bladder cancer (LG-NMIBC)Â ,Phase 3,6/13/2024,"Phase 3 data reported a 82.3% 12-month duration of response (DOR), noted June 13, 2024.",46.0,632.27712,76.5746,12.72,17.5,15.47,0.319025323,0.195727107,0.022310566,0.042791352,14.54632,0.02007,127.6191,1312,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
OCUL,AXPAXLI (OTX-TKI) - (HELIOS),Non-proliferative diabetic retinopathy (NPDR)Â ,Phase 1,6/13/2024,"Phase 1 HELIOS study data reported that 23.1% of patients in AXPAXLI arm experienced â‰¥2-step DRSS improvement with no patients experiencing worsening of DRSS or vision threatening complications, noted",174.0,780.64013,89.8877,4.93,5.04,6.08,0.022067094,0.209665708,0.022310566,0.042791352,14.50972,0.06443,14.87342,1313,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
SNY,IPH6101/ SAR443579,Hematological malignanciesÂ ,Phase 1/2,6/13/2024,Phase 1/2 data presented at EHA reported that treatment was well tolerated up to doses of 6 mg/kg QW with observed clinical benefit in adult pts with R/R AMLand a maximum response rate seen at a targ,0.0,109922.7973,20.0741,48.44,47.53,46.85,-0.018964828,-0.03337491,0.022310566,0.042791352,0.0,0.0,106.6924,1314,0,0,0,1,0,1,0,0,0,0,0,0,2,0,0,1
IPHA,IPH6101/ SAR443579,Hematological malignanciesÂ ,Phase 1/2,6/13/2024,Phase 1/2 data presented at EHA reported that treatment was well tolerated up to doses of 6 mg/kg QW with observed clinical benefit in adult pts with R/R AMLand a maximum response rate seen at a targ,92.0,178.25658,67.3122,2.48,2.3703,2.14,-0.045242031,-0.147452731,0.022310566,0.042791352,0.0,0.0,0.00358,1315,0,0,0,1,0,1,0,0,0,0,0,0,2,0,0,1
TNXP,Tonmya (TNX-102 SL) - (RELIEF/RESILIENT),FibromyalgiaÂ ,Phase 3,6/14/2024,"Phase 3 data presented at EULAR reported significant improvement on the primary pain endpoint and on all six key secondary endpoints, noted June 14, 2024.",8.0,4.81287,171.8919,109.0,115.0,130.0,0.053584246,0.176186568,0.035034221,0.015467548,0.58984,0.01324,7.68488,1316,1,0,0,0,0,1,0,0,1,0,1,0,4,0,0,1
KROS,Elritercept (KER-050),Myelodysplastic syndromes (MDS)Â ,Phase 2,6/14/2024,"Phase 2 trial data presented at EHA reported that 55.6% of the mITT24 patients achieved an overall erythroid response over the first 24 weeks of treatment, noted June 14, 2024.",40.0,1781.10061,54.8908,49.5,49.36,46.44,-0.00283229,-0.063811513,0.035034221,0.015467548,6.51196,0.02973,13.83788,1317,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1
TAK,Elritercept (KER-050),Myelodysplastic syndromes (MDS)Â ,Phase 2,6/14/2024,"Phase 2 trial data presented at EHA reported that 55.6% of the mITT24 patients achieved an overall erythroid response over the first 24 weeks of treatment, noted June 14, 2024.",0.0,6498524.011,16.3996,13.08,13.1,12.6,0.001527884,-0.037387532,0.035034221,0.015467548,0.0,0.0,14.03679,1318,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1
HCM,HMPL-523 - (ESLIM-01),Primary immune thrombocytopenia (ITP)Â ,Phase 3,6/14/2024,"Phase 3 data presented at EHA reported a durable response rate of 48.4% vs. 0% with placebo, noted June 14, 2024.",174.0,2501.20076,57.1123,2.96,2.93,2.82,-0.010186845,-0.048452383,0.035034221,0.015467548,0.0,0.05936,0.01126,1319,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
HCM,HMPL-760,Bruton's Tyrosine Kinase (BTK) Relapsed/Refractory (R/R) LymphomasÂ ,Phase 1,6/14/2024,"Phase 1 data presented at EHA reported that 3 complete response (CR)(1 DLBCL, 2 MCL), 1 complete remission with incomplete recovery (CRi)(CLL/SLL), 14 partial responses (PR)(8 CLL/SLL, 3 DLBCL, 1 MCL,",174.0,2501.20076,57.1123,2.96,2.93,2.82,-0.010186845,-0.048452383,0.035034221,0.015467548,0.0,0.05936,0.01126,1320,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
IRON,Bitopertin - (BEACON),Erythropoietic Protoporphyria (EPP)Â ,Phase 2,6/14/2024,"Phase 2 data shared at EHA reported that the cumulative total time in light observed over 6-month treatment period with bitopertin represents >3x increase relative to historical control, noted June 14",34.0,1372.63037,102.0973,39.16,46.27,44.18,0.166837985,0.12061638,0.035034221,0.015467548,6.33301,0.0784,55.5165,1321,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
IRON,MWTX-003 - (DISC-3405),Polycythemia vera (PV)Â ,Phase 1,6/14/2024,"Phase 1 initial data in healthy volunteers shared at EHA reported that mean serum iron reduction of more than 50% from baseline was achieved for both 150- and 300-mg doses, noted June 14, 2024.",34.0,1372.63037,102.0973,39.16,46.27,44.18,0.166837985,0.12061638,0.035034221,0.015467548,6.33301,0.0784,55.5165,1322,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1
MOLN,MP0621,Acute myeloid leukemia (AML)Â ,Preclinical,6/14/2024,"Preclinical data reported that MP0621 depleted cKit+ cells in bone marrow of humanized mice without affecting circulating immune cells, noted June 14 2024.",40.0,197.76523,63.4242,5.3,5.96,9.0,0.117363661,0.529517757,0.035034221,0.015467548,0.0,2e-05,1.34181,1323,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
BPTH,Prexigebersen + DACOGEN (decitabine) + VENCLEXTA (venetoclax),Acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)Â ,Phase 2,6/14/2024,"Phase 2 presented at EHA continues to be well-tolerated and has now demonstrated compelling efficacy results in two reporting cohorts, noted June 14, 2024.",8.0,4.49331,136.2878,2.0,2.16,2.11,0.076961041,0.053540767,0.035034221,0.015467548,1.52944,0.00533,10.90406,1324,0,0,0,1,0,1,0,0,0,0,0,0,2,0,0,1
KYMR,KT-333 - (STAT3),Peripheral T-cell Lymphoma (PTCL)Â ,Phase 1,6/14/2024,"Phase 1 study presented at EHA demonstrated initial clinical proof of concept across multiple hematological malignancies, including complete responses in two patients with Hodgkin's lymphoma, noted Ju",71.0,2042.61654,57.2119,34.87,33.29,31.99,-0.046369809,-0.086203507,0.035034221,0.015467548,16.27733,0.29595,13.59723,1325,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CABA,rese-cel (resecabtagene autoleucel (CABA-201) - (RESET-Myositis),"Active idiopathic inflammatory myopathy (IIM, or myositis)Â ",Phase 1/2,6/14/2024,"Phase 1/2 trial data reported a decline in creatinine kinase from 617 at infusion to 308 and a total improvement score (TIS) of 30, noted June 14, 2024.",91.0,514.62773,74.1696,12.56,10.66,8.48,-0.164018742,-0.392806711,0.035034221,0.015467548,19.62052,0.16946,50.4178,1326,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CABA,CABA-201 - (RESET-SLE),Systemic Lupus ErythematosusÂ ,Phase 1/2,6/14/2024,"Phase 1/2 clinical data demonstrated an improvement in the SLEDAI-2K (systemic lupus erythematosus disease activity index) score from 26 at baseline to 10, noted June 14, 2024.",91.0,514.62773,74.1696,12.56,10.66,8.48,-0.164018742,-0.392806711,0.035034221,0.015467548,19.62052,0.16946,50.4178,1327,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
BEAM,BEAM-101 - (BEACON),Sickle cell diseaseÂ ,Phase 1/2,6/14/2024,Phase 1/2 manufacturing data presented at EHA reported that reproducibly met the high viability threshold across 14 development runs using healthy and sickle cell trait donor cells and nine GMP clinic,101.0,1962.46924,74.2076,25.24,24.87,22.94,-0.01476778,-0.095547926,0.035034221,0.015467548,17.52272,0.26598,43.99811,1328,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1
GILD,Axicabtagene Ciloleucel - (ZUMA-24),Relapsed/Refractory Large B-Cell LymphomaÂ ,Phase 2,6/14/2024,"Phase 2 data presented at EHA reported that data demonstrated that the safety and efficacy of Yescarta was consistent with previous clinical and real-world studies., noted June 14, 2024.",0.0,81055.20978,23.7708,63.56,65.06,70.67,0.023325579,0.106036813,0.035034221,0.015467548,2.04143,0.07228,637.17097,1329,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
EDIT,Renizgamglogene autogedtemcel (reni-cel; EDIT-301) - (EdiTHAL),Transfusion-Dependent Beta Thalassemia (TDT)Â ,Phase 1/2,6/14/2024,Phase 1/2 data presented at EHA reported that treatment was well-tolerated and demonstrated a safety profile consistent with myeloablative conditioning with busulfan and autologous hematopoietic stem,89.0,416.12415,73.5451,5.49,5.06,5.11,-0.081561772,-0.071728851,0.035034221,0.015467548,26.77541,0.20601,16.84296,1330,0,0,0,1,0,1,0,0,0,0,0,0,2,0,0,1
AUTL,AUCATZYL (obecabtagene autoleucel) - (FELIX),B-Cell Acute Lymphoblastic LeukemiaÂ ,Phase 3,6/14/2024,"Data presented at EHA showed an overall response rate (ORR) (Complete Response/CRi) in all patients who received obe-cel in the FELIX study was 78% (99/127 patients), noted June 14, 2024.",266.0,1197.16258,66.2624,4.53,4.5,3.83,-0.006644543,-0.167857136,0.035034221,0.015467548,1.35004,0.2095,7.626,1331,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
EDIT,Renizgamglogene autogedtemcel (reni-cel; EDIT-301) - (RUBY),Sickle Cell DiseaseÂ ,Phase 1/2,6/14/2024,"Phase 1/2 data presented at EHA reported that mean (SD)Hb levels rapidly increased and were maintained at â‰¥14.4 (2.5) g/dL from Month 5, noted June 14, 2024.",89.0,416.12415,73.5451,5.49,5.06,5.11,-0.081561772,-0.071728851,0.035034221,0.015467548,26.77541,0.20601,16.84296,1332,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
DYN,DYNE-302,Facioscapulohumeral Muscular DystrophyÂ ,Preclinical,6/14/2024,"Preclinical data reported that a single intravenous dose of DYNE-302 resulted in dose-dependent and robust reduction of the DUX4 transcriptome (D4T) that lasted up to three months, with benefit on mus",142.0,3279.37494,84.1514,33.69,33.07,35.02,-0.01857453,0.038718269,0.035034221,0.015467548,10.20002,0.15506,19.16582,1333,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
BMY,Augtyro (repotrectinib),Solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) for adults and pediatric patients 12+Â ,Approved,6/14/2024,"Approved June 14, 2024.",0.0,83516.52396,23.1226,41.48,41.2,41.93,-0.006773127,0.010790178,0.035034221,0.015467548,1.41727,0.02516,587.96944,1334,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1
COGT,Bezuclastinib - (SUMMIT),Non-Advanced Systemic MastocytosisÂ ,Phase 2,6/14/2024,"Phase 2 data from part 1 presented at EHA showed that patients treated with 100 mg bezuclastinib showed substantial reduction in their most severe symptoms and mast cell reactions, noted June 14, 2024",139.0,921.21666,103.7986,8.98,8.425,8.79,-0.063796406,-0.021385171,0.035034221,0.015467548,13.16764,0.00029,8.6714,1335,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
SNDX,SNDX-5613 - (AUGMENT-102) - (BEAT AML),MLLr or NPM1 acute leukemiasÂ ,Phase 1/2,6/14/2024,Phase 1/2 data presented at EHA continue to support revumenib's potential to enhance current standard of care agents. 52% CRc (14 of 27 pts) observed in AUGMENT-102 trial. 96% CRc (23 of 24 pts) obser,86.0,1709.08978,44.9486,20.7,20.11,20.05,-0.028916496,-0.031904547,0.035034221,0.015467548,11.35249,0.29533,15.74792,1336,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
BPTH,Prexigebersen (BP1001),Acute Myeloid Leukemia (AML)Â ,Phase 2,6/14/2024,"Phase 2 data presented at EHA trial demonstrated compelling efficacy, with 75% of evaluable newly diagnosed AML patients and 55% of evaluable relapsed/refractory AML patients achieving complete or par",8.0,4.49331,136.2878,2.0,2.16,2.11,0.076961041,0.053540767,0.035034221,0.015467548,1.52944,0.00533,10.90406,1337,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
IVVD,PEMGARDA (VYD222 (pemivibart)) - (CANOPY),COVID-19 PreventionÂ ,Preclinical,6/14/2024,Preclinical new data is broadly concordant with preliminary pseudovirus data showing neutralizing activity of VYD222 against KP.2 FLiRT and KP.3 variants recently publicized by an independent academic,120.0,188.51894,151.7893,1.7,1.58,1.24,-0.073203404,-0.315516871,0.035034221,0.015467548,5.77907,0.02317,0.39288,1338,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
PTGX,Rusfertide - (REVIVE),Polycythemia veraÂ ,Phase 2,6/14/2024,"Phase 2 data presented at EHA reported durable hematocrit (Hct) control (< 45%), decreased phlebotomy use, long-term tolerability, and no new safety signals in patients with polycythemia vera, noted J",62.0,1958.39472,56.034,34.35,33.39,32.26,-0.028345565,-0.062773946,0.035034221,0.015467548,5.76451,0.20094,14.76803,1339,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
IRON,Bitopertin - (APOLLO),Erythropoietic Protoporphyria (EPP)Â ,Phase 2,6/14/2024,"Phase 2 additional data shared at EHA demonstrated the clinical activity of bitopertin and highlighted meaningful improvements in light tolerance, phototoxic reactions, and quality of life, noted June",34.0,1372.63037,102.0973,39.16,46.27,44.18,0.166837985,0.12061638,0.035034221,0.015467548,6.33301,0.0784,55.5165,1340,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
IRON,DISC-0974,Myelofibrosis (MF) patients with anemiaÂ ,Phase 1/2,6/14/2024,"Phase 1b updated data shared at EHA demonstrated durable increases in hemoglobin and reduced transfusion burden in a majority of evaluable patients, noted June 14, 2024.",34.0,1372.63037,102.0973,39.16,46.27,44.18,0.166837985,0.12061638,0.035034221,0.015467548,6.33301,0.0784,55.5165,1341,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
STTK,SL-172154 + Azacitidine (AZA),Acute Myeloid Leukemia (AML) and Higher-Risk Myelodysplastic Syndromes/Neoplasms (HR-MDS)Â ,Phase 1b,6/14/2024,"Phase 1b data presented at EHA reported a 67% objective Response Rate (ORR) in frontline HR-MDS patients, noted June 14, 2024.",47.0,294.3399,80.7361,6.84,6.19,4.37,-0.099852645,-0.448024723,0.035034221,0.015467548,3.75657,0.05229,3.16125,1342,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ZURA,Tibulizumab (ZB-106),Sjogren's SyndromeÂ ,Phase 1,6/14/2024,"Phase 1 data presented at EULAR reported that treatment was generally well tolerated, with total B cell counts were dose-dependently reduced in all participants, noted June 14, 2024.",65.0,234.96894,102.5701,3.73,3.77,3.42,0.010666768,-0.086767683,0.035034221,0.015467548,0.91399,0.00059,0.39572,1343,0,0,0,1,0,1,0,0,0,0,1,0,3,0,0,1
MBRX,"Annamycin (MB-106) in combination with Cytarabine - (Ara-C, MIRACLE)",Acute Myeloid Leukemia (AML)Â ,Phase 1/2,6/14/2024,"Phase 1/2 additional data presented at EHA showed that out of 20 evaluable subjects across all treatment lines, 45% achieved a composite complete remission (CRc), including 89% with poor prognosis cy",30.0,9.56976,93.926,4.35,4.14,3.74,-0.049480057,-0.151090234,0.035034221,0.015467548,0.91355,0.02097,0.78937,1344,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1
GLUE,MRT-6160,Autoimmune conditionsÂ ,Preclinical,6/14/2024,"Preclinical data reported that MRT-6160 inhibited disease progression, pro-inflammatory cytokines and autoantibody production in a model of rheumatoid arthritis, noted June 14, 2024.",61.0,234.16808,102.8294,4.01,3.83,3.63,-0.045926438,-0.099558593,0.035034221,0.015467548,3.11584,0.15316,1.08531,1345,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
AMGN,BLINCYTO,CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (B-ALL)Â ,Approved,6/14/2024,"Approved June 14, 2024.",538.0,160190.1277,26.6201,298.5,298.62,308.16,0.000401929,0.031849196,0.035034221,0.015467548,1.68676,0.01241,511.72001,1346,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1
GLPG,GLPG5101 - (ATALANTA-1),Relapsed/refractory Non-Hodgkin Lymphoma (rrNHL)Â ,Phase 1/2,6/14/2024,"Phase 1/2 data presented at EHA reported that 14 of 16 efficacy-evaluable patients responded to treatment (objective response rate, ORR 87.5%), with 12 patients achieving a complete response (CR), not",65.0,1568.35029,22.5676,23.9,23.8,24.08,-0.004192878,0.007503162,0.035034221,0.015467548,0.0,0.08048,1.63094,1347,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
INAB,INB-100,"Allogeneic hematopoietic stem cell transplantation (HSCT), leukemias undergoing haploidentical stem cell transplantationÂ ",Phase 1b,6/15/2024,"Phase 1b data reported that 100% of treated leukemia patients (n=10/10) achieved durable complete remission (CR) at 1-year, noted June 15, 2024.",4.0,48.09508,122.0655,32.70003,32.70003,26.66703,0.0,-0.203948024,0.012723655,-0.006843018,0.14981,0.00449,0.0,1348,1,0,0,0,1,1,0,0,0,0,0,0,3,0,0,1
NRIX,NX-5948,B-cell malignancies / graft-versus-host diseaseÂ ,Phase 1b,6/16/2024,Phase 1a/1b data presented at EHA reported that treatment resulted in a robust objective response rate (ORR) of 69.2% across all doses tested with responses observed as early as the first scan (8 week,76.0,976.9322,80.6966,15.18,15.18,21.3,0.0,0.338728301,0.012723655,-0.006843018,11.47545,0.18253,0.0,1349,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
FBIO,MB-106,Waldenstrom macroglobulinemia (WM)Â ,Phase 1/2,6/17/2024,"Phase 1/2 data reported an overall response rate of 90% in cohort with durable responses observed; one patient remains in complete remission at 31 months, noted June 17, 2024.",29.0,37.84064,86.3128,1.87,1.9,1.7,0.015915455,-0.09531018,0.022596718,-0.021457506,8.10454,0.09662,1.21962,1350,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
MBIO,MB-106,Waldenstrom macroglobulinemia (WM)Â ,Phase 1/2,6/17/2024,"Phase 1/2 data reported an overall response rate of 90% in cohort with durable responses observed; one patient remains in complete remission at 31 months, noted June 17, 2024.",7.0,52.1961,277.4598,6.5,37.5,28.515,1.752538756,1.478628088,0.022596718,-0.021457506,3.34986,0.1667,847.63099,1351,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
EVAX,EVX-01 + KEYTRUDA (pembrolizumab) / OPDIVO (nivolumab),Metastatic MelanomaÂ ,Phase 2,6/17/2024,"Phase 2 data publication reported that eight out of 12 patients (67%) experienced objective clinical responses (ORR) with six partial and two complete responses, noted June 17, 2024.",6.0,13.36529,176.5152,15.5,12.35,13.45,-0.227183961,-0.141860918,0.022596718,-0.021457506,0.78951,0.01344,2.89079,1352,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
MRK,EVX-01 + KEYTRUDA (pembrolizumab) / OPDIVO (nivolumab),Metastatic MelanomaÂ ,Phase 2,6/17/2024,"Phase 2 data publication reported that eight out of 12 patients (67%) experienced objective clinical responses (ORR) with six partial and two complete responses, noted June 17, 2024.",0.0,322932.8041,16.9672,129.48,127.5,132.96,-0.015410064,0.026521902,0.022596718,-0.021457506,0.80572,0.02683,1086.81395,1353,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
MIRM,Volixibat - (VANTAGE),Pruritus associated with primary biliary cholangitisÂ ,Phase 2b,6/17/2024,"Phase 2b interim analysis demonstrated a statistically significant (-3.82, p<0.0001) improvement in pruritus for volixibat and a placebo-adjusted difference of -2.32 points in the primary endpoint, p=",50.0,1555.38969,52.2219,25.92,33.0,34.85,0.24149269,0.296038266,0.022596718,-0.021457506,18.87676,0.04705,121.20375,1354,1,1,0,0,0,1,0,0,0,0,0,0,3,0,0,1
ATNM,Actimab-A with revumenib,Acute myeloid leukemia (AML)Â ,Preclinical,6/17/2024,"Preclinical data reported potent in vitro AML cell killing activity in both MV-4-11 and MOLM-13 KMT2A mutant cell lines, compared to the non-radio conjugated CD33 antibody lintuzumab, noted June 17, 2",31.0,236.18277,82.7252,7.82,7.93,7.48,0.013968481,-0.044451763,0.022596718,-0.021457506,6.07733,0.04019,1.93208,1355,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
SLRX,Seclidemstat,Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)Â ,Phase 1/2,6/17/2024,"Phase 1/2 data presented at EHA reported a 43% overall response rate among 14 predominantly higher risk myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML) patients, noted June 1",0.0,2.07772,72.5237,50.72397,52.19997,36.29998,0.02868334,-0.33458139,0.022596718,-0.021457506,0.57146,0.01444,0.6253,1356,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ENLV,Allocetra - (ENX-CL-05-001),Knee osteoarthritis (OA)Â ,Phase 1/2,6/17/2024,"Phase 1/2 data reported a substantial reduction (64%) in average reported pain was observed compared to baseline, with 89% (8/9) of treated patients reporting an improvement in their knee pain compare",23.0,29.01177,156.7162,1.46,1.39,1.41,-0.049132689,-0.034846731,0.022596718,-0.021457506,0.75383,0.02716,0.50491,1357,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
AZN,"Calquence (acalabrutinib) with chemoimmunotherapy, bendamustine and rituximab - (ECHO)",Mantle cell lymphoma (MCL)Â ,Phase 3,6/17/2024,"Phase 3 results reported a reduced the risk of disease progression or death by 27% compared to standard-of-care chemoimmunotherapy, noted June 17, 2024.",0.0,192665.8532,21.2157,125.1,124.28,124.78,-0.006576333,-0.002561231,0.022596718,-0.021457506,0.0,0.1818,139.47547,1358,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
AGIO,PYRUKYND (Mitapivat) - (ENERGIZE),ThalassemiaÂ ,Phase 3,6/17/2024,"Phase 3 data presented at EHA reported that 42.3% (n=55/130) of patients in the mitapivat arm achieved a hemoglobin response, compared to 1.6% (n=1/64) of patients in the placebo arm, noted June 17, 2",58.0,2417.96062,60.4438,44.11,42.59,45.23,-0.03506703,0.025074069,0.022596718,-0.021457506,7.86703,0.12864,41.50762,1359,0,0,0,0,1,1,0,0,0,0,0,0,2,0,0,1
JNJ,Nipocalimab - (DAHLIAS),SjÃ¶gren's disease (SjD)Â ,Phase 2,6/17/2024,"Phase 2 data reported that greater than 70 percent relative average improvement on the primary endpoint compared to patients who received placebo, noted June 17, 2024.",0.0,351254.8268,15.0366,145.54,145.95,149.12,0.002813134,0.024300388,0.022596718,-0.021457506,0.8283,0.1081,972.98779,1360,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
MRK,KEYTRUDA (pembrolizumab) Plus Carboplatin and Paclitaxel,Endometrial carcinomaÂ ,Approved,6/17/2024,"Approved June 17, 2024.",0.0,322932.8041,16.9672,129.48,127.5,132.96,-0.015410064,0.026521902,0.022596718,-0.021457506,0.80572,0.02683,1086.81395,1361,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1
OVID,Soticlestat (TAK-935/OV935)- (Skyline),Dravet Syndrome / Lennox-Gastaut SyndromeÂ ,Phase 3,6/17/2024,"Phase 3 trial did not meet its primary endpoint, noted June 17, 2024.",71.0,56.01788,208.6692,3.29,0.7896,0.79,-1.427116356,-1.426609898,0.022596718,-0.021457506,4.04345,0.02122,17.5964,1362,1,0,0,0,0,1,0,0,0,0,0,0,0,2,0,-1
TAK,Soticlestat (TAK-935/OV935)- (Skyline),Dravet Syndrome / Lennox-Gastaut SyndromeÂ ,Phase 3,6/17/2024,"Phase 3 trial did not meet its primary endpoint, noted June 17, 2024.",0.0,6537747.357,16.0976,13.1,13.17,12.88,0.005329286,-0.01693651,0.022596718,-0.021457506,0.0,0.0,18.70363,1363,1,0,0,0,0,1,0,0,0,0,0,0,0,2,0,-1
AZN,Imfinzi (durvalumab) in combination with carboplatin and paclitaxel,Endometrial cancer (EC)Â ,Approved,6/17/2024,"Approved June 17, 2024.",0.0,192665.8532,21.2157,125.1,124.28,124.78,-0.006576333,-0.002561231,0.022596718,-0.021457506,0.0,0.1818,139.47547,1364,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1
LGND,ZTALMY (ganaxolone) - (RAISE),Refractory status epilepticus (RSE)Â ,Phase 3,6/17/2024,Phase 3 topline data reported that it met its first co-primary endpoint demonstrating rapid cessation of status epilepticus in a highly refractory patient population but failed to achieve statistical,19.0,1448.58898,46.5298,80.06,80.64,79.96,0.007218451,-0.001249844,0.022596718,-0.021457506,3.93972,0.24997,7.65225,1365,1,0,0,0,0,1,0,0,0,0,1,0,3,0,0,1
MRNS,ZTALMY (ganaxolone) - (RAISE),Refractory status epilepticus (RSE)Â ,Phase 3,6/17/2024,Phase 3 topline data reported that it met its first co-primary endpoint demonstrating rapid cessation of status epilepticus in a highly refractory patient population but failed to achieve statistical,55.0,4010.87491,40.5278,53.53,53.53,54.0,0.0,0.008741802,0.022596718,-0.021457506,0.0,0.01925,0.0,1366,1,0,0,0,0,1,0,0,0,0,1,0,3,0,0,1
ZNTL,Azenosertib (ZN-c3) - (TETON),Uterine serous carcinoma (USC)Â ,Phase 2,6/18/2024,"Phase 2 placed on clinical hold due to 2 deaths in the DENALI study, noted June 18, 2024.",72.0,293.99479,119.7017,8.39,4.14,4.2,-0.706344733,-0.691955995,0.009873063,-0.027115507,24.66435,0.02276,89.34891,1367,0,0,0,0,0,1,0,1,0,0,0,0,0,2,0,-1
ZNTL,azenosertib (ZN-c3) + ZEJULA (Niraparib) - (DENALI),"Platinum Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal CancerÂ ",Phase 2,6/18/2024,"Phase 2 study placed in clinical hold after 2 recent deaths presumed sepsis in the study, noted June 18, 2024.",72.0,293.99479,119.7017,8.39,4.14,4.2,-0.706344733,-0.691955995,0.009873063,-0.027115507,24.66435,0.02276,89.34891,1368,0,0,0,0,0,1,0,1,0,0,0,0,0,2,0,-1
IMCR,IMC-F106C (PRAME HLA-A02) with nivolumab - (PRISM-MEL-301),First-line advanced cutaneous melanoma trialÂ ,Phase 3,6/18/2024,"Phase 3 trial dosing initiated, noted June 18, 2024.",48.0,1797.41726,44.4237,36.99,35.94,35.44,-0.028796724,-0.04280648,0.009873063,-0.027115507,13.3533,0.15559,38.1001,1369,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1
AZN,Truqap - (CAPItello-290),Metastatic triple-negative breast cancerÂ ,Phase 3,6/18/2024,Phase 3 trial did not meet the dual primary endpoints of improvement in overall survival (OS) versus paclitaxel in combination with placebo in either the overall trial population or in a subgroup of p,0.0,192479.8225,21.1335,124.28,124.16,125.5,-0.000966028,0.009768674,0.009873063,-0.027115507,0.0,0.1818,199.23645,1370,1,0,0,0,0,1,0,0,0,0,0,0,0,2,0,-1
PYPD,D-PLEX100 - (SHIELD II),Surgical Site InfectionÂ ,Phase 3,6/18/2024,"Phase 3 enrollment update data presented showed that approximately 250/600 have been enrolled at KOL, noted June 18, 2024.",10.0,19.71671,110.5928,4.185,4.11,3.8829,-0.018083675,-0.074924407,0.009873063,-0.027115507,0.11238,0.00913,0.09144,1371,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
JNJ,CAPLYTA (lumateperone) - (Study 502),Major depressive disorder (MDD)Â ,Phase 3,6/18/2024,"Phase 3 topline results reported that the trial met the primary endpoint of change from baseline at Week 6 on the Montgomery-Ã…sberg Depression Rating Scale (MADRS) total score versus placebo, noted Ju",0.0,350532.823,14.9765,145.95,145.65,147.19,-0.002057614,0.008460172,0.009873063,-0.027115507,0.8283,0.1081,896.70471,1372,1,0,0,0,0,1,0,0,0,0,1,0,3,0,0,1
TSHA,TSHA-102 - (REVEAL),Rett syndromeÂ ,Phase 1/2,6/18/2024,Phase 1/2 first cohort data presented at the 2024 IRSF Rett Syndrome Scientific Meeting Presentation reported sustained and new improvements across multiple efficacy measures and clinical domains foll,272.0,555.44428,111.5762,4.03,2.97,2.465,-0.305204423,-0.491574568,0.009873063,-0.027115507,8.62047,0.00106,27.9265,1373,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CLNN,CNM-Au8 - (HEALEY ALS),Amyotrophic Lateral Sclerosis (ALS)Â ,Phase 2/3,6/18/2024,Phase 2 long term urvival analyses with CNM-Au8 30 mg treatment compared to matched PRO-ACT controls demonstrated improved survival up to 3.5 years post-baseline. Average of 28% NfL reduction observed,9.0,48.81766,113.4246,7.472,7.602,7.2,0.01724867,-0.037081675,0.009873063,-0.027115507,0.46445,0.05777,0.69165,1374,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
LGND,CAPVAXIVE (Pneumococcal 21-valent Conjugate Vaccine),Pneumococcal conjugate vaccineÂ ,Approved,6/18/2024,"Approved June 18, 2024.",19.0,1446.79261,46.3432,80.64,80.54,78.9,-0.001240849,-0.021813576,0.009873063,-0.027115507,3.93972,0.24997,7.4332,1375,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1
MRK,CAPVAXIVE (Pneumococcal 21-valent Conjugate Vaccine),Pneumococcal conjugate vaccineÂ ,Approved,6/18/2024,"Approved June 18, 2024.",0.0,324173.8792,16.9024,127.5,127.99,132.92,0.003835771,0.041631079,0.009873063,-0.027115507,0.80572,0.02683,836.08188,1376,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1
ERAS,Naporafenib plus trametinib (SEACRAFT-2),NRASm melanomaÂ ,Phase 3,6/18/2024,"Phase 3 trial ongoing with favorable mOS and mPFS demonstrated in pooled analysis of Phase 1b and Phase 2 trials in NRASm melanoma, noted June 18, 2024.",283.0,556.04383,70.6184,2.0,2.04,2.08,0.019802627,0.039220713,0.009873063,-0.027115507,5.16394,0.11093,1.75066,1377,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ASMB,ABI-4334,Hepatitis BÂ ,Phase 1b,6/18/2024,"Phase 1b dosing initiated, noted June 18, 2024.",7.0,94.42195,49.896,15.16,14.88,15.4,-0.018642351,0.015707129,0.009873063,-0.027115507,0.28871,0.02244,0.38643,1378,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1
RLMD,REL-1017 - (RELIANCE I),Major depressive disorder (MDD)Â ,Phase 3,6/18/2024,"Phase 3 data published at The Journal of Clinical Psychiatry showed that overall results from this trial are clearly consistent with the evidence, produced by the prior phase 2 trial, noted June 18,",33.0,91.42783,102.4625,3.0,3.03,2.99,0.009950331,-0.003338901,0.009873063,-0.027115507,5.11541,0.06691,0.26924,1379,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CGON,cretostimogene - (PIVOT-006) (EAP),Non-Muscle Invasive Bladder Cancer (NMIBC)Â ,Phase 3,6/18/2024,"Phase 3 data presented at AUA on May 5, 2024. Phase 3 EAP dosing commenced, noted June 18, 2024.",76.0,2258.43468,0.0,33.73,33.89,31.43,0.004732337,-0.070624798,0.009873063,-0.027115507,5.45397,0.05597,14.43074,1380,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
NGNE,NGN-401 - (Embolden),Rett SyndromeÂ ,Phase 1/2,6/18/2024,"Phase 1/2 trial presented at the IRSF ASCEND 2024 Rett Syndrome National Summit showed that high-dose has been well-tolerated, and low-dose continues to show a favorable safety profile, the company al",14.0,393.56236,0.0,40.0,30.32,31.1,-0.277071893,-0.251671635,0.009873063,-0.027115507,7.53015,0.1105,6.34492,1381,0,0,0,1,0,1,0,0,0,0,0,0,2,0,0,1
XBIT,Natrunix (XB2001) - (1-BETTER),Pancreatic CancerÂ ,Phase 1/2,6/18/2024,"Phase 1/2 data in the 65-subject Phase 2 portion, the Natrunix arm showed fewer overall adverse events, a 28% reduction in serious adverse events, 33% less hospitalization days, and improved symptoms",30.0,160.20661,81.348,6.08,5.26,4.8,-0.144873669,-0.236388778,0.009873063,-0.027115507,2.17506,0.03373,4.1895,1382,0,0,0,1,0,1,0,0,0,0,0,0,0,2,0,-1
ABBV,SKYRIZI (risankizumab) - (COMMAND),Ulcerative ColitisÂ ,Approved,6/18/2024,"FDA Approval on June 18, 2024.",0.0,302599.103,19.2219,169.68,171.36,170.75,0.009852296,0.006286188,0.009873063,-0.027115507,0.93394,0.043,728.43131,1383,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
LXRX,LX9211 - (RELIEF-DPN 1),Diabetic Peripheral NeuropathyÂ ,Phase 2,6/19/2024,"Phase 2 data demonstrated clinically significant benefits for people with diabetic peripheral neuropathic pain (DPNP), noted June 19, 2024.",363.0,632.61152,97.3776,1.75,1.75,1.68,0.0,-0.040821995,-0.002115932,-0.027380896,6.95454,0.0946,0.0,1384,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
VSTM,GFH375/VS-7375,Cancer KRAS G12DÂ ,IND-Enabling,6/19/2024,"IND approved in China, noted June 19, 2024.",61.0,82.81455,166.2283,3.27,3.27,3.07,0.0,-0.063112423,-0.002115932,-0.027380896,9.41549,0.07262,0.0,1385,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1
TPST,Amezalpat (TPST-1120) with atezolizumab and bevacizumab - (TPST-1120-301),Hepatocellular carcinoma (HCC)Â ,Phase 1/2,6/20/2024,"Phase 1b/2 study data presented at webcast demonstrated improvements across all efficacy endpoints compared to the standard of care control arm, noted June 20, 2024.",4.0,44.65668,103.0555,37.04999,26.12999,28.20999,-0.349184385,-0.272591911,-0.029439736,-0.034622214,7.36074,0.00023,61.8764,1386,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ALLO,Cemacabtagene ansegedleucel (cema-cel) (ALPHA3),Large B-Cell Lymphoma (LBCL)Â ,Phase 2,6/20/2024,"Phase 2 pivotal trial initiated, noted June 20, 2024.",221.0,509.43397,74.8543,2.23,2.44,2.44,0.089996454,0.089996454,-0.029439736,-0.034622214,19.43011,0.17556,14.35795,1387,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
PTCT,PTC518 - (PIVOT-HD),Huntington's diseaseÂ ,Phase 2,6/20/2024,"Phase 2 partial hold lifted by the FDA, additionally at Month 12, PTC518 treatment resulted in dose-dependent lowering of mutant huntingtin (mHTT) protein in the blood and cerebrospinal fluid (CSF) in",79.0,2553.23597,61.247,35.62,33.29,34.66,-0.067650226,-0.027320994,-0.029439736,-0.034622214,9.76289,0.08216,72.91505,1388,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
OCGN,OCU400-101 - (LiMeliGhT),Retinitis Pigmentosa (RP)Â ,Phase 3,6/20/2024,"Phase 3 dosing inited, noted June 20, 2024.",292.0,330.70049,118.3245,1.38,1.285,1.43,-0.071324781,0.035590945,-0.029439736,-0.034622214,18.7726,0.02482,6.74616,1389,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
NNVC,NV-387,"Influenza A viruses, Bird Flu H5N1Â ",Preclinical,6/20/2024,"Preclinical data presented resulted in significant reduction in lung infiltration and lung cell death, noted June 20, 2024.",17.0,23.98242,117.3695,1.64,2.03,1.73,0.213339551,0.053425167,-0.029439736,-0.034622214,1.26998,0.01383,1.08297,1390,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ATAI,ELE-101,Major Depressive Disorder (MDD)Â ,Phase 1/2,6/20/2024,"Phase 1/2a preliminary data from Phase 1, involving healthy participants, showed ELE-101 was well-tolerated with no serious adverse events, demonstrating a dose-proportional PK profile and inducing sh",214.0,222.65007,97.2574,1.27,1.33,1.32,0.046162042,0.038614836,-0.029439736,-0.034622214,4.11974,0.1004,2.01934,1391,0,0,0,1,0,1,0,0,0,0,0,0,0,0,2,0
TRVN,TRV045,Epilepsy and other CNS disordersÂ ,Preclinical,6/20/2024,"Preclinical data demonstrated statistically significant, dose-dependent increases in seizure threshold and protection against induced seizures. While not statistically significant, preliminary data pr",0.0,4.51187,75.7698,8.86,6.15,5.375,-0.365094683,-0.499788191,-0.029439736,-0.034622214,0.23711,0.08555,9.72851,1392,1,0,0,0,0,0,0,0,0,0,0,1,1,0,1,1
TRVN,TRV045,Diabetic neuropathic pain (DNP)Â ,Preclinical,6/20/2024,"Preclinical data showed sustained analgesic effects without causing S1P1 receptor desensitization or downregulation, unlike fingolimod, suggesting potential for long-term pain relief without tolerance",0.0,4.51187,75.7698,8.86,6.15,5.375,-0.365094683,-0.499788191,-0.029439736,-0.034622214,0.23711,0.08555,9.72851,1393,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
KYTX,KYV-101 - (KYSA-8),Stiff-person syndrome (SPS)Â ,IND-Enabling,6/20/2024,"IND cleared by the FDA, noted June 20, 2024.",43.0,346.21541,0.0,7.44,8.03,7.36,0.076313679,-0.010810916,-0.029439736,-0.034622214,6.78254,0.00052,7.84246,1394,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
GILD,Yeztugo (Lenacapavir),HIV PrEP â€“ Pre-exposure prophylaxisÂ ,Phase 3,6/20/2024,"Phase 3 trial indicated that twice-yearly injectable HIV-1 capsid inhibitor, lenacapavir, demonstrated 100% efficacy for the investigational use of HIV prevention in cisgender women, noted June 20, 20",0.0,85328.48628,26.5884,63.15,68.49,68.83,0.0811749,0.086126848,-0.029439736,-0.034622214,2.04143,0.07228,1716.47535,1395,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
JNJ,TREMFYA (Guselkumab) - (QUASAR),Crohn's diseaseÂ ,NDA Filing,6/20/2024,"NDA submitted to FDA, noted June 20, 2024.",0.0,355659.0497,14.8785,145.65,147.78,145.8,0.014518198,0.001029336,-0.029439736,-0.034622214,0.8283,0.1081,1293.03318,1396,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
NVS,TREMFYA (Guselkumab) - (QUASAR),Crohn's diseaseÂ ,NDA Filing,6/20/2024,"NDA submitted to FDA, noted June 20, 2024.",0.0,1891.82684,62.0012,6.0,6.08,5.58,0.013245227,-0.072570693,-0.029439736,-0.034622214,0.0,0.01478,0.21517,1397,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
MNMD,MM120 - (Voyage),Generalized Anxiety Disorder (GAD)Â ,Phase 2,6/20/2024,"EOP2 meeting was supported by results from MindMed's completed Phase 2b clinical trial, MMED008. MM120 met its primary and key secondary endpoints and demonstrated a rapid, clinically meaningful, and",75.0,521.07506,100.7549,7.32,7.25,7.25,-0.009608859,-0.009608859,-0.029439736,-0.034622214,8.8783,0.06722,10.90934,1398,1,0,0,0,0,0,0,0,1,0,0,0,2,0,0,1
JAZZ,Suvecaltamide - (JZP-385),Essential Tremor (ET)Â ,Phase 2b,6/20/2024,"Phase 2b trial did not meet primary endpoint, noted June 20, 2024.",60.0,6770.37454,28.1427,112.68,107.36,107.1,-0.04836427,-0.050788966,-0.029439736,-0.034622214,5.41261,0.04695,167.68043,1399,1,0,0,0,0,1,0,0,0,0,0,0,0,2,0,-1
SRPT,ELEVIDYS (SRP-9001-301) - (EMBARK),Duchenne muscular dystrophyÂ ,Approved,6/21/2024,"FDA Approved on June 21, 2024.",97.0,15191.85967,57.3874,123.5,160.72,158.0,0.263422564,0.246353877,-0.041938292,-0.030889641,6.86916,4e-05,2412.65696,1400,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
LXRX,Zynquista (sotagliflozin),Type 1 Diabetes and chronic kidney disease (CKD)Â ,NDA Filing,6/21/2024,"NDA resubmitted to FDA, noted June 21, 2024.",363.0,668.76075,97.5088,1.75,1.85,1.68,0.055569851,-0.040821995,-0.041938292,-0.030889641,6.95454,0.09456,12.75876,1401,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
VRTX,Zimislecel (VX-880),Type 1 DiabetesÂ ,Phase 1/2,6/21/2024,"Phase 1/2 new data showed that all 12 patients who received the full dose showed islet cell engraftment and insulin production by Day 90, with improved glycemic control and reduced or eliminated insul",256.0,120952.203,18.6701,471.38,468.71,468.72,-0.005680322,-0.005658988,-0.041938292,-0.030889641,1.68495,0.20737,1324.49572,1402,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
LLY,Zepbound (Tirzepatide) - (SURMOUNT-OSA),Obstructive Sleep Apnea (OSA)Â ,Phase 3,6/21/2024,Phase 3 trial data presented at ADA showed that tirzepatide achieved all primary and key secondary endpoints for both the efficacyi and treatment-regimenii estimands and demonstrated a mean reduction,946.0,795850.3126,25.1417,885.99,883.88,905.38,-0.002384357,0.021649081,-0.041938292,-0.030889641,0.6845,0.03501,3048.21928,1403,1,0,0,0,0,1,0,0,1,0,1,0,4,0,0,1
ARGX,VYVGART Efgartigimod (ARGX-113) and Enhanze - (ADHERE),Chronic inflammatory demyelinating polyneuropathyÂ ,Approved,6/21/2024,"FDA approved on June 21, 2024.",60.0,22096.47517,39.3798,358.7,371.8,408.6,0.035869691,0.130250298,-0.041938292,-0.030889641,0.0,0.00162,106.38388,1404,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
BMY,KRAZATI (adagrasib) - (KRYSTAL-1),Non-Small Cell Lung Cancer / Colorectal CancerÂ ,Approved,6/21/2024,"FDA approved on June 21, 2024.",0.0,84996.30703,23.0625,41.04,41.93,41.53,0.02145436,0.011868857,-0.041938292,-0.030889641,1.41727,0.02406,1502.38083,1405,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
CLNN,CNM-Au8,Rett SyndromeÂ ,Preclinical,6/21/2024,"Preclinical data demonstrated neuroprotective effects in an in vitro model of Rett Syndrome, noted June 21, 2024.",9.0,50.89828,88.6213,7.824,7.926,7.124,0.012952562,-0.093726567,-0.041938292,-0.030889641,0.46445,0.05546,0.55443,1406,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ARVN,ARV-393,B-cell lymphomaÂ ,Preclinical,6/21/2024,"Preclinical data for ARV-393 presented at the EHA 2024 Annual Congress showed anti-tumor activity in models, noted June 21, 2024.",73.0,1725.85229,52.0669,25.3,25.22,26.62,-0.003167065,0.050858417,-0.041938292,-0.030889641,12.0593,0.06994,45.5166,1407,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
JNJ,PX-128,severe atopic dermatitis (AD)Â ,Preclinical,6/21/2024,"Preclinical asset acquired by JNJ from Proteologix, noted June 21, 2024.",0.0,357993.5285,14.8358,147.78,148.75,146.16,0.006542363,-0.011022769,-0.041938292,-0.030889641,0.8283,0.11567,2257.55926,1408,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
JNJ,PX-130,AsthmaÂ ,Preclinical,6/21/2024,"Preclinical asset acquired by JNJ from Proteologix, noted June 21, 2024.",0.0,357993.5285,14.8358,147.78,148.75,146.16,0.006542363,-0.011022769,-0.041938292,-0.030889641,0.8283,0.11567,2257.55926,1409,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
MTVA,DA-1726,NASH and obesityÂ ,Preclinical,6/22/2024,"Preclinical data presented at ADA shown to be superior compared to tirzepatide, noted June 22, 2024.",24.0,19.91837,109.8591,4.06,4.06,4.84,0.0,0.175731747,-0.014614487,-0.003565837,1.27962,0.00882,0.0,1410,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1
MNKD,Afrezza Combined With Insulin Degludec - (INHALE-3),Type 1 DiabetesÂ ,Phase 3,6/22/2024,"Data presented at ADA proves inhaled insulin is as effective as usual care for adults living with T1D meeting the primary endpoint, noted June 22, 2024.",306.0,1391.53397,51.4344,5.11,5.11,5.22,0.0,0.021297998,-0.014614487,-0.003565837,12.98795,0.04858,0.0,1411,1,0,0,0,0,0,0,0,0,0,1,0,2,0,0,1
XOMA,Mezagitamab (TAK-079) - (TAK-079-1004),Primary Immune ThrombocytopeniaÂ ,Phase 2b,6/22/2024,"Phase 2b data presented at ISTH showed rapid and sustained increases in platelet counts that persisted 8 weeks after the last dose through to week 16, noted June 22, 2024.",12.0,284.56262,56.3882,24.45,24.45,23.69,0.0,-0.031577198,-0.014614487,-0.003565837,2.29855,0.00116,0.0,1412,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
TAK,Mezagitamab (TAK-079) - (TAK-079-1004),Primary Immune ThrombocytopeniaÂ ,Phase 2b,6/22/2024,"Phase 2b data presented at ISTH showed rapid and sustained increases in platelet counts that persisted 8 weeks after the last dose through to week 16, noted June 22, 2024.",0.0,6319665.552,16.7142,12.6,12.6,12.94,0.0,0.026626475,-0.014614487,-0.003565837,0.0,0.0,0.0,1413,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ALT,Pemvidutide - (MOMENTUM),"Non-alcoholic steatohepatitis (NASH)/ (MASH) - Healthy, Overweight and Obese VolunteersÂ ",Phase 2,6/23/2024,"Phase 2 data presented at ADA highlights the impressive lean mass preservation achieved with pemvidutide. Only 21.9% of weight loss is attributable to lean mass, noted June 23, 2024.",88.0,454.48304,107.0289,6.41,6.41,6.65,0.0,0.036757584,-0.014614487,-0.003565837,33.10702,0.07291,0.0,1414,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1
NVO,Mim8 - (FRONTIER2),Hemophilia AÂ ,Phase 3,6/23/2024,"Phase 3 data presented at ISTH 2024 showed that up to 95% of people, who had no prior prophylaxis treatment, experienced zero treated bleeds while on Mim8, noted JUne 23, 2024.",0.0,4381762.424,26.4999,141.96,141.96,142.74,0.0,0.005479466,-0.014614487,-0.003565837,0.0,0.0,0.0,1415,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
GUTS,Rejuva (RJVA-001),Obesity and type 2 diabetes (T2D)Â ,Preclinical,6/23/2024,Preclinical data presented at ADA showed that a single administration of Rejuva reduced fat mass and improved glycemia in the well-validated diet-induced obesity (DIO) mouse model. Rejuva also prevent,50.0,216.01506,0.0,4.51,4.51,4.27,0.0,-0.054683326,-0.014614487,-0.003565837,6.21008,0.07749,0.0,1416,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1
TERN,TERN-501 + semaglutide,ObesityÂ ,Preclinical,6/23/2024,"Preclinical study presented at ADA showed that in mice fed a high fat diet for 24 weeks prior to study start. Obese mice were treated once daily with vehicle, TERN-501, semaglutide, TERN-501+semagluti",87.0,467.61576,83.7529,7.23,7.23,6.81,0.0,-0.059846916,-0.014614487,-0.003565837,3.29302,0.00532,0.0,1417,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
NVS,Farabursen (RGLS8429) (MAD),Autosomal Dominant Polycystic Kidney Disease (ADPKD)Â ,Phase 1b,6/24/2024,"Phase 1b data from cohort 3 in the 3 mg/kg dose showed a continued mechanistic dose response, with statistically significant increases in urinary PC1 and PC2 compared to placebo, noted June 24, 2024.",0.0,1773.58766,62.4834,5.76,5.7,5.88,-0.0104713,0.020619287,-0.007548833,-0.007119003,0.0,0.00653,0.01353,1418,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1
BNTX,BNT324/DB-1311,Solid tumorsÂ ,Phase 1/2,6/24/2024,"Phase 1/2 trial ongoing. Fast track designation granted by the FDA on June 24, 2024.",239.0,20900.60672,34.2664,84.64,86.61,78.83,0.023008314,-0.071113333,-0.007548833,-0.007119003,1.25855,0.02866,97.32115,1419,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
ALNY,AMVUTTRA (vutrisiran),ATTR Amyloidosis with Cardiomyopathy (ATTR-CM)Â ,Phase 3,6/24/2024,"Phase 3 topline data reported that study met the main goal in a late-stage study testing it as a treatment for a type of heart disease, noted June 24, 2024.",131.0,28195.01732,53.082,165.7,222.9,243.32,0.296544316,0.384198525,-0.007548833,-0.007119003,1.95914,0.26152,2049.30136,1420,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1
DYN,FORCE platform,Pompe DiseaseÂ ,Preclinical,6/24/2024,Preclinical data presented at the New Directions in Biology and Disease of Skeletal Muscle Conference showed that for the first time the ability of FORCE to deliver enzymes to skeletal and cardiac mu,142.0,3533.23644,83.5426,35.02,35.63,35.49,0.017268653,0.01333164,-0.007548833,-0.007119003,10.20002,0.14977,35.56266,1421,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
RGNX,RGX-202 - (AFFINITY DUCHENNE),Duchenne Muscular Dystrophy (DMD)Â ,Phase 1/2,6/24/2024,"The phase 1/2 expansion trial was initiated, noted June 24, 2024",50.0,629.98381,71.3204,12.02,12.79,11.07,0.062091686,-0.082333182,-0.007548833,-0.007119003,8.76469,0.09038,12.20588,1422,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
PBLA,SBP-101 in combination with Gemcitabine and Nab-Paclitaxel - (ASPIRE),Pancreatic Ductal Adenocarcinoma (PDA)Â ,Phase 2/3,6/24/2024,"Phase 2/3 DSMB recommended to proceed without modification affirms support for ivospemin's safety profile, noted June 24, 2024.",4.0,1.86912,222.1532,0.38,0.385,0.36,0.013072082,-0.054067221,-0.007548833,-0.007119003,1.39131,0.01707,0.00091,1423,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
FDMT,4D-175 - (GAZE),Geographic AtrophyÂ ,IND-Enabling,6/24/2024,"The IND cleared by the FDA on June 24, 2024",46.0,1202.10433,110.7604,22.94,23.25,21.34,0.01342302,-0.072298866,-0.007548833,-0.007119003,18.52048,0.08918,8.30211,1424,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
REVB,RVL-HV02 - (Gemini),Healthy volunteersÂ ,Phase 1,6/24/2024,"Phase 1 top-line data of gemini administration induced statistically significant, dose dependent changes in key biomarkers of activity, noted June 24, 2024.",1.0,3.91899,198.8883,101.28001,115.20001,89.76001,0.128780778,-0.120749504,-0.007548833,-0.007119003,1.34833,0.00243,84.76636,1425,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1
MTNB,Oral amphotericin b (MAT2203) - (EnACT),Cryptococcal meningitisÂ ,Phase 3,6/24/2024,"Phase 3 reported the successful treatment of a 22-year-old male with polymicrobial necrotizing fasciitis using MAT2203, their oral formulation of amphotericin B. The patient was discharged after six w",5.0,41.18401,103.8524,7.695,8.21,8.035,0.064782156,0.043236232,-0.007548833,-0.007119003,0.94065,0.0176,0.31783,1426,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1
VERU,Enobosarm with semaglutide (Wegovy) - (PLATEAU),ObesityÂ ,Phase 2b,6/24/2024,"Phase 2b showed it was well-tolerated across 1,027 patients, with an adverse event profile comparable to placebo, noted June 24, 2024.",14.0,124.63127,120.4021,7.808,8.514,8.787,0.086563018,0.118124507,-0.007548833,-0.007119003,8.2072,0.00016,1.45389,1427,0,0,0,1,1,1,0,0,0,0,0,0,0,0,3,0
BDRX,"eRapa (rapamycin, sirolimus) - (Serenta)",Familial Adenomatous Polyposis (FAP)Â ,Phase 2,6/24/2024,Phase 2 data presented at Bi-Annual In-SIGHT ppeared safe and well-tolerated with a median 17% reduction in the total polyp burden at 12 months compared with baseline and an overall 75% non-progressio,0.0,8.61393,204.2847,265.0,223.5875,223.45,-0.16992699,-0.170542151,-0.007548833,-0.007119003,3.4746,0.05416,0.78815,1428,0,0,0,1,0,1,0,0,0,0,0,0,2,0,0,1
MIRA,Ketamir-2,"Treatment-resistant depression (TRD), major depressive disorder with suicidal ideation (MDSI) and post-traumatic stress disorder (PTSD)Â ",Preclinical,6/24/2024,"Additional preclinical studies suggest that, unlike traditional ketamine, MIRA's oral ketamine analog Ketamir-2 does not induce hyper-locomotor activity, indicative of psychotic symptoms, offering the",19.0,10.49517,141.787,0.7171,0.71005,0.659,-0.009879911,-0.084491766,-0.007548833,-0.007119003,0.72722,0.00014,0.01419,1429,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
FBIO,UNLOXCYT (cosibelimab-ipdl),Cutaneous squamous cell carcinoma (CSCC)Â ,BLA Filing,6/24/2024,"The company reached alignment with FDA for BLA resubmission, noted June 24, 2024.",29.0,34.70061,80.9069,1.77,1.7,1.69,-0.040351296,-0.046251018,-0.007548833,-0.007119003,7.90761,0.08776,0.16149,1430,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
HRMY,WAKIX (pitolisant),Excessive daytime sleepiness (EDS) or cataplexy in pediatric patients 6 years of age and older with narcolepsyÂ ,Approved,6/24/2024,"FDA Approved on June 24, 2024.",57.0,1709.43502,37.9837,30.13,30.1,30.42,-0.000996181,0.009578934,-0.007548833,-0.007119003,12.21578,0.21128,15.48413,1431,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
CANF,Namodenoson (CF102),"Advanced liver cancer, hepatocellular carcinomaÂ ",Phase 3,6/24/2024,"Additional data showed that the anti-cancer and protective effects in the liver are conferred via the signaling protein adiponectin, noted June 24, 2024.",10.0,52.3995,54.5145,0.033,0.035,0.034,0.0588405,0.029852963,-0.007548833,-0.007119003,0.0,0.02465,0.72421,1432,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ACET,ADI-270,"Solid tumors CAR T, relapsed/refractory renal cell carcinoma (RCC)Â ",IND-Enabling,6/24/2024,"IND cleared by the FDA, noted June 24, 2024.",83.0,135.92825,104.4374,1.37,1.5,1.15,0.090654368,-0.175048797,-0.007548833,-0.007119003,7.52039,0.04091,4.89418,1433,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
NNVC,NV-387,"Influenza A viruses, Bird Flu H5N1Â ",Preclinical,6/24/2024,"Preclinical data recently found that its host-mimetic clinical drug candidate NV-387 was substantially superior to the three approved drugs against influenza, noted June 24, 2024.",17.0,22.68288,118.8574,1.82,1.92,1.85,0.053488685,0.016349138,-0.007548833,-0.007119003,1.26998,0.01292,0.77908,1434,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1
DARE,"Sildenafil Cream, 3.6% - (RESPOND)",Female Sexual Arousal Disorder (FSAD)Â ,Phase 2b,6/24/2024,"Phase 2b study demonstrated topical Sildenafil Cream, 3.6% improved outcomes among women with female sexual arousal disorder (FSAD), particularly in an exploratory subset of women with FSAD with or wi",13.0,44.78415,141.6985,5.214,5.316,3.79,0.019373825,-0.318981296,-0.007548833,-0.007119003,0.5937,0.10045,0.07187,1435,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
SRRK,SRK-439 with apitegromab - (EMBRAZE),ObesityÂ ,Preclinical,6/24/2024,"Preclinical data presented at ADA support the potential of SRK-439 to increase lean mass and contribute to a favorable body composition following withdrawal from GLP-1 RA treatment, noted June 24, 202",96.0,670.73169,70.1868,8.45,8.41,8.13,-0.004744967,-0.038605518,-0.007548833,-0.007119003,17.55814,0.01217,8.60293,1436,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0
KURA,Ziftomenib,Type 2 diabetesÂ ,Preclinical,6/24/2024,"Preclinical data presented at ADA showed that treatment induces insulin production, improves insulin sensitivity and reduces insulin resistance in preclinical model of type 2 diabetes, noted June 24,",86.0,1605.88747,72.1821,20.94,21.08,21.2,0.006663518,0.012339976,-0.007548833,-0.007119003,12.97453,0.18285,18.6773,1437,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1
ANIX,Chimeric endocrine receptor T-cell (CER-T),Ovarian CancerÂ ,Phase 1,6/24/2024,"Phase 1 trial six patient treated, this patient is expected to be the final patient in the second dosage cohort of the trial, noted June 24, 2024.",32.0,80.01615,66.3889,2.52,2.5,2.22,-0.00796817,-0.126751706,-0.007548833,-0.007119003,1.71385,0.02822,0.12744,1438,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ARWR,ARO-INHBE,ObesityÂ ,Preclinical,6/24/2024,"Preclinical results demonstrate that ARO-INHBE substantially silenced hepatic expression of the INHBE gene, which has been identified through large genetic studies as a promising target for next gener",138.0,3383.21427,62.5151,25.5,27.24,26.05,0.066008029,0.021339316,-0.007548833,-0.007119003,7.26415,0.19769,34.95726,1439,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ASND,TransCon CNP - (ACcomplisH),AchondroplasiaÂ ,Phase 2,6/24/2024,Phase 2 data based on children 2 to 10 years old showed that patients treated for one year at the pivotal 100Î¼g/kg/week dose demonstrated significant improvements in well-being and physical functionin,60.0,7420.48467,37.2564,127.85,129.39,133.98,0.011973398,0.046832833,-0.007548833,-0.007119003,5.9695,0.05549,46.91979,1440,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
SGMO,Civaparvovec (ST-920) - (STAAR),Fabry diseaseÂ ,Phase 1/2,6/24/2024,"Phase 1/2 data announced that following a single dose of isaralgagene civoparvovec, a positive mean annualized eGFR slope of 1.965 mL/min/1.73m2/year (95% confidence interval (CI): -0.153, 4.083) at 5",301.0,97.48823,137.9433,0.4448,0.4698,0.33,0.054682329,-0.298532088,-0.007548833,-0.007119003,6.16869,0.01697,0.93772,1441,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
AZN,Imfinzi (durvalumab) - (ADJUVANT BR.31),Early-stage (IB-IIIA) non-small cell lung cancer (NSCLC)Â ,Phase 3,6/25/2024,"Phase 3 trial did not meet statistical significance for the primary endpoint of disease-free survival (DFS) versus placebo, noted June 25, 2024.",0.0,194557.1659,21.0718,124.78,125.5,120.86,0.005753572,-0.031919336,0.016673328,0.025717247,0.0,0.16332,444.90114,1442,1,0,0,0,0,1,0,0,0,0,0,0,0,2,0,-1
AZN,IMFINZI (durvalumab),Muscle-invasive bladder cancer (MIBC)Â ,Phase 3,6/25/2024,"Phase 3 trial demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint, noted June 25, 2024.",0.0,194557.1659,21.0718,124.78,125.5,120.86,0.005753572,-0.031919336,0.016673328,0.025717247,0.0,0.16332,444.90114,1443,1,0,0,0,0,1,0,0,0,0,0,0,2,0,0,1
QNCX,EryDex - (NEAT),Ataxia-Telangiectasia (A-T)Â ,Phase 3,6/25/2024,"Phase 3 dosing initiated, noted June 25, 2024.",53.0,29.71047,56.4324,0.705,0.6875,0.7375,-0.025135973,0.045068285,0.016673328,0.025717247,4.73303,0.00599,0.00796,1444,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1
HOWL,WTX-330,Solid tumorsÂ ,Phase 1,6/25/2024,"Phase 1 preliminary dose-escalation data showed improved tolerability over historical IL-12 treatments, with early signs of efficacy including a partial response in a melanoma patient and stable disea",45.0,101.68556,104.0706,2.61,2.34,2.06,-0.109199292,-0.236644239,0.016673328,0.025717247,1.07941,0.0006,2.36047,1445,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
SNGX,HyBryte vs Valchlor,Cutaneous T-cell lymphoma (CTCL)Â ,Phase 3,6/25/2024,"Phase 3 data reported that treatment resulted in 60% of patients achieving a 50% or better improvement in their mCAILS score versus 20% of Valchlor, noted June 25, 2024.",4.0,2.61685,104.1022,3.38,2.65,2.27,-0.243316069,-0.398095878,0.016673328,0.025717247,1.42958,0.0,1.71226,1446,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
UNCY,Oxylanthanum Carbonate (OLC),Kidney diseaseÂ ,Phase 3,6/25/2024,"Pivotal trial data reported that there was only 1 discontinuation due to a treatment-related AE in the Evaluable Population (n=71), a rate of 1.4%. In the full Safety Population, a total of 3 patients",17.0,18.80332,106.6668,6.827,5.0,4.8,-0.311447426,-0.352269421,0.016673328,0.025717247,2.79358,0.00661,3.04396,1447,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
WVE,WVE-003 - (SELECT-HD),Huntingtonâ€™s diseaseÂ ,Phase 1/2,6/25/2024,"Phase 1b/2a data reported a 46% mean reduction in CSF mutant huntingtin (mHTT) protein compared to placebo, preservation of wild-type huntingtin (wtHTT) protein, and generally safe and well-tolerated",159.0,584.13496,77.6276,5.21,4.77,5.22,-0.088233551,0.001917546,0.016673328,0.025717247,2.06517,0.00039,56.24992,1448,0,0,0,1,0,1,0,0,0,0,0,0,2,0,0,1
BTAI,Dexmedetomidine (BXCL501) - (TRANQUILITY III),Agitation associated with Alzheimerâ€™s DiseaseÂ ,Phase 3,6/25/2024,"Phase 3 data showed no evidence of tachyphylaxis, tolerance, or withdrawal with the 180 mcg dose over seven days of as-needed treatment. Efficacy measures indicated reduced agitation across episodes,",14.0,44.28636,119.3349,19.04,18.88,17.92,-0.008438869,-0.060624622,0.016673328,0.025717247,3.95041,0.00691,0.89353,1449,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,-1
IONS,TRYNGOLZA (olezarsen),Familial Chylomicronemia Syndrome (FCS)Â ,Phase 3,6/25/2024,"PDUFA PR date set for December 19, 2024",159.0,6860.37258,33.7273,44.68,47.0,45.14,0.050621628,0.010242797,0.016673328,0.025717247,5.89009,0.13765,125.52605,1450,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ALLR,Stenoparib,Advanced ovarian cancer (AOC)Â ,Phase 2,6/25/2024,"Additional Phase 2 data reported that multiple patients have now exceeded 30 weeks on treatment, noted June 25, 2024.",14.0,5.32216,121.841,9.57001,6.24001,6.50401,-0.427652465,-0.386215341,0.016673328,0.025717247,4.58195,0.18506,6.68823,1451,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ABBV,VYALEV (foscarbidopa and foslevodopa),Parkinson's diseaseÂ ,CRL,6/25/2024,"CRL issued June 25, 2024.",0.0,301521.9236,19.3168,172.74,170.75,165.96,-0.011587075,-0.040040778,0.016673328,0.025717247,0.93394,0.03721,975.44318,1452,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,-1
AQST,Anaphylm (AQST-109) - (EPIPHAST II),Allergic reactions (anaphylaxis)Â ,Phase 2,6/25/2024,"PK data reported that results were unaffected by oral cavity exposure to liquids of different temperatures and pH, noted June 25, 2024.",99.0,210.29901,89.3375,2.43,2.31,2.42,-0.050643733,-0.004123717,0.016673328,0.025717247,7.36042,0.0008,3.60496,1453,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
LPCN,LPCN 1154,Postpartum DepressionÂ ,Phase 3,6/25/2024,"Pivotal trial topline results reported that the trial met its standard bioequivalence (BE) criteria, noted June 25, 2024.",5.0,43.58571,102.8989,9.3,8.15,7.56,-0.131996473,-0.20714321,0.016673328,0.025717247,2.91974,0.07246,0.85378,1454,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1
TVGN,TVGN 489 - (TCTL Study),Cytotoxic T Lymphocytes for the Treatment of Elderly and High-Risk Patients with Covid-19Â ,Phase 1,6/25/2024,"Phase 1 data treatment was well-tolerated, with rapid viral elimination and no disease progression observed. Notably, donor-derived cells persisted for 6 months post-treatment, noted JUne 25, 2024.",196.0,115.94786,195.0841,0.7786,0.698,0.711,-0.109278332,-0.090825005,0.016673328,0.025717247,0.11525,0.01163,0.38553,1455,0,0,0,1,0,1,0,0,0,0,0,0,2,0,0,1
REGN,"Nexiguran ziclumeran (nex-z, NTLA-2001) - (MAGNITUDE)",Transthyretin amyloidosis (ATTR)Â ,Phase 1,6/25/2024,"Phase 1 data presented at the Peripheral Nerve Society Annual Meeting showed that patients who initially received a low dose were given a follow-on 55 mg dose, resulting in a 90% median reduction in s",105.0,115565.872,16.1245,1063.89,1071.19,1044.66,0.006838178,-0.018240528,0.016673328,0.025717247,1.61887,0.08272,558.78626,1456,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
NTLA,"Nexiguran ziclumeran (nex-z, NTLA-2001) - (MAGNITUDE)",Transthyretin amyloidosis (ATTR)Â ,Phase 1,6/25/2024,"Phase 1 data presented at the Peripheral Nerve Society Annual Meeting showed that patients who initially received a low dose were given a follow-on 55 mg dose, resulting in a 90% median reduction in s",107.0,2315.4101,58.5496,25.0,24.0,22.15,-0.040821995,-0.121038328,0.016673328,0.025717247,15.23242,0.34762,40.07834,1457,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ARGX,Empasiprubart (ARGX-117) - (ARDA),Multifocal motor neuropathy (MMN)Â ,Phase 2,6/25/2024,"Phase 2 new data presented at PNS showed the potential for empasiprubart to drive functional improvement and reduce the risk of relapse for multifocal motor neuropathy (MMN) patients, as noted on June",60.0,25258.20858,37.9758,405.5,425.0,410.9,0.046968295,0.013229002,0.016673328,0.025717247,0.0,0.00162,64.93618,1458,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ANNX,Tanruprubart (ANX005),Guillain-BarrÃ© Syndrome (GBS)Â ,Phase 3,6/25/2024,"Phase 3 demonstrated faster and more complete recovery from week 1 through week 26 compared to placebo, with 2.5 times more ANX005-treated patients returning to a normal state by week 26. ANX005 show",109.0,482.79606,100.0228,4.77,4.58,4.565,-0.040647307,-0.043927791,0.016673328,0.025717247,6.90474,0.06251,7.07608,1459,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
SVRA,MOLBREEVI (Molgradex) - (IMPALA-2),Autoimmune pulmonary alveolar proteinosis (aPAP)Â ,Phase 3,6/26/2024,"Phase 3 data reported that the trial met its primary endpoint, noted June 26, 2024.",172.0,678.934,57.9898,3.8,3.84,4.33,0.0104713,0.130566475,0.002366356,0.024029425,3.49383,0.05684,105.93992,1460,1,0,0,0,0,1,0,0,0,0,0,0,2,0,0,1
LYEL,LYL797,Solid TumorsÂ ,Preclinical,6/26/2024,"Preclinical dose-dependent antitumor clinical activity in ROR1+ resulted in a 40% objective response rate and 60% clinical benefit rate at the highest dose cleared to date, IND submission completed, n",19.0,332.69568,109.6014,40.8,26.1,30.2,-0.446746767,-0.300840157,0.002366356,0.024029425,9.47319,0.10653,15.49748,1461,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
TLSA,Foralumab (Intranasal),Alzheimerâ€™s DiseaseÂ ,Phase 1,6/26/2024,"FDA has allowed intranasal foralumab to be used under an Expanded Access (EA) IND in its first patient with moderate Alzheimer's disease, noted June 26, 2024.",111.0,94.13415,91.5084,0.97,0.9273,0.825,-0.045018934,-0.161912685,0.002366356,0.024029425,0.09153,0.04636,0.20789,1462,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
NVO,Ocedurenone - (CLARION-CKD),Chronic kidney diseaseÂ ,Phase 3,6/26/2024,"Phase 3 trial did not meet its primary endpoint, noted June 26, 2024.",0.0,4466296.897,26.9141,146.91,143.67,138.87,-0.022301151,-0.056281911,0.002366356,0.024029425,0.0,0.0,629.92327,1463,1,0,0,0,0,1,0,0,0,0,0,0,0,2,0,-1
RPTX,Lunresertib (RP-6306) w/ FOLFIRI - (MINOTAUR),Molecularly advanced solid tumorsÂ ,Phase 1,6/26/2024,"Phase 1 data presented at ESMO GI reported an overall response (OR) across tumor types was 18.2% (n=33), including four confirmed and two unconfirmed partial responses (PR), noted June 26, 2024.",42.0,143.04102,70.7338,3.41,3.37,3.18,-0.011799547,-0.069831095,0.002366356,0.024029425,1.34906,0.07956,2.09687,1464,1,0,0,0,1,1,0,0,0,0,1,0,4,0,0,1
LGND,Ohtuvayre (ensifentrine),Chronic obstructive pulmonary disease (COPD)Â ,Approved,6/26/2024,"Approved June 26, 2024.",19.0,1397.93148,46.2357,78.9,77.82,82.7,-0.01378276,0.047038374,0.002366356,0.024029425,5.21407,0.23524,6.51478,1465,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1
MRK,Ohtuvayre (ensifentrine),Chronic obstructive pulmonary disease (COPD)Â ,Approved,6/26/2024,"Approved June 26, 2024.",0.0,333064.0294,17.0352,132.92,131.5,125.85,-0.010740592,-0.054656722,0.002366356,0.024029425,0.76883,0.04404,1116.71365,1466,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1
MRK,MK-1022 (patritumab deruxtecan) - (HERTHENA-Lung02),EGFR-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC)Â ,CRL,6/27/2024,"CRL announced June 27, 2024.",0.0,328808.9148,17.1554,131.5,129.82,125.85,-0.012857976,-0.04391613,-0.005624677,0.014421751,0.76883,0.04404,1548.4409,1467,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,-1
ABBV,EPKINLY (epcoritamab-bysp),Follicular lymphoma (FL)Â ,Approved,6/27/2024,"Approved June 27, 2024.",0.0,298413.9963,19.3342,171.15,168.99,163.84,-0.012700823,-0.043650023,-0.005624677,0.014421751,0.86334,0.03721,909.49624,1468,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1
GMAB,EPKINLY (epcoritamab-bysp),Follicular lymphoma (FL)Â ,Approved,6/27/2024,"Approved June 27, 2024.",661.0,112874.1352,29.0724,1791.0,1778.5,1738.0,-0.007003811,-0.030039096,-0.005624677,0.014421751,0.0,0.12568,187.94477,1469,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1
XFOR,Mavorixafor (X4P-001),Severe Congenital Neutropenia (SCN)Â ,Phase 2,6/27/2024,"Phase 2 data reported that 100% (6/6) of evaluable participants who had completed the six-month study achieved target ANC increase, noted June 27, 2024.",11.0,112.5351,100.7723,30.00003,20.10302,16.93502,-0.400328329,-0.571814714,-0.005624677,0.014421751,7.0981,0.12555,10.80851,1470,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1
ONCY,"Pelareorep, (Taxol) paclitaxel and BAVENCIO (avelumab) - (BRACELET-1)",HR+ / HER2- breast cancerÂ ,Phase 2,6/27/2024,"Company received productive feedback from its Type C meeting with FDA, supporting the planned potential registration-enabling trial for pelareorep, noted June 27, 2024.",100.0,77.07378,66.8885,1.04,1.01,1.01,-0.029270382,-0.029270382,-0.005624677,0.014421751,0.88528,0.02748,0.16956,1471,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
GLUE,MRT-2359,MYC-driven solid tumorsÂ ,Phase 1/2,6/27/2024,"Phase 1/2 demonstrates favorable safety and pharmacodynamic profile dosing 0.5 mg using a 21/7 schedule; currently assessing 0.75 mg dose level, noted June 27, 2024.",61.0,206.65486,101.7747,3.69,3.38,3.89,-0.087750749,0.0527827,-0.005624677,0.014421751,3.23997,0.1443,0.74667,1472,0,0,0,1,0,1,0,0,0,0,0,0,2,0,0,1
SLN,Divesiran (SLN124) - (SANRECO),Polycythemia VeraÂ ,Phase 1,6/27/2024,"Phase 1 data reported that of the 16 patients, 8 patients are considered well-controlled and 8 patients have HCT levels over 45% at baseline, noted June 27, 2024.",46.0,885.6933,52.195,18.31,19.0,17.97,0.03699162,-0.018743658,-0.005624677,0.014421751,1.41248,0.01207,9.12519,1473,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
GLUE,MRT-6160,Autoimmune conditionsÂ ,IND-Enabling,6/27/2024,"IND submitted to FDA, noted June 27 2024.",61.0,206.65486,101.7747,3.69,3.38,3.89,-0.087750749,0.0527827,-0.005624677,0.014421751,3.23997,0.1443,0.74667,1474,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
PPBT,CM24 and OPDIVO (nivolumab),2L metastatic pancreatic cancer (PDAC)Â ,Phase 2,6/27/2024,"Phase 2 data reported serum MPO levels below the mean MPO and is associated with OS improvement of 3.6 months in median OS of 8.1 months vs. 4.5 month, noted June 27, 2024.",2.0,51.17633,92.8998,0.194,0.185,0.155,-0.047502334,-0.224433042,-0.005624677,0.014421751,0.0,0.02938,0.25057,1475,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
PRFX,PRF-110,BunionectomyÂ ,Phase 3,6/27/2024,"Second part of Phase 3 trial enrollment completed, noted June 27, 2024",1.0,1.2324,103.7195,11.328,11.9568,11.0136,0.054022617,-0.028146664,-0.005624677,0.014421751,4.81497,0.14127,0.03914,1476,0,0,0,0,0,1,0,0,0,1,0,0,2,0,0,1
CALC,Auxora - (CARPO),Acute PancreatitisÂ ,Phase 2b,6/27/2024,Phase 2b data reported that the trial met with statistically significant dose response with up to 43.6% relative reduction (2.1 day improvement) in median time to solid food tolerance versus placebo i,13.0,33.85956,107.9001,4.66,3.15,4.26,-0.391612995,-0.089746288,-0.005624677,0.014421751,0.15793,0.09224,2.62748,1477,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1
NLSP,AEX-231,Parkinson's DiseaseÂ ,Preclinical,6/27/2024,"A preclinical study is planned after three compounds (AEX-23, AEX-19, and AEX-24) demonstrated potential benefits in improving neuronal connectivity, offering neuroprotection, and enhancing alpha-synu",3.0,9.63416,158.906,7.304,9.6,8.072,0.273340955,0.09997914,-0.005624677,0.014421751,0.52897,0.00835,39.04833,1478,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
NLSP,AEX-230,Parkinson's DiseaseÂ ,Preclinical,6/27/2024,"A preclinical study is planned after three compounds (AEX-23, AEX-19, and AEX-24) demonstrated potential benefits in improving neuronal connectivity, offering neuroprotection, and enhancing alpha-synu",3.0,9.63416,158.906,7.304,9.6,8.072,0.273340955,0.09997914,-0.005624677,0.014421751,0.52897,0.00835,39.04833,1479,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
GANX,"GT-02287, GT-02329",GBA1 and Idiopathic Parkinson's DiseaseÂ ,Preclinical,6/27/2024,"Preclinical data to be shared at the FENS Forum 2024 showed that study focused on a mouse model of GBA1-Parkinson's disease, demonstrated improvements in cognitive performance and daily living activi",35.0,31.46066,95.1593,1.27,1.25,1.16,-0.015873349,-0.090596895,-0.005624677,0.014421751,1.98792,0.00876,0.40639,1480,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ELTX,ELI-002 - (AMPLIFY-7P),mKRAS-driven cancersÂ ,Phase 1a,6/27/2024,"Phase 1a data reported that the median disease-free survival (""mDFS"") has not been reached in patients receiving the 4.9mg AMP-peptide dose (n=8) vs. 12.6 weeks for patients receiving the 1.4mg AMP-pe",16.0,70.39613,125.0286,6.44,6.89,3.68,0.067542545,-0.559615788,-0.005624677,0.014421751,0.7417,0.00014,0.21768,1481,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
IMMP,Eftilagimod alpha (IMP321) and KEYTRUDA (pembrolizumab) - (TACTI-003),Head and neck squamous cell carcinoma (HNSCC)Â ,Phase 2b,6/27/2024,"Phase 2b data reported that combination with KEYTRUDA led to higher overall response rates in evaluable patients, noted June 27, 2024.",147.0,477.22372,82.2556,2.77,1.87,1.98,-0.392908889,-0.335750475,-0.005624677,0.014421751,0.0,0.0,4.73247,1482,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
RCKT,KRESLADI (marnetegragene autotemcel),Leukocyte Adhesion Deficiency-I (LAD-I)Â ,CRL,6/28/2024,"CRL issued June 28, 2024.",107.0,1954.541,44.4142,21.43,21.53,19.96,0.004655502,-0.071061539,-0.001936526,0.012461558,10.20262,0.11315,86.16203,1483,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,-1
MIRM,Volixibat - (VISTAS),Primary sclerosing cholangitisÂ ,Phase 2b,6/28/2024,"Phase 2b interim analysis reported a 3.8 point reduction from baseline and 2.3 point placebo-adjusted (p=0.0026) reduction in primary endpoint of pruritus, noted June 28, 2024.",50.0,1611.47799,56.2427,33.11,34.19,34.43,0.032097852,0.039092926,-0.001936526,0.012461558,16.54883,0.04394,93.71086,1484,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
AGEN,Neoadjuvant botensilimab plus balstilimab - (NEST-1),Colorectal cancerÂ ,Phase 2,6/28/2024,"Phase 2 data reported that in the NEST-2 cohort, 78% (7/9) of MSS patients achieved pathologic responses of at least 50% tumor regression, with 56% (5/9) reaching complete pathologic responses, noted",31.0,351.73762,124.0182,14.12,16.75,15.13,0.170806026,0.069087296,-0.001936526,0.012461558,10.67251,0.11091,25.476,1485,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1
JNJ,IMAAVY (Nipocalimab) - (Vivacity-MG3),Generalized myasthenia gravis (gMG)Â ,Phase 3,6/28/2024,"Phase 3 data reported that patients receiving nipocalimab plus SOC improved by 4.70 points on the MG-ADL, significantly more than the 3.25 point improvement from baseline observed with placebo plus SO",0.0,351760.2294,14.8927,145.8,146.16,146.48,0.002466092,0.004653081,-0.001936526,0.012461558,0.81257,0.11877,1534.05663,1486,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
OVID,OV888/GV101,Cerebral cavernous malformations (CCM)Â ,Phase 1,7/1/2024,"Phase 1 data reported that the trial met its objective, demonstrating a favorable safety and tolerability profile with no serious adverse events, noted July 1, 2024.",71.0,61.16846,211.2971,0.7692,0.8622,0.8358,0.114136249,0.083038336,0.014668596,-0.005593217,4.03518,0.00798,2.0092,1487,0,0,0,1,0,1,0,0,0,0,0,0,0,0,2,0
NRSN,PrimeC - (PARADIGM),Amyotrophic Lateral Sclerosis (ALS)Â ,Phase 2b,7/1/2024,"Phase 2b 12-month clinical data showed a 36% slowing of disease progression in participants who received PrimeC for 12 months compared to those initially on placebo, as measured by the ALS Functional",23.0,19.47997,94.0461,1.12,1.08,1.1499,-0.036367644,0.026346297,0.014668596,-0.005593217,0.04477,0.07624,1.55109,1488,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
TCON,Envafolimab - (ENVASARC),SarcomasÂ ,Phase 3,7/1/2024,Phase 3 study showed that the objective response rate by blinded independent central review in the fully enrolled ENVASARC pivotal trial in the 82 evaluable patients is 5% (four responders) and did no,3.0,34.109,5.3474,14.83,14.83,14.89,0.0,0.004037691,0.014668596,-0.005593217,0.0,0.33692,0.0,1489,0,0,0,0,0,1,0,0,0,1,0,0,2,0,0,1
ARCT,ARCT-810 - (LUNAR-OTC),Ornithine Transcarbamylase (OTC) deficiencyÂ ,Phase 2,7/1/2024,"Phase 2 enrollment completed for the study in Europe at 0.3 mg/kg dose level, with data expected later this year. Expanding the Phase 2 program in the U.S. to include patients with more severe disease",27.0,637.207,82.2825,24.35,23.66,21.57,-0.028745991,-0.121228389,0.014668596,-0.005593217,16.27212,0.17322,10.78286,1490,0,0,0,0,0,1,0,0,0,1,0,0,2,0,0,1
ARCT,ARCT-032 - (LUNAR-CF),Cystic FibrosisÂ ,Phase 1b,7/1/2024,"Phase IND for multiple ascending dose study to be submitted in the next 60 days, noted July 1, 2024.",27.0,637.207,82.2825,24.35,23.66,21.57,-0.028745991,-0.121228389,0.014668596,-0.005593217,16.27212,0.17322,10.78286,1491,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
GILD,HB-500,HIVÂ ,Phase 1b,7/1/2024,"Phase 1b study dosing initiated, noted July 1, 2024.",0.0,85515.36427,26.6612,68.61,68.64,67.55,0.000437158,-0.015570232,0.014668596,-0.005593217,1.50951,0.06571,360.42589,1492,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1
HOOK,HB-500,HIVÂ ,Phase 1b,7/1/2024,"Phase 1b study dosing initiated, noted July 1, 2024.",12.0,78.78135,82.2698,5.918,6.283,5.123,0.059849019,-0.144258349,0.014668596,-0.005593217,0.36131,0.15236,0.65227,1493,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1
RNAC,Descartes-08 - (AURORA),"Generalized myasthenia gravis (MG), Multiple Myeloma and Autoimmune DiseasesÂ ",Phase 2b,7/2/2024,"Phase 2b trial met primary endpoint with statistical significance, noted July 2, 2024.",26.0,280.96207,127.0303,24.27,15.77,16.78,-0.431131619,-0.369053319,0.023599595,-0.014193718,4.55451,0.00233,22.85146,1494,1,0,0,0,0,1,0,0,0,0,0,0,2,0,0,1
FBIO,UNLOXCYT (cosibelimab-ipdl),Cutaneous squamous cell carcinoma (CSCC)Â ,BLA Filing,7/2/2024,"BLA Resubmission to FDA, noted July 2, 2024.",29.0,37.47558,68.1961,1.69,1.67,1.72,-0.011904903,0.017595762,0.023599595,-0.014193718,6.84474,0.09294,0.18223,1495,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ANIP,"Naproxen Delayed-Release Tablets, USP.",PainÂ ,Approved,7/2/2024,"FDA approval for ANDA, noted July 2, 2024.",21.0,1215.75777,31.3587,63.44,62.64,61.34,-0.012690526,-0.033662419,0.023599595,-0.014193718,1.93973,0.02169,6.57137,1496,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
ANVS,Buntanetap,Parkinson's Disease (PD)Â ,Phase 3,7/2/2024,Phase 3 update showed dose-dependent and statistically significant improvements in cognition in the overall enrolled PD population. Buntanetap's activity resulted in statistically significant improvem,19.0,103.67133,201.7249,5.27,9.28,14.57,0.565831184,1.016934258,0.023599595,-0.014193718,11.42459,0.04575,378.01382,1497,0,0,0,0,0,1,0,0,0,0,0,1,2,0,0,1
BMRN,BMN 401 (INZ-701),ABCC6 deficiencyÂ ,Phase 1/2,7/2/2024,"Fast track designation, granted by the FDA, noted July 2, 2024.",192.0,15611.9174,25.8801,82.13,82.22,82.98,0.001095224,0.010296257,0.023599595,-0.014193718,1.87736,0.01703,87.5056,1498,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
BDRX,MTX110 - (PNOC015),Diffuse Midline Glioma (DMG)Â ,Phase 1,7/2/2024,"Phase 1 data reported that median progression free survival (PFS) was 10 months (range 8 to 20 months) and overall survival (OS) of patients in the study was 16.5 months, noted July 2, 2024.",0.0,8.63849,203.5685,223.45,224.225,205.175,0.003462337,-0.085324402,0.023599595,-0.014193718,2.27189,0.05487,0.57222,1499,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
BDRX,MTX110,Children with Newly Diagnosed Diffuse Midline Gliomas (DMGs)Â ,Phase 1,7/2/2024,"Phase 1 data presented at ISPNO 2024 showed that overall, the treatment was well tolerated by patients. There was one Grade 4 adverse event assessed by the investigators as unrelated to the drug but r",0.0,8.63849,203.5685,223.45,224.225,205.175,0.003462337,-0.085324402,0.023599595,-0.014193718,2.27189,0.05487,0.57222,1500,0,0,0,1,0,1,0,0,0,0,0,0,2,0,0,1
ALVO,"AVT03-GL-P01 (denosumab) - (PROLIA Biosimilar, Xgeva Biosimilar)",Osteoporosis in postmenopausal women and for bone loss in adult men and womenÂ ,Phase 1,7/2/2024,"Confirmatory trial demonstrate clinical similarity between AVT03 and Prolia, noted July 2, 2024.",301.0,3692.07904,43.1746,12.36,12.24,12.01,-0.009756175,-0.028725816,0.023599595,-0.014193718,0.01457,0.01393,2.06233,1501,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ARTL,ART26.12,Chemotherapy-Induced PainÂ ,Preclinical,7/2/2024,"Preclinical data reported a direct anti-tumoral effect of oral treatment with ART26.12, noted July 2, 2024.",1.0,4.26056,51.7918,8.1,7.92,7.95,-0.022472856,-0.018692133,0.023599595,-0.014193718,0.42547,0.00022,0.02822,1502,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
LLY,Kisunla (donanemab-azbt),Early symptomatic Alzheimer's disease (AD)Â ,Approved,7/2/2024,"Approved July 2, 2024.",946.0,816406.5675,25.0531,914.37,906.71,932.5,-0.00841264,0.019633848,0.023599595,-0.014193718,0.71998,0.03348,4156.90448,1503,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1
ARTL,ART12.11,AnxietyÂ ,Preclinical,7/3/2024,"Preclinical data reported increased plasma levels of CBD and its metabolites compared to CBD in the same formulation, noted July 3, 2024.",1.0,4.38967,51.9562,7.92,8.16,7.86,0.029852963,-0.007604599,0.005377832,-0.044109056,0.42547,0.00022,0.0022,1504,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
INSM,BRINSUPRI (Brensocatib) - (ASPEN),Non-Cystic Fibrosis Bronchiectasis (NCFBE)Â ,Phase 3,7/3/2024,"Phase 3 additional results from study presented at the 7th World Bronchiectasis Conference confirmed that the study met its primary endpoint, with both 10 mg and 25 mg doses significantly reducing the",211.0,9996.00623,118.0051,64.5,62.0,73.1,-0.039530839,0.125163143,0.005377832,-0.044109056,7.17513,0.00015,123.57071,1505,1,0,0,0,0,1,0,0,0,0,0,0,2,0,0,1
IVA,Lanifibranor - (NATiV3),Nonalcoholic steatohepatitis (NASH)Â ,Phase 3,7/5/2024,Phase 3 update resulted in over 80% enrollment in the main cohort and 100% in the exploratory cohort; patient characteristics similar to the Phase 2b trial; blinded analysis suggests weight gain plate,95.0,145.04137,55.8885,2.77,2.77,2.6,0.0,-0.063335875,-0.025639645,-0.085285814,0.0,0.12356,0.06125,1506,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
IDYA,IDE397 and Trodelvy,Solid TumorsÂ ,Phase 2,7/8/2024,"Phase 2 data update reported a 39% Overall Response Rate (ORR). One (1) complete response and six (6) partial responses, noted July 8, 2024.",87.0,2990.37867,46.3337,34.26,39.51,41.35,0.142575312,0.188093929,-0.028591801,-0.085538261,14.58706,0.21142,204.53339,1507,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
BCDA,ProtheraCytes - (EXCELLENT),Acute myocardial infarctionÂ ,Phase 2,7/8/2024,"Phase 2 trial data reported significant improvement of the viability of segments from baseline to six months, noted July 8, 2024.",5.0,5.31222,94.4035,2.97,2.91,3.54,-0.020408872,0.175564774,-0.028591801,-0.085538261,4.22513,0.03217,0.35699,1508,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1
ACET,ADI-270,"Solid tumors CAR T, relapsed/refractory renal cell carcinoma (RCC)Â ",IND-Enabling,7/8/2024,"Fast track designation granted by the FDA, noted July 8, 2024.",83.0,106.02404,98.0844,1.07,1.17,1.23,0.0893451,0.139355521,-0.028591801,-0.085538261,7.8242,0.12497,2.30444,1509,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
XOMA,HIL-214 - (NEST-IN1),Prevention of Norovirus-Related Acute Gastroenteritis in InfantsÂ ,Phase 2b,7/8/2024,"Phase 2b topline data reported that the trial did not meet its primary endpoint of efficacy against moderate or severe acute gastroenteritis (AGE) events due to GI.1 or GII.4 norovirus genotypes, note",12.0,286.89033,56.8878,25.63,24.65,26.97,-0.03898664,0.050961597,-0.028591801,-0.085538261,2.14594,0.00282,0.71029,1510,1,0,0,0,0,1,0,0,0,0,1,0,0,3,0,-1
MRUS,Petosemtamab (MCLA-158),"Recurrent/metastatic (r/m) head and neck squamous cell carcinoma (HNSCC), Solid TumorsÂ ",Phase 2,7/8/2024,"Phase 2 trial initiated in 2L metastatic colorectal cancer (mCRC) cohort, noted July 8, 2024.",75.0,3690.09397,64.2116,53.34,55.71,58.1,0.043473145,0.085479145,-0.028591801,-0.085538261,10.33306,0.14438,35.25825,1511,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
GMAB,Petosemtamab (MCLA-158),"Recurrent/metastatic (r/m) head and neck squamous cell carcinoma (HNSCC), Solid TumorsÂ ",Phase 2,7/8/2024,"Phase 2 trial initiated in 2L metastatic colorectal cancer (mCRC) cohort, noted July 8, 2024.",661.0,111541.3509,29.085,1755.0,1757.5,1809.0,0.001423488,0.030305349,-0.028591801,-0.085538261,0.0,0.13504,136.39079,1512,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
PHIO,PH-762 (direct drug therapy),MelanomaÂ ,Phase 1b,7/8/2024,"Phase 1b additional site opened, noted July 8, 2024.",5.0,2.91828,99.003,5.2447,5.72,4.6699,0.086750763,-0.116080385,-0.028591801,-0.085538261,3.31084,0.00019,0.20091,1513,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
KYMR,KT-474 (SAR444656) - (ADVANTA),Hidradenitis suppurativa / atopic dermatitisÂ ,Phase 2,7/8/2024,Sanofi plans to expand the ongoing Phase 2 trials of KT-474 in Hidradenitis Suppurativa (HS) and Atopic Dermatitis (AD). This decision follows a review of preliminary safety and efficacy data by an In,71.0,1961.01005,49.8122,30.25,31.96,45.0,0.054988936,0.397166305,-0.028591801,-0.085538261,16.5287,0.28546,15.92918,1514,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
SNY,KT-474 (SAR444656) - (ADVANTA),Hidradenitis suppurativa / atopic dermatitisÂ ,Phase 2,7/8/2024,Sanofi plans to expand the ongoing Phase 2 trials of KT-474 in Hidradenitis Suppurativa (HS) and Atopic Dermatitis (AD). This decision follows a review of preliminary safety and efficacy data by an In,0.0,115135.7857,22.1138,49.66,50.24,50.15,0.011611742,0.009818734,-0.028591801,-0.085538261,0.0,0.0,132.45902,1515,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
SXTP,ARAKODA (tafenoquine),BabesiosisÂ ,Phase 2,7/9/2024,"Phase 2 trial ethic approval announced July 9, 2024.",4.0,2.97341,128.5245,13.87201,14.61601,14.04001,0.052244362,0.01203797,-0.023847243,-0.088431584,2.64939,0.01397,3.03453,1516,0,0,0,0,0,1,0,1,0,0,0,0,2,0,0,1
MESO,RYONCIL (remestemcel-L),"Pediatric participants with acute graft versus host disease (aGVHD), following allogeneic hematopoietic stem cell transplant (HSCT)Â ",BLA Filing,7/9/2024,"BLA resubmitted on July 9, 2024.",128.0,1249.65913,125.3638,7.73,7.595,7.67,-0.017618727,-0.007792247,-0.023847243,-0.088431584,0.0,0.0,2.20457,1517,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
PLUR,RYONCIL (remestemcel-L),"Pediatric participants with acute graft versus host disease (aGVHD), following allogeneic hematopoietic stem cell transplant (HSCT)Â ",BLA Filing,7/9/2024,"BLA resubmitted on July 9, 2024.",8.0,30.84291,87.0243,5.78,5.7965,5.85,0.002850604,0.012037979,-0.023847243,-0.088431584,0.38978,0.03613,0.02108,1518,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
AVTX,AVTX-009 (anti-IL-1Î² mAb) - (LOTUS),Hidradenitis suppurativa (HS)Â ,Phase 2,7/9/2024,"Phase 2 allowed to commence after IND active, noted July 9, 2024.",13.0,13.29891,242.7839,13.15,12.86,12.5,-0.02230004,-0.050693114,-0.023847243,-0.088431584,7.28719,0.00305,0.05997,1519,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
MNPR,MNPR-101-Zr (uPAR),Solid tumorsÂ ,Phase 1,7/9/2024,"Phase 1 dosing commenced, noted July 9, 2024.",6.0,12.95577,176.5753,3.6895,3.705,3.695,0.004192311,0.001489607,-0.023847243,-0.088431584,0.496,0.01221,0.0467,1520,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
GANX,"GT-02287, GT-02329",GBA1 and Idiopathic Parkinson's DiseaseÂ ,Phase 1,7/9/2024,"Phase 1 dosing completed the highest planned dose levels. No discontinuations or serious adverse events were reported, noted July 9, 2024.",35.0,29.69886,94.9094,1.12,1.18,1.3,0.052185753,0.149035579,-0.023847243,-0.088431584,1.98792,0.00914,0.4879,1521,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,-1
SNGX,HyBryte (SGX301/hypericin sodium) - (FLASH),Cutaneous T-Cell Lymphoma (CTCL) cancerÂ ,Phase 3,7/9/2024,"Additional Phase 3 data reported that 75% (3 of the 4 subjects who have completed at least 12 weeks of therapy) already achieving ""Treatment Success,"" noted July 9, 2024.",4.0,7.32717,211.6686,2.0,7.42,7.19,1.311031877,1.279543991,-0.023847243,-0.088431584,4.0443,8e-05,995.91877,1522,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
QURE,AMT-130,Huntington's diseaseÂ ,Phase 1/2,7/9/2024,Additional Phase 1/2 data reported an 80% slowing of disease progression in the composite Unified Huntington's Disease Rating Scale (cUHDRS) at 24 months compared to a propensity score-weighted extern,54.0,323.82475,99.5706,3.78,6.67,9.21,0.56789585,0.890565841,-0.023847243,-0.088431584,5.38795,0.1244,343.47479,1523,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
QURE,AMT-130 - (Europe Trial),Huntingtonâ€™s diseaseÂ ,Phase 1/2,7/9/2024,Additional Phase 1/2 data reported an 80% slowing of disease progression in the composite Unified Huntington's Disease Rating Scale (cUHDRS) at 24 months compared to a propensity score-weighted extern,54.0,323.82475,99.5706,3.78,6.67,9.21,0.56789585,0.890565841,-0.023847243,-0.088431584,5.38795,0.1244,343.47479,1524,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
KNSA,Abiprubart,Sjogren's DiseaseÂ ,Phase 2b,7/9/2024,"Phase 2b study enrollment commenced, noted July 9, 2024.",75.0,1437.99448,33.3589,19.86,20.23,22.35,0.018458993,0.118118662,-0.023847243,-0.088431584,6.56029,0.16066,6.94093,1525,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ARQT,"ZORYVE (roflumilast) cream, 0.15%",Atopic dermatitisÂ ,PDUFA priority review,7/9/2024,"PDUFA Date on July 7, 2024. PDUFA date PASSED, although the FDA has not requested additional information or extended the PDUFA goal date of July 7, 2024, suggesting a complete submission, noted July 9",122.0,1159.95692,92.9884,10.43,10.02,10.67,-0.040103173,0.022749796,-0.023847243,-0.088431584,22.47472,0.10189,24.6459,1526,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
NRSN,PrimeC - (PARADIGM),Amyotrophic Lateral Sclerosis (ALS)Â ,Phase 2b,7/9/2024,"Phase 2b 12-month study showed a 57% difference in complication-free survival favoring PrimeC over placebo in the Intent to Treat population, and a 73% difference in the Per Protocol Population. Prim",23.0,16.77622,101.721,1.1499,0.9301,0.8785,-0.212138154,-0.269214353,-0.023847243,-0.088431584,0.04477,0.07547,0.81957,1527,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ARQT,"ZORYVE (roflumilast) cream, 0.15%",Atopic dermatitisÂ ,Approved,7/9/2024,"FDA Approved on July 9, 2024.",122.0,1159.95692,92.9884,10.43,10.02,10.67,-0.040103173,0.022749796,-0.023847243,-0.088431584,22.47472,0.10189,24.6459,1528,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
LSTA,Certepetide (LSTA1),Intrahepatic CholangiocarcinomaÂ ,Preclinical,7/9/2024,"Preclinical data reported that certepetide combined with standard-of-care chemotherapy and immunotherapy improved survival in mice with intrahepatic cholangiocarcinoma, noted July 10, 2024.",8.0,27.91298,60.4564,3.34,3.36,3.7,0.005970167,0.102362013,-0.023847243,-0.088431584,0.15797,0.04714,0.03612,1529,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
VRPX,Probudur,Pain ReliefÂ ,Preclinical,7/10/2024,"Swine Model data reported that treatment was well-tolerated by all of the pigs and demonstrated a long-term, slow-release profile, noted July 10, 2024.",1.0,4.66072,223.5604,29.0,42.5,36.25,0.382208246,0.223143551,-0.037336006,-0.055944957,1.33604,0.00029,199.21446,1530,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1
OKYO,urcosimod (OK-101),Dry Eye Disease (DED)Â ,Phase 2,7/10/2024,"Data reported a 68% improvement in responder rate results from patients who achieved both the conjunctival staining ""sign"" and ocular pain ""symptom"" endpoints, noted July 10, 2024.",33.0,38.88618,73.104,1.19,1.17,1.6,-0.016949558,0.296050322,-0.037336006,-0.055944957,0.1195,0.0231,0.01818,1531,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1
KZIA,Paxalisib (GDC-0084) - (GBM AGILE),Glioblastoma multiformeÂ ,Phase 2/3,7/10/2024,"Phase 2/3 study demonstrated a 3.8-month improvement in overall survival compared to standard care, with a median overall survival of 15.54 months versus 11.89 months. These results align with previou",1.0,19.90792,206.3038,9.6,33.41,32.93,1.247092158,1.232620998,-0.037336006,-0.055944957,0.15819,0.0055,300.85247,1532,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
MBRX,"Annamycin (MB-106) in combination with Cytarabine - (Ara-C, MIRACLE)",Acute Myeloid Leukemia (AML)Â ,Phase 1/2,7/10/2024,"Phase 1b/2 was completed with its EoP2 meeting with the FDA, noted July 10, 2024.",30.0,7.83611,84.7807,3.252,3.39,4.435,0.04155973,0.310257424,-0.037336006,-0.055944957,1.29585,0.01547,0.07465,1533,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
OGEN,ONP-002,Moderate-to-severe concussion in the acute through subacute phasesÂ ,Phase 2,7/10/2024,"Phase 2 in preparation with NCE designed and formulation, noted July 10, 2024.",4.0,6.5852,172.439,31.80318,35.40354,33.60336,0.10724553,0.055059777,-0.037336006,-0.055944957,1.02222,0.03904,0.43507,1534,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
PFE,Danuglipron (PF-06882961) - (PK Study),ObesityÂ ,Phase 1,7/11/2024,"PK trial data reported encouraging pharmacokinetic data for several candidates with one showing the most favorable profile, noted July 11, 2024.",0.0,162404.5525,23.8309,28.35,28.66,29.71,0.010875392,0.046856659,-0.035798927,-0.021345749,1.0569,0.0116,1356.26431,1535,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
NVO,Insulin icodec,"Diabetes mellitus, Type 1 diabetesÂ ",CRL,7/11/2024,"CRL announced July 10, 2024.",0.0,4289867.009,27.349,142.74,139.79,129.99,-0.020883497,-0.093567269,-0.035798927,-0.021345749,0.0,0.0,536.48872,1536,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,-1
BDRX,"eRapa (rapamycin, sirolimus) - (Serenta)",Familial Adenomatous Polyposis (FAP)Â ,Phase 2,7/11/2024,"Phase 2 12-month data complementing recent data presented at the 2024 InSIGHT meeting, showed a 17% median decrease in polyp burden and a 75% non-progression rate. For Cohort 2, 89% were non-progresso",0.0,10.40202,213.2577,177.775,270.0,235.125,0.417903253,0.279598582,-0.035798927,-0.021345749,1.46325,0.04746,68.64075,1537,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ARMP,AP-PA02 - (Tailwind),Non-cystic fibrosis bronchiectasis (NCFB)Â ,Phase 2,7/11/2024,"Phase 2 trial enrollment completed, noted July 11, 2024.",36.0,108.46385,86.6717,2.68,3.0,3.02,0.112795494,0.119440037,-0.035798927,-0.021345749,0.01544,0.00888,0.07076,1538,0,0,0,0,0,1,0,0,0,1,0,0,2,0,0,1
CANF,Namodenoson - (CF102-222PC),Pancreatic CancerÂ ,Phase 2a,7/11/2024,"Fast Track designation application submitted to the FDA, noted July 11, 2024.",10.0,62.95568,58.9037,0.035,0.038,0.046,0.082238098,0.273293335,-0.035798927,-0.021345749,0.0,0.01812,0.4597,1539,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
IMMP,Eftilagimod alpha (IMP321) and KEYTRUDA (pembrolizumab) - (TACTI-003),Head and neck squamous cell carcinoma (HNSCC)Â ,Phase 2b,7/11/2024,"Phase 2b data presented at the ESMO Virtual Plenary session reported a 35.5% response rate in evaluable patients, noted July 11, 2024.",147.0,420.24178,82.6003,2.0,2.01,1.94,0.004987542,-0.030459207,-0.035798927,-0.021345749,0.0,0.0,2.0185,1540,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
VSTM,GFH375/VS-7375,Cancer KRAS G12DÂ ,Phase 1/2,7/12/2024,"Phase 1/2 dosing initiated in China, noted July 12, 2024.",61.0,85.09385,168.8846,2.98,3.36,3.32,0.120017673,0.108041482,-0.019610454,0.004604295,5.04876,0.07147,4.6983,1541,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1
ABBV,Upadacitinib (RINVOQ) - (SELECT-GCA),Giant cell arteritis (GCA)Â ,NDA Filing,7/12/2024,"NDA submitted July 12, 2024.",0.0,300691.9658,19.603,169.91,170.28,172.32,0.002175256,0.014084328,-0.019610454,0.004604295,0.91857,0.03647,703.85579,1542,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
BNTC,BB-301,Oculopharyngeal muscular dystrophy (OPMD)Â ,Phase 1/2,7/15/2024,"Additional interim safety data and efficacy data reported that for three of the four food types evaluated during the radiographic swallowing study assessments for Subject 1, the post-dose average Tota",26.0,95.54835,104.6287,9.47,10.2,8.96,0.074258813,-0.05535868,-0.028785415,0.000707607,0.98501,0.01477,0.46457,1543,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
LXEO,LX2006 - (SUNRISE-FA),Cardiac Friedreichâ€™s AtaxiaÂ ,Phase 1/2,7/15/2024,"Phase 1/2 interim update reported a mean reduction in left ventricular mass index (LVMI) of 11.4% at 12 months and 18.3% at 18 months, noted July 15, 2024.",54.0,428.61889,84.3949,17.6,13.01,11.54,-0.30218061,-0.422079641,-0.028785415,0.000707607,2.35427,0.02461,29.94036,1544,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
LXEO,LX2006 - (Weill Cornell Medicine),Cardiomyopathy associated with Friedreich's ataxia (FA)Â ,Phase 1a,7/15/2024,"Phase 1a data reported that treatment was well tolerated with no treatment-related serious adverse events, noted July 15, 2024.",54.0,428.61889,84.3949,17.6,13.01,11.54,-0.30218061,-0.422079641,-0.028785415,0.000707607,2.35427,0.02461,29.94036,1545,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0
SCNI,Nanosized VHH antibodies (nanoAbs),Plaque psoriasisÂ ,Preclinical,7/15/2024,"Preclinical results showed that Scinai's NanoAb had similar effects on inflammatory markers as the comparator drugs, demonstrating its potential to reduce psoriatic lesion severity and improve skin in",0.0,4.93922,133.4497,4.06,5.89,4.31,0.372073024,0.059754931,-0.028785415,0.000707607,2.46202,0.07018,173.71227,1546,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
MIRA,MIRA-55,Neurological and neuropsychiatric disordersÂ ,Preclinical,7/15/2024,"Preclinical new data confirms MIRA's earlier beliefs regarding MIRA-55's pharmacological profile and potential for potency and efficacy, noted July 15, 2024.",19.0,10.93786,143.7192,0.5892,0.74,5.01,0.227884502,2.140425509,-0.028785415,0.000707607,0.10581,0.00018,22.55299,1547,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ADXN,GABAB PAM (Compound A),Chronic coughÂ ,Preclinical,7/15/2024,"Preclinical data reported a significantly and dose-dependently reduced citric acid-induced cough frequency (minimal efficacious dose 1 mg/kg), increased cough latency and showed no signs of tolerance",1.0,6.25234,141.2621,0.0592,0.0636,0.062,0.071691928,0.046212843,-0.028785415,0.000707607,0.0,8e-05,0.00735,1548,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ANIP,L-Glutamine Oral Powder (Endari),BiosimilarÂ ,Approved,7/15/2024,"FDA ANDA Approval on July 15, 2024.",21.0,1227.01479,31.6908,63.5,63.22,62.07,-0.004419199,-0.022777125,-0.028785415,0.000707607,1.901,0.02036,9.60249,1549,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
PLRX,Bexotegrast (PLN-74809) - (INTEGRIS-PSC),Primary sclerosing cholangitis (PSC)Â ,Phase 2a,7/15/2024,"Phase 2a final 320mg data of the cohort met its primary endpoint of safety, demonstrating that bexotegrast was well tolerated up to 40 weeks of treatment, noted July 15, 2024.",61.0,798.11076,57.4791,12.75,13.23,12.53,0.036955707,-0.017405503,-0.028785415,0.000707607,11.46764,0.0956,10.44634,1550,1,0,0,1,0,1,0,0,0,0,0,0,3,0,0,1
ARTL,ART26.12,Chemotherapy-Induced PainÂ ,IND-Enabling,7/15/2024,"IND Cleared by the FDA, noted July 15, 2024.",1.0,4.29284,51.8013,7.7694,7.98,8.34,0.02674547,0.070870275,-0.028785415,0.000707607,0.43768,0.00073,5.47365,1551,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
KYTX,KYV-101 - (KYSA-8),Stiff-person syndrome (SPS)Â ,Phase 2,7/15/2024,"FDA granted Regenerative Medicine Advanced Therapies (RMAT) designation, noted July 15, 2024.",43.0,427.27207,0.0,9.79,9.91,9.71,0.012182892,-0.008205174,-0.028785415,0.000707607,6.66641,0.00027,3.35786,1552,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
SLS,Tambiciclib (SLS009) (GFH009) with venetoclax,"Hematologic malignancies, acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) and lymphomaÂ ",Phase 2,7/16/2024,"Rare Pediatric Disease Designation (RPDD) granted by the FDA, noted July 16, 2024.",105.0,65.84062,96.402,1.09,1.14,1.175,0.044850566,0.075090451,0.001001502,0.001402384,15.33972,0.03219,2.11982,1553,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
PASG,PBFT02 - (upliFT-D),Frontotemporal dementiaÂ ,Phase 1/2,7/16/2024,"Phase 1/2 study to be expanded in FTD patients with C9orf72 gene mutations after FDA feedback from Type C meeting, noted July 16, 2024.",3.0,58.62636,91.1621,18.426,19.022,16.62,0.031833493,-0.103155921,0.001001502,0.001402384,2.73729,0.08643,1.32233,1554,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ANVS,Buntanetap (ANVS401),Alzheimerâ€™s disease (AD)Â ,Phase 2/3,7/16/2024,Company received FDA approval to use a new crystalline form of their drug buntanetap in future clinical trials for neurodegenerative disorders following June's 2024 patent filings for the new crystal,19.0,139.75522,209.512,12.64,12.51,10.65,-0.010338064,-0.171306497,0.001001502,0.001402384,11.91649,0.06302,12.02457,1555,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
CLDX,Barzolvolimab (CDX-0159) - (EMBARQ-CSU1),Chronic Spontaneous Urticaria (CSU)Â ,Phase 3,7/16/2024,"Phase 3 trial enrollment commenced, noted July 16, 2024.",66.0,2635.10371,55.3193,39.55,39.98,38.84,0.010813635,-0.018115051,0.001001502,0.001402384,10.59924,0.12804,25.94322,1556,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CLDX,Barzolvolimab (CDX-0159) - (EMBARQ-CSU2),Chronic Spontaneous Urticaria (CSU)Â ,Phase 3,7/16/2024,"Phase 3 trial enrollment commenced, noted July 16, 2024.",66.0,2635.10371,55.3193,39.55,39.98,38.84,0.010813635,-0.018115051,0.001001502,0.001402384,10.59924,0.12804,25.94322,1557,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
LSTA,Certepetide (LSTA1) - (BOLSTER),Intrahepatic CholangiocarcinomaÂ ,Phase 2a,7/16/2024,"Phase 2a trial enrollment completed, noted July 16, 2024.",8.0,30.7375,60.7015,3.65,3.7,3.495,0.013605652,-0.043393792,0.001001502,0.001402384,0.17443,0.04655,0.13237,1558,0,0,0,0,0,1,0,0,0,1,0,0,2,0,0,1
CMND,CMND-100,Alcohol use disorder (AUD)Â ,Phase 1/2,7/16/2024,"IND Cleared by the FDA, noted July 16, 2024.",5.0,6.05843,112.1739,2.22,1.83,1.66,-0.193191229,-0.290689594,0.001001502,0.001402384,10.33095,0.01829,4.29742,1559,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
FDMT,4D-150 - (PRISM),Wet age-related macular degeneration (AMD)Â ,Phase 2,7/17/2024,Phase 2 24-week data reported reduction in anti-VEGF injection treatment burden through Week 24 achieved in 30 patients at planned Phase 3 dose (3E10 vg/eye) with 89% reduction in annualized injection,46.0,941.0021,123.7763,26.75,18.2,17.94,-0.385112879,-0.399501617,0.043238592,0.027977334,19.13193,0.09162,115.88963,1560,0,0,0,0,1,1,0,0,0,0,0,0,2,0,0,1
ADVM,"Ixo-vec (ixoberogene soroparvovec, ADVM-022) - (ARTEMIS)",Wet age-related macular degeneration (AMD)Â ,Phase 2,7/17/2024,"Additional LUNA data reported that 76% of 6E10 patients were injection free, with maintained visual acuity and fluid control, noted July 17, 2024.",20.0,182.24514,107.9776,8.92,8.78,7.87,-0.015819539,-0.125237884,0.043238592,0.027977334,3.93028,0.00252,19.41823,1561,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ATHE,ATH434-202 - (biomarker data),Multiple System Atrophy (MSA)Â ,Phase 2,7/17/2024,"Phase 2 data demonstrated that after 6 months of treatment, 43% of participants showed improved daily living activities, and 29% had stable or improved neurological symptoms. Clinical responders showe",15.0,36.71581,83.8351,2.0077,2.135,1.595,0.061476858,-0.230116052,0.043238592,0.027977334,0.0,0.0,2.0076,1562,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
IMMP,IMP761,Autoimmune diseasesÂ ,Phase 1,7/17/2024,"Phase 1 regulatory clearance in the Netherlands to initiate the first-in-human Phase 1 study, noted July 17, 2024.",147.0,420.24178,86.1452,2.03,2.0,2.1,-0.014888612,0.033901552,0.043238592,0.027977334,0.0,0.0,0.96496,1563,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
NVCR,Optune Lua is (Tumor Treating Fields (TTFields)) - (LUNAR),Non-small cell lung cancer (NSCLC)Â ,Phase 3,7/17/2024,"Additional Phase 3 data shared at ASRS reported a â‰¥ 90% reduction in annualized anti-VEGF injections at both doses, noted July 17, 2024.",111.0,2056.44768,70.1045,19.28,19.11,18.79,-0.008856531,-0.025743476,0.043238592,0.027977334,5.75247,0.1012,17.46761,1564,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ZLAB,Optune Lua is (Tumor Treating Fields (TTFields)) - (LUNAR),Non-small cell lung cancer (NSCLC)Â ,Phase 3,7/17/2024,"Additional Phase 3 data shared at ASRS reported a â‰¥ 90% reduction in annualized anti-VEGF injections at both doses, noted July 17, 2024.",109.0,1857.46283,64.4045,18.58,18.74,19.08,0.008574543,0.026554933,0.043238592,0.027977334,2.84631,0.14272,12.62265,1565,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
IONS,Zilganersen (ION373),Alexander diseaseÂ ,Phase 3,7/18/2024,"Phase 3 enrollment completed, noted July 18, 2024",159.0,6908.54115,33.6008,47.96,47.33,51.86,-0.013222986,0.07818045,0.023213246,-0.011754294,6.52278,0.08437,53.65783,1566,0,0,0,0,0,1,0,0,0,1,0,0,2,0,0,1
SNY,iluzanebart (VGL101) - (IGNITE),Adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP)Â ,Phase 2,7/18/2024,"Phase 2 study update following a Type C Meeting with the FDA which stated that it was open to considering the accelerated approval pathway, noted July 18, 2024.",0.0,115335.8044,22.2846,50.21,50.36,53.1,0.002982999,0.055962718,0.023213246,-0.011754294,0.0,0.0,169.51644,1567,0,0,0,0,0,1,0,1,0,0,0,0,2,0,0,1
AGEN,Botensilimab plus balstilimab,Relapsed/refractory microsatellite stable colorectal cancer with no active liver metastases (r/r MSS CRC NLM)Â ,Phase 2,7/18/2024,"Phase 2 preliminary data showed a 19.4% overall response rate and 90% 6-month survival rate, and FDA advice against seeking Accelerated Approval. noted July 18, 2024.",31.0,153.29461,177.5983,17.73,7.3,5.965,-0.887383772,-1.089349065,0.023213246,-0.011754294,11.22812,0.10456,66.64585,1568,0,0,0,0,0,1,0,1,0,0,0,0,2,0,0,1
BCTX,Bria-IMT + check point inhibitor (CPI) - (investigator-initiated trial),Metastatic breast cancerÂ ,Phase 2,7/18/2024,"Phase 2 study of the Bria-IMT regimen for metastatic breast cancer. A top responder patient achieved 9.1 months of progression-free survival, quadrupling the PFS of patients in similar studies. This h",1.0,19.19877,97.2353,138.16493,113.99994,115.48494,-0.192250194,-0.179307985,0.023213246,-0.011754294,0.0,0.0,9.7975,1569,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1
PHAT,VOQUEZNA (vonoprazan) - (PHALCON-NERD-301),Heartburn associated with Non-Erosive gastroesophageal reflux disease (GERD)Â ,Approved,7/18/2024,"FDA Approved on July 18, 2024.",70.0,654.29924,85.1712,12.11,11.18,11.28,-0.07990509,-0.071000311,0.023213246,-0.011754294,22.90422,0.10193,27.74904,1570,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
COCP,CDI-988,"Healthy volunteers, Pandemic Norovirus and CoronavirusÂ ",Phase 1,7/18/2024,"Phase 1 SAD data reported no serious adverse events or severe treatment-emergent adverse events, noted July 18, 2024.",10.0,23.90841,62.7981,2.26,2.35,2.22,0.039050515,-0.017857617,0.023213246,-0.011754294,0.17754,0.02379,0.06672,1571,0,0,0,1,0,1,0,0,0,0,0,0,0,2,0,-1
TEVA,AJOVY (fremanezumab-vfrm),Episodic migraine in children and adolescent patients aged 6-17 years who weigh 45 kilograms (99 pounds) or moreÂ ,Phase 3,7/18/2024,"Phase 3 trial met its primary end point, noted July 18, 2024.",0.0,18506.55977,33.2893,16.38,16.34,16.8,-0.002444989,0.025317808,0.023213246,-0.011754294,1.97005,0.08823,187.93727,1572,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1
OCUL,AXPAXLI (OTX-TKI) - (HELIOS),Non-proliferative diabetic retinopathy (NPDR)Â ,Phase 1,7/18/2024,"Phase 1 additional data presented at ASRS reported that 23.1% of patients in the OTX-TKI arm demonstrated a â‰¥2-step DRSS improvement, and 46.2% of patients demonstrated a 1- or â‰¥2-step DRSS improvemen",174.0,1200.38909,90.7147,8.0,7.75,8.28,-0.031748698,0.034401427,0.023213246,-0.011754294,13.77724,0.11632,11.10503,1573,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
EDAP,Transrectal High-intensity focused ultrasound (TR-HIFU),Rectal Deep Infiltrating EndometriosisÂ ,Phase 3,7/19/2024,"Phase 3 did not meet the primary endpoint of reduced acute pelvic pain compared to the Sham treatment at three months post-procedure. However, both arms showed significant pain reduction from baseline",37.0,189.22927,46.5029,4.96,5.1,4.65,0.027834799,-0.064538521,-0.013745571,-0.040190259,0.2085,0.01889,0.03394,1574,1,0,0,0,0,1,0,0,0,0,0,0,0,2,0,-1
ADXN,ADX71149 (mGlu2 PAM) - (JNJ-40411813),EpilepsyÂ ,Phase 2,7/22/2024,"Phase 2 study was discontinued after disappointing results on April, noted July 22, 2024.",1.0,6.09505,141.455,0.0602,0.062,0.063,0.029462033,0.045462374,-0.022812365,-0.027911611,0.0,0.00016,0.02554,1575,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
JNJ,ADX71149 (mGlu2 PAM) - (JNJ-40411813),EpilepsyÂ ,Phase 2,7/22/2024,"Phase 2 study was discontinued after disappointing results on April, noted July 22, 2024.",0.0,371206.1972,15.745,154.69,154.24,158.56,-0.002913283,0.024709956,-0.022812365,-0.027911611,0.87981,0.08459,1055.09553,1576,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ZYME,ZW191,"Non-small cell lung cancer, endometrial cancer, and triple-negative breast cancerÂ ",IND-Enabling,7/22/2024,"IND Cleared by the FDA, noted July 22, 2024",75.0,731.28691,43.0939,9.78,10.26,10.6,0.047913356,0.080514517,-0.022812365,-0.027911611,4.58729,0.07426,7.82864,1577,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
MESO,Rexlemestrocel-L (MPC-06-ID),Chronic low back painÂ ,Phase 3,7/22/2024,"Phase 3 second trial enrollment initiated, noted July 22, 2024",128.0,1318.1336,123.4047,7.23,7.55,6.79,0.043308527,-0.062788095,-0.022812365,-0.027911611,0.0,0.0,1.74618,1578,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
NUVL,Zidesamtinib - (NVL-330) - (HEROEX-1),HER2-mutant tumorsÂ ,Phase 1,7/22/2024,"Phase 1a/1b initiated, noted July 22, 2024.",72.0,5238.08439,41.4148,78.96,81.14,79.12,0.027234663,0.002024292,-0.022812365,-0.027911611,11.20221,0.16392,19.07163,1579,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
JNJ,SPRAVATO (esketamine) monotherapy,Treatment Resistant Depression (TRD4005)Â ,sNDA Filing,7/22/2024,"Supplemental New Drug Application (sNDA) submitted to FDA, noted July 22, 2024.",0.0,371206.1972,15.745,154.69,154.24,158.56,-0.002913283,0.024709956,-0.022812365,-0.027911611,0.87981,0.08459,1055.09553,1580,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
MIRA,Ketamir-2,"Treatment-resistant depression (TRD), major depressive disorder with suicidal ideation (MDSI) and post-traumatic stress disorder (PTSD)Â ",Preclinical,7/22/2024,Preclinical study results showed that the drug has potential for treating various neurological and neuropsychiatric disorders. It has high oral bioavailability and better brain penetration than tradit,19.0,74.05223,315.9021,0.6888,5.01,2.29,1.984240241,1.201356143,-0.022812365,-0.027911611,0.10581,0.00113,792.31946,1581,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
BIIB,ION582 (BIIB121) - (HALOS),Angelman SyndromeÂ ,Phase 1/2,7/22/2024,"Phase 1/2a data showed robust and consistent benefits in communication, cognition, and motor function in a broad patient population evaluated with a comprehensive set of assessment tools that collect",146.0,32996.62431,27.2367,226.4,226.63,214.43,0.001015385,-0.054320002,-0.022812365,-0.027911611,1.88337,0.16822,156.91204,1582,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
IONS,ION582 (BIIB121) - (HALOS),Angelman SyndromeÂ ,Phase 1/2,7/22/2024,"Phase 1/2a data showed robust and consistent benefits in communication, cognition, and motor function in a broad patient population evaluated with a comprehensive set of assessment tools that collect",159.0,7387.30758,34.5811,47.82,50.61,50.24,0.056705223,0.04936756,-0.022812365,-0.027911611,6.52278,0.08781,90.67642,1583,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
IMMP,Eftilagimod alpha (efti) - (TACTI-004),1L Non-small cell lung cancer (NSCLC)Â ,Phase 3,7/22/2024,"Phase 3 Type-C meeting FDA feedback resulted in successful preparatory regulatory interactions for the design of this registrational trial, noted July 22, 2024.",147.0,420.24178,85.791,1.94,1.9,2.17,-0.020834087,0.112039194,-0.022812365,-0.027911611,0.0,0.0,0.4997,1584,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1
ATOS,(Z)-endoxifen with abemaciclib (VERZENIO) - (EVANGELINE),Pre-menopausal women w/ early-stage estrogen receptor positive and Human Epidermal Growth Factor Receptor 2 negative breast cancerÂ ,Phase 2,7/22/2024,"Phase 2 Run-in cohort enrollment completed, noted July 22, 2024.",129.0,186.12098,79.7179,1.34,1.48,1.4,0.099372474,0.043802623,-0.022812365,-0.027911611,8.17742,0.04618,1.80099,1585,0,0,0,0,0,1,0,0,0,1,0,0,2,0,0,1
LLY,(Z)-endoxifen with abemaciclib (VERZENIO) - (EVANGELINE),Pre-menopausal women w/ early-stage estrogen receptor positive and Human Epidermal Growth Factor Receptor 2 negative breast cancerÂ ,Phase 2,7/22/2024,"Phase 2 Run-in cohort enrollment completed, noted July 22, 2024.",946.0,779724.0521,26.9837,857.47,865.97,807.79,0.009864073,-0.059684069,-0.022812365,-0.027911611,0.66581,0.05422,2515.25143,1586,0,0,0,0,0,1,0,0,0,1,0,0,2,0,0,1
JAGX,Mytesi (crofelemer) - (OnTarget),Cancer Therapy-Related DiarrheaÂ ,Phase 3,7/23/2024,"Phase 3 study did not meet its primary endpoint, noted July 23, 2023.",2.0,10.09875,229.6715,106.75,44.0,29.0,-0.886300018,-1.303193822,-0.001515688,-0.001010714,5.45511,0.00973,27.225,1587,1,0,0,0,0,1,0,0,0,0,0,0,0,2,0,-1
ADIL,AD04 - (ONWARD),Alcohol use disorderÂ ,Phase 3,7/23/2024,"Phase 3 study advanced to its second cohort after completing the first, noted July 23, 2024.",21.0,5.54563,192.4594,1.06,1.31,1.0,0.211758229,-0.058268908,-0.001515688,-0.001010714,3.85826,0.00596,209.65014,1588,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
RYTM,Bivamelagon (LB54640),Healthy overweight adultsÂ ,Phase 2,7/23/2024,"Phase 2 dosing initiated, noted July 23, 2024.",66.0,3036.45087,53.9801,49.78,49.8,47.66,0.000401687,-0.043520825,-0.001515688,-0.001010714,15.15402,0.15288,18.79093,1589,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1
MRK,ENFLONSIA (Clesrovimab) (MK-1654-004) - (CLEVER),Respiratory syncytial virus (RSV) infantsÂ ,Phase 2/3,7/23/2024,"Phase 2b/3 study met its primary safety and efficacy endpoints, including reducing medically attended lower respiratory infections (MALRI) caused by RSV through Day 150, noted July 23, 2024.",0.0,315030.4485,18.7697,125.69,124.38,115.25,-0.010477162,-0.086714876,-0.001515688,-0.001010714,0.92191,0.05231,533.02129,1590,0,0,0,1,0,1,0,0,0,0,0,0,2,0,0,1
ANIX,Chimeric endocrine receptor T-cell (CER-T),Ovarian CancerÂ ,IND-Enabling,7/23/2024,"IND cleared by the FDA for collaborator Moffitt Cancer Center, noted July 23, 2024.",32.0,92.49867,68.5945,3.13,2.89,3.09,-0.079776502,-0.012861914,-0.001515688,-0.001010714,1.6816,0.01187,4.25827,1591,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
VIRI,IMC-2 with Valacyclovir and Celecoxib - (Bateman Horne Center trial),Long COVID-19Â ,Phase 2,7/23/2024,"Phase 2 enrollment completed, noted July 23, 2024.",27.0,353.54923,58.1827,51.32,49.37,45.8,-0.038737587,-0.113796449,-0.001515688,-0.001010714,0.0,0.04049,1.87265,1592,0,0,0,0,0,1,0,0,0,1,0,0,2,0,0,1
CLRB,Iopofosine (CLR 131) - (CLOVER-WaM),Waldenstromâ€™s macroglobulinemiaÂ ,Phase 2b,7/23/2024,"Phase 2b study showed an 80% overall response rate and a 56.4% major response rate, exceeding the primary endpoint. The treatment was effective across various patient subgroups, including those resist",3.0,88.18828,85.6993,90.60009,73.80007,64.50006,-0.205095526,-0.339789052,-0.001515688,-0.001010714,6.341,0.05058,15.22488,1593,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
MESO,RYONCIL (remestemcel-L),"Pediatric participants with acute graft versus host disease (aGVHD), following allogeneic hematopoietic stem cell transplant (HSCT)Â ",PDUFA,7/23/2024,"The FDA accepted BLA resubmission, noted on July 23, 2024.",128.0,1489.31978,123.8759,7.55,8.27,6.47,0.091086946,-0.154371455,-0.001515688,-0.001010714,0.0,0.0,7.28981,1594,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
PLUR,RYONCIL (remestemcel-L),"Pediatric participants with acute graft versus host disease (aGVHD), following allogeneic hematopoietic stem cell transplant (HSCT)Â ",PDUFA,7/23/2024,"The FDA accepted BLA resubmission, noted on July 23, 2024.",8.0,30.32944,82.0611,5.6,5.7,5.91,0.017699577,0.053879234,-0.001515688,-0.001010714,0.4446,0.03818,0.01541,1595,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
REGN,Ateganosine (THIO-101),Non-small cell lung cancer (NSCLC)Â ,Phase 2,7/23/2024,"Phase 2 clinical trial treatment has shown good tolerability with lower toxicity compared to standard care. Notably, six patients have been on the trial regimen for over 12 months, completing up to 21",105.0,113880.7004,16.2256,1069.74,1055.57,1077.8,-0.013334723,0.007506298,-0.001515688,-0.001010714,1.88894,0.13405,329.38217,1596,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
MAIA,Ateganosine (THIO-101),Non-small cell lung cancer (NSCLC)Â ,Phase 2,7/23/2024,"Phase 2 clinical trial treatment has shown good tolerability with lower toxicity compared to standard care. Notably, six patients have been on the trial regimen for over 12 months, completing up to 21",32.0,80.79745,102.461,3.75,3.7,3.15,-0.01342302,-0.174353387,-0.001515688,-0.001010714,3.08499,0.01136,3.66137,1597,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ARQT,ZORYVE (roflumilast),Scalp psoriasisÂ ,sNDA Filing,7/23/2024,"sNDA submitted to the FDA, noted July 23, 2024.",122.0,1180.79447,88.2766,9.85,10.2,9.63,0.034916265,-0.022588229,-0.001515688,-0.001010714,18.43461,0.10927,19.38435,1598,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
BCAB,Ozuriftamab Vedotin (BA3021),"Solid Tumors, Non-small cell lung cancer (NSCLC), recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN)Â ",Phase 2,7/23/2024,"Fast Track Designation (FTD) granted by the FDA, noted July 23, 2024.",58.0,84.20286,132.063,1.74,1.75,1.63,0.005730675,-0.065305098,-0.001515688,-0.001010714,10.90224,0.29641,3.0058,1599,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
GILD,Yeztugo (Lenacapavir),HIV PrEP â€“ Pre-exposure prophylaxisÂ ,Phase 3,7/24/2024,"Phase 3 trial ata showed zero Infections and 100% Efficacy and Superiority of lenacapavir to background HIV incidence and daily Truvada for PrEP, noted July 24, 2024.",0.0,91570.21086,22.721,71.17,73.5,76.06,0.032214025,0.066451121,-0.012155176,0.007041574,1.70566,0.02721,485.09941,1600,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
SGMO,Giroctocogene fitelparvovec (SB-525) - (AFFINE),Hemophilia AÂ ,Phase 3,7/24/2024,"Phase 3 data met its primary and key secondary objectives of superiority compared to prophylaxis, noted on July 24, 2024.",301.0,116.20564,142.984,0.4013,0.56,0.7826,0.333227506,0.667912433,-0.012155176,0.007041574,6.13622,0.02081,147.35474,1601,0,0,0,0,0,1,0,0,1,0,0,0,2,0,0,1
TLSA,Foralumab (Intranasal),Secondary Progressive Multiple Sclerosis (SPMS)Â ,Phase 2a,7/24/2024,"Fast track designation granted by the FDA, noted July 24, 2024.",111.0,101.51423,92.5251,0.9001,1.0,1.07,0.105249411,0.172908059,-0.012155176,0.007041574,0.07053,0.05157,1.08076,1602,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
MRUS,Petosemtamab (MCLA-158) - (LiGeR-HN2),Recurrent/metastatic head and neck squamous cell carcinoma (r/m HNSCC)Â ,Phase 3,7/24/2024,"Phase 3 study dosing initiated, noted July 24, 2024.",75.0,3623.19404,62.055,55.52,54.7,53.04,-0.014879607,-0.04569697,-0.012155176,0.007041574,10.6916,0.15305,27.70243,1603,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1
GMAB,Petosemtamab (MCLA-158) - (LiGeR-HN2),Recurrent/metastatic head and neck squamous cell carcinoma (r/m HNSCC)Â ,Phase 3,7/24/2024,"Phase 3 study dosing initiated, noted July 24, 2024.",661.0,120870.8408,27.7648,1910.0,1904.5,1955.0,-0.002883735,0.023286951,-0.012155176,0.007041574,0.0,0.14604,240.22982,1604,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1
SAGE,SAGE-324 (BIIB124) - (KINETIC 2),Essential tremorÂ ,Phase 2b,7/24/2024,"Phase 2b topline data did not demonstrate a statistically significant dose-response relationship on the primary endpoint in participants with essential tremor, noted July 24, 2025.",62.0,96399.20113,63.8717,13.0,12.0,11.0,-0.080042708,-0.167054085,-0.012155176,0.007041574,0.0,0.00981,54.1992,1605,1,0,0,0,0,1,0,0,0,0,1,0,3,0,0,1
BIIB,SAGE-324 (BIIB124) - (KINETIC 2),Essential tremorÂ ,Phase 2b,7/24/2024,"Phase 2b topline data did not demonstrate a statistically significant dose-response relationship on the primary endpoint in participants with essential tremor, noted July 24, 2025.",146.0,32909.26618,27.1102,224.29,226.03,213.2,0.007727876,-0.050709165,-0.012155176,0.007041574,2.49116,0.16822,205.36724,1606,1,0,0,0,0,1,0,0,0,0,1,0,3,0,0,1
SNY,VG-3927,Alzheimer's diseaseÂ ,Phase 1,7/24/2024,"Phase 1 interim data on healthy volunteers showed that VG-3927 had a significant impact on sTREM2, a key biomarker in AD, and supports treatment as a potent molecule that functionally engages TREM2 re",0.0,117269.1431,22.2166,50.43,51.2,51.81,0.015153296,0.026996945,-0.012155176,0.007041574,0.0,0.0,108.65992,1607,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
SONN,SON-080 - (SB211),Chemotherapy Induced Peripheral Neuropathy (CIPN)Â ,Phase 1/2,7/24/2024,"Phase 1b/2a unblinded safety data indicated that SON-080 was well-tolerated at both doses, with no evidence of a pro-inflammatory cytokine response, noted July 24, 2024.",6.0,4.53384,97.1262,6.816,6.9504,6.28,0.019526422,-0.081902809,-0.012155176,0.007041574,0.30708,0.06837,0.43751,1608,0,0,0,1,0,1,0,0,0,0,0,0,2,0,0,1
BMRN,BRINEURA (cerliponase alfa) - (Study 190-203),CLN2 Batten Disease Children of All AgesÂ ,Approved,7/24/2024,"FDA supplemental Approval on July 24, 2024.",192.0,16069.52773,25.4706,84.43,84.63,84.33,0.002366025,-0.001185115,-0.012155176,0.007041574,3.93311,0.01412,65.55101,1609,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
RARE,GTX-102 - (Aspire),Angelman SyndromeÂ ,Phase 1/2,7/24/2024,"Phase 1/2 previously disclosed results presented at ASF Presentation on July 24, 2024.",96.0,4082.7105,44.1327,45.18,45.11,45.02,-0.00155056,-0.003547676,-0.012155176,0.007041574,4.8203,0.23083,17.65384,1610,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
SNY,Duvakitug (TEV-'574/SAR447189) - (RELIEVE UCCD),Moderate-to-severe inflammatory bowel disease (IBD); this includes ulcerative colitis (UC) and Crohn's disease (CD)Â ,Phase 2b,7/25/2024,"Phase 2b trial completed early, noted July 25, 2024.",0.0,122181.9896,22.7984,51.2,53.1,51.66,0.036437396,0.008944256,-0.024929001,0.00374286,0.0,0.0,248.98707,1611,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
TEVA,Duvakitug (TEV-'574/SAR447189) - (RELIEVE UCCD),Moderate-to-severe inflammatory bowel disease (IBD); this includes ulcerative colitis (UC) and Crohn's disease (CD)Â ,Phase 2b,7/25/2024,"Phase 2b trial completed early, noted July 25, 2024.",0.0,19027.55227,33.0569,16.5,16.8,17.54,0.018018506,0.061123606,-0.024929001,0.00374286,1.56116,0.09722,173.23822,1612,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
OCGN,OCU410 - (ArMaDa),Geographic Atrophy (GA)Â ,Phase 1/2,7/25/2024,"Phase 1/2 third cohort dosing completed and Phase 2 initiated, noted July 25, 2024.",292.0,419.48778,116.1204,1.6,1.63,1.3,0.018576386,-0.207639365,-0.024929001,0.00374286,23.90513,0.03435,3.81209,1613,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ACIU,JNJ-2056 (ACI-35.030) - (ReTain),Alzheimerâ€™s DiseaseÂ ,Preclinical,7/25/2024,"Fast Track designation granted by the FDA, noted July 25, 2024.",100.0,367.35964,88.6576,3.53,3.91,3.82,0.102239503,0.078952552,-0.024929001,0.00374286,1.02703,0.01323,4.1499,1614,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
JNJ,JNJ-2056 (ACI-35.030) - (ReTain),Alzheimerâ€™s DiseaseÂ ,Preclinical,7/25/2024,"Fast Track designation granted by the FDA, noted July 25, 2024.",0.0,384292.379,16.3474,156.28,159.64,160.76,0.02127201,0.028263299,-0.024929001,0.00374286,0.74714,0.08459,1599.52543,1615,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
MIRM,LIVMARLI (maralixibat),Progressive Familial Intrahepatic Cholestasis (PFIC)Â ,Approved,7/25/2024,"FDA Approval of label expansion on patients 12 months and older, noted July 25, 2024.",50.0,1902.76006,57.31,39.07,40.37,40.13,0.032732026,0.026769275,-0.024929001,0.00374286,17.34408,0.04738,32.30048,1616,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
CMMB,nebokitug (CM-101) - (SPRING),Primary Sclerosing CholangitisÂ ,Phase 2,7/25/2024,"Phase 2 topline 15-week data met its primary safety and tolerability endpoint and demonstrated anti-fibrotic, anti-inflammatory, and anti-cholestatic effects across multiple disease-related secondary",5.0,16.92061,100.279,5.68,4.76,4.66,-0.176703564,-0.197935785,-0.024929001,0.00374286,0.73855,0.03649,3.74723,1617,0,0,0,1,0,1,0,0,1,0,0,0,3,0,0,1
BCDA,CardiAMP (BCDA-01),Ischemic Heart FailureÂ ,Phase 3,7/25/2024,"Phase 3 enrollment in the US commenced, noted July 25, 2024.",5.0,5.38524,87.622,2.84,2.95,2.96,0.038001118,0.041385216,-0.024929001,0.00374286,1.60996,0.0456,0.1136,1618,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ENVB,EB-003 (EVM301 series),Mental health disordersÂ ,Preclinical,7/25/2024,"Preclinical results indicate the potential for the drug candidate to be delivered via oral administration with significant brain exposure in rodent models at potential therapeutic doses, noted July 25",0.0,3.71913,123.5233,86.21999,84.77999,95.03999,-0.016842505,0.097395697,-0.024929001,0.00374286,1.6679,0.00434,0.29097,1619,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ALT,Pemvidutide - (IMPACT),Metabolic dysfunction-associated steatohepatitis (MASH)Â ,Phase 2b,7/25/2024,"Phase 2b intiatl data showed that weekly subcutaneous doses of pemvidutide resulted in up to 68.5% relative reduction in liver fat content (LFC), with up to 55.6% of subjects achieving LFC normalizati",88.0,474.33566,101.623,6.27,6.69,6.09,0.064837519,-0.029128273,-0.024929001,0.00374286,31.88304,0.10058,22.89655,1620,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
VRDN,Veligrotug (VRDN-001) - (THRIVE-2),Thyroid Eye Disease (TED)Â ,Phase 1/2,7/25/2024,"Phase 1/2 exceeded its enrollment target due to patient demand; 188 patients enrolled with approximately 40% from US sites, noted July 25, 2024.",81.0,1042.85913,61.6312,15.82,16.34,16.28,0.032341127,0.028662398,-0.024929001,0.00374286,13.51977,0.10697,30.91365,1621,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ATNM,Iomab-ACT,Sickle cell diseaseÂ ,IND-Enabling,7/25/2024,"IND cleared by the FDA, noted July 25, 2024.",31.0,235.28926,79.6767,7.74,7.9,6.62,0.020461072,-0.156306318,-0.024929001,0.00374286,7.20283,0.04162,2.64182,1622,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
ZVSA,IC 100 (AIM2 and NLRP3 inflammasome),Obesity and Type 1 diabetesÂ ,Preclinical,7/25/2024,"Preclinical program near completion, selected as lead drug for obesity and IND submission planned on 4Q 2024, noted July 25, 2024.",8.0,3.21435,127.9663,3.69,3.85,3.42,0.04244669,-0.075985907,-0.024929001,0.00374286,4.00409,0.00402,1.1836,1623,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
AQST,Anaphylm (AQ-109)- (103),AnaphylaxisÂ ,Phase 3,7/25/2024,"Phase 3 data met all primary and secondary pharmacokinetic endpoints, study expected to be completed by late 3Q / early 4Q 2024. NDA filing expected 4Q 2024/ early 1Q 2025, noted July 25, 2024.",99.0,314.08294,90.7004,3.37,3.45,3.59,0.023461487,0.063239458,-0.024929001,0.00374286,11.3931,0.00027,6.60552,1624,0,0,0,0,0,1,0,1,1,0,0,0,3,0,0,1
CRVS,Soquelitinib - (CPI-818),Peripheral T-cell lymphoma (PTCL)Â ,Preclinical,7/25/2024,"Preclinical data demonstrated in vitro and in vivo ITK inhibition with soquelitinib induced switching of proinflammatory Th17 cells into anti-inflammatory Treg cells, noted July 25, 2024.",74.0,144.49346,68.5692,2.17,2.31,2.99,0.062520357,0.32054622,-0.024929001,0.00374286,2.00554,0.09152,0.39175,1625,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
WINT,Istaroxime - (SEISMiC C),Cardiogenic Shock in severe acute heart failureÂ ,Phase 2,7/25/2024,Phase 2 extension study in SCAI Stage B enrollment to be completed by the end of 3Q 2024.,29.0,1.94735,83.5126,184.0,164.5,500.5,-0.112025187,1.000671841,-0.024929001,0.00374286,7.95624,0.03615,6.78003,1626,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
AZN,IMFINZI (durvalumab),Non-Small Cell Lung Cancer (before and after surgery)Â ,PDUFA,7/25/2024,"FDA Oncologic Drugs Advisory Committee (ODAC) acknowledged that treatment met the primary endpoint of event-free survival (EFS), noted July 25, 2024.",0.0,186962.3299,20.9975,122.14,120.6,125.12,-0.012688644,0.024105349,-0.024929001,0.00374286,0.0,0.14707,288.31191,1627,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1
CLLS,UCART22 - (BALLI-01),Relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL)Â ,Phase 1/2,7/25/2024,"Phase 1/2 trial FDA granted Orphan drug designation and Rare Pediatric Disease Designation, noted July 25, 2024.",72.0,128.6565,57.3843,2.04,2.05,2.17,0.004889985,0.06177736,-0.024929001,0.00374286,0.0,0.0,1.09818,1628,0,0,0,0,0,1,0,1,0,0,0,0,2,0,0,1
PMN,PMN310 - (PRECISE-AD),Alzheimer's disease (AD)Â ,Phase 1a,7/26/2024,Phase 1a topline data demonstrated a favorable safety profile and tolerability across four ascending dose levels in healthy volunteers and showed dose dependent levels of PMN310 antibody in Cerebrospi,53.0,30.33779,92.8508,2.0177,1.6,1.33,-0.23195462,-0.416779307,0.00705593,0.045690398,0.13991,0.03387,10.71374,1629,0,0,0,1,0,0,0,0,0,0,1,0,2,0,0,1
CVM,Multikine - (IT-MATTERS),Head and Neck cancerÂ ,Phase 3,7/26/2024,"Phase 3 bias analysis analysis found no bias or confounding factors between the treatment and control groups, supporting the validity of the study's efficacy results. In the target population, Multiki",6.0,70.94949,79.1233,36.30363,39.30393,34.50345,0.079406778,-0.050858417,0.00705593,0.045690398,15.61777,0.13913,76.72005,1630,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CALT,Setanaxib - (TRANSFORM),Primary biliary cholangitis (PBC)Â ,Phase 2b,7/26/2024,"Phase 2b topline data met its primary endpoint, showing statistically significant improvement in ALP (Alkaline Phosphatase) for both doses tested versus placebo, noted July 26, 2024.",26.0,672.672,24.4997,5.6,5.6,5.72,0.0,0.021202208,0.00705593,0.045690398,0.0,0.0104,0.05294,1631,1,0,0,0,0,1,0,0,0,0,1,0,3,0,0,1
VTVT,Cadisegliatin (TTP399),Type 1 DiabetesÂ ,Phase 3,7/26/2024,"Phase 3 FDA placed a clinical hold based on the discovery of a chromatographic signal in a recent human absorption, distribution, metabolism, and excretion (ADME) study of cadisegliatin that could not",3.0,135.75301,139.8233,21.01,21.2,14.775,0.009002667,-0.352061952,0.00705593,0.045690398,0.30231,0.0035,1.19591,1632,0,0,0,0,0,1,0,1,0,0,0,0,0,2,0,-1
CERO,CER-1236 - (CertainT-1),"Acute myeloid leukemia (AML), Hematologic malignanciesÂ ",IND-Enabling,7/26/2024,"IND placed on clinical hold, noted July 26, 2024.",1.0,3.85587,203.9637,482.4,512.0,313.6,0.05955098,-0.430655357,0.00705593,0.045690398,8.54704,0.01382,3.73043,1633,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,-1
LGVN,Laromestrocel (lomecel-B) - (CLEAR MIND),Alzheimer's DiseaseÂ ,Phase 2a,7/28/2024,"Phase 2a results from AAIC reported that treatment demonstrated in MRI biomarker results showing 49% reduction in brain volume loss and improvement in inflammation, noted July 28, 2024.",15.0,49.3966,225.8831,3.44,3.44,2.89,0.0,-0.174214969,0.012586262,0.05122073,15.29346,0.00987,0.0,1634,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ABOS,Sabirnetug (ACU193) - (INTERCEPT-AD),Alzheimerâ€™s disease (AD)Â ,Phase 1,7/28/2024,"Phase 1 data from AAIC reported that three administrations of sabirnetug significantly lowered CSF levels of both pre- and post-synaptic proteins, noted July 28, 2024.",60.0,209.07763,73.2668,3.48,3.48,2.99,0.0,-0.151758906,0.012586262,0.05122073,2.75695,0.07829,0.0,1635,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
SNDX,Revuforj (revumenib),Adult and pediatric relapsed or refractory (R/R) KMT2A-rearranged (KMT2Ar) acute leukemiaÂ ,PDUFA,7/29/2024,"PDUFA action was extended by 3 months to December 26, 2024.",86.0,1868.86545,46.8887,24.49,21.99,19.66,-0.107677066,-0.219678756,0.025433975,0.083240317,10.02824,0.27045,69.51554,1636,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CGTX,Zervimesine (CT1812) - (SHINE),Mild-to-Moderate Alzheimer's DiseaseÂ ,Phase 2,7/29/2024,"Phase 2 data presented at AAIC showed a consistent trend in cognitive improvement compared to placebo across multiple measures, with participants treated for six months demonstrating a 39% slowing of",73.0,53.2778,110.7414,2.37,1.33,0.6561,-0.577711013,-1.284332018,0.025433975,0.083240317,0.53623,0.00488,35.22698,1637,0,0,1,0,0,1,0,0,0,0,1,0,3,0,0,1
AVXL,Blarcamesine (ANAVEX2-73-AD-004) - (ATTENTION-AD),Mild to moderate Alzheimerâ€™s diseaseÂ ,Phase 2/3,7/29/2024,"Phase 2b/3 results reported that Blarcamesine significantly slowed clinical progression by 38.5% and 34.6% at 48 weeks in 50 mg and 30 mg groups vs. placebo, respectively, on the prespecified primary",85.0,596.96044,67.7281,6.74,7.04,6.45,0.043548245,-0.043979794,0.025433975,0.083240317,21.74759,0.10513,24.40055,1638,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ZVSA,IC100,Parkinson's diseaseÂ ,Preclinical,7/29/2024,Preclinical data presented at the International Journal of Molecular Sciences demonstrating that plasma levels of inflammasome ASC show promise as a biomarker of early cognitive decline in older adult,8.0,3.00563,128.2177,3.85,3.6,3.25,-0.067139303,-0.169418152,0.025433975,0.083240317,4.00409,0.00443,0.29347,1639,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
VTYX,VTX958,Crohn's diseaseÂ ,Phase 2,7/29/2024,"Phase 2 trial did not meet its primary endpoint of change from baseline in mean CDAI score in either VTX958 dose group, noted July 29, 2024.",71.0,160.7264,152.7175,2.95,2.28,2.02,-0.257629727,-0.378707659,0.025433975,0.083240317,12.26005,0.00968,9.41106,1640,1,0,0,0,0,1,0,0,0,0,0,0,0,2,0,-1
HALO,Sabirnetug (ACU193) with ENHANZE,Alzheimer's disease (AD)Â ,Phase 1,7/29/2024,"Phase 1 dosing initiated, noted July 29, 2024.",116.0,7059.88878,30.8781,56.23,55.47,52.11,-0.013608088,-0.076093553,0.025433975,0.083240317,6.84208,0.15514,55.0481,1641,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1
ABOS,Sabirnetug (ACU193) with ENHANZE,Alzheimer's disease (AD)Â ,Phase 1,7/29/2024,"Phase 1 dosing initiated, noted July 29, 2024.",60.0,197.66247,73.3032,3.48,3.29,2.83,-0.056144729,-0.206755582,0.025433975,0.083240317,2.75695,0.07829,1.78502,1642,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1
CGEN,COM503,Solid tumorsÂ ,IND-Enabling,7/29/2024,"IND cleared by the FDA, noted July 29, 2024.",93.0,153.09663,79.838,1.77,1.71,1.64,-0.034486176,-0.076283305,0.025433975,0.083240317,1.95357,0.02869,0.74019,1643,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
GILD,COM503,Solid tumorsÂ ,IND-Enabling,7/29/2024,"IND cleared by the FDA, noted July 29, 2024.",0.0,96840.16994,23.4198,77.01,77.73,74.83,0.009306,-0.028716409,0.025433975,0.083240317,1.70566,0.02142,355.32163,1644,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
PALI,PALI-2108,Moderate-to-severe ulcerative colitis (UC)Â ,Preclinical,7/29/2024,"Preclinical findings demonstrate that the microbiome and enzymes are sufficient in mouse, dog, and Normal Healthy Volunteers (NHV) and Ulcerative Colitis (UC) patients, noted July 29, 2024.",9.0,3.51151,120.9192,4.265,3.75,3.51,-0.128686341,-0.194826143,0.025433975,0.083240317,5.82837,0.04693,6.24474,1645,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CRVO,Neflamapimod - (AscenD-LB),Dementia with Lewy bodies (DLB)Â ,Phase 2a,7/29/2024,"Phase 2a data presented at AAIC reported that there was a mean 14.1 pg/mL increase in the placebo treatment group (N=13) vs. mean 10.6 pg/mL reduction with neflamapimod treatment, noted July 29, 2024.",9.0,118.93641,98.6741,14.03,14.41,13.33,0.026724516,-0.05118076,0.025433975,0.083240317,7.28982,0.00129,1.10048,1646,0,0,0,0,1,1,0,0,0,0,1,0,3,0,0,1
AZN,Calquence (acalabrutinib) - (AMPLIFY),Chronic lymphocytic leukaemia (CLL)Â ,Phase 3,7/29/2024,"Phase 3 data reported a a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to standard-of-care chemoimmunotherapy, noted July 29, 2024.",0.0,191675.1448,21.0924,121.8,123.64,124.58,0.014993762,0.022567725,0.025433975,0.083240317,0.0,0.14147,412.13972,1647,1,0,0,0,0,1,0,0,0,0,0,0,2,0,0,1
CLDX,Barzolvolimab - (CindU),"Chronic inducible urticaria (CIndU), cold urticaria (ColdU) and symptomatic dermographism (SD), Chronic Spontaneous Urticaria (CSU)Â ",Phase 2,7/29/2024,"Phase 2 study met its primary endpoint, showing statistically significant and clinically meaningful complete response rates in both dose groups compared to placebo.",66.0,2767.58391,58.5164,44.56,41.99,32.72,-0.059405101,-0.308850084,0.025433975,0.083240317,11.21323,0.10797,24.46581,1648,1,0,0,0,0,1,0,0,0,0,0,0,2,0,0,1
VSTM,VS-6766 and defactinib - (RAMP 205),Metastatic pancreatic cancerÂ ,Phase 1/2,7/29/2024,"Phase 1/2 study granted Orphan Drug Designation (ODD) by the FDA, noted July 29, 2024.",61.0,105.92535,169.7827,2.96,2.74,2.2,-0.077231348,-0.296731908,0.025433975,0.083240317,5.8636,0.07156,2.86908,1649,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
AMRX,Potassium Phosphates in 0.9% Injection IV RTU bags,HyperphosphatemiaÂ ,Approved,7/29/2024,"FDA approved via 505(b)(2) pathway, noted July 29, 2024.",314.0,2265.50108,40.5246,7.44,7.34,6.7,-0.013532006,-0.104763322,0.025433975,0.083240317,1.48662,0.03712,5.76415,1650,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
ACOG,ZUNVEYL (benzgalantamine),Mild-to-moderate Alzheimer's diseaseÂ ,Approved,7/29/2024,"FDA approved on July 29, 2024.",16.0,86.07106,73.8408,13.7575,14.2875,12.5,0.037800899,-0.095855486,0.025433975,0.083240317,0.26092,0.02125,0.49388,1651,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
REGN,"SAR4442454, BNT111 and LIBTAYO (cemiplimab)",MelanomaÂ ,Phase 2,7/30/2024,"Phase 2 trial met its primary endpoint, noted July 30, 2024.",105.0,116278.9951,16.0802,1077.19,1077.8,1066.19,0.000566128,-0.010264252,0.01214082,0.059901835,1.7541,0.12873,385.87719,1652,1,0,0,0,0,1,0,0,0,0,0,0,2,0,0,1
SNY,"SAR4442454, BNT111 and LIBTAYO (cemiplimab)",MelanomaÂ ,Phase 2,7/30/2024,"Phase 2 trial met its primary endpoint, noted July 30, 2024.",0.0,119550.1075,22.9139,52.09,51.69,51.01,-0.007708653,-0.0209513,0.01214082,0.059901835,0.0,0.0,97.65016,1653,1,0,0,0,0,1,0,0,0,0,0,0,2,0,0,1
BNTX,"SAR4442454, BNT111 and LIBTAYO (cemiplimab)",MelanomaÂ ,Phase 2,7/30/2024,"Phase 2 trial met its primary endpoint, noted July 30, 2024.",239.0,20931.97814,32.2284,86.61,86.74,79.5,0.001499856,-0.085658261,0.01214082,0.059901835,1.39604,0.02317,65.79238,1654,1,0,0,0,0,1,0,0,0,0,0,0,2,0,0,1
AVXL,ANAVEX 2-73,Fragile X SyndromeÂ ,Preclinical,7/30/2024,"Preclinical data reported positive results in directly to humans' translatable electroencephalogram (EEG) biomarkers present in both individuals with FXS and animal models of FXS, noted July 30, 2024.",85.0,535.05971,68.7637,7.04,6.31,6.815,-0.109472494,-0.032482105,0.01214082,0.059901835,21.74759,0.10513,12.72068,1655,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
INCY,INCA33989 (mCALR),Myelofibrosis (MF)Â ,Phase 1/2,7/30/2024,Phase 1 ongoing .,196.0,13056.22025,24.7685,68.59,67.79,61.27,-0.01173206,-0.112856425,0.01214082,0.059901835,6.65297,0.10401,314.23173,1656,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
IMNN,IMNN-001 - (OVATION 2),Ovarian cancerÂ ,Phase 3,7/30/2024,"Phase 2 data reported an 11.1 month increase in median OS, and three-month improvement in PFS, noted July 30, 2024.",2.0,31.21094,190.0055,15.52173,43.30433,15.13043,1.026011652,-0.02553303,0.01214082,0.059901835,2.95908,0.04912,468.90431,1657,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
PTCT,SEPHIENCE (Sepiapterin (PTC923)) - (APHENITY),Phenylketonuria (PKU)Â ,NDA Filing,7/30/2024,"NDA submitted to FDA, noted July 30, 2024.",79.0,2533.29481,61.9158,32.52,33.03,32.09,0.015560955,-0.01331083,0.01214082,0.059901835,7.76689,0.09338,21.59475,1658,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
NKGN,Troculeucel (SNK01),Alzheimer's DiseaseÂ ,Preclinical,7/30/2024,"Preclinical new biomarker data to be presented at AAIC showed the ability to reduce Î±-synuclein levels in cerebrospinal fluid. Notably, 60% of patients exhibited decreased Î±-synuclein levels, and 90%",124.0,27.57511,195.3544,1.25,1.07,0.97,-0.155484903,-0.253602759,0.01214082,0.059901835,2.35384,0.00768,0.93637,1659,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1
PMN,PMN310 - (PRECISE-AD),Alzheimer's disease (AD)Â ,Preclinical,7/30/2024,"Preclinical data reported a strong antibody responses with no measurable pro-inflammatory T cell responses against AÃŸO and support novel approach for potential Alzheimer's disease vaccine, noted July",53.0,25.98811,96.7388,1.66,1.3706,1.42,-0.191569002,-0.156160731,0.01214082,0.059901835,0.13991,0.03387,0.30902,1660,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
NAMS,Obicetrapib - (BROOKLYN),Heterozygous familial hypercholesterolemia (HeFH)Â ,Phase 3,7/30/2024,"Phase 3 data reported that ldl-c reduction applied to prevail baseline data continues to suggest hypothetical 20%+ mace benefit, noted July 30, 2024.",112.0,1455.96999,52.7326,17.25,16.18,16.23,-0.064036232,-0.060950762,0.01214082,0.059901835,0.19045,0.25158,7.12122,1661,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
FGEN,"SM-88, Gemcitabine, nab-paclitaxel, and pamrevlumab - (PanCAN_Precision Promise)",Metastatic pancreatic ductal adenocarcinoma (mPDAC)Â ,Phase 2/3,7/30/2024,"Phase 2/3 data did not meet the primary endpoint of overall survival as determined by the protocol pre-specified Bayesian statistical analysis, noted July 30, 2024.",4.0,102.45964,130.8582,28.0,25.75,11.0,-0.083769883,-0.934309237,0.01214082,0.059901835,5.97327,0.10629,4.13483,1662,1,0,0,0,0,1,0,0,0,0,0,0,0,2,0,-1
FGEN,Pamrevlumab (LAPIS),Pancreatic cancerÂ ,Phase 3,7/30/2024,"Phase 3 trial did not meet the primary endpoint of overall survival, noted July 30, 2024.",4.0,102.45964,130.8582,28.0,25.75,11.0,-0.083769883,-0.934309237,0.01214082,0.059901835,5.97327,0.10629,4.13483,1663,1,0,0,0,0,1,0,0,0,0,0,0,0,2,0,-1
PEPG,PGN-EDO51 - (CONNECT1),Duchenne muscular dystrophy (DMD)Â ,Phase 1,7/30/2024,Phase 1 Proof of concept data from the first dose cohort (5 mg/kg) of PGN-EDO51 demonstrated higher exon skipping levels than previously reported studies with similar oligonucleotide therapies. After,32.0,550.44373,96.8685,17.51,16.98,9.39,-0.030735965,-0.623126853,0.01214082,0.059901835,1.77914,0.01767,1.34906,1664,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
JNJ,DARZALEX FASPRO (daratumumab and hyaluronidase-fihj),Frontline multiple myeloma transplant eligibleÂ ,Approved,7/31/2024,"Approved July 31, 2024.",0.0,379983.4128,16.9356,161.33,157.85,158.9,-0.021806742,-0.015176883,0.003237886,0.06932485,0.74714,0.06368,1309.08778,1665,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1
HUMA,ATEV - (V007),Acellular tissue engineered vessel (ATEV) in arteriovenous access for patients with end-stage renal disease.Â ,Phase 3,7/31/2024,"Phase 3 data demonstrated superiority at six and 12 months (co-primary endpoints) compared to autogenous fistula, the current standard of care for hemodialysis, noted July 31, 2024.",158.0,1126.53798,115.1369,8.2,9.46,7.83,0.142938229,-0.046171644,0.003237886,0.06932485,12.26439,0.03947,61.47186,1666,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ACHV,Cytisinicline - (ORCA-V1),E-cigarette & vape cessationÂ ,Phase 2,7/31/2024,"Breakthrough Therapy Designation granted by the FDA, noted July 31, 2024.",51.0,171.01969,47.7362,4.93,4.98,4.405,0.010090903,-0.112598729,0.003237886,0.06932485,7.02517,0.02133,1.63921,1667,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
VCNX,Pepinemab - (SIGNAL-AD),Alzheimerâ€™s Disease (AD)Â ,Phase 1/2,7/31/2024,"Phase 1/2 trial met primary endpoint, noted July 31, 2024.",2.0,8.07993,123.1391,8.06,5.1,4.8,-0.457673017,-0.518297639,0.003237886,0.06932485,0.96005,0.01959,5.4133,1668,1,0,0,0,0,1,0,0,0,0,0,0,2,0,0,1
ALXO,ALX148 + HERCEPTIN (Trastuzumab) + CYRAMZA (ramucirumab) and TAXOL (paclitaxel) - (ASPEN-06),2nd line or greater gastric/gastroesophageal junction cancerÂ ,Phase 2,7/31/2024,"Phase 2 final analysis reported an ORR of 40.3%, noted July 31, 2024.",53.0,250.08051,94.4889,5.45,4.8,2.57,-0.126999691,-0.75170971,0.003237886,0.06932485,14.87765,0.04314,41.53523,1669,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
HCM,Savolitinib + TAGRISSO (osimertinib) - (SAVANNAH),Non-small cell lung cancer (NSCLC)Â ,Phase 2,7/31/2024,"Phase 2 enrollment completed, noted July 31, 2024.",174.0,2563.32014,58.4926,2.82,3.0,3.11,0.061875404,0.097885841,0.003237886,0.06932485,0.0,0.0246,1.07054,1670,0,0,0,0,0,1,0,0,0,1,0,0,2,0,0,1
HCM,IMG-004,Immunological diseasesÂ ,Phase 1,7/31/2024,"Phase 1 topline results indicated a once-daily dosing potential. It was well tolerated, without reports of liver enzyme elevation or bleeding events, across once daily doses ranges for 10 days. Prelim",174.0,2563.32014,58.4926,2.82,3.0,3.11,0.061875404,0.097885841,0.003237886,0.06932485,0.0,0.0246,1.07054,1671,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1
HCM,IMG-007,Atopic dermatitis and other immunological diseasesÂ ,Phase 2a,7/31/2024,"Phase 2a teatment led to rapid, marked, and durable improvement of skin signs in patients with atopic dermatitis, noted July 31, 2024.",174.0,2563.32014,58.4926,2.82,3.0,3.11,0.061875404,0.097885841,0.003237886,0.06932485,0.0,0.0246,1.07054,1672,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
AGIO,Mitapivat (AG-348) - (ACTIVATE kids-T study),Pediatric PK DeficiencyÂ ,Phase 3,8/1/2024,"Phase 3 data reported that 28.1% of patients in the mitapivat arm achieved the primary endpoint of transfusion reduction response, compared to 11.8% of patients in the placebo arm, noted August 1, 202",58.0,2531.74429,58.5923,46.4,44.5,43.79,-0.04181027,-0.057893978,0.026493648,0.041848836,5.60924,0.11828,39.0103,1673,1,0,0,0,0,1,0,0,0,0,0,0,2,0,0,1
LLY,Tirzepatide - (SUMMIT),Heart failure with preserved ejection fraction (HFpEF) and obesityÂ ,Phase 3,8/1/2024,"Phase 3 data reported a statistically significant improvements in both primary endpoints, noted August 1, 2024.",946.0,749533.4595,28.6091,804.27,832.44,845.31,0.034426113,0.04976839,0.026493648,0.041848836,0.70131,0.06396,3380.31575,1674,1,0,0,0,0,1,0,0,0,0,0,0,2,0,0,1
RDHL,RHB-104 MAP,Crohnâ€™s diseaseÂ ,Phase 3,8/1/2024,"Phase 3 data is 64% more effective than the standard of care alone. It achieved a statistically significant higher clinical remission rate at week 26 compared to the placebo, noted on August 1, 2024.",3.0,24.2189,113.9479,9.6025,19.0,11.35,0.682415498,0.167194263,0.026493648,0.041848836,1.06433,8e-05,273.68058,1675,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1
NRSN,PrimeC - (PARADIGM),Amyotrophic Lateral Sclerosis (ALS)Â ,Phase 2b,8/1/2024,"Phase 2b demonstrated regulation of iron levels, which aligns with improved ALS survival and disease mitigation, noted August 1, 2024.",23.0,12.26516,101.9866,0.7598,0.68,0.628,-0.110962443,-0.190515074,0.026493648,0.041848836,0.80951,0.08718,2.80215,1676,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
GSK,Jemperli (dostarlimab-gxly) plus chemotherapy,Primary advanced or recurrent endometrial cancerÂ ,Approved,8/1/2024,"Approved August 1, 2024.",0.0,62244.89922,22.634,15.12,15.26,15.6,0.009216655,0.031252544,0.026493648,0.041848836,0.0,0.02422,173.58265,1677,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1
SUPN,ONAPGO (apomorphine hydrochloride) injection (SPN-830),Motor fluctuations in Parkinsonâ€™s disease (PD)Â ,NDA Filing,8/1/2024,"NDA resubmitted August 1, 2024.",56.0,1625.58869,34.9527,29.82,29.57,31.48,-0.008418975,0.054173114,0.026493648,0.041848836,11.47971,0.10593,13.13254,1678,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
RGNX,RGX-314 - (AAVIATE),Wet AMD using suprachoroidal deliveryÂ ,Phase 2,8/1/2024,"Phase 2 update reported that treatment was well tolerated with no drug-related SAEs and no cases of intraocular inflammation, noted August 1, 2024.",50.0,657.82263,72.2375,14.25,13.31,11.89,-0.068241274,-0.181059196,0.026493648,0.041848836,9.73278,0.0613,14.02218,1679,0,0,0,1,0,1,0,0,0,0,0,0,2,0,0,1
CLSD,RGX-314 - (AAVIATE),Wet AMD using suprachoroidal deliveryÂ ,Phase 2,8/1/2024,"Phase 2 update reported that treatment was well tolerated with no drug-related SAEs and no cases of intraocular inflammation, noted August 1, 2024.",5.0,84.44618,79.7843,17.09999,16.94999,15.89999,-0.008810635,-0.072759398,0.026493648,0.041848836,0.15658,0.12085,0.26922,1680,0,0,0,1,0,1,0,0,0,0,0,0,2,0,0,1
MRK,Ifinatamab deruxtecan (DS-7300) - (IDeate-Lung02 ),Extensive-stage small cell lung cancer (SCLC)Â ,Phase 3,8/1/2024,"Phase 3 trial initiated, noted August 1, 2024.",0.0,288284.0139,23.1858,113.13,113.82,113.92,0.006080653,0.006958848,0.026493648,0.041848836,0.97003,0.0627,1606.84907,1681,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
PDSB,PDS0101 in combination with KEYTRUDA - (VERSATILE-003),Human papillomavirus (HPV) 16-positive head and neck squamous cell carcinoma (HNSCC)Â ,Phase 3,8/1/2024,"Phase 3 trial to be initiated in 4Q 2024 after FDA meeting, noted August 1, 2024.",46.0,118.47406,81.9473,3.56,3.23,3.05,-0.097278408,-0.154618954,0.026493648,0.041848836,15.54195,0.10076,1.93692,1682,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
IONS,IONIS-FB-LRx - (GOLDEN),Geographic atrophy due to age-related macular degeneration (AMD)Â ,Phase 3,8/1/2024,"Phase 3 trial discontinued development, noted August 1, 2024.",159.0,7494.01563,34.9305,49.46,51.32,47.51,0.036916278,-0.040224047,0.026493648,0.041848836,6.41351,0.07305,77.1337,1683,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
RGNX,RGX-202 - (AFFINITY DUCHENNE),Duchenne Muscular Dystrophy (DMD)Â ,Phase 1/2,8/1/2024,"Phase 1/2 data in the pivotal dose group, patients aged 5.8 and 8.5 years showed microdystrophin expression levels of 77.2% and 46.5% of control, respectively, at three months post-treatment. The ther",50.0,657.82263,72.2375,14.25,13.31,11.89,-0.068241274,-0.181059196,0.026493648,0.041848836,9.73278,0.0613,14.02218,1684,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
JAGX,Mytesi (crofelemer),Inflammatory bowel disease (IBS-D)Â ,Phase 2,8/1/2024,"Phase 2 showed a benefit in patients with chronic refractory diarrhea noted August 1, 2024.",2.0,6.82813,230.8937,30.75,29.75,27.75,-0.033060862,-0.102654154,0.026493648,0.041848836,4.97633,0.00326,0.70969,1685,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
XOMA,MIPLYFFA (MY-PLY-FAH) (arimoclomol),Niemann-Pick disease Type C (NPC)Â ,PDUFA,8/2/2024,"FDA Advisory Committee votes resulted in 11 voting Yes, 5 voting no , none abstained, noted August 2, 2024.",12.0,289.68358,58.1069,25.77,24.89,23.82,-0.034744908,-0.078685461,0.054568456,0.032235941,2.38295,0.00027,0.31227,1686,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ZVRA,MIPLYFFA (MY-PLY-FAH) (arimoclomol),Niemann-Pick disease Type C (NPC)Â ,PDUFA,8/2/2024,"FDA Advisory Committee votes resulted in 11 voting Yes, 5 voting no , none abstained, noted August 2, 2024.",56.0,263.67701,65.3153,6.3,6.3,6.61,0.0,0.04803402,0.054568456,0.032235941,7.57312,0.02158,0.0,1687,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ATNM,Iomab-B - (SIERRA),Acute myeloid leukemia (AML)Â ,Phase 3,8/5/2024,"Phase 3 study determined by the FDA that the trial is not adequate to support a BLA filing for Iomab-B despite its statistically significant primary endpoint, noted August 5, 2024.",31.0,77.26285,151.5838,6.17,2.48,1.99,-0.911440278,-1.131564199,0.021267367,0.006865016,6.88587,0.0539,39.64386,1688,1,0,0,0,0,1,0,1,0,0,0,0,3,0,0,1
IXHL,PSX-001 (Psilocybin treatment) - (PsiGAD2),Generalized anxiety disorder (GAD)Â ,Phase 2b,8/5/2024,"IND for Phase 2b (PsiGAD2) trial completed August 5, 2024.",347.0,32.38115,138.9252,1.8361,2.04,1.97,0.105306051,0.070389786,0.021267367,0.006865016,0.088,0.03581,0.39185,1689,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
XOMA,RZ358,Hypoglycemia in patients with tumor hyperinsulinism (HI)Â ,Phase 3,8/5/2024,"Phase 3 IND cleared August 5, 2024.",12.0,273.97154,58.6571,24.89,23.54,23.13,-0.055765015,-0.07333564,0.021267367,0.006865016,2.38295,0.00027,0.4749,1690,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
RZLT,RZ358,Hypoglycemia in patients with tumor hyperinsulinism (HI)Â ,Phase 3,8/5/2024,"Phase 3 IND cleared August 5, 2024.",90.0,243.5705,102.7883,4.3,4.4,4.27,0.022989518,-0.007001195,0.021267367,0.006865016,2.50458,0.01131,2.08967,1691,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ANNX,ANX007 - (ARCHER-II),Geographic atrophyÂ ,Phase 3,8/5/2024,"Additional data demonstrated both significant vision protection in standard and low light conditions, and significant structural protection in regions of the eye Important for visual acuity. Phase 3 p",109.0,570.28966,99.3161,5.97,5.41,5.61,-0.098497835,-0.062196208,0.021267367,0.006865016,5.5383,0.07044,6.11718,1692,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
LTRN,LP-300 - (Harmonic),Non-small cell lung cancer (NSCLC)Â ,Phase 2,8/5/2024,"Phase 2 data reported that 3 patients showed partial responses with an average tumor size reduction of 51% and 3 patients have stable disease with an average tumor size reduction of 13%, noted August",10.0,37.87099,123.8411,3.74,3.52,3.86,-0.060624622,0.031581572,0.021267367,0.006865016,2.26323,0.05635,0.568,1693,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
TFFP,TFF TAC (Tacrolimus Inhalation Powder),Lung transplant (post)Â ,Phase 2,8/6/2024,"Phase 2 additional data reported a 6.5-fold reduction in the number of abnormally expressed rejection-related gene sets after treatment with TFF TAC, noted August 6, 2024.",4.0,815.168,71.0469,42.05,42.05,42.05,0.0,0.0,0.011518508,-0.036982889,0.0,0.0,0.0,1694,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ADTX,ATI-1701,Francisella tularensis vaccineÂ ,Preclinical,8/6/2024,"Preclinical data reported a 100% survival in rats challenged with aerosolized SCHU S4 up to one-year post-vaccination, even at challenge doses >10,000x the median lethal dose (LD50), noted August 6, 2",4.0,3.07076,104.0516,9060.0,9970.0,11100.0,0.095711464,0.203075988,0.011518508,-0.036982889,7.14146,0.04974,0.10967,1695,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
EQ,Itolizumab - (EQUATOR),1st line Acute graft-versus-host disease (aGVHD)Â ,Phase 3,8/6/2024,"Phase 3 IDMC issued a positive recommendation based on the interim data, noted August 6, 2024.",59.0,25.73244,126.0642,0.6355,0.7299,0.72995,0.138495448,0.138563948,0.011518508,-0.036982889,0.64902,0.00352,0.56972,1696,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CLNN,CNM-Au8 - (RESCUE-ALS),Amyotrophic Lateral SclerosisÂ ,Phase 2,8/6/2024,"Additional Phase 2 data reported that it demonstrated a 28% mean reduction in NfL levels compared to baseline, noted August 6, 2024.",9.0,37.8378,100.9573,4.0,5.88,5.07,0.385262401,0.237046456,0.011518508,-0.036982889,0.26064,0.0512,21.96682,1697,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ANVS,Buntanetap (ANVS401),Alzheimerâ€™s disease (AD)Â ,Preclinical,8/6/2024,"Preclinical data reported that buntanetap significantly amplifies the effects of dulaglutide on memory and learning, with a 6- to 10-fold increase in efficacy, noted August 6, 2024.",19.0,93.28186,205.0247,8.4,8.35,7.96,-0.005970167,-0.053802706,0.011518508,-0.036982889,13.77543,0.08052,2.19933,1698,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
AGIO,VORANIGO (vorasidenib),Grade 2 IDH-mutant GliomaÂ ,Approved,8/7/2024,"Approved August 6, 2024.",58.0,2421.94054,58.6697,42.61,42.57,44.68,-0.000939188,0.047437007,-0.005912179,-0.01732054,5.60924,0.12623,24.31275,1699,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1
EYPT,DURAVYU ( EYP-1901 vorolanib intravitreal) - (PAVIA),Non-proliferative diabetic retinopathy (NPDR)Â ,Phase 2,8/7/2024,"Phase 2 data demonstrated stable or improved diabetic retinopathy severity scores (DRSS) and a favorable safety profile at nine-months., noted August 7, 2024.",68.0,450.52984,104.2951,9.02,8.65,7.58,-0.041885013,-0.173931134,-0.005912179,-0.01732054,19.3588,0.02239,5.7607,1700,1,0,0,1,0,1,0,0,0,0,0,0,3,0,0,1
PRFX,PRF-110,BunionectomyÂ ,Phase 3,8/7/2024,"Phase 3 data reported a promising safety profile, with maximum blood levels (Cmax) recorded at approximately 10% of the FDA-established safety threshold, noting August 7, 2024.",1.0,1.06926,101.8744,7.7808,7.3992,7.344,-0.050287274,-0.057775507,-0.005912179,-0.01732054,1.48499,0.12776,0.2066,1701,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
AMRX,CREXONT (Carbidopa and Levodopa),Parkinson's diseaseÂ ,Approved,8/7/2024,"Approved August 7, 2024.",314.0,2101.91585,40.1309,6.88,6.81,7.81,-0.010226532,0.126786312,-0.005912179,-0.01732054,1.48662,0.16664,13.907,1702,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1
NVS,Fabhalta (iptacopan),IgA nephropathy (IgAN)Â ,Approved,8/8/2024,"Approved August 8, 2024.",0.0,1944.72331,67.7328,6.25,6.25,6.01,0.0,-0.039156715,-0.033851023,-0.056309923,0.0,0.00998,0.06604,1703,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1
APLS,EMPAVELI (pegcetacoplan) - (VALIANT),C3G and IC-MPGNÂ ,Phase 3,8/8/2024,"Phase 3 top-line data reported that the trial met its primary endpoint, noted August 8, 2024.",126.0,4585.71991,55.1912,33.59,37.66,37.62,0.11437012,0.11330742,-0.033851023,-0.056309923,12.45698,0.02024,163.29184,1704,1,0,0,0,0,1,0,0,0,0,1,0,3,0,0,1
ALDX,Reproxalap (ADX-102) - (TRANQUILITY),Dry eye diseaseÂ ,Phase 3,8/8/2024,"Phase 3 trial met primary endpoint, noted August 8, 2024.",59.0,248.9763,79.6182,3.26,4.19,5.25,0.250973539,0.476500881,-0.033851023,-0.056309923,4.55352,0.20983,19.94046,1705,1,0,0,0,0,1,0,0,0,0,0,0,2,0,0,1
CTXR,LYMPHIR (denileukin diftitox-cxdl),CTCL non-Hodgkin lymphomaÂ ,Approved,8/8/2024,"Approved August 8, 2024.",17.0,160.79928,84.7143,22.6475,22.25,14.6575,-0.017707462,-0.435097321,-0.033851023,-0.056309923,6.6444,5e-05,5.30952,1706,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1
OGEN,ONP-002,Moderate-to-severe concussion in the acute through subacute phasesÂ ,Phase 2,8/8/2024,"Cleared FDA-required cardiotoxicity testing, noted August 8, 2024.",4.0,6.02713,149.6801,28.9979,32.40324,43.20432,0.111035004,0.398717077,-0.033851023,-0.056309923,1.27565,0.03814,11.91652,1707,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CARM,CT-0508 with pembrolizumab,HER2+ solid tumorsÂ ,Phase 1,8/8/2024,"Phase 1 trial met primary endpoint, noted August 8, 2024.",41.0,37.43202,92.0523,0.8,0.901,1.05,0.11889353,0.271933715,-0.033851023,-0.056309923,2.48547,0.06608,0.27916,1708,1,0,0,0,0,1,0,0,0,0,0,0,2,0,0,1
NTLA,"Lonvoguran ziclumeran (lonvo-z, formerly NTLA-2002) - (HAELO)",Hereditary angioedema (HAE)Â ,Phase 2,8/8/2024,"Phase 2 trial met its primary endpoint, noted August 8, 2024.",107.0,2273.34223,59.2642,21.31,22.38,22.87,0.048991257,0.070649562,-0.033851023,-0.056309923,13.63307,0.32078,34.99834,1709,1,0,0,0,0,1,0,0,0,0,0,0,2,0,0,1
ANTX,EBO-301,Treatment-Refractory MAC Lung DiseaseÂ ,Phase 2/3,8/8/2024,"Phase 2/3 data reported higher PRO-based clinical response rate in the epetraborole + OBR arm (39.5%) vs. placebo + OBR (25.0%; treatment difference 13.9%, p=0.19), noted August 8, 2024.",27.0,78.74867,207.8613,2.47,2.64,1.02,0.066560767,-0.884415523,-0.033851023,-0.056309923,2.31544,0.01387,0.42007,1710,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
RNA,Delpacibart zotadirsen (del-zota) - (EXPLORE44),Duchenne Muscular Dystrophy (DMD) Mutations Amenable to Exon 44 SkippingÂ ,Phase 1/2,8/9/2024,"Phase 1/2 5 mg/kg cohort data reported a statistically significant 37% increase in exon 44 skipping and up to 66% skipping with delpacibart zotadirsen 5 mg/kg at four months, noted August 9, 2024.",128.0,5155.17559,77.4299,41.87,46.95,44.98,0.114513626,0.071648367,-0.008490172,-0.02874089,11.79675,0.16925,116.77719,1711,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1
SPRY,Neffy (epinephrine nasal spray),Allergic reactions (type I) including anaphylaxisÂ ,Approved,8/9/2024,"Approved August 9, 2024.",98.0,1054.72471,58.5448,9.89,10.88,13.33,0.095402096,0.298492989,-0.008490172,-0.02874089,10.23914,0.18007,39.68798,1712,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1
PSTV,REYOBIQ (rhenium Re186 obisbemeda) - (ReSPECT-LM),Leptomeningeal metastases (LM)Â ,Phase 1,8/9/2024,"Phase 1 dose escalation data from SNO/ASCO reported continued feasibility and safety of up to 44 mCi of intrathecal Rhenium (186Re) Obisbemeda, noted August 9, 2024.",99.0,8.27112,73.3016,1.55,1.45,1.36,-0.066691374,-0.130770231,-0.008490172,-0.02874089,2.26168,0.21188,0.10835,1713,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
HUMA,SYMVESS (acellular tissue engineered vessel-tyod),Extremity Vascular TraumaÂ ,PDUFA priority review,8/9/2024,"PDUFA date was expected for August 10, 2024, however the FDA to require additional time for review, noted August 9, 2024.",158.0,941.95723,109.369,8.0,7.91,6.48,-0.01131376,-0.210721031,-0.008490172,-0.02874089,10.08415,0.04138,40.16221,1714,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
PFE,ABRYSVO - (MONeT),Respiratory syncytial virus (RSV)-associated lower respiratory tract disease (LRTD)Â ,Phase 3,8/12/2024,"Phase 3 data reported that ABRYSVO was well-tolerated and generated strong neutralizing responses after a single dose in adults â‰¥ 18 years of age, noted August 12, 2024.",0.0,161217.4746,24.0475,28.55,28.45,28.8,-0.003508776,0.008718451,-0.014650374,-0.054089256,1.15296,0.00212,601.4773,1715,0,0,0,1,0,1,0,0,0,0,0,0,2,0,0,1
NVS,Enzeevu (aflibercept-abzv),Neovascular age-related macular degeneration (nAMD)Â ,Approved,8/12/2024,"Approved August 12, 2024.",0.0,1947.83487,67.8909,6.25,6.26,6.06,0.001598721,-0.030871664,-0.014650374,-0.054089256,0.0,0.02973,0.17383,1716,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1
ASND,YORVIPATH (Palopegteriparatide),HypoparathyroidismÂ ,Approved,8/12/2024,"Approved August 12, 2024.",60.0,7368.29639,34.2601,126.97,128.48,137.82,0.011822412,0.081997648,-0.014650374,-0.054089256,6.11097,0.07159,195.94176,1717,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1
TNXP,Tonmya (TNX-102 SL) - (RELIEF/RESILIENT),FibromyalgiaÂ ,Phase 3,8/12/2024,"Phase 3 results presented at IASP showed correlations between improvements in pain and sleep quality at Week 14, noted August 12, 2024.",8.0,10.83617,175.5807,47.85,51.2,44.5,0.067668414,-0.072581929,-0.014650374,-0.054089256,2.64794,0.01701,0.43617,1718,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
OGEN,ONP-002,Moderate-to-severe concussion in the acute through subacute phasesÂ ,Preclinical,8/12/2024,"Animal data reported no cancer-causing DNA damage, noted August 12, 2024.",4.0,11.60781,164.4795,42.0042,62.40624,30.60306,0.395895657,-0.316669609,-0.014650374,-0.054089256,0.76582,0.02998,16.87359,1719,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
AMLX,AMX0035 - (PEGASUS),Alzheimer's DiseaseÂ ,Phase 2,8/12/2024,"Phase 2 data reported that AMX0035 reduced levels of p-tau181 and total tau. AMX0035 treatment also reduced levels of synaptic and neuronal degeneration biomarkers in the CSF, specifically neurogranin",89.0,134.80329,256.6125,1.9,1.98,2.2,0.041242959,0.146603474,-0.014650374,-0.054089256,2.72644,0.03254,1.54616,1720,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CMPX,CTX-009 - (COMPANION-003),Colorectal cancer (CRC)Â ,Phase 2,8/12/2024,"Phase 2 data reported an objective response rate (ORR) of 5% (2 out of 41 patients), median progression free survival (PFS) of 3.9 months, disease control rate (DCR) of 71%, noted August 12, 2024.",138.0,155.47576,85.527,1.09,1.13,1.19,0.036039936,0.087775611,-0.014650374,-0.054089256,1.37322,0.01781,0.62121,1721,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
SYRS,Tamibarotene (SY-1425) with VENCLEXTA (venetoclax) and VIDAZA (azacitidine) - (SELECT-AML-1),Acute myeloid leukemia (AML)Â ,Phase 2,8/12/2024,"Phase 2 probability for success of the SELECT-AML-1 study to demonstrate superiority at the final analysis in 80 randomized patients was considered low, enrollment discontinued, noted August 12, 2024.",26.0,134.31692,69.1606,5.07,5.01,1.74,-0.011904903,-1.069455704,-0.014650374,-0.054089256,4.94908,0.01834,5.81483,1722,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CATX,[212Pb]VMT-Î±-NET,Neuroendocrine tumors (NETs)Â ,Phase 1,8/12/2024,"Phase 1 preliminary data reported that the average renal doses for the three patients who received amino acids was 0.46Â±0.20 Gy/mCi, as compared to 0.56Â±0.16 Gy/mCi for the seven patients who did not",74.0,815.2287,87.5619,12.02,12.09,14.16,0.005806736,0.163849159,-0.014650374,-0.054089256,10.05831,0.00051,7.33735,1723,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
VCNX,Pepinemab - (SIGNAL-AD),Alzheimerâ€™s Disease (AD)Â ,Phase 1/2,8/12/2024,"Phase 1/2a trial changes in the levels of GFAP and pTau-217 biomarkers in blood correlated over 12-months of treatment, with a positive relationship between the two measures (correlation coefficient >",2.0,8.27568,123.0363,4.58,4.79,5.13,0.044831413,0.113406661,-0.014650374,-0.054089256,2.54274,0.03218,0.19973,1724,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ATAI,VLS-01 - (Elumina),Treatment Resistant DepressionÂ ,Phase 1b,8/13/2024,"Phase 1b topline data reported that treatment demonstrated a favorable safety profile and was well tolerated, with all adverse events classified as either mild or moderate, and most resolving on the d",214.0,204.71473,79.0522,1.24,1.22,1.31,-0.016260521,0.054915758,-0.002918189,-0.051068867,5.23086,0.09918,0.88873,1725,0,0,0,1,0,1,0,0,0,0,1,0,3,0,0,1
PSTV,CNSide - (FORESEE),Breast or Non-Small Cell Lung Cancer (NSCLC) who have suspicious or confirmed Leptomeningeal Metastases (LM)Â ,Phase 1,8/13/2024,"Trial data reported that the trial achieved its primary endpoint, demonstrating that CNSide influenced treatment decisions in over 90% of cases, surpassing the 20% primary endpoint target, noted Augus",99.0,8.49929,73.6178,1.41,1.49,1.55,0.055186416,0.094665227,-0.002918189,-0.051068867,2.26168,0.21188,0.13238,1726,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1
ALMS,Izokibep,Hidradenitis Suppurativa (HS)Â ,Phase 3,8/13/2024,"Phase 3 data reported statistically signiï¬cant responses across multiple eï¬ƒcacy endpoints at 12 weeks, including 33% of patients receiving izokibep 160mg weekly (QW) achieving HiSCR75, compared to 21%",104.0,682.21741,0.0,11.99,12.54,13.0,0.044850566,0.080876388,-0.002918189,-0.051068867,1.25023,0.78546,0.6724,1727,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
SLS,Tambiciclib (SLS009) (GFH009) with venetoclax,"Hematologic malignancies, acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) and lymphomaÂ ",Phase 2a,8/13/2024,"Phase 2a data reported that except for one, all patients in this Phase 2a trial had adverse risk AML (97%), noted August 13, 2024.",105.0,76.55567,92.3385,1.18,1.19,1.31,0.008438869,0.104512699,-0.002918189,-0.051068867,16.55475,0.02474,0.55575,1728,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
KZR,KZR-261 (101),Solid TumorsÂ ,Phase 1,8/13/2024,"Phase 1 data reported no objective responses have been observed to date, noted August 13, 2024.",7.0,42.33268,50.7688,5.909,5.802,6.005,-0.018273927,0.016115843,-0.002918189,-0.051068867,1.4249,0.18678,0.17284,1729,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ANTX,Epetraborole - (EBO-103),"Mycobacterium avium complex (MAC) lung disease, Chronic non-tuberculous mycobacterial (NTM) lung diseaseÂ ",Phase 2,8/13/2024,"Phase 2 topline data reported that trial met primary endpoint, noted August 13, 2024.",27.0,32.52825,149.7765,1.03,1.09,1.05,0.056618894,0.019231362,-0.002918189,-0.051068867,2.29003,0.01461,0.84023,1730,1,0,0,0,0,1,0,0,0,0,1,0,3,0,0,1
VRCA,VP-315 (LTX-315),Basal cell carcinomaÂ ,Phase 2,8/14/2024,"Phase 2 topline data reported an overall reduction in tumor size of all lesions treated in Part 2 of approximately 86%, noted August 14, 2024.",9.0,133.12588,100.6363,52.7,31.2,29.1,-0.524197361,-0.593877281,-0.007808526,-0.049011167,8.64091,0.17593,16.93031,1731,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
GILD,Livdelzi (Seladelpar),Primary biliary cholangitis (PBC)Â ,Approved,8/14/2024,"Approved August 14, 2024.",0.0,92303.71289,23.4673,73.98,74.14,75.13,0.002160411,0.01542516,-0.007808526,-0.049011167,1.43331,0.03243,351.99974,1732,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1
SNDX,Niktimvo (axatilimab-csfr),Chronic Graft versus host disease (cGvHD)Â ,Approved,8/14/2024,"Approved August 14, 2024.",86.0,1666.18669,45.6665,19.87,19.58,20.32,-0.014702419,0.022394566,-0.007808526,-0.049011167,10.09211,0.28125,17.25517,1733,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1
INCY,Niktimvo (axatilimab-csfr),Chronic Graft versus host disease (cGvHD)Â ,Approved,8/14/2024,"Approved August 14, 2024.",196.0,11783.14729,25.1986,62.02,61.18,64.15,-0.013636575,0.033767177,-0.007808526,-0.049011167,6.30649,0.14063,92.02573,1734,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1
LYRA,LYR-210 - (ENLIGHTEN I),Chronic rhinosinusitisÂ ,Phase 3,8/14/2024,"Phase 3 data reported that treatment resulted in a mean (standard error; SE) improvement in the 3CS score of 3.21 (0.436) points, compared to 0.96 (0.619) points in sham control for a difference of 2",1.0,18.75989,297.8296,14.995,14.33,16.745,-0.04536157,0.110382894,-0.007808526,-0.049011167,5.34334,0.00117,0.32701,1735,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
SIGA,PALM 007 (Tecovirimat for Treatment of Monkeypox Virus),Monkeypox (mpox)Â ,Phase 2,8/15/2024,"Phase 2 data reported that the study did not reach statistical significance on its primary endpoint of tecovirimat being superior to placebo in lesion resolution for all patients, noted August 15, 202",71.0,686.57242,90.819,11.97,9.62,9.34,-0.218559255,-0.248097267,-0.017332529,-0.041283955,7.73129,0.00038,160.18028,1736,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
VCEL,NexoBrid (CIDS),Severe burns - pediatricÂ ,Approved,8/15/2024,"Approved 15, 2024.",50.0,2262.25228,37.5188,45.31,46.14,47.5,0.018152494,0.047201952,-0.017332529,-0.041283955,6.11452,0.18054,12.45185,1737,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1
MDWD,NexoBrid (CIDS),Severe burns - pediatricÂ ,Approved,8/15/2024,"Approved 15, 2024.",11.0,195.98931,75.9168,17.47,18.17,18.77,0.039286758,0.071774726,-0.017332529,-0.041283955,5.42607,0.02806,0.87505,1738,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1
XNCR,MONJUVI (tafasitamab) with REVLIMID (lenalidomide) and RITUXAN (rituximab),Follicular lymphoma (FL) / marginal zone lymphoma (MZL)Â ,Phase 3,8/15/2024,"Phase 3 data reported that that it met its primary endpoint of progression free survival (PFS) in relapsed or refractory follicular lymphoma (FL), noted August 15, 2024.",71.0,991.19149,57.2752,15.73,16.03,16.67,0.01889225,0.05804098,-0.017332529,-0.041283955,7.10464,0.0866,8.57932,1739,1,0,0,0,0,1,0,0,0,0,0,0,2,0,0,1
NVS,MONJUVI (tafasitamab) with REVLIMID (lenalidomide) and RITUXAN (rituximab),Follicular lymphoma (FL) / marginal zone lymphoma (MZL)Â ,Phase 3,8/15/2024,"Phase 3 data reported that that it met its primary endpoint of progression free survival (PFS) in relapsed or refractory follicular lymphoma (FL), noted August 15, 2024.",0.0,1870.04594,66.7035,6.3,6.01,6.09,-0.047124885,-0.033901552,-0.017332529,-0.041283955,0.0,0.02973,0.10866,1740,1,0,0,0,0,1,0,0,0,0,0,0,2,0,0,1
INCY,MONJUVI (tafasitamab) with REVLIMID (lenalidomide) and RITUXAN (rituximab),Follicular lymphoma (FL) / marginal zone lymphoma (MZL)Â ,Phase 3,8/15/2024,"Phase 3 data reported that that it met its primary endpoint of progression free survival (PFS) in relapsed or refractory follicular lymphoma (FL), noted August 15, 2024.",196.0,11879.44631,25.0911,61.18,61.68,63.02,0.008139391,0.029631798,-0.017332529,-0.041283955,6.30649,0.14063,80.96228,1741,1,0,0,0,0,1,0,0,0,0,0,0,2,0,0,1
AZN,IMFINZI (durvalumab),Non-Small Cell Lung Cancer (before and after surgery)Â ,Approved,8/16/2024,"Approved August 16, 2024.",0.0,202249.1376,18.5483,131.66,130.46,130.76,-0.009156176,-0.00685926,-0.031630356,-0.038153408,0.0,0.09508,162.63679,1742,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1
PFE,Modified RNA (modRNA) vaccine,InfluenzaÂ ,Phase 2,8/16/2024,"Phase 2 data reported that the primary endpoints for this qIRV first-generation candidate were not met in adults aged 65 and older, as statistical non-inferior relative vaccine efficacy (""rVE"") compar",0.0,160367.4703,23.8546,28.71,28.3,28.9,-0.014383689,0.006596101,-0.031630356,-0.038153408,1.15296,0.00347,1424.42155,1743,1,0,0,0,0,1,0,0,0,0,0,0,2,0,0,1
LQDA,YUTREPIA,Interstitial lung disease (PH-ILD)Â ,Approved,8/19/2024,"Tentative approval announced August 19, 2024.",86.0,751.81026,71.5987,14.11,9.79,9.83,-0.365522309,-0.361444832,-0.030818149,-0.039409522,16.764,0.04956,151.13068,1744,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
APGE,APG777 + APG990,Atopic dermatitis (AD)Â ,Phase 1,8/19/2024,"Phase 1 initiated in healthy volunteers, noted August 19, 2024.",59.0,2836.31504,80.9685,45.25,50.04,47.41,0.100620015,0.046630507,-0.030818149,-0.039409522,13.73139,0.07087,15.66237,1745,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
RDHL,Opaganib (ABC294640),ObesityÂ ,Preclinical,8/19/2024,"Invivo study done by RedHill's partner, Apogee Biotechnology Corporation has shown the impact of opaganib on weight gain and glucose tolerance in a high fat diet (HFD) model, supporting the potential",3.0,10.27953,135.4577,7.2525,8.0275,8.43,0.10152691,0.150450535,-0.030818149,-0.039409522,1.30394,0.00423,7.47836,1746,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
GLUE,MRT-6160,Autoimmune conditionsÂ ,Phase 1,8/19/2024,"Phase 1 dosing initiated, noted August 19, 2024.",61.0,297.01874,96.5127,4.68,4.84,6.97,0.033616611,0.398317115,-0.030818149,-0.039409522,4.52997,0.1626,0.77767,1747,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1
PCSA,SN-38,CancerÂ ,Preclinical,8/19/2024,"Preclinical data reported that accumulation of SN-38 in the tumor compared with other tissues, such as muscle, was greater after NGC-Iri administration than after irinotecan or Onivyde administration,",50.0,4.95056,128.7679,1.45,1.52,1.45,0.047146778,0.0,-0.030818149,-0.039409522,28.93065,0.01812,0.35356,1748,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
SONN,SON-1210,Solid TumorsÂ ,Preclinical,8/19/2024,"Preclinical data has demonstrated the potential of SON-1210, the first albumin-binding bifunctional IL-12/IL-15 fusion protein, for solid tumor immunotherapy. IIOC, led by Oncology experts funded by t",6.0,3.49348,99.6892,5.26,5.372,6.156,0.021069252,0.157296189,-0.030818149,-0.039409522,0.82526,0.07173,0.53937,1749,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
LLY,Tirzepatide - (SURMOUNT-1),Pre-diabetes and obesity or overweightÂ ,Phase 3,8/20/2024,"Phase 3 176-week data reported that treatment significantly reduced the risk of progression to type 2 diabetes by 94% ii among adults with pre-diabetes and obesity or overweight compared to placebo, n",946.0,855377.4763,31.9184,921.81,949.97,954.48,0.030091277,0.034827561,-0.009572284,-0.002179082,0.60072,0.10311,4713.27426,1750,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
JNJ,RYBREVANT (amivantamab-vmjw) plus LAZCLUZE - (MARIPOSA),1L locally advanced or metastatic non-small cell lung cancer (NSCLC)Â ,Approved,8/20/2024,"FDA approved on August 20, 2024.",0.0,385544.1457,17.1822,159.63,160.16,162.95,0.003314678,0.020584768,-0.009572284,-0.002179082,0.783,0.0321,1165.1853,1751,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
TNXP,TNX-1300 - (CATALYST),Drug overdoseÂ ,Phase 2,8/20/2024,"Phase 2 dosing commenced, noted August 20, 2024.",8.0,8.36156,175.5222,44.5,38.0,36.33,-0.157903029,-0.202845343,-0.009572284,-0.002179082,2.54689,0.01593,15.79899,1752,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
INM,INM-901,Alzheimerâ€™s diseaseÂ ,Preclinical,8/20/2024,"Preclinical studies confirmed that INM-901 as an oral formulation that will be utilized in its development programs for Alzheimerâ€™s disease, noted August 20, 2024.",1.0,3.84585,184.209,2.96,8.624,8.076,1.069359746,1.003707432,-0.009572284,-0.002179082,2.83924,0.01488,144.96782,1753,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
AMRX,Propofol emulsion (Diprivan generic),Anesthetic and sedationÂ ,Approved,8/20/2024,"FDA approved under ANDA approval on August 20, 2024.",314.0,2507.29513,43.0323,8.15,8.1,8.48,-0.006153866,0.039692523,-0.009572284,-0.002179082,1.43469,0.14104,10.45325,1754,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
SPRC,SCI-210,Autism Spectrum DisorderÂ ,Phase 1,8/20/2024,"First 5 patients enrolled, noted August 20, 2024.",0.0,1.38565,91.7282,8.82001,8.94601,8.82001,0.014184619,0.0,-0.009572284,-0.002179082,4.68095,0.12609,0.73079,1755,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
PRFX,PRF-110,BunionectomyÂ ,Phase 3,8/20/2024,"Phase 3 safety data revealed a low incidence of adverse events, averaging just one per subject, noted August 20, 2024.",1.0,0.91319,106.0391,7.452,6.3192,6.54,-0.164889835,-0.130545287,-0.009572284,-0.002179082,2.60415,0.12102,9.92869,1756,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
AZTR,ATR12-351,Netherton SyndromeÂ ,Phase 1b,8/20/2024,"Phase 1b first patient successfully screened, noted August 20, 2024.",3.0,4.84191,306.3773,4.27572,4.2291,4.6953,-0.010963305,0.093609499,-0.009572284,-0.002179082,4.0769,0.02422,7.45751,1757,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
WHWK,FYARRO - (PRECISION 1),Solid tumorsÂ ,Phase 2,8/20/2024,"Phase 2 analysis by the IDMC demonstrated that the study was unlikely to exceed an efficacy threshold necessary to support an accelerated approval, to preserve cash the company is halting the registra",47.0,39.87603,75.1863,1.56,1.62,1.68,0.037740328,0.074107972,-0.009572284,-0.002179082,0.76516,0.00856,1.07585,1758,0,0,0,0,0,1,0,1,0,0,0,0,2,0,0,1
REGN,Lynozyfic (linvoseltamab-gcpt),Multiple myelomaÂ ,CRL,8/20/2024,"CRL announced August 20, 2024.",105.0,128682.7835,17.5143,1196.88,1192.23,1201.76,-0.003892668,0.004068978,-0.009572284,-0.002179082,1.86263,0.19604,443.80285,1759,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,-1
BPTH,Prexigebersen (BP1001),Acute Myeloid Leukemia (AML)Â ,Phase 2,8/21/2024,"Additional Phase 2 interim data reported that the first patient received 16 cycles of treatment over 21 months and continues in complete remission, whole a second patient is completing their twelfth c",8.0,3.82829,134.9059,1.4795,1.5,0.9679,0.013760915,-0.424330696,0.006866724,0.002880272,2.3968,0.00823,22.55472,1760,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CGTX,CT1812 - (SEQUEL),Mild-to-Moderate Alzheimer's DiseaseÂ ,Phase 2,8/22/2024,Phase 2 study published in the Journal of Prevention of Alzheimer's Disease exhibited consistent trends of improvement across all prespecified electroencephalography (EEG) parameters with several reac,73.0,30.44085,121.5674,0.7498,0.7585,0.71,0.011536294,-0.054541534,0.003049233,0.008977518,4.40217,0.05822,2.104,1761,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ALKS,alixorexton (ALKS 2680) - (Vibrance-2),Narcolepsy and excessive daytime sleepinessÂ ,Phase 2,8/22/2024,"Phase 2 initiated, noted August 22, 2024.",165.0,4609.06653,28.5585,28.26,27.99,28.35,-0.009600074,0.003179653,0.003049233,0.008977518,11.26096,0.04754,31.35683,1762,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
SKYE,Nimacimab - (CBeyond),ObesityÂ ,Phase 2,8/22/2024,"Phase 2 dosing initiated, noted August 22, 2024.",30.0,160.18617,154.7998,5.49,5.28,6.39,-0.039002158,0.151806013,0.003049233,0.008977518,3.34135,4e-05,0.42744,1763,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1
MRNA,Spikevax (2024-2025 formula),COVID-19 VaccineÂ ,Approved,8/22/2024,"Approved August 22, 2024.",389.0,31151.45427,63.2835,86.65,81.04,77.59,-0.066934156,-0.110438463,0.003049233,0.008977518,5.87675,0.12658,433.18806,1764,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1
JAZZ,Cannabidiol oral solution (GWP42003-P),Treatment-Resistant EpilepsiesÂ ,Phase 3,8/22/2024,"Phase 3 trial did not meet its primary endpoint, noted August 22, 2024.",60.0,7073.86457,27.9925,114.36,114.55,115.6,0.001660041,0.010784589,0.003049233,0.008977518,3.70036,0.01145,51.36445,1765,1,0,0,0,0,1,0,0,0,0,0,0,0,2,0,-1
PFE,COMIRNATY,Omicron KP.2-adapted COVID-19 VaccineÂ ,Approved,8/22/2024,"Approved August 22, 2024.",0.0,163087.4839,23.9163,29.03,28.78,28.72,-0.008649077,-0.010736034,0.003049233,0.008977518,1.15296,0.00347,582.55146,1766,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1
BNTX,COMIRNATY,Omicron KP.2-adapted COVID-19 VaccineÂ ,Approved,8/22/2024,"Approved August 22, 2024.",239.0,20740.34868,35.008,88.99,87.23,87.6,-0.019975695,-0.015743006,0.003049233,0.008977518,1.32253,0.06341,34.06715,1767,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1
VTRS,Cenerimod (ACT-333441) - (CARE),Moderate to severe systemic lupus erythematosus (SLE) in Japanese patientsÂ ,Phase 2,8/23/2024,"Phase 2 data showed a clinically meaningful improvement in disease activity consistent with results from other global Phase 2 studies, noted August 23, 2024.",0.0,14035.80065,26.6058,11.7,11.76,12.08,0.005115101,0.031962351,-0.015458096,-0.01112226,3.24564,0.00777,71.26766,1768,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
RDHL,Opaganib (ABC294640),NeuroblastomaÂ ,Phase 2,8/26/2024,"Phase 2 is ongoing with orphan drug designation granted by the FDA, noted August 26, 2024.",3.0,10.79494,141.202,9.02,8.43,8.5,-0.067647562,-0.059378171,0.00434397,0.002465849,1.69135,0.00371,5.60454,1769,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ELAB,Elevai Enfinity Topical Exosome Serum,Facial appearanceÂ ,Phase 1,8/26/2024,"Trial data reported that treatment was safe and tolerable with significant improvement noted across many aspects of skin appearance, noted August 26, 2024.",0.0,6.65616,78.2632,1504.30024,1568.00025,1305.36021,0.041473248,-0.141848808,0.00434397,0.002465849,0.43521,0.00786,12.33703,1770,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1
VCEL,MACI Arthro,Arthroscopic AdministrationÂ ,Approved,8/26/2024,"FDA approved on August 26, 2024.",50.0,2448.56694,37.6675,49.29,49.94,51.65,0.013101064,0.046768975,0.00434397,0.002465849,6.41419,0.19228,20.51525,1771,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
MIRA,Ketamir-2 (Topical),"Neuropathic pain and chemo-induced depression, as well as neuropathic pain and PTSDÂ ",Preclinical,8/26/2024,"Preclinical data reported that low oral doses of Ketamir-2 led to a significant reversal of pain for 14 and 22 days following the operation. At higher oral dose, Ketamir-2 achieved complete normalizat",19.0,31.18767,325.3557,1.85,2.11,1.93,0.131502308,0.042334364,0.00434397,0.002465849,2.51954,0.01116,58.6231,1772,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1
DARE,"Sildenafil Cream, 3.6% - (RESPOND)",Female Sexual Arousal Disorder (FSAD)Â ,Phase 2b,8/26/2024,"Phase 2b data published at the Journal of sexual medicine showed that topical Sildenafil Cream, 3.6% was safe and well tolerated by women and their partners across 1,357 sexual experiences. Use of top",13.0,30.33958,139.779,3.55,3.55,3.58,0.0,0.008415197,0.00434397,0.002465849,0.38282,0.08689,0.18458,1773,0,0,0,1,0,1,0,0,0,0,0,0,2,0,0,1
CSCI,MACRILEN (Macimorelin Acetate) - (DETECT AEZS-130-P02),Pediatric patients with suspected growth hormone deficiency (GHD)Â ,Phase 3,8/27/2024,"Phase 3 topline data reported that the trial did not meet its primary endpoint, noted August 27, 2024.",3.0,16.91974,107.119,8.12,5.43,5.38,-0.40239102,-0.41164178,0.011471645,0.030347707,0.0,0.06257,0.06491,1774,1,0,0,0,0,1,0,0,0,0,1,0,0,3,0,-1
CLSD,CLS-AX - (ODYSSEY),Neovascular age-related macular degeneration (wet AMD)Â ,Phase 2b,8/27/2024,"Phase 2b trial completed, noted August 27, 2024.",5.0,75.49302,78.9984,15.14999,15.14999,14.99999,0.0,-0.009950337,0.011471645,0.030347707,0.24102,0.06736,0.93622,1775,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
IVVD,PEMGARDA (VYD222 (pemivibart)) - (CANOPY),COVID-19 PreventionÂ ,Phase 3,8/27/2024,"Phase 3 data in Cohort B showed showed a relative risk reduction of 84% with pemivibart compared to placebo in the likelihood of trial participants contracting confirmed symptomatic COVID-19, with no",120.0,109.89917,119.9484,1.29,0.9201,0.8518,-0.337915138,-0.41504574,0.011471645,0.030347707,6.60833,0.02142,2.40083,1776,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
HUMA,SYMVESS (acellular tissue engineered vessel-tyod),Extremity Vascular TraumaÂ ,BLA Filing,8/27/2024,Phase 3 results presented at the Department of Defense's Military Health System Research Symposium (MHSRS) showed that in real-world military setting the ATEV was observed to have 12-month patency of,158.0,794.87847,110.2291,7.05,6.66,5.535,-0.056908132,-0.241936051,0.011471645,0.030347707,9.56345,0.02234,14.16382,1777,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ENSC,PF614-MPAR-102 - (MPAR),Overdose ProtectionÂ ,Phase 1,8/27/2024,"IRB has approved a single and multiple doser study, noted August 27, 2024.",2.0,5.45882,91.2365,6.57262,9.666,5.4795,0.385702038,-0.181898679,0.011471645,0.030347707,0.20429,0.06603,61.29171,1778,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1
NBIX,NBI-1117568 (NBI-'568),SchizophreniaÂ ,Phase 2,8/28/2024,"Phase 2 met the primary endpoint, showing significant improvement in PANSS scores versus placebo, and was well-tolerated. Secondary endpoints were also met, noted August 28, 2024.",99.0,12496.82058,40.621,152.55,123.76,122.54,-0.209148205,-0.219054904,0.001584316,0.025553773,2.26299,0.08378,597.48494,1779,1,0,0,1,0,1,0,0,1,0,1,0,6,0,0,1
VXRT,Mucosal Vaccine,HPV-Related Cervical DysplasiaÂ ,Preclinical,8/28/2024,"Preclinical data reported that the vaccine constructs stimulate specific T cell immune responses, reduce tumor size, and increase survival in an animal model of human papillomavirus (HPV)-related tumo",228.0,193.3234,100.5114,0.8882,0.85,0.856,-0.043960593,-0.036926567,0.001584316,0.025553773,5.94259,0.12963,1.36794,1780,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
NVS,Leqvio - (V-Mono),CVRR (Primary prevention)Â ,Phase 3,8/28/2024,"Phase 3 data reported that the trial met its primary endpoints, demonstrating superiority of Leqvio (inclisiran) monotherapy vs both placebo and ezetimibe in LDL-C reduction, noted August 28, 2024.",0.0,1907.38463,58.3804,6.34,6.13,6.15,-0.033684019,-0.030426687,0.001584316,0.025553773,0.0,0.00989,0.18549,1781,1,0,0,0,0,1,0,0,0,0,0,0,2,0,0,1
TNXP,Tonmya (TNX-102 SL) - (RELIEF/RESILIENT),FibromyalgiaÂ ,Phase 3,8/28/2024,Phase 3 data presented at MHSRS highlighted results from confirmatory Phase 3 RESILIENT study of TNX-102 SL (sublingual cyclobenzaprine HCl) treatment demonstrating statistically significant improveme,8.0,6.60563,176.6654,36.33,30.02,16.46,-0.19078002,-0.791710651,0.001584316,0.025553773,5.92328,0.01264,12.06033,1782,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1
KRYS,KB301 - (PEARL-1),Wrinkles and acne scarsÂ ,Phase 1,8/28/2024,"Phase 1 cohort 3 & 4 data showed meaningful improvements in both dÃ©colletÃ© and lateral canthal regions. In the dÃ©colletÃ© cohort, 94% of subjects showed improvement at 2 months post-treatment. For late",28.0,5858.32411,37.6374,198.22,203.91,185.95,0.028301195,-0.063899705,0.001584316,0.025553773,12.33642,0.05331,50.53033,1783,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
AZTR,ATR12-351,Netherton SyndromeÂ ,Phase 1b,8/28/2024,"Phase 1b dosing iniutiated, noted August 28, 2024.",3.0,5.15835,307.1821,4.6953,4.50549,3.94938,-0.041265355,-0.173003404,0.001584316,0.025553773,3.632,0.02797,0.23612,1784,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
GANX,"GT-02287, GT-02329",GBA1 and Idiopathic Parkinson's DiseaseÂ ,Phase 1,8/29/2024,"Phase 1 data reported that single and multiple doses of GT-02287 were safe and generally well tolerated up to and including the highest planned dose levels across all age groups, with no discontinuati",35.0,27.32294,102.8104,1.34,1.07,1.085,-0.225010965,-0.211089627,-0.007135808,0.024772186,0.73699,0.00749,4.77148,1785,0,0,0,1,0,1,0,0,0,0,0,0,2,0,0,1
JNJ,IMAAVY (Nipocalimab) - (Vivacity-MG3),Generalized myasthenia gravis (gMG)Â ,BLA Filing,8/29/2024,"BLA submitted August 29, 2024.",0.0,395341.6274,17.2297,163.92,164.23,164.99,0.00188938,0.006506362,-0.007135808,0.024772186,0.82311,0.0403,1213.68023,1786,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
SCLX,GLOPERBA (colchicine),Acute and chronic painÂ ,Approved,8/29/2024,"FDA final approval on August 29, 2024.",6.0,146.21134,131.6456,38.85004,38.85004,38.85004,0.0,0.0,-0.007135808,0.024772186,6.25129,0.04157,0.72964,1787,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
LEXX,DehydraTECH-GLP-1 - (GLP-1-H24-2),"Healthy volunteers, Diabetes-related control, weight lossÂ ",Phase 1,8/29/2024,"Phase 1 PK data reported that 13 or 81%, experienced mild or moderate side effects with the Rybelsus tablet and only 7 people, or 44%, experienced only mild side effects with the Rybelsus that was pro",19.0,51.06696,127.3386,2.92,3.23,3.3,0.100898521,0.122338852,-0.007135808,0.024772186,0.98917,0.00017,0.79475,1788,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
NCNA,NUC-3373 (NuTide: 323),2L Colorectal cancerÂ ,Phase 2,8/29/2024,"Phase 2 trial discontinued, noted August 29, 2024.",1.0,17.36467,171.7496,1482.0,1546.0,546.0,0.042278423,-0.99852883,-0.007135808,0.024772186,1.96363,0.02503,1.32492,1789,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ALNY,AMVUTTRA (vutrisiran),ATTR Amyloidosis with Cardiomyopathy (ATTR-CM)Â ,Phase 3,8/30/2024,"Phase 3 data presented at ESC reported a a lack of statistical significance in ACM with vutrisiran monotherapy group for all-cause mortality up to month 36, with a hazard ratio (HR) of 0.706 (p = 0.11",131.0,33724.27696,53.784,287.01,262.69,246.78,-0.088542429,-0.151019807,-0.003462436,0.04447879,3.5177,0.03225,988.38636,1790,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
EBS,ACAM2000,Smallpox and Mpox (Vaccinia) VaccineÂ ,Approved,8/30/2024,"Approved August 30, 2024.",53.0,439.65405,168.7565,8.91,8.31,7.52,-0.069714633,-0.169608104,-0.003462436,0.04447879,6.53966,0.11162,82.52605,1791,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1
IOBT,"Cylembio (imsapepimut and etimupepimut, adjuvanted (IO102-IO103)) w/ pembrolizumab (KEYTRUDA) - (IOB-013/KN-D18)",Advanced melanomaÂ ,Phase 3,8/30/2024,"Phase 3 interim analysis by IDMC concluded with the recommendation to continue without modifications with primary endpoint data due in 1H 2025, noted August 30, 2024.",65.0,98.82137,72.013,1.54,1.5,0.844,-0.026317308,-0.601385201,-0.003462436,0.04447879,0.11458,0.05768,1.63797,1792,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
AMRN,VASCEPA (icosapent ethyl) - (REDUCE-IT),Cardiovascular diseaseÂ ,Phase 1,8/30/2024,Phase 1 subgroup data shared at the ESC reported that Icosapent ethyl reduced the rate of the primary outcome compared with placebo (17.2% vs 22.0%; hazard ratio,20.0,257.18754,76.1587,12.124,12.51,12.01,0.031341365,-0.009447323,-0.003462436,0.04447879,4.52514,0.0767,0.40439,1793,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CYTK,Aficamten (CK-274) - (SEQUOIA-HCM),Hypertrophic cardiomyopathy (HCM)Â ,Phase 3,9/1/2024,"Phase3 additional data reported treatment with aficamten significantly improved LVMI (-15.4 g/m2, p=0.001) and resulted in favorable cardiac remodeling as demonstrated by reductions in left ventricula",119.0,6716.00871,49.1703,57.08,57.08,54.09,0.0,-0.053804467,0.0,0.047941226,15.83759,0.01297,0.0,1794,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ARWR,Plozasiran (ARO-APOC3-3001) - (PALISADE),"Familial chylomicronemia syndrome (FCS), HypertriglyceridemiaÂ ",Phase 3,9/2/2024,"Phase 3 data from ESC reported that plozasiran reduced triglycerides by 80% from baseline and reduced the risk of developing acute pancreatitis by 83%, noted September 2, 2024.",138.0,2962.43298,57.3953,23.83,23.83,21.76,0.0,-0.090871869,0.026011871,0.033847067,8.40643,0.14853,0.0,1795,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
PFE,VLA15-221,Lyme diseaseÂ ,Phase 2,9/3/2024,Additional Phase 2 data reported a significant anamnestic antibody response across all six serotypes covered by the vaccine candidate in pediatric (5 to 11 years of age) and adolescent (12 to 17 years,0.0,160367.4703,23.5036,29.01,28.3,29.74,-0.024778793,0.024852343,0.027431893,0.0317041,1.08937,0.00597,1259.33738,1796,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
VALN,VLA15-221,Lyme diseaseÂ ,Phase 2,9/3/2024,Additional Phase 2 data reported a significant anamnestic antibody response across all six serotypes covered by the vaccine candidate in pediatric (5 to 11 years of age) and adolescent (12 to 17 years,81.0,444.45334,57.3574,7.32,7.27,7.1699,-0.006854036,-0.02071862,0.027431893,0.0317041,0.0,0.0,0.28445,1797,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
UNCY,Oxylanthanum Carbonate (OLC),Kidney diseaseÂ ,NDA Filing,9/3/2024,"NDA submitted to the FDA under 505(b)(2) pathway, noted September 3, 2024",17.0,29.99584,120.0322,3.378,3.179,3.909,-0.060717136,0.145997768,0.027431893,0.0317041,1.95052,0.01203,1.17519,1798,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
PRAX,PRAX-562 - (EMBOLD),Developmental epileptic encephalopathies (DEEs)Â ,Phase 2,9/3/2024,"Phase 2 topline results reported placebo-adjusted monthly motor seizure reduction of 46% during double-blind period, noted September 3, 2024.",21.0,983.38648,65.2283,53.15,55.38,59.32,0.041100413,0.109828412,0.027431893,0.0317041,10.47992,0.04328,36.43871,1799,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ELAB,Exosomes,HairlossÂ ,Phase 2,9/3/2024,"Trial data reported ceased crown inflammation, reversal of miniaturized hairs and recovered hair from the dormant phase, among other benefits, noted September 3, 2024.",0.0,6.65616,83.7466,1305.36021,1568.00025,1430.80023,0.183322056,0.091754863,0.027431893,0.0317041,0.43521,0.00844,15.0528,1800,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
IFRX,INF904,Chronic Autoimmune and Inflammatory DiseasesÂ ,Preclinical,9/3/2024,"Preclinical data presented at EMCHD demonstrated INF904's efficacy in reducing neutrophil activation and inflammation in various disease models, with potentially fewer drug interactions due to minimal",59.0,94.80207,64.803,1.59,1.61,1.47,0.012500163,-0.078471615,0.027431893,0.0317041,0.3865,0.01866,0.09305,1801,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
PCVX,VAX-31,Invasive Pneumococcal Disease (IPD)Â ,Phase 1/2,9/3/2024,"Phase 1/2 topline data reported that at the high and middle doses, VAX-31 met or exceeded the regulatory immunogenicity criteria for all 31 serotypes and, at the low dose, for 29 of 31 serotypes, note",129.0,12293.80526,55.9027,80.76,110.15,116.23,0.31036128,0.364089193,0.027431893,0.0317041,10.06977,0.13035,822.91292,1802,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1
DYN,DYNE-251 - (DELIVER),Duchenne muscular dystrophy (DMD)Â ,Phase 1/2,9/3/2024,"Phase 1/2 update reported increased dystrophin expression and functional improvements across multiple patient cohorts, noted September 3, 2024.",142.0,3206.80149,82.9703,46.09,31.94,32.43,-0.366736864,-0.351512086,0.027431893,0.0317041,7.34887,0.13097,438.51554,1803,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CRBU,CB-010 - (GALLOP),"Lupus nephritis (LN), extrarenal lupus (ERL)Â ",Phase 1,9/3/2024,"Fast Track Designation granted by the FDA, noted September 3, 2024.",93.0,178.91829,96.81,2.16,1.98,1.96,-0.087011377,-0.097163748,0.027431893,0.0317041,12.74956,0.1459,2.46731,1804,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
KROS,Cibotercept (KER-012) - (TROPOS),Pulmonary arterial hypertension (PAH) and disorders associated with bone lossÂ ,Phase 2,9/3/2024,"Phase 2 screening closed, noted September 3, 2024.",40.0,1793.18102,48.0144,45.35,47.79,54.69,0.052406236,0.187270701,0.027431893,0.0317041,9.29179,0.01951,18.13181,1805,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
DNLI,Tividenofusp alfa (DNL310) - (COMPASS),Hunter syndrome MPS IIÂ ,Phase 1/2,9/3/2024,"Phase 1/2 data from SSIEM reported a 90% mean reduction in CSF HS from baseline at Week 24, noted September 3, 2024.",146.0,3596.31143,52.9128,24.44,25.12,26.34,0.027443207,0.074867562,0.027431893,0.0317041,5.84173,0.21508,36.16207,1806,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
RXRX,REC-994 - (SYCAMORE),Cerebral Cavernous Malformation (CCM)Â ,Phase 2,9/3/2024,"Phase 2 trial met its primary endpoint, noted September 3, 2024.",434.0,1705.47744,72.8462,7.28,6.07,6.32,-0.181772257,-0.141411654,0.027431893,0.0317041,19.27164,0.17734,81.15405,1807,1,0,0,0,0,1,0,0,0,0,0,0,2,0,0,1
RGNX,clemidsogene lanparvovec (RGX-121) - (CAMPSIITE),MPS II (Hunter Syndrome)Â ,Phase 3,9/3/2024,"Phase 1/2/3 additional interim data presented at SSIEM 2024 demonstrated an 85% median reduction of cerebrospinal fluid (CSF) levels of heparan sulfate (HS) D2S6, a key biomarker of brain disease acti",50.0,560.45895,56.7961,12.22,11.34,11.79,-0.074737655,-0.035822239,0.027431893,0.0317041,11.59145,0.07464,9.03752,1808,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ATHA,Fosgonimeton (ATH-1017) - (LIFT-AD),Alzheimerâ€™s diseaseÂ ,Phase 2/3,9/3/2024,"Phase 2/3 topline data did not meet primary endpoint of GST and key secondary endpoints of cognition (ADAS-Cog11) and function (ADCS-ADL23), noted September 3, 2024.",3.0,108.78342,93.273,30.9,28.3,4.9,-0.087894379,-1.841520979,0.027431893,0.0317041,2.57739,0.05336,9.39249,1809,1,0,0,0,0,1,0,0,1,0,1,0,0,4,0,-1
RNAC,Descartes-15,Solid tumorsÂ ,Phase 1,9/3/2024,"Preclinical data observed to achieve an approximately ten-fold increase relative to Descartes-08 in CAR expression and selective target-specific killing. Phase 1 data to dosing initiated, noted Septem",26.0,280.5382,116.473,13.96,13.12,14.86,-0.062058314,0.062476942,0.027431893,0.0317041,9.40933,0.00416,0.86571,1810,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1
INDV,AEF0117,Cannabis-Related Disorders (CrD)Â ,Phase 2b,9/4/2024,"Phase 2b trial did not meet its primary or secondary endpoints, noted September 4, 2024.",124.0,1595.91619,74.0115,12.17,12.14,9.58,-0.002468121,-0.239296315,0.005896124,-0.002429643,0.17086,0.00279,9.20656,1811,1,0,0,0,0,1,0,0,1,0,0,0,0,3,0,-1
BIIB,SPINRAZA (Nusinersen) - (DEVOTE),Spinal muscular atrophy (SMA)Â ,Phase 2/3,9/4/2024,"Phase 2/3 data reported statistically significant improvement compared to a prespecified matched sham control group, noted September 4, 2024.",146.0,29853.35353,27.047,204.84,204.95,199.09,0.00053686,-0.028472203,0.005896124,-0.002429643,1.83896,0.19539,160.93432,1812,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1
IONS,SPINRAZA (Nusinersen) - (DEVOTE),Spinal muscular atrophy (SMA)Â ,Phase 2/3,9/4/2024,"Phase 2/3 data reported statistically significant improvement compared to a prespecified matched sham control group, noted September 4, 2024.",159.0,6958.10297,33.4063,47.31,47.65,42.53,0.00716094,-0.10651198,0.005896124,-0.002429643,6.78156,0.07069,64.42023,1813,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1
WINT,Istaroxime - (SEISMiC C),Cardiogenic Shock in severe acute heart failureÂ ,Phase 2b,9/4/2024,"Phase 2 extension study in SCAI Stage B enrollment to be completed, noted September 4, 2024.",29.0,1.96511,224.9391,159.5,166.0,152.5,0.039943866,-0.044879326,0.005896124,-0.002429643,19.11117,0.00202,50.66735,1814,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
IVVD,VYD2311 - (DECLARATION),COVID-19Â ,Phase 1,9/4/2024,"Phase 1 initiated, noted September 4, 2024.",120.0,101.53818,119.1657,0.8518,0.8501,1.02,-0.001997768,0.180206149,0.005896124,-0.002429643,6.60833,0.02293,0.26975,1815,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ALXO,evorpacept in combination with SARCLISA (isatuximab-irfc) - (UMBRELLA),Multiple myeloma (MM)Â ,Phase 1/2,9/4/2024,"Phase 1/2 initiated, noted September 4, 2024.",53.0,108.50389,117.077,2.14,2.06,2.18,-0.038099846,0.018519048,0.005896124,-0.002429643,17.61613,0.05275,1.62894,1816,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
SNY,evorpacept in combination with SARCLISA (isatuximab-irfc) - (UMBRELLA),Multiple myeloma (MM)Â ,Phase 1/2,9/4/2024,"Phase 1/2 initiated, noted September 4, 2024.",0.0,132295.9362,22.8475,57.53,58.53,57.46,0.017232892,-0.001217497,0.005896124,-0.002429643,0.0,0.0,116.64971,1817,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ELDN,Tegoprubart (AT-1501) - (BESTOW),Kidney transplant rejectionÂ ,Phase 2,9/4/2024,"Phase 2 study enrollment completed, noted September 4, 2024.",59.0,102.31171,80.1242,2.74,2.58,2.56,-0.060168521,-0.067950662,0.005896124,-0.002429643,0.25391,2e-05,0.09727,1818,0,0,0,0,0,1,0,0,0,1,0,0,2,0,0,1
CYTH,Trappsol Cyclo - (TransportNPC),Niemann-Pick Disease Type CÂ ,Phase 3,9/5/2024,"Phase 3 data to be presented at the SSIEM Annual Symposium 2024 showed that study was well tolerated, noted September 5, 2024.",28.0,5592.4553,150.8375,4.845,4.9275,5.443,0.016884515,0.116383134,0.020509332,-0.005466154,0.0,0.0,0.01165,1819,0,0,0,1,0,1,0,0,0,0,0,0,2,0,0,1
RFL,Trappsol Cyclo - (TransportNPC),Niemann-Pick Disease Type CÂ ,Phase 3,9/5/2024,"Phase 3 data to be presented at the SSIEM Annual Symposium 2024 showed that study was well tolerated, noted September 5, 2024.",35.0,37.4035,38.0928,1.53,1.52,1.53,-0.006557401,0.0,0.020509332,-0.005466154,0.15771,0.09735,0.01737,1820,0,0,0,1,0,1,0,0,0,0,0,0,2,0,0,1
ARQT,ARQ-255,Alopecia AreataÂ ,Phase 1b,9/5/2024,"Phase 1b enrollment completed, noted September 5, 2024.",122.0,1265.92978,78.8071,10.46,10.83,10.52,0.034761602,0.005719749,0.020509332,-0.005466154,20.3644,0.05891,10.92175,1821,0,0,0,0,0,1,0,0,0,1,0,0,2,0,0,1
CATX,212Pb-VMT01,MC1R-positive metastatic melanomaÂ ,Phase 1/2,9/5/2024,"Phase 1/2 FDA granted Fast Track designation, noted September 5, 2024",74.0,1041.08318,87.505,14.98,15.44,15.84,0.030245567,0.055822408,0.020509332,-0.005466154,10.30946,0.00033,24.30065,1822,0,0,0,0,0,1,0,1,0,0,0,0,2,0,0,1
LLY,Insulin efsitora alfa (efsitora) - (QWINT-1),Type 2 diabetesÂ ,Phase 3,9/5/2024,"Phase 3 topline data reported that the trial met its primary endpoint of non-inferior A1C reduction with efsitora compared to insulin glargine at week 52, noted September 5, 2024.",946.0,821863.6289,31.4741,946.31,912.75,935.02,-0.03610819,-0.012002291,0.020509332,-0.005466154,0.69997,0.11083,2921.84784,1823,1,0,0,0,0,1,0,0,0,0,1,0,3,0,0,1
LLY,Insulin efsitora alfa (efsitora) - (QWINT-3),Type 2 diabetesÂ ,Phase 3,9/5/2024,"Phase 3 topline data reported that the trial met its primary endpoint of non-inferior A1C reduction with efsitora compared to insulin degludec at week 26, noted September 5, 2024.",946.0,821863.6289,31.4741,946.31,912.75,935.02,-0.03610819,-0.012002291,0.020509332,-0.005466154,0.69997,0.11083,2921.84784,1824,1,0,0,0,0,1,0,0,0,0,1,0,3,0,0,1
LSTA,Certepetide (LSTA1) - (BOLSTER),Intrahepatic CholangiocarcinomaÂ ,Phase 2a,9/5/2024,"FDA granted orphan drug designation, noted September 5, 2024.",8.0,27.20509,57.8934,3.0,3.27,3.01,0.086177696,0.00332779,0.020509332,-0.005466154,0.08908,0.1219,0.05939,1825,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
HOTH,HT-001 - (CLEER-001),EGFRI-induced skin toxicityÂ ,Phase 2a,9/5/2024,"Phase 2a data from study showed that during this first-of-its-kind human patient case, the patient was able to cease treatment after just one week due to the rapid and successful resolution of symptom",13.0,8.69879,116.0097,0.7099,1.26,1.13,0.573742885,0.464848797,0.020509332,-0.005466154,3.07738,0.16332,209.63597,1826,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1
BTAI,BXCL501 - (SERENITY III),Agitation associated with bipolar I or II disorder or schizophreniaÂ ,Phase 3,9/5/2024,"Phase 3 at-home trial initiated, noted September 5, 2024.",14.0,24.04289,71.2414,9.6,9.4416,8.8,-0.016637641,-0.087011377,0.020509332,-0.005466154,1.79459,0.02036,0.10826,1827,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
VOR,Trem-cel + Mylotarg (VBP101),Acute myeloid leukemia (AML)Â ,Phase 1/2,9/5/2024,"Phase 1/2 data reported reliable engraftment, shielding from Mylotarg on-target toxicity, a broadened Mylotarg therapeutic window, and early evidence of patient benefit, noted September 5, 2024.",6.0,56.42903,68.4127,16.9,16.5,21.0,-0.023953241,0.217208816,0.020509332,-0.005466154,2.43197,0.05799,5.23415,1828,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
TVTX,FILSPARI (sparsentan),IgA nephropathy (IgAN)Â ,Approved,9/5/2024,"Approved September 5, 2024.",89.0,759.56045,57.1914,10.05,9.93,12.6,-0.012012156,0.226124179,0.020509332,-0.005466154,12.15241,0.05335,12.2757,1829,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1
LGND,FILSPARI (sparsentan),IgA nephropathy (IgAN)Â ,Approved,9/5/2024,"Approved September 5, 2024.",19.0,1884.44219,40.0186,102.56,103.15,102.1,0.005736246,-0.004495268,0.020509332,-0.005466154,5.82413,0.1932,8.51978,1830,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1
RIGL,REZLIDHIA (olutasidenib) in combination with decitabine and venetoclax,Acute myeloid leukemiaÂ ,Phase 1/2,9/5/2024,"Phase 1b/2 triplet therapy initiated, noted September 5, 2024.",17.0,235.94864,77.3145,13.18,13.41,12.95,0.017300168,-0.017604741,0.020509332,-0.005466154,3.20828,0.19263,1.30221,1831,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
VTYX,VTX3232,Parkinson's diseaseÂ ,Phase 2a,9/6/2024,"Phase 2a initiated, noted September 6, 2024.",71.0,153.35201,116.4098,2.17,2.17,2.29,0.0,0.05382465,0.001939073,-0.031414094,13.20989,0.00981,0.96924,1832,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
KALV,Sebetralstat - (KONFIDENT-S),Hereditary angioedema (HAE)Â ,Phase 3,9/6/2024,Data presentation from Bradykinin Symposium reported a median time to treatment was 9 minutes for all attacks and 8 minutes for laryngeal attacks; the median time to beginning of symptom relief was 1.,50.0,533.27892,51.4961,12.87,12.34,11.14,-0.042053003,-0.144356787,0.001939073,-0.031414094,13.1363,0.09,2.89575,1833,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
GSK,Nucala (mepolizumab),Chronic obstructive pulmonary disease (COPD)Â ,Phase 3,9/6/2024,"Phase 3 data reported that it met its primary endpoint with the addition of Nucala to inhaled maintenance therapy, noted September 6, 2024.",0.0,67364.04293,22.3968,16.39,16.515,16.335,0.007597666,-0.003361348,0.001939073,-0.031414094,0.0,0.02576,96.91874,1834,1,0,0,0,0,1,0,0,0,0,0,0,2,0,0,1
AXGN,Avance Nerve Graf - (RECON),Severed peripheral nervesÂ ,BLA Filing,9/6/2024,"BLA submission completed, noted September 6, 2024.",46.0,570.66401,65.2552,13.25,13.02,13.79,-0.017510916,0.039946139,0.001939073,-0.031414094,4.11138,0.04623,3.92294,1835,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
ZVRA,Arimoclomol (EAP),Niemann-Pick disease type C (NPC)Â ,Phase 3,9/6/2024,"Phase 3 new clinical efficacy and safety data demonstrated clinically meaningful reduction in disease progression, noted September 6, 2024.",56.0,385.16222,70.8603,7.23,7.32,7.85,0.012371292,0.082274496,0.001939073,-0.031414094,7.26885,0.02835,5.98384,1836,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CYTK,CK-4021586 (CK-586) - (AMBER-HFpEF),Heart failure with preserved ejection fraction (HFpEF)Â ,Phase 1,9/8/2024,"Phase 1 data presented at ACCP reported dose-linearity without a change in half-life over a wide range of exposures, with steady state appearing evident within seven days of dosing, noted September 8,",119.0,6364.20657,48.0982,54.09,54.09,55.88,0.0,0.032557209,-0.014094159,-0.047447325,15.83759,0.01687,0.0,1837,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
SVRA,MOLBREEVI (Molgradex) - (IMPALA-2),Autoimmune pulmonary alveolar proteinosis (aPAP)Â ,Phase 3,9/8/2024,Phase 3 results presented at ERS reported statistical significance in change from baseline in hemoglobin-adjusted percent predicted diffusing capacity of the lungs for carbon monoxide (DLCO%) through,172.0,898.22109,62.7823,4.42,4.42,4.2,0.0,-0.051055171,-0.014094159,-0.047447325,4.31653,0.07814,0.0,1838,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
SMMT,Ivonescimab (SMT112) with chemotherapy - (HARMONi-2),"Epidermal growth factor receptor (EGFR)-mutated, locally advanced or metastatic non-squamous NSCLCÂ ",Phase 3,9/8/2024,"Additional Phase 3 data presented at WCLC reported a hazard ratio (HR) of 0.51, and a clinically meaningful benefit was demonstrated across clinical subgroups, noted September 8, 2024.",744.0,8890.07821,218.9798,12.27,12.27,31.93,0.0,0.956388748,-0.014094159,-0.047447325,2.38176,0.00018,0.0,1839,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1
AZN,DATROWAY (datopotamab deruxtecan-dlnk)- (TROPION-Lung01),Non-small cell lung cancer (NSCLC)Â ,Phase 3,9/8/2024,"Phase 3 data reported a meaningfully greater magnitude of progression-free survival benefit in patients with this biomarker, noted September 8, 2024.",0.0,196111.2596,18.1546,126.5,126.5,119.28,0.0,-0.058768638,-0.014094159,-0.047447325,0.0,0.13248,0.0,1840,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
JNJ,Amivantamab and Lazertinib - (MARIPOSA),GFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung CancerÂ ,Phase 3,9/8/2024,"Phase 3 longer-term data from the MARIPOSA study confirm superior outcomes of chemotherapy-free RYBREVANTÂ® plus LAZCLUZEâ„¢ regimen compared to osimertinib monotherapy as first-line therapy, noted Septe",0.0,395702.714,17.2392,164.38,164.38,165.52,0.0,0.006911213,-0.014094159,-0.047447325,0.82311,0.06321,0.0,1841,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
NUVL,Zidesamtinib (NVL-520) - (ARROS-1),ROS1 Non-small cell lung cancer (NSCLC)Â ,Phase 1,9/9/2024,"Phase 1 data demonstrated encouraging efficacy and durability in patients with pretreated ROS1-positive NSCLC, noted September 9, 2024. This data is to be presented at ESMO on September 14, 2024.",72.0,5782.53809,42.1358,86.25,89.24,112.17,0.034079314,0.262765522,-0.016237126,-0.048138718,10.54698,0.1269,42.42782,1842,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
AGEN,Botensilimab plus balstilimab,Relapsed/refractory microsatellite stable colorectal cancer with no active liver metastases (r/r MSS CRC NLM)Â ,Phase 1,9/9/2024,"Phase 1 data from ESMO reported that in EE pts (n=50), ORR was 23%, DCR 66%, and median DOR 8.3 mos with 64% responses ongoing at 6-mos and longest ongoing response at 20.8+ mos, noted September 9, 2",31.0,110.66406,171.1567,4.95,5.13,6.08,0.035718083,0.205617119,-0.016237126,-0.048138718,12.28819,0.13647,1.47903,1843,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
EVAX,EVX-01 + KEYTRUDA (pembrolizumab) / OPDIVO (nivolumab),Metastatic MelanomaÂ ,Phase 2,9/9/2024,"Phase 2 data from a one-year interim analysis of the ongoing phase 2 trial show that 11 out of 16 patients had objective clinical responses, equaling a 69% Overall Response Rate to be presented, noted",6.0,18.12216,82.0674,17.25,16.25,16.25,-0.059719235,-0.059719235,-0.016237126,-0.048138718,0.81448,0.01333,0.13502,1844,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
MRK,EVX-01 + KEYTRUDA (pembrolizumab) / OPDIVO (nivolumab),Metastatic MelanomaÂ ,Phase 2,9/9/2024,"Phase 2 data from a one-year interim analysis of the ongoing phase 2 trial show that 11 out of 16 patients had objective clinical responses, equaling a 69% Overall Response Rate to be presented, noted",0.0,292542.3427,23.8784,117.84,115.41,117.96,-0.020836767,0.001017812,-0.016237126,-0.048138718,0.97882,0.09313,1717.32307,1845,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
MBRX,WP1066,Glioblastoma (NU 21C06)Â ,Phase 2,9/9/2024,"Phase 2 patient dosing initiated, noted September 9, 2024.",30.0,6.71308,100.8988,2.4,2.36,2.41,-0.016807118,0.00415801,-0.016237126,-0.048138718,1.80455,0.02216,0.04992,1846,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1
PDSB,PDS0101 + KEYTRUDA (pembrolizumab) - (VERSATILE-002),HPV16-positive first-line recurrent and/or metastatic head and neck squamous cell cancer with low PD-L1 expression (CPS 1-19)Â ,Phase 2,9/9/2024,"Phase 2 full data presented at ESMO reported that the median OS was 30 months (95% CI 18.4, NE) and the 12-month OS rate was 80%, noted September 9, 2024.",46.0,110.82763,77.0758,2.93,3.01,3.06,0.026937656,0.043412493,-0.016237126,-0.048138718,13.65362,0.18342,0.49071,1847,1,0,0,0,0,1,0,0,0,0,1,0,3,0,0,1
ACTU,Elraglusib (9-ING-41) - (Actuate-1902),Ewing Sarcoma (Pediatric)Â ,Phase 1,9/9/2024,"Phase 1 update reported that two patients with recurrent /refractory EWS are experiencing ongoing complete responses (CR), two patients achieved stable disease (SD), and two patients withdrew from the",20.0,158.05323,0.0,8.15,8.27,8.37,0.014616582,0.026635957,-0.016237126,-0.048138718,0.02245,0.62126,0.46496,1848,1,0,0,0,0,1,0,0,0,0,0,0,2,0,0,1
PRLD,PRT3789 with KEYTRUDA (pembrolizumab) - (SMARCA2/BRM),"SMARCA4-deleted cancers, solid tumorsÂ ",Phase 1,9/9/2024,"Phase 1 data presented at ESMO reported partial responses, tumor shrinkage and prolonged stable disease, noted September 9, 2024.",56.0,376.24817,114.3859,4.85,4.96,2.6,0.022427036,-0.62346726,-0.016237126,-0.048138718,1.89086,0.10137,1.99308,1849,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1
MRK,PRT3789 with KEYTRUDA (pembrolizumab) - (SMARCA2/BRM),"SMARCA4-deleted cancers, solid tumorsÂ ",Phase 1,9/9/2024,"Phase 1 data presented at ESMO reported partial responses, tumor shrinkage and prolonged stable disease, noted September 9, 2024.",0.0,292542.3427,23.8784,117.84,115.41,117.96,-0.020836767,0.001017812,-0.016237126,-0.048138718,0.97882,0.09313,1717.32307,1850,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1
REGN,Libtayo (cemiplimab) combined with Fianlimab,MelanomaÂ ,Phase 1,9/9/2024,"Phase 1 data from ESMO reported that the median PFS was 24 months (85% CI: 12 months to NE) and median OS was not reached, noted September 9, 2024.",105.0,123560.2108,17.6929,1131.5,1144.77,1153.08,0.011659557,0.018892437,-0.016237126,-0.048138718,1.95555,0.25651,587.59556,1851,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
EVAX,EVX-B2,Gonorrhea vaccineÂ ,Preclinical,9/9/2024,"Preclinical data reported that the vaccine triggers a targeted immune response, noted September 9, 2024.",6.0,18.12216,82.0674,17.25,16.25,16.25,-0.059719235,-0.059719235,-0.016237126,-0.048138718,0.81448,0.01333,0.13502,1852,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
IBRX,Anktiva (N-803) + various Checkpoint Inhibitors (QUILT-3.055),"NSCLC, Various tumorsÂ ",Phase 2b,9/9/2024,"Phase 2b study showed long-term overall survival of 57 percent (49/86) and 34 percent (29/86) at 12 and 18 months respectively, exceeding the current standard of care, noted September 9, 2024.",945.0,2472.69363,101.4237,3.38,3.55,3.49,0.049071894,0.032026027,-0.016237126,-0.048138718,7.06126,0.03197,14.51932,1853,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CTMX,Conditionally Activated Interferon Alpha-2b (CX-801),Solid tumorsÂ ,Phase 1,9/9/2024,"Phase 1 dosing initiated, noted September 9, 2024.",164.0,97.647,201.5288,1.2,1.25,1.21,0.040821995,0.008298803,-0.016237126,-0.048138718,10.08007,0.01086,0.92729,1854,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1
REPL,RP1 (vusolimogene oderparepvec) and OPDIVO (nivolumab) - (IGNYTE-3),Non-melanoma (NMSC) / Non-small cell lung cancer (NSCLC)Â ,Phase 3,9/9/2024,"Phase 3 pre BLA review successfully completed, noted September 9, 2024.",78.0,719.4243,76.7374,10.37,10.53,10.46,0.015311304,0.008641436,-0.016237126,-0.048138718,8.86812,0.0348,12.36823,1855,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
AMGN,Tarlatamab (AMG 757) - (DeLLphi-303),Small cell lung cancer (SCLC)Â ,Phase 1b,9/9/2024,"Phase 1b trial presented at the WCLC demonstrated sustained disease control, with a 9-month overall survival rate of up to 91.8%, noted September 9, 2024.",538.0,175126.3394,25.8121,320.56,325.92,335.26,0.016582486,0.044836884,-0.016237126,-0.048138718,1.71928,0.03772,556.6065,1856,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
AMGN,Tarlatamab (AMG 757) - (DeLLphi-301),Brain metastasisÂ ,Phase 2,9/9/2024,"Phase 2 presented at the WCLC showed a long-term follow-up confirmed sustained efficacy and safety in previously treated ES-SCLC patients, with a 40% objective response rate and a median overall survi",538.0,175126.3394,25.8121,320.56,325.92,335.26,0.016582486,0.044836884,-0.016237126,-0.048138718,1.71928,0.03772,556.6065,1857,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
AVBP,Firmonertinib monotherapy - (FURTHER),Non-small cell lung cancer (NSCLC) harboring EGFR PACC mutationsÂ ,Phase 1b,9/9/2024,"Phase 1b data presented at WCLC showed an 81.8% ORR by BICR and 63.6% confirmed ORR by BICR at the 240 mg dose; 46.2% confirmed ORR in CNS Metastases, noted September 9, 2024.",40.0,931.33681,48.1662,28.01,27.73,24.54,-0.01004673,-0.13225715,-0.016237126,-0.048138718,4.86043,0.00833,24.00899,1858,1,0,0,0,0,1,0,0,0,0,1,0,3,0,0,1
SPRY,Neffy 1 mg (epinephrine nasal spray),AnaphylaxisÂ ,sNDA Filing,9/9/2024,"sNDA submission to the FDA, noted September 9, 2024.",98.0,1135.18624,65.1777,11.36,11.71,12.95,0.030344764,0.130997375,-0.016237126,-0.048138718,12.44656,0.2496,9.01471,1859,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ITRM,ORLYNVAH (Oral Sulopenem),Uncomplicated urinary tract infections (uUTI)Â ,PDUFA,9/9/2024,"FDA's AdCom reviewed the drug's benefits and risks and considerations for its appropriate use but did not vote on the matter, noted September 9, 2024.",44.0,24.52247,77.0726,1.08,1.08,1.06,0.0,-0.018692133,-0.016237126,-0.048138718,1.95367,0.06996,0.0,1860,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
PLRX,Bexotegrast (PLN-74809) - (INTEGRIS-PSC),Primary sclerosing cholangitis (PSC)Â ,Phase 2a,9/9/2024,"Phase 2a safety and tolerability data presented at the European Respiratory Society (ERS) reported that integrin beta-6, were reduced in participants receiving bexotegrast at the 320 mg dose versus p",61.0,783.12235,50.7229,12.87,12.88,11.87,0.000776699,-0.080884813,-0.016237126,-0.048138718,12.07092,0.11756,2.96655,1861,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
PHGE,BX004,P. aeruginosa in patients with Cystic Fibrosis (CF)Â ,Phase 1/2,9/9/2024,"Phase 1b/2a study data presented at the European Respiratory Society (ERS) Congress reported that treatment was well tolerated and no adverse events of special interest, noted September 9, 2024.",26.0,20.15072,103.5772,1.1901,1.126,0.9851,-0.055365807,-0.189049457,-0.016237126,-0.048138718,0.32484,0.01175,0.08893,1862,0,0,0,1,0,1,0,0,0,0,0,0,2,0,0,1
LLY,Insulin efsitora alfa (efsitora) - (QWINT-2 and QWINT-4),Type 2 diabetesÂ ,Phase 3,9/9/2024,"Phase 3 QWINT-2 data presented at EASD helped adults naÃ¯ve to insulin therapy currently using and not using GLP-1 receptor agonists achieve an A1C below 7% , noted May 16, 2024.",946.0,817829.7214,31.4615,902.71,908.27,923.54,0.006140341,0.022812762,-0.016237126,-0.048138718,0.69997,0.17164,2185.21406,1863,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
LLY,Insulin efsitora alfa (efsitora) - (QWINT-5),Type 2 diabetesÂ ,Phase 3,9/9/2024,"Phase 3 data presented at EASD efsitora met the primary endpoint of non-inferior A1C reduction at week 26, noted September 9, 2024.",946.0,817829.7214,31.4615,902.71,908.27,923.54,0.006140341,0.022812762,-0.016237126,-0.048138718,0.69997,0.17164,2185.21406,1864,1,0,0,0,0,1,0,0,0,0,0,0,2,0,0,1
MRK,Ifinatamab deruxtecan (DS-7300) - (IDeate-Lung02 ),Extensive-stage small cell lung cancer (SCLC)Â ,Phase 2,9/9/2024,Phase 2 IDeate-Lung01 data reported that a confirmed objective response rate (ORR) of 54.8% (95% CI: 38.7-70.2) and 26.1% (95% CI: 14.3-41.1) were observed in patients with ES-SCLC receiving ifinatama,0.0,292542.3427,23.8784,117.84,115.41,117.96,-0.020836767,0.001017812,-0.016237126,-0.048138718,0.97882,0.09313,1717.32307,1865,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CCCC,CFT1946,Solid tumorsÂ ,Phase 1,9/9/2024,"Phase 1 dose escalation data presented at ESMO reported that 1 pt had an unconfirmed partial response (uPR) and 7/14 (50%) efficacy evaluable pts had a best response of stable disease or better, noted",71.0,397.30533,75.5484,5.4,5.73,6.36,0.059316577,0.163629424,-0.016237126,-0.048138718,15.14815,0.05555,16.66922,1866,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1
IPHA,Monalizuma - (NeoCOAST-2),Early-stage non-small cell lung cancer (NSCLC)Â ,Phase 2,9/9/2024,"Phase 2 data reported a pathological complete response rate of 26.7% and a major pathological response rate of 53.3%, noted September 9, 2024.",92.0,176.47271,69.9085,2.31,2.2499,2.17,-0.026361754,-0.062520357,-0.016237126,-0.048138718,0.0,0.0,0.02904,1867,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
TNXP,TNX-801 - (Kenya study),"Monkeypox, horse pox and smallpox infectionÂ ",Phase 1/2,9/9/2024,"Phase 1/2 vaccination demonstrated efficacy in protecting animals from lethal challenge with clade I monkeypox and is in development as an mpox vaccine, new data show improved tolerability in immunoco",8.0,3.63288,183.7584,14.25,16.51,14.75,0.147209351,0.034486176,-0.016237126,-0.048138718,5.92328,0.02854,37.88466,1868,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
OABI,Batoclimab,Graves' DiseaseÂ ,Phase 2,9/9/2024,"Phase 2 additional results reported a 76% response rate in patients uncontrolled on antithyroid drugs (ATDs) at week 12, noted September 9, 2024.",122.0,485.64866,41.9239,3.97,4.11,4.56,0.034656934,0.138556529,-0.016237126,-0.048138718,6.00711,0.05894,2.68876,1869,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
IMVT,Batoclimab,Graves' DiseaseÂ ,Phase 2,9/9/2024,"Phase 2 additional results reported a 76% response rate in patients uncontrolled on antithyroid drugs (ATDs) at week 12, noted September 9, 2024.",174.0,4601.79024,45.0213,34.03,31.44,29.43,-0.079161521,-0.145227926,-0.016237126,-0.048138718,8.35649,0.00113,86.20433,1870,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CVAC,CVGBM,GlioblastomaÂ ,Phase 1,9/9/2024,"Phase 1 data presented at ESMO reported that 7 pts had 9 â‰¥ Gr 3 AEs assessed as potentially related to CVGBM, noted September 9, 2024.",224.0,654.99692,75.0503,2.74,2.92,3.27,0.063625696,0.176832065,-0.016237126,-0.048138718,2.51737,0.0377,1.69837,1871,0,0,0,1,0,1,0,0,0,0,1,0,3,0,0,1
TERN,TERN-601 - (FALCON),ObesityÂ ,Phase 1,9/9/2024,"Phase 1 data reported a statistically significant mean weight loss up to 5.5% over 28 days, noted September 9, 2024.",87.0,641.79183,86.4899,7.81,9.12,9.41,0.15506484,0.18636799,-0.016237126,-0.048138718,2.56409,0.02762,214.13161,1872,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1
RLAY,RLY-2608 + fulvestrant + ribociclib triplet combination - (ReDiscover),"PIK3CA (PI3KÎ±) mutant tumors, including HR+/HER2- breast cancerÂ ",Phase 1,9/9/2024,"Phase 1 data resulted on 9.2-month median PFS in heavily pre-treated patients, 33% ORR across all patients & 53% ORR in patients with kinase mutations at RP2D. Data support planned initiation of 2L pi",172.0,1273.29358,91.3645,6.24,9.51,8.11,0.421363694,0.262117686,-0.016237126,-0.048138718,6.76191,0.16847,181.34183,1873,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
NVO,Efruxifermin - (SYMMETRY),Metabolic-associated steatohepatitis (MASH)Â ,Phase 3,9/9/2024,"Phase 3 Outcomes study dosing initiated, noted September 9, 2024.",0.0,3932202.326,30.1096,131.14,131.91,136.9,0.005854417,0.042985277,-0.016237126,-0.048138718,0.0,0.0,248.2289,1874,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1
AKRO,Efruxifermin - (SYMMETRY),Metabolic-associated steatohepatitis (MASH)Â ,Phase 3,9/9/2024,"Phase 3 Outcomes study dosing initiated, noted September 9, 2024.",79.0,1826.02883,53.988,26.41,26.3,26.77,-0.004173787,0.013539131,-0.016237126,-0.048138718,10.3606,0.09295,9.57404,1875,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1
XNCR,XmAb819,Renal Cell Carcinoma (RCC)Â ,Phase 1,9/9/2024,"Phase 1 update reported evidence of anti-tumor activity has been observed in recent dose-escalation cohorts, noted September 9, 2024.",71.0,1229.86891,57.7495,16.18,19.89,21.15,0.206441181,0.267863994,-0.016237126,-0.048138718,7.74512,0.10091,29.58677,1876,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
XNCR,XmAb808 + pembrolizumab,Solid tumorsÂ ,Phase 1,9/9/2024,"Phase 1 trial update reported prostate specific antigen (PSA) declines have been observed during the four-week monotherapy safety run-in period, noted September 9, 2024.",71.0,1229.86891,57.7495,16.18,19.89,21.15,0.206441181,0.267863994,-0.016237126,-0.048138718,7.74512,0.10091,29.58677,1877,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
NUVL,Neladalkib (NVL-655) - (ALKove-1),ALK non-small cell lung cancer (NSCLC)Â ,Phase 1,9/9/2024,"Additional Phase 1 data demonstrated encouraging efficacy and durability in heavily pretreated ALK-positive NSCLC patients, noted September 9, 2024. This data is expected to be presented at ESMO Septe",72.0,5782.53809,42.1358,86.25,89.24,112.17,0.034079314,0.262765522,-0.016237126,-0.048138718,10.54698,0.1269,42.42782,1878,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
REGN,Ateganosine (THIO-101),Non-small cell lung cancer (NSCLC)Â ,Phase 2,9/10/2024,"Phase 2 update reported that 16 patients surpassed 12-month survival follow-up, with a median survival follow-up in third line of 10.6 months, noted September 10, 2024.",105.0,122651.402,17.7167,1144.77,1136.35,1146.75,-0.007382372,0.001728111,-0.010264839,-0.030780945,1.95555,0.25651,405.06559,1879,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
MAIA,Ateganosine (THIO-101),Non-small cell lung cancer (NSCLC)Â ,Phase 2,9/10/2024,"Phase 2 update reported that 16 patients surpassed 12-month survival follow-up, with a median survival follow-up in third line of 10.6 months, noted September 10, 2024.",32.0,78.41566,105.0556,3.48,3.28,2.94,-0.059188871,-0.168622712,-0.010264839,-0.030780945,2.79941,0.01126,0.89454,1880,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
BYSI,Plinabulin (Trial 103) - (DUBLIN-3),Non small cell lung cancerÂ ,Phase 3,9/10/2024,"Phase 3 study presented data at the 2024 WCLC showing that its combination with docetaxel, significantly improved overall survival (OS), progression-free survival (PFS), and objective response rate (O",40.0,84.22773,91.276,2.025,2.09,2.215,0.031594365,0.089682703,-0.010264839,-0.030780945,5.56504,0.01302,0.16411,1881,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
VRDN,VRDN-001 - (THRIVE),Active Thyroid Eye Disease (TED)Â ,Phase 3,9/10/2024,"Phase 3 data presented at Webcast achieved all primary and secondary endpoints, noted September 10, 2024.",81.0,1197.936,70.0492,14.19,18.75,21.18,0.278656261,0.400519849,-0.010264839,-0.030780945,12.52406,0.10823,311.06876,1882,1,0,0,0,0,1,0,0,1,0,0,0,3,0,0,1
ALT,Pemvidutide - (IMPACT),Metabolic dysfunction-associated steatohepatitis (MASH)Â ,Phase 2,9/10/2024,"Phase 2 data presented at the Annual Meeting of the European Association for the Study of Diabetes reported that the lean loss ratio, defined as the change in lean mass compared to the change in total",88.0,494.65382,86.0298,6.38,6.96,7.57,0.087011377,0.17102497,-0.010264839,-0.030780945,30.53366,0.09018,29.37117,1883,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CNTA,ORX750 - (CRYSTAL-1),Narcolepsy and other sleep-wake disordersÂ ,Phase 1,9/10/2024,"Phase 1 study showed a favorable safety profile with no on-target adverse events commonly associated with other OX2R agonists, such as hepatotoxicity or visual disturbances. Based on these results, Ce",134.0,1652.12242,60.1133,14.93,14.58,16.28,-0.023721885,0.086564749,-0.010264839,-0.030780945,0.97079,0.06836,75.36861,1884,0,0,0,1,0,1,0,0,0,0,0,0,2,0,0,1
LXRX,Sotagliflozin - (SOTA-INS CGM),Basal Insulin-Treated Type 2 DiabetesÂ ,Phase 3,9/10/2024,"Phase 3 data reported that 200 mg and 400 mg once daily TIR (15.3 and 15.9 hours, respectively) approached the ADA target, with modest reductions in time-above-range (TAR) and mild increases in time-b",363.0,603.69213,80.8531,1.67,1.67,1.62,0.0,-0.030397477,-0.010264839,-0.030780945,6.78666,0.11695,2.53503,1885,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
RNAZ,TTX-MC138,Metastatic solid tumorsÂ ,Preclinical,9/10/2024,"Study published the journal Oncotarget showed that stem-like breast cancer cells increase expression of miR-10b, noted September 10, 2024.",0.0,4.42846,230.6486,236.22075,237.00615,267.96017,0.003319341,0.126071601,-0.010264839,-0.030780945,1.01805,0.01412,0.12988,1886,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
TFFP,TFF-dry powder hemagglutinin (HA) antigen,Influenza VaccineÂ ,Preclinical,9/10/2024,"Preclinical data for its TFF-dry powder hemagglutinin (HA) antigen vaccine candidates showing induced neutralizing antibody titers in ferrets against H1 and H3 influenza strains, noted September 10, 2",4.0,839.016,71.0469,42.05,42.05,42.05,0.0,0.0,-0.010264839,-0.030780945,0.0,0.0,0.0,1887,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
BBIO,BBP-812 - (CANaspire),Canavan DiseaseÂ ,Phase 1/2,9/10/2024,"FDA Granted RMAT designation, noted September 10, 2024.",191.0,5639.10181,51.4882,30.7,29.99,26.73,-0.023398662,-0.138476124,-0.010264839,-0.030780945,9.58253,0.15867,42.6256,1888,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
BBIO,BBP-631 - (ADventure),Congenital adrenal hyperplasia (CAH)Â ,Phase 1/2,9/10/2024,Phase 1/2 trial topline data showed increased endogenous cortisol production in all patients at higher dose levelsâ€”a first for CAH. The therapy was well-tolerated with no treatment-related serious adv,191.0,5639.10181,51.4882,30.7,29.99,26.73,-0.023398662,-0.138476124,-0.010264839,-0.030780945,9.58253,0.15867,42.6256,1889,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1
IMAB,Uliledlimab (TJ004309),Solid tumorsÂ ,Phase 1,9/10/2024,"Phase 1 PK/PD data showed a positive correlation between uliledlimab concentration and overall response rate, supporting dose selection for future trials. A Phase 2 study combining uliledlimab with pe",81.0,88.7638,51.9578,1.08,1.09,1.09,0.009216655,0.009216655,-0.010264839,-0.030780945,1.04663,0.1846,0.09275,1890,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
NUVB,Taletrectinib - (TRUST-I) (China),ROS1-positive non-small cell lung cancer (NSCLC)Â ,Phase 2,9/10/2024,Phase 2 data from ESMO reported that tumors shrank in 89% of taletrectinib-treated patients with advanced ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC) who were tyrosine kinase inhibitor (T,342.0,984.25405,91.0309,2.97,2.94,3.07,-0.010152371,0.033115609,-0.010264839,-0.030780945,4.92941,0.14625,3.3034,1891,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
NUVB,IBTROZI (taletrectinib),ROS1+ Nonâ€“Small Cell Lung CancerÂ ,Phase 2,9/10/2024,Phase 2 data from ESMO demonstrated durable responses and prolonged progression-free survival (PFS) with long-term follow up; median duration of response (DOR) and median PFS in TKI-naÃ¯ve patients wer,342.0,984.25405,91.0309,2.97,2.94,3.07,-0.010152371,0.033115609,-0.010264839,-0.030780945,4.92941,0.14625,3.3034,1892,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
AGIO,AG-946,Myelodysplastic syndrome (MDS)Â ,Phase 2a,9/11/2024,"Phase 2a FDA granted Orphan drug designation, noted Septemeber 11, 2024.",58.0,2520.93459,53.7698,44.52,44.31,45.54,-0.004728141,0.022652534,-0.009738361,-0.02725019,5.10277,0.12582,13.23141,1893,0,0,0,0,0,1,0,1,0,0,0,0,2,0,0,1
MRK,GARDASIL9 (V503-064 ),Human Papillomavirus (HPV) vaccineÂ ,Phase 3,9/11/2024,"Phase 3 met its primary and secondary endpoints, noted September 11, 2024.",0.0,290767.9762,23.7819,115.33,114.71,118.64,-0.00539038,0.028296114,-0.009738361,-0.02725019,1.02235,0.09313,898.9396,1894,1,0,0,0,0,1,0,0,1,0,0,0,3,0,0,1
GSK,GSK3943104 - (TH HSV REC-003),Herpes simplex virus (HSV) vaccineÂ ,Phase 1/2,9/11/2024,"Phase 1/2 trial did not meet the study's primary efficacy objective, noted September 11, 2024.",0.0,67486.41176,22.0189,16.71,16.545,16.04,-0.009923401,-0.04092174,-0.009738361,-0.02725019,0.0,0.02576,121.74031,1895,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,-1
REGN,Dupixent (dupilumab),Chronic spontaneous urticaria (CSU)Â ,Phase 3,9/11/2024,"Phase 3 met its primary and key secondary endpoints, noted September 11, 2024.",105.0,123201.8681,17.6518,1136.35,1141.45,1138.81,0.004478013,0.002162486,-0.009738361,-0.02725019,1.94525,0.25651,550.11612,1896,1,0,0,0,0,1,0,0,1,0,0,0,3,0,0,1
SNY,Dupixent (dupilumab),Chronic spontaneous urticaria (CSU)Â ,Phase 3,9/11/2024,"Phase 3 met its primary and key secondary endpoints, noted September 11, 2024.",0.0,131059.4643,23.0372,58.13,57.46,57.47,-0.011592828,-0.011418809,-0.009738361,-0.02725019,0.0,0.0,94.5402,1897,1,0,0,0,0,1,0,0,1,0,0,0,3,0,0,1
REGN,DUPIXENT (dupilumab),Bullous pemphigoid (BP)Â ,Phase 3,9/11/2024,"Phase 3 trial met its primary and key secondary endpoints, noted September 11, 2024.",105.0,123201.8681,17.6518,1136.35,1141.45,1138.81,0.004478013,0.002162486,-0.009738361,-0.02725019,1.94525,0.25651,550.11612,1898,1,0,0,0,0,1,0,0,1,0,0,0,3,0,0,1
SNY,DUPIXENT (dupilumab),Bullous pemphigoid (BP)Â ,Phase 3,9/11/2024,"Phase 3 trial met its primary and key secondary endpoints, noted September 11, 2024.",0.0,131059.4643,23.0372,58.13,57.46,57.47,-0.011592828,-0.011418809,-0.009738361,-0.02725019,0.0,0.0,94.5402,1899,1,0,0,0,0,1,0,0,1,0,0,0,3,0,0,1
BCTX,Bria-IMT + check point inhibitor (CPI) - (investigator-initiated trial),Metastatic breast cancerÂ ,Phase 2,9/11/2024,"Phase 2 data reported a median overall survival of 15.6 months and OS of 15.6 months, noted September 11, 2024.",1.0,26.71725,104.0785,92.92495,95.99995,78.49496,0.032555493,-0.168757759,-0.009738361,-0.02725019,0.0,0.0,107.35147,1900,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
OSTX,OST-tADC-FRA-H,Ovarian CancerÂ ,Preclinical,9/11/2024,"Preclinical data reported an average tumor volume of 10mm3 as compared with 1000 mm3 for the untreated animals, noted September 11, 2024.",31.0,73.30486,0.0,3.75,3.51,3.52,-0.066139803,-0.06329485,-0.009738361,-0.02725019,0.11822,0.09213,0.37548,1901,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
AIM,Ampligen (AMP-518),Post-COVID conditionsÂ ,Phase 2,9/11/2024,"Phase 2 further analysis showed that patients with Long COVID were, on average, able to walk farther in a Six-Minute Walk Test (6MWT) when compared to subjects who received a placebo, noted September",2.0,151.39018,58.9117,0.685,0.725,0.74,0.056752817,0.077231348,-0.009738361,-0.02725019,0.0,0.02736,0.78269,1902,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
JNJ,TREMFYA (Guselkumab),Ulcerative colitisÂ ,Approved,9/11/2024,"Approved September 11, 2024.",0.0,396761.9012,17.4131,167.38,164.82,166.15,-0.015412707,-0.007375682,-0.009738361,-0.02725019,0.87761,0.06321,975.7616,1903,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1
NVS,TREMFYA (Guselkumab),Ulcerative colitisÂ ,Approved,9/11/2024,"Approved September 11, 2024.",0.0,1913.60774,57.0064,6.22,6.15,6.58,-0.011317825,0.056264839,-0.009738361,-0.02725019,0.0,0.00573,1.20899,1904,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1
AMRN,VASCEPA (icosapent ethyl) - (REDUCE-IT),Cardiovascular diseaseÂ ,Phase 1,9/11/2024,"Phase 1 trial data presented at EASD reported that absolute risk reduction was 7.9% and 9.4% in first events with a number needed to treat of 13 and 11 for the primary and key secondary endpoints, not",20.0,241.7275,73.6542,11.94,11.758,11.934,-0.015360248,-0.000502639,-0.009738361,-0.02725019,4.37314,0.0731,0.42272,1905,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
AURA,AU-011 (belzupacap sarotalocan) (IVT administration) - (CoMpass),Uveal melanoma including choroidal melanomaÂ ,Phase 2,9/12/2024,"Phase 2 final results reported an 80% Tumor Control Rate, and 90% Visual Acuity Preservation, noted September 12, 2024.",62.0,485.64387,59.9505,9.07,9.79,9.69,0.076389192,0.066122162,-0.023088328,-0.0350704,2.62216,0.13482,4.32828,1906,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
SNY,Losmapimod - (REACH),Facioscapulohumeral muscular dystrophy (FSHD)Â ,Phase 3,9/12/2024,"Phase 3 trial study failed to show an improvement in relative surface area (RSA), a measure of reachable workspace (RWS), versus placebo at week 48, study did not meet primary endpoint. Fulcrum to sus",0.0,128853.4137,23.1178,57.46,56.75,58.26,-0.012433397,0.013826698,-0.023088328,-0.0350704,0.0,0.0,208.70335,1907,1,0,0,0,0,1,0,0,0,0,0,0,0,2,0,-1
FULC,Losmapimod - (REACH),Facioscapulohumeral muscular dystrophy (FSHD)Â ,Phase 3,9/12/2024,"Phase 3 trial study failed to show an improvement in relative surface area (RSA), a measure of reachable workspace (RWS), versus placebo at week 48, study did not meet primary endpoint. Fulcrum to sus",54.0,214.65865,148.1401,8.85,3.44,3.45,-0.944945988,-0.942043228,-0.023088328,-0.0350704,12.91047,0.09868,117.91958,1908,1,0,0,0,0,1,0,0,0,0,0,0,0,2,0,-1
CVAC,Multivalent seasonal influenza vaccine,Influenza B strainÂ ,Phase 2,9/12/2024,"Phase 2 data suggest the vaccine candidates have an acceptable safety and reactogenicity profile for all mRNA formulations tested, noted September 12, 2024.",224.0,693.1303,74.9918,3.03,3.09,3.29,0.019608471,0.082324945,-0.023088328,-0.0350704,2.46944,0.0377,1.244,1909,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
GSK,Multivalent seasonal influenza vaccine,Influenza B strainÂ ,Phase 2,9/12/2024,"Phase 2 data suggest the vaccine candidates have an acceptable safety and reactogenicity profile for all mRNA formulations tested, noted September 12, 2024.",0.0,66833.77798,22.0427,16.545,16.385,15.745,-0.009717659,-0.049561087,-0.023088328,-0.0350704,0.0,0.02576,149.80845,1910,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
PMN,PMN310 - (PRECISE-AD),Alzheimer's disease (AD)Â ,Preclinical,9/12/2024,"Preclinical data showed little interaction with non-toxic species and did not bind to amyloid plaques, potentially reducing the risk of amyloid-related imaging abnormalities, noted September 12, 2024.",53.0,37.35682,96.2898,1.23,1.25,1.23,0.016129382,0.0,-0.023088328,-0.0350704,0.43108,0.02437,0.03222,1911,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
MCRB,SER-155,"Gastrointestinal infections, bacteremia and graft versus host disease (GvHD)Â ",Phase 1b,9/12/2024,"Phase 1b placebo-controlled Cohort 2 data readout significantly reduced bacterial bloodstream infections (BSIs) and systemic antibiotic exposure, with fewer cases of febrile neutropenia compared to pl",8.0,145.66174,141.4281,21.0,19.2,21.0,-0.089612159,0.0,-0.023088328,-0.0350704,10.50557,0.0071,7.79171,1912,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
MNPR,MNPR-101-Zr (uPAR),Solid tumorsÂ ,Phase 1,9/12/2024,"Phase 1 Initial results showed high specificity and durable uptake of MNPR-101-Zr in metastatic tumors compared to normal tissue, aligning with conventional PET imaging, noted September 12, 2024.",6.0,13.90544,121.2085,2.4,3.95,4.5,0.498246842,0.628608659,-0.023088328,-0.0350704,2.63595,0.01105,161.96831,1913,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
NKGN,Troculeucel (SNK01),Alzheimer's DiseaseÂ ,Phase 1,9/12/2024,"Phase 1 data from two of the first three patients in the cohort, treated with the highest dose of 6 billion cells, showed cognitive improvement from moderate to mild AD after three months, noted Septe",124.0,30.78649,141.9768,0.78,0.8706,0.4275,0.109888709,-0.601339631,-0.023088328,-0.0350704,1.80561,0.00876,2.27979,1914,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
DRUG,BMB-101 - (BREAKTHROUGH),Dravet SyndromeÂ ,Phase 2,9/12/2024,"Phase 2 study initiated, noted September 12, 2024.",7.0,6.56184,169.37,1.47,1.47,1.47,0.0,0.0,-0.023088328,-0.0350704,0.0,0.05275,0.0,1915,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
VYNE,VYN202,Moderate-to-severe plaque psoriasisÂ ,Phase 1a,9/12/2024,"Phase 1a pharmacokinetic results demonstrated dose-dependent exposure of VYN202 in blood, study was generally well tolerated with no drug-related adverse events, noted September 12, 2024.",25.0,26.40142,79.3289,1.85,1.79,1.9,-0.032970019,0.026668247,-0.023088328,-0.0350704,0.31527,0.20716,0.24459,1916,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1
VERA,Atacicept - (ORIGIN 3),IgA NephropathyÂ ,Phase 3,9/12/2024,"Phase 3 enrollment completed, noted September 12, 2024.",63.0,1955.15453,55.3889,37.57,35.66,41.99,-0.052176247,0.111225635,-0.023088328,-0.0350704,11.03012,0.05176,22.63626,1917,0,0,0,0,0,1,0,0,0,1,0,0,2,0,0,1
IPHA,IPH5301 - (CHANCES),Solid tumorsÂ ,Phase 1,9/12/2024,"Phase 1 data from ESMO noted that treatment was safe and well-tolerated with preliminary signals of monotherapy antitumor activity, noted September 12, 2024.",92.0,171.61566,68.3258,2.36,2.28,2.25,-0.034486176,-0.047731403,-0.023088328,-0.0350704,0.0,0.0,0.01875,1918,0,0,0,1,0,1,0,0,0,0,0,0,2,0,0,1
NBIX,Luvadaxistat (NBI-1065844),Cognitive Impairment Associated with Schizophrenia (CIAS)Â ,Phase 2,9/12/2024,"Phase 2 trial failed to meet its primary endpoint, noted September 12, 2024.",99.0,12246.39948,40.4724,121.47,121.28,120.46,-0.001565397,-0.008349571,-0.023088328,-0.0350704,2.11473,0.07626,64.36863,1919,1,0,0,0,0,1,0,0,0,0,0,0,0,2,0,-1
IMRX,Atebimetinib (IMM-1-104) + mGnP,"Solid tumors, pancreatic cancer, melanomaÂ ",Phase 2a,9/12/2024,"Phase 2a data reported a complete or partial responses have been observed in the first two patients (2/5) to date, for an initial response rate of 40% and an initial disease control rate of 80%, with",36.0,42.4043,152.1988,1.29,1.43,2.42,0.103032226,0.629125322,-0.023088328,-0.0350704,5.12689,0.0496,18.15342,1920,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
HALO,Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs) with ENHANZE,"Lung, liver, skin and soft tissue cancerÂ ",Approved,9/12/2024,"Approved September 12, 2024.",116.0,7669.10307,30.9634,59.39,60.54,59.5,0.019178442,0.001850451,-0.023088328,-0.0350704,7.92561,0.23743,66.23488,1921,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1
CVAC,CVGBM,GlioblastomaÂ ,Phase 1,9/13/2024,"Phase 1 data from ESMO reported the induction of cancer antigen-specific T-cell responses in 77% of evaluable patients following CVGBM monotherapy, noted September 13, 2024.",224.0,771.64021,76.4908,3.09,3.44,3.23,0.10730038,0.044311046,-0.022163231,-0.025416228,2.46944,0.07158,4.02602,1922,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
PRLD,PRT3789 with KEYTRUDA (pembrolizumab) - (SMARCA2/BRM),"SMARCA4-deleted cancers, solid tumorsÂ ",Phase 1,9/13/2024,"Phase 1 data presented at ESMO showed signs of anti-tumor activity, including partial responses in 3 of 26 patients with heavily pre-treated NSCLC or esophageal cancer, and additional patients with pr",56.0,210.12246,137.6002,4.83,2.77,2.55,-0.555999147,-0.638753108,-0.022163231,-0.025416228,3.20814,0.03037,6.89164,1923,1,0,0,0,1,1,0,0,0,0,1,0,4,0,0,1
MRK,PRT3789 with KEYTRUDA (pembrolizumab) - (SMARCA2/BRM),"SMARCA4-deleted cancers, solid tumorsÂ ",Phase 1,9/13/2024,"Phase 1 data presented at ESMO showed signs of anti-tumor activity, including partial responses in 3 of 26 patients with heavily pre-treated NSCLC or esophageal cancer, and additional patients with pr",0.0,293683.0069,23.8009,115.25,115.86,117.17,0.005278884,0.01652219,-0.022163231,-0.025416228,1.02235,0.06952,777.37669,1924,1,0,0,0,1,1,0,0,0,0,1,0,4,0,0,1
HALO,Ocrevus Zunovo,Multiple sclerosis (MS) or primary progressive MSÂ ,Approved,9/13/2024,"FDA approval on September 13, 2024.",116.0,7892.05684,31.0757,60.54,62.3,59.24,0.028657122,-0.021707314,-0.022163231,-0.025416228,7.92561,0.25331,58.71688,1925,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
REGN,Dupixent (dupilumab),Chronic rhinosinusitis with nasal polyposis (CRSwNP) in adolescents aged 12 to 17 yearsÂ ,Approved,9/13/2024,"FDA approved on September 13, 2024.",105.0,124486.289,17.8732,1164.46,1153.35,1145.03,-0.009586709,-0.016826623,-0.022163231,-0.025416228,1.94525,0.25331,407.86377,1926,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
LLY,EBGLYSS (lebrikizumab-lbkz),Atopic DermatitisÂ ,Approved,9/13/2024,"Approved September 13, 2024.",946.0,831732.2954,30.9176,935.02,923.71,921.49,-0.01216975,-0.014575994,-0.022163231,-0.025416228,0.69654,0.16746,1889.31579,1927,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1
CCCC,CFT1946,Solid tumorsÂ ,Phase 1,9/13/2024,"Phase 1 dose escalation data presented at ESMO showed it was well-tolerated across all doses with no dose-limiting toxicities and achieved dose-proportional pharmacokinetics, noted September 13, 2024.",71.0,446.53513,78.8498,6.41,6.44,6.35,0.004669269,-0.009404458,-0.022163231,-0.025416228,16.77271,0.0569,21.47133,1928,0,0,0,1,0,1,0,0,0,0,1,0,3,0,0,1
PFE,SGN-PDL1V,Non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinomas (HNSCC)Â ,Phase 1,9/13/2024,"Phase 1 data presented at ESMO reported that treatment was generally well tolerated with no unexpected adverse events, and encouraging antitumor activity, noted September 13, 2023.",0.0,165864.1645,22.185,29.16,29.27,29.42,0.003765194,0.008876808,-0.022163231,-0.025416228,1.15375,0.00983,585.03948,1929,0,0,0,1,0,1,0,0,0,0,1,0,3,0,0,1
BNTX,BNT211,Solid tumorsÂ ,Phase 1/2,9/13/2024,"Additional Phase 1/2 data from ESMO reported an objective response rate (ORR) was 38%, noted September 13, 2024.",239.0,29340.3534,44.06,105.0,123.4,112.28,0.161470761,0.067035401,-0.022163231,-0.025416228,1.08445,0.10558,777.1774,1930,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
IMCR,Brenetafusp (IMC-F106C) - (PRAME-A02),Solid tumorsÂ ,Phase 1,9/14/2024,"Phase 1 ovarian data from ESMO reported that the median progression-free survival (PFS) was 3.3 months, and the overall survival (OS), while still maturing, was 73% at 6 months, noted September 14, 20",48.0,1678.12926,42.6275,33.55,33.55,33.18,0.0,-0.011089579,-0.000691392,-0.003944389,13.75819,0.14202,0.0,1931,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ACRV,ACR-368,"Platinum-resistant ovarian,(PROC) endometrial, and urothelial cancersÂ ",Phase 2,9/14/2024,"Phase 2 update from ESMO reported a overall response rate (ORR) = 62.5% observed in prospectively-selected ACR-368 OncoSignature-positive (BM+) patients with endometrial cancer, noted September 14, 20",31.0,275.96197,113.7503,8.91,8.91,7.47,0.0,-0.176279242,-0.000691392,-0.003944389,3.3158,0.01816,0.0,1932,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
PFE,Ponsegromab,Cancer-associated cachexiaÂ ,Phase 2,9/14/2024,"Phase 2 data from ESMO reported a significant and robust increases in body weight after 12 weeks across all doses: 2.02% (95% confidence interval (CI), -0.97 to 5.01%) in the 100 mg treatment group, 3",0.0,165864.1645,22.185,29.27,29.27,29.42,0.0,0.005111614,-0.000691392,-0.003944389,1.15375,0.00983,0.0,1933,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
INCY,INCB123667,"Late-stage cancers, ovarian cancerÂ ",Phase 1,9/14/2024,"Phase 1 safety and efficacy data from ESMO reported that the highest OR rate of 31.3% (5 responders, including 2 CRs) was found in the 50mg BID cohort, noted September 14, 2024.",196.0,12241.5306,25.0358,63.56,63.56,65.74,0.0,0.033723227,-0.000691392,-0.003944389,5.60863,0.18236,0.0,1934,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
APVO,ALG.APV-527,Solid tumorsÂ ,Phase 1,9/14/2024,"Phase 1 interim data from ESMO report nine of 15 efficacy evaluable patients (60%) have a best overall response to date of stable disease (SD), noted September 14, 2024.",3.0,3.34323,204.4681,262.62626,262.62626,125.87413,0.0,-0.735449517,-0.000691392,-0.003944389,0.65211,0.01177,0.0,1935,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ALMS,Subcutaneous lonigutamab - (LONGITUDE),Thyroid eye disease (TED)Â ,Phase 1/2,9/14/2024,"Phase 1/2 preliminary safety, efficacy, and quality of life outcomes at ESOPRS reported that patients in cohort 1 (40 mg Q3W) achieved early clinical responses across manifestations of disease, noted",104.0,630.53427,0.0,11.59,11.59,11.47,0.0,-0.010407726,-0.000691392,-0.003944389,2.35608,0.01163,0.0,1936,0,0,0,1,0,1,0,0,0,0,0,0,2,0,0,1
PFE,Atirmociclib (PF-07220060) + PF-07104091,HR+/HER2- breast cancerÂ ,Phase 1/2,9/14/2024,"Phase 1b/2 data from ESMO showed a manageable safety profile and encouraging efficacy in patients with heavily pretreated HR+/HER2- breast cancer, noted September 14, 2024.",0.0,165864.1645,22.185,29.27,29.27,29.42,0.0,0.005111614,-0.000691392,-0.003944389,1.15375,0.00983,0.0,1937,0,0,0,1,0,1,0,0,0,0,0,0,2,0,0,1
BCYC,BT5528 and OPDIVO (nivolumab),Solid tumorsÂ ,Phase 1/2,9/14/2024,"Phase 1/2 data from ESMO reported that the ORR was 43% (6/14) (unconfirmed & confirmed) among patients who were EphA2+, compared with 20% (2/10) among patients who were EphA2, noted September 14, 202",69.0,1864.20324,60.0817,27.02,27.02,25.41,0.0,-0.061434535,-0.000691392,-0.003944389,3.04734,0.09898,0.0,1938,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
RPTX,Camonsertib (RP-3500)/ RG6526)- (TRESR),Solid TumorsÂ ,Phase 1/2,9/14/2024,"Phase 1/2 data from ESMO reported that the overall response was 15% (7/46); 21% (7/33) excluding pts with confirmed non-biallelic LoF, noted September 14, 2024.",42.0,149.83273,65.652,3.53,3.53,3.52,0.0,-0.002836881,-0.000691392,-0.003944389,1.69935,0.15054,0.0,1939,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ZLAB,ZL-1218,Solid tumorsÂ ,Phase 1,9/14/2024,"Phase 1 trial data from ESMO demonstrated reductions of more than 60% in CCR8+ cells and increased of CD8+ T cells, noted September 14, 2024.",109.0,2012.84759,59.4065,20.51,20.51,21.85,0.0,0.063288349,-0.000691392,-0.003944389,5.02696,0.07168,0.0,1940,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
BCAB,Ozuriftamab Vedotin (BA3021),"Solid Tumors, Non-small cell lung cancer (NSCLC), recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN)Â ",Phase 2,9/14/2024,"Phase 2 data from ESMO reported that treatment with ozuriftamab vedotin achieved durable responses and promising tumor control among a patient population with a median of 3 prior lines of therapy, not",58.0,87.48768,125.0902,1.81,1.81,1.72,0.0,-0.051002554,-0.000691392,-0.003944389,9.20734,0.27438,0.0,1941,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1
INCY,Zynyz (retifanlimab-dlwr),Advanced Anal Cancer PatientsÂ ,Phase 3,9/14/2024,"Phase 3 data reported that the median PFS was significantly higher in the R vs P arm (9.30 vs 7.39 mo) noted September 14, 2024.",196.0,12241.5306,25.0358,63.56,63.56,65.74,0.0,0.033723227,-0.000691392,-0.003944389,5.60863,0.18236,0.0,1942,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
BNTX,BNT113 and KEYTRUDA (pembrolizumab),Head and Neck Cancer / HPVÂ ,Phase 2,9/14/2024,"Phase 2 preliminary data from ESMO reported that 70% of patients mounted cellular immune responses against E6/7 as measured ex vivo by IFNÎ³ ELISpot, noted September 14, 2024.",239.0,29340.3534,44.06,123.4,123.4,112.28,0.0,-0.09443536,-0.000691392,-0.003944389,1.08445,0.10558,0.0,1943,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
MGNX,MGC018 - (TAMARACK),Metastatic castration-resistant prostate cancer (mCRPC)Â ,Phase 2,9/15/2024,"Phase 2 data from ESMO reported a confirmed objective response rate (ORR) was 20.0% (n=9) and the unconfirmed ORR was 26.7%, noted September 15, 2024.",63.0,232.0723,231.7459,3.7,3.7,3.28,0.0,-0.120489397,-0.000691392,-0.003944389,10.4612,0.02382,0.0,1944,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
LLY,177Lu-PNT2002 - (SPLASH),Metastatic Castration-Resistant Prostate CancerÂ ,Phase 3,9/15/2024,"Phase 3 data from ESMO reported that the Overall Response Rate was 38.1% vs. 12.0% for the ARPI switch arm, including 9.3% Complete Responses, noted September 15, 2024.",946.0,831732.2954,30.9176,923.71,923.71,921.49,0.0,-0.002406244,-0.000691392,-0.003944389,0.69654,0.16746,0.0,1945,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
LNTH,177Lu-PNT2002 - (SPLASH),Metastatic Castration-Resistant Prostate CancerÂ ,Phase 3,9/15/2024,"Phase 3 data from ESMO reported that the Overall Response Rate was 38.1% vs. 12.0% for the ARPI switch arm, including 9.3% Complete Responses, noted September 15, 2024.",67.0,7328.40426,61.8352,105.55,105.55,110.05,0.0,0.041750034,-0.000691392,-0.003944389,6.12475,0.01015,0.0,1946,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
REPL,RP1 (vusolimogene oderparepvec) and OPDIVO (nivolumab) - (IGNYTE-3),Non-melanoma (NMSC) / Non-small cell lung cancer (NSCLC)Â ,Phase 3,9/15/2024,"Phase 3 data from ESMO reported a primary analysis shows clinically meaningful activity across all subgroups, including those who had received prior anti-PD1 and anti-CTLA-4 or had primary resistance",78.0,760.41714,76.8639,11.13,11.13,10.91,0.0,-0.019964365,-0.000691392,-0.003944389,7.65,0.04008,0.0,1947,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
AZN,IMFINZI (durvalumab),Muscle-invasive bladder cancer (MIBC)Â ,Phase 3,9/15/2024,"Phase 3 data from ESMO reported a 32% reduction in the risk of disease progression, recurrence, not undergoing surgery, or death versus the comparator arm , notedSeptember 15, 2024.",0.0,184918.1901,18.5705,119.28,119.28,117.8,0.0,-0.012485399,-0.000691392,-0.003944389,0.0,0.10308,0.0,1948,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
AMGN,LUMAKRAS (Sotorasib) + Vectibix (panitumumab) - (CodeBreak 101),Colorectal Cancer (CRC)Â ,Phase 1b,9/15/2024,"Phase 1b data presented at ESMO reported that 30 pts had confirmed partial responses, with an overall response rate of 75%, noted September 15, 2024.",538.0,178635.0992,25.733,332.45,332.45,337.38,0.0,0.014720419,-0.000691392,-0.003944389,1.57768,0.04805,0.0,1949,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1
ZNTL,Azenosertib Combination with Topoisomerase I,HER2+ breast cancerÂ ,Preclinical,9/15/2024,"Preclinical data from ESMO reported that 50% of animals showing complete tumor regression (CR) noted September 15, 2024.",72.0,230.38981,130.3918,3.24,3.24,4.22,0.0,0.264261798,-0.000691392,-0.003944389,17.27111,0.04111,0.0,1950,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
IMMP,Eftilagimod alpha (IMP321) and KEYTRUDA (pembrolizumab) - (TACTI-003),Head and neck squamous cell carcinoma (HNSCC)Â ,Phase 2b,9/15/2024,"Additional Phase 2b data presented at ESMO reported that E+P resulted in numerically higher ORR & DCR compared to P only in CPS â‰¥1 pts noted September 15, 2024.",147.0,581.04492,85.8796,2.64,2.64,2.31,0.0,-0.133531393,-0.000691392,-0.003944389,0.0,0.0,0.0,1951,1,0,0,0,0,1,0,0,0,0,1,0,3,0,0,1
GSK,Belrestotug (EOS-448/GSK4428859A) - (GALAXIES Lung-201),1L non-small cell lung cancer (NSCLC)Â ,Phase 2,9/16/2024,"Phase 2 interim data from ESMO reported an objective response rate (ORR) of 63.3-76.7% observed with belrestotug + dostarlimab combinations, with confirmed ORR (cORR) at ~60% for every dose, noted Sep",0.0,66568.64551,21.8751,16.335,16.32,15.275,-0.000918696,-0.06709254,0.002572221,0.020160363,0.0,0.01808,42.1149,1952,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ZNTL,azenosertib (ZN-c3) + ZEJULA (Niraparib) - (DENALI),"Platinum Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal CancerÂ ",Phase 2,9/16/2024,"Phase 2 clinical hold lifted by the FDA, noted September 16, 2024.",72.0,261.67732,131.9192,3.24,3.68,4.06,0.127339422,0.225609644,0.002572221,0.020160363,17.27111,0.04111,164.21527,1953,0,0,0,0,0,1,0,1,0,0,0,0,0,2,0,-1
IOBT,IO102-IO103 - (IOB-032),Squamous cell carcinoma of the head and neck (SCCHN)Â ,Phase 2,9/16/2024,"Phase 2 data from ESMO confirmed 44.4% overall response rate (ORR) in a PD-L1 high population of patients with SCCHN irrespective of HPV status, noted September 16, 2024.",65.0,51.07089,92.1424,0.751,0.7752,1.12,0.031715409,0.399678313,0.002572221,0.020160363,0.07849,0.10425,4.14013,1954,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ZNTL,Azenosertib (ZN-c3) - (TETON),Uterine serous carcinoma (USC)Â ,Phase 2,9/16/2024,"Phase 2 clinical hold lifted by the FDA, noted September 16, 2024.",72.0,261.67732,131.9192,3.24,3.68,4.06,0.127339422,0.225609644,0.002572221,0.020160363,17.27111,0.04111,164.21527,1955,0,0,0,0,0,1,0,1,0,0,0,0,0,2,0,-1
TNXP,TNX-801 - (Kenya study),"Monkeypox, horse pox and smallpox infectionÂ ",Phase 1/2,9/16/2024,"Phase 1/2 vaccine candidate, aligns closely with the World Health Organization's (WHO) preferred target product profile (TPP) for mpox vaccines, noted Septemeber 16, 2024.",8.0,18.86149,184.0161,15.68,14.75,13.49,-0.061142932,-0.150437345,0.002572221,0.020160363,1.22672,0.03964,1.86362,1956,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
BCYC,Bicycle Toxin Conjugates zelenectide pevedotin (BT8009) - (Duravelo-2),Solid tumorsÂ ,Phase 1/2,9/16/2024,"Phase 1/2 data from ESMO reported a 45% overall response rate (ORR), 11.1 months median duration of response and a generally well-tolerated safety profile, noted September 16, 2024.",69.0,1722.76665,59.2136,27.02,24.97,23.97,-0.078902228,-0.119774284,0.002572221,0.020160363,3.04734,0.09898,23.21556,1957,1,0,0,1,0,1,0,0,0,0,0,0,3,0,0,1
NCNA,NUC-7738 (NuTide:701) in combination with pembrolizumab,MelanomaÂ ,Phase 1/2,9/16/2024,"Phase 1/2 data from ESMO reported that 75% of patients achieved disease control, including two patients who achieved Partial Responses, noted September 16, 2024.",1.0,14.30957,239.5726,508.0,1274.0,646.0,0.919435389,0.240318056,0.002572221,0.020160363,2.778,0.03654,425.69309,1958,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1
EVAX,EVX-01 + KEYTRUDA (pembrolizumab) / OPDIVO (nivolumab),Metastatic MelanomaÂ ,Phase 2,9/16/2024,"Phase 2 data presented at ESMO 24 showed a 69% overall response rate (ORR), with tumor reductions in 15 out of 16 patients and a 79% rate of targeted immune responses to the vaccine's neoantigens, not",6.0,18.12216,82.7963,15.0,16.25,14.75,0.080042708,-0.016807118,0.002572221,0.020160363,0.6119,0.00644,1.62425,1959,1,0,0,0,1,1,0,0,0,0,1,0,4,0,0,1
MRK,EVX-01 + KEYTRUDA (pembrolizumab) / OPDIVO (nivolumab),Metastatic MelanomaÂ ,Phase 2,9/16/2024,"Phase 2 data presented at ESMO 24 showed a 69% overall response rate (ORR), with tumor reductions in 15 out of 16 patients and a 79% rate of targeted immune responses to the vaccine's neoantigens, not",0.0,299006.1064,23.9305,115.86,117.96,115.63,0.017963018,-0.001987128,0.002572221,0.020160363,1.02235,0.06952,925.52607,1960,1,0,0,0,1,1,0,0,0,0,1,0,4,0,0,1
JNJ,TAR-200 with Cetrelimab - (SunRISe-4),High-Risk Non-Muscle Invasive Bladder Cancer (NMIBC)Â ,Phase 2b,9/16/2024,"Phase 2b data reported that the overall efficacy with a centrally confirmed pathologic complete response (pCR, [T0]) rate of 42 percent compared to 23% with CET alone in patients with histologically p",0.0,401985.62,17.3214,165.52,166.99,163.22,0.008841897,-0.013993049,0.002572221,0.020160363,0.87761,0.06462,866.32525,1961,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
PASG,PBFT02 - (upliFT-D),Frontotemporal dementiaÂ ,Phase 1/2,9/16/2024,"Phase 1/2 data to be presented at ISFTD showed sustained increases in cerebrospinal fluid (CSF) progranulin levels in all treated patients for up to 12 months, with no serious adverse events observed",3.0,45.121,83.1726,16.134,14.61,12.924,-0.099222621,-0.221842799,0.002572221,0.020160363,2.82242,0.09074,0.41045,1962,0,0,0,1,0,1,0,0,0,0,0,0,0,2,0,-1
CGEM,Zipalertinib (CLN-081/TAS6417) - (REZILIENT1),Non-small cell lung cancerÂ ,Phase 2b,9/16/2024,"Phase 2b data reported an objective response rate of 40% , noted September 16, 2024.",59.0,981.54453,75.9294,17.95,16.93,16.63,-0.058502919,-0.076381822,0.002572221,0.020160363,13.88059,0.08847,7.40318,1963,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ASND,TransCon IL-2 Î²/Î³ - (IL-Î²elieÎ³e),Solid tumorsÂ ,Phase 1/2,9/16/2024,"Phase 1/2 initial clinical results presented at ESMO 2024 showed anti-tumor responses in 29% (4/14) of efficacy-evaluable, heavily pre-treated patients with platinum-resistant ovarian cancer (PROC) wh",60.0,8004.40049,43.7628,119.22,139.57,146.6,0.157595742,0.206737264,0.002572221,0.020160363,6.14633,0.16608,406.6044,1964,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1
ASND,TransCon CNP - (ApproaCH),AchondroplasiaÂ ,Phase 3,9/16/2024,"Phase 3 topline data presented at ESMO demonstrated a significant increase in annualized growth velocity (AGV) compared to placebo, with an LS mean treatment difference of 1.49 cm/year at Week 52. Sub",60.0,8004.40049,43.7628,119.22,139.57,146.6,0.157595742,0.206737264,0.002572221,0.020160363,6.14633,0.16608,406.6044,1965,0,0,1,0,0,1,0,0,0,0,1,0,3,0,0,1
CGEM,CLN-978,Systemic Lupus Erythematosus (SLE)Â ,IND-Enabling,9/16/2024,"IND submitted to the FDA, noted September 16, 2024.",59.0,981.54453,75.9294,17.95,16.93,16.63,-0.058502919,-0.076381822,0.002572221,0.020160363,13.88059,0.08847,7.40318,1966,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
JNJ,INLEXZO (gemcitabine intravesical system) (TAR-200) - (SunRISe-1),"Bacillus Calmette-GuÃ©rin (BCG)-unresponsive, high-risk non-muscle-invasive bladder cancer (HR-NMIBC)Â ",Phase 2b,9/16/2024,"Phase 2b reported a 46.4% centrally-confirmed CR, noted September 16, 2024.",0.0,401985.62,17.3214,165.52,166.99,163.22,0.008841897,-0.013993049,0.002572221,0.020160363,0.87761,0.06462,866.32525,1967,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
BYSI,Plinabulin (Trial 103) - (DUBLIN-3),Non small cell lung cancerÂ ,Phase 3,9/16/2024,"Phase 3 study presented data shared at ESMO demonstrated a substantial reduction in Grade 4 neutropenia (over 80% reduction) and a favorable safety profile, with fewer serious adverse events and impro",40.0,87.85476,91.8531,2.3,2.18,2.08,-0.053584246,-0.100541229,0.002572221,0.020160363,5.48492,0.01885,0.07182,1968,0,0,0,1,0,1,0,0,0,0,0,0,0,0,2,0
MRK,KEYTRUDA plus LENVIMA with TACE - (LEAP-012),"Unresectable, non-metastatic hepatocellular carcinomaÂ ",Phase 3,9/16/2024,"Phase 3 results from ESMO reported a reduced the risk of disease progression or death by 34% compared to TACE alone, noted September 16, 2024.",0.0,299006.1064,23.9305,115.86,117.96,115.63,0.017963018,-0.001987128,0.002572221,0.020160363,1.02235,0.06952,925.52607,1969,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
MRK,KEYTRUDA (pembrolizumab) + plinabulin / docetaxel - (KeyPelms-004 / 303 Study) (TROPION Lung-01),2L/3L Non-small cell lung cancer (NSCLC)Â ,Phase 2,9/16/2024,"Phase 2 data from the 303 Study at ESMO 2024 showed that among 19 evaluable patients, the combination achieved a 21.1% overall response rate (ORR), a median progression-free survival (PFS) of 8.63 mon",0.0,299006.1064,23.9305,115.86,117.96,115.63,0.017963018,-0.001987128,0.002572221,0.020160363,1.02235,0.06952,925.52607,1970,1,0,0,0,0,1,0,0,0,0,0,0,2,0,0,1
BYSI,KEYTRUDA (pembrolizumab) + plinabulin / docetaxel - (KeyPelms-004 / 303 Study) (TROPION Lung-01),2L/3L Non-small cell lung cancer (NSCLC)Â ,Phase 2,9/16/2024,"Phase 2 data from the 303 Study at ESMO 2024 showed that among 19 evaluable patients, the combination achieved a 21.1% overall response rate (ORR), a median progression-free survival (PFS) of 8.63 mon",40.0,87.85476,91.8531,2.3,2.18,2.08,-0.053584246,-0.100541229,0.002572221,0.020160363,5.48492,0.01885,0.07182,1971,1,0,0,0,0,1,0,0,0,0,0,0,2,0,0,1
EXEL,CABOMETYX (cabozantinib) and TECENTRIQ (atezolizumab) - (CONTACT-02),Castration-Resistant Prostate CancerÂ ,Phase 3,9/16/2024,"Phase 3 final analysis of OS showed a numerical but not statistically significant improvement favoring cabozantinib in combination with atezolizumab, noted September 16, 2024.",269.0,7835.86489,28.4305,26.46,27.47,26.36,0.037460341,-0.003786449,0.002572221,0.020160363,4.21666,0.05349,54.76949,1972,1,0,0,0,0,1,0,0,0,0,1,0,0,0,3,0
MRK,KEYTRUDA (pembrolizumab) vs Ipilimumab - (KEYNOTE-006),Advanced MelanomaÂ ,Phase 3,9/16/2024,"Phase 3 data reported that KEYTRUDA demonstrated a sustained OS benefit, reducing the risk of death by 29%, noted September 16, 2024.",0.0,299006.1064,23.9305,115.86,117.96,115.63,0.017963018,-0.001987128,0.002572221,0.020160363,1.02235,0.06952,925.52607,1973,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
GMAB,Rinatabart sesutecan (Rina-S) - (RAINFOL),"Ovarian cancer, Endometrial Cancers, Solid tumorsÂ ",Phase 1/2,9/16/2024,"Phase 1/2 data demonstrated a confirmed objective response rate (ORR) of 50.0% (95% CI) in ovarian cancer patients treated with Rina-S 120 mg/m2 once every 3 weeks (Q3W), regardless of FRÎ± expression",661.0,112818.1248,25.5054,1800.0,1776.5,1620.5,-0.013141528,-0.105051921,0.002572221,0.020160363,0.0,0.09171,177.64289,1974,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ADAG,muzastotug (ADG126) combined with KEYTRUDA (pembrolizumab) - (ADG126-P001/KEYNOTE-C98),Solid tumorsÂ ,Phase 1/2,9/16/2024,"Phase 1/2 data from ESMO reported a confirmed partial responses (PRs) doubled to four since ASCO GI in MSS CRC patients without liver and peritoneal metastases for overall response rate (ORR) of 24%,",47.0,121.74466,93.2445,3.49,2.75,2.25,-0.238300825,-0.43897152,0.002572221,0.020160363,0.02831,0.02929,0.86498,1975,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
NVS,Kisqali (ribociclib) - (NATALEE),Adjuvant breast cancerÂ ,Phase 3,9/16/2024,"Phase 3 data showed a deepening benefit beyond the three-year treatment period, reducing the risk of recurrence by 28.5% (HR=0.715; 95% CI 0.609â€“0.840; P<0.0001), compared to ET alone, noted September",0.0,2041.18159,57.1186,6.5,6.56,6.79,0.009188426,0.043648765,0.002572221,0.020160363,0.0,0.00426,0.85751,1976,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
IMTX,TCER IMA401 (MAGEA4/8),Solid tumorsÂ ,Phase 1,9/16/2024,"Phase 1 data from ESMO reported a 29% ORR, noted September 16, 2024.",121.0,1312.53818,47.9069,12.68,12.73,11.77,0.003935464,-0.074472028,0.002572221,0.020160363,10.10186,0.18034,14.06483,1977,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
SMMT,AK112-206,Metastatic microsatellite-stable (MSS) colorectal cancer (CRC)Â ,Phase 2,9/16/2024,"Phase 2 data reported that an 81.8% in ORR in group A with an ORR of 88.2% in group B, noted September 16, 2024.",744.0,21359.3729,231.5625,31.93,29.48,21.91,-0.079833939,-0.376602853,0.002572221,0.020160363,2.51618,0.03689,433.14501,1978,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
SMMT,AK117-203,Triple-negative breast cancer (TNBC)Â ,Phase 2,9/16/2024,"Phase 2 data reported an ORR of 72.4%, noted September 16, 2024.",744.0,21359.3729,231.5625,31.93,29.48,21.91,-0.079833939,-0.376602853,0.002572221,0.020160363,2.51618,0.03689,433.14501,1979,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
SMMT,AK117-201,Recurrent / metastatic head and neck squamous cell carcinoma (HNSCC)Â ,Phase 2,9/16/2024,"Phase 2 data reported an ORR of 30.0% in the monotherapy, and of 60% in the combo, noted September 16, 2024.",744.0,21359.3729,231.5625,31.93,29.48,21.91,-0.079833939,-0.376602853,0.002572221,0.020160363,2.51618,0.03689,433.14501,1980,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
COYA,COYA 302,Parkinson's disease (PD)Â ,Preclinical,9/16/2024,"Preclinical data reported that COYA 302 significantly reduced inflammation and microglial activation in nigrostriatal brain regions responsible for motor control, noted September 16, 2024.",16.0,95.58981,64.7524,6.4,6.28,5.87,-0.01892801,-0.086443357,0.002572221,0.020160363,1.06311,0.09641,0.29338,1981,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
MRK,WELIREG - (LITESPARK-005),Advanced renal cell carcinoma (RCC)Â ,Phase 3,9/16/2024,"Phase 3 data from ESMO reported that the median OS was 21.4 mo with belzutifan vs 18.2 mo with everolimus, noted September 16, 2024.",0.0,299006.1064,23.9305,115.86,117.96,115.63,0.017963018,-0.001987128,0.002572221,0.020160363,1.02235,0.06952,925.52607,1982,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
PDSB,PDS0101 + KEYTRUDA (pembrolizumab) - (VERSATILE-002),HPV16-positive first-line recurrent and/or metastatic head and neck squamous cell cancer with low PD-L1 expression (CPS 1-19)Â ,Phase 2,9/16/2024,"Phase 2 full data presented at ESMO reported that the median OS was 30 months (95% CI 18.4, NE), ORR of 36% and the 12-month OS rate was 77%, noted September 16, 2024.",46.0,112.66862,75.4235,3.0,3.06,3.14,0.019802627,0.045610511,0.002572221,0.020160363,12.93105,0.17658,1.41429,1983,1,0,0,0,0,1,0,0,0,0,1,0,3,0,0,1
NXTC,NC410 in combination w/ pembrolizumab - (LAIR-2),Solid TumorsÂ ,Phase 1/2,9/16/2024,"Phase 1b/2 data presented at ESMO showed clinical activity in hard-to-treat cancers, including ovarian cancer and immune checkpoint inhibitor (ICI)-naÃ¯ve and refractory microsatellite stable (MSS)/mic",2.0,37.20787,85.7072,16.80001,15.96001,16.80001,-0.051293263,0.0,0.002572221,0.020160363,0.27823,0.07094,0.21122,1984,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1
IMAB,Givastomig (TJ033721 / ABL111),"First-line metastatic gastric cancers, solid tumorsÂ ",Phase 1,9/16/2024,"Phase 1 study determined the recommended Phase 2 dose to be 8-12 mg/kg, with givastomig being well-tolerated up to the highest study doses. In 43 patients with advanced gastroesophageal carcinoma, the",81.0,86.32076,51.8313,1.06,1.06,1.05,0.0,-0.009478744,0.002572221,0.020160363,0.88001,0.17963,0.07352,1985,0,0,0,1,0,1,0,0,0,0,0,0,2,0,0,1
MRK,KEYTRUDA (pembrolizumab) in combination with trastuzumab - (KEYNOTE-811),HER2-positive gastric or Gastroesophageal junction (GEJ) adenocarcinomaÂ ,Phase 3,9/16/2024,"Phase 3 data presented at ESMO reported that ORR was 72.6% vs 60.1% with pembro + SOC vs pbo + SOC, noted September 16, 2024.",0.0,299006.1064,23.9305,115.86,117.96,115.63,0.017963018,-0.001987128,0.002572221,0.020160363,1.02235,0.06952,925.52607,1986,1,0,0,0,0,1,0,0,0,0,1,0,3,0,0,1
ZYME,Zanidatamab (ZW25) - (mGEA),"HER2-expressing Gastrointestinal Cancers (Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer)Â ",Phase 2,9/16/2024,"Phase 2 data presented at ESMO showed a confirmed objective response rate (cORR) of 84%, a median duration of response (DoR) of 18.7 months, a median progression-free survival (mPFS) of 15.2 months, a",75.0,888.80285,38.7806,12.54,12.51,12.76,-0.002395211,0.017391743,0.002572221,0.020160363,5.92325,0.12106,8.46844,1987,1,0,0,0,0,1,0,0,0,0,1,0,3,0,0,1
MRK,MK-1022 (patritumab deruxtecan) - (HERTHENA-Lung02),EGFR-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC)Â ,Phase 3,9/17/2024,Phase 3 data reported a statistically significant progression-free survival improvement in this EGFR-mutated non-small cell lung cancer population with high unmet need following prior EGFR TKI treatme,0.0,299842.5935,23.9337,117.96,118.29,114.96,0.002793653,-0.025761342,0.004651401,0.0257027,1.02235,0.06952,936.28286,1988,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1
SNY,VG-3927,Alzheimer's diseaseÂ ,Phase 1,9/17/2024,"Phase 1 partial clinical hold removed by the FDA, noted September 17, 2024.",0.0,128978.7574,23.1795,57.33,56.91,57.62,-0.007352974,0.005045683,0.004651401,0.0257027,0.0,0.0,108.43028,1989,0,0,0,0,0,1,0,1,0,0,0,0,0,2,0,-1
ACRS,ATI-2138,Atopic dermatitis (AD)Â ,Phase 2a,9/17/2024,"Phase 2a initiated, noted September 17, 2024.",108.0,83.47313,50.9601,1.19,1.17,1.16,-0.016949558,-0.025533302,0.004651401,0.0257027,2.40646,0.00574,0.28027,1990,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
RCKT,RP-A501,Danon diseaseÂ ,Phase 2,9/17/2024,"Phase 2 enrollment completed, noted September 17, 2024",107.0,1984.11551,51.9135,19.2,21.8,18.29,0.126999691,-0.048555817,0.004651401,0.0257027,12.00834,0.18483,61.23136,1991,0,0,0,0,0,1,0,0,0,1,0,0,2,0,0,1
RNAZ,TTX-MC138,Metastatic solid tumorsÂ ,Phase 1,9/17/2024,"Phase 1 dosing initiated September 17, 2024.",0.0,5.00684,230.2217,240.60975,267.96017,385.21584,0.107662024,0.470627474,0.004651401,0.0257027,1.61345,0.01289,1.18814,1992,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1
HOTH,HT-ALZ,Alzheimer's DiseaseÂ ,Preclinical,9/17/2024,"Preclinical data reported significant reductions in astrocyte activity were observed in key areas of the brain, suggesting a potential link between reduced reactive astrocytes, and improved cognitive",13.0,7.38707,121.4836,1.01,1.07,0.86,0.057708318,-0.160773221,0.004651401,0.0257027,3.17741,0.00726,11.58974,1993,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
LSTA,Certepetide (LSTA1) - (BOLSTER),Intrahepatic CholangiocarcinomaÂ ,Phase 2a,9/17/2024,"Phase 2a trial dosing initiated, noted September 17, 2024.",8.0,25.79076,59.7228,2.91,3.1,2.97,0.06324903,0.020408872,0.004651401,0.0257027,0.26948,0.0393,0.0801,1994,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1
ALLR,Stenoparib,Advanced ovarian cancer (AOC)Â ,Phase 2,9/17/2024,"Phase 2 study showed that two heavily pre-treated ovarian cancer patients have surpassed one year on therapy, highlighting the drug's potential for durable clinical benefit, noted September 17, 2024.",14.0,4.22382,146.1621,3.38,2.99,2.22,-0.122602322,-0.420368514,0.004651401,0.0257027,1.36173,0.06871,33.81123,1995,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
INMB,AD02,Alzheimer's Disease (AD)Â ,Phase 2,9/17/2024,"Phase 2 data reported a highly significant correlation (p<0.001) between baseline scores on EMACC and CDR-SB, noted September 17, 2024.",26.0,122.63699,79.1755,5.385,5.55,5.12,0.030180617,-0.050462872,0.004651401,0.0257027,13.6556,0.05309,4.40718,1996,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
NVS,Kisqali (ribociclib) - (NATALEE),Adjuvant breast cancerÂ ,Approved,9/17/2024,"FDA Approved on September 17, 2024.",0.0,2053.62782,56.7123,6.56,6.6,6.79,0.006079046,0.034460339,0.004651401,0.0257027,0.0,0.00426,0.2572,1997,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
PPBT,CM24 and OPDIVO (nivolumab),2L metastatic pancreatic cancer (PDAC)Â ,Phase 2,9/17/2024,"Phase 2 data reported a potential 62% reduction in risk of death (HR=0.38) for CM24+nivolumab+Nal-IRI/5FU/LV therapy in PDAC patients, and prolongation of 3.3 months in median OS, noted September 17,",2.0,44.51461,87.8481,0.141,0.137,0.125,-0.028778965,-0.120446153,0.004651401,0.0257027,0.0,0.02905,0.07063,1998,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
IMUX,IMU-838 - (CALLIPER),Progressive Multiple SclerosisÂ ,Phase 2,9/18/2024,Phase 2 data reported a 10% decrease in NfL versus a 20% increase for placebo among those with an Expanded Disability Status Scale (EDSS) score â‰¤ 5.5; and a 2% decrease for vidofludimus calcium versus,98.0,161.24144,67.3707,1.61,1.79,1.5,0.105981441,-0.070769071,-0.014554294,0.032212146,2.59094,0.11567,4.99549,1999,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
AZN,FASENRA (benralizumab) - (MANDARA),Eosinophilic granulomatosis with polyangiitis (EGPA)Â ,Approved,9/18/2024,"FDA Approved on September 18, 2024.",0.0,183801.9837,18.5705,119.68,118.56,115.66,-0.009402353,-0.034166661,-0.014554294,0.032212146,0.0,0.10308,317.32406,2000,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
TGTX,BRIUMVI (ublituximab-xiiy) - (ENHANCE),Relapsing forms of Multiple Sclerosis (RMS)Â ,Phase 3,9/18/2024,"Phase 3b additional data presented at ECTRIMS showed that 30-minute BRIUMVI infusions were well-tolerated, with only mild (Grade 1) infusion-related reactions, and patients switching from prior anti-",158.0,3622.12396,56.7186,25.08,25.25,23.35,0.00675544,-0.071473732,-0.014554294,0.032212146,20.5708,0.21229,107.84113,2001,0,0,0,1,0,1,0,0,0,0,0,0,2,0,0,1
BCTX,Bria-OTS,Advanced breast cancerÂ ,Phase 1/2,9/18/2024,"FDA granted Expanded Access Policy (EAP), noted September 18, 2024.",1.0,21.80384,107.7309,70.49996,78.49496,113.99994,0.107422276,0.48058578,-0.014554294,0.032212146,0.0,0.0,7.23088,2002,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
FDMT,4D-150 - (PRISM),Wet age-related macular degeneration (AMD)Â ,Phase 1/2,9/18/2024,"Phase 1/2 data reported a 83% overall reduction in annualized injections through 52 weeks, noted September 18, 2024.",46.0,874.1285,88.4821,16.16,16.82,11.28,0.040029601,-0.359507807,-0.014554294,0.032212146,18.99886,0.0894,26.2667,2003,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
VNDA,Tradipitant - (VP-VLY-686-3303),GastroparesisÂ ,CRL,9/19/2024,"CRL issued by the FDA on September 18, 2024.",59.0,271.04761,77.5723,4.95,4.65,4.74,-0.062520357,-0.043350441,-0.007904398,0.02633318,5.67335,0.00928,8.58136,2004,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,-1
EWTX,EDG-7500 - (CIRRUS-HCM),Hypertrophic Cardiomyopathy (HCM)Â ,Phase 2,9/19/2024,Phase 2 data showed that a single dose significantly reduced left ventricular outflow tract gradients without reducing LVEF. The company has initiated a 28-day trial and expects to report data in ear,105.0,2766.2825,87.9271,19.07,29.5,25.99,0.436273844,0.309595429,-0.007904398,0.02633318,8.30195,0.15654,352.00362,2005,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
AZN,Ampligen (rintatolimod) with Imfinzi (durvalumab) - (DURIPANC),Pancreatic CancerÂ ,Phase 1/2,9/19/2024,"Phase 1b/2 data reported stable disease in two out of three patients at 6 months in the first subject cohort, noted September 19, 2024.",0.0,184453.1041,18.5452,118.56,118.98,117.2,0.00353625,-0.011537284,-0.007904398,0.02633318,0.0,0.10308,332.08258,2006,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
AIM,Ampligen (rintatolimod) with Imfinzi (durvalumab) - (DURIPANC),Pancreatic CancerÂ ,Phase 1/2,9/19/2024,"Phase 1b/2 data reported stable disease in two out of three patients at 6 months in the first subject cohort, noted September 19, 2024.",2.0,156.61054,58.7235,0.74,0.75,0.685,0.01342302,-0.077231348,-0.007904398,0.02633318,0.0,0.03701,0.15993,2007,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ALGS,ALG-055009 - (HERALD),Metabolic dysfunction-associated steatohepatitis (MASH)Â ,Phase 2a,9/19/2024,"Phase 2a topline data reported that the trial met the primary endpoint with statistically significant reductions in liver fat at Week 12 as measured by MRI-PDFF, noted September 19, 2024.",6.0,32.53632,119.3538,14.16,10.18,8.02,-0.329996077,-0.568482666,-0.007904398,0.02633318,0.46744,0.12296,8.91259,2008,1,0,0,0,0,1,0,0,0,0,1,0,3,0,0,1
JNJ,RYBREVANT (amivantamab-vmjw),Second-line EGFR-mutated advanced lung cancerÂ ,Approved,9/19/2024,"Approved September 19, 2024.",0.0,396761.9012,17.2534,166.15,164.82,161.39,-0.008037025,-0.029067199,-0.007904398,0.02633318,0.87761,0.06462,816.86753,2009,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1
JNJ,Amivantamab and Lazertinib - (MARIPOSA),GFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung CancerÂ ,Approved,9/20/2024,"Approved September 20, 2024.",0.0,395173.1204,17.2581,164.82,164.16,161.4,-0.004012407,-0.020968213,0.032142436,0.039834003,0.87761,0.06131,1943.48482,2010,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1
NVO,Monlunabant (INV-202),ObesityÂ ,Phase 2a,9/20/2024,"Phase 2a trial data reported that all doses of monlunabant achieved a statistically significant weight loss compared to placebo, noted September 20, 2024.",0.0,3767995.702,31.6876,134.88,127.51,120.76,-0.056190701,-0.110580389,0.032142436,0.039834003,0.0,0.0,1234.74321,2011,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1
AZN,"FLUMIST QUADRIVALENT (Influenza Vaccine Live, Intranasal)","Influenza Vaccine Live, IntranasalÂ ",Approved,9/20/2024,"Approved September 20, 2024.",0.0,182623.7658,18.5815,118.98,117.8,116.54,-0.009967141,-0.02072085,0.032142436,0.039834003,0.0,0.11082,408.49176,2012,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1
SNY,"SARCLISA (isatuximab) with bortezomib, lenalidomide and dexamethasone (VRd)",Transplant-ineligible newly diagnosed multiple myeloma (NDMM)Â ,Approved,9/20/2024,"Approval announced September 20, 2024.",0.0,129780.9577,23.1273,58.26,57.63,57.65,-0.010872486,-0.010525505,0.032142436,0.039834003,0.0,0.0,111.97734,2013,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
TEVA,Olanzapine LAI (44749) - (SOLARIS),SchizophreniaÂ ,Phase 3,9/23/2024,"Additional Phase 3 data reported that statistically significant mean differences in the change in PANSS total scores from baseline to week 8 of -9.71 points, -11.25 points, and -9.69 points versus pla",0.0,20076.62528,34.1305,17.51,17.72,18.02,0.011921799,0.028710106,0.028955697,0.028044351,2.11406,0.18837,101.66655,2014,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1
IDYA,Darovasertib - (IDE196-009),Uveal MelanomaÂ ,Phase 2,9/23/2024,"Phase 2 efficacy data reported that 49% of patients with >30% tumor shrinkage by product of diameters, and 61% eye preservation rate for enucleation patients noted September 23, 2024.",87.0,2849.56079,46.5029,35.0,33.73,31.68,-0.036960412,-0.099662495,0.028955697,0.028044351,13.51931,0.25423,97.19178,2015,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
BDTX,BDTX-1535,Glioblastoma multiforme (GBM) and NSCLCÂ ,Phase 2,9/23/2024,"Phase 2 results showed that a 200 mg daily dose was selected for pivotal development, demonstrating a favorable safety profile and a 42% objective response rate (ORR) in 19 evaluable patients, noted S",56.0,254.27203,88.2687,4.76,4.5,4.35,-0.056170271,-0.090071823,0.028955697,0.028044351,10.74483,0.07246,133.18786,2016,1,0,0,1,0,1,0,0,0,0,0,0,3,0,0,1
RPTX,Lunresertib (RP-6306) + Debio 0123 - (MYTHIC),Solid TumorsÂ ,Phase 1,9/23/2024,"Phase 1 data preesented at AACR Ovarian Cancer Research Symposium showing that ovarian and endometrial cancers with CCNE1 amplifications, FBXW7, or PPP2R1A mutations carry a significantly poor prognos",42.0,143.4659,66.324,3.52,3.38,3.44,-0.04058528,-0.022989518,0.028955697,0.028044351,1.69935,0.21814,0.36003,2017,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
AZN,Datopotamab Deruxtecan - (TROPION-Breast01),"HR Positive, HER2 Negative Breast CancerÂ ",Phase 3,9/23/2024,"Phase 3 trial did not meet its primary endpoint, noted September 23, 2024.",0.0,179585.204,18.4898,117.8,115.84,115.88,-0.016778343,-0.016433098,0.028955697,0.028044351,0.0,0.11082,281.49688,2018,1,0,0,0,0,1,0,0,0,0,0,0,0,2,0,-1
IVVD,PEMGARDA (VYD222 (pemivibart)) - (CANOPY),COVID-19 PreventionÂ ,Phase 3,9/23/2024,"Additional data continues to demonstrate stable neutralization potency against contemporary SARS-CoV-2 variants, including KP.3.1.1 and LB.1. Structural analysis of the spike protein shows minimal mut",120.0,143.33116,112.8664,1.2,1.2,1.02,0.0,-0.162518929,0.028955697,0.028044351,6.39282,0.04135,0.63758,2019,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
BHVN,Troriluzole (BHV4157-206-RWE),Spinocerebellar AtaxiaÂ ,Phase 3,9/23/2024,"Phase 3 study achieved the primary endpoint and showed statistically significant improvements on the f-SARA at years 1 and 2 , noted September 23, 2024.",105.0,4343.2711,63.0732,40.39,45.94,49.97,0.128753968,0.212840596,0.028955697,0.028044351,10.80338,0.04597,287.11549,2020,1,0,0,0,0,1,0,0,0,0,0,0,2,0,0,1
QURE,AMT-191,Fabry diseaseÂ ,Phase 1/2,9/23/2024,"Orphan Drug Designation granted by the FDA, noted September 23, 2024.",54.0,245.92298,113.5811,5.36,5.05,4.93,-0.059575732,-0.083624987,0.028955697,0.028044351,9.25754,0.02252,3.71094,2021,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
KZIA,EVT801,Renal cell carcinoma and soft-tissue sarcomaÂ ,Phase 1,9/23/2024,"Phase 1 data one patient had a partial response (-39% decrease) after 2 cycles of EVT801 therapy, noted September 23, 2024.",1.0,9.9629,240.2129,16.235,16.72,21.495,0.029436202,0.280650944,0.028955697,0.028044351,1.10019,0.00223,0.1097,2022,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ASMB,ABI-5366,HSV-2Â ,Phase 1a,9/23/2024,"Phase 1a interim data reported that treatment was well-tolerated, with a favorable safety profile observed with exposure of up to 70 days, noted September 23, 2024.",7.0,103.17882,60.3916,19.43,16.26,15.14,-0.178110159,-0.249478015,0.028955697,0.028044351,0.25475,0.0106,1.54187,2023,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1
SPRC,SCI-110,Tourette SyndromeÂ ,Phase 1/2,9/23/2024,"IND Cleared by the FDA, noted September 23, 2024. Phase 1/2 planned.",0.0,0.85871,92.2737,5.53141,5.54401,5.10721,0.00227531,-0.079789489,0.028955697,0.028044351,1.06484,0.12121,1.05974,2024,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
BIIB,Dapirolizumab pegol (anti-CD40L),Systemic lupus erythematosusÂ ,Phase 3,9/24/2024,"Phase 3 trial met its primary endpoint, noted September 24, 2024.",146.0,28275.83795,26.7212,195.81,194.12,190.8,-0.008668277,-0.025919042,0.014624004,0.012375893,2.51806,0.17468,230.62815,2025,1,0,0,0,0,1,0,0,0,0,0,0,2,0,0,1
HOOK,HB-700,KRAS-mutated cancersÂ ,Preclinical,9/24/2024,"Preclinical data presented Annual RAS-Targeted Drug Development Summit demonstrated safety, induction of target-specific CD8+ T-cells, and target cell killing in several different animal and translati",12.0,56.42448,86.2622,4.56,4.5,4.06,-0.013245227,-0.11613965,0.014624004,0.012375893,0.41052,0.16369,0.12381,2026,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
LIPO,LP-310,Oral Lichen Planus (OLP)Â ,Phase 2a,9/24/2024,"Phase 2a initial results reported that three participants have completed the four-week treatment with LP-310, an oral rinse, with encouraging findings: The treatment was well tolerated and had no unpl",4.0,3.67223,148.1685,3.2856,3.62482,3.528,0.098255348,0.071181854,0.014624004,0.012375893,1.48732,0.07448,3.38101,2027,0,0,0,1,0,1,0,0,0,0,0,0,2,0,0,1
CYDY,Leronlimab,Metabolic dysfunction associated steatohepatitis (MASH)Â ,Preclinical,9/24/2024,"Preclinical data showed that monotherapy (700 mg) demonstrated statistically significant fibrosis reversal compared to an isotype IgG4 control arm, noted September 24, 2024.",0.0,213.18637,93.1813,0.15679,0.1749,0.15464,0.109307052,-0.013807495,0.014624004,0.012375893,1.06506,0.00563,1.09907,2028,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1
WVE,WVE-N531 - (FORWARD-53),Duchenne muscular dystrophy (DMD) in boysÂ ,Phase 1/2,9/24/2024,"Phase 1b/2 data reported that mean muscle content-adjusted dystrophin expression of 9.0% and unadjusted dystrophin of 5.5%, with high consistency across participants, noted September 24, 2024.",159.0,1025.51807,90.1218,5.34,8.19,8.3,0.427688245,0.441029862,0.014624004,0.012375893,2.82091,0.05457,128.81212,2029,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
TECX,RXFP1 Agonist (TX45 â€“ Fc-relaxin),Heart Failure with Preserved Ejection Fraction (HFpEF)Â ,Phase 1a,9/24/2024,"Phase 1a was well-tolerated with no observed immunogenicity, and demonstrated a favorable PK/PD relationship, noted September 24, 2024.",18.0,357.16377,0.0,20.92,24.24,28.0,0.147298522,0.291498871,0.014624004,0.012375893,0.57617,0.11425,6.30776,2030,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1
ENLV,Allocetra - (ENX-CL-05-001),Knee osteoarthritis (OA)Â ,Phase 1/2,9/24/2024,"Phase 1/2 completed independent DSMB completed confirming that the safety profile of Allocetra allows the Company to move forward to the Phase 2 stage of the Phase 1/2 trial, noted September 24, 2024.",23.0,31.5739,134.1264,1.48,1.475,1.61,-0.003384098,0.084192091,0.014624004,0.012375893,0.63596,0.02514,0.1149,2031,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
SAVA,Simufilam (PTI-125) - (RETHINK-ALZ),Alzheimerâ€™s diseaseÂ ,Phase 3,9/24/2024,"Phase 3 independent DSMB recommended studies to continue without modification, noted September 24, 2024.",48.0,1419.13499,136.3416,27.005,29.58,27.42,0.091076423,0.01525064,0.014624004,0.012375893,33.1703,0.00047,64.16671,2032,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ACXP,Ibezapolstat,C. difficile InfectionÂ ,Phase 2b,9/24/2024,"Phase 2b results feature high-resolution elucidation of interaction of ibezapolstat with its molecular target, noted September 24, 2024.",1.0,29.7285,71.7347,37.4,36.6,38.4,-0.021622464,0.026386755,0.014624004,0.012375893,2.94398,0.0189,0.07221,2033,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CAPR,CAP-1002 - (HOPE-3),Duchenne Muscular Dystrophy (DMD)Â ,Phase 3,9/24/2024,"Phase 3 HOPE-3 clinical trial to combine Cohorts A and B, study planned to serve as a post-approval study and does not intend to unblind Cohort A at this time, which was expected to occur in the 4Q 20",45.0,321.57068,88.373,5.97,9.1,15.01,0.421527486,0.921969718,0.014624004,0.012375893,21.29523,0.10505,277.80738,2034,0,0,0,0,0,1,0,1,0,0,0,0,2,0,0,1
MRK,Favezelimab and Pembrolizumab - (KEYFORM-007),PD-L1 positive microsatellite stable (MSS) metastatic colorectal cancer (mCRC)Â ,Phase 3,9/25/2024,"Phase 3 trial did not meet its primary endpoint, noted September 25, 2024.",0.0,290818.6724,23.8167,114.96,114.73,112.08,-0.0020027,-0.02537134,0.005281881,0.006300834,0.97893,0.06639,906.6474,2035,1,0,0,0,0,1,0,0,0,0,0,0,0,2,0,-1
ARQT,ZORYVE (roflumilast) Cream 0.05%,Atopic Dermatitis - ages of 2-5 years oldÂ ,Phase 3,9/25/2024,"Phase 3 data from EADV reported consistent efficacy in disease clearance and reduction in itch for individuals with atopic dermatitis (AD) regardless of race, ethnicity, and Fitzpatrick skin type, not",122.0,1063.70831,74.7167,9.68,9.1,10.23,-0.061787488,0.055262679,0.005281881,0.006300834,21.27108,0.02975,15.04504,2036,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ORKA,ORKA-001 - (EVERLAST-A),Moderate-to-severe plaque psoriasisÂ ,Preclinical,9/25/2024,"Preclinical data reported a half-life in non-human primates (NHP) of 30.3 days after subcutaneous (SQ) administration and 33.8 days after intravenous (IV) administration, noted September 25, 2024.",37.0,834.36543,0.0,23.85,23.84,25.0,-0.000419375,0.047091608,0.005281881,0.006300834,1.1459,0.8653,2.62908,2037,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
KYMR,KT-621 (STAT6),Type 2 inflammation in allergic diseasesÂ ,Preclinical,9/25/2024,Preclinical data presented at EADV demonstrated strong degradation of STAT6 in human sensory neurons resulting in inhibition of IL-13-induced itch- and pain-related gene transcripts with the potential,71.0,3310.82602,61.6533,52.4,51.93,45.0,-0.009009933,-0.152244102,0.005281881,0.006300834,14.88119,0.22569,26.44743,2038,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
HRTX,ZYNRELEF (bupivacaine and meloxicam) extended-release solution,Pain relief following surgeryÂ ,Approved,9/25/2024,"Approved September 25, 2024.",153.0,286.65255,84.8819,1.96,1.89,2.09,-0.036367644,0.064219593,0.005281881,0.006300834,23.36785,0.06404,6.81319,2039,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1
WINT,Istaroxime - (SEISMiC C),Cardiogenic Shock in severe acute heart failureÂ ,Phase 2b,9/25/2024,Phase 2b data reported that treatment significantly improved primary endpoint of the systolic blood pressure profile over six hours and showed significant improvements in many secondary endpoint asses,29.0,4.67103,228.9204,163.0,145.0,72.0,-0.117016458,-0.817084082,0.005281881,0.006300834,2.22953,0.00832,3.48566,2040,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CERO,CER-1236 - (CertainT-1),"Acute myeloid leukemia (AML), Hematologic malignanciesÂ ",IND-Enabling,9/25/2024,"Type A Meeting requested to FDA regarding clinical hold after new financing, noted September 25, 2024.",1.0,5.1582,184.5426,187.4,200.0,176.0,0.065071997,-0.062761375,0.005281881,0.006300834,0.51634,0.00132,12.3592,2041,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,-1
CLDX,Barzolvolimab (CDX-0159),Chronic spontaneous urticaria (CSU)Â ,Phase 2,9/25/2024,"Phase 2 52-week results from EADV reported that 71% of patients (150 mg Q4W) achieved complete response at Week 52, noted September 25, 2024.",66.0,2387.67921,51.8297,40.96,36.02,30.21,-0.128521641,-0.304422985,0.005281881,0.006300834,12.68722,0.07559,444.59591,2042,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1
ABVX,Obefazimod with etrasimod,Inflammatory Bowel Disease (IBD)Â ,Preclinical,9/25/2024,"Preclinical data reported a synergistic and statistically significant reduction of several cytokines (TNF-alpha, IL-17, IL-6, IFN-gamma) in the blood compared to each treatment alone, noted September",77.0,635.36355,40.3934,10.0,10.04,9.3,0.003992021,-0.072570693,0.005281881,0.006300834,0.0,0.19531,0.10233,2043,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1
CDTX,JNJ-0953 (CD388) - (ANCHOR),Seasonal InfluenzaÂ ,Phase 1/2,9/25/2024,"Phase 1 and Phase 2a data reported that there was no dose-, route- or repeat-dose-related treatment-emergent adverse events (TEAEs), noted September 25, 2024.",25.0,76.15377,87.9682,10.77,10.82,10.55,0.004631782,-0.020638631,0.005281881,0.006300834,0.92547,0.06861,0.10919,2044,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
JNJ,JNJ-0953 (CD388) - (ANCHOR),Seasonal InfluenzaÂ ,Phase 1/2,9/25/2024,"Phase 1 and Phase 2a data reported that there was no dose-, route- or repeat-dose-related treatment-emergent adverse events (TEAEs), noted September 25, 2024.",0.0,386603.3329,17.3862,162.78,160.6,161.17,-0.013482794,-0.009939887,0.005281881,0.006300834,0.95659,0.06131,870.45377,2045,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ANIP,"Ketoconazole Shampoo, 2%",FungusÂ ,Approved,9/26/2024,"Approved September 26, 2024.",21.0,1137.90342,37.6469,57.28,58.3,56.79,0.017650571,-0.008591269,-0.006932437,0.011420465,11.3851,0.03085,9.63204,2046,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1
AZN,TAGRISSO (osimertinib) - (LAURA),"Unresectable, Stage III epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC)Â ",Approved,9/26/2024,"FDA Approved on September 26, 2024.",0.0,181693.5939,18.4709,115.66,117.2,119.64,0.013227024,0.033832381,-0.006932437,0.011420465,0.0,0.11082,467.00297,2047,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
ENGN,Detalimogene voraplasmid (EG-70) - (LEGEND),BCG-unresponsive non-muscle invasive bladder cancer (NMIBC)Â ,Phase 1/2,9/26/2024,"Phase 1/2 preliminary data reported that the Complete Response (CR) rate at any time was 71%, the CR rate at three months was 67% and the CR rate at six months was 47%, noted September 26, 2024.",51.0,243.18567,82.6572,6.25,5.5,6.5,-0.127833372,0.039220713,-0.006932437,0.011420465,0.49007,0.08056,12.65891,2048,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CNTA,ORX142,Excessive daytime sleepiness (EDS)Â ,Preclinical,9/26/2024,"Preclinical data shared at the European Sleep Research Society reported that the oral administration of ORX142 showed significant activity at the lowest dose tested, which was 0.03 mg/kg, noted Septem",134.0,2014.6689,61.0588,15.34,15.67,15.88,0.02128426,0.03459666,-0.006932437,0.011420465,1.16873,0.0718,9.58866,2049,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ENTA,Zelicapavir (EDP-323) - (RSVPED),Respiratory Syncytial Virus RSV-A and RSV-BÂ ,Phase 2a,9/26/2024,"Phase 2a topline data reported that trial met its primary and secondary endpoints, noted September 26, 2024.",21.0,221.84434,55.9043,10.67,10.47,11.19,-0.01892204,0.047584457,-0.006932437,0.011420465,13.76798,0.06594,2.71916,2050,1,0,0,0,0,1,0,0,1,0,1,0,4,0,0,1
OVID,OV329,Drug-resistant epilepsies (DREs)Â ,Preclinical,9/26/2024,"Preclinical study found showed cleared and remained undetectable in the retina, eye, and brain tissues of mice unlike vigabatrin which has repeatedly shown to preferentially accumulate in mouse retina",71.0,79.48817,213.6387,1.12,1.12,1.13,0.0,0.008888947,-0.006932437,0.011420465,0.92134,0.07296,0.24502,2051,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ABBV,Tavapadon - (TEMPO-1),Early Parkinsonâ€™s diseaseÂ ,Phase 3,9/26/2024,"Phase 3 trial data reported that trial met its primary endpoint, noted September 26, 2024.",0.0,338961.3647,21.6885,191.26,191.9,195.45,0.003340644,0.021670833,-0.006932437,0.011420465,1.00736,0.01622,1192.80972,2052,1,0,0,0,0,1,0,0,0,0,0,0,2,0,0,1
INMB,INKmune - (CaRe PC),Metastatic castration-resistant prostate cancer (mCRPC)Â ,Phase 1/2,9/26/2024,"Phase 1/2 data reported that one patient showed a transient 21% decrease in PSA associated with the increase in NK cell activity and function, noted September 26, 2024.",26.0,109.5999,78.8719,4.86,4.96,5.3,0.020367303,0.086668383,-0.006932437,0.011420465,14.28285,0.03642,1.47917,2053,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
BMEA,Icovamenib (BMF-219) - (COVALENT-111),"Healthy volunteers, type 2 diabetesÂ ",Phase 1/2,9/26/2024,"Clinical hold lifted September 26, 2024.",59.0,346.5313,164.9191,8.77,9.57,10.09,0.087296399,0.140208028,-0.006932437,0.011420465,20.95124,0.00659,41.06132,2054,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,-1
BMEA,Icovamenib (BMF-219) - (COVALENT-112),Type 1 diabetes (T1D)Â ,Phase 2,9/26/2024,"Clinical hold lifted September 26, 2024",59.0,346.5313,164.9191,8.77,9.57,10.09,0.087296399,0.140208028,-0.006932437,0.011420465,20.95124,0.00659,41.06132,2055,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,-1
BMY,"COBENFY (KarXT, xanomeline and trospium chloride)",SchizophreniaÂ ,Approved,9/27/2024,"Approved September 27, 2024.",0.0,103214.6885,30.2266,50.12,50.91,53.96,0.015639238,0.073822901,-0.006193228,0.00694944,1.07488,0.01025,1172.7258,2056,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1
PRTC,"COBENFY (KarXT, xanomeline and trospium chloride)",SchizophreniaÂ ,Approved,9/27/2024,"Approved September 27, 2024.",24.0,369.66651,25.8026,1.504,1.544,1.5,0.026248226,-0.002663117,-0.006193228,0.00694944,0.0,0.09417,4.14331,2057,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1
ONC,TEVIMBRA (tislelizumab-jsgr) - (RATIONALE 305),Gastric or gastroesophageal junction (G/GEJ) adenocarcinomaÂ ,BLA Filing,9/27/2024,"Advisory committee voted 10 to 2 in favor of a favorable benefit-risk profile, noted September 27, 2024.",110.0,23222.62277,40.5863,212.53,218.42,246.04,0.02733666,0.146410969,-0.006193228,0.00694944,1.88413,0.11765,86.11274,2058,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ALMS,ESK-001 - (ONWARD3),Moderate-to-severe plaque psoriasisÂ ,Phase 2,9/27/2024,"Phase 2 28-week data presented at EADV 2024 show ESK-001 was generally well tolerated, and most patients treated with the top dose of 40 mg twice daily achieved PASI 75, noted September 27, 2024.",104.0,607.14085,0.0,11.97,11.16,9.74,-0.070067563,-0.206162402,-0.006193228,0.00694944,2.7122,0.01184,1.90522,2059,0,0,0,1,0,1,0,0,0,0,0,0,2,0,0,1
SVRA,MOLBREEVI (Molgradex) - (IMPALA-2),Autoimmune pulmonary alveolar proteinosis (aPAP)Â ,Phase 3,9/27/2024,"FDA granted Expanded Access Program (EAP), noted September 27, 2024.",172.0,861.64195,62.8977,4.24,4.24,3.82,0.0,-0.104312847,-0.006193228,0.00694944,5.04443,0.06649,3.19295,2060,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
REGN,Dupixent (dupilumab) - (NOTUS),Chronic obstructive pulmonary disease (COPD)Â ,Approved,9/27/2024,"Approved September 27, 2024.",105.0,112542.254,20.2686,1039.96,1042.69,1012.82,0.002621661,-0.026443731,-0.006193228,0.00694944,1.83089,0.20174,687.89179,2061,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1
ESLA,EB103 (CD19) - (STARLIGHT-1),"Diffuse large B cell lymphoma (DLBCL), Follicular Lymphoma (FL), and other types of B-cell LymphomaÂ ",Phase 1/2,9/27/2024,"Phase 1/2 first patient achieved a complete response (CR) one month after receiving dose, noted September 27, 2024.",37.0,43.06717,109.5713,0.9699,1.19,1.15,0.204515613,0.170324248,-0.006193228,0.00694944,0.0265,0.0013,6.25265,2062,1,0,0,0,0,1,0,0,0,0,0,0,2,0,0,1
JNJ,TALVEY (talquetamab-tgvs) and TECVAYLI (teclistamab-cqyv) - (RedirecTT-1 ),Multiple MyelomaÂ ,Phase 1b,9/27/2024,"Phase 1b data demonstrated a safety profile consistent to TALVEY and TECVAYLI monotherapies, noted September 27, 2024.",0.0,388529.1279,17.285,161.39,161.4,160.29,6.19598e-05,-0.006839121,-0.006193228,0.00694944,0.95659,0.05369,1219.20027,2063,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
JNJ,TALVEY (talquetamab-tgvs) with DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) and pomalidomide - (TRIMM-2),Multiple MyelomaÂ ,Phase 1b,9/27/2024,"Phase 1b updated data show 100 percent overall response rate with 56 percent of patients achieving complete response or better with weekly dosing, supporting the combinability of the GPRC5D bispecific",0.0,388529.1279,17.285,161.39,161.4,160.29,6.19598e-05,-0.006839121,-0.006193228,0.00694944,0.95659,0.05369,1219.20027,2064,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ABBV,telisotuzumab-vedotin (Teliso-V),Advanced/metastatic nonsquamous non-small cell lung cancer (NSCLC)Â ,BLA Filing,9/27/2024,"BLA submitted to the FDA, and it was noted on September 27, 2024.",0.0,344066.0981,21.7675,191.9,194.79,194.29,0.014947652,0.012377485,-0.006193228,0.00694944,1.00736,0.01299,952.91755,2065,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
GEHC,flurpiridaz F 18,Coronary artery disease (CAD)Â ,Approved,9/27/2024,"FDA Approved on September 27, 2024.",456.0,42008.36065,30.5444,92.49,91.99,91.42,-0.005420655,-0.011636258,-0.006193228,0.00694944,2.21108,0.19986,1161.2652,2066,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
LNTH,flurpiridaz F 18,Coronary artery disease (CAD)Â ,Approved,9/27/2024,"FDA Approved on September 27, 2024.",67.0,7454.07373,61.968,104.43,107.36,107.785,0.027670683,0.031621512,-0.006193228,0.00694944,6.01496,0.01024,72.26273,2067,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
ELVN,ELVN-001 - (ENABLE),Chronic Myeloid Leukemia (CML)Â ,Phase 1,9/28/2024,"Data form ESH-iCMLf reported a cumulative MMR rate of 44% (8/18) by 24 weeks, with stable or deepening responses between weeks 12 and 24, which continues to compare favorably to precedent Phase 1 tria",59.0,1139.83381,69.2982,24.13,24.13,27.53,0.0,0.13182044,-0.003751969,0.009390699,11.71195,0.09661,0.0,2068,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
RDHL,YELIVA (Opaganib),COVID-19Â ,Phase 2/3,9/30/2024,"Phase 2/3 post-hoc data showed that patients with â‰¤60% FiO2 levels had better outcomes after 14 days' opaganib treatment (n=117) compared to placebo (n=134), including: increased number of patients no",3.0,11.19268,143.7793,8.63,8.7406,8.3,0.012734332,-0.03898899,0.004684326,0.021565839,3.88555,0.00603,0.40924,2069,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
GANX,"GT-02287, GT-02329",GBA1 and Idiopathic Parkinson's DiseaseÂ ,Preclinical,9/30/2024,"Preclinical data to be shared at a webinar showed CNS exposure, supporting its potential as a disease-modifying treatment for Parkinsonâ€™s disease. The drug was well tolerated with no serious adverse e",35.0,45.45312,109.5713,1.99,1.78,2.135,-0.111521274,0.070332008,0.004684326,0.021565839,2.27244,0.03258,1.08607,2070,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1
MNKD,Afrezza Combined With Insulin Degludec - (INHALE-3),Type 1 DiabetesÂ ,Phase 3,9/30/2024,"Phase 4 data reported that switching from usual care to Afrezza (plus degludec) at week-17 allowed more than double the subjects to achieve A1c <7% at week-30, compared to the number at goal at week-1",306.0,1729.71878,40.3301,6.2,6.29,6.34,0.014411779,0.022329476,0.004684326,0.021565839,15.3238,0.04768,11.76857,2071,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ONC,DKN-01 with bevacizumab - (DeFianCe),Colorectal cancerÂ ,Phase 2,9/30/2024,"Phase 2 enrollment completed, noted September 30, 2024.",110.0,23875.16414,40.8345,218.42,224.51,243.02,0.027500435,0.10672393,0.004684326,0.021565839,1.88374,0.11765,111.54532,2072,0,0,0,0,0,1,0,0,0,1,0,0,2,0,0,1
LPTX,DKN-01 with bevacizumab - (DeFianCe),Colorectal cancerÂ ,Phase 2,9/30/2024,"Phase 2 enrollment completed, noted September 30, 2024.",41.0,98.33967,83.1157,2.7,2.57,2.38,-0.049345874,-0.126151285,0.004684326,0.021565839,2.64716,0.05963,0.36911,2073,0,0,0,0,0,1,0,0,0,1,0,0,2,0,0,1
NRXP,HTX-100 (NRX-100) (Ketamine Hydrochloride),Acute Suicidal Ideation and Behavior in Bipolar DepressionÂ ,Phase 3,9/30/2024,"Phase 3 reported that twelve-month real-time stability on the first manufactured lot, noted September 30, 2024.",19.0,18.05402,116.3734,1.75,1.69,1.5,-0.034887259,-0.15415068,0.004684326,0.021565839,3.99228,0.07339,0.14318,2074,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
MRNA,Trivalentâ€¯(mRNA-1403) - (Nova 301),NorovirusÂ ,Phase 3,9/30/2024,"Phase 3 study dosing initiated, noted September 30, 2024.",389.0,25689.18669,64.569,65.75,66.83,58.72,0.01629241,-0.113079287,0.004684326,0.021565839,7.18351,0.08358,321.52468,2075,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1
ALNY,AMVUTTRA (vutrisiran),ATTR Amyloidosis with Cardiomyopathy (ATTR-CM)Â ,Phase 3,9/30/2024,"Phase 3 data reported that at month 30, the relative reduction in the fold change in NT-proBNP in patients treated with vutrisiran compared to placebo was 32% in the overall population and 43% in the",131.0,35308.49249,53.8583,274.91,275.03,266.77,0.000436411,-0.030056907,0.004684326,0.021565839,3.46851,0.0419,233.70894,2076,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
MRUS,Petosemtamab (MCLA-158) - (LiGeR-HN1),PD-L1+ recurrent/metastatic head and neck squamous cell carcinoma (r/m HNSCC)Â ,Phase 3,9/30/2024,"Phase 3 study dosing initiated, noted September 30, 2024.",75.0,3407.79553,59.6801,47.74,49.96,51.63,0.045453064,0.078333278,0.004684326,0.021565839,10.42566,0.12254,28.40116,2077,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1
GMAB,Petosemtamab (MCLA-158) - (LiGeR-HN1),PD-L1+ recurrent/metastatic head and neck squamous cell carcinoma (r/m HNSCC)Â ,Phase 3,9/30/2024,"Phase 3 study dosing initiated, noted September 30, 2024.",661.0,102879.4608,26.1568,1622.0,1620.0,1599.0,-0.001233806,-0.014281522,0.004684326,0.021565839,0.0,0.04804,135.9909,2078,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1
MDGL,Resmetirom - (MAESTRO-NASH Outcomes),Nonalcoholic Steatohepatitis (NASH)Â ,Phase 3,9/30/2024,"Phase 3 results improved health-related quality of life (HRQL) in patients with NASH with moderate to advanced fibrosis, noted September 30, 2024.",22.0,4607.86431,49.6825,212.43,212.22,214.83,-0.00098905,0.011234495,0.004684326,0.021565839,17.17323,0.11642,100.4433,2079,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
WINT,Istaroxime - (SEISMiC C),Cardiogenic Shock in severe acute heart failureÂ ,Phase 2b,9/30/2024,"Phase 2b data reported that treatment significantly improved systolic blood pressure as well as cardiac output and renal function without increasing heart rate or clinically significant arrhythmias, n",29.0,3.84957,229.2177,128.5,119.5,54.0,-0.072612533,-0.866944858,0.004684326,0.021565839,2.22953,0.00821,1.51227,2080,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ARCT,Kostaive (ARCT-154),COVID-19 variant vaccineÂ ,Phase 3,9/30/2024,"Phase 3 data reported that the vaccine maintained superior immunogenicity compared to the conventional mRNA vaccine Comirnaty for up to one year against Wuhan-Hu-1, Omicron BA.4-5 and certain other va",27.0,627.65053,81.816,22.03,23.21,23.87,0.052178059,0.08021728,0.004684326,0.021565839,19.32384,0.21759,9.78924,2081,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CYTK,Aficamten (CK-274) - (SEQUOIA-HCM),Hypertrophic cardiomyopathy (HCM)Â ,Phase 3,9/30/2024,"Phase 3 data reported an improvement in maximal wall thickness by â‰¥1.5 mm (n = 282; 47.9% vs 30.7%; p=0.003), noted September 30, 2024.",119.0,6212.42572,47.3851,52.34,52.8,55.47,0.008750294,0.058081437,0.004684326,0.021565839,15.16607,0.00838,55.82227,2082,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
AQST,AQST-108 (epinephrine) Topical Gel,Alopecia areata (AA)Â ,Preclinical,9/30/2024,"Preclinical data reported that the treatment demonstrated immunomodulation across multiple cytokines monitored in the PCA model, noted September 30, 2024.",99.0,453.47761,76.1318,4.72,4.98,4.85,0.053621091,0.027169905,0.004684326,0.021565839,11.85827,0.01261,12.16676,2083,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
RPTX,Camonsertib (RP-3500)/ RG6526)- (ATTACC),Solid TumorsÂ ,Phase 1/2,9/30/2024,"Phase 1 data showed notable efficacy in those with pathogenic ATM mutations, with a 2-month response rate of 2 complete responses (CR), 5 partial responses (PR), and 4 stable disease (SD). At 6 months",42.0,146.01263,65.9714,3.44,3.44,3.45,0.0,0.00290276,0.004684326,0.021565839,1.74085,0.221,2.22392,2084,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
JNJ,"DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) in combination with bortezomib, lenalidomide and dexamethasone (D-VRd) - (CEPHEUS)",Newly diagnosed multiple myeloma (NDMM)Â ,BLA Filing,9/30/2024,"sBLA submitted to the FDA, noted September 30, 2024.",0.0,390117.9087,17.3562,161.4,162.06,159.53,0.004080881,-0.011653764,0.004684326,0.021565839,0.95659,0.05369,974.04656,2085,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
IRWD,CNP-104,Primary Biliary Cholangitis (PBC)Â ,Phase 2,9/30/2024,"Phase 2 data topline data resulted in the decision by the company to not to exercise the option to acquire an exclusive license to CNP-104, noted September 30, 2024.",162.0,658.12468,82.79,4.02,4.12,4.01,0.024571261,-0.002490661,0.004684326,0.021565839,7.27097,0.02236,11.36044,2086,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
IONS,Zilganersen (ION373),Alexander diseaseÂ ,Phase 1,10/1/2024,"Fast track designation granted by FDA, noted October 1, 2024.",159.0,6154.51136,39.2138,40.06,39.07,37.8,-0.025023421,-0.058069228,0.00721218,0.017356229,6.73813,0.04177,65.97454,2087,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
SGMT,Denifanstat - (FASCINATE-3),Nonalcoholic steatohepatitis (NASH)Â ,Phase 2b,10/1/2024,"FDA granted Breakthrough Therapy designation, noted October 1, 2024.",32.0,99.57133,92.2927,2.77,3.12,3.965,0.118985682,0.358658535,0.00721218,0.017356229,6.47174,0.12705,136.77682,2088,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
PSTV,REYOBIQ (rhenium Re186 obisbemeda) - (ReSPECT-GBM),GliomaÂ ,Phase 2b,10/1/2024,"Phase 2b data from CNS reported a statistically significant reduction in tumor volume rate change was seen in tumors receiving > 100 Gy absorbed dose, noted October 1, 2024.",99.0,7.7242,86.8029,1.46,1.31,1.35,-0.108409299,-0.078331843,0.00721218,0.017356229,0.89364,0.1373,0.19353,2089,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1
BCTX,Bria-IMT - (BRIA-ABC),Advanced breast cancerÂ ,Phase 2,10/1/2024,"Phase 2 data showed a complete 100% resolution of brain metastasis in the right temporal lobe after 8 and 11 months of treatment. The patient, who also experienced marked reduction of an orbital tumor",1.0,38.3468,135.2269,185.99991,121.49994,161.99992,-0.425832421,-0.138150348,0.00721218,0.017356229,0.0,0.0,32.54412,2090,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
JAGX,Mytesi (crofelemer) - (OnTarget),Cancer Therapy-Related DiarrheaÂ ,Phase 3,10/1/2024,"Phase 3 OnTarget trial showed statistical significance for crofelemer in a prespecified subgroup of breast cancer patients for the prophylaxis of cancer therapy-related diarrhea, noted October 1, 2024",2.0,11.36671,199.6915,33.75,30.75,32.25,-0.093090423,-0.045462374,0.00721218,0.017356229,4.01091,0.00141,0.81863,2091,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ATHE,ATH434-202 - (biomarker data),Multiple System Atrophy (MSA)Â ,Phase 2,10/2/2024,"Phase 2 interim data from MDS reported that at 6 months all participants exhibited brain volume declines consistent with MSA progression; however, the clinical responders maintained stable brain volum",15.0,21.28134,85.9902,1.375,1.43,1.31,0.039220713,-0.048426594,0.013668575,0.017089154,0.0,0.0,0.03376,2092,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
PDSB,PDS0101 and chemoradiotherapy - (IMMUNOCERV),Cervical cancerÂ ,Phase 2,10/2/2024,"Phase 2 data presented at ASTRO showed 100% 36-month overall survival (OS) and progression-free survival (PFS) rates in fully treated patients. Notably, 88% of patients achieved a complete metabolic r",46.0,151.32942,75.8709,3.65,4.11,3.4,0.118695861,-0.070951736,0.013668575,0.017089154,12.51734,0.18477,5.69641,2093,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1
RXRX,REC-1245 - (DAHLIA),Solid tumorsÂ ,IND-Enabling,10/2/2024,"IND cleared by the FDA, noted October 2, 2024.",434.0,1716.71617,71.2619,6.17,6.11,6.15,-0.009772065,-0.003246756,0.013668575,0.017089154,21.05662,0.21784,29.10744,2094,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
ATYR,Efzofitimod - (EFZO-FIT),Pulmonary sarcoidosisÂ ,Phase 1/2,10/2/2024,Additional Phase 1b/2a data from post hoc analysis emonstrated statistically significant difference in time-to-first-relapse for corticosteroid use in therapeutic (3.0 and 5.0 mg/kg efzofitimod) vs su,97.0,134.91723,60.5118,1.72,1.78,2.11,0.034289073,0.204363657,0.013668575,0.017089154,0.90477,0.04272,0.84088,2095,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1
URGN,UGN-103 - (UTOPIA),Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder CancerÂ ,Phase 3,10/2/2024,"Phase 3 trial dosing initiated, noted October 2, 2024.",46.0,529.795,69.8373,12.48,12.58,11.89,0.007980888,-0.048429652,0.013668575,0.017089154,15.12399,0.09377,2.58367,2096,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1
KZIA,Paxalisib (GDC-0084) with radiotherapy,Brain MetastasesÂ ,Phase 1,10/2/2024,"Phase 1 data at the 2024 ASTRO Annual Meeting showed a 67% partial response (PR) in patients treated with 45mg paxalisib combined with radiotherapy, noted October 2, 2024.",1.0,13.00182,239.1125,21.55,21.82,19.8,0.012451164,-0.084693879,0.013668575,0.017089154,5.3867,0.0021,0.77636,2097,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
IMMX,NXC-201 (HBI10101) - (NEXICART-2),Relapsed/refractory AL AmyloidosisÂ ,Phase 1/2,10/2/2024,Phase 1b/2 data presented at ASGCT showed that study is now dosing at dose expansion level of 450 million NXC-201 CAR+T cells. First cohort at 150 million CAR+T cells already successfully completed.Th,28.0,40.0777,78.1699,1.48,1.46,1.54,-0.013605652,0.039740329,0.013668575,0.017089154,1.74749,0.06936,0.4811,2098,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
BMY,Opdivo (nivolumab) - (CheckMate -77T),Non-metastatic non-small cell lung cancerÂ ,Approved,10/3/2024,"Approved October 3, 2024.",0.0,109884.8187,30.2519,53.76,54.2,52.4,0.008151212,-0.025623105,0.005930488,0.019248188,1.07488,0.01025,834.59556,2099,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1
ABVX,Obefazimod,Ulcerative ColitisÂ ,Phase 2b,10/3/2024,"Phase 2b OLM data reported clinical remission and a safety profile consistent with prior studies of oral, once-daily obefazimod when administered at a reduced dose of 25mg for up to an additional two",77.0,573.34599,41.4843,9.3,9.06,8.17,-0.02614528,-0.129545491,0.005930488,0.019248188,0.0,0.17672,0.36258,2100,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
RNA,del-desiran (AOC 1001) - (HARBOR),Myotonic dystrophy type 1 (DM1)Â ,Phase 3,10/3/2024,"Phase 3 partial clinical hold removed by the FDA, noted October 3, 2024.",128.0,5510.56173,70.8271,47.12,47.05,44.22,-0.001486673,-0.063520364,0.005930488,0.019248188,10.22823,0.10401,59.88924,2101,0,0,0,0,0,1,0,1,0,0,0,0,0,2,0,-1
PHVS,Bradykinin B2 receptor - (CHAPTER-1),Hereditary angioedema (HAE) attacksÂ ,Phase 2,10/3/2024,"Phase 2 OLE long term safety data to be presented on October 5, 2024.",54.0,966.19795,70.8477,18.32,17.89,17.83,-0.023751462,-0.027110927,0.005930488,0.019248188,1.19026,0.07182,0.40025,2102,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
IONS,DAWNZERA (Donidalorsen),Hereditary Angioedema (HAE)Â ,Phase 2,10/3/2024,Phase 2 new 3 year OLE data that continues to demonstrate donidalorsen potential to deliver significant and sustained reductions in HAE attacks up to three years with monthly or every two-month dosing,159.0,5956.02955,39.432,39.38,37.81,37.95,-0.040684455,-0.036988569,0.005930488,0.019248188,6.73813,0.04177,87.00032,2103,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
TOVX,SYN-004 (Ribaxamase),Allogeneic hematopoietic cell transplantation (HCT) for the prevention of acute graft-versus-host-disease (aGVHD)Â ,Phase 1/2,10/3/2024,"Phase 1b/2 DSMC positive review with 15 SAEs were reported among 10 patients, with the most common SAE being infections and infestations, including sepsis, noted October 3, 2024.",9.0,4.06771,153.5302,1.24,1.79,1.56,0.36710424,0.229574442,0.005930488,0.019248188,4.00376,0.02115,137.23093,2104,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
IMRN,"CampETEC HBC product, ProMilk 85, C. jejuni CG8421 Challenge strain","Campylobacter and Enterotoxigenic Escherichia coli (ETEC), Healthy VolunteersÂ ",Phase 2,10/4/2024,"Phase 2 data reported a 10.4% protective efficacy against moderate to severe campylobacteriosis following challenge with Campylobacter compared to the placebo group, noted October 4, 2024.",6.0,22.79984,70.533,2.7377,2.69,2.2,-0.017576958,-0.218660791,0.003212937,-0.020889557,0.0,0.0,0.0141,2105,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
BMY,Neoadjuvant Opdivo (nivolumab) and Chemotherapy,Stage IIA to IIIB non-small cell lung cancer (NSCLC)Â ,Approved,10/4/2024,"Approved October 4, 2024.",0.0,109398.2438,30.1824,54.2,53.96,52.2,-0.004437877,-0.037598414,0.003212937,-0.020889557,1.07488,0.00876,692.40852,2106,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1
RARE,UX701 - (Cyprus2+),Wilson DiseaseÂ ,Phase 1/2,10/4/2024,"Phase 1/2/3 data reported that six of the patients have completely tapered off of standard-of-care treatment with chelators and/or zinc therapy, and a seventh patient has begun to taper as of the data",96.0,4954.06583,44.6877,53.66,53.79,55.1,0.002419731,0.026481871,0.003212937,-0.020889557,3.92457,0.15955,41.9008,2107,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
BDRX,MTX110 - (MAGIC-G1),Recurrent Glioblastoma (GBM)Â ,Phase 1,10/4/2024,"Phase 1 open label data reported that Patients #1 and #2 have deceased with overall survival (OS) since start of treatment of 12 months and 13 months, respectively, noted October 4, 2024.",0.0,3.22361,186.2313,60.075,55.5,52.5,-0.079210761,-0.134780612,0.003212937,-0.020889557,0.56046,0.09213,0.49811,2108,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
KZR,Zetomipzomib - (PALIZADE),Lupus nephritisÂ ,Phase 2b,10/4/2024,"Phase 2b IND placed on clinical hold, noted October 4, 2024.",7.0,58.18737,69.3725,8.256,7.975,8.476,-0.03462856,0.026298432,0.003212937,-0.020889557,1.18641,0.12323,1.04055,2109,0,0,0,0,0,1,0,1,0,0,0,0,0,2,0,-1
PHVS,Bradykinin B2 receptor - (CHAPTER-1),Hereditary angioedema (HAE) attacksÂ ,Phase 2,10/5/2024,Phase 2 OLE long term safety data reported that the attack rate remained low through >1.5 years. An early-onset reduction of attack rate in participants switching from placebo to deucrictibant 40 mg/d,54.0,982.94034,70.8888,18.2,18.2,19.73,0.0,0.080718726,0.01217514,-0.011927355,1.19026,0.07215,0.0,2110,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
SRRK,Apitegromab - (SAPPHIRE),Type 2 and Type 3 Spinal Muscular Atrophy (SMA)Â ,Phase 3,10/7/2024,"Phase 3 study met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in motor function, as measured by the Hammersmith Functional Motor Scale Expande",96.0,2743.51832,225.1463,7.42,34.28,28.52,1.530383037,1.346426538,0.004213562,-0.015871734,20.76753,0.05797,1462.64992,2111,1,0,0,0,0,1,0,0,0,0,0,0,2,0,0,1
RARE,UX143 (setrusumab) - (Orbit),Osteogenesis ImperfectaÂ ,Phase 2/3,10/7/2024,"Breakthrough Therapy Designation granted by the FDA, noted October 7, 2024.",96.0,4828.80966,44.0932,53.79,52.43,56.19,-0.02560863,0.043651229,0.004213562,-0.015871734,3.92457,0.15955,34.70756,2112,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
GANX,"GT-02287, GT-02329",GBA1 and Idiopathic Parkinson's DiseaseÂ ,Preclinical,10/7/2024,"Preclinical data demonstrated improvements in motor and cognitive function, which persisted even after the treatment was discontinued, suggesting a lasting neuroprotective effect, noted October 7, 202",35.0,54.51821,111.962,1.82,2.135,2.35,0.159630146,0.255578827,0.004213562,-0.015871734,2.27244,0.03325,1.27708,2113,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
BFRI,Ameluz (aminolevulinic acid HCI) Topical Gel - (3 tubes),Actinic keratosis (AK)Â ,Approved,10/7/2024,"Approved October 7, 2024.",10.0,4.81732,113.2554,0.96,0.869,0.819,-0.099590159,-0.158849201,0.004213562,-0.015871734,2.42366,0.00138,2.25428,2114,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1
VINC,VIP943 (anti-CD123),Hematologic malignanciesÂ ,Phase 1,10/7/2024,"Phase 1 data demonstrated a favorable safety profile with no dose-limiting toxicities, noted October 7, 2024.",5.0,21.55487,228.0176,14.6,13.96,8.1,-0.044825431,-0.589157467,0.004213562,-0.015871734,1.30491,0.02982,3.73196,2115,0,0,0,1,0,1,0,0,0,0,0,0,2,0,0,1
BDTX,BDTX-4933,Brain tumors harboring all-class BRAF or RAS mutationsÂ ,Phase 1,10/7/2024,"Phase 1 deprioritized, looking for a partnership to continue program, noted October 7, 2024.",56.0,206.80792,88.4853,3.75,3.66,3.48,-0.024292693,-0.074723546,0.004213562,-0.015871734,10.36932,0.06589,2.33482,2116,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
KRRO,KRRO-110 - (REWRITE),Alpha-1 Antitrypsin Deficiency (AATD)Â ,Preclinical,10/7/2024,"Preclinical data from the Oligonucleotide Therapeutics Society reported that treatment achieved AAT levels between MM and MZ in rodents as early as Week 1, noted October 7, 2024.",9.0,333.45551,81.835,33.59,35.86,39.25,0.065394065,0.155723041,0.004213562,-0.015871734,2.72114,0.05455,2.58773,2117,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1
AZN,Airsupra (albuterol/budesonide) - (BATURA),Severe exacerbations in patients with intermittent or mild persistent asthmaÂ ,Phase 3,10/7/2024,"Phase 3 trial met primary endpoint, noted October 7, 2024.",0.0,183089.7991,18.289,117.38,118.1,119.36,0.006115188,0.016727601,0.004213562,-0.015871734,0.0,0.07857,144.0931,2118,1,0,0,0,0,1,0,0,0,0,0,0,2,0,0,1
MRK,KEYTRUDA (pembrolizumab) - (KEYNOTE-689),Head and Neck Squamous Cell CarcinomaÂ ,Phase 3,10/8/2024,"Phase 3 trial met its primary endpoint, noted October 8, 2024.",0.0,275077.5065,23.1036,108.59,108.52,111.53,-0.000644834,0.026714291,0.000207641,-0.030466474,0.97893,0.0584,958.49368,2119,1,0,0,0,0,1,0,0,0,0,0,0,2,0,0,1
SAGE,Dalzanemdor (SAGE-718) - (LIGHTWAVE),Mild cognitive impairment and mild dementia due to ADÂ ,Phase 2,10/8/2024,"Phase 2 topline data reported that the trial did not demonstrate a statistically significant difference from baseline in participants treated with dalzanemdor versus placebo on the primary endpoint, n",62.0,104432.4708,84.6431,14.0,13.0,13.0,-0.074107972,-0.074107972,0.000207641,-0.030466474,0.0,1e-05,7.8585,2120,1,0,0,0,0,1,0,0,0,0,1,0,3,0,0,1
SUPN,Dalzanemdor (SAGE-718) - (LIGHTWAVE),Mild cognitive impairment and mild dementia due to ADÂ ,Phase 2,10/8/2024,"Phase 2 topline data reported that the trial did not demonstrate a statistically significant difference from baseline in participants treated with dalzanemdor versus placebo on the primary endpoint, n",56.0,1790.92508,34.3581,32.06,32.5,33.52,0.013630942,0.044533128,0.000207641,-0.030466474,12.33641,0.07172,11.1073,2121,1,0,0,0,0,1,0,0,0,0,1,0,3,0,0,1
AVTX,AVTX-009 (anti-IL-1Î² mAb) - (LOTUS),Hidradenitis suppurativa (HS)Â ,Phase 2,10/8/2024,"Phase 2 patient dosing commenced, noted October 8, 2024",13.0,93.24126,97.2843,9.6325,9.63,9.69,-0.000259572,0.005951628,0.000207641,-0.030466474,0.61421,0.00251,0.19538,2122,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
BIIB,SPINRAZA (Nusinersen) - (DEVOTE),Spinal muscular atrophy (SMA)Â ,Phase 2/3,10/8/2024,"Phase 2/3 results reported clinical benefits of a higher dose regimen of nusinersen (50/28 mg) in both individuals previously treated and treatment-naÃ¯ve to nusinersen, noted October 8, 2024.",146.0,26554.11734,26.6596,183.34,182.3,191.55,-0.005688671,0.043806519,0.000207641,-0.030466474,2.51806,0.17802,220.16772,2123,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
IONS,SPINRAZA (Nusinersen) - (DEVOTE),Spinal muscular atrophy (SMA)Â ,Phase 2/3,10/8/2024,"Phase 2/3 results reported clinical benefits of a higher dose regimen of nusinersen (50/28 mg) in both individuals previously treated and treatment-naÃ¯ve to nusinersen, noted October 8, 2024.",159.0,5954.4543,39.179,37.86,37.8,37.84,-0.001586043,-0.000528402,0.000207641,-0.030466474,6.73813,0.04269,54.99265,2124,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
BPTH,BP1001-A (Prexigebersen-A),Obesity in Type 2 diabetes patientsÂ ,Phase 1,10/8/2024,"Phase 1 initiated, noted October 8, 2024.",8.0,3.03711,133.3564,0.8513,1.19,1.15,0.334943993,0.300752628,0.000207641,-0.030466474,0.64063,0.01153,78.14987,2125,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
OGEN,ONP-002,Moderate-to-severe concussion in the acute through subacute phasesÂ ,Phase 2,10/8/2024,"Phase 2 data reported that the drug spreads well in the areas of the nose where it can be quickly absorbed into the brain, noted October 8, 2024.",4.0,3.11726,180.0142,11.89622,10.80108,8.9559,-0.096574573,-0.28390817,0.000207641,-0.030466474,2.01454,0.03634,0.68377,2126,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
PHIO,INTASYL,Hematological malignanciesÂ ,Preclinical,10/8/2024,"Preclinical data shared at the Oligonucleotide Therapeutics Society (OTS) Meeting showed that compounds also improve the functionality and outcomes of adoptive cell therapies such as NK, TIL and CAR-",5.0,2.41863,93.1654,2.89,2.81,2.76,-0.028072019,-0.046025822,0.000207641,-0.030466474,1.98194,0.07377,0.08766,2127,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
PTCT,Vatiquinone - (MOVE-FA),Friedreich ataxiaÂ ,Phase 3,10/8/2024,"Phase 3 trial met pre-specified endpoint for two different FA long-term extension studie with highly statistically significant evidence of durable treatment benefit on disease progression, noted Octob",79.0,3136.19841,60.0343,34.99,40.77,37.56,0.15288421,0.070877348,0.000207641,-0.030466474,6.79174,0.15938,89.21964,2128,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1
TVGN,TVGN 489 - (TCTL Study),Cytotoxic T Lymphocytes for the Treatment of Elderly and High-Risk Patients with Covid-19Â ,Phase 1,10/8/2024,"Phase 1 data published at the Blood Advances Journal showed that all patients treated with TVGN 489 returned to baseline health within 14 days, with no evidence of reinfection or Long COVID during a s",196.0,53.56605,127.9916,0.3195,0.3139,1.37,-0.01768281,1.455808745,0.000207641,-0.030466474,0.40429,0.00038,0.47203,2129,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
INSM,BRINSUPRI (Brensocatib) - (ASPEN),Non-Cystic Fibrosis Bronchiectasis (NCFBE)Â ,Phase 3,10/8/2024,"Phase 3 additional data presented at CHEST 2024 showed that treatment was well-tolerated, noted October 8, 2024.",211.0,12264.87048,117.6589,70.5,71.37,74.66,0.012264903,0.057331764,0.000207641,-0.030466474,7.10983,0.00027,73.75761,2130,0,0,0,1,0,1,0,0,0,0,0,0,2,0,0,1
TEVA,Prolia (denosumab) biosimilar - (TVB-009P),OsteoporosisÂ ,Approved,10/8/2024,"FDA biosimilar approved on October 8, 2024.",0.0,19861.35672,34.1194,17.28,17.53,18.15,0.014363936,0.049120797,0.000207641,-0.030466474,2.67798,0.1971,80.28707,2131,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1
GSK,Arexvy (60+ at increased risk) - (AReSVi-006),"Respiratory Syncytial Virus Vaccine, AdjuvantedÂ ",Phase 3,10/8/2024,"Phase 3 data presented at CHEST showed that trial met primary endpoint, noted October 8, 2024.",0.0,59267.69295,22.3035,14.8,14.53,14.94,-0.018411703,0.009414999,0.000207641,-0.030466474,0.0,0.03746,111.95792,2132,1,0,0,0,0,1,0,0,0,0,0,0,2,0,0,1
CLSD,CLS-AX - (ODYSSEY),Neovascular age-related macular degeneration (wet AMD)Â ,Phase 2b,10/9/2024,"Phase 2b with topline data reported that the trial achieved both its primary and secondary outcomes. noted October 9, 2024.",5.0,97.91669,72.9885,22.19999,19.64999,16.79999,-0.122015009,-0.278713547,0.009104139,-0.031925691,0.34947,0.11206,24.17075,2133,0,0,0,0,0,1,0,0,1,0,1,0,3,0,0,1
OCGN,OCU200,Diabetic macular edema (DME)Â ,IND-Enabling,10/9/2024,"Clinical hold lifted October 9, 2024.",292.0,273.14824,86.0978,0.9582,0.9489,0.9391,-0.009753105,-0.020134555,0.009104139,-0.031925691,17.58504,0.04027,2.29494,2134,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,-1
KYMR,KT-621 (STAT6),Type 2 inflammation in allergic diseasesÂ ,Phase 1,10/9/2024,"IND cleared by the FDA, noted October 9, 2024.",71.0,2763.1658,62.0929,43.04,43.34,49.02,0.00694608,0.130098462,0.009104139,-0.031925691,13.8139,0.21627,16.09713,2135,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
VKTX,VK0214,X-linked adrenoleukodystrophy (X-ALD)Â ,Phase 1b,10/9/2024,"Phase 1b results after 28 days of once-daily dosing, treatment shown to be safe and well-tolerated, with significant reductions in very long-chain fatty acids (VLCFAs), key biomarkers of X-ALD, noted",113.0,6940.27397,79.0965,66.68,62.64,65.85,-0.062501006,-0.01252563,0.009104139,-0.031925691,13.06707,0.07486,215.91006,2136,0,0,0,1,0,1,0,0,0,0,0,0,2,0,0,1
ALNY,AMVUTTRA (vutrisiran),ATTR Amyloidosis with Cardiomyopathy (ATTR-CM)Â ,sNDA Filing,10/9/2024,"sNDA submitted to the FDA, noted October 9, 2024. Priority review voucher utilized to accelerate review period",131.0,34778.28097,53.6971,271.19,270.9,300.55,-0.001069933,0.102794447,0.009104139,-0.031925691,3.51078,0.04236,116.9329,2137,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
CANF,Namodenoson - (CF102-222PC),Pancreatic CancerÂ ,Phase 1,10/9/2024,"Orphan Drug Designation granted by the FDA, noted October 9, 2024.",10.0,55.18993,76.407,0.027,0.027,0.031,0.0,0.138150338,0.009104139,-0.031925691,0.0,1e-05,0.48204,2138,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
BIIB,Felzartamab - (TRANSCEND),Antibody-mediated rejection (AMR) in kidney transplant recipientsÂ ,Phase 3,10/9/2024,"Breakthrough Therapy Designation granted by the FDA, noted October 9, 2024.",146.0,27058.10662,26.7766,182.3,185.76,189.0,0.018801836,0.036093333,0.009104139,-0.031925691,1.95592,0.17802,215.66179,2139,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
DYN,DYNE-101 - (ACHIEVE),Myotonic Dystrophy Type 1 (DM1)Â ,Phase 1/2,10/9/2024,"Phase 1/2 update presented at the World Muscle Society demonstrated robust muscle delivery and dose-dependent, consistent splicing correction while also showing improvement in myotonia, muscle strengt",142.0,3214.83355,80.529,33.13,32.02,35.4,-0.034078509,0.066272604,0.009104139,-0.031925691,8.84399,0.17346,15.06208,2140,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
DYN,DYNE-251 - (DELIVER),Duchenne muscular dystrophy (DMD)Â ,Phase 1/2,10/9/2024,"Phase 1/2 update demonstrated dose dependent exon skipping and dystrophin expression and improvement in multiple functional endpoints in both cohorts, noted October 9, 2024.",142.0,3214.83355,80.529,33.13,32.02,35.4,-0.034078509,0.066272604,0.009104139,-0.031925691,8.84399,0.17346,15.06208,2141,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
VTRS,EFFEXOR (venlafaxine) - (B2411367),Generalized anxiety disorder (GAD)Â ,Phase 3,10/9/2024,"Phase 3 study met primary and all secondary efficacy endpoints, noted October 9, 2024.",0.0,13618.06848,25.9718,11.32,11.41,11.82,0.007919091,0.043221939,0.009104139,-0.031925691,2.20444,0.02561,48.03867,2142,0,0,0,0,0,1,0,0,1,0,0,0,2,0,0,1
TRDA,ENTR-601-44,Duchenne Muscular Dystrophy (DMD)Â ,Phase 1,10/9/2024,"Phase 1 interim data presented at the World Muscle Society reinforced its safety profile and supports the planned 4Q 2024 global regulatory filings for a Phase 2 clinical trial, noted October 9, 2024",38.0,568.97407,58.7978,16.39,16.17,17.66,-0.013513719,0.074630802,0.009104139,-0.031925691,5.78754,0.12834,3.45013,2143,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
UNCY,UNI-494,Acute kidney injury (AKI)Â ,Phase 1,10/9/2024,"Phase 1 study completed, noted October 9, 2024.",17.0,34.14751,121.1611,3.599,3.619,4.084,0.005541715,0.126420871,0.009104139,-0.031925691,1.05327,0.0182,0.40622,2144,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
PEPG,PGN-EDO51 - (CONNECT1),Duchenne muscular dystrophy (DMD)Â ,Phase 2,10/9/2024,"Phase 2 OLE 12-week data from WMS reported that all participants at 5 mg/kg demonstrated increased dystrophin production and exon skipping at just 3 months and after 4 doses, noted October 9, 2024.",32.0,310.25396,90.8617,9.76,9.52,8.99,-0.024897552,-0.082179552,0.009104139,-0.031925691,2.96251,0.04883,0.73007,2145,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
IMTX,"Anzu-cel (anzutresgene autoleucel, IMA203) (ACTengine) - (SUPRAME)",MelanomaÂ ,Phase 1b,10/10/2024,"Phase 1b cohorts data reported an cORR of 54% in both all melanoma patients and in cutaneous melanoma patients, noted October 10, 2024.",121.0,963.52469,52.7199,11.07,9.345,9.55,-0.169397306,-0.147697592,-0.024310136,-0.030573415,9.23177,0.1776,22.30681,2146,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
RNAZ,TTX-MC138,Metastatic solid tumorsÂ ,Phase 1,10/10/2024,"Phase 1 initial dosing completed, noted October 10, 2024.",0.0,12.59306,253.2526,499.79192,673.96602,553.47635,0.298987842,0.102027171,-0.024310136,-0.030573415,8.00983,0.01288,3.20875,2147,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
JNJ,TREMFYA (Guselkumab) - (QUASAR),Crohn's diseaseÂ ,Approved,10/10/2024,"FDA Approved on October 10, 2024.",0.0,386386.681,16.8281,160.65,160.51,164.47,-0.00087184,0.023500097,-0.024310136,-0.030573415,0.82,0.05469,769.46712,2148,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
NVS,TREMFYA (Guselkumab) - (QUASAR),Crohn's diseaseÂ ,Approved,10/10/2024,"FDA Approved on October 10, 2024.",0.0,2178.09011,56.0008,7.15,7.0,7.65,-0.021202208,0.067593291,-0.024310136,-0.030573415,0.0,0.02199,0.092,2149,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
FHTX,FHD-909 (LY4050784),Non-small cell lung cancer (NSCLC)Â ,Phase 1,10/10/2024,"Phase 1 trial initiated, noted October 10, 2024.",56.0,390.6203,94.7007,7.26,7.06,7.74,-0.027934777,0.064021859,-0.024310136,-0.030573415,2.16044,0.07958,0.81319,2150,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
LLY,FHD-909 (LY4050784),Non-small cell lung cancer (NSCLC)Â ,Phase 1,10/10/2024,"Phase 1 trial initiated, noted October 10, 2024.",946.0,820008.7518,31.0409,919.74,910.69,917.12,-0.009888467,-0.002852696,-0.024310136,-0.030573415,0.64295,0.13326,1531.82885,2151,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
PFE,CRDF-004,Metastatic colorectal cancer (mCRC)Â ,Phase 2,10/10/2024,"Phase 2 data reported a 64% ORR in the 30mg onvansertib dose arm versus 33% ORR in the control arm, noted December 10, 2024.",0.0,166260.8332,23.3265,30.19,29.34,29.27,-0.028558971,-0.030947643,-0.024310136,-0.030573415,1.19329,0.00487,1007.7624,2152,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CRDF,CRDF-004,Metastatic colorectal cancer (mCRC)Â ,Phase 2,10/10/2024,"Phase 2 data reported a 64% ORR in the 30mg onvansertib dose arm versus 33% ORR in the control arm, noted December 10, 2024.",66.0,117.30508,75.0582,2.52,2.52,2.79,0.0,0.101782694,-0.024310136,-0.030573415,14.66537,0.06302,1.105,2153,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
SGMT,Denifanstat - (FASCINATE-3),Nonalcoholic steatohepatitis (NASH)Â ,Phase 2b,10/11/2024,"Phase 2b study showed 36% of patients on denifanstat achieved MASH resolution without worsening fibrosis, and 52% had a â‰¥2-point NAS reduction. With secondary endpoints and a favorable safety profile,",32.0,137.54885,97.2211,4.14,4.31,5.41,0.040242116,0.267553305,-0.029189435,-0.036831503,6.17731,0.11696,2.93656,2154,1,0,0,1,0,1,0,0,1,0,0,0,4,0,0,1
CATX,212Pb-VMT01,MC1R-positive metastatic melanomaÂ ,Phase 1/2,10/11/2024,"Phase 1/2 safety and efficacy update reported that one patient experiencing a RECIST version 1.1 objective response after completion of treatment, and two patients experiencing stable disease at 9 and",74.0,853.63426,80.2064,13.25,12.66,12.65,-0.045550136,-0.046340337,-0.029189435,-0.036831503,14.22178,0.00116,65.61648,2155,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CAPR,Deramiocel (CAP-1002) - (HOPE-2),Duchenne Muscular Dystrophy (DMD)Â ,BLA Filing,10/11/2024,"Phase 3 OLE data presented at the 29th Annual Congress of the World Muscle Society, demonstrated sustained improvements in cardiac and skeletal muscle function over three years. Key outcomes included",45.0,627.94626,116.5046,17.14,17.77,18.86,0.036096729,0.095628364,-0.029189435,-0.036831503,14.82773,0.01283,81.63072,2156,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
BCAB,Evalstotug (BA3071),Oncology (various)Â ,Phase 2,10/11/2024,"Phase 2 data presented at SMR reported 1 cCR (cervical cancer) and 2 cPRs (melanoma and gastric), noted October 11, 2024.",58.0,100.05498,121.7066,1.93,2.07,1.94,0.070028604,0.00516797,-0.029189435,-0.036831503,9.24147,0.22892,1.71552,2157,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
PFE,Hympavzi (marstacimab-hncq),Hemophilia A or BÂ ,Approved,10/11/2024,"Approved October 11, 2024.",0.0,165240.8281,23.3471,29.34,29.16,29.22,-0.006153866,-0.004098366,-0.029189435,-0.036831503,1.19329,0.00529,863.64951,2158,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1
BNTC,BB-301,Oculopharyngeal muscular dystrophy (OPMD)Â ,Phase 1/2,10/12/2024,"Phase 1b/2a data from the Annual Congress of the World Muscle Society reported that Subject 1 and Subject 2 experienced durable, clinically meaningful improvements in swallowing at 9-months and 6-mont",26.0,194.32629,96.9333,10.86,10.86,11.48,0.0,0.055520076,-0.003944379,-0.011586448,0.29686,0.00415,0.0,2159,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
LLY,Mirikizumab - (VIVID-1),Crohn's diseaseÂ ,Phase 3,10/14/2024,"Phase 3 1-year data reported that a greater number of patients that achieved histologic response were observed with mirikizumab at Week 52 in the overall population (58.2% versus 48.8%; p=0.0075), not",946.0,836954.7649,31.2654,932.06,929.51,906.13,-0.002739625,-0.028214407,-0.006363979,0.005385371,0.64295,0.14459,1441.09836,2160,0,1,0,0,0,1,0,0,0,0,0,0,2,0,0,1
GSK,Depemokimab - (ANCHOR 1/2),Chronic rhinosinusitis with nasal polypsÂ ,Phase 3,10/14/2024,"Phase 3 data reported that trial met primary endpoint, noted October 14, 2024.",0.0,60960.4729,22.9597,14.8,14.945,14.64,0.009749615,-0.010869672,-0.006363979,0.005385371,0.0,0.03646,124.65501,2161,1,0,0,0,0,1,0,0,0,0,0,0,2,0,0,1
RPTX,RP-3467 - (POLAR),Solid tumorsÂ ,Phase 1,10/14/2024,"Phase 1 dosing commenced, noted October 14, 2024.",42.0,143.89036,66.4869,3.14,3.39,3.6,0.076607121,0.136711046,-0.006363979,0.005385371,1.67812,0.26281,0.2971,2162,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CMND,CMND-100,Alcohol use disorder (AUD)Â ,Phase 1/2,10/14/2024,"IRB approval on US clinical sites for part A of Phase 1/2a, noted October 14, 2024.",5.0,5.71943,92.4239,1.36,1.41,1.54,0.036105005,0.124297717,-0.006363979,0.005385371,4.96446,0.02251,0.46278,2163,0,0,0,0,0,1,0,1,0,0,0,0,2,0,0,1
ENVB,EB-003 (EVM301 series),Mental health disordersÂ ,Preclinical,10/15/2024,"In vitro data showed no meaningful activity against hERG or 5-HT2B, targets related to cardiovascular adverse drug reactions (ADRs), noted October 15, 2024.",0.0,3.77312,77.6845,74.15999,76.13999,96.53399,0.026348833,0.263670388,-0.011840395,0.008107879,2.23068,6e-05,8.2401,2164,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
AMGN,UPLIZNA (Inebilizumab) - (MINT),Myasthenia gravisÂ ,Phase 3,10/15/2024,"Phase 3 trial met its primary endpoint, noted October 15, 2024.",538.0,174680.3561,26.5173,324.62,325.09,319.66,0.0014468,-0.015397337,-0.011840395,0.008107879,1.82641,0.06745,635.94171,2165,1,0,0,0,0,1,0,0,0,0,0,0,2,0,0,1
ANVS,Buntanetap (ANVS401),Alzheimerâ€™s disease (AD)Â ,Phase 2/3,10/15/2024,"Phase 2 EoP2 meeting. During the meeting, the FDA granted clearance to proceed with pivotal Phase 3 studies, based on the Company's Phase 2/3 clinical data showing symptomatic improvement in early AD",19.0,104.17106,200.3682,7.51,7.98,9.63,0.060702946,0.24864776,-0.011840395,0.008107879,9.26706,0.07295,11.92494,2166,0,0,0,0,0,1,0,1,0,0,0,0,2,0,0,1
JNJ,Nipocalimab - (Vibrance-MG),Generalized myasthenia gravisÂ ,Phase 2/3,10/15/2024,"Phase 2/3 data reported sustained disease control over 24 weeks in antibody positive adolescents aged 12 â€“ 17 years, noted October 15, 2024.",0.0,395028.6858,16.8597,161.6,164.1,163.45,0.015351852,0.011382987,-0.011840395,0.008107879,0.82,0.05522,1730.92122,2167,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
VTYX,Tamuzimod (VTX002),Ulcerative Colitis (UC)Â ,Phase 2,10/15/2024,"Phase 2 data reported that endoscopic remission occurred in 43.8% (14/32) and 46.4% (13/28) of patients who received tamuzimod 30 mg and 60 mg, respectively, compared to 18.2% (4/22) of patients who r",71.0,170.31261,110.3461,2.34,2.41,2.25,0.029475818,-0.039220713,-0.011840395,0.008107879,12.11676,0.01119,1.74632,2168,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
MGTX,AAV-GAD,Parkinson's DiseaseÂ ,Phase 1,10/15/2024,"Phase 1 met its primary endpoint, noted October 15, 2024.",80.0,412.53623,58.6081,4.64,5.33,5.98,0.138636872,0.253706202,-0.011840395,0.008107879,2.49991,0.14649,10.87835,2169,1,0,0,0,0,1,0,0,0,0,0,0,2,0,0,1
NVCR,Optune Lua is (Tumor Treating Fields (TTFields)) - (LUNAR),Non-small cell lung cancer (NSCLC)Â ,Approved,10/15/2024,"FDA approved by the FDA, noted October 15, 2024.",111.0,1924.10697,68.2641,16.06,17.78,16.15,0.101742522,0.005588341,-0.011840395,0.008107879,5.07193,0.10998,49.28344,2170,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
ZLAB,Optune Lua is (Tumor Treating Fields (TTFields)) - (LUNAR),Non-small cell lung cancer (NSCLC)Â ,Approved,10/15/2024,"FDA approved by the FDA, noted October 15, 2024.",109.0,2432.88599,61.1221,24.72,24.79,28.82,0.002827713,0.153456958,-0.011840395,0.008107879,4.95339,0.05973,18.47562,2171,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
GNPX,REQORSA Immunogene Therapy (quratusugene ozeplasmid) - (Acclaim-3),Extensive-stage small cell lung cancer (ES-SCLC)Â ,Phase 1,10/15/2024,"Phase 1 portion to continue following review from safety review committee approval to advance to highest dose, noted October 15, 2024.",0.0,1.20802,103.5093,17.09,16.785,179.5,-0.018007867,2.351681711,-0.011840395,0.008107879,2.25149,0.05297,1.00577,2172,0,0,0,1,0,1,0,1,0,0,0,0,3,0,0,1
JAZZ,Zepzelca (lurbinectedin) and Atezolizumab (Tecentriq),"First-line, Small Cell Lung Cancer (SCLC)Â ",Phase 3,10/15/2024,"Phase 3 topline data demonstrated a statistically significant improvement in the primary endpoints of overall survival (OS) and progression-free survival (PFS), as assessed by an independent review f",60.0,7242.45165,26.9647,111.03,117.28,113.1,0.054763803,0.018471948,-0.011840395,0.008107879,5.46908,0.03397,151.526,2173,1,0,0,0,0,1,0,0,0,0,1,0,3,0,0,1
LYRA,LYR-210 - (ENLIGHTEN II),Chronic rhinosinusitisÂ ,Phase 3,10/15/2024,"Phase 3 enrollment to be completed, noted Ocrtober 15, 2024",1.0,14.95031,295.1749,11.125,11.42,12.6,0.026171376,0.124501986,-0.011840395,0.008107879,4.36044,0.00613,0.19955,2174,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
QURE,AMT-162,SOD1-ALSÂ ,Phase 1/2,10/15/2024,"Phase 1/2 dosing commenced, noted October 15, 2024.",54.0,274.65457,118.6249,5.64,5.64,6.65,0.0,0.164732789,-0.011840395,0.008107879,10.79556,0.02051,2.85159,2175,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
HCM,Savolitinib + TAGRISSO (osimertinib) - (SAVANNAH),Non-small cell lung cancer (NSCLC)Â ,Phase 2,10/16/2024,"Phase 2 data demonstrated a high, clinically meaningful and durable objective response rate (ORR) for patients with epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC)",174.0,2589.28664,50.2138,2.84,3.03,3.25,0.064758567,0.134850944,0.0001007,0.026943154,0.0,9e-05,0.652,2176,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
AZN,IVX-A12,RSV/human Metapneumovirus (hMPV)Â ,Phase 2,10/16/2024,"Phase 2 interim data from ID week reported that treatment was well-tolerated and immunogenic against both RSV and hMPV in older adults 60 to 85 years of age, noted October 16, 2024.",0.0,186407.4297,18.1325,118.5,120.24,118.28,0.014576785,-0.001858266,0.0001007,0.026943154,0.0,0.07853,161.07964,2177,0,0,0,1,0,1,0,0,0,0,0,0,2,0,0,1
ACET,ADI-001,Idiopathic inflammatory myopathy (IIM) and stiff person syndrome (SPS)Â ,IND-Enabling,10/16/2024,"IND Clearance by the FDA, noted October 16, 2024.",83.0,135.36098,76.6536,1.4,1.49,1.44,0.062303883,0.028170877,0.0001007,0.026943154,4.09374,0.04421,0.82838,2178,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CGEM,CLN-978,Systemic Lupus Erythematosus (SLE)Â ,IND-Enabling,10/16/2024,"IND Cleared by the FDA, noted October 16, 2024.",59.0,1020.96865,77.7335,16.24,17.61,15.61,0.080989588,-0.0395656,0.0001007,0.026943154,15.88336,0.07858,11.47589,2179,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
NVAX,NVX-CoV2373 - (COVID-19-Influenza Combination),"COVID-19, COVID-19 vaccine, InfluenzaÂ ",Phase 2,10/16/2024,"Phase 2 IND placed on hold October 16, 2024.",162.0,1624.95044,151.0699,12.6,10.15,10.0,-0.216223108,-0.231111721,0.0001007,0.026943154,21.16203,0.05963,328.1459,2180,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
WVE,WVE-006 - (RestorAATion-2),"Healthy volunteers, AATD who have the homozygous PiZZ mutationÂ ",Phase 1/2,10/16/2024,"Phase 1b/2a data resulted in mean plasma total AAT levels of ~11 micromolar, with mean wild-type M-AAT representing more than 60% of total AAT; durable editing with M-AAT protein observed through 57 d",159.0,2266.61615,119.7713,8.56,14.9,14.67,0.554261023,0.538704402,0.0001007,0.026943154,3.67571,0.04298,258.15888,2181,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
GRI,GRI-0621,Idiopathic pulmonary fibrosis (IPF)Â ,Preclinical,10/16/2024,"Preclinical data reported an increase in IFN-Î³ producing NKT cells in IPF, compared to controls and confirmed iNKT cell phenotype in a second cohort, using an antibody against VÎ±24-JÎ±18 of the iNKT TC",2.0,1.35874,140.8494,6.29,7.8897,13.70201,0.226597041,0.778581467,0.0001007,0.026943154,5.7767,0.03016,7.35574,2182,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
DRUG,BMB-201,PainÂ ,Preclinical,10/16/2024,"Preclinical data reported dose-dependent efficacy with similar efficacy to morphin, noted October 16, 2024.",7.0,175.38416,907.8615,44.11,39.29,64.21,-0.115716481,0.375472448,0.0001007,0.026943154,0.0,0.00982,5.76911,2183,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
GKOS,Epioxa (Epi-on),Progressive keratoconusÂ ,Phase 3,10/16/2024,"Second Phase 3 trial met primary endpoint, noted October 16, 2024.",57.0,7041.05924,28.8321,127.61,128.2,129.94,0.004612807,0.018094068,0.0001007,0.026943154,5.74407,0.04178,31.0485,2184,1,0,0,0,0,1,0,0,0,0,0,0,2,0,0,1
PHIO,INTASYL(PH-894),Solid tumorsÂ ,Preclinical,10/16/2024,"Preclinical data shared at ASGCT 2024 showed that treatment leads to potent and specific silencing of BRD4 in NK cells, without affecting cell viability., noted October 16, 2024.",5.0,2.79734,97.9183,2.76,3.25,2.93,0.163424317,0.059771743,0.0001007,0.026943154,5.6089,0.07068,3.52065,2185,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
VSTM,AVMAPKI FAKZYNJA CO-PACK,Recurrent low-grade serous ovarian cancer (LGSOC)Â ,Phase 3,10/17/2024,"Phase 3 data reported overall response rates observed (31% overall, 44% in KRAS mutant, 17% in KRAS wild-type) in patients whose cancer had progressed despite prior treatment with chemotherapy and/or",61.0,107.04836,173.0224,3.33,2.66,3.29,-0.224646181,-0.012084739,0.004198327,0.030382084,5.83711,0.13491,11.75655,2186,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
LGND,ZTALMY (ganaxolone) - (RAISE),Refractory status epilepticus (RSE)Â ,Phase 3,10/17/2024,"Phase 3 data at the NCS showed that the trial met one of its two co-primary endpoints, with 80% of patients achieving SE cessation within 30 minutes. IV ganaxolone also showed faster SE cessation. How",19.0,1934.49912,39.9459,107.16,105.89,110.99,-0.011922225,0.035117062,0.004198327,0.030382084,5.45261,0.1619,7.72584,2187,1,0,0,0,0,1,0,0,0,0,0,0,2,0,0,1
MRNS,ZTALMY (ganaxolone) - (RAISE),Refractory status epilepticus (RSE)Â ,Phase 3,10/17/2024,"Phase 3 data at the NCS showed that the trial met one of its two co-primary endpoints, with 80% of patients achieving SE cessation within 30 minutes. IV ganaxolone also showed faster SE cessation. How",55.0,3222.63646,36.284,42.61,43.01,42.0,0.009343679,-0.014419349,0.004198327,0.030382084,0.0,0.0447,0.24972,2188,1,0,0,0,0,1,0,0,0,0,0,0,2,0,0,1
BDRX,MTX110 - (MAGIC-G1),Recurrent Glioblastoma (GBM)Â ,Phase 1,10/17/2024,"Phase 1 data reported that patient #3 has achieved 13 months OS to date, with six months progression free survival (PFS). Patient #4 has not progressed and achieved 12 months PFS and 12 months OS to d",0.0,3.40947,207.3395,84.0,58.7,66.15,-0.358377072,-0.238891908,0.004198327,0.030382084,2.2857,0.09625,2.79688,2189,1,0,0,0,0,1,0,0,0,0,0,0,3,0,0,1
AVXL,ANAVEX 3-71 (AF710B),SchizophreniaÂ ,Phase 2,10/17/2024,"Phase 2 data reported that ANAVEX3-71 demonstrates a dose-dependent pharmacodynamic effect on objective EEG biomarkers of schizophrenia, noted October 17, 2024.",85.0,466.79932,66.528,5.525,5.505,5.33,-0.003626477,-0.035932009,0.004198327,0.030382084,20.74988,0.11947,2.57239,2190,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ADTX,ATI-1701,Francisella tularensis vaccineÂ ,Preclinical,10/17/2024,"Preclinical data presented at IDweek reported full protection against lethal tularemia in animal models after one year, noted October 17, 2024.",4.0,4.55868,166.6362,277.5,270.0,198.75,-0.027398974,-0.33377318,0.004198327,0.030382084,0.13618,0.03385,2.9322,2191,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
KZR,Zetomipzomib (KZR-616-208) - (PORTOLA),Autoimmune Hepatitis (AIH)Â ,Phase 2a,10/17/2024,"Phase 2a IDMC ecommended that the trial may proceed without modification following its third scheduled meeting., noted October 17, 2024.",7.0,59.53717,72.5253,8.947,8.16,8.018,-0.092074112,-0.109629266,0.004198327,0.030382084,1.34714,0.12455,1.01234,2192,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
AMLX,AMX0035 - (HELIOS),Wolfram SyndromeÂ ,Phase 2,10/17/2024,"Phase 2 topline data from ISPAD reported improvement in pancreatic function, as measured by C-peptide response after 24 weeks of treatment with AMX0035, the study's primary efficacy endpoint, noted Oc",89.0,266.88328,69.8215,4.08,3.92,4.9,-0.040005335,0.183138217,0.004198327,0.030382084,1.87972,0.03649,13.00308,2193,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
AVDL,LUMRYZ (sodium oxybate) Extended-Release Oral Suspension (CIII),Pediatric narcolepsyÂ ,Approved,10/17/2024,"Approved October 17, 2024.",97.0,1340.08575,37.5078,13.24,13.92,13.0,0.050084104,-0.018293193,0.004198327,0.030382084,11.39087,0.01115,19.68777,2194,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1
AURA,Belzupacap sarotalocan (AU-011),Non-muscular invasive bladder cancer (NMIBC)Â ,Phase 1,10/17/2024,Phase 1 updated data reported that 4 out of 5 patients with low grade disease demonstrated a clinical complete response with no tumor cells remaining on histopathological evaluation and 2 out of 3 pat,62.0,510.44692,57.1882,10.25,10.29,11.24,0.003894844,0.092201139,0.004198327,0.030382084,2.31998,0.17466,2.56788,2195,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
SUPN,SPN-820,Treatment-resistant depressionÂ ,Phase 2a,10/17/2024,"Phase 2a open label data reported a rapid and substantial decrease in depressive symptoms, noted October 17, 2024.",56.0,1864.7663,33.7194,33.98,33.84,33.8,-0.004128582,-0.005311314,0.004198327,0.030382084,12.64906,0.078,9.06638,2196,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
RANI,RT-114,ObesityÂ ,Preclinical,10/17/2024,"Preclinical pharmacokinetic data provided further evidence of the RaniPill platform's potential to enable oral delivery of multiple obesity treatments, noted October 17, 2024.",71.0,84.92287,128.6731,2.6,2.63,2.39,0.011472401,-0.084218079,0.004198327,0.030382084,2.44221,0.00223,6.79806,2197,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ABBV,VYALEV (foscarbidopa and foslevodopa),Parkinson's diseaseÂ ,Approved,10/17/2024,"Approved October 17, 2024.",0.0,333079.44,19.8322,190.46,188.57,189.65,-0.009972908,-0.004261931,0.004198327,0.030382084,0.84108,0.01275,833.29121,2198,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1
KZR,Zetomipzomib - (PALIZADE),Lupus nephritisÂ ,Phase 2b,10/18/2024,"Phase 2b IND placed on clinical hold, noted October 4, 2024. Phase 2b will be discontinued after clinical hold following the recommendation of the IDMC after its assessment of four Grade 5 (fatal), no",7.0,60.10628,72.3561,8.16,8.238,7.857,0.009513427,-0.037839315,0.01164865,0.021889395,1.34714,0.12985,0.19613,2199,0,0,0,0,0,1,0,1,0,0,0,0,0,4,0,-1
MRK,ENFLONSIA (Clesrovimab) (MK-1654-004) - (CLEVER),Respiratory syncytial virus (RSV) infantsÂ ,Phase 2/3,10/18/2024,Phase 2b/3 data presented at IDweek reported that treatment reduced RSV-associated hospitalizations (secondary endpoint) and RSV-associated lower respiratory infection hospitalizations (tertiary endpo,0.0,275533.7722,23.4135,109.75,108.7,103.98,-0.009613258,-0.054006479,0.01164865,0.021889395,1.07549,0.05257,1035.15412,2200,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
PFE,VYLOY (zolbetuximab-clzb),Advanced Gastric and GEJ CancerÂ ,Approved,10/18/2024,"Approved October 18, 2024.",0.0,165580.8298,23.2633,29.27,29.22,28.45,-0.001709694,-0.02841494,0.01164865,0.021889395,1.19329,0.00078,708.43516,2201,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1
REGN,EYLEA HD (aflibercept) - (PHOTON ext),Diabetic macular edema (DME)Â ,Phase 3,10/21/2024,"Phase 3 extension data reported that 88% of EYLEA HD patients had a last assigned dosing interval of â‰¥12 weeks at week 156, while sustaining visual and anatomic improvements achieved in the first 96 w",105.0,104534.5913,20.7683,990.68,968.5,928.61,-0.022643093,-0.064702732,0.015749947,0.013513719,1.6045,0.17293,769.2873,2202,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1
ACXP,Ibezapolstat,C. difficile InfectionÂ ,Phase 2b,10/21/2024,"Phase 2b microbiome analysis presented at ID Week indicate a favorable gut bile acid profile which may contribute to ibezapostat's beneficial anti-recurrence effect in patients, noted October 21, 2024",1.0,31.84036,61.8589,40.2,39.2,37.8,-0.025190249,-0.061557893,0.015749947,0.013513719,3.02701,0.03814,0.15033,2203,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ABBV,BOTOX (OnabotulinumtoxinA),Platysma prominence associated with platysma muscle activity (M21-310)Â ,Approved,10/21/2024,"Approved October 21, 2024.",0.0,329493.7622,19.9223,188.86,186.54,189.68,-0.012360307,0.004332442,0.015749947,0.013513719,0.84108,0.00815,838.79427,2204,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1
NRIX,Bexobrutideg (NX-5948),Relapsed/Refractory Waldenstrom's MacroglobulinemiaÂ ,Phase 1/2,10/21/2024,"Phase 1a/1b data reported an objective responses observed in 7 of 9 (77.8%), noted October 21, 2024.",76.0,1804.90847,66.675,25.05,25.48,26.45,0.017020003,0.054382331,0.015749947,0.013513719,12.8151,0.14869,15.28466,2205,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
PYPD,D-PLEX100 - (SHIELD I),Abdominal (soft tissue) sternal surgical site infectionsÂ ,Phase 3,10/21/2024,"Phase 3 data published at the Journal of Surgery trial showed that despite study did not meet its primary endpoint due to COVID-19-related impacts, pre-specified and post-hoc analyses indicated poten",10.0,22.45148,63.1965,3.59,3.3,3.4194,-0.084229734,-0.048687105,0.015749947,0.013513719,0.10689,0.01043,0.01221,2206,1,0,0,0,0,1,0,0,0,0,0,0,0,2,0,-1
ELAB,EL-32,ObesityÂ ,Preclinical,10/21/2024,"Preclinical data reported statistically significant increases in grip strength, motor function and body composition in aged C57BL/6J mouse model, noted October 21, 2024.",0.0,4.88787,176.5658,456.19007,485.10008,485.10008,0.061445677,0.061445677,0.015749947,0.013513719,1.39023,0.00197,6.82584,2207,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1
RGNX,ABBV-RGX-314,Wet age-related macular degeneration (wet AMD)Â ,Phase 2,10/21/2024,"Phase 2 data reported a 97% reduction in treatment burden at nine months after treatment, noted October 21, 2024.",50.0,512.51846,56.8657,11.1,10.37,9.38,-0.068028086,-0.168365345,0.015749947,0.013513719,10.74272,0.09524,7.9352,2208,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
MIRA,Ketamir-2 (Topical),"Neuropathic pain and chemo-induced depression, as well as neuropathic pain and PTSDÂ ",Preclinical,10/21/2024,"Preclinical data has shown greater pain relief compared to FDA-approved treatments Gabapentin (Neurontin) and Pregabalin (Lyrica), noted October 21, 2024.",19.0,17.07946,316.1708,1.1,1.05,1.57,-0.046520016,0.35576544,0.015749947,0.013513719,2.70652,0.00538,3.08175,2209,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1
NVO,Semaglutide - (SOUL),Major adverse cardiovascular events (MACE)Â ,Phase 3,10/21/2024,"Trial data reported that trial met its primary endpoint, noted October 21, 2024.",0.0,3579127.915,32.4007,118.09,117.33,112.36,-0.006456568,-0.049739043,0.015749947,0.013513719,0.0,0.0,379.04536,2210,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1
GILD,Islatravir (MK-8591D) and Lenacapavir - (ISLEND),Human immunodeficiency virus (HIV)Â ,Phase 2,10/21/2024,"Phase 2 data reported that the combination maintained a high rate (n=49; 94.2%) of viral suppression (HIV-1 RNA <50 copies/mL) in virologically suppressed adults, a secondary endpoint of the study, no",0.0,107430.3667,22.8712,86.72,86.29,88.76,-0.004970821,0.02325156,0.015749947,0.013513719,1.42451,0.03715,384.10069,2211,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
MRK,Islatravir (MK-8591D) and Lenacapavir - (ISLEND),Human immunodeficiency virus (HIV)Â ,Phase 2,10/21/2024,"Phase 2 data reported that the combination maintained a high rate (n=49; 94.2%) of viral suppression (HIV-1 RNA <50 copies/mL) in virologically suppressed adults, a secondary endpoint of the study, no",0.0,269551.6222,23.6301,108.7,106.34,104.23,-0.021950286,-0.041991798,0.015749947,0.013513719,1.07549,0.05257,1217.04588,2212,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
TARA,IV choline chloride - (THRIVE-3),Parenteral nutrition (PN)Â ,Phase 3,10/21/2024,"Fast Track Designation graned by the FDA, noted October 21, 2024.",38.0,41.46584,64.9737,1.91,2.01,2.4,0.05103148,0.228365495,0.015749947,0.013513719,10.39934,0.13773,1.34445,2213,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
AMRX,Pyridostigmine Bromide Extended-Release (PB ER) Tablets USP 105 mg,Lethal effects of soman nerve agent poisoningÂ ,Approved,10/21/2024,"NDA Approved by the FDA, noted October 21, 2024.",314.0,2621.82589,38.5766,8.58,8.47,8.54,-0.012903405,-0.004672906,0.015749947,0.013513719,1.46329,0.10454,6.74534,2214,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
MDGL,Resmetirom - (MAESTRO-NASH Outcomes),Nonalcoholic Steatohepatitis (NASH)Â ,Phase 3,10/21/2024,"Phase 3 enrollment completed, noted October 21, 2024.",22.0,4535.5611,48.8635,214.44,208.89,217.0,-0.026222181,0.011867375,0.015749947,0.013513719,17.78707,0.10631,34.50382,2215,0,0,0,0,0,1,0,0,0,1,0,0,2,0,0,1
RGNX,RGX-314 - (ALTITUDE),Diabetic retinopathyÂ ,Phase 1/2,10/21/2024,"Phase 1/2a long-term results reported that treatment was well-tolerated with 78% of patiences injection-free and 97% reduction in anti-VEGF treatment burden, noted October 21, 2024.",50.0,512.51846,56.8657,11.1,10.37,9.38,-0.068028086,-0.168365345,0.015749947,0.013513719,10.74272,0.09524,7.9352,2216,0,0,0,1,0,1,0,0,0,0,0,0,2,0,0,1
CLSD,RGX-314 - (ALTITUDE),Diabetic retinopathyÂ ,Phase 1/2,10/21/2024,"Phase 1/2a long-term results reported that treatment was well-tolerated with 78% of patiences injection-free and 97% reduction in anti-VEGF treatment burden, noted October 21, 2024.",5.0,98.66414,73.017,17.24999,19.79999,16.49999,0.137869869,-0.044451789,0.015749947,0.013513719,0.34947,0.09325,2.93165,2217,0,0,0,1,0,1,0,0,0,0,0,0,2,0,0,1
ABBV,RGX-314 - (ALTITUDE),Diabetic retinopathyÂ ,Phase 1/2,10/21/2024,"Phase 1/2a long-term results reported that treatment was well-tolerated with 78% of patiences injection-free and 97% reduction in anti-VEGF treatment burden, noted October 21, 2024.",0.0,329493.7622,19.9223,188.86,186.54,189.68,-0.012360307,0.004332442,0.015749947,0.013513719,0.84108,0.00815,838.79427,2218,0,0,0,1,0,1,0,0,0,0,0,0,2,0,0,1
RVMD,Daraxonrasib (RMC-6236) - (RASolute 302),Metastatic pancreatic ductal adenocarcinoma (PDAC)Â ,Phase 3,10/21/2024,"Phase 3 dosing commenced, noted October 21, 2024.",186.0,7976.10953,38.5656,50.43,47.75,47.75,-0.054607169,-0.054607169,0.015749947,0.013513719,9.78379,0.12358,52.75134,2219,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
OCGN,OCU410ST - (GARDian),"Stargardt, Retinitis Pigmentosa 19 (RP19), and Cone-rod dystrophy 3 (CORD3) diseasesÂ ",Phase 1/2,10/21/2024,"Phase 1/2 DSMB convened and approved enrollment for the second phase, noted October 21, 2024.",292.0,270.12573,83.1157,0.94,0.9384,1.01,-0.001703578,0.071825735,0.015749947,0.013513719,17.58504,0.03548,1.61805,2220,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1
IMRN,Travelan - (CHIM),Enterotoxigenic Escherichia coli (ETEC)Â ,Phase 2,10/22/2024,"Phase 2 final results reported no SAEs and that all subjects challenged had ETEC negative stool at discharge, noted October 22, 2024.",6.0,17.6442,73.466,1.96,2.0019,1.92,0.021152256,-0.020619287,0.015193804,-0.004168579,0.0,0.0,0.00628,2221,0,0,0,1,0,1,0,0,0,0,0,0,2,0,0,1
TEVA,SELARSDI (ustekinumab-aekn) 130 mg/26 mL - (STELARA Biosimilar),Crohn's diseaseÂ ,Approved,10/22/2024,"FDA Biosimilar approval on October 22, 2024.",0.0,20824.40026,34.0056,18.18,18.38,18.43,0.010941028,0.013657683,0.015193804,-0.004168579,2.16174,0.17744,68.37176,2222,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
ALVO,SELARSDI (ustekinumab-aekn) 130 mg/26 mL - (STELARA Biosimilar),Crohn's diseaseÂ ,Approved,10/22/2024,"FDA Biosimilar approval on October 22, 2024.",301.0,3740.34151,31.0267,12.25,12.4,12.96,0.012170536,0.056341754,0.015193804,-0.004168579,0.02659,0.02681,0.55904,2223,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
IMUX,Vidofludimus Calcium - (ENSURE),Progressive Multiple SclerosisÂ ,Phase 3,10/22/2024,"Phase 3 trial had positive outcome of the non-binding, interim futility analysis, noted October 22, 2024.",98.0,126.11062,69.5859,1.55,1.4,1.31,-0.101782694,-0.168227794,0.015193804,-0.004168579,2.97726,0.11123,15.52777,2224,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,-1
MOLN,MP0712,Small-cell lung cancer (SCLC) and other DLL3+ neuroendocrine tumorsÂ ,Preclinical,10/22/2024,"Preclinical data presented at EANM led to strong and dose-dependent efficacy in mice bearing established tumors with clinically-relevant levels of DLL3 expression and at a clinically-relevant dose, as",40.0,192.52542,86.4915,5.7,5.8,5.6,0.017391743,-0.017699577,0.015193804,-0.004168579,0.0,0.00011,1.28474,2225,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ANNX,ANX007 - (ARCHER-II),Geographic atrophyÂ ,Phase 2,10/22/2024,"Phase 2 data from AAO reported that 0% (0/56) ANX007 monthly-treated patients with less advanced disease lost 15 letters, or three lines on an eye chart, vs. 17% (10/59) sham patients, and 6% (5/89) A",109.0,799.80049,78.8957,7.48,7.57,7.57,0.011960275,0.011960275,0.015193804,-0.004168579,8.22682,0.0773,5.10154,2226,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
BCTX,Bria-IMT - (BRIA-ABC),Advanced breast cancerÂ ,Phase 2,10/22/2024,"Phase 2 new survival data showing a 55% one-year survival rate with the Bria-IMT regimen, surpassing current SoC, noted October 22, 2024.",1.0,44.43928,141.308,119.42994,130.82993,124.84494,0.091168312,0.044342564,0.015193804,-0.004168579,0.0,0.0,5.55766,2227,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
MNPR,MNPR-101-Zr (uPAR),Solid tumorsÂ ,Phase 1,10/22/2024,"Phase 1 data presented at EANM reported favorable biodistribution, tumor uptake, and low off-target binding, noted October 22, 2024.",6.0,18.48192,128.1719,5.25,5.25,16.21,0.0,1.127400259,0.015193804,-0.004168579,3.19223,0.0236,0.20525,2228,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
GNLX,Olvimulogene Nanivacirepvec (Olvi-Vec) - (VIRO-25),Malignant pleural effusion (MPE) due to non-small cell lung cancer (NSCLC) or breast cancerÂ ,Phase 2,10/22/2024,"Phase 2 dosing commenced, noted October 22, 2024.",37.0,88.66556,128.1592,2.65,2.6,3.09,-0.019048195,0.153611451,0.015193804,-0.004168579,3.28066,0.01013,1.11352,2229,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
PFE,ABRYSVO - (MONeT),Respiratory syncytial virus (RSV)-associated lower respiratory tract disease (LRTD)Â ,Approved,10/22/2024,"FDA Approved on October 22, 2024.",0.0,163427.4857,23.0641,28.93,28.84,28.46,-0.003115807,-0.016379526,0.015193804,-0.004168579,1.19329,0.00078,837.40943,2230,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
ANRO,ALTO-100,Major depressive disorderÂ ,Phase 2b,10/22/2024,"Phase 2b study did not demonstrate improvement in depressive symptoms compared to placebo in patients with a memory-based cognitive biomarker, noted October 22, 2024.",27.0,391.71388,82.8185,14.29,14.53,4.01,0.016655486,-1.270768751,0.015193804,-0.004168579,15.26856,0.08361,24.71915,2231,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
RXRX,REC-3964,Difficile ColitisÂ ,Phase 2,10/22/2024,"Phase 2 dosing initiated, noted October 22, 2024.",434.0,1857.2003,71.7869,6.76,6.61,6.74,-0.022439236,-0.002962965,0.015193804,-0.004168579,22.27253,0.2161,18.79568,2232,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1
GYRE,Hydronidone (F351),Chronic hepatitis B (CHB)-associated liver fibrosis in the PRCÂ ,Phase 3,10/22/2024,"Phase 3 last patient completed, noted October 22, 2024.",96.0,1307.00433,87.2488,14.15,13.99,14.97,-0.011371835,0.056333574,0.015193804,-0.004168579,0.48949,0.10156,0.13712,2233,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
OKYO,Urcosimod (OK-101),Neuropathic corneal pain (NCP)Â ,Phase 2,10/23/2024,"Phase 2 initiated, noted October 23, 2024.",33.0,41.61867,96.9286,1.03,1.23,1.165,0.177455367,0.123162285,0.01043381,-0.001525243,0.61964,0.08539,1.24299,2234,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
GLUE,MRT-50969,CCNE1-amplified solid tumorsÂ ,Preclinical,10/23/2024,"Preclinical data from EORTC-NCI-AACR reported that treatment induced robust tumor growth suppression and regression, noted October 23, 2024.",61.0,298.85977,91.8041,5.31,4.87,9.22,-0.086497898,0.551783202,0.01043381,-0.001525243,7.13245,0.11693,0.81293,2235,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
RPTX,Lunresertib (RP-6306) + Debio 0123 - (MYTHIC),Solid TumorsÂ ,Phase 1,10/23/2024,"Phase 1 data reported that after 9 weeks on therapy, there was no observed impact on Progression Free Survival (PFS) in patients who started on or switched to the schedule of 2 weeks on / 1 week off o",42.0,145.58818,65.358,3.52,3.43,3.45,-0.025900728,-0.020086759,0.01043381,-0.001525243,1.67812,0.23552,0.26968,2236,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
SDGR,SGR-3515,Solid tumorsÂ ,Preclinical,10/23/2024,"Preclinical data presented at EORTC-NCI-AACR reported superior anti-tumor activity of SGR-3515 compared to inhibitors of Wee1 or Myt1 alone due to strong target engagement of both Wee1 and Myt1, noted",73.0,1319.07318,52.5808,18.68,18.12,17.58,-0.030437132,-0.060691541,0.01043381,-0.001525243,12.07283,0.20089,16.02283,2237,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
RVMD,Daraxonrasib (RMC-6236),Advanced Solid TumorsÂ ,Phase 1,10/23/2024,"Updated Phase 1 data from AACR-NCI-EORTC reported progression-free survival (PFS) and overall survival (OS) at daily doses ranging from 160 mg to 300 mg, noted October 23, 2024.",186.0,8103.05913,38.643,47.13,48.51,50.5,0.028860221,0.069063595,0.01043381,-0.001525243,9.78379,0.12358,125.22323,2238,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
GANX,GT-03842,OncologyÂ ,Preclinical,10/23/2024,"Presentation at ENA reported that GT-03842 and its analogues were found to inhibit DDR2 phosphorylation in a dose-dependent manner, noted October 23, 2024.",35.0,68.43503,116.9268,2.69,2.68,2.18,-0.003724399,-0.210216317,0.01043381,-0.001525243,2.56222,0.02924,0.5884,2239,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
COGT,CGT6297,Solid tumorsÂ ,Preclinical,10/23/2024,"Preclinical data presented at EORTC-NCI-AACR 2024 demonstrated robust inhibition of downstream signaling and efficacy, noted October 23, 2024.",139.0,1346.2407,60.039,12.24,12.3,12.01,0.004889985,-0.018969641,0.01043381,-0.001525243,7.58192,0.00095,10.27425,2240,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
OLMA,OP-3136,Breast CancerÂ ,Preclinical,10/23/2024,"Preclinical data presented at the EORTC-NCI-AACR demonstrated robust anti-tumor activity as a single agent, as well as synergy and enhanced anti-tumor activity in combination with palazestrant; IND su",68.0,681.56173,71.605,12.46,11.91,11.63,-0.04514513,-0.068935547,0.01043381,-0.001525243,14.8728,0.04439,6.8005,2241,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ORIC,ORIC-114,"Tumors - EGFR/HER2 Exon 20 Inhibitor, 1L NSCLCÂ ",Preclinical,10/23/2024,"Preclinical data presented at the EORTC-NCI-AACR 2024 demonstrated systemic and intracranial clinical responses in heavily pre-treated patients with EGFR and HER2 exon 20 insertion mutations, noted Oc",97.0,622.18464,71.0279,8.71,8.82,9.42,0.012550079,0.078363298,0.01043381,-0.001525243,17.38366,0.06252,7.75117,2242,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
APRE,APR-1051 - (ACESOT-1051),Solid tumorsÂ ,Phase 1,10/23/2024,"Phase 1 clinical efficacy and safety from EORTC-NCI-AACR reported that one patient had disease progression at 49 days, a second withdrew following 36 days of treatment and dosing is ongoing in the thi",5.0,21.18442,71.4722,4.18,3.9,4.01,-0.069334693,-0.041520005,0.01043381,-0.001525243,0.24222,0.05931,0.07627,2243,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CATX,[203/212Pb]Pb-PSV359,Solid TumorsÂ ,Preclinical,10/23/2024,"Preclinical findings presented at EANM demonstrated that drug exhibits strong binding affinity and selectivity for hFAP, noted October 23, 2024.",74.0,788.22943,79.419,12.39,11.69,11.47,-0.05815592,-0.077154764,0.01043381,-0.001525243,14.22178,0.00241,6.71654,2244,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
MAIA,MAIA-2021-020,Solid TumorsÂ ,Preclinical,10/23/2024,"Preclinical data shared at EORTC-NCI-AACR Symposium reported that MAIA-2022-12 and MAIA-2021-20 resulted in tumor growth inhibition in preclinical models of lung cancer, colorectal carcinoma, melanoma",32.0,63.59318,91.3313,2.7501,2.66,2.8,-0.033311152,0.017982143,0.01043381,-0.001525243,2.90092,0.0147,0.11466,2245,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
RNAZ,TTX-MC138,Metastatic solid tumorsÂ ,Preclinical,10/23/2024,"Phase 1 progressed to Cohort 2. The Safety Review Committee approved the move after a favorable safety assessment of Cohort 1, with no significant safety issues or dose-limiting toxicities observed, n",0.0,11.61931,253.5245,563.64036,621.85239,465.69629,0.098286361,-0.190882705,0.01043381,-0.001525243,8.00983,0.01098,1.79467,2246,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1
ZLAB,ZL-1310 (DLL3 ADC),"Solid tumors, relapsed and refractory second-line+ SCLCÂ ",Phase 1b,10/24/2024,"Phase 1a/1b trial preliminary data shared at the EORTC-NCI-AACR Symposium reported an objective response rate (ORR) of 74% across all tested dose levels, noted October 24, 2024.",109.0,3256.27903,63.2297,28.94,33.18,30.22,0.136722564,0.043279236,-0.004953059,-0.003717093,4.83903,0.05229,140.27718,2247,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
PTN,PL9643 - (MELODY-1),Dry eye disease (DED)Â ,Phase 3,10/24/2024,"Phase 3 data presentation reported that PL9643 has a positive effect across multiple regions of the eye in patients with moderate and severe dry eye disease (DED), with an excellent ocular safety/tole",46.0,104.79346,52.5033,0.064,0.064,0.069,0.0,0.075223421,-0.004953059,-0.003717093,0.0,0.05883,0.07627,2248,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
PTN,PL9654,Retinal diseasesÂ ,Preclinical,10/24/2024,"Preclinical data reported that PL9654 0.05 mg/kg causes a reduction in microglia and negative enrichment of genes associated with immune-related pathways, noted October 24, 2024.",46.0,104.79346,52.5033,0.064,0.064,0.069,0.0,0.075223421,-0.004953059,-0.003717093,0.0,0.05883,0.07627,2249,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
BBIO,BBP-812 - (CANaspire),Canavan DiseaseÂ ,Phase 1/2,10/24/2024,"Phase 1/2 preliminary data showed significant and sustained reductions in N-acetylaspartate (NAA) levels in urine, cerebrospinal fluid (CSF), and brain in all participants who received low dose, noted",191.0,4544.75128,53.2306,24.45,24.17,23.41,-0.011518021,-0.043466934,-0.004953059,-0.003717093,9.4557,0.06292,40.50034,2250,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
KURA,Ziftomenib and imatinib - (KOMET-015),Gastrointestinal Stromal Tumors (GIST)Â ,Preclinical,10/24/2024,"Preclinical data showed robust and durable antitumor activity in imatinib-sensitive (1L) and imatinib-resistant (2L/3L) GIST models, noted October 24, 2024.",86.0,1362.56134,38.1766,17.02,17.78,16.72,0.043685107,-0.017783515,-0.004953059,-0.003717093,12.12585,0.28331,27.73337,2251,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
RCUS,Casdatifan (AB521) + volrustomig,Clear cell renal cell carcinoma (ccRCC)Â ,Phase 2,10/24/2024,"Phase 2 first clinical data presented at EORTC-NCI-AACR reported an objective response rate of 34%, noted October 24, 2024.",107.0,1630.15241,55.1185,17.33,17.83,15.3,0.028443328,-0.124586275,-0.004953059,-0.003717093,6.93216,0.20296,34.68643,2252,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
PRLD,PRT3789 with KEYTRUDA (pembrolizumab) - (SMARCA2/BRM),"SMARCA4-deleted cancers, solid tumorsÂ ",Phase 1,10/24/2024,"Phase 1 data update shared at the EORTC-NCI-AACR reported confirmed partial responses (PRs) were observed in 4 patients (2 esophageal, 2 NSCLC), including 2 of 9 NSCLC patients with confirmed PRs at d",56.0,117.57755,133.328,1.64,1.55,1.2,-0.056441311,-0.312374685,-0.004953059,-0.003717093,3.28459,0.02296,0.53687,2253,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
MRK,PRT3789 with KEYTRUDA (pembrolizumab) - (SMARCA2/BRM),"SMARCA4-deleted cancers, solid tumorsÂ ",Phase 1,10/24/2024,"Phase 1 data update shared at the EORTC-NCI-AACR reported confirmed partial responses (PRs) were observed in 4 patients (2 esophageal, 2 NSCLC), including 2 of 9 NSCLC patients with confirmed PRs at d",0.0,268385.61,23.5447,106.38,105.88,102.32,-0.004711212,-0.038912432,-0.004953059,-0.003717093,1.02737,0.05257,878.37339,2254,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
VRCA,VP-315 (LTX-315),Basal cell carcinomaÂ ,Phase 2,10/24/2024,Phase 2 presented data at the Fall Clinical Dermatology Conference highlighting that approximately 51% of tumors treated in Part 2 achieved complete histological clearance and patients with residual t,9.0,64.00283,116.8493,15.1,15.0,14.0,-0.006644543,-0.075637414,-0.004953059,-0.003717093,10.62455,0.05797,0.48753,2255,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1
NRSN,PrimeC - (PARADIGM),Amyotrophic Lateral Sclerosis (ALS)Â ,Phase 2b,10/24/2024,"Phase 2b data presented at the NEALS meeting reported a 2-fold reduction of several miRNAs following PrimeC treatment, noted October 24, 2024.",23.0,23.55992,90.2988,1.15,1.21,1.25,0.050858417,0.083381609,-0.004953059,-0.003717093,1.21061,0.08246,0.378,2256,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
LEXX,DehydraTECH-powered GLP-1 drugs (semaglutide) - (WEIGHT-A24-1),DiabetesÂ ,Preclinical,10/24/2024,"Preclinical data reported that of the eight Study groups reported on today, DehydraTECH-CBD group B and the sole DehydraTECH-liraglutide group H were both successful in reducing blood sugar levels, wh",19.0,47.64558,87.8908,2.7,2.73,2.15,0.011049836,-0.227783931,-0.004953059,-0.003717093,1.5796,0.01561,0.19022,2257,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1
ERAS,Naporafenib plus trametinib - (SEACRAFT-1),RAS Q61X solid tumorsÂ ,Phase 1b,10/24/2024,"Phase 1b data from EORTC-NCI-AACR reported that 40% (4/10) response rate observed in the melanoma cohort, including three confirmed partial responses (cPR) and one unconfirmed partial response (uPR),",283.0,728.54132,70.4049,2.58,2.58,2.59,0.0,0.003868477,-0.004953059,-0.003717093,11.93473,0.07876,3.14512,2258,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
APGE,APG777 - (APEX),"Healthy volunteers, Atopic dermatitis (AD)Â ",Phase 1,10/24/2024,"Phase 1 9 month data reported that MAD cohorts showed similar inhibition of pSTAT6 through available follow-up. Single doses of APG777 suppressed TARC, an inflammatory mediator and the most strongly c",59.0,2944.57566,54.7374,51.43,51.95,52.04,0.010060058,0.011790994,-0.004953059,-0.003717093,12.11178,0.06891,13.31546,2259,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
REGN,Dupixent (dupilumab),Chronic spontaneous urticaria (CSU)Â ,Phase 3,10/24/2024,"Phase 3 data reported that dupixent significantly reduced itch and hive activity from baseline; 41% of patients achieved well-controlled disease status, noted October 24, 2024.",105.0,100260.384,21.0086,941.39,928.9,838.2,-0.013356416,-0.116100771,-0.004953059,-0.003717093,1.58978,0.17293,486.20948,2260,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1
SNY,Dupixent (dupilumab),Chronic spontaneous urticaria (CSU)Â ,Phase 3,10/24/2024,"Phase 3 data reported that dupixent significantly reduced itch and hive activity from baseline; 41% of patients achieved well-controlled disease status, noted October 24, 2024.",0.0,122349.8341,22.4395,52.89,52.05,52.88,-0.01600949,-0.00018909,-0.004953059,-0.003717093,0.0,0.0,172.09349,2261,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1
GSK,Arexvy (60+ at increased risk) - (AReSVi-006),"Respiratory Syncytial Virus Vaccine, AdjuvantedÂ ",Phase 3,10/24/2024,"Additional Phase 3 data reported that a single dose of vaccine elicited robust immune response with acceptable safety profile in adults aged 18-49 at increased risk for RSV-LRTD. noted October 24, 202",0.0,59369.66765,22.3779,14.48,14.555,13.925,0.00516619,-0.039082601,-0.004953059,-0.003717093,0.0,0.02581,95.3868,2262,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
PFE,"PREVNAR 20 + seasonal influenza vaccine (SIIV, Fluad Quadrivalent)",Pneumonia and influenza for >65 yrsÂ ,NDA Filing,10/24/2024,"ACIP voted to expand the recommendation, noted October 24, 2024.",0.0,162294.1466,23.0894,28.86,28.64,28.3,-0.007652211,-0.019594749,-0.004953059,-0.003717093,1.25195,0.00078,901.40353,2263,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
MRNS,Ganaxolone - (TrustTSC),Tuberous Sclerosis ComplexÂ ,Phase 3,10/24/2024,"Phase 3 study did not meet the primary endpoint of percent change in 28-day TSC-associated seizure frequency, noted October 24, 2024.",55.0,3146.95958,36.1322,42.0,42.0,42.47,0.0,0.011128326,-0.004953059,-0.003717093,0.0,0.05341,0.46145,2264,1,0,0,0,0,1,0,0,0,0,0,0,0,2,0,-1
LYEL,LYL845,Solid TumorsÂ ,Phase 1,10/24/2024,"Program discontinued, noted October 24, 2024.",19.0,279.04338,106.6589,23.0,21.8,19.206,-0.053584246,-0.180271486,-0.004953059,-0.003717093,4.20272,0.07407,3.21343,2265,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
NTLA,"Lonvoguran ziclumeran (lonvo-z, formerly NTLA-2002) - (HAELO)",Hereditary angioedema (HAE)Â ,Phase 2,10/24/2024,Phase 2 data presentation at ACAAI showed that deep attack rate reductions achieved in both dose levels tested; a single 50 mg dose resulted in a mean monthly attack rate reduction of 77% and 81% comp,107.0,1610.03013,63.3847,19.94,15.85,14.22,-0.229558264,-0.33807834,-0.004953059,-0.003717093,16.10642,0.33781,180.36815,2266,0,0,1,0,0,1,0,0,0,0,0,0,2,0,0,1
PHVS,Deucrictibant (PHVS416) - (CHAPTER-3),Hereditary angioedema - prophylactic useÂ ,Phase 2,10/24/2024,"Phase 2 data presented at ACAAI provided further evidence on the long-term safety and efficacy of deucrictibant for prevention of HAE attacks , noted October 24, 2024.",54.0,1151.98448,68.0411,22.21,21.33,24.87,-0.040428105,0.11311962,-0.004953059,-0.003717093,0.24397,0.06274,1.56121,2267,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
DTIL,PBGENE-PMM,Primary mitochondrial myopathiesÂ ,Preclinical,10/24/2024,"Preclinical data reported that targeted gene insertion can be achieved using ARCUS in greater than 85% of T cells and 39% of non-dividing primary human hepatocytes, noted October 24, 2024.",11.0,61.34229,44.8332,8.55,8.48,8.56,-0.008220833,0.001168907,-0.004953059,-0.003717093,2.96472,0.22886,0.72675,2268,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1
PROK,RMCL-002 - (REACT),"Type 2 diabetes, prevent/delay CKDÂ ",Phase 2,10/24/2024,Phase 2 interim results presented at Kidney Week reported that six SAEs in 51 patients were related to the kidney biopsy procedure and one SAE was related to the injection procedure. No product relate,294.0,217.43864,121.6323,1.7,1.725,1.6,0.014598799,-0.060624622,-0.004953059,-0.003717093,8.51685,0.01285,0.43113,2269,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
EYPT,DURAVYU (EYP-1901) - (LUGANO),Wet age-related macular degeneration (AMD)Â ,Phase 3,10/24/2024,"Phase 3 trial dosing was initiated based on DAVIO-2 study results, noted October 24, 2024.",68.0,511.63409,108.4392,9.96,9.56,11.76,-0.040989345,0.166126871,-0.004953059,-0.003717093,17.13697,0.01884,2.68936,2270,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
RXRX,EXS73565 (â€˜565),Haematological cancersÂ ,Preclinical,10/24/2024,"Preclinical data from the EORTC-NCI-AACR (ENA) reported that combining â€˜565 with zanu in models of B-cell malignancies provided deeper, more durable efficacy than either agent alone, including in ABC-",434.0,1786.95824,71.8628,6.33,6.36,6.32,0.004728141,-0.001581028,-0.004953059,-0.003717093,21.15415,0.2161,18.66331,2271,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
EXAI,EXS73565 (â€˜565),Haematological cancersÂ ,Preclinical,10/24/2024,"Preclinical data from the EORTC-NCI-AACR (ENA) reported that combining â€˜565 with zanu in models of B-cell malignancies provided deeper, more durable efficacy than either agent alone, including in ABC-",125.0,134.68206,43.3627,1.366,1.384,1.346,0.013091096,-0.01474953,-0.004953059,-0.003717093,0.0,0.00404,0.13298,2272,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
GILD,IDE397 + Trodelvy (sacituzumab-govitecan-hziy),MTAP-Deletion Bladder CancerÂ ,Phase 1,10/25/2024,"Phase 1 trial presentation at EORTC-NCI-AACR reported an 33% ORR by RECIST 1.1: 1 CR + 8 PRs out of 27 evaluable heavily pre-treated (median 2-3 prior lines, ranging from 1-7) MTAP-deletion UC and NSC",0.0,110804.2952,22.7336,88.78,89.0,89.51,0.00247497,0.008188951,-0.012670038,-0.020558428,1.32391,0.02712,510.41456,2273,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
IDYA,IDE397 + Trodelvy (sacituzumab-govitecan-hziy),MTAP-Deletion Bladder CancerÂ ,Phase 1,10/25/2024,"Phase 1 trial presentation at EORTC-NCI-AACR reported an 33% ORR by RECIST 1.1: 1 CR + 8 PRs out of 27 evaluable heavily pre-treated (median 2-3 prior lines, ranging from 1-7) MTAP-deletion UC and NSC",87.0,2475.30777,48.5647,29.2,29.3,28.6,0.003418807,-0.020761991,-0.012670038,-0.020558428,11.37237,0.27874,29.71723,2274,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ZYME,ZW220,"NSCLC, ovarian and uterine cancerÂ ",Preclinical,10/25/2024,"Preclinical data presented at EORTC-NCI-AACR reported a strong anti-tumor activity across a wide range of hepatocellular carcinoma (HCC) models, including those with lower and heterogenous GPC3 expres",75.0,918.64275,35.6041,12.92,12.93,13.28,0.000773694,0.027482646,-0.012670038,-0.020558428,5.86041,0.13112,3.28167,2275,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
TYRA,TYRA-300 - (SURF301),Bladder and solid tumorsÂ ,Phase 1/2,10/25/2024,"Phase 1/2 trial dosing initiated, noted November 29, 2022. Phase 1/2 data presented at EORTC-NCI-AACR reported that 6 out of 11 (54.5%) patients with FGFR3+ mUC achieved a confirmed partial response",53.0,1158.03858,70.4508,28.61,21.93,16.39,-0.265900745,-0.557084914,-0.012670038,-0.020558428,4.165,0.15915,54.44087,2276,0,0,0,0,0,1,0,0,0,0,1,0,3,0,0,1
PPBT,IM1240 - (CAPTN-3),CancerÂ ,Preclinical,10/25/2024,Preclinical data presented at EORTC-NCI-AACR reported sustained tumor regression in a triple negative breast cancer in-vivo model; A dose dependent activity and a synergistic effect of the engager arm,2.0,29.35465,90.8744,0.081,0.081,0.062,0.0,-0.26731477,-0.012670038,-0.020558428,0.0,0.00975,0.0,2277,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ANIP,"Estradiol Gel, 0.06% - (generic version of EstroGel Gel, 0.06%)",Hot flashes and to treat moderate to severe menopausal changesÂ ,Approved,10/25/2024,"Approved October 25, 2025.",21.0,1138.29378,39.0383,59.28,58.32,58.19,-0.016326893,-0.018558462,-0.012670038,-0.020558428,10.49602,0.04312,9.06649,2278,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1
AQST,Anaphylm (AQST-109) - (EPIPHAST II),Allergic reactions (anaphylaxis)Â ,Phase 2,10/25/2024,"Trial PK and PD data reported that 87.5% of subjects showing no change in film location between 1.5 to 3 minutes after administration of Anaphylm, noted October 25, 2024.",99.0,499.91808,70.8888,5.48,5.49,5.52,0.001823155,0.007272759,-0.012670038,-0.020558428,11.85041,0.00533,8.53072,2279,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
JNJ,TREMFYA (guselkumab) - (SPECTREM),Plaque psoriasis (PsO)Â ,Phase 3,10/25/2024,"Phase 3b data reported statistical significance across all primary and secondary endpoints in low body surface area psoriasis with special site involvement, noted October 25, 2024.",0.0,387338.3837,16.8296,163.67,160.88,160.13,-0.01719346,-0.02186622,-0.012670038,-0.020558428,0.77501,0.02418,1029.70424,2280,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ITRM,ORLYNVAH (Oral Sulopenem),Uncomplicated urinary tract infections (uUTI)Â ,Approved,10/25/2024,"Approved October 25, 2024.",44.0,42.68727,99.6782,1.17,1.88,1.22,0.474268028,0.04184711,-0.012670038,-0.020558428,0.94188,0.02634,196.53692,2281,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1
VRTX,Povetacicept (ALPN-303) - (RAINIER),"Lupus nephritis, IgA nephropathyÂ ",Phase 1/2,10/25/2024,"Phase 1b/2a new data on 80 mg SC Q4 weeks in IgA nephropathy showed mean UPCR reduction from baseline of 66% observed at 48 weeks, associated with stable renal function (eGFR) and 63% achieving clinic",256.0,123295.4224,20.1374,471.91,477.7,471.12,0.012194631,-0.001675451,-0.012670038,-0.020558428,1.66269,0.19003,487.11165,2282,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ALPN,Povetacicept (ALPN-303) - (RAINIER),"Lupus nephritis, IgA nephropathyÂ ",Phase 1/2,10/25/2024,"Phase 1b/2a new data on 80 mg SC Q4 weeks in IgA nephropathy showed mean UPCR reduction from baseline of 66% observed at 48 weeks, associated with stable renal function (eGFR) and 63% achieving clinic",68.0,66.19524,20.4773,7.6,7.6,7.8,0.0,0.025975486,-0.012670038,-0.020558428,0.0,0.06131,0.0,2283,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
IRON,DISC-0974,Patients with non-dialysis dependent chronic kidney disease (NDD-CKD) and anemiaÂ ,Phase 1/2,10/25/2024,"Phase 1b/2 data presented at ASN demonstrated that a single dose results in sustained suppression of hepcidin and mobilization of iron, and increased erythropoiesis and levels of hemoglobin in NDD-CKD",34.0,1367.68236,51.6969,46.0,46.01,47.13,0.000217368,0.024268344,-0.012670038,-0.020558428,4.97094,0.12263,18.8509,2284,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
KALV,Sebetralstat - (KONFIDENT-S),Hereditary angioedema (HAE)Â ,Phase 3,10/25/2024,"Phase 3 data presented at ACAAI reported that patients treated with sebetralstat 300mg (n=49, P=0.002) and sebetralstat 600mg (n=52, P=0.034) achieved a faster reduction in substantial symptom burden",50.0,504.75671,59.3354,12.07,11.68,10.61,-0.032845058,-0.128926082,-0.012670038,-0.020558428,15.75893,0.03311,1.39144,2285,0,1,0,0,1,1,0,0,0,0,0,0,3,0,0,1
NVCT,NXP900,Non-small cell lung cancer (NSCLC)Â ,Phase 1,10/25/2024,"Data reported at AACR-NCI-EORT noted that NXP900 as a single agent potently inhibits cell proliferation of ALK fusion driven cell lines that are resistant to crizotinib, alectinib and lorlatinib, note",25.0,163.39755,70.0429,8.75,8.76,6.41,0.001142205,-0.311194429,-0.012670038,-0.020558428,5.61216,0.00286,0.79798,2286,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ATXS,Navenibart (STAR-0215) - (ALPHA-ORBIT),"Hereditary angioedema (HAE), healthy volunteersÂ ",Phase 1/2,10/25/2024,Phase 1b/2 data presented at the ACAAI reported rapid inhibition of plasma kallikrein was associated with reductions in HAE attacks and with a favorable safety profile during the first 28 days of the,56.0,647.19799,58.7203,11.68,11.47,11.32,-0.018143046,-0.031306905,-0.012670038,-0.020558428,6.19255,0.08349,1.86798,2287,0,0,0,1,0,1,0,0,0,0,0,0,2,0,0,1
RVMD,RMC-9805,"Pancreatic cancer, non-small cell lung cancer (NSCLC), and colorectal cancer.Â ",Phase 1,10/25/2024,"Phase 1 preliminary safety data presented at AACR-NCI-EORTC reported acceptable tolerability and encouraging initial antitumor activity, with durability assessment pending longer follow-up, noted Octo",186.0,7753.94773,38.8185,47.25,46.42,55.09,-0.017722253,0.153515558,-0.012670038,-0.020558428,9.97546,0.07546,96.68061,2288,0,0,0,1,0,1,0,0,0,0,1,0,3,0,0,1
KURA,KO-2806 - (FIT-001),Solid TumorsÂ ,Preclinical,10/25/2024,"Preclinical and clinical data presented at EORTC-NCI-AACR showed improved tumor growth inhibition compared to the combinations with a SHP2 or SOS1 inhibitors, noted October 25, 2024.",86.0,1341.87003,38.1845,17.78,17.51,16.88,-0.015302084,-0.051944741,-0.012670038,-0.020558428,12.12585,0.26813,10.21596,2289,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ZYME,ZW251,Hepatocellular carcinomaÂ ,Preclinical,10/25/2024,"Preclinical data presented at EORTC-NCI-AACR reported a strong anti-tumor activity in models with a breadth of NaPi2b expression, noted October 25, 2024.",75.0,918.64275,35.6041,12.92,12.93,13.28,0.000773694,0.027482646,-0.012670038,-0.020558428,5.86041,0.13112,3.28167,2290,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
NKGN,Troculeucel (SNK01),Alzheimer's DiseaseÂ ,Phase 1/2,10/25/2024,"Phase 1/2a data from WSC 2024 reported that treatment appears to cross the BBB to reduce neuroinflammation noted October 25, 2024.",124.0,14.37806,204.1598,0.3871,0.3992,0.2672,0.030779487,-0.370685616,-0.012670038,-0.020558428,1.19949,0.01037,0.39769,2291,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
VERA,Atacicept - (ORIGIN 3),IgA NephropathyÂ ,Phase 2b,10/26/2024,"Phase 2b 96-week data presented at Kidney Week reported that -66% reduction in galactose-deficient IgA1 (Gd-IgA1), resolution of hematuria in 75% of participants, a -52% reduction in proteinuria, and",63.0,2252.86876,47.246,41.09,41.09,43.82,0.0,0.064325551,-0.013698844,-0.021587235,11.28951,0.02891,0.0,2292,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
BIIB,Felzartamab - (PREVAIL),IgA nephropathy (IgAN)Â ,Phase 2,10/26/2024,"Phase 2 trial final results presented at ASN reported that patients maintained a mean reduction of approximately 50% in the UPCR through month 24, which was more than 18 months after the last dose was",146.0,26465.26374,25.918,181.69,181.69,173.79,0.0,-0.044454264,-0.013698844,-0.021587235,2.10575,0.14976,0.0,2293,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CLDX,Barzolvolimab - (CindU),"Chronic inducible urticaria (CIndU), cold urticaria (ColdU) and symptomatic dermographism (SD), Chronic Spontaneous Urticaria (CSU)Â ",Phase 2,10/26/2024,"Phase 2 efficacy and safety data from ACAAI reported that trial met all primary end secondary endpoints, noted October 26, 2024.",66.0,1786.45071,54.6283,26.95,26.95,25.68,0.0,-0.048270819,-0.013698844,-0.021587235,12.66806,0.0593,0.0,2294,1,0,0,1,0,1,0,0,1,0,0,0,4,0,0,1
APLS,EMPAVELI (pegcetacoplan) - (VALIANT),C3G and IC-MPGNÂ ,Phase 3,10/26/2024,"Phase 3 study results presented at ASN Kidney Week reported a statistically significant 68% (p<0.0001) proteinuria reduction compared to placebo, with reduction observed as early as Week 4, noted Octo",126.0,3248.72563,54.6457,26.68,26.68,27.98,0.0,0.047575748,-0.013698844,-0.021587235,17.31847,0.00224,0.0,2295,0,1,1,0,0,1,0,0,0,0,0,0,3,0,0,1
LGVN,Laromestrocel (lomecel-B) - (ELPIS II),Hypoplastic Left Heart SyndromeÂ ,Phase 2b,10/27/2024,Phase 2b long term survival data shared at the Congenital Heart Surgeons' Society (CHSS) reported a 5-year survival after stage 2 Glenn surgery of 100% with none requiring heart transplant; this comp,15.0,31.73445,184.3703,2.21,2.21,2.03,0.0,-0.084956722,-0.013698844,-0.021587235,4.13603,0.01152,0.0,2296,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
HUMA,ATEV - (V007),Acellular tissue engineered vessel (ATEV) in arteriovenous access for patients with end-stage renal disease.Â ,Phase 3,10/28/2024,"Phase 3 detailed results presented at ASN showed superior patency and function over the standard autogenous fistula at six and 12 months, noted October 28, 2024.",158.0,677.67855,106.2968,5.59,5.42,5.07,-0.030883472,-0.09763847,-0.014409324,-0.021083431,13.33676,0.00213,14.72295,2297,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
UNCY,UNI-494,Acute kidney injury (AKI)Â ,Preclinical,10/28/2024,"Preclinical data and Phase 1 presented at the American Society of Nephrology (ASN) Kidney Week indicated therapeutic administration of UNI-494 slows down and may even halt or reverse AKI progression,",17.0,47.08375,124.0451,4.15,4.99,4.799,0.184327576,0.145299229,-0.014409324,-0.021083431,1.10764,0.00667,2.01627,2298,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
EYPT,EYP-1901 - (VERONA),Diabetic macular edema (DME)Â ,Phase 2,10/28/2024,"Phase 2 interim data demonstrated that the 2.7mg dose showed a +8.9-letter improvement in best-corrected visual acuity (BCVA) and a 68-micron reduction in CST, outperforming the aflibercept control. T",68.0,648.64071,113.9258,9.5,12.12,11.7,0.243565182,0.208297043,-0.014409324,-0.021083431,17.13697,0.01478,55.33904,2299,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
BCLI,NurOwn,Amytrophic lateral sclerosis (ALS)Â ,Phase 3,10/28/2024,"Phase 3 expanded access data reported a statistically significant difference in favor of debamestrocel (LRT, p= 0.0379) with a median survival time of 46.6 months for the debamestrocel group compared",10.0,10.73753,110.8521,1.9596,2.02,1.8,0.030357141,-0.084953706,-0.014409324,-0.021083431,3.12085,0.16001,0.21246,2300,0,1,0,0,0,1,0,0,0,0,0,0,2,0,0,1
PLUR,NurOwn,Amytrophic lateral sclerosis (ALS)Â ,Phase 3,10/28/2024,"Phase 3 expanded access data reported a statistically significant difference in favor of debamestrocel (LRT, p= 0.0379) with a median survival time of 46.6 months for the debamestrocel group compared",8.0,23.6311,67.3439,4.37,4.32,4.5601,-0.011507607,0.042581544,-0.014409324,-0.021083431,0.0421,0.01735,0.04834,2301,0,1,0,0,0,1,0,0,0,0,0,0,2,0,0,1
IRWD,Apraglutide - (STARS),Short Bowel Syndrome with Intestinal Failure (SBS-IF)Â ,Phase 3,10/28/2024,"New Phase 3 data demonstrated a steady treatment effect across patient demographics and SBS characteristics. Safety results showed high treatment compliance and low rates of adverse events, noted Octo",162.0,662.91685,84.0106,3.96,4.15,4.19,0.046864309,0.056456709,-0.014409324,-0.021083431,7.46931,0.02384,4.37745,2302,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
TYRA,TYRA-300 - (BEACH301),AchondroplasiaÂ ,IND-Enabling,10/28/2024,"IND cleared by the FDA, noted October 28, 2024.",53.0,1050.31407,71.6683,21.93,19.89,16.42,-0.09763847,-0.289355458,-0.014409324,-0.021083431,4.165,0.15915,23.87096,2303,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
MIRA,Ketamir-2 (Topical),"Neuropathic pain and chemo-induced depression, as well as neuropathic pain and PTSDÂ ",Preclinical,10/28/2024,"Preclinical data reported that on Day 9, at the optimal dose of 300 mg/kg, Ketamir-2 led to near-complete normalization of pain sensitivity, outperforming FDA-approved gabapentin by 60%, which provide",19.0,25.53785,317.831,1.29,1.57,1.85,0.196433401,0.360543421,-0.014409324,-0.021083431,2.10607,0.01088,36.56714,2304,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1
AGIO,Mitapivat (AG-348) - (RISE UP),Sickle cell diseaseÂ ,Phase 3,10/28/2024,"Phase 3 portion of the study enrollment completed, noted October 23, 2024.",58.0,2621.63543,55.03,45.09,46.08,44.83,0.021718524,-0.005782934,-0.014409324,-0.021083431,7.22073,0.09075,23.18082,2305,0,0,0,0,0,1,0,0,0,1,0,0,2,0,0,1
CADL,CAN-3110,GliomaÂ ,Phase 1b,10/28/2024,"Phase 1b data presented at IOVC showed improved survival and immune activation, with 3 out of 6 patients surviving over a year post-treatment, noted October 28, 2024.",54.0,176.78712,101.8016,5.6,5.51,5.19,-0.016201975,-0.076032901,-0.014409324,-0.021083431,5.11279,0.00548,2.31203,2306,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
JNJ,TREMFYA (guselkumab),Ulcerative Colitis Subcutaneous Induction (ASTRO) Crohn's Disease Subcutaneous InductionÂ ,Phase 3,10/28/2024,Phase 3 results reported that a greater number of patients treated with subcutaneous TREMFYA induction and maintenance achieved clinical and endoscopic remission at 48 weeks in the Phase 3 GRAVITI stu,0.0,389071.8723,16.8802,160.88,161.6,158.24,0.004465401,-0.016545878,-0.014409324,-0.021083431,0.77501,0.02418,782.57273,2307,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1
LLY,Mirikizumab - (LUCENT-3),Ulcerative colitis (UC)Â ,Phase 3,10/28/2024,"Phase 3 data reported that 81% of patients maintained long-term clinical remission and 82% achieved long-term endoscopic remission, noted October 28, 2024.",946.0,806412.3225,30.9302,892.7,895.59,806.14,0.003232141,-0.101993153,-0.014409324,-0.021083431,0.64267,0.11018,1866.50091,2308,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1
LLY,Mirikizumab - (VIVID-2),Crohn's diseaseÂ ,Phase 2,10/28/2024,"Phase 2 data reported that 96% of patients had clinical response as measured by the Crohn's Disease Activity Index (CDAI) and 87% were in clinical remission as measured by CDAI, noted October 28, 2024",946.0,806412.3225,30.9302,892.7,895.59,806.14,0.003232141,-0.101993153,-0.014409324,-0.021083431,0.64267,0.11018,1866.50091,2309,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
NVS,Fabhalta (iptacopan),C3 glomerulopathy (C3G)Â ,Phase 3,10/28/2024,"Phase 3 data reported that Fabhalta sustained proteinuria reduction at 12 months, noted October 28, 2024.",0.0,2455.01871,52.4511,7.81,7.89,7.62,0.010191171,-0.024628594,-0.014409324,-0.021083431,0.0,0.01853,0.58903,2310,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
SHPH,Ropidoxuridine,GlioblastomaÂ ,Phase 2,10/28/2024,"Phase 2 study engaged all six of the planned clinical trial site locations to administer the clinical trial, noted October 28, 2024.",1.0,2.96184,99.7177,31.25,33.25,40.0,0.062035391,0.246860078,-0.014409324,-0.021083431,1.51333,0.01135,10.60695,2311,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
GNPX,REQORSA (GPX-001) with KEYTRUDA (pembrolizumab) - (Acclaim-2),Non-Small Cell Lung Cancer (NSCLC)Â ,Preclinical,10/28/2024,"Preclinical data presented at EORTC-NCI-AACR demonstrated Reqorsaâ€™s potential effectiveness across these challenging cancer types, expanding its applicability beyond KRAS G12C mutant lung cancer, not",0.0,9.85989,254.9033,99.0,137.0,101.0,0.324861076,0.020000667,-0.014409324,-0.021083431,2.36815,0.00533,51.54255,2312,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
THAR,TH104 (AV104),Primary biliary cholangitis (PBC)Â ,Phase 1,10/28/2024,"Phase 1 results presented at ACG Meeting showed no opioid withdrawal effects, reinforcing safety profile, noted October 28, 2024.",4.0,2.27455,105.8588,1.95,1.98,2.95,0.015267472,0.413975798,-0.014409324,-0.021083431,1.54053,0.00056,0.08174,2313,0,0,0,1,0,1,0,0,0,0,0,0,0,2,0,-1
BCDA,CardiAMP (Heart Failure II),Ischemic heart failure of reduced ejection fraction (HFrEF)Â ,Phase 3,10/28/2024,"Phase 3 completed, noted October 28, 2024.",5.0,9.20991,138.9315,2.42,2.63,2.38,0.083216306,-0.016667052,-0.014409324,-0.021083431,1.42655,0.12702,0.59182,2314,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
COYA,Low Dose Interleukin-2 (LD IL-2) - (COYA 301),Alzheimerâ€™s Disease (AD)Â ,Phase 2,10/29/2024,"Phase 2 trial met primary and secondary endpoints, noted October 29, 2024.",16.0,112.18104,84.5166,10.19,7.37,6.74,-0.323989141,-0.413346922,0.000710985,-0.021396025,1.22253,0.05633,6.70266,2315,1,0,0,0,0,1,0,0,1,0,0,0,3,0,0,1
ZLAB,Xanomeline-Trospium (KarXT) (ZL-2701-001) - (China Bridging Trial),SchizophreniaÂ ,Phase 3,10/29/2024,"Phase 3 trial demonstrated a statistically significant 9.2-point reduction in PANSS Total score from baseline at Week 5 compared to placebo, noted October 29, 2024.",109.0,3084.53435,63.614,32.54,31.43,30.92,-0.034707251,-0.051066878,0.000710985,-0.021396025,4.83903,0.03065,25.07881,2316,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1
ABEO,ZEVASKYN (prademagene zamikeracel),Recessive dystrophic epidermolysis bullosa (RDEB)Â ,BLA Filing,10/29/2024,"BLA resubmitted on October 29, 2024.",51.0,284.57559,60.6035,6.39,6.57,6.21,0.027779564,-0.028573372,0.000710985,-0.021396025,6.39391,0.00224,3.28917,2317,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
SGMT,Denifanstat - (FASCINATE-3),Nonalcoholic steatohepatitis (NASH)Â ,Phase 2b,10/29/2024,"Phase 2b completed and Phase 3 expected to commenced by year end 2024, noted October 29, 2024.",32.0,186.05796,99.3698,5.99,5.83,5.81,-0.027074412,-0.030510841,0.000710985,-0.021396025,12.47934,0.09099,3.38002,2318,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
IVVD,PEMGARDA (VYD222 (pemivibart)) - (CANOPY),COVID-19 PreventionÂ ,Phase 3,10/29/2024,"Phase 3 study following strong protection (84% relative risk reduction versus placebo) demonstrated through month 6 with pemivibart, CANOPY clinical trial participants were followed for an additional",120.0,108.32253,107.8005,1.04,0.9069,0.9235,-0.136943802,-0.118805192,0.000710985,-0.021396025,5.97937,0.04539,0.90449,2319,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
NKGN,Troculeucel (SNK01),Alzheimer's DiseaseÂ ,Phase 1/2,10/29/2024,Phase 1/2a study Six-month interim data shared at the 17th Annual Clinical Trials on Alzheimer's Disease Conference (CTAD) newly analyzed biomarker data from the initial dose-escalation Phase 1 AD tri,124.0,11.19774,203.5084,0.35,0.3109,0.259,-0.118461837,-0.301105093,0.000710985,-0.021396025,1.19949,0.01037,0.90128,2320,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
IMNM,IM-1021,Advanced B-cell lymphomas and advanced solid tumorsÂ ,Preclinical,10/29/2024,"Preclinical data reported that IM-1021 showed superior efficacy compared to zilovertamab vedotin in both the Jeko-1 mantle cell lymphoma model and the MDA-MB-468 triple negative breast cancer model, n",87.0,737.85154,63.0289,12.43,12.2,12.97,-0.018676954,0.042526093,0.000710985,-0.021396025,18.06291,0.06285,4.64836,2321,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
LGVN,Laromestrocel (lomecel-B) - (CLEAR MIND),Alzheimer's DiseaseÂ ,Phase 2a,10/29/2024,Phase 2a data presented at CTAD in late breaking presentation showed that that Lomecel-B's ability to inhibit MMP14 activity correlates with improved clinical and biomarker outcomes in Alzheimer's pat,15.0,31.44726,184.2027,2.18,2.19,2.25,0.004576667,0.031605339,0.000710985,-0.021396025,4.13603,0.01152,2.1277,2322,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1
JAGX,Mytesi (crofelemer) - (OnTarget),Cancer Therapy-Related DiarrheaÂ ,Phase 3,10/29/2024,"Additional data from pilot study on functional diarrhea, crofelemer significantly improved stool consistency and reduced abdominal pain without causing constipation, marking it as a potentially effect",2.0,9.98052,176.2322,28.25,27.0,26.0,-0.045256592,-0.08299692,0.000710985,-0.021396025,1.50858,0.00077,0.62324,2323,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
NVS,Scemblix - (ASC4FIRST),1L Chronic myeloid leukemia (CML)Â ,Approved,10/29/2024,"FDA Approved on October 29, 2024.",0.0,2473.68805,52.2424,7.89,7.95,7.79,0.007575794,-0.012755275,0.000710985,-0.021396025,0.0,0.01853,0.42098,2324,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
CGTX,Zervimesine (CT1812) - (SHINE),Mild-to-Moderate Alzheimer's DiseaseÂ ,Phase 2,10/29/2024,"Phase 2 results presented at CTAD showed a significant slowdown in cognitive decline, particularly in participants with lower plasma p-tau217 levels, an Alzheimerâ€™s biomarker, noted October 29, 2024.",73.0,22.87579,129.5554,0.5421,0.57,0.4882,0.050185875,-0.104725328,0.000710985,-0.021396025,1.22267,0.09294,0.54111,2325,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1
SPRO,SPR720,Nontuberculous mycobacterial (NTM) pulmonary disease (PD)Â ,Phase 2,10/29/2024,"Phase 2 study did not meet its primary endpoint, based on the planned interim analysis of 16 patients; current development was suspended, noted on October 29, 2024.",56.0,70.80437,40.9831,1.29,1.31,1.31,0.015384919,0.015384919,0.000710985,-0.021396025,0.71614,0.09637,1.18046,2326,1,0,0,0,1,1,0,0,0,0,0,0,0,3,0,-1
CALC,Auxora - (CARPO),Acute PancreatitisÂ ,Phase 2b,10/30/2024,Phase 2 full results presented at ACG showed high and medium doses of Auxora led to a 100% reduction in severe respiratory failure and a 64.2% reduction in persistent respiratory failure compared to l,13.0,51.60075,104.4896,3.93,4.8,3.5,0.199976492,-0.115876457,0.015645291,-0.038611762,0.31774,2e-05,1.41437,2327,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
LXEO,LX1001 - (LEAD),Alzheimerâ€™s diseaseÂ ,Phase 1/2,10/30/2024,"Phase 1/2 interim data from CTAD reported a dose-dependent increase in neuroprotective APOE2 expression in all participants with ongoing durability at 12 months, noted October 30, 2024.",54.0,273.57981,90.9439,9.97,8.275,8.2,-0.186341663,-0.19544643,0.015645291,-0.038611762,6.22649,0.03627,9.50734,2328,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
PMN,PMN310 - (PRECISE-AD),Alzheimer's disease (AD)Â ,Phase 1a,10/30/2024,"Phase 1a topline data from 5 cohorts reported that generally well tolerated and achieved concentrations in the cerebrospinal fluid indicating its potential for target engagement in AD patients, noted",53.0,32.57514,89.8893,1.03,1.09,1.03,0.056618894,0.0,0.015645291,-0.038611762,0.46099,0.02003,0.32653,2329,0,0,0,1,0,0,0,0,0,0,1,0,2,0,0,1
MLYS,Lorundrostat - (Launch-HTN),Uncontrolled hypertension (uHTN) or resistant hypertension (rHTN).Â ,Phase 3,10/30/2024,"Phase 3 enrollment completed, noted October 30, 2024.",66.0,685.23358,59.4571,13.96,13.78,14.95,-0.012977832,0.068515203,0.015645291,-0.038611762,3.24408,0.12272,5.6081,2330,0,0,0,0,0,1,0,0,0,1,0,0,2,0,0,1
TLSA,Foralumab + Ozempic (semaglutide),ObesityÂ ,Preclinical,10/30/2024,"Preclinical data reported that nasal anti-CD3 in combination with semaglutide demonstrated synergistic effects in promoting liver homeostasis in preclinical models of diet-induced obesity, noted Octob",111.0,122.51084,106.7601,1.02,1.18,0.898,0.145711811,-0.127387838,0.015645291,-0.038611762,0.05176,0.05447,3.60078,2331,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
NVO,Foralumab + Ozempic (semaglutide),ObesityÂ ,Preclinical,10/30/2024,"Preclinical data reported that nasal anti-CD3 in combination with semaglutide demonstrated synergistic effects in promoting liver homeostasis in preclinical models of diet-induced obesity, noted Octob",0.0,3418959.512,32.026,111.98,113.24,105.36,0.011189176,-0.060937226,0.015645291,-0.038611762,0.0,0.0,1258.01056,2332,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
BMEA,Icovamenib (BMF-219) with a GLP-1-Based Therapy - (COVALENT-211),Diabetes and obesityÂ ,Preclinical,10/30/2024,"Preclinical data reported that pretreatment improved insulin secretion, approximately doubling the effect-size depending on the dose, noted October 30, 2024.",59.0,374.70802,164.6503,12.06,10.34,8.88,-0.153874322,-0.306092634,0.015645291,-0.038611762,22.59277,0.00573,9.44104,2333,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
BMEA,BMF-650,ObesityÂ ,Preclinical,10/30/2024,"Preclinical data reported a higher bioavailability and a less variable pharmacokinetic profile, with significant improvements in glucose stimulated insulin secretion, noted October 30, 2024.",59.0,374.70802,164.6503,12.06,10.34,8.88,-0.153874322,-0.306092634,0.015645291,-0.038611762,22.59277,0.00573,9.44104,2334,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CORT,Relacorilant - (GRADIENT),Cushingâ€™s syndromeÂ ,Phase 3,10/30/2024,"Phase 3 data reported statistically significant improvements in mean SBP at 22 weeks, noted October 30, 2024.",105.0,4912.90617,44.1976,48.21,46.89,54.23,-0.027762035,0.117667792,0.015645291,-0.038611762,19.73326,0.03215,66.88432,2335,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1
NRIX,NX-5948,B-cell malignancies / graft-versus-host diseaseÂ ,Preclinical,10/30/2024,"Preclinical data reported that clinical activity in patients with CLL with 69.2% ORR and all responses ongoing as of April 17, 2024:, noted October 30, 2024.",76.0,1705.02931,65.1398,25.2,24.07,27.0,-0.045877743,0.068992871,0.015645291,-0.038611762,13.04496,0.13259,18.34252,2336,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
VINC,VIP236,Solid tumorsÂ ,Phase 1,10/31/2024,"Phase 1 data reported a 45% disease control rate, noted October 2024.",5.0,10.77743,105.7118,7.0,6.98,6.444,-0.002861232,-0.082760684,-0.008599375,-0.045582035,2.71133,0.02236,0.10462,2337,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
MTNB,MAT2203 - (ORALTO),Invasive aspergillosisÂ ,Phase 3,10/31/2024,"Trial development ceased as company non-bidding term-sheet terminated following notification from the prospective partner, company looking for potential asset sale to avoid wind-down or dissolution, n",5.0,3.11012,181.0056,1.93,0.62,0.555,-1.135555804,-1.246307168,-0.008599375,-0.045582035,1.60345,0.09104,1.92383,2338,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,-1
MTNB,Oral amphotericin b (MAT2203) - (EnACT),Cryptococcal meningitisÂ ,Phase 3,10/31/2024,"Trial development ceased as company non-bidding term-sheet terminated following notification from the prospective partner, company looking for potential asset sale to avoid wind-down or dissolution, n",5.0,3.11012,181.0056,1.93,0.62,0.555,-1.135555804,-1.246307168,-0.008599375,-0.045582035,1.60345,0.09104,1.92383,2339,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,-1
KYMR,KT-621 (STAT6),Type 2 inflammation in allergic diseasesÂ ,Phase 1,10/31/2024,"Phase 1 clinical trial initiated, noted October 31, 2024.",71.0,2990.2127,61.4842,47.67,46.17,49.86,-0.031972033,0.044916809,-0.008599375,-0.045582035,13.99943,0.19531,34.5269,2340,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
AVXL,Blarcamesine (ANAVEX2-73-AD-004) - (ATTENTION-AD),Mild to moderate Alzheimerâ€™s diseaseÂ ,Phase 2/3,10/31/2024,"Phase 2b/3 data confirmed the mechanism of action (MoA) by pre-specified SIGMAR1 gene analysis, noted October 31, 2024.",85.0,561.34632,69.1954,5.71,6.62,7.635,0.147876346,0.290523915,-0.008599375,-0.045582035,21.11591,0.11109,38.73158,2341,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
SILO,SPC-15,Post-traumatic stress disorder (PTSD)Â ,Phase 1,10/31/2024,"Additional data reported a sustained 80%+ drug release over a 7-day period and minimal variation in key physical properties, noted October 31, 2024.",9.0,5.06744,185.0233,1.13,1.13,1.28,0.0,0.124642445,-0.008599375,-0.045582035,2.88298,0.00688,1.04957,2342,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ABOS,ACU193 - (ALTITUDE-AD),Early Alzheimer's diseaseÂ ,Phase 2,10/31/2024,Phase 2 data at CTAD highlighted the pTau217 assay as an effective and efficient tool to screen participants for ALTITUDE-AD that reduces unnecessary amyloid PET scans and lumbar puncture procedures f,60.0,173.02976,75.2922,3.03,2.88,3.17,-0.050772325,0.045168968,-0.008599375,-0.045582035,2.11165,0.0601,0.45543,2343,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ATOS,(Z)-Endoxifen - (I-SPY 2),Locally advanced breast cancerÂ ,Phase 2,10/31/2024,"Phase 2 study met the primary endpoint at 10mg once daily, noted October 31, 2024.",129.0,173.54523,58.5575,1.41,1.38,1.5,-0.021506205,0.061875404,-0.008599375,-0.045582035,10.37847,0.10099,0.87853,2344,1,0,0,0,0,1,0,0,0,0,0,0,2,0,0,1
PALI,PALI-2108,Moderate-to-severe ulcerative colitis (UC)Â ,Preclinical,10/31/2024,"Preclinical data reported a high conversion rate of 90.1% at 24 hours with significant inhibition of TNFÎ± production in human whole blood, with an IC50 of 0.022 Î¼M, indicating strong potency, noted Oc",9.0,3.22181,72.4588,3.1,2.72,2.54,-0.130770231,-0.19923803,-0.008599375,-0.045582035,1.4077,0.06541,6.65242,2345,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
INTS,INT230-6 - (INVINCIBLE-4),Triple Negative Breast CancerÂ ,Phase 2,10/31/2024,"Phase 2 trial dosing intiated, noted October 31, 2024",47.0,44.75852,48.6627,3.05,3.25,3.22,0.063513406,0.054239769,-0.008599375,-0.045582035,0.29861,0.0016,0.07883,2346,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
BFRI,Ameluz (BF-200 ALA),Basal cell carcinomaÂ ,Phase 3,10/31/2024,"Phase 3 data reported primary and secondary endpoints were all highly statistically significant, noted October 31, 2024.",10.0,6.81853,111.4276,0.9339,1.23,0.88,0.275400082,-0.059447459,-0.008599375,-0.045582035,8.54625,0.0052,163.38872,2347,1,0,0,0,0,1,0,0,1,0,0,0,3,0,0,1
VCNX,Pepinemab - (SIGNAL-AD),Alzheimerâ€™s Disease (AD)Â ,Phase 1/2,10/31/2024,"Phase 1/2 data presented at CTAD reported that the expression of plasma GFAP and p-tau 217 biomarkers appears to increase predominantly during MCI and that this is inhibited by pepinemab treatment, no",2.0,7.79859,141.6353,4.03,2.79,3.3,-0.36772478,-0.199843907,-0.008599375,-0.045582035,1.2343,0.00023,1.26711,2348,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1
SUPN,SPN-820,Treatment-resistant depressionÂ ,Phase 2a,10/31/2024,"Phase 2a data reported that suicidal ideation decreased by 80%, noted October 31, 2024.",56.0,1877.44054,33.3288,34.87,34.07,36.4,-0.023209629,0.042941914,-0.008599375,-0.045582035,12.28528,0.06478,12.86804,2349,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
LXRX,Zynquista (sotagliflozin),Type 1 Diabetes and chronic kidney disease (CKD)Â ,NDA Filing,11/1/2024,"Advisory Committee voted 11 to 3 that the benefits of Zynquista do not outweigh the risks in adults with T1D and CKD, noted November 1, 2024.",363.0,441.0206,99.5074,1.95,1.22,1.27,-0.468978514,-0.428812472,-0.022319398,-0.071099963,7.64887,0.05349,25.61995,2350,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
TNXP,TNX-801 - (Kenya study),"Monkeypox, horse pox and smallpox infectionÂ ",Preclinical,11/1/2024,"Preclinical data showed tolerability and no evidence of spreading to blood or tissues, noted November 1, 2024.",8.0,24.87678,169.9867,14.53,13.93,14.1,-0.04217069,-0.03004068,-0.022319398,-0.071099963,3.05917,0.06023,1.74121,2351,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
NVO,Wegovy (semaglutide) injection - (ESSENCE),Metabolic dysfunction-associated steatohepatitis (MASH)Â ,Phase 3,11/1/2024,"Phase 3 trial met its primary endpoint, noted November 1, 2024.",0.0,3407437.419,31.9137,111.95,111.94,107.2,-8.93296e-05,-0.043356094,-0.022319398,-0.071099963,0.0,0.0,509.85636,2352,1,0,0,0,0,1,0,0,0,0,0,0,2,0,0,1
TEVA,Olanzapine LAI (44749) - (SOLARIS),SchizophreniaÂ ,Phase 3,11/1/2024,"Phase 3 data reported no occurrence of Post-Injection Delirium/Sedation Syndrome (PDSS) events to date, noted November 1, 2024.",0.0,20903.70973,33.5945,18.44,18.45,17.11,0.000542152,-0.07485913,-0.022319398,-0.071099963,1.75723,0.10489,130.99751,2353,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
VKTX,VK2735 - (VENTURE),ObesityÂ ,Phase 2a,11/3/2024,"Phase 2a 13 week data presented at Obesity week demonstrated reductions in mean body weight relative to placebo, ranging up to 6.8%, noted November 3, 2024.",113.0,8121.48367,82.7473,72.88,72.88,68.48,0.0,-0.062272521,0.000503804,-0.048276762,12.91659,0.05732,0.0,2354,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
SUPN,SPN-817,Treatment-resisted seizuresÂ ,Phase 2,11/4/2024,Phase 2 data reported that treatment was safe and had acceptable tolerability with 2 subjects discontinuing because of treatment related adverse events out of the 26 subjects who entered the maintenan,56.0,1916.10877,33.4885,33.97,34.7,36.61,0.021261905,0.074843645,-0.013507634,-0.042018015,12.25994,0.05608,15.63676,2355,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
FBIO,"Emrosi (Minocycline Hydrochloride ER Capsules, 40 mg) (DFD-29) - (MVOR-2)",Papulopustular RosaceaÂ ,Approved,11/4/2024,"FDA approved on November 4, 2024.",29.0,47.68485,70.6674,1.9,1.73,1.76,-0.093732478,-0.076540077,-0.013507634,-0.042018015,9.33219,0.03554,2.89286,2356,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
DERM,"Emrosi (Minocycline Hydrochloride ER Capsules, 40 mg) (DFD-29) - (MVOR-2)",Papulopustular RosaceaÂ ,Approved,11/4/2024,"FDA approved on November 4, 2024.",24.0,110.2689,72.4383,6.17,5.32,5.58,-0.148225535,-0.100510062,-0.013507634,-0.042018015,0.37,0.02988,4.7599,2357,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
CRBP,CRB-913,ObesityÂ ,Preclinical,11/4/2024,"Preclinical results presented at Obesity Week suggest CRB-913's clinical potential as a standalone therapy, in combination with incretin analogs, or as a maintenance therapy , noted November 4, 2024.",12.0,220.52454,157.279,16.92,18.31,18.59,0.078951005,0.094127448,-0.013507634,-0.042018015,22.82851,0.00623,10.25298,2358,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
XNCR,XmAb942 - (XENITH-UC),Inflammatory bowel diseases (IBD)Â ,Phase 1,11/4/2024,"Phase 1 dosing commenced, noted November 4, 2024. Phase",71.0,1504.83425,53.4678,21.26,21.52,23.31,0.012155362,0.09205508,-0.013507634,-0.042018015,6.8399,0.12325,8.22804,2359,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
PTN,PL7737,Obesity Due to Leptin Receptor DeficiencyÂ ,Preclinical,11/4/2024,"Preclinical data reported that L7737 significantly decreased food intake and body weight in DIO mice, but not in MC4R-KO mice, noted November 4, 2024.",46.0,109.70565,53.6164,0.068,0.067,0.063,-0.014815086,-0.076372979,-0.013507634,-0.042018015,0.0,0.02421,0.05177,2360,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
PPBT,CM24 and OPDIVO (nivolumab),2L metastatic pancreatic cancer (PDAC)Â ,Phase 2,11/4/2024,Phase 2 additional new data demonstrated significant improvements in both progression-free survival (PFS) and overall survival (OS) when treated with CM24 in combination with nivolumab and chemotherap,2.0,21.79054,92.0001,0.062,0.06,0.053,-0.032789823,-0.156842471,-0.013507634,-0.042018015,0.0,0.00216,0.21333,2361,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
IRON,Bitopertin - (APOLLO),Erythropoietic Protoporphyria (EPP)Â ,Phase 2,11/4/2024,End of Phase 2 meeting with the FDA resulted in positive feedback to initiate its Phase 3 APOLLO trial by mid-2025.,34.0,1731.5257,59.3196,47.13,58.25,66.57,0.211834352,0.345344285,-0.013507634,-0.042018015,4.97094,0.0925,121.54037,2362,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CRVO,Neflamapimod - (AscenD-LB),Dementia with Lewy bodies (DLB)Â ,Phase 2a,11/4/2024,Phase 2a data presented at CTAD confirmed recent scientific literature indicating that plasma glial fibrillary acid protein (GFAP) is a robust measure of neurodegenerative disease activity in DLB. Nef,9.0,102.92415,101.0269,12.81,12.47,12.14,-0.026900356,-0.05372033,-0.013507634,-0.042018015,15.38266,0.06144,0.79845,2363,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1
SKYE,Nimacimab - (CBeyond),ObesityÂ ,Preclinical,11/4/2024,"Preclinical preliminary data from a diet-induced obesity (DIO) model in mice, achieved significant dose-dependent weight loss of up to 16% compared to vehicle, highlighting a novel peripherally-driven",30.0,165.0403,127.5362,5.56,5.44,5.5,-0.021819047,-0.010850016,-0.013507634,-0.042018015,4.67158,3e-05,1.28775,2364,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1
SRRK,SRK-439 with apitegromab - (EMBRAZE),ObesityÂ ,Preclinical,11/4/2024,"Preclinical data show that SRK-439 increased lean mass and lowered fat mass gain in mice receiving metformin, noted November 4, 2024.",96.0,2542.62483,225.6886,28.42,27.67,28.15,-0.026744329,-0.009545768,-0.013507634,-0.042018015,16.2457,0.02021,27.73071,2365,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CYDY,Leronlimab with trifluridine plus tipiracil (TAS-102) and bevacizumab,"CCR5+, microsatellite stable (MSS), relapsed or refractory metastatic colorectal cancer (mCRC)Â ",Phase 2,11/4/2024,"The FDA cleared the Phase 2 trial, noted on November 4, 2024.",0.0,150.32293,94.2406,0.127,0.123,0.1265,-0.032002731,-0.003944778,-0.013507634,-0.042018015,1.07839,0.02152,0.6143,2366,0,0,0,0,0,1,0,1,0,0,0,0,2,0,0,1
ATOS,Z-Endoxifen - (Karisma),"Mammographic breast density (MBD), breast cancerÂ ",Phase 2,11/4/2024,"Phase 2 data reported that the relative significant density change was -19.3 percent and -26.5 percent for the 1 and 2 mg arms, respectively, using the placebo arm as a reference. No significant diffe",129.0,177.31796,57.5519,1.42,1.41,1.62,-0.007067167,0.131769278,-0.013507634,-0.042018015,10.37847,0.11019,0.95434,2367,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
GUTS,Revita - (REVITALIZE-1),Type 2 DiabetesÂ ,Phase 1,11/4/2024,"Phase 1 data showed that a single Revita procedure led to sustained, clinically meaningful weight loss in the majority of patients with T2D, noted November 4, 2024.",50.0,122.69367,102.7788,2.84,2.56,2.51,-0.103796794,-0.123521299,-0.013507634,-0.042018015,3.95964,0.13667,1.06111,2368,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
GPCR,GSBR-1290 -(ACCESS and ACCESS II ),"Type 2 Diabetes, obesityÂ ",Phase 2a,11/4/2024,"Poster presented at Obesity week reported a 6.8% placebo-adjusted weight loss at 60 and 120 mg, respectively, with QD dosing at 12 weeks, noted November 4, 2024.",57.0,2272.98971,85.5317,41.14,39.74,38.7,-0.034622647,-0.061141284,-0.013507634,-0.042018015,18.88962,0.05536,32.76778,2369,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
GUTS,Rejuva (RJVA-001),Obesity and type 2 diabetes (T2D)Â ,Preclinical,11/5/2024,"Preclinical study 13-week follow-up represents the longest data to-date demonstrating durable efficacy of RJVA-001 on weight and blood sugar in the diet-induced obesity (DIO) mouse model, noted Novemb",50.0,115.02531,103.057,2.56,2.4,2.43,-0.064538521,-0.052116001,-0.031937654,-0.012917618,3.95964,0.13667,1.41871,2370,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
RCUS,Domvanalimab + zimberelimab vs. zimberelimab vs. chemotherapy - (ARC-10),Non Small Cell Lung Cancer (NSCLC)Â ,Phase 3,11/5/2024,"Phase 3 data presented reported results from Part 1 of its ARC-10 study, showing that treatment led to greater PFS, overall survival, and objective response rates compared to zimberelimab alone or che",107.0,1397.92655,56.0577,15.56,15.29,16.77,-0.017504499,0.074888057,-0.031937654,-0.012917618,6.93216,0.15679,8.21104,2371,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
NXTC,LNCB74,B7-H4 expressing cancersÂ ,Preclinical,11/5/2024,Preclinical data presented at SITC demonstrated strong anti-tumor activity in multiple CDX and PDX tumor models. A single dose of 3 mg/kg resulted in durable tumor regression in multiple tumor models,2.0,36.64835,64.6132,15.72001,15.72001,18.48001,0.0,0.161755184,-0.031937654,-0.012917618,0.26371,0.03547,0.00704,2372,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1
RYTM,Setmelanotide - (DAYBREAK),Variants in one of 31 additional genes with MC4R pathway relevanceÂ ,Phase 2,11/5/2024,"Phase 2 trial showed that patients with acquired hypothalamic obesity who were on therapy for more than one year achieved a mean overall percent reduction in fat mass of 29.6%, versus a reduction in l",66.0,3455.78912,49.0453,52.99,56.25,64.06,0.059702825,0.189716928,-0.031937654,-0.012917618,13.77088,0.12492,49.56126,2373,0,0,0,0,0,1,1,0,0,0,0,0,2,0,0,1
JNJ,CAPLYTA (Lumateperone) 42mg - (Study 304),Prevention of relapse in schizophreniaÂ ,Phase 3,11/5/2024,"Phase 3 study demonstrated a statistically significant (p=0.0002) longer time to relapse in schizophrenia patients treated with lumateperone compared to placebo, noted November 5, 2024.",0.0,381247.0976,15.5711,158.24,158.35,152.64,0.000694905,-0.03603066,-0.031937654,-0.012917618,0.77501,0.00373,1036.72917,2374,0,1,0,0,0,1,0,0,0,0,0,0,2,0,0,1
SANA,SC291 - (ARDENT),"Solid tumors, B-cell lymphomas and leukemiasÂ ",Phase 1,11/5/2024,"Sana is halting enrollment and further internal investment in the Phase 1 ARDENT trial. It is actively seeking a licensing partner to support advancement, noted November 2024.",237.0,754.15952,79.4633,3.76,3.39,2.84,-0.103589036,-0.280614905,-0.031937654,-0.012917618,14.9594,0.04651,12.38173,2375,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
NXTC,NC410 in combination w/ pembrolizumab - (LAIR-2),Solid TumorsÂ ,Phase 1/2,11/6/2024,"Phase 1/2 data presented at SITC reported a disease control rates were 86% and 47% for the 200 mg and 100 mg NC410 doses, respectively, noted November 6, 2024.",2.0,36.50847,63.7025,15.72001,15.66001,16.92001,-0.003824094,0.073562522,-0.023475026,0.006080864,0.26371,0.03547,0.04892,2376,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1
HCM,HMPL-523 - (ESLIM-01),Primary immune thrombocytopenia (ITP)Â ,Phase 3,11/6/2024,"Phase 3 data presented at ESMO Asia with an overall response was achieved by 81%, noted November 6, 2024.",174.0,2427.18405,50.1253,2.86,2.84,2.68,-0.007017573,-0.06500483,-0.023475026,0.006080864,0.0,0.00119,0.38506,2377,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1
TNGX,TNG462 with daraxonrasib or zoldonrasib,Solid TumorsÂ ,Phase 1/2,11/6/2024,"Phase 1/2 data demonstrated durable clinical activity across multiple tumor types, noted November 6, 2024.",111.0,348.03373,96.7372,5.18,3.24,3.56,-0.469231726,-0.375044511,-0.023475026,0.006080864,8.28978,0.11029,48.38103,2378,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
TNGX,TNG908,MTAP-deleted tumorsÂ ,Phase 1/2,11/6/2024,"TNG908 enrollment being stopped to fully resource TNG462 and TNG456, noted November 6, 2024.",111.0,348.03373,96.7372,5.18,3.24,3.56,-0.469231726,-0.375044511,-0.023475026,0.006080864,8.28978,0.11029,48.38103,2379,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CCCC,CFT8919,Non-Small Cell Lung Cancer (NSCLC)Â ,Phase 1,11/6/2024,"Phase 1 dosing commenced, noted November 6, 2024.",71.0,421.41609,80.5495,6.09,5.97,5.13,-0.019901154,-0.171542423,-0.023475026,0.006080864,9.42186,0.05108,5.7369,2380,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
IONS,ION582 - (REVEAL),Angelman SyndromeÂ ,Phase 3,11/6/2024,"Phase 2 EoP2 discussion with FDA went well, including alignment on Phase 3 design, noted November 6, 2024.",159.0,6164.31008,39.3024,38.8,39.04,37.78,0.006166515,-0.026640385,-0.023475026,0.006080864,6.2508,0.00759,67.48127,2381,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
VINC,OQY-3258 (ESG401),Unresectable recurrent or metastatic triple-negative breast cancerÂ ,Phase 3,11/6/2024,"Phase 3 garnered Breakthrough Designation from China's National Medical Products Administration (NMPA) on November 6, 2024.",5.0,10.09805,105.0904,6.92,6.54,6.48,-0.056478604,-0.065695259,-0.023475026,0.006080864,2.71133,0.02415,0.13967,2382,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
DVAX,CpG 1018 adjuvant with rF1V vaccine - (DoD Trial),Recombinant plague vaccineÂ ,Phase 2,11/7/2024,"Based on the results from a randomized, active-controlled Phase 2 clinical trial of the two-dose plague vaccine adjuvanted with CpG 1018, Dynavax has submitted a proposal to the DoD regarding addition",117.0,1580.08382,33.351,12.29,12.02,13.39,-0.022213994,0.085722236,-0.016842911,0.054978739,12.97771,0.00047,26.68119,2383,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
HOWL,WTX-330,Solid tumorsÂ ,Phase 1,11/7/2024,"Phase 1 data presented at SITC revealed the clinical potential of the tumor-activated IL-12 prodrug WTX-330, with favorable tolerability profile and encouraging efficacy signal, noted November 7, 2024",45.0,99.82146,114.9551,2.44,2.24,1.93,-0.085522173,-0.234478036,-0.016842911,0.054978739,1.74132,2e-05,1.88764,2384,0,0,0,1,0,1,0,0,0,0,1,0,3,0,0,1
INDP,Decoy-20 - (INDP-D101),Advanced/metastatic solid tumorsÂ ,Phase 1,11/7/2024,"Phase 1 data from SITC reported that confirmed that Decoy20 quickly disappeared from the bloodstream after administration, supporting the Company's ""pulse"" approach, noted November 7, 2024.",1.0,12.13427,97.9041,32.47999,33.31999,31.49999,0.02553331,-0.030636979,-0.016842911,0.054978739,0.30333,0.09814,0.03139,2385,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
INKT,AGENT-797,Solid TumorsÂ ,Preclinical,11/7/2024,"Preclinical data presented at SITC reported durable disease control in majority of heavily pretreated patients, noted November 7, 2024.",4.0,29.06957,55.2893,7.323,7.352,7.5,0.003952305,0.02388294,-0.016842911,0.054978739,0.16526,0.00506,0.02951,2386,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1
IOBT,IO102-IO103 in combination with pembrolizumab - (IOB-022),Non-small cell lung cancer (NSCLC)Â ,Phase 2,11/7/2024,"Phase 2 data presented at SITC reported an overall response rate of 55% unconfirmed/48% confirmed, disease control rate of 81%, and approximately 50% of patients without disease progression at 12 mont",65.0,81.03352,113.6823,1.16,1.23,0.89,0.058594164,-0.264953821,-0.016842911,0.054978739,0.42053,0.07535,0.23723,2387,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1
BOLT,BDC-4182,"gastric/gastroesophageal junction cancer, pancreatic cancerÂ ",Preclinical,11/7/2024,"Preclinical data from SITC reported that treatment demonstrated anti-tumor activity in a wide range of tumor models and elicits immunological memory, noted November 7, 2024.",1.0,24.92189,73.8091,12.952,13.026,12.448,0.005697144,-0.039690249,-0.016842911,0.054978739,0.31216,0.00437,0.04275,2388,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
BOLT,Trastuzumab imbotolimod (BDC-1001) with Opdivo,"HER2-Expressing Solid Tumors, gastric cancer, including gastroesophageal junction cancerÂ ",Phase 1,11/7/2024,"Phase 1 data reported pharmacodynamic changes were observed in HER2 IHC3+ and HER2 IHC2+, with both the greatest increase and statistical significance in patients with HER2 IHC 3+ tumors, noted Novemb",1.0,24.92189,73.8091,12.952,13.026,12.448,0.005697144,-0.039690249,-0.016842911,0.054978739,0.31216,0.00437,0.04275,2389,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ALLO,ALLO-316 - (TRAVERSE),Clear cell renal cell carcinoma (ccRCC)Â ,Phase 1,11/7/2024,"Phase 1 update presented at SITC reported an Overall Response Rate of 50% and Confirmed Response Rate of 33% in Patients with CD70 Tumor Proportion Score (TPS) of Greater than 50%, noted November 7, 2",221.0,668.85397,82.1433,3.22,3.19,2.46,-0.009360443,-0.26922001,-0.016842911,0.054978739,18.75238,0.06465,8.02628,2390,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CLLS,ALLO-316 - (TRAVERSE),Clear cell renal cell carcinoma (ccRCC)Â ,Phase 1,11/7/2024,"Phase 1 update presented at SITC reported an Overall Response Rate of 50% and Confirmed Response Rate of 33% in Patients with CD70 Tumor Proportion Score (TPS) of Greater than 50%, noted November 7, 2",72.0,121.46094,48.4651,1.77,1.75,1.91,-0.011363759,0.076123695,-0.016842911,0.054978739,0.0,0.0,0.12991,2391,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
NKTR,NKTR-255,Locally advanced non-small cell lung cancer (NSCLC)Â ,Phase 2,11/7/2024,Phase 2 data reported at SITC demonstrated statistically significant superiority of the eight-week absolute lymphocyte count with NKTR-255 post chemoradiation and in combination with durvalumab versus,19.0,252.18887,73.3585,20.84999,20.54999,17.54999,-0.014493014,-0.172300089,-0.016842911,0.054978739,3.27964,0.08952,2.55556,2392,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1
PALI,PALI-2108,Moderate-to-severe ulcerative colitis (UC)Â ,Phase 1,11/7/2024,"Phase 1 clinical study commenced, noted November 7, 2024.",9.0,3.0086,67.464,2.55,2.54,2.62,-0.003929278,0.027080959,-0.016842911,0.054978739,1.4077,0.07293,0.11516,2393,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
NKTX,NKX019,Non-Hodgkin lymphoma (NHL)Â ,Phase 1,11/7/2024,"No further NKX019 development in lymphoma planned, noted November 7, 2024.",71.0,230.75983,78.2158,3.35,3.27,2.7,-0.024170361,-0.215708573,-0.016842911,0.054978739,14.76544,0.04234,1.94662,2394,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
MOLN,MP0317,Solid TumorsÂ ,Preclinical,11/7/2024,"Preclnical PoC data presented at SITC supports the potential of CD3 Switch-DARPin platform to activate and boost T cells in the presence of tumor targets only, November 7, 2024.",40.0,191.68809,91.8199,5.54,5.2,4.85,-0.063335875,-0.133015796,-0.016842911,0.054978739,0.0,0.03184,0.08763,2395,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1
AVIR,Bemnifosbuvir (AT-527) - (SUNRISE-3),COVID-19Â ,Phase 3,11/7/2024,"Phase 3 trial did not meet primary endpoint, noted November 7, 2024.",79.0,290.55292,48.2548,3.58,3.44,3.31,-0.039891329,-0.078414611,-0.016842911,0.054978739,3.11325,0.13189,0.97043,2396,1,0,0,0,0,1,0,0,0,0,0,0,0,2,0,-1
IMNN,IMNN-001 - (OVATION 2),Ovarian cancerÂ ,Phase 2,11/8/2024,"Phase 2 data presented at SITC reported a 35% improvement in overall survival and 25% improvement in progression-free survival versus standard-of-care alone, noted November 8, 2024.",2.0,11.59909,206.3528,10.71521,10.43347,9.39913,-0.02664532,-0.131047096,-0.005035355,0.114887029,2.32795,0.02656,0.23232,2397,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1
MURA,Nemvaleukin (ALKS 4230) - (ARTISTRY-3),Solid TumorsÂ ,Phase 1/2,11/8/2024,"Phase 1/2 microenvironment pharmacodynamic data shared at SITC demonstrated tumor-site-specific pharmacodynamic activity and immune activation, noted November 8, 2024.",17.0,59.97373,43.0133,3.38,3.52,3.45,0.04058528,0.020498522,-0.005035355,0.114887029,2.30539,0.00594,0.34225,2398,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ALKS,Nemvaleukin (ALKS 4230) - (ARTISTRY-3),Solid TumorsÂ ,Phase 1/2,11/8/2024,"Phase 1/2 microenvironment pharmacodynamic data shared at SITC demonstrated tumor-site-specific pharmacodynamic activity and immune activation, noted November 8, 2024.",165.0,4669.62038,32.8276,28.97,28.86,28.19,-0.003804258,-0.027293507,-0.005035355,0.114887029,9.77951,0.05223,53.02026,2399,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ELTX,ELI-002 - (AMPLIFY-7P),mKRAS-driven cancersÂ ,Phase 1a,11/8/2024,"Phase 1a data presented at SITC reported that the highest three quartiles of T cell responders have not yet reached mDFS, whereas the lowest quartile achieved a mDFS of 3.1 months, noted November 8, 2",16.0,54.66141,109.5539,4.61,5.08,5.48,0.097083405,0.172877244,-0.005035355,0.114887029,0.37098,0.0141,0.0629,2400,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1
AMGN,TEZSPIRE (tezepelumab-ekko),Chronic Rhinosinusitis with Nasal Polyps (CRwNP)Â ,Phase 3,11/8/2024,"Phase 3 data reported a statistically significant and clinically meaningful reduction in nasal polyp size and reduced nasal congestion compared to placebo, noted November 8, 2024.",538.0,174848.6441,20.1769,321.91,325.28,283.61,0.010414347,-0.126671948,-0.005035355,0.114887029,1.74354,0.03195,643.45133,2401,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1
AZN,TEZSPIRE (tezepelumab-ekko),Chronic Rhinosinusitis with Nasal Polyps (CRwNP)Â ,Phase 3,11/8/2024,"Phase 3 data reported a statistically significant and clinically meaningful reduction in nasal polyp size and reduced nasal congestion compared to placebo, noted November 8, 2024.",0.0,153524.9558,20.6939,97.25,99.03,99.78,0.018137852,0.02568278,-0.005035355,0.114887029,0.0,0.05065,402.29858,2402,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1
AMGN,Tezepelumab - (WAYPOINT),Chronic Rhinosinusitis With Nasal PolypsÂ ,Phase 3,11/8/2024,"Phase 3 trial had a statistically significant and clinically meaningful reduction in the size of nasal polyps and reduced nasal congestion compared to placebo, noted November 8, 2024.",538.0,174848.6441,20.1769,321.91,325.28,283.61,0.010414347,-0.126671948,-0.005035355,0.114887029,1.74354,0.03195,643.45133,2403,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1
IPHA,IPH6501,Relapsed and/or Refractory CD20-expressing B-cell Non-Hodgkin's Lymphoma (NHL)Â ,Preclinical,11/8/2024,"Preclinical data reported that IPH6501 targets on NK cells and show effective IPH6501-induced killing of CD20+ B-NHL target cells, noted November 8, 2024.",92.0,130.33076,65.9952,1.8447,1.8413,1.44,-0.001844819,-0.247673549,-0.005035355,0.114887029,0.0,0.0,0.01303,2404,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
IOVA,LN-145 and KEYTRUDA (pembrolizumab) - (IOV-COM-202),Solid TumorsÂ ,Phase 2,11/8/2024,"Phase 2 updated cohort 1a data at ASCO noted that 30% confirmed complete response rate, noted November 8, 2024",361.0,3226.10466,75.6164,12.28,10.585,8.18,-0.148534018,-0.406279772,-0.005035355,0.114887029,19.79727,0.07329,288.97813,2405,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CARM,CAR-M therapy,Hepatocellular carcinoma (HCC)Â ,Preclinical,11/8/2024,"Preclinical data reported the treatment produced pro-inflammatory cytokines and adopted an inflammatory, activated macrophage phenotype upon antigen engagement, noted November 8, 2024.",41.0,42.16761,86.0282,1.03,1.01,0.8832,-0.019608471,-0.153762406,-0.005035355,0.114887029,2.50483,0.05521,0.85874,2406,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
MRNA,CAR-M therapy,Hepatocellular carcinoma (HCC)Â ,Preclinical,11/8/2024,"Preclinical data reported the treatment produced pro-inflammatory cytokines and adopted an inflammatory, activated macrophage phenotype upon antigen engagement, noted November 8, 2024.",389.0,18021.01809,61.7213,50.28,46.83,36.85,-0.071083361,-0.310751765,-0.005035355,0.114887029,8.64321,0.00507,635.08683,2407,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
VTYX,VTX958,Crohn's diseaseÂ ,Phase 2,11/8/2024,"The company does not plan to commit significant internal resources to further development of VTX958, noted November 8, 2024.",71.0,155.56347,106.5292,2.24,2.2,1.87,-0.018018506,-0.180537435,-0.005035355,0.114887029,11.84596,0.01515,1.95322,2408,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CMPX,CTX-471 (CD137 agonist),Solid tumorsÂ ,Phase 1,11/8/2024,Phase 1 new data presented at SITC showed a correlation between the levels of neural cell adhesion molecule (NCAM or CD56) expression and response and disease control in patients treated with CTX-471,138.0,247.66051,84.2921,1.84,1.8,1.38,-0.021978907,-0.287682072,-0.005035355,0.114887029,1.60388,0.02468,1.00988,2409,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1
ANIX,Î±-lactalbumin,Breast cancer vaccineÂ ,Phase 1a,11/8/2024,"Phase 1a additional data presented at SITC showed that vaccine was safe and well tolerated by participants in all 3 cohorts, noted November 8, 2024.",32.0,110.69745,68.5234,3.62,3.44,3.08,-0.051002554,-0.161544429,-0.005035355,0.114887029,1.84503,0.00455,1.60485,2410,0,0,0,1,0,0,0,0,0,0,1,0,2,0,0,1
CUE,CUE-101 and KEYTRUDA (pembrolizumab) - (KEYNOTE-A78),HPV16+ head and neck cancerÂ ,Phase 1,11/8/2024,"Phase 1 presented at SITC showed an objective response rate (ORR) of 46%, 12-month overall survival (OS) of 91.3% and a median overall survival (mOS) of 21.8 months, noted November 8, 2024.",76.0,103.55727,136.2531,1.78,1.72,1.245,-0.034289073,-0.357477834,-0.005035355,0.114887029,3.23451,0.00454,0.96089,2411,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
AUTL,AUCATZYL (obecabtagene autoleucel) - (FELIX),B-Cell Acute Lymphoblastic LeukemiaÂ ,Approved,11/8/2024,"FDA Approved on November 8, 2024.",266.0,992.53233,69.5938,4.04,3.73,3.08,-0.079836458,-0.271315095,-0.005035355,0.114887029,3.28712,0.08637,17.38236,2412,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
CADL,CAN-3110,MelanomaÂ ,Preclinical,11/8/2024,"Data presented in a poster at SITC reported that CAN-3110 demonstrated potent antitumor activity both in vitro and in vivo, highlighting its potential as a promising therapeutic agent for treating me",54.0,154.96947,95.798,5.09,4.83,3.8,-0.052431363,-0.292276764,-0.005035355,0.114887029,5.11279,0.00223,2.01545,2413,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
REGN,Ateganosine (THIO-101),Non-small cell lung cancer (NSCLC)Â ,Phase 2,11/8/2024,"Phase 2 update presented at SITC reported an ORR in the 3L setting with the 180 mg dose is 38% (3/8), noted November 8, 2024.",105.0,89129.31927,23.9985,824.48,828.42,756.81,0.004767388,-0.085640653,-0.005035355,0.114887029,1.59488,0.11222,466.88509,2414,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
MAIA,Ateganosine (THIO-101),Non-small cell lung cancer (NSCLC)Â ,Phase 2,11/8/2024,"Phase 2 update presented at SITC reported an ORR in the 3L setting with the 180 mg dose is 38% (3/8), noted November 8, 2024.",32.0,72.8856,89.3786,3.32,2.91,2.26,-0.131811702,-0.38459997,-0.005035355,0.114887029,2.78053,0.00155,0.94841,2415,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CGEN,"COM701, COM902 and Pembrolizumab","Advanced malignancies, Ovarian cancerÂ ",Phase 1,11/8/2024,"Report initial findings at SITC reported a Confirmed ORR of 17.4%, noted November 8, 2024.",93.0,159.37485,72.364,1.81,1.78,1.41,-0.016713481,-0.249737141,-0.005035355,0.114887029,1.72927,0.01783,0.37774,2416,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
SILO,SPC-15,Post-traumatic stress disorder (PTSD)Â ,Preclinical,11/8/2024,"Preclinical data reported that the combined treatment demonstrated significant improvement in behavioral outcomes related to severe stress-induced conditions as compared to using either agent alone, n",9.0,5.7401,185.6937,1.28,1.28,1.13,0.0,-0.124642445,-0.005035355,0.114887029,2.88298,0.00845,0.20922,2417,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1
ADAG,muzastotug (ADG126) combined with KEYTRUDA (pembrolizumab) - (ADG126-P001/KEYNOTE-C98),Solid tumorsÂ ,Phase 1/2,11/9/2024,"Phase 1/2 data presented at SITC showed a three-fold increased active (e.g., cleaved) drug exposure in homogenized tumor tissue samples at 10 mg/kg versus a single dose of ipilimumab at 1 mg/kg while",47.0,116.87487,92.8619,2.64,2.64,2.16,0.0,-0.200670695,0.006258747,0.126181131,0.04823,0.00706,0.0,2418,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1
PHIO,PH-762,Cutaneous Squamous Cell CarcinomaÂ ,Phase 1b,11/9/2024,"Phase 1b additional data shared at SITC reported one complete response and one partial response, noted November 9, 2024.",5.0,2.53913,93.6034,2.95,2.95,2.21,0.0,-0.288812655,0.006258747,0.126181131,2.47943,0.0488,0.0,2419,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
REPL,RP1 (vusolimogene oderparepvec) and OPDIVO (nivolumab) - (IGNYTE-3),Non-melanoma (NMSC) / Non-small cell lung cancer (NSCLC)Â ,Phase 3,11/9/2024,"Phase 3 data presented at SITC reported that the median overall survival for the trial has not been reached, however, one-, two-, and three-year survival rates were 75.3%, 63.3%, and 54.8%, respective",78.0,849.91817,76.7232,12.44,12.44,10.8,0.0,-0.141370953,0.006258747,0.126181131,10.48438,0.03269,0.0,2420,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1
SRRK,SRK-181 - (DRAGON),Solid TumorsÂ ,Phase 1,11/9/2024,"Phase 1 data presented at SITC demonstrated durable antitumor activity in heavily pretreated patients with antiâ€“PD-1â€“resistant cancer across multiple cancer types , noted November 9, 2024.",96.0,2672.19118,224.8285,29.08,29.08,26.49,0.0,-0.093283349,0.006258747,0.126181131,16.2457,0.01866,0.0,2421,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1
CUE,CUE-102,Wilms' Tumor (WT1)-expressing cancersÂ ,Phase 1,11/9/2024,Phase 1 trial presentation SITC reported that patients with HPV16+ R/M HNSCC refractory to platinum-based treatments and checkpoint inhibitors (2L+) receiving CUE-101 4 mg/kg monotherapy exhibit an,76.0,103.55727,136.2531,1.72,1.72,1.245,0.0,-0.323188761,0.006258747,0.126181131,3.23451,0.00454,0.0,2422,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
IMAB,Givastomig (TJ033721 / ABL111),"First-line metastatic gastric cancers, solid tumorsÂ ",Phase 1,11/9/2024,"Phase 1 data presented at SITC 2024 reported that a dose range between 8-12 mg/kg Q2W was identified as the preferred dose range for heavily pre-treated GEC patients., noted November 9, 2024.",81.0,89.57815,73.2636,1.1,1.1,1.04,0.0,-0.056089467,0.006258747,0.126181131,0.60365,0.06287,0.0,2423,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1
RCUS,Etrumadenant (AB928) and zimberelimab - (ARC-9),Colorectal CancerÂ ,Phase 1/2,11/9/2024,"Phase 1b/2 data presented at SITC reported that OS was greater with zim than with chemo, noted November 9, 2024.",107.0,1633.48222,57.2752,17.85,17.85,15.7,0.0,-0.128342796,0.006258747,0.126181131,6.92579,0.2319,0.0,2424,1,0,0,0,0,1,0,0,0,0,1,0,3,0,0,1
XAIR,Beyond Cancer (UNO),Solid tumorsÂ ,Preclinical,11/11/2024,"Preclinical efficacy data from Low Volume UNO (LV UNO, < 100 mL) presented at SITC showed that LV UNO in combination with anti-rPD-L1 resulted in prolonged survival and doubled the tumor growth inhibi",5.0,36.82291,148.0278,9.478,10.202,10.176,0.073610456,0.071058683,0.035862947,0.124766472,2.01308,0.01643,0.6718,2425,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CANF,Namodenoson - (CF102-222PC),Pancreatic CancerÂ ,Phase 2a,11/11/2024,"Phase 2a dosing initiated, noted November 11, 2024.",10.0,57.234,79.6862,0.028,0.028,0.026,0.0,-0.074107972,0.035862947,0.124766472,0.0,0.00877,0.1082,2426,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1
NCNA,NUC-3373 in Combination with Pembrolizumab or Docetaxel - NuTide: 303),Non Small Cell Lung Cancer (NSCLC)Â ,Phase 1/2,11/11/2024,"Phase 1b/2 commenced, noted October 26, 2022. Phase 1b/2 initial data showed that among patients who had exhausted all other treatment options, including prior PD-(L)1 therapy, a 22% objective respons",1.0,3.50438,246.7668,301.0,312.0,288.0,0.035892923,-0.044149785,0.035862947,0.124766472,2.82826,0.0391,0.79123,2427,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
MRK,KEYTRUDA (pembrolizumab) + plinabulin / docetaxel - (KeyPelms-004 / 303 Study) (TROPION Lung-01),2L/3L Non-small cell lung cancer (NSCLC)Â ,Phase 2,11/11/2024,"Phase 2 data reported an overall response rate (ORR) of 12.8% and median PFS (mPFS) of 3.7 months, noted November 11, 2024.",0.0,254810.1985,23.5922,102.92,100.73,96.56,-0.021508317,-0.063787411,0.035862947,0.124766472,1.03685,0.08711,1014.88064,2428,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
BYSI,KEYTRUDA (pembrolizumab) + plinabulin / docetaxel - (KeyPelms-004 / 303 Study) (TROPION Lung-01),2L/3L Non-small cell lung cancer (NSCLC)Â ,Phase 2,11/11/2024,"Phase 2 data reported an overall response rate (ORR) of 12.8% and median PFS (mPFS) of 3.7 months, noted November 11, 2024.",40.0,79.79469,73.7823,1.94,1.98,1.72,0.020408872,-0.120363682,0.035862947,0.124766472,5.17658,0.01866,0.03971,2429,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CERO,CER-1236,"Solid tumors, non-small cell lung cancer (NSCLC) and ovarian cancerÂ ",Preclinical,11/11/2024,"Preclinical study presented ar SITC highlighted CER-1236's ability to increase TIM-4-L expression in ovarian cancer cells, resulting in tumor cell death while sparing healthy cells, noted November 11,",1.0,29.45998,216.7077,140.0,392.0,479.4,1.029619417,1.230892899,0.035862947,0.124766472,1.06563,5e-05,283.5677,2430,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
NVAX,NVX-CoV2373 - (COVID-19-Influenza Combination),"COVID-19, COVID-19 vaccine, InfluenzaÂ ",Phase 2,11/11/2024,"Phase 2 hold removed, FDA cleared study to begin enrolling in planned Phase 3 trial, noted November 11, 2024.",162.0,1442.44369,116.0066,8.91,9.01,7.83,0.01116083,-0.129211731,0.035862947,0.124766472,24.97341,0.03918,132.08874,2431,0,0,0,0,0,1,0,1,0,0,0,0,2,0,0,1
CTXR,LYMPHIR (denileukin diftitox),B-cell lymphomasÂ ,Phase 1,11/11/2024,"Phase 1 preliminary efficacy results strongly suggests that LYMPHIR may have the ability to improve and prolong the anti-tumor activity of immune checkpoint inhibitors. To date, this unique regimen ha",17.0,81.18185,87.8718,10.2875,11.23,5.605,0.087659203,-0.607270509,0.035862947,0.124766472,6.5224,0.00132,1.96114,2432,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ABBV,Emraclidine (CVL-231) - (EMPOWER-1),SchizophreniaÂ ,Phase 2,11/11/2024,"Phase 2 trial did not meet their primary endpoint, noted November 11, 2024.",0.0,308242.2865,27.953,199.5,174.43,166.28,-0.134290721,-0.182141122,0.035862947,0.124766472,1.02568,0.0105,3621.21041,2433,1,0,0,0,0,1,0,0,0,0,0,0,0,2,0,-1
APVO,ALG.APV-527,Solid tumorsÂ ,Phase 1,11/11/2024,"Phase 1 data presented at SITC indicated that trial endpoints of adequate exposure, safety, tolerability and biological activity were met, noted November 11, 2024.",3.0,5.33142,180.0901,204.6842,213.12021,159.61816,0.040388069,-0.248683841,0.035862947,0.124766472,6.49236,0.01935,1.1306,2434,0,0,0,1,0,1,0,0,0,0,1,0,3,0,0,1
AIMD,VELDONA,SjÃ¶gren's syndromeÂ ,Phase 3,11/11/2024,"IRB approval on track as scheduled, company plans new phase of treatment evaluation expected 1Q 2025, noted November 11, 2024.",4.0,6.91803,100.0734,2.399,2.4995,2.155,0.041038728,-0.10726126,0.035862947,0.124766472,1.0351,0.0089,0.12946,2435,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
CRVS,Ciforadenant,Metastatic castration resistant prostate cancer (mCRPC)Â ,Phase 1/2,11/11/2024,"Phase 1/2 data reported that 5 of 24 (21%) receiving combination therapy had PSA partial responses defined as PSA reductions >30%, compared to 1 of 11 (9%) receiving monotherapy, noted November 11, 20",74.0,597.99025,78.736,9.45,9.56,8.34,0.011572986,-0.124951525,0.035862947,0.124766472,4.67621,0.00423,5.49273,2436,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
FATE,FT825/ONO-8250,Solid TumorsÂ ,Phase 1,11/11/2024,"Phase 1 data reported that treatment was well-tolerated with no DLTs and no events of any grade of CRS, ICANS, or GvHD, noted November 11, 2024.",115.0,291.52738,80.1622,2.42,2.56,2.27,0.056239718,-0.063987709,0.035862947,0.124766472,13.96433,0.06567,3.06839,2437,0,0,0,1,0,1,0,0,0,0,0,0,0,0,2,0
RARE,GTX-102 - (Aspire),Angelman SyndromeÂ ,Phase 1/2,11/11/2024,"Phase 1/2 data reported statistically significant separation between the GTX-102 and sham arms, noted November 11, 2024.",96.0,4681.12825,39.8352,50.36,50.73,43.78,0.007320242,-0.140020117,0.035862947,0.124766472,3.4458,0.09183,53.80591,2438,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1
IMTX,"Anzu-cel (anzutresgene autoleucel, IMA203) (ACTengine) - (SUPRAME)",MelanomaÂ ,Phase 1b,11/11/2024,"Phase 1b data reported a 54% cORR, 12.1 months mDOR and 6 months mPFS in heavily pretreated metastatic melanoma patients and >1-year mPFS in patients with deep responses, noted November 11, 2024.",121.0,1078.97739,51.5293,9.25,9.04,7.82,-0.022964377,-0.167938997,0.035862947,0.124766472,5.60642,0.01629,4.57316,2439,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
FATE,FT836,Solid TumorsÂ ,Preclinical,11/11/2024,"Preclinical data presented at SITC showed robust antigen-mediated expansion, functional persistence, and durable anti-tumor activity in the presence of alloreactive T cells, noted November 11, 2024.",115.0,291.52738,80.1622,2.42,2.56,2.27,0.056239718,-0.063987709,0.035862947,0.124766472,13.96433,0.06567,3.06839,2440,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1
NGNE,NGN-101,CLN5 Batten DiseaseÂ ,Phase 1/2,11/11/2024,"Phase 1/2 was discontinued due to RMAT application denial by the FDA, noted November 11, 2024.",14.0,1060.69069,92.9267,68.21,71.53,19.82,0.04752576,-1.235899653,0.035862947,0.124766472,6.16501,0.1759,30.42715,2441,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
NGNE,NGN-401 - (Embolden),Rett SyndromeÂ ,Phase 1/2,11/11/2024,"Phase 1/2 data showed that all four participants in the low-dose cohort showed consistent and durable improvements across key clinical domains, including hand function, language, and ambulation, with",14.0,1060.69069,92.9267,68.21,71.53,19.82,0.04752576,-1.235899653,0.035862947,0.124766472,6.16501,0.1759,30.42715,2442,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ZVRA,Arimoclomol (EAP),Niemann-Pick disease type C (NPC)Â ,Phase 3,11/11/2024,Additional data presented at the 53rd Child Neurology Society Annual Meeting showed that the NPCCSS swallow score reflects the patient's level of dysfunction. Study indicates that a change in score re,56.0,471.45539,73.4186,9.0,8.96,8.6,-0.00445435,-0.045462374,0.035862947,0.124766472,7.4833,0.02666,5.19676,2443,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ARCT,"ARCT-2304 - (LUNAR-H5N1, BARDA)",Influenza disease caused by H5N1 virusÂ ,IND-Enabling,11/11/2024,"IND cleared after receiving ""Study May Proceed"" notification by the FDA, noted November 11, 2024",27.0,551.7695,80.4531,19.625,20.37,16.27,0.037258967,-0.187481342,0.035862947,0.124766472,16.90918,0.20481,13.69392,2444,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
SNDX,Revuforj (revumenib) - (AUGMENT-101),Relapsed/refractory (R/R) acute leukemiasÂ ,Phase 2,11/12/2024,"Phase 2 topline results showed that the trial met its primary endpoint. Revumenib demonstrated a favorable safety profile with only 5% treatment-related discontinuation, noted November 12, 2024.",86.0,1383.64791,59.8841,21.78,16.21,15.77,-0.295363782,-0.322882717,0.034591245,0.105435644,12.48581,0.2245,135.72931,2445,1,0,0,1,0,1,0,0,0,0,1,0,4,0,0,1
IVVD,PEMGARDA (VYD222 (pemivibart)) - (CANOPY),COVID-19 PreventionÂ ,Phase 3,11/12/2024,"Phase 3 data from long-term follow-up from months 7-12 after cessation of drug noted a 64% relative risk reduction in symptomatic disease versus placebo, noted November 12, 2024.",120.0,119.44264,107.1633,0.9775,1.0,0.7674,0.022756987,-0.241990114,0.034591245,0.105435644,6.9255,0.0651,0.42698,2446,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
EQ,EQ302 - (IL-15 and IL-21),Solid TumorsÂ ,Preclinical,11/12/2024,Preclinical data shared at SITC reported a modest effect on reversing the phenotype and function of terminally exhausted CD8+ T cells as shown by the increase in the percentage of TCF-1 positive cells,59.0,30.10719,122.0497,0.7505,0.8499,0.7,0.124379044,-0.069659316,0.034591245,0.105435644,0.33186,0.01086,0.32161,2447,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
AZN,KOSELUGO (selumetinib) - (KOMET),Neurofibromatosis Type 1-Plexiform Neurofibromas (NF1-PN) in AdultsÂ ,Phase 3,11/12/2024,"Phase 3 results showed reduction in tumor volume, building on the established safety and efficacy profile of KOSELUGO in certain children and has the potential to support expanded use in certain adult",0.0,154873.7058,20.7857,99.85,99.9,100.24,0.000500626,0.003898251,0.034591245,0.105435644,0.0,0.05065,356.36448,2448,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
EVAX,EVX-V1,Cytomegalovirus (CMV) vaccineÂ ,Preclinical,11/12/2024,"Preclinical data reported successfully induced a specific immune response comparable to that of the conventional gB antigen, noted November 12, 2024.",6.0,13.27576,79.1834,12.1,11.9,7.7995,-0.016667052,-0.439145824,0.034591245,0.105435644,0.94205,0.01404,0.15274,2449,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
AZN,DATROWAY (datopotamab deruxtecan-dlnk)- (TROPION-Lung01),Non-small cell lung cancer (NSCLC)Â ,BLA Filing,11/12/2024,"Voluntarily withdrawn November 12, 2024.",0.0,154873.7058,20.7857,99.85,99.9,100.24,0.000500626,0.003898251,0.034591245,0.105435644,0.0,0.05065,356.36448,2450,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,-1
AZN,Datopotamab deruxtecan - (TROPION-Lung05),EGFR non-small cell lung cancer (NSCLC)Â ,BLA Filing,11/12/2024,"BLA submitted November 12, 2024.",0.0,154873.7058,20.7857,99.85,99.9,100.24,0.000500626,0.003898251,0.034591245,0.105435644,0.0,0.05065,356.36448,2451,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
RVPH,Brilaroxazine - (RECOVER),SchizophreniaÂ ,Phase 3,11/12/2024,"108 patients have completed 1-year of treatment which is generally well tolerated to date in patients with acute and stable schizophrenia, noted November 12, 2024.",68.0,44.14238,125.4839,1.0,1.32,1.26,0.277631737,0.231111721,0.034591245,0.105435644,15.84101,0.00786,5.27589,2452,0,0,0,1,1,0,0,0,0,0,0,0,2,0,0,1
XBIO,DNase,Pancreatic carcinomaÂ ,Phase 1,11/12/2024,"Phase 1 data reported that treatment demonstrated beneficial effects of targeting NETs with systemic DNase I in models of primary tumor and metastatic CRC, improving the efficacy of CTLA-4 immune chec",1.0,6.36903,78.6174,3.95,4.13,3.9,0.044561828,-0.012739026,0.034591245,0.105435644,0.96178,0.00289,0.4268,2453,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
SYRE,SPY001,Inflammatory Bowel Disease (IBD)Â ,Phase 1,11/12/2024,"Phase 1 interim data showed a favorable safety profile and strong pharmacokinetics with a half-life over 90 daysâ€”four times longer than vedolizumab, noted November 12, 2024.",60.0,1842.2663,69.8942,39.35,35.82,26.9,-0.093989578,-0.380369688,0.034591245,0.105435644,16.04199,0.01556,43.71122,2454,0,0,0,1,0,1,0,0,0,0,0,0,2,0,0,1
GILD,Lenacapavir - (PURPOSE 2),HIV PrePÂ ,Phase 3,11/13/2024,"Phase 3 data reported that results demonstrated superiority of twice-yearly lenacapavir over bHIV, with 96% relative risk reduction, noted November 13, 2024.",0.0,115441.6063,24.5345,94.35,92.63,88.63,-0.018398209,-0.062540871,0.035958703,0.066856065,1.42383,0.03425,1024.53384,2455,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
AMGN,AMG 133 (maridebart cafraglutide) - (MariTide),Obesity and without diabetesÂ ,Phase 1,11/13/2024,"Phase 1 data reported that the company did not see an association between the administration of MariTide and bone mineral density changes, noted November 13, 2024.",538.0,162033.864,22.6024,298.84,301.44,287.87,0.008662678,-0.037399324,0.035958703,0.066856065,1.64135,0.03195,1123.04366,2456,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
LYRA,LYR-210 - (ENLIGHTEN I),Chronic rhinosinusitisÂ ,Phase 3,11/13/2024,"Phase 3 52 week extension data indicated that LYR-210 was generally well tolerated over the extended treatment period, including among patients who received repeat dosing for a total of 12 months. No",1.0,12.94097,80.306,13.75,9.885,8.9,-0.330020367,-0.434987547,0.035958703,0.066856065,3.11784,0.00063,1.47529,2457,0,0,0,1,0,1,0,0,0,0,0,0,2,0,0,1
INO,INO-3107,HPV 6 and HPV 11-associated Recurrent respiratory papillomatosisÂ ,Phase 1/2,11/13/2024,"New immunology on Phase 1/2 data shows INO-3107 induced an expansion of new clonal T cells in blood that were not detectable prior to treatment, noted November 13, 2024.",53.0,128.52313,61.3909,5.15,4.95,3.97,-0.039609138,-0.26023062,0.035958703,0.066856065,13.49834,0.03159,3.03012,2458,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
BRTX,BRTX-100,Chronic lumbar disc diseaseÂ ,Phase 2,11/13/2024,"Phase 2 blinded preliminary data presented demonstrate a positive trend and clear signal in Primary and Secondary endpoints November 13, 2024.",7.0,10.65668,90.3289,1.64,1.54,1.4,-0.062913825,-0.158224005,0.035958703,0.066856065,0.63928,0.03657,0.16541,2459,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
GSK,Lete-cel - (IGNYTE-ESO),SarcomaÂ ,Phase 2,11/13/2024,"Phase 2 data reported six complete responses (6/64); twenty-one partial responses (21/64) noted November 13, 2024.",0.0,55576.40593,22.585,13.695,13.62,13.0,-0.005491502,-0.052081445,0.035958703,0.066856065,0.0,0.05556,168.22552,2460,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
RNA,AOC1086,PLN CardiomyopathyÂ ,Preclinical,11/13/2024,"Preclinical data demonstrated robust siRNA delivery to the heart and targeted knockdown with potent reduction of approximately 80% in cardiac PLN mRNA, noted November 13, 2024.",128.0,6263.73914,71.2177,46.73,52.5,43.65,0.116426813,-0.068183074,0.035958703,0.066856065,12.28701,0.08359,168.966,2461,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
GILD,Biktarvy - (ALLIANCE),HIV/HBV CoinfectionÂ ,Phase 3,11/13/2024,"Phase 3 data reported that after 3 years of treatment, Biktarvy maintained high rates of HIV-1 and HBV virologic suppression, defined as HIV RNA <50 copies/ mL and HBV RNA <29 IU/ mL, respectively, no",0.0,115441.6063,24.5345,94.35,92.63,88.63,-0.018398209,-0.062540871,0.035958703,0.066856065,1.42383,0.03425,1024.53384,2462,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
GILD,Bictegravir and Lenacapavir - (ARTISTRY-1),HIVÂ ,Phase 2/3,11/13/2024,"Phase 2/3 data reported that at Week 48, fasting lipid parameters generally improved from baseline in both BIC+LEN groups (BIC 75 mg +LEN 25 mg and BIC 75 mg +LEN 50 mg) versus the complex antiretrovi",0.0,115441.6063,24.5345,94.35,92.63,88.63,-0.018398209,-0.062540871,0.035958703,0.066856065,1.42383,0.03425,1024.53384,2463,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
GILD,Lenacapavir (GS-6207),HIVÂ ,Phase 1b,11/13/2024,"Phase 1b data reported that at Week 26, 21% (n=3) of participants who received LEN + TAB and the low dose of ZAB and 0% (n=0) participants who received LEN +TAB and the high dose of ZAB had an HIV vir",0.0,115441.6063,24.5345,94.35,92.63,88.63,-0.018398209,-0.062540871,0.035958703,0.066856065,1.42383,0.03425,1024.53384,2464,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CLPT,Upstaza (PTC-AADC),AADC deficiencyÂ ,Approved,11/13/2024,"Approved November 13, 2024.",28.0,302.05245,79.5392,11.12,10.95,10.96,-0.015405833,-0.014493007,0.035958703,0.066856065,2.49255,0.07398,2.75022,2465,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1
PTCT,Upstaza (PTC-AADC),AADC deficiencyÂ ,Approved,11/13/2024,"Approved November 13, 2024.",79.0,3395.82005,57.0918,44.62,44.03,41.96,-0.013310969,-0.061465405,0.035958703,0.066856065,6.33617,0.21341,28.55504,2466,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1
GSK,Blenrep,Multiple myelomaÂ ,Phase 3,11/14/2024,"Additional Phase 3 data reported that the trial met the key secondary endpoint of overall survival (OS), noted November 14, 2024.",0.0,55229.56345,22.5897,13.62,13.535,13.095,-0.006260378,-0.039308823,0.085331139,0.058788991,0.0,0.05556,117.33072,2467,1,0,0,0,0,1,0,0,1,0,0,0,3,0,0,1
ACIU,ACI-7104.056 - (VacSYn),Parkinson's disease (PD)Â ,Phase 2,11/14/2024,"Phase 2 interim safety and immunogenicity data reported that 100% of patients receiving ACI-7104.056 responded against the target antigen, noted November 14, 2024.",100.0,351.23802,64.8741,3.13,3.55,3.29,0.125914599,0.04985456,0.085331139,0.058788991,0.99501,0.03435,2.69418,2468,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
LLY,Tirzepatide - (SURMOUNT-1),Pre-diabetes and obesity or overweightÂ ,Phase 3,11/14/2024,"Phase 3 data reported a 94% reduction in risk of progression to type 2 diabetes across all pooled doses of tirzepatide compared to placebo over three years, noted November 14, 2024.",946.0,707946.686,31.7667,811.81,786.23,749.92,-0.032016952,-0.079299788,0.085331139,0.058788991,0.73572,0.13891,3144.01348,2469,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
IMMP,Eftilagimod alpha with pembrolizumab and radiotherapy - (EFTISARC-NEO),Soft tissue sarcomaÂ ,Phase 2,11/14/2024,"Phase 2 data presented at CTOS demonstrated a greater than three-fold increase in tumor hyalinization/fibrosis (median 50%), compared to the historical median of 15% with radiotherapy alone, November",147.0,494.55307,85.6898,1.87,2.09,1.84,0.111225635,-0.016172859,0.085331139,0.058788991,0.0,0.0,0.87482,2470,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
IMMP,Eftilagimod alpha + chemo+ anti-PD-1 - (INSIGHT-003),Solid tumorsÂ ,Phase 1,11/14/2024,"Phase 1 data update data in patients with a minimum follow-up of 22 months with a median overall survival is 32.9 months, with median progression free survival reaching 12.7 months, and a 24-month ove",147.0,494.55307,85.6898,1.87,2.09,1.84,0.111225635,-0.016172859,0.085331139,0.058788991,0.0,0.0,0.87482,2471,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ADIL,AD04 - (ONWARD),Alcohol use disorderÂ ,Phase 3,11/14/2024,Phase 3 topline results demonstrated that AD04 delivers lower ondansetron PK exposure compared to the marketed 4mg ondansetron tablet and can be taken in both fed and fasted states. Adial plans to eng,21.0,7.30259,76.9983,0.991,1.14,1.02,0.140069007,0.028843372,0.085331139,0.058788991,1.23142,0.00033,2.14036,2472,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
MBRX,"Annamycin (MB-106) in combination with Cytarabine - (Ara-C, MIRACLE)",Acute Myeloid Leukemia (AML)Â ,Phase 3,11/14/2024,"Phase 3 protocol amended with preliminary data now expected on 2H 2025, noted November 14, 2024.",30.0,9.27586,94.2375,2.51,3.09,2.83,0.207888338,0.119993959,0.085331139,0.058788991,4.07676,0.05143,1.64759,2473,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ANTX,Epetraborole - (EBO-103),"Mycobacterium avium complex (MAC) lung disease, Chronic non-tuberculous mycobacterial (NTM) lung diseaseÂ ",Phase 2,11/14/2024,"Phase 2 data reported nominally statistically significant improvements in MACrO2 measured from baseline to month 6 in post-hoc analysis, noted November 14, 2024.",27.0,29.87889,143.112,1.01,1.0,1.23,-0.009950331,0.197063839,0.085331139,0.058788991,0.44705,0.05553,0.69798,2474,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1
CRVS,Soquelitinib - (CPI-818),Systemic sclerosisÂ ,Preclinical,11/14/2024,"Preclinical findings showed a reduced Th2 helper T cell infiltration and pulmonary fibrosis. These data support the broader application of ITK inhibitors in immune-mediated fibrotic diseases, noted No",74.0,547.47178,79.7685,8.87,8.52,8.94,-0.040258455,0.007860793,0.085331139,0.058788991,4.55206,0.00423,10.38646,2475,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
DTIL,PBGENE-HBV - (ELIMINATE-B),Chronic Hepatitis B Virus (HBV)Â ,Preclinical,11/15/2024,"Preclinical data reinforced safety profile and potential to deliver a functional cure for chronic hepatitis B, supporting advancement into first-in-human clinical study, noted November 15, 2024.",11.0,58.45347,43.3074,7.7,7.62,7.26,-0.010443959,-0.0588405,0.052944822,0.007453451,2.79685,0.06083,0.54792,2476,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ETNB,Pegozafermin - (ENLIVEN),Nonalcoholic Steatohepatitis (NASH)Â ,Phase 2b,11/15/2024,"Phase 2b data presented at AASLD reported that treatment improved patients' FAST scores but also achieved both MASH resolution and fibrosis improvement, noted November 15, 2024.",148.0,932.42701,64.8267,8.75,7.93,8.76,-0.098400665,0.001142205,0.052944822,0.007453451,4.57728,0.05644,11.37091,2477,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1
CERO,CER-1236 - (CertainT-1),"Acute myeloid leukemia (AML), Hematologic malignanciesÂ ",IND-Enabling,11/15/2024,"IND cleared by the FDA, noted November 15, 2024.",1.0,42.8823,231.4044,374.4,570.6,436.2,0.421363694,0.152776109,0.052944822,0.007453451,1.06563,0.04062,334.57759,2478,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
ABUS,Imdusiran (AB-729 w/ NA therapy and Peginterferon alfa-2a) - (IM-PROVE II),Chronic Hepatitis BÂ ,Phase 2a,11/15/2024,"Phase 2a data presented at AASLD reported that 50% of patients who had baseline HBsAg levels less than 1000 IU/mL achieved functional cure in Cohort A1, noted November 15, 2024.",191.0,689.74973,42.0883,3.63,3.64,3.51,0.002751033,-0.033616611,0.052944822,0.007453451,3.45311,0.01583,6.5201,2479,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1
GILD,Livdelzi (Seladelpar) - (ASSURE),Pruritus (itch) in people living with primary biliary cholangitis (PBC)Â ,Phase 3,11/15/2024,"Phase 3 data reported that 81% (30 out of 37) of participants with primary biliary cholangitis (PBC) treated with LivdelziÂ® (seladelpar) achieved a composite biochemical response, noted November 15, 2",0.0,110169.9018,25.2492,92.11,88.4,90.19,-0.041111545,-0.021064959,0.052944822,0.007453451,1.42383,0.0648,1012.57939,2480,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1
AVIR,Bemnifosbuvir and ruzasvir (RZR) - (C-FORWARD),Hepatitis C Virus (HCV)Â ,Phase 2,11/15/2024,"Phase 2 results from AASLD reported a SVR12 rate of 97%, noted November 15, 2024.",79.0,271.97105,47.5923,3.31,3.22,3.37,-0.02756683,0.017964555,0.052944822,0.007453451,3.06702,0.19011,1.01051,2481,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ALT,Pemvidutide - (IMPACT),Metabolic dysfunction-associated steatohepatitis (MASH)Â ,Phase 1b,11/15/2024,"Phase 1b data presented at AASLD reported that treatment reduced LFC relative to baseline by up to 68.5% and decreased total cholesterol and triglycerides by up to 12.2% and 44.6%, respectively, after",88.0,541.2584,85.9033,8.455,7.61,8.68,-0.10529481,0.026263546,0.052944822,0.007453451,32.2486,0.10046,41.19094,2482,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1
ALNY,ALN-HBV02 (VIR-2218) and VIR-3434 - (MARCH),Hepatitis BÂ ,Phase 2,11/15/2024,"Phase 2 data reported that 39% of participants with low baseline Hepatitis B surface antigen (HBsAg) achieved HBsAg loss with tobevibart + elebsiran, and 46% with tobevibart + elebsiran + pegylated in",131.0,30382.74481,56.4135,257.91,235.56,244.89,-0.090645029,-0.051801557,0.052944822,0.007453451,2.86639,0.03543,414.89112,2483,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1
VIR,ALN-HBV02 (VIR-2218) and VIR-3434 - (MARCH),Hepatitis BÂ ,Phase 2,11/15/2024,"Phase 2 data reported that 39% of participants with low baseline Hepatitis B surface antigen (HBsAg) achieved HBsAg loss with tobevibart + elebsiran, and 46% with tobevibart + elebsiran + pegylated in",138.0,1103.13816,63.5539,8.64,8.01,7.12,-0.075711822,-0.193494857,0.052944822,0.007453451,4.15466,0.0282,11.86062,2484,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1
SNDX,Revuforj (revumenib),Adult and pediatric relapsed or refractory (R/R) KMT2A-rearranged (KMT2Ar) acute leukemiaÂ ,Approved,11/15/2024,"FDA approved on November 15, 2024.",86.0,1351.212,60.0912,16.79,15.83,16.09,-0.058876597,-0.04258551,0.052944822,0.007453451,12.48581,0.24298,79.9381,2485,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
AMGN,UPLIZNA (INEBILIZUMAB-CDON),Immunoglobulin G4-related disease (IgG4-RD)Â ,Phase 3,11/15/2024,"Phase 3 data presented at ACR Convergence with statistically significant 87% reduction in the risk of IgG4-RD flare compared to placebo, noted November 15, 2024.",538.0,152449.6556,23.189,295.93,283.61,294.53,-0.042522885,-0.004742074,0.052944822,0.007453451,1.64135,0.06958,1510.2604,2486,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1
REGN,"Nexiguran ziclumeran (nex-z, NTLA-2001) - (MAGNITUDE)",Transthyretin amyloidosis (ATTR)Â ,Phase 1,11/16/2024,"Phase 1 interim data presented at AHA reported that a ll patients with NYHA Class III at baseline (n=18) showed improvement or no change in their NYHA Class at month 12, noted November 16, 2024.",105.0,81424.83296,24.6737,756.81,756.81,738.0,0.0,-0.025168407,-0.001414658,-0.04690603,1.72212,0.14752,0.0,2487,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
NTLA,"Nexiguran ziclumeran (nex-z, NTLA-2001) - (MAGNITUDE)",Transthyretin amyloidosis (ATTR)Â ,Phase 1,11/16/2024,"Phase 1 interim data presented at AHA reported that a ll patients with NYHA Class III at baseline (n=18) showed improvement or no change in their NYHA Class at month 12, noted November 16, 2024.",107.0,1422.82455,64.316,13.97,13.97,14.3,0.0,0.023347364,-0.001414658,-0.04690603,15.85826,0.3262,0.0,2488,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
NVO,Efruxifermin - (HARMONY),Nonalcoholic SteatohepatitisÂ ,Phase 2b,11/17/2024,"Phase 2b additional 96-Week data presented at AASLD reported an over 40% of participants treated with EFX 50mg for 96 weeks, compared with 0% for placebo, showed regression of liver fibrosis by all of",0.0,3146282.727,32.1382,101.74,101.74,105.06,0.0,0.032111076,-0.001414658,-0.04690603,0.0,0.0,0.0,2489,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1
AKRO,Efruxifermin - (HARMONY),Nonalcoholic SteatohepatitisÂ ,Phase 2b,11/17/2024,"Phase 2b additional 96-Week data presented at AASLD reported an over 40% of participants treated with EFX 50mg for 96 weeks, compared with 0% for placebo, showed regression of liver fibrosis by all of",79.0,1960.65807,51.6748,28.09,28.09,32.73,0.0,0.152878447,-0.001414658,-0.04690603,5.47423,0.07967,0.0,2490,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1
SGMT,Denifanstat - (FASCINATE-3),Nonalcoholic steatohepatitis (NASH)Â ,Phase 2b,11/17/2024,"Additional data shared at AASLD reported that denifanstat treatment improved fibrosis by â‰¥ 1 stage in more than 50% of F3 patients as follows, noted November 17, 2024.",32.0,152.28398,101.5518,4.73,4.73,4.76,0.0,0.006322466,-0.001414658,-0.04690603,12.956,0.12618,0.0,2491,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ALNY,Nucresiran (ALN-TTRsc04) - (TRITON-CM),ATTR amyloidosisÂ ,Phase 1,11/17/2024,"Phase 1 additional data from AHA reported mean reductions of greater than 90% from baseline achieved at Day 15 and sustained through at least Day 180, noted November 17, 2024.",131.0,30382.74481,56.4135,235.56,235.56,244.89,0.0,0.038843472,-0.001414658,-0.04690603,2.86639,0.03543,0.0,2492,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1
CYTK,Aficamten (CK-274) - (SEQUOIA-HCM),Hypertrophic cardiomyopathy (HCM)Â ,Phase 3,11/17/2024,"Phase 3 data shared at AHA reported shortened times for VO2Rec to decline by 12.5% (VO2Rec T12.5%), 25% (VO2Rec T25%) and 50% (VO2Rec T50%) of peak VO2, corresponding to absolute reductions relative t",119.0,5926.67513,47.82,50.22,50.22,49.1,0.0,-0.022554319,-0.001414658,-0.04690603,13.29487,0.01014,0.0,2493,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CYTK,Aficamten - (FOREST-HCM) (OLE),Non-obstructive hypertrophic cardiomyopathy (HCM)Â ,Phase 3,11/17/2024,"Phase 3 data shared at AHA reported that treatment rapidly improved the symptom and LVOT gradient criteria used to define guidelineeligibility in 97% of patients, noted November 17, 2024.",119.0,5926.67513,47.82,50.22,50.22,49.1,0.0,-0.022554319,-0.001414658,-0.04690603,13.29487,0.01014,0.0,2494,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
IVA,Lanifibranor in combination with empagliflozin (Jardiance1) - (LEGEND),"Metabolic dysfunction-associated steatohepatitis (MASH), and type 2 diabetes (T2D)Â ",Phase 2a,11/18/2024,"Phase 2a data presented at AASLD reported that 50% percent of patients saw their HbA1c levels below 6.5% at week 24 following treatment with lanifibranor alone or in combination with empagliflozin, no",95.0,223.35429,85.3009,2.505,2.565,2.435,0.023669744,-0.028341978,-0.01448674,-0.061245782,0.0,0.00805,0.057,2495,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1
NGNE,NGN-401 - (Embolden),Rett SyndromeÂ ,Phase 1/2,11/18/2024,"Phase 1/2 discontinuation of 3E15 vg dose announced November 18, 2024.",14.0,293.90311,147.1629,34.515,19.82,22.315,-0.554702483,-0.436134914,-0.01448674,-0.061245782,6.16501,0.21487,39.62561,2496,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ACET,ADI-001,Lupus nephritis and Systemic Lupus Erythematosus (SLE)Â ,Phase 1,11/18/2024,"Phase 1 clinical trial initiated, noted November 18, 2024.",83.0,87.93013,66.1944,0.9469,0.9679,0.904,0.021935285,-0.046364131,-0.01448674,-0.061245782,3.78912,0.03864,0.66685,2497,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ADVM,"Ixo-vec (ixoberogene soroparvovec, ADVM-022) - (ARTEMIS)",Wet age-related macular degeneration (AMD)Â ,Phase 2,11/18/2024,"Phase 2 52-week data combined with follow-up from OPTIC at 4 years continue to support long-term potential best-in-class product profile of Ixo-vec, The therapy reduced injection burden by 80%-90%, ac",20.0,142.49687,59.7718,6.86,6.85,6.15,-0.001458789,-0.10925536,-0.01448674,-0.061245782,7.71421,0.02835,2.82995,2498,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
TNXP,Tonmya (TNX-102 SL) - (RELIEF/RESILIENT),FibromyalgiaÂ ,Phase 3,11/18/2024,"Phase 3 data presented at ACR Convergence demonstrated statistically significant improvement in the primary endpoint of fibromyalgia neoplastic pain and in all six key secondary endpoints, including s",8.0,24.85693,168.687,13.11,13.3,19.2,0.014388737,0.381534981,-0.01448674,-0.061245782,4.10413,0.05779,1.20408,2499,1,0,0,0,0,1,0,0,1,0,1,0,4,0,0,1
RGNX,RGX-202 - (AFFINITY DUCHENNE),Duchenne Muscular Dystrophy (DMD)Â ,Phase 1/2,11/18/2024,"Phase 1/2 data showed functional improvements in all patients, with dose-dependent performance exceeding natural history benchmarks. Biomarker data confirmed robust microdystrophin expression, and th",50.0,502.88247,67.4751,9.63,10.15,9.58,0.05259048,-0.005205634,-0.01448674,-0.061245782,9.90886,0.15488,31.19794,2500,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
IMTX,IMA402,Solid TumorsÂ ,Phase 1/2,11/18/2024,"Phase 1/2 initial clinical data demonstrated a favorable tolerability profile and signs of dose-dependent and PRAME expression-dependent clinical activity, including first objective responses in melan",121.0,933.36319,51.7965,8.17,7.82,7.59,-0.043784354,-0.073637317,-0.01448674,-0.061245782,5.60642,0.04155,9.28618,2501,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CYBN,CYB003 - (EXTEND and EMBRACE),Major Depressive Disorder (MDD) and Alcohol use disorder (AUD)Â ,Phase 2,11/18/2024,"Phase 2 12-month data showed that 100% of participants were responsive to treatment and 71% of participants were in remission at 12 months after just two 16 mg doses, noted November 18, 2024.",23.0,212.0149,61.9506,11.6,10.6,10.64,-0.090151097,-0.086384614,-0.01448674,-0.061245782,3.04843,0.02947,31.55966,2502,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
LRMR,Nomlabofusp (CTI-1601),Friedreichâ€™s ataxia (FA)Â ,Phase 2,11/18/2024,"Phase 2 data presented at ICAR demonstrated alignment between FXN levels and disease progression, reinforcing the drug's potential efficacy, noted November 18, 2024.",85.0,393.04883,86.9184,6.69,6.16,6.33,-0.082537097,-0.055313638,-0.01448674,-0.061245782,4.26987,0.03392,6.89329,2503,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CABA,CABA-201 - (RESET-SLE),Systemic Lupus ErythematosusÂ ,Phase 1/2,11/18/2024,"Phase 1/2 additional data to presented at ACR showed that demonstrated compelling efficacy, including 100% B cell depletion within one month and early naÃ¯ve B cell repopulation, indicating potential i",91.0,131.96834,109.7389,3.03,2.7,2.29,-0.115310847,-0.280010802,-0.01448674,-0.061245782,7.58212,0.24846,8.3672,2504,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CABA,rese-cel (resecabtagene autoleucel (CABA-201) - (RESET-Myositis),"Active idiopathic inflammatory myopathy (IIM, or myositis)Â ",Phase 1/2,11/18/2024,"Phase 1/2 data presented at ACR showed a safety profile was favorable, with low-grade CRS in three patients and no additional ICANS events reported, noted November 18, 2024.",91.0,131.96834,109.7389,3.03,2.7,2.29,-0.115310847,-0.280010802,-0.01448674,-0.061245782,7.58212,0.24846,8.3672,2505,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CABA,CABA-201 - (RESET-SSc),Systemic sclerosis (SSc)Â ,Phase 1/2,11/18/2024,"Phase 1/2 initial data presented at ACR showed that first SSc patient demonstrated an emerging, drug-free clinical response, noted November 18, 2024.",91.0,131.96834,109.7389,3.03,2.7,2.29,-0.115310847,-0.280010802,-0.01448674,-0.061245782,7.58212,0.24846,8.3672,2506,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
THAR,TH104 (AV104),Primary biliary cholangitis (PBC)Â ,Phase 1,11/18/2024,"Phase 1 results at AASLD demonstrated a significant correlation between blood levels of TH104 and reductions in pruritus, measured by the Worst-Itch Numerical Rating Scale (WI-NRS). Patients experienc",4.0,3.52191,133.845,2.17,2.37,2.45,0.088162788,0.121360857,-0.01448674,-0.061245782,33.43584,0.01279,20.79411,2507,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CTNM,PIPE-791,Osteoarthritis and low back painÂ ,IND-Enabling,11/18/2024,"IND cleared by the FDA, noted November 18, 2024.",28.0,408.06246,75.4187,17.21,15.83,15.36,-0.083583736,-0.113723883,-0.01448674,-0.061245782,4.34308,0.35228,0.83475,2508,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
MBRX,Annamycin and Ara-C,Acute myeloid leukemia (AML)Â ,Phase 1/2,11/18/2024,"Phase 1/2 data demonstrated median overall survival (""OS"") of 9.1 months for subjects with a wide range of (0-6) prior lines of therapy (n=22) and 11.6 months (n=10) for subjects with 1 prior line of",30.0,7.56478,96.6266,2.71,2.52,2.65,-0.072689733,-0.022388995,-0.01448674,-0.061245782,4.07676,0.03438,0.12899,2509,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
INTS,INT230-6 (VINblastine CIsplatin) - (INVINCIBLE-3),Early-stage presurgical breast cancerÂ ,Phase 3,11/18/2024,"Phase 3 data reported a median overall survival (""mOS"") of 21.3 months versus a synthetic control of 6.7 months, noted November 18, 2024.",47.0,43.54457,45.4989,3.15,3.14,2.86,-0.003179653,-0.096580828,-0.01448674,-0.061245782,0.31928,0.00802,0.02857,2510,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CLDI,CLD-400 - (RTNova),Metastatic Solid Tumors & Lung cancerÂ ,Phase 1,11/18/2024,"Phase 1 data reported that treatment successfully kills and transforms tumor microenvironments and can additionally induce expression of engineered payloads in the tumor cells, noted November 18, 2024",3.0,45.39395,171.5978,26.28105,28.20113,24.24097,0.070513901,-0.08080397,-0.01448674,-0.061245782,3.03173,0.00284,4.44842,2511,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ALLR,Stenoparib,Advanced ovarian cancer (AOC)Â ,Phase 2,11/18/2024,"Phase 2 update reported that two patients exceed 14 months on treatment, noted November 18, 2024.",14.0,5.36464,132.822,1.32,1.21,1.28,-0.087011377,-0.030771659,-0.01448674,-0.061245782,4.0472,0.05005,0.72138,2512,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
BMEA,Icovamenib (BMF-219) - (COVALENT-111),"Healthy volunteers, type 2 diabetesÂ ",Phase 2,11/18/2024,"Phase 2 trial data presented at ATTD-ASIA reported that 83% of patients with insulin deficiency responded to icovamenib, and showed a greater mean HbA1c reduction at Week 26 compared to baseline, than",59.0,233.01476,164.5143,6.53,6.43,6.93,-0.015432405,0.05945287,-0.01448674,-0.061245782,23.39179,0.01892,5.46661,2513,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ARWR,Plozasiran (ARO-APOC3-3001) - (PALISADE),"Familial chylomicronemia syndrome (FCS), HypertriglyceridemiaÂ ",NDA Filing,11/18/2024,"NDA submitted November 18, 2024.",138.0,2364.47651,50.8131,18.57,19.02,18.79,0.023943682,0.011777438,-0.01448674,-0.061245782,7.5522,0.11889,24.63497,2514,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
ARWR,Plozasiran (ARO-APOC3-2001) - (SHASTA-2),HypertriglyceridemiaÂ ,Phase 2b,11/18/2024,"Additional Phase 2b data reported that 10, 25, or 50 mg of plozasiran in the blinded portion of the studies produced mean reductions up to -74% at 24 weeks, noted November 18, 2024.",138.0,2364.47651,50.8131,18.57,19.02,18.79,0.023943682,0.011777438,-0.01448674,-0.061245782,7.5522,0.11889,24.63497,2515,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
LLY,Tirzepatide - (SUMMIT),Heart failure with preserved ejection fraction (HFpEF) and obesityÂ ,Phase 3,11/18/2024,"Phase 3 data showed a 38% reduction in the risk of heart failure outcomes, noted November 18, 2024.",946.0,654794.1824,32.5319,746.2,727.2,755.0,-0.025792118,0.011724088,-0.01448674,-0.061245782,0.73572,0.18443,6657.04405,2516,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CYTK,Omecamtiv mecarbil - (GALACTIC-HF),Heart failure with reduced ejection fraction (HFrEF)Â ,Phase 3,11/18/2024,"Phase 3 data shared at AHA reported that there was a significantly higher risk of the primary endpoint of cardiovascular death or heart failure events and all-cause mortality, noted November 18, 2024.",119.0,6129.65963,48.2405,50.22,51.94,50.25,0.033675853,0.000597193,-0.01448674,-0.061245782,13.29487,0.01014,66.94225,2517,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
AMGN,Omecamtiv mecarbil - (GALACTIC-HF),Heart failure with reduced ejection fraction (HFrEF)Â ,Phase 3,11/18/2024,"Phase 3 data shared at AHA reported that there was a significantly higher risk of the primary endpoint of cardiovascular death or heart failure events and all-cause mortality, noted November 18, 2024.",538.0,149842.6219,23.3091,283.61,278.76,294.0,-0.017248858,0.035979712,-0.01448674,-0.061245782,1.64135,0.06958,885.30803,2518,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ACET,ADI-001,Non-Hodgkinâ€™s lymphomaÂ ,Phase 1,11/18/2024,"Phase 1 clinical update presented at ACR reported tissue trafficking and activation, complete depletion of CD19+ B cells within analyzed lymph node tissue was also observed, noted November 18, 2024.",83.0,87.93013,66.1944,0.9469,0.9679,0.904,0.021935285,-0.046364131,-0.01448674,-0.061245782,3.78912,0.03864,0.66685,2519,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ALGS,Pevifoscorvir (ALG-000184) - (CAM-2),HBeAg-positive chronic hepatitis B (CHB)Â ,Phase 1b,11/18/2024,Phase 1a/1b data presented at the Liver Meeting reported that treatment decreased serum total cholesterol in young healthy dogs maintained on a normal diet in the 2-week study at â‰¥50 Âµg/kg/day (up to,6.0,74.67709,137.48,19.17,20.12,20.46,0.048367788,0.065125203,-0.01448674,-0.061245782,3.26801,0.00023,7.84308,2520,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
NAMS,Obicetrapib - (BROOKLYN),Heterozygous familial hypercholesterolemia (HeFH)Â ,Phase 3,11/18/2024,"Phase 3 data presented at AHA showed that the trial met its primary endpoint with an LDL-C mean reduction versus placebo of 36.3% at day 84 and 41.5% at day 365, noted November 18, 2024.",112.0,2278.2356,48.903,24.9,24.66,21.05,-0.009685306,-0.167967243,-0.01448674,-0.061245782,0.77722,0.11049,28.16256,2521,1,0,1,0,0,1,0,0,0,0,0,0,3,0,0,1
NKTR,NKTR-422,Autoimmune diseasesÂ ,Preclinical,11/18/2024,"Preclinical study presented at ACR 2024 demonstrated inflammation resolution and tissue repair in multiple preclinical models of chronic inflammatory conditions, noted November 18, 2024.",19.0,189.99203,73.5103,16.04999,15.44999,16.34999,-0.03809987,0.018519059,-0.01448674,-0.061245782,2.83326,0.14903,1.43246,2522,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
JNJ,Icotrokinra (JNJ-2113) - (ICONIC-LEAD),Moderate-to-severe psoriasisÂ ,Phase 3,11/18/2024,"Phase 3 study met its co-primary endpoints in patients with moderate to severe plaque psoriasis, noted November 18, 2024.",0.0,372627.8074,15.8383,154.0,154.77,155.78,0.004987542,0.011492153,-0.01448674,-0.061245782,0.75208,0.0,1162.96917,2523,1,0,0,0,0,1,0,0,0,0,0,0,2,0,0,1
PTGX,Icotrokinra (JNJ-2113) - (ICONIC-LEAD),Moderate-to-severe psoriasisÂ ,Phase 3,11/18/2024,"Phase 3 study met its co-primary endpoints in patients with moderate to severe plaque psoriasis, noted November 18, 2024.",62.0,2407.16395,46.2957,41.11,40.39,45.53,-0.017669171,0.102120048,-0.01448674,-0.061245782,5.5069,0.1537,19.78609,2524,1,0,0,0,0,1,0,0,0,0,0,0,2,0,0,1
JNJ,Icotrokinra (JNJ-2113) - (ICONIC-TOTAL),Moderate-to-severe psoriasisÂ ,Phase 3,11/18/2024,"Phase 3 study showed once daily icotrokinra met the primary endpoint of IGA of 0/1 at week 16 compared to placebo, noted November 18, 2024.",0.0,372627.8074,15.8383,154.0,154.77,155.78,0.004987542,0.011492153,-0.01448674,-0.061245782,0.75208,0.0,1162.96917,2525,1,0,0,0,0,1,0,0,0,0,0,0,2,0,0,1
PTGX,Icotrokinra (JNJ-2113) - (ICONIC-TOTAL),Moderate-to-severe psoriasisÂ ,Phase 3,11/18/2024,"Phase 3 study showed once daily icotrokinra met the primary endpoint of IGA of 0/1 at week 16 compared to placebo, noted November 18, 2024.",62.0,2407.16395,46.2957,41.11,40.39,45.53,-0.017669171,0.102120048,-0.01448674,-0.061245782,5.5069,0.1537,19.78609,2526,1,0,0,0,0,1,0,0,0,0,0,0,2,0,0,1
INCY,MRGPRX2 (INCB000262),Spontaneous urticaria (CSU)Â ,Phase 2,11/18/2024,"Phase 2 enrollment paused, noted November 18, 2024.",196.0,14828.28967,30.5255,75.87,76.97,73.52,0.014394386,-0.031463871,-0.01448674,-0.061245782,3.85109,0.09206,141.90066,2527,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,-1
INCY,MRGPRX4 (INCB000547),Cholestatic pruritus (CP)Â ,Phase 2,11/18/2024,"Phase 2 study data does not support further development, noted November 18, 2024.",196.0,14828.28967,30.5255,75.87,76.97,73.52,0.014394386,-0.031463871,-0.01448674,-0.061245782,3.85109,0.09206,141.90066,2528,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
SLN,Zerlasiran (formerly SLN360) - (ALPACAR-360),Cardiovascular diseases and Polycythemia veraÂ ,Phase 2,11/18/2024,"Phase 2 data presented at AHA showed significant time-averaged Lp(a) reductions, with effects persisting 60 weeks following the first dose, noted November 18, 2024.",46.0,520.30742,53.2338,12.7,11.02,7.21,-0.14189019,-0.566133042,-0.01448674,-0.061245782,0.74832,0.0302,8.83399,2529,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
PLRX,Bexotegrast (PLN-74809) - (INTEGRIS-PSC),Primary sclerosing cholangitis (PSC)Â ,Phase 2a,11/18/2024,"Phase 2a data presented at AASLD reported a stable ELF score from Week 12 to Week 24, with a reduction in participants with an ELF score of >9.8 at baseline, noted November 18, 2024.",61.0,749.71664,56.7218,12.43,12.32,13.46,-0.008888947,0.079609419,-0.01448674,-0.061245782,11.85768,0.06371,16.99721,2530,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1
ALLO,ALLO-329 - (RESOLUTION),Autoimmune Disease (AID)Â ,Preclinical,11/18/2024,"Preclinical data shared at ACR demonstrated that ALLO-329 could be effective in treating autoimmune diseases with reduced or no lymphodepleting chemotherapy, noted November 18, 2024.",221.0,450.795,84.1403,2.27,2.15,2.28,-0.054311989,0.004395611,-0.01448674,-0.061245782,17.66607,0.13102,6.286,2531,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ALNY,Elebsiran (VIR-2218) and tobevibart (VIR-3434) - (SOLSTICE),Hepatitis Delta Virus (HDV)Â ,Phase 2,11/18/2024,"Phase 2, 24-week data from AASLD reported 100% virologic suppression, noted November 18, 2024.",131.0,29958.39759,56.5637,235.56,232.27,250.98,-0.01406517,0.063407597,-0.01448674,-0.061245782,2.86639,0.03543,362.7493,2532,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
VIR,Elebsiran (VIR-2218) and tobevibart (VIR-3434) - (SOLSTICE),Hepatitis Delta Virus (HDV)Â ,Phase 2,11/18/2024,"Phase 2, 24-week data from AASLD reported 100% virologic suppression, noted November 18, 2024.",138.0,968.17244,66.2608,8.01,7.03,7.44,-0.130504055,-0.073819912,-0.01448674,-0.061245782,4.15466,0.0282,15.82726,2533,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
MIRM,Volixibat - (VANTAGE),Pruritus associated with primary biliary cholangitisÂ ,Phase 2b,11/18/2024,"Phase 2b data presented at AASLD reported rapid and statistically significant reductions in cholestatic pruritus were observed after treatment, noted November 18, 2024.",50.0,1988.34979,60.7189,44.5,41.42,44.27,-0.071725333,-0.005181942,-0.01448674,-0.061245782,14.25961,0.01405,24.67704,2534,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1
ADVM,"Lxo-vec (ixoberogene soroparvovec, ADVM-022) - (OPTIC)",Wet age-related macular degeneration (Wet-AMD)Â ,Phase 2,11/18/2024,"Phase 2 long term data reported that 78% of patients who were injection free through year 1 remained injection free through year 4, noted November 18, 2024.",20.0,142.49687,59.7718,6.86,6.85,6.15,-0.001458789,-0.10925536,-0.01448674,-0.061245782,7.71421,0.02835,2.82995,2535,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
LLY,Muvalaplin,Heart diseaseÂ ,Phase 2,11/18/2024,"Phase 2 study met at the 12-week its primary endpoint, noted November 18, 2024.",946.0,654794.1824,32.5319,746.2,727.2,755.0,-0.025792118,0.011724088,-0.01448674,-0.061245782,0.73572,0.18443,6657.04405,2536,1,0,0,0,0,1,0,0,0,0,0,0,2,0,0,1
RCKT,RP-A501,Danon diseaseÂ ,Phase 2,11/18/2024,Phase 2 demonstrated safety and meaningful efficacy; all evaluable patients show cardiac LAMP2 expression and â‰¥10% reduction in LV mass index at 12 months and sustained through most recent follow up (,107.0,1245.20578,57.0254,13.98,13.66,14.1,-0.023155883,0.008547061,-0.01448674,-0.061245782,13.05165,0.14621,20.29291,2537,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
FATE,FT819,B-cell Leukemias and LymphomasÂ ,Phase 1b,11/18/2024,"Phase 1b data presenteed at ACR showed patient treated with fludarabine-free conditioning and single-dose FT819; favorable safety profile with no grade â‰¥3 adverse events and no events of CRS, ICANS, o",115.0,258.54014,83.1726,2.02,2.27,2.42,0.11668232,0.180670029,-0.01448674,-0.061245782,13.96232,0.0712,56.18804,2538,0,0,0,1,0,1,0,0,0,0,0,0,2,0,0,1
FATE,FT522,LupusÂ ,Phase 1,11/18/2024,"Phase 1 initial data showed a favorable safety profile, complete responses, and persistence of FT522 live cells, noted November 18, 2024.",115.0,258.54014,83.1726,2.02,2.27,2.42,0.11668232,0.180670029,-0.01448674,-0.061245782,13.96232,0.0712,56.18804,2539,0,0,0,1,0,1,0,0,0,0,0,0,2,0,0,1
CMMB,nebokitug (CM-101) - (SPRING),Primary Sclerosing CholangitisÂ ,Phase 2,11/19/2024,"Phase 2 data presented at AASLD met the trial's primary endpoint, demonstrating a favorable safety profile over the 15-week treatment period on November 19, 2024.",5.0,30.54771,110.4505,6.6,6.48,6.36,-0.018349139,-0.037041272,-0.02204746,-0.07224985,0.86389,0.02463,0.16479,2540,1,0,0,1,0,1,0,0,0,0,1,0,4,0,0,1
MRK,KEYTRUDA QLEX (pembrolizumab and berahyaluronidase alfa-pmph),Solid tumorsÂ ,Phase 3,11/19/2024,"Phase 3 data reported that the trial met its primary endpoint, noted November 19, 2024.",0.0,244211.0252,23.608,96.56,96.54,101.62,-0.000207147,0.051075789,-0.02204746,-0.07224985,1.03685,0.11705,1264.00488,2541,1,0,0,0,0,1,0,0,0,0,0,0,2,0,0,1
PHIO,PH-762,Cutaneous Squamous Cell CarcinomaÂ ,Phase 1b,11/19/2024,"Phase 1b 2nd cohort completion, noted November 19, 2024.",5.0,2.69292,94.4509,2.27,2.552,2.51,0.117097534,0.100502922,-0.02204746,-0.07224985,4.87965,0.07484,0.69783,2542,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
GSK,Linerixibat - (GLISTEN),Primary biliary cholangitis (PBC)Â ,Phase 3,11/19/2024,"Phase 3 trial met primary endpoint, noted November 19, 2024.",0.0,53189.3136,23.2159,13.1,13.035,13.38,-0.004974183,0.021148824,-0.02204746,-0.07224985,0.0,0.0807,211.86151,2543,1,0,0,0,0,1,0,0,0,0,0,0,2,0,0,1
BIIB,Dapirolizumab pegol (anti-CD40L),Systemic lupus erythematosusÂ ,Phase 3,11/19/2024,Phase 3 data reported that a greater response was observed across multiple clinical endpoints among participants treated with DZP including 50% less severe disease flares compared to participants on s,146.0,22649.15702,25.2903,157.94,155.43,157.69,-0.016019745,-0.001584134,-0.02204746,-0.07224985,2.14149,0.15644,201.57064,2544,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ALGS,Pevifoscorvir (ALG-000184) - (CAM-2),HBeAg-positive chronic hepatitis B (CHB)Â ,Phase 1b,11/19/2024,"Phase 1a/1b data presented at AALSD from â‰¤84 weeks demonstrated sustained HBV DNA suppression in 7/7 (100%) HBeAg-positive CHB subjects, noted November 19, 2024.",6.0,68.66432,137.948,20.12,18.5,21.35,-0.083943613,0.059337394,-0.02204746,-0.07224985,3.26801,0.00023,28.21659,2545,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
NVO,Icosema - (COMBINE 3),Type 2 diabetesÂ ,Phase 3,11/19/2024,"Phase 3a data reported that treatment had safe and well-tolerated profile, noted November 19, 2024.",0.0,3207922.258,32.5572,99.81,102.63,106.13,0.027861909,0.061396379,-0.02204746,-0.07224985,0.0,0.0,593.07044,2546,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1
GOVX,COVID-19 booster with GEO-CM04S1 or Pfizer-BioNTech Bivalent vaccine,"COVID-19 Infection, Chronic Lymphocytic LeukemiaÂ ",Phase 2,11/19/2024,"Phase 2 DSMB review of interim data completed, the DSMB determined that, while the mRNA control arm of the study failed to meet the predetermined primary endpoint, the study should continue enrollment",25.0,27.45896,223.9857,3.03,2.91,2.7,-0.040409538,-0.115310847,-0.02204746,-0.07224985,3.19011,0.07303,4.53699,2547,1,0,0,0,0,1,0,0,0,0,0,0,0,2,0,-1
NXTC,NC605,Osteogenesis Imperfecta (OI)Â ,Preclinical,11/19/2024,"Preclinical data demonstrating that treatment with NC605, a novel anti-Siglec-15 (S15) antibody, resulted in enhanced generation of quality bone with better mechanical properties, noted November 19,",2.0,36.68875,66.1865,15.48001,15.72001,14.04001,0.015384909,-0.097638403,-0.02204746,-0.07224985,0.23608,0.01757,0.04935,2548,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
LTRN,LP-300 - (Harmonic),Non-small cell lung cancer (NSCLC)Â ,Phase 2,11/19/2024,"Phase 2 additional expansion cohort dosing initiated, noted November 19, 2024.",10.0,33.21695,72.9822,3.16,3.08,3.072,-0.025642431,-0.028243212,-0.02204746,-0.07224985,1.53517,0.07001,0.14762,2549,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1
OCGN,OCU410 - (ArMaDa),Geographic Atrophy (GA)Â ,Phase 1/2,11/19/2024,"Phase 1/2 preliminary data showed an considerably slower lesion growth (21.4%) from baseline in treated vs. untreated fellow eyes that followed the natural history of the disease, noted November 19, 2",292.0,254.4974,74.1017,0.9112,0.8736,0.9086,-0.042139807,-0.002857459,-0.02204746,-0.07224985,17.38472,0.03,5.12646,2550,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
SGMO,ST-503,Chronic neuropathic painÂ ,Phase 1/2,11/19/2024,"IND Clearance by the FDA, noted November 19, 2024.",301.0,408.94787,151.6628,1.9,1.96,2.14,0.031090587,0.118951943,-0.02204746,-0.07224985,9.09599,0.001,12.56473,2551,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
VKTX,VK2809 - (VOYAGE),Non-alcoholic steatohepatitis (NASH) and fibrosisÂ ,Phase 2b,11/19/2024,"Phase 2b 52 week data presented at AASLD summarized results including successful achievement of study's primary and secondary endpoints, noted November 19, 2024.",113.0,5740.08814,85.4305,49.11,51.51,53.42,0.047713284,0.084122528,-0.02204746,-0.07224985,11.91762,0.05502,284.05679,2552,1,0,0,0,0,1,0,0,1,0,1,0,4,0,0,1
LGND,VK2809 - (VOYAGE),Non-alcoholic steatohepatitis (NASH) and fibrosisÂ ,Phase 2b,11/19/2024,"Phase 2b 52 week data presented at AASLD summarized results including successful achievement of study's primary and secondary endpoints, noted November 19, 2024.",19.0,2112.5027,40.8582,111.67,111.8,124.33,0.001163467,0.107391228,-0.02204746,-0.07224985,4.86165,0.13992,10.97697,2553,1,0,0,0,0,1,0,0,1,0,1,0,4,0,0,1
CRDL,CardiolRx - (MAvERIC-Pilot),Recurrent PericarditisÂ ,Phase 2,11/19/2024,"The phase 2 study marked rapid reductions in pericarditis pain and inflammation throughout the 26-week study. Episodes of pericarditis per year substantially reduced, noted November 18, 2024.",83.0,13.42958,52.1823,0.0625,0.0625,0.0675,0.0,0.076961041,-0.02204746,-0.07224985,0.0,0.04607,0.00526,2554,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
SAGE,Dalzanemdor (SAGE-718) - (DIMENSION),Huntington's disease (HD)Â ,Phase 2,11/20/2024,"Phase 2 topline data reported that the trial did not meet its primary endpoint, noted November 20, 2024.",62.0,104432.4764,89.7992,13.0,13.0,14.0,0.0,0.074107972,-0.012055408,-0.070744405,0.0,9e-05,23.764,2555,1,0,0,0,0,1,0,0,0,0,1,0,0,3,0,-1
SUPN,Dalzanemdor (SAGE-718) - (DIMENSION),Huntington's disease (HD)Â ,Phase 2,11/20/2024,"Phase 2 topline data reported that the trial did not meet its primary endpoint, noted November 20, 2024.",56.0,1994.52014,35.1361,35.53,36.12,36.99,0.016469319,0.040270196,-0.012055408,-0.070744405,12.32065,0.08592,7.36545,2556,1,0,0,0,0,1,0,0,0,0,1,0,0,3,0,-1
ARGX,Efgartigimod - (ALKIVIA),"Myositis subsets (Immune-mediated necrotizing myopathy (IMNM), anti-synthetase syndrome (ASyS), and dermatomyositis (DM))Â ",Phase 2/3,11/20/2024,"Phase 2/3 data reported that the trial met its primary endpoint, noted November 20, 2024.",60.0,33419.53104,30.8338,532.2,553.6,582.4,0.039423046,0.090138138,-0.012055408,-0.070744405,0.0,0.00017,54.10886,2557,1,0,0,0,0,1,0,0,0,0,0,0,2,0,0,1
CLDX,CDX-622,Chronic inflammationÂ ,Phase 1a,11/20/2024,"Phase 1a dosing commenced, noted November 20, 2024.",66.0,1751.48783,57.9298,24.98,26.4,27.89,0.055288505,0.110192697,-0.012055408,-0.070744405,12.41981,0.03867,29.65401,2558,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
PRFX,PRF-110,BunionectomyÂ ,Phase 3,11/20/2024,"Phase 3 partial topline data indicated that PRF-110 demonstrated statistically significant superiority over placebo in reducing pain during the first 48 hours following surgery, noted November 20, 202",1.0,2.31551,192.2712,5.6,4.16,2.75,-0.297251523,-0.711165686,-0.012055408,-0.070744405,5.43807,0.0191,5.29806,2559,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1
VYGR,VY1706,Alzheimer's diseaseÂ ,Preclinical,11/20/2024,"Preclinical candidate VY1706 demonstrated significant reductions of tau at low doses in NHP study, noted November 20, 2024. I",55.0,292.79314,67.6886,5.27,5.36,5.78,0.016933613,0.09237332,-0.012055408,-0.070744405,5.40482,0.0681,2.489,2560,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
NAMS,Obicetrapib & ezetimibe - (TANDEM),Cardiovascular diseaseÂ ,Phase 3,11/20/2024,"Phase 3 study achieved all co-primary endpoints of LS mean reduction in LDL-C on top of maximally tolerated lipid-modifying therapies versus each of placebo, ezetimibe 10 mg, and obicetrapib 10 mg mon",112.0,1848.6413,54.4671,23.68,20.01,20.8,-0.168398661,-0.129677823,-0.012055408,-0.070744405,0.77722,0.11049,60.28489,2561,1,0,1,0,0,1,0,0,0,0,0,0,3,0,0,1
VRTX,Povetacicept (ALPN-303) - (RAINIER),"Lupus nephritis, IgA nephropathyÂ ",Phase 1/2,11/20/2024,"Phase 1b/2a study achieved a 90% reduction in leukemic blasts within the first 30 days of treatment, continuing the overall efficacy trend seen in prior studies, noted November 20, 2024.",256.0,116204.9415,23.5953,448.01,451.23,464.56,0.007161634,0.036275167,-0.012055408,-0.070744405,1.7492,0.31655,745.06376,2562,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1
ALPN,Povetacicept (ALPN-303) - (RAINIER),"Lupus nephritis, IgA nephropathyÂ ",Phase 1/2,11/20/2024,"Phase 1b/2a study achieved a 90% reduction in leukemic blasts within the first 30 days of treatment, continuing the overall efficacy trend seen in prior studies, noted November 20, 2024.",68.0,64.45326,21.4893,7.4,7.4,7.4,0.0,0.0,-0.012055408,-0.070744405,0.0,0.00879,0.0,2563,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1
PBYI,PUMA-ALI-1201 - (ALISCA-Breast1),HER-2 Recurrent or metastatic breast cancerÂ ,Phase 2,11/20/2024,"Phase 2 was initiated, noted November 20, 2024.",50.0,139.40902,81.4824,2.74,2.84,3.23,0.035846132,0.164524217,-0.012055408,-0.070744405,6.49624,0.00077,0.76897,2564,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
RXRX,REC-4881,AXIN1 or APC Mutant CancersÂ ,Phase 2,11/20/2024,"Phase 2 was deprioritized as part of a disciplined strategic portfolio prioritization, noted November 20, 2024.",434.0,1732.50295,73.066,6.27,6.04,6.38,-0.037372343,0.017391743,-0.012055408,-0.070744405,21.76405,0.21578,102.70556,2565,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
PYXS,PYX-201-101,Pancreatic CancerÂ ,Phase 1,11/20/2024,"Phase 1 preliminary clinical data achieved a confirmed 50% objective response rate (ORR) based on RECIST 1.1 criteria, including one complete response and a disease control rate (DCR) of 100% in six h",62.0,227.15909,67.4071,4.16,3.82,1.83,-0.085264652,-0.821199107,-0.012055408,-0.070744405,9.84749,0.01513,20.84633,2566,1,0,0,0,0,1,0,0,0,0,0,0,2,0,0,1
KTTA,PAS-004,Neurofibromatosis Type 1 (NF1) and solid tumorsÂ ,Phase 1,11/20/2024,"Phase 1 external Safety Review Committee recommended proceeding to cohort 4, 15mg capsule, without modifications. This recommendation was based on the absence of any dose limiting toxicities (DLT's),",7.0,4.0399,114.1835,3.15,3.19,2.9,0.012618464,-0.082691716,-0.012055408,-0.070744405,0.91446,0.00249,2.39119,2567,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,-1
PALI,PALI-2108,Moderate-to-severe ulcerative colitis (UC)Â ,Preclinical,11/21/2024,"Preclinical data reported that treatment reduced key intracellular markers of inflammation and fibrosis in the colon, including PDE4B expression, while increasing cAMP levels, noted November 21, 2024.",9.0,3.24402,69.6191,2.44,2.44,2.42,0.0,-0.008230499,-0.023443912,-0.061769026,3.24268,0.03854,0.2343,2568,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
XBIO,DNase I,Melanoma Lung MetastasisÂ ,Preclinical,11/21/2024,"Preclinical data demonstrated to significantly suppress metastatic tumor burden, decreases the number of metastatic foci, and substantially prolongs survival compared to the CAR T cell monotherapy gro",1.0,6.18799,78.7628,3.99,4.0126,4.2,0.005648179,0.051293294,-0.023443912,-0.061769026,0.96178,0.00404,0.02083,2569,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
TELO,Telomir-1,Age-related conditionsÂ ,Preclinical,11/21/2024,"Preclinical results confirmed the efficacy of Telomir-1 to turn back the biological clock and support longevity effectively, noted November 21, 2024.",32.0,132.35587,127.1046,4.2,4.47,4.28,0.062303883,0.018868484,-0.023443912,-0.061769026,1.84515,0.00134,0.98046,2570,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
QURE,AMT-260 - (GenTLE),Refractory Temporal Lobe Epilepsy (rTLE)Â ,Phase 1/2,11/21/2024,"Phase 1/2a trial dosing commenced, noted November 21, 2024.",54.0,284.90365,125.7432,5.7,5.845,6.02,0.02512042,0.054621084,-0.023443912,-0.061769026,6.87183,0.04256,4.01419,2571,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ONC,Ziihera (zanidatamab-hrii),HER2-amplified biliary tract cancersÂ ,Approved,11/21/2024,"Approved November 21, 2024.",110.0,20671.25951,40.0755,194.26,194.56,206.16,0.001543131,0.059455098,-0.023443912,-0.061769026,1.02502,0.1016,43.08959,2572,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1
JAZZ,Ziihera (zanidatamab-hrii),HER2-amplified biliary tract cancersÂ ,Approved,11/21/2024,"Approved November 21, 2024.",60.0,7562.86946,29.9989,119.24,125.1,122.64,0.047975149,0.028114966,-0.023443912,-0.061769026,5.94397,0.0876,122.61526,2573,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1
ZYME,Ziihera (zanidatamab-hrii),HER2-amplified biliary tract cancersÂ ,Approved,11/21/2024,"Approved November 21, 2024.",75.0,942.24456,42.0978,14.55,13.68,14.42,-0.061656081,-0.008974862,-0.023443912,-0.061769026,6.82389,0.17287,9.76781,2574,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1
AMRX,Brekiya (dihydroergotamine mesylate) injection,Migraine with or without aura and cluster headache in adultsÂ ,NDA Filing,11/21/2024,"Resubmitted NDA November 21, 2024.",314.0,2577.90566,34.7202,8.41,8.32,8.35,-0.010759219,-0.007159935,-0.023443912,-0.061769026,1.12998,0.09121,6.63007,2575,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CATX,[212Pb]VMT-Î±-NET,Neuroendocrine tumors (NETs)Â ,Phase 1,11/22/2024,"Phase 1 data reported that eight of nine patients had durable control of disease, noted November 22, 2024.",74.0,234.52876,131.5792,3.0,3.47,4.35,0.145542305,0.371563556,-0.034703634,-0.054881758,11.86921,1e-05,33.5004,2576,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
PSTV,CNSide - (FORESEE),Breast or Non-Small Cell Lung Cancer (NSCLC) who have suspicious or confirmed Leptomeningeal Metastases (LM)Â ,Phase 2,11/22/2024,"Additional trial data demonstrated enhanced sensitivity in detecting tumor cells (80%) vs. CSF cytology (29%) in patients with LM, noted November 22, 2024.",99.0,6.95767,88.6054,1.2,1.18,1.28,-0.016807118,0.064538521,-0.034703634,-0.054881758,0.88765,0.03272,0.54641,2577,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
VRPX,Probudur,Pain ReliefÂ ,Preclinical,11/22/2024,"Preclinical data results from a minipig Dose Range Finding (DRF) study for Probudur demonstrated positive tolerance to it, and no adverse effects were reported, noted November 22, 2024.",1.0,4.58566,180.8744,14.7425,14.175,11.5275,-0.039254629,-0.245998994,-0.034703634,-0.054881758,4.33821,0.00035,90.88677,2578,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
AZN,Attruby (Acoramidis) - (ATTRibute-CM),Amyloid cardiomyopathy (ATTR-CM)Â ,Approved,11/22/2024,"FDA approved on November 22, 2024.",0.0,162377.0965,21.9968,100.62,104.74,106.12,0.040130044,0.053219484,-0.034703634,-0.054881758,0.0,0.03667,300.46334,2579,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
BBIO,Attruby (Acoramidis) - (ATTRibute-CM),Amyloid cardiomyopathy (ATTR-CM)Â ,Approved,11/22/2024,"FDA approved on November 22, 2024.",191.0,4426.14116,54.7944,23.24,23.42,27.09,0.007715426,0.153289724,-0.034703634,-0.054881758,9.10073,0.03495,48.91122,2580,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
CNSP,Berubicin,Glioblastoma (GBM) (adult)Â ,Phase 2,11/22/2024,"Phase 2 update reported a slightly greater percentage of patients with all grades or Grades 3-5 with anaemia, headache, and decrease in neutrophil counts were shown in patients receiving Berubicin, wh",0.0,7.15134,207.9387,78.00003,74.64003,67.20003,-0.044032253,-0.149035517,-0.034703634,-0.054881758,1.97895,0.01626,1.23044,2581,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
PSTV,REYOBIQ (rhenium Re186 obisbemeda) - (ReSPECT-LM),Leptomeningeal metastases (LM)Â ,Phase 1,11/22/2024,"Phase 1 data presented at SNO reported 86% (12/14 patients), with 2 responses and 10 stable cases, noted on November 22, 2024.",99.0,6.95767,88.6054,1.2,1.18,1.28,-0.016807118,0.064538521,-0.034703634,-0.054881758,0.88765,0.03272,0.54641,2582,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
MRK,WINREVAIR (sotatercept-csrk) - (ZENITH),"Pulmonary arterial hypertension (PAH, WHO* Group 1)Â ",Phase 3,11/25/2024,"Phase 3 trial met primary endpoint, noted November 25, 2024.",0.0,255897.9419,24.1139,99.18,101.16,100.61,0.019767041,0.014315275,-0.026758478,-0.031401199,1.03685,0.12301,3506.11365,2583,1,0,0,0,0,1,0,0,0,0,0,0,2,0,0,1
AZN,Truqap - (CAPItello-281),Dephosphorylated Phosphatase and Tensin Homolog (dPTEN) Hormone-Sensitive Prostate Cancer (HSPC)Â ,Phase 3,11/25/2024,"Phase 3 trial data demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of radiographic progression-free survival (rPFS), noted November 25, 2024.",0.0,162377.0965,22.0474,104.74,104.74,105.54,0.0,0.007608939,-0.026758478,-0.031401199,0.0,0.03667,577.06136,2584,1,0,0,0,0,1,0,0,0,0,0,0,2,0,0,1
INAB,INB-200,GlioblastomaÂ ,Phase 1,11/25/2024,Phase 1 study presented at SNO reported that 50% of patients who received repeated doses (n=10) remained alive and in remission beyond the expected median OS from standard-of-care Stupp regimen while,4.0,22.02041,153.7152,9.52801,9.11401,11.04001,-0.044423092,0.147290065,-0.026758478,-0.031401199,1.38458,0.09331,0.09844,2585,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CGTX,Zervimesine (CT1812) - (SHINE),Mild-to-Moderate Alzheimer's DiseaseÂ ,Phase 2,11/25/2024,"Phase 2 additional analysis demonstrated that individuals who entered the study with plasma p-tau217 below the median experienced a normalization of several key indicators, such as the neuroinflammato",73.0,16.91003,131.4638,0.4277,0.407,0.4,-0.04960883,-0.066957468,-0.026758478,-0.031401199,1.96326,0.14858,19.23975,2586,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
SAVA,Simufilam (PTI-125) - (RETHINK-ALZ),Alzheimerâ€™s diseaseÂ ,Phase 3,11/25/2024,"Phase 3 trial did not meet primary endpoint, noted November 25, 2024.",48.0,206.63449,291.0718,26.48,4.295,3.445,-1.818938176,-2.039465827,-0.026758478,-0.031401199,38.60158,2e-05,406.82366,2587,1,0,0,0,0,1,0,0,0,0,0,0,0,2,0,-1
CTXR,Mino-Lok,Catheter related blood stream infection (CRBSI)Â ,Phase 3,11/25/2024,"Phase 3 EoP Type C Meeting with the FDA resulted in clear, constructive, and actionable guidance underscoring a pathway to support a future NDA submission, noted November 25, 2024.",17.0,25.78948,122.8829,3.345,3.3375,3.22,-0.00224467,-0.038085334,-0.026758478,-0.031401199,6.1019,0.00254,19.71713,2588,0,0,0,0,0,1,0,1,0,0,0,0,2,0,0,1
BMY,Taldefgrobep - (RESILIENT),Spinal Muscular Atrophy (SMA)Â ,Phase 3,11/25/2024,Phase 3 topline results reported clinically meaningful improvements in motor function at all timepoints on the Motor Function Measurement-32 scale (MFM-32) but the treatment arm did not statistically,0.0,119216.2249,32.075,58.87,58.78,59.94,-0.001529962,0.018012439,-0.026758478,-0.031401199,1.15479,0.00308,829.95744,2589,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
PFE,Taldefgrobep - (RESILIENT),Spinal Muscular Atrophy (SMA)Â ,Phase 3,11/25/2024,Phase 3 topline results reported clinically meaningful improvements in motor function at all timepoints on the Motor Function Measurement-32 scale (MFM-32) but the treatment arm did not statistically,0.0,148305.1292,22.0616,25.65,26.17,25.82,0.020070145,0.006605814,-0.026758478,-0.031401199,1.09175,0.00092,1510.20912,2590,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
BHVN,Taldefgrobep - (RESILIENT),Spinal Muscular Atrophy (SMA)Â ,Phase 3,11/25/2024,Phase 3 topline results reported clinically meaningful improvements in motor function at all timepoints on the Motor Function Measurement-32 scale (MFM-32) but the treatment arm did not statistically,105.0,4573.75919,55.43,45.59,45.23,44.74,-0.007927811,-0.018820438,-0.026758478,-0.031401199,9.05087,0.14194,104.78249,2591,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
TNYA,TN-401 - (RIDGE-1),Arrhythmogenic Right Ventricular CardiomyopathyÂ ,Phase 1b,11/25/2024,"Phase 1b dosing commenced, noted on November 25, 2024.",162.0,234.49273,101.8143,2.38,2.96,3.58,0.218088781,0.408262313,-0.026758478,-0.031401199,6.61994,0.15058,22.12231,2592,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ABBV,AL002 - (INVOKE-2),Alzheimerâ€™s diseaseÂ ,Phase 2,11/25/2024,"Phase 2 failed to meet primary and secondary endpoints. Based upon the results, Alector is stopping the long-term extension study, noted November 25, 2024.",0.0,312889.8656,28.4921,176.95,177.06,181.77,0.000621451,0.026874945,-0.026758478,-0.031401199,1.02568,0.00927,2207.04653,2593,1,0,0,0,0,1,0,0,1,0,0,0,0,3,0,-1
ALEC,AL002 - (INVOKE-2),Alzheimerâ€™s diseaseÂ ,Phase 2,11/25/2024,"Phase 2 failed to meet primary and secondary endpoints. Based upon the results, Alector is stopping the long-term extension study, noted November 25, 2024.",101.0,387.81312,76.4022,3.94,3.96,2.51,0.005063302,-0.45089797,-0.026758478,-0.031401199,4.80274,0.20933,11.20239,2594,1,0,0,0,0,1,0,0,1,0,0,0,0,3,0,-1
ALEC,AL101/GSK4527226 - (PROGRESS-AD),Early Alzheimer's disease (AD)Â ,Phase 2,11/25/2024,"Phase 2 study reached a third of target enrollment, noted November 25, 2024.",101.0,387.81312,76.4022,3.94,3.96,2.51,0.005063302,-0.45089797,-0.026758478,-0.031401199,4.80274,0.20933,11.20239,2595,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
GSK,AL101/GSK4527226 - (PROGRESS-AD),Early Alzheimer's disease (AD)Â ,Phase 2,11/25/2024,"Phase 2 study reached a third of target enrollment, noted November 25, 2024.",0.0,54943.92847,23.355,13.42,13.465,13.415,0.003347595,-0.000372648,-0.026758478,-0.031401199,0.0,0.07581,161.82049,2596,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
AMGN,AMG 133 (maridebart cafraglutide) - (MariTide),Obesity and without diabetesÂ ,Phase 2,11/26/2024,"Phase 2 52-week data demonstrated up to ~20% average weight loss at week 52 without a weight loss plateau, indicating the potential for further weight loss beyond 52 weeks, noted November 26, 2024.",538.0,150514.5378,24.4523,294.0,280.01,278.32,-0.048754451,-0.054808236,-0.023985363,-0.000614376,1.82413,0.0746,4763.06306,2597,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
PTCT,PTC857 - (CardinALS),Amyotrophic Lateral Sclerosis (ALS)Â ,Phase 2,11/26/2024,"Phase 2 study failed to meet primary and secondary efficacy endpoints. Due to the lack of efficacy and biomarker signal, further development is not planned at this time, noted November 26, 2024.",79.0,3548.52783,51.8645,42.99,46.01,50.29,0.067891234,0.15683872,-0.023985363,-0.000614376,6.05902,0.23631,69.56063,2598,0,0,0,0,0,1,0,0,1,0,0,0,0,2,0,-1
VALN,IXCHIQ (VLA1553-303),Chikungunya vaccineÂ ,BLA Filing,11/26/2024,"BLA submitted, noted November 26, 2024.",81.0,307.20344,49.0216,4.2971,4.0,3.89,-0.071646015,-0.099531219,-0.023985363,-0.000614376,0.0,0.0,0.11678,2599,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
LTRN,LP-184 (STAR-001),Solid tumorsÂ ,Preclinical,11/26/2024,"Preclinical data, including previously published research by Lantern Pharma, demonstrate an up to 6-fold increase in GBM cell sensitivity when LP-184 is combined with spironolactone, noted November 26",10.0,33.13068,72.4146,3.13,3.072,3.19,-0.018704189,0.018987912,-0.023985363,-0.000614376,1.49148,0.06314,0.22743,2600,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
LXRX,Pilavapadin (LX9211) - (PROGRESS),Diabetic Peripheral Neuropathic Pain (DPNP)Â ,Phase 2b,11/26/2024,"Phase 2b enrollment completed, noted November 26, 2024.",363.0,296.49598,102.7487,0.8132,0.8202,0.7129,0.008571131,-0.131635924,-0.023985363,-0.000614376,8.6802,0.07675,2.40466,2601,0,0,0,0,0,1,0,0,0,1,0,0,2,0,0,1
OTLK,ONS-5010 / LYTENAVA (bevacizumab-vikg) - (NORSE EIGHT),Wet age-related macular degeneration (wet AMD)Â ,Phase 3,11/27/2024,"NORSE EIGHT trial did not meet the SPA primary endpoint, noted November 27, 2024.",44.0,40.21458,160.7117,4.89,1.7,1.66,-1.056564052,-1.080374701,-0.011566636,0.000607165,14.36845,0.00329,105.86973,2602,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,-1
CRVO,Neflamapimod - (RewinD-LB),Dementia with Lewy bodies (DLB)Â ,Phase 2b,11/27/2024,"Phase 2b Orphan Drug Designation granted on November 27, 2024.",9.0,75.563,101.1676,7.98,9.155,9.7,0.137361767,0.195187474,-0.011566636,0.000607165,20.2242,0.05823,5.37073,2603,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
SLS,Tambiciclib (SLS009) (GFH009) with venetoclax,"Hematologic malignancies, acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) and lymphomaÂ ",Preclinical,11/27/2024,"Preclinical data reported CRC MSI-H, ASXL1 mutations were observed in 7/12 (58%) of PDCs, aligning with predicted frequency of ~55%, noted November 27, 2024.",105.0,82.34692,61.6802,1.2,1.17,1.11,-0.025317808,-0.077961541,-0.011566636,0.000607165,12.45421,0.01769,1.68917,2604,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
APLT,Govorestat (AT-007) - (ACTION-Galactosemia kids),GalactosemiaÂ ,CRL,11/27/2024,"CRL announced November 27, 2024.",144.0,997.17498,100.4877,10.21,8.57,1.38,-0.1750999,-2.001284133,-0.011566636,0.000607165,11.65558,0.01947,131.41225,2605,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,-1
MRUS,Petosemtamab (MCLA-158),"Recurrent/metastatic (r/m) head and neck squamous cell carcinoma (HNSCC), Solid TumorsÂ ",Phase 2,12/2/2024,"Phase 2 additional data from ESMO Asia Congress reported 1 complete response, 3 PRs, and 1 unconfirmed PR, noted December 2, 2024.",75.0,3322.54244,38.1149,44.84,48.53,43.74,0.079081565,-0.024837583,0.019563748,0.013949483,12.79469,0.08617,47.59847,2606,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
GMAB,Petosemtamab (MCLA-158),"Recurrent/metastatic (r/m) head and neck squamous cell carcinoma (HNSCC), Solid TumorsÂ ",Phase 2,12/2/2024,"Phase 2 additional data from ESMO Asia Congress reported 1 complete response, 3 PRs, and 1 unconfirmed PR, noted December 2, 2024.",661.0,98541.38453,24.3227,1526.0,1551.5,1561.5,0.016572272,0.022996965,0.019563748,0.013949483,0.0,0.06278,166.74436,2607,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
APGE,APG808,"Healthy volunteer, asthma, COPDÂ ",Phase 1,12/2/2024,"Phase 1 PK data reported that treatment was well-tolerated with half-life of approximately 55 days, supporting potential for 2- to 3- month dosing and demonstrating deep and sustained inhibition of bi",59.0,2625.50027,56.6364,45.15,46.14,49.07,0.021689973,0.08325757,0.019563748,0.013949483,11.63953,0.0616,52.6695,2608,0,0,0,1,0,1,0,0,0,0,0,0,2,0,0,1
SNTI,SENTI-202,Acute Myeloid Leukemia (AML)Â ,Phase 1,12/2/2024,"Phase 1 initial data reported that 2 of 3 patients achieved MRD negative CR in the first dose level evaluated in the trial with a generally well-tolerated preliminary safety profile, noted December 2,",26.0,45.88645,243.1554,2.16,10.0,6.52,1.532476871,1.104766154,0.019563748,0.013949483,1.26349,0.06642,1306.54257,2609,1,0,0,1,0,1,0,0,0,0,0,0,3,0,0,1
NVCR,Tumor Treating Fields (TTFields) - (PANOVA-3),Pancreatic cancerÂ ,Phase 3,12/2/2024,"Phase 3 final data showed that study met its primary endpoint with a statistically significant improvement in overall survival for patients, noted December 2, 2024.",111.0,3229.81281,86.9563,20.04,29.85,28.65,0.398454564,0.357423167,0.019563748,0.013949483,5.23957,0.13259,364.61065,2610,1,0,0,0,0,1,0,0,0,0,1,0,3,0,0,1
PPBT,CM24 and OPDIVO (nivolumab),2L metastatic pancreatic cancer (PDAC)Â ,Phase 2,12/2/2024,"Phase 2 Final data demonstrated that combination showed clear and consistent improvement across all efficacy endpoints, noted December 2, 2024.",2.0,47.36839,143.3966,0.068,0.129,0.079,0.640304699,0.149940147,0.019563748,0.013949483,0.0,0.00362,4.3785,2611,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
SNGX,HyBryte (synthetic hypericin) - (HPN-CTCL-04),Cutaneous T-Cell LymphomaÂ ,Phase 1,12/2/2024,"Trial data reported a statistically significantly improved compared to the Valchlor treated plaques (63%, [10/16] treatment success with HyBryteâ„¢ vs. 17%, [2/12] with Valchlor, p=0.02), noted December",4.0,8.33154,218.1972,3.35,3.32,3.49,-0.008995563,0.04094139,0.019563748,0.013949483,1.83228,0.00362,0.93694,2612,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
RVMD,Daraxonrasib (RMC-6236) - (RASolute 302),Metastatic pancreatic ductal adenocarcinoma (PDAC)Â ,Phase 1,12/2/2024,"Phase 1 data reported an objective response rate (ORR) of 36% and 27% in patients with PDAC harboring a KRAS G12X mutation and patients with PDAC harboring any RAS mutation, respectively, noted Decemb",186.0,8713.76445,42.8441,57.85,51.8,47.04,-0.110463304,-0.20685515,0.019563748,0.013949483,9.72012,0.02775,221.45795,2613,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
RVMD,Elironrasib (RMC-6291),Solid TumorsÂ ,Phase 1b,12/2/2024,"Phase 1b data reported an ORR of 25%, in the cohort of RMC-6291 in combination RMC-6236, noted December 2, 2024.",186.0,8713.76445,42.8441,57.85,51.8,47.04,-0.110463304,-0.20685515,0.019563748,0.013949483,9.72012,0.02775,221.45795,2614,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
RIGL,R289,Myeloid dysplastic syndrome (MDS)Â ,Phase 1/2,12/2/2024,"FDA Fast track designation granted by the FDA, noted December 2, 2024.",17.0,476.48683,93.1133,27.61,27.05,23.16,-0.020491021,-0.175751373,0.019563748,0.013949483,2.62655,0.14312,8.85255,2615,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
JNJ,TREMFYA (guselkumab),Pediatric Juvenile Psoriatic ArthritisÂ ,BLA Filing,12/2/2024,"BLA submission on December 2, 2024.",0.0,372700.0361,14.8042,155.01,154.8,149.6,-0.00135567,-0.035524565,0.019563748,0.013949483,0.7259,7e-05,1075.31727,2616,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
JANX,PSMA-TRACTr (JANX007) - (ENGAGER-PSMA-01),Metastatic castration-resistant prostate cancer (mCPRC)Â ,Phase 1,12/2/2024,"Phase 1a interim update achieved 100% PSA50 declines, 63% PSA90 declines, and 31% PSA99 declines, with durable responses observed at â‰¥12 weeks. Anti-tumor activity showed a 50% objective response rat",60.0,2108.63583,59.5156,45.21,40.18,61.65,-0.117948942,0.310154928,0.019563748,0.013949483,7.9757,0.01162,120.79603,2617,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1
JSPR,Briquilimab - (ETESIAN),AsthmaÂ ,Phase 1/2,12/2/2024,"Phase 1b/2a dosing initiated, noted December 2, 2024.",16.0,359.58243,71.4532,22.81,23.97,22.4,0.049604012,-0.018138077,0.019563748,0.013949483,12.92303,0.13074,8.63867,2618,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1
BCTX,Bria-IMT - (BRIA-ABC),Advanced breast cancerÂ ,Phase 2,12/2/2024,"Phase 3 DSMB recommended continuation of the study, noted December 3, 2024.",1.0,56.44569,144.6552,147.35993,166.49992,178.49991,0.122116731,0.19171,0.019563748,0.013949483,0.0,0.0,3.55561,2619,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
SYRE,SPY002,Inflammatory Bowel Disease (IBD)Â ,Phase 1,12/2/2024,"Phase 1 dosing initiated, noted December 2, 2024.",60.0,1623.22698,69.9338,28.43,27.65,26.81,-0.027819198,-0.058669973,0.019563748,0.013949483,13.69623,0.04064,16.31107,2620,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1
JNJ,CAPLYTA (lumateperone) - (Study 502),Major depressive disorder (MDD)Â ,sNDA Filing,12/3/2024,"sNDA submitted December 3, 2024.",0.0,366825.436,14.9212,154.8,152.36,149.23,-0.01588782,-0.036645221,0.005249886,0.019214743,0.7259,7e-05,1321.63387,2621,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
TELO,Telomir-1,Age-related conditionsÂ ,Preclinical,12/3/2024,"Preclinical results reported success demonstrating age reversal, longevity, and increased healthspan, noted December 3, 2024.",32.0,144.49589,127.4635,4.25,4.88,5.58,0.138226237,0.272269793,0.005249886,0.019214743,2.20944,0.00194,2.40139,2622,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CRBP,CRB-701 (SYS6002) with Pembrolizumab,"Solid tumors, Locally advanced or metastatic urothelial carcinomaÂ ",Phase 1,12/3/2024,"Fast Track Designation granted by the FDA, noted December 3, 2024.",12.0,204.00632,155.1477,17.84,16.75,16.04,-0.063044869,-0.106357525,0.005249886,0.019214743,19.71872,0.00677,5.09143,2623,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
TERN,TERN-701 - (CARDINAL),Chronic myeloid leukemia (CML)Â ,Phase 1,12/3/2024,"Phase 1 study showed a safety profile with no dose-limiting toxicities, adverse event-related treatment discontinuations, or dose reductions across three dose escalation cohorts, noted December 3, 202",87.0,540.21112,81.7559,6.15,6.36,6.92,0.033576296,0.117963688,0.005249886,0.019214743,4.68187,0.08389,16.17872,2624,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ROIV,Namilumab - (RESOLVE-Lung),SarcoidosisÂ ,Phase 2,12/3/2024,"Phase 2 data did not meet its primary endpoints. Further development of namilumab for the treatment of sarcoidosis will be discontinued, as noted on December 3, 2024.",682.0,8822.7509,27.5751,12.48,12.12,12.09,-0.029270382,-0.031748698,0.005249886,0.019214743,5.95494,0.07453,62.97632,2625,1,0,0,0,0,1,0,0,0,0,0,0,0,2,0,-1
PALI,PALI-2108,Moderate-to-severe ulcerative colitis (UC)Â ,Phase 1,12/3/2024,"Phase 1 data reported no treatment related adverse events, noted December 3, 2024.",9.0,3.0313,68.895,2.4,2.28,1.44,-0.051293294,-0.510825624,0.005249886,0.019214743,8.62585,0.03807,0.49669,2626,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
TRVI,Haduvio - (Human Abuse Potential trial),Abuse Potential studyÂ ,Phase 1,12/3/2024,"The phase 1 study showed statistically significant lower ""Drug Liking"" scores for clinical doses of oral nalbuphine (81mg and 162mg) compared to IV butorphanol (6mg), supporting its low abuse potentia",121.0,213.68668,63.9492,2.86,2.78,2.68,-0.028370697,-0.06500483,0.005249886,0.019214743,2.28044,0.00815,0.82804,2627,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1
LTRN,LP-184,Triple Negative Breast Cancer (TNBC)Â ,Phase 1a,12/3/2024,"FDA granted Fast Track Designation on December 3, 2024.",10.0,34.40327,71.9387,3.16,3.19,3.98,0.009448889,0.230709792,0.005249886,0.019214743,1.49148,0.06456,0.17926,2628,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
ENLV,Allocetra - (ENX-CL-05-001),Knee osteoarthritis (OA)Â ,Phase 1/2,12/3/2024,"Phase 1/2 treatment showed significant improvements in pain (50% reduction, p<0.0007), functionality (42%, p<0.0008), and stiffness (37%, p<0.003) at three months, with no serious adverse reactions, n",23.0,28.5864,74.6487,1.08,1.3,1.25,0.185403223,0.14618251,0.005249886,0.019214743,0.45127,0.00585,5.927,2629,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
RXRX,REC-1245 - (DAHLIA),Solid tumorsÂ ,Phase 1,12/3/2024,"Phase 1 dosing initiated, noted December 3, 2024.",434.0,2033.68309,76.1413,7.58,7.09,7.46,-0.066827859,-0.015957785,0.005249886,0.019214743,22.5121,0.19816,82.3796,2630,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1
ELTX,ELI-002 - (AMPLIFY-7P),mKRAS-driven cancersÂ ,Phase 2,12/3/2024,"Phase 2 enrollment completed, noted December 3, 2024",16.0,53.88436,107.3356,5.2,5.0,5.59,-0.039220713,0.072320662,0.005249886,0.019214743,0.5522,0.00799,0.10514,2631,0,0,0,0,0,1,0,0,0,1,0,0,2,0,0,1
TEVA,AJOVY (fremanezumab-vfrm),Episodic migraine in children and adolescent patients aged 6-17 years who weigh 45 kilograms (99 pounds) or moreÂ ,Phase 3,12/4/2024,"Phase 3 data reported a significant reduction in monthly migraine & headaches days (MMD) vs placebo, noted December 4, 2024.",0.0,20195.74467,30.9239,17.53,17.8,17.45,0.015284758,-0.00457405,0.003691933,0.007397547,1.86774,0.04847,167.39364,2632,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
LLY,Zepbound (tirzepatide) - (SURMOUNT-5),ObesityÂ ,Phase 3,12/4/2024,"Phase 3 data reported that participants using Zepbound lost 50.3 lbs (22.8 kg) and participants on Wegovy lost 33.1 lbs (15.0 kg), noted December 4, 2024.",946.0,747214.5274,33.3494,813.33,829.84,796.03,0.02009598,-0.021500058,0.003691933,0.007397547,0.72669,0.18572,3212.38533,2633,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
AVIR,SVR12 in combination of bemnifosbuvir and ruzasvir,Hepatitis C virus (HCV)Â ,Phase 2,12/4/2024,"Phase 2 data met its primary endpoints of safety and sustained virologic response at 12 weeks post-treatment (SVR12), noted December 4, 2024.",79.0,263.10243,49.3837,3.48,3.115,2.96,-0.110803142,-0.161843025,0.003691933,0.007397547,3.12156,0.2113,2.03499,2634,1,0,0,1,0,1,0,0,0,0,0,0,3,0,0,1
RLMD,REL-1017 - (RELIANCE II),Major depressive disorder (MDD)Â ,Phase 3,12/4/2024,"Phase 3 pre-planned interim analysis conducted by IDMC indicated that the Reliance II Phase 3 study is futile and is unlikely to meet the primary efficacy endpoint with statistical significance, note",33.0,19.00975,225.9606,2.77,0.63,0.4175,-1.48088278,-1.892318055,0.003691933,0.007397547,3.82226,0.11561,11.3327,2635,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
APVO,APVO442 (PSMA x CD3),PSMA-expressing prostate tumor cellsÂ ,Preclinical,12/4/2024,"Preclinical study showed that the molecule readily localizes to solid tumors by avoiding unwanted binding to immune cells circulating in the bloodstream, noted December 4, 2024.",3.0,5.0032,189.4932,173.90017,200.0,200.2,0.139835968,0.140835468,0.003691933,0.007397547,3.9689,0.03056,1.4286,2636,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
NRSN,PrimeC - (PARADIGM),Amyotrophic Lateral Sclerosis (ALS)Â ,Phase 2b,12/4/2024,Phase 2b 18-month data showed statistically significant results. Participants on PrimeC throughout the study showed a 33% slower disease progression and a 58% improvement in survival rates compared to,23.0,22.15915,92.5741,1.13,1.07,0.9102,-0.054558984,-0.216308556,0.003691933,0.007397547,1.2464,0.07386,0.25808,2637,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1
CGON,Cretostimogene - (BOND-003),BCG-unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) with Carcinoma in SituÂ ,Phase 3,12/5/2024,"Phase 3 data presented at SUO showed a 74.5% CR rate at any time, a median response duration exceeding 27 months, and 97.3% PFS at 12 months with no Grade 3+ adverse events, noted December 5, 2024.",76.0,2269.65189,46.4001,35.91,33.56,28.87,-0.067680927,-0.218212815,-0.003536608,0.047576203,7.97934,0.05874,63.88804,2638,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
AZN,IMFINZI (Durvalumab) - (ADRIATIC),Small cell lung cancer (SCLC) limited diseaseÂ ,Approved,12/5/2024,"Approved December 5, 2024.",0.0,164612.6791,22.1913,104.8,106.18,105.68,0.013081995,0.008361888,-0.003536608,0.047576203,0.0,0.03876,394.48153,2639,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1
GLUE,MRT-2359,MYC-driven solid tumorsÂ ,Phase 2,12/5/2024,"Phase 2 initial data demonstrated a favorable safety profile and targeted levels of GSPT1 degradation using a 21 days on, 7 days off drug dosing schedule in heavily pretreated solid tumor patients, no",61.0,542.4809,131.312,9.24,8.83,7.79,-0.045386871,-0.170701026,-0.003536608,0.047576203,18.15252,0.02003,5.45722,2640,0,0,0,1,0,1,0,0,0,0,0,0,2,0,0,1
HEPA,P2B001,Early-stage Parkinson's disease (PD)Â ,Phase 3,12/5/2024,"Phase 3 data reported that treatment had significantly greater effect on the UPDRS Part II (Activities of Daily Living, or ADL), Part III (Motor), and Total (Parts II and III) scores versus placebo, n",11.0,4.38376,81.8429,31.4,31.5,31.0,0.003179653,-0.012820688,-0.003536608,0.047576203,0.92466,0.0094,0.0264,2641,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
URGN,ZUSDURI (VesiGel UGN-102 (mitomycin)) - (ENVISION),Low grade non-muscle invasive bladder cancer (LG-NMIBC)Â ,Phase 3,12/5/2024,"Phase 3 data from SUO reported a 79.6% complete response rate at 3 months in patients treated with UGN-102, noted December 5, 2024.",46.0,515.25485,69.461,12.46,12.21,11.47,-0.020268225,-0.082788582,-0.003536608,0.047576203,15.26575,0.06739,5.85979,2642,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
MRUS,BIZENGRI (zenocutuzumab-zbco),Solid tumors - NRG1+ NSCLC and PDAC cancerÂ ,Approved,12/5/2024,"Approved December 5, 2024.",75.0,3002.81705,37.8872,45.485,43.86,41.45,-0.036379858,-0.09289472,-0.003536608,0.047576203,12.79469,0.08617,23.0708,2643,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1
GMAB,BIZENGRI (zenocutuzumab-zbco),Solid tumors - NRG1+ NSCLC and PDAC cancerÂ ,Approved,12/5/2024,"Approved December 5, 2024.",661.0,98557.45032,24.2784,1528.5,1551.5,1488.0,0.014935343,-0.026853926,-0.003536608,0.047576203,0.0,0.06278,120.7579,2644,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1
TARA,TARA-002 - (ADVANCED-2),High-grade non-muscle invasive bladder cancer (NMIBC) patients with Bacillus Calmette-GuÃ©rin (BCG)-naÃ¯ve and BCG-unresponsive carcinoma in situ (CIS)Â ,Phase 1/2,12/5/2024,"Phase 1b/2 OLE data presented at the Annual Meeting of the SUO included a 72% six-month CR rate, 100% CR rate in BCG-unresponsive patients, and no Grade 2+ treatment-related AE. Durable responses wer",38.0,124.19123,106.3901,3.54,6.02,6.25,0.530960532,0.568454737,-0.003536608,0.047576203,13.20959,0.0748,669.83229,2645,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
NVS,Fabhalta - (APPULSE-PNH),Paroxysmal nocturnal hemoglobinuria (PNH)Â ,Phase 3,12/6/2024,"Phase 3b data reported that treatment improved the average hemoglobin (Hb) level versus baseline, noted December 6, 2024.",0.0,2181.20167,51.4898,7.01,7.01,6.72,0.0,-0.042249547,-0.009306198,0.041215921,0.0,0.00714,0.0,2646,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
BNTX,BNT324/DB-1311,Solid tumorsÂ ,Phase 1/2,12/6/2024,"Phase 1/2 data reported that the patients with SCLC with at least one post-baseline tumor assessment and who had received prior immunotherapy but no prior topoisomerase 1 inhibitor, the unconfirmed ob",239.0,29181.12261,47.3931,118.84,121.72,120.38,0.023945274,0.012875356,-0.009306198,0.041215921,1.03101,0.06375,120.80053,2647,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
AZN,Datopotamab deruxtecan - (TROPION-Lung05),EGFR non-small cell lung cancer (NSCLC)Â ,Phase 3,12/6/2024,"Phase 3 data reported a confirmed objective response rate (ORR) of 42.7%, noted December 6, 2024.",0.0,165170.7933,22.1786,106.18,106.54,104.68,0.003384734,-0.014227689,-0.009306198,0.041215921,0.0,0.03907,250.55129,2648,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
AZN,DATROWAY (datopotamab deruxtecan-dlnk)- (TROPION-Lung01),Non-small cell lung cancer (NSCLC)Â ,Phase 3,12/6/2024,"Phase 3 data reported a confirmed objective response rate (ORR) of 42.7%, noted December 6, 2024.",0.0,165170.7933,22.1786,106.18,106.54,104.68,0.003384734,-0.014227689,-0.009306198,0.041215921,0.0,0.03907,250.55129,2649,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
PFE,BHV-7000,Focal EpilepsyÂ ,Phase 1,12/6/2024,"Phase 1 data demonstrated excellent tolerability at all doses evaluated without central nervous system (CNS) adverse effects typically associated with other anti-seizure medications (ASMs), such as so",0.0,145811.6536,21.5683,25.7,25.73,25.58,0.001166634,-0.004680196,-0.009306198,0.041215921,1.66828,0.00061,819.00461,2650,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
BHVN,BHV-7000,Focal EpilepsyÂ ,Phase 1,12/6/2024,"Phase 1 data demonstrated excellent tolerability at all doses evaluated without central nervous system (CNS) adverse effects typically associated with other anti-seizure medications (ASMs), such as so",105.0,4530.27662,52.3468,43.49,44.8,38.47,0.029677113,-0.12265231,-0.009306198,0.041215921,7.73803,0.14004,32.07801,2651,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
MNOV,Ibudilast (MN-166) - (COMBAT-ALS),Amyotrophic lateral sclerosis (ALS)Â ,Phase 2/3,12/6/2024,"Phase 2b/3 trial update from International Symposium on ALS / MND reported positive correlations were observed between the 6-month and 12-month data for CAFS score (0.71), modified CAFS score (0.70),",49.0,114.76822,92.3765,2.26,2.34,2.1,0.034786116,-0.073427469,-0.009306198,0.041215921,0.71717,0.10035,0.15347,2652,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
XENE,Azetukalner (XEN1101) - (X-TOLE2),Adult Focal EpilepsyÂ ,Phase 3,12/6/2024,Phase 3 OLE long-term safety and efficacy data presented at AES showed that drug achieved 85% sustained monthly seizure reduction at 36 months and one-year seizure freedom in 33% of patients. The drug,77.0,3256.9558,34.1431,41.41,42.72,40.05,0.031144797,-0.033393724,-0.009306198,0.041215921,3.85542,0.127,15.33302,2653,0,0,0,1,0,1,0,0,0,0,0,0,2,0,0,1
RAPP,RAP-219 - (PET),Drug-resistant focal epilepsyÂ ,Phase 2a,12/6/2024,Phase 2a Pk data presented at the American Epilepsy Society Annual Meeting showed 30% reduction in long episodes associated with a 50% or greater reduction in clinical seizures in a post-hoc analysis,36.0,748.35431,0.0,20.27,20.46,18.77,0.0093298,-0.07688211,-0.009306198,0.041215921,4.75103,0.21156,1.89044,2654,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
STOK,Zorevunersen (STK-001),Dravet SyndromeÂ ,Phase 1/2,12/6/2024,"Phase 1/2 data presented at AES showed substantial and durable seizure reductions and cognitive and behavioral improvements. In studies, patients treated for over two years experienced an 87% median r",54.0,702.87179,63.3973,12.57,13.27,12.06,0.054192826,-0.041418831,-0.009306198,0.041215921,12.08914,0.00737,12.34731,2655,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ALT,Pemvidutide - (MOMENTUM),"Non-alcoholic steatohepatitis (NASH)/ (MASH) - Healthy, Overweight and Obese VolunteersÂ ",Phase 2,12/6/2024,"Phase 2 data presentation reported a mean weight loss of 15.6% with pemvidutide 2.4 mg at Week 48, noted December 6, 2024.",88.0,647.94533,86.5326,9.14,9.11,9.03,-0.003287674,-0.012108018,-0.009306198,0.041215921,32.10813,0.21878,30.27424,2656,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
IPHA,Lacutamab (IPH4102) - (TELLOMAK),"Mycosis Fungoides, SÃ©zary SyndromeÂ ",Phase 2,12/7/2024,"Phase 2 data presented at ASH reported a clinically significant 2-point decrease on the VAS scale to mild by Week 13 (VAS<4), in SÃ©zary Syndrome Patients, and improvement in Itch intensity from Week 5",92.0,119.96906,74.342,1.47,1.47,3.02,0.0,0.719994431,0.009119528,0.059641647,0.0,0.0,0.0,2657,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1
BEAM,BEAM-101 - (BEACON),Sickle cell diseaseÂ ,Phase 1/2,12/7/2024,"Phase 1/2 data presented at ASH reported that all seven patients treated with BEAM-101 achieved hemoglobin F (HbF) induction of >60%, noted December 7, 2024.",101.0,2125.90929,67.3565,26.71,26.71,27.93,0.0,0.044663353,0.009119528,0.059641647,15.03485,0.17503,0.0,2658,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1
AGIO,PYRUKYND (Mitapivat) - (ENERGIZE),ThalassemiaÂ ,sNDA Filing,12/8/2024,"sNDA filing submitted on December 8, 2024.",58.0,3515.34122,41.8654,61.64,61.64,38.965,0.0,-0.458647203,0.009119528,0.059641647,7.98079,0.16471,0.0,2659,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CCCC,Cemsidomide (CFT7455),Hematologic malignanciesÂ ,Phase 1/2,12/8/2024,"Phase 1/2 escalation data from ASH reported that across all dose levels explored, cemsidomide achieved a 38 percent ORR and 19 percent CMR rate, and in patients with PTCL, cemsidomide achieved a 44 pe",71.0,312.0032,84.7554,4.42,4.42,4.38,0.0,-0.009090972,0.009119528,0.059641647,10.485,0.05449,0.0,2660,1,0,0,0,0,1,0,0,0,0,0,0,2,0,0,1
IRON,DISC-0974,Myelofibrosis (MF) patients with anemiaÂ ,Phase 1b,12/8/2024,"Phase 1b data presented at ASH reported that 68% of baseline nTD patients achieved a hemoglobin increase of â‰¥1.5 g/dL during study period and 50% had sustained increases for â‰¥12 weeks, noted December",34.0,1928.89619,61.1474,64.82,64.82,64.89,0.0,0.001079331,0.009119528,0.059641647,5.52203,0.18755,0.0,2661,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1
BEAM,BEAM-103 - (ESCAPE),Sickle Cell Disease (SCD)Â ,Preclinical,12/8/2024,"Preclinical data presented at ASH reported that all NHPs achieved >40% Î³-globin, a key constituent of HbF, post-transplant, noted December 8, 2024.",101.0,2125.90929,67.3565,26.71,26.71,27.93,0.0,0.044663353,0.009119528,0.059641647,15.03485,0.17503,0.0,2662,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1
AGIO,Mitapivat - (ENERGIZE-T),Transfusion-dependent thalassemiaÂ ,Phase 3,12/8/2024,"Phase 3 data presented at ASH reported that TRR was achieved by 30.4% (n=52/171) of patients in the mitapivat arm compared to 12.6% (n=11/87) of patients in the placebo arm, noted December 8, 2024.",58.0,3515.34122,41.8654,61.64,61.64,38.965,0.0,-0.458647203,0.009119528,0.059641647,7.98079,0.16471,0.0,2663,0,0,0,0,1,1,0,0,0,0,1,0,3,0,0,1
COGT,Bezuclastinib - (APEX),Advanced Systemic MastocytosisÂ ,Phase 2,12/8/2024,"Phase 2 presentation due at ASH reported 52% ORR per mIWG criteria, including 83% ORR for patients receiving 100 mg BID, noted December 8, 2024.",139.0,982.00477,55.0885,8.89,8.89,8.15,0.0,-0.086909122,0.009119528,0.059641647,6.98495,0.00641,0.0,2664,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
SLS,Tambiciclib (SLS009) (GFH009) with venetoclax,"Hematologic malignancies, acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) and lymphomaÂ ",Phase 2a,12/8/2024,Phase 2a presented at ASH showed that Median Overall Survival (mOS) in the 30 mg BIW cohort for relapsed/refractory AML patients exceeds 7.7 months. Acute Myeloid Leukemia with Myelodysplasia-Related,105.0,80.23546,62.3459,1.14,1.14,0.8721,0.0,-0.267879445,0.009119528,0.059641647,12.45421,0.0168,0.0,2665,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ACLX,CART-ddBCMA - (iMMagine-1),Multiple MyelomaÂ ,Phase 2,12/9/2024,"Phase 2 data presented at ASH reported 30.2-month median progression-free survival with a median follow-up of 38.1 months in the Phase 1 study of anito-cel; median overall survival not reached, noted",55.0,4485.49388,52.2535,84.55,82.95,83.42,-0.019105059,-0.013454987,0.017501464,0.045185613,8.23435,0.26116,73.51875,2666,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1
GILD,CART-ddBCMA - (iMMagine-1),Multiple MyelomaÂ ,Phase 2,12/9/2024,"Phase 2 data presented at ASH reported 30.2-month median progression-free survival with a median follow-up of 38.1 months in the Phase 1 study of anito-cel; median overall survival not reached, noted",0.0,112899.224,25.2113,92.13,90.59,92.05,-0.016856791,-0.000868715,0.017501464,0.045185613,1.44908,0.06896,670.03671,2667,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1
MCRB,SER-155,"Gastrointestinal infections, bacteremia and graft versus host disease (GvHD)Â ",Phase 1b,12/9/2024,"Breakthrough Therapy designation (BTD) granted by the FDA, noted December 9, 2024.",8.0,145.99812,114.2689,16.466,17.102,17.8,0.037897767,0.077900808,0.017501464,0.045185613,9.5089,0.00771,11.91195,2668,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
OLMA,OP-3136,Breast CancerÂ ,IND-Enabling,12/9/2024,"IND granted by the FDA, noted December 9, 2024.",68.0,696.35451,67.2743,10.45,9.44,6.44,-0.101645998,-0.484073438,0.017501464,0.045185613,11.60747,0.07652,5.93886,2669,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
KURA,Ziftomenib (in combination with SoC cytarabine/daunorubicin (7+3) and venetoclax/azacitidine (ven/aza))- (KOMET-007),Acute myeloid leukemia (AML)Â ,Phase 1a,12/9/2024,"Phase 1a interim data presented at ASH showed 100% CR rate in NPM1-m and 83% CR rate in KMT2A-r 1L adverse risk AML with 7+3, noted December 9, 2024.",86.0,818.85229,75.3191,10.67,10.53,9.975,-0.013207739,-0.067354103,0.017501464,0.045185613,14.19024,0.12336,18.17982,2670,1,0,0,0,0,0,0,0,0,0,1,0,2,0,0,1
MRK,KEYTRUDA (pembrolizumab) plus chemotherapy - (KEYLYNK-001),Advanced Epithelial Ovarian CancerÂ ,Phase 3,12/9/2024,"Phase 3 data reported that trial met its primary endpoint, noted December 9, 2024.",0.0,262550.8836,24.0934,103.09,103.79,100.06,0.006767234,-0.029832387,0.017501464,0.045185613,1.04058,0.12559,1988.87245,2671,1,0,0,0,0,1,0,0,0,0,0,0,2,0,0,1
ENTA,Zelicapavir (EDP-323) - (RSVPED),Respiratory Syncytial Virus RSV-A and RSV-BÂ ,Phase 2,12/9/2024,"Phase 2 data reported an antiviral effect for the primary and secondary virology endpoints in the overall population, with a viral load decline of 1.4 log at the end of treatment in Part 2, noted Dece",21.0,189.47727,53.2132,8.0,8.94,6.31,0.111094048,-0.237305865,0.017501464,0.045185613,15.94146,0.03258,8.92268,2672,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
COGT,Bezuclastinib - (SUMMIT),Non-Advanced Systemic MastocytosisÂ ,Phase 2,12/9/2024,"Phase 2 data presented at ASH included a 56% mean improvement in Total Symptom Score (TSS) at 24 weeks, with 76% of patients achieving a â‰¥50% TSS reduction and 95% of patients with elevated serum tryp",139.0,1068.16492,56.4482,8.89,9.67,8.26,0.08410126,-0.073502462,0.017501464,0.045185613,6.98495,0.00641,62.63744,2673,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1
VTVT,Azeliragon combined with stereotactic radiosurgery - (RAGE),Brain metastasis from breast cancerÂ ,Phase 2,12/9/2024,"Orphan drug designation granted on December 9, 2024.",3.0,115.59474,90.2214,17.92,17.56,15.44,-0.020293819,-0.148955863,0.017501464,0.045185613,0.41306,0.00748,0.28732,2674,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
VOR,Trem-cel + Mylotarg (VBP101),Acute myeloid leukemia (AML)Â ,Phase 1/2,12/9/2024,"Phase 1/2 preliminary data presented at ASH suggests improved relapse-free survival compared to published groups of acute myeloid leukemia (AML) patients at high risk of relapse post-transplant, noted",6.0,71.42054,81.7449,16.392,20.8,20.4,0.238159576,0.21874149,0.017501464,0.045185613,2.25309,0.10455,3.12909,2675,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1
PRTC,LYT-200,Relapsed/refractory AML and MDSÂ ,Phase 1b,12/9/2024,"Phase 1b data reported LYT-200 demonstrates clinical benefit as a single agent, with two partial responses and 59% of evaluable patients achieving stable disease or better, and in combination, two com",24.0,413.72003,31.9295,1.66,1.728,1.7,0.040147068,0.023810649,0.017501464,0.045185613,0.0,0.04923,2.1972,2676,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
RLMD,REL-1017 - (RELIANCE II),Major depressive disorder (MDD)Â ,Phase 3,12/9/2024,"Phase 3 study discontinued, noted December 9, 2024.",33.0,14.51379,231.3254,0.4575,0.481,0.3888,0.050090385,-0.162711812,0.017501464,0.045185613,3.82226,0.0526,1.19218,2677,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
RLMD,REL-1017 - (Relight),Major Depressive Disorder (MDD)Â ,Phase 3,12/9/2024,"Phase 3 discontinued after recent data monitoring committee (DMC), noted December 9, 2024.",33.0,14.51379,231.3254,0.4575,0.481,0.3888,0.050090385,-0.162711812,0.017501464,0.045185613,3.82226,0.0526,1.19218,2678,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
SNDX,Revuforj (revumenib) - (AUGMENT-101),Relapsed/refractory (R/R) acute leukemiasÂ ,Phase 2,12/9/2024,"Phase 2 data presented at ASH from subgroup analyses (N=64) showed responses across all major subgroups, including heavily pretreated patients, noted December 9, 2024.",86.0,1328.16542,61.5775,17.01,15.56,13.79,-0.089097888,-0.209857715,0.017501464,0.045185613,12.4228,0.24649,40.12986,2679,0,0,0,0,1,1,0,0,0,0,1,0,3,0,0,1
ADCT,ZYNLONTA (loncastuximab tesirine-lpyl),Relapsed/refractory (r/r) marginal zone lymphoma (MZL)Â ,Phase 2,12/9/2024,"Additional Phase 2 data presented at ASH showed best ORR of 97% and CR rate of 77% with 12-month PFS of 95%, data also presented at ASH on ZYNLONTA monotherapy in marginal zone lymphoma shows ORR of",112.0,310.37367,112.419,3.13,3.21,2.0,0.025237933,-0.447885824,0.017501464,0.045185613,3.2728,0.05734,10.22024,2680,1,0,0,0,0,1,0,0,0,0,1,0,3,0,0,1
MGTX,AAV2-hAQP1 - (AQUAx2),XerostomiaÂ ,Phase 1,12/9/2024,"Regenerative Medicine Advanced Therapy (RMAT) designation granted by the FDA, noted December 9, 2024.",80.0,506.43404,63.0226,6.14,6.48,6.28,0.053895768,0.022545238,0.017501464,0.045185613,1.91062,0.05377,1.67435,2681,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
SONN,SON-1010 with Trabectedin - (SB101),Solid tumorsÂ ,Phase 1,12/9/2024,"Phase 1 topline data in 21 evaluable patients, 48% achieved stable disease at four months, including one partial response with a 45% tumor reduction at the MTD. SON-1010 demonstrated favorable safety,",6.0,1.65857,115.0263,2.1,1.98,1.81,-0.0588405,-0.148610499,0.017501464,0.045185613,4.20171,0.00716,98.7371,2682,0,0,0,1,0,1,0,0,0,0,1,0,3,0,0,1
JNJ,"DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) in combination with bortezomib, lenalidomide and dexamethasone (D-VRd) - (CEPHEUS)",Newly diagnosed multiple myeloma (NDMM)Â ,Phase 3,12/9/2024,"Phase 3 data reported that 85 percent of patients who achieved MRD negativity (10-6) with DARZALEX FASPROÂ® were progression free at 4.5 years, noted December 9, 2024.",0.0,360180.3966,14.9939,149.31,149.6,143.85,0.001940384,-0.037253592,0.017501464,0.045185613,0.7259,0.00046,1258.18133,2683,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1
GILD,"YESCARTA (Axicabtagene Ciloleucel), KTE-C19 and utomilumab - (ZUMA-7)",Refractory Large B-cell LymphomaÂ ,Phase 1,12/9/2024,"Phase 1 data from ASH reported that 71% overall survival rate, noted December 9, 2024.",0.0,112899.224,25.2113,92.13,90.59,92.05,-0.016856791,-0.000868715,0.017501464,0.045185613,1.44908,0.06896,670.03671,2684,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
MOLN,MP0621,Acute myeloid leukemia (AML)Â ,Preclinical,12/9/2024,"Additional preclinical data presented at ASH reported that treatment demonstrated intended mechanism in vivo, achieving killing of cKit+ cells while reducing off-target effects seen with systemic anti",40.0,183.76253,93.5512,5.06,4.985,4.62,-0.01493308,-0.090971778,0.017501464,0.045185613,0.0,0.01896,0.04371,2685,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1
JNJ,DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) - (AQUILA),Active multiple myelomaÂ ,Phase 3,12/9/2024,"Phase 3 data reported that overall survival was also extended with DARZALEX FASPROÂ®, with 5-year survival rates of 93 percent versus 86.9 percent for active monitoring, noted December 9, 2024.",0.0,360180.3966,14.9939,149.31,149.6,143.85,0.001940384,-0.037253592,0.017501464,0.045185613,0.7259,0.00046,1258.18133,2686,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
AZN,Calquence (acalabrutinib) - (AMPLIFY),Chronic lymphocytic leukaemia (CLL)Â ,Phase 3,12/9/2024,"Phase 3 data presented at ASH reported that treatment reduced the risk of disease progression or death by 58% versus standard of care, noted December 9, 2024.",0.0,165914.9456,22.2688,106.54,107.02,105.24,0.004495231,-0.012277045,0.017501464,0.045185613,0.0,0.03907,282.50958,2687,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1
GMAB,EPCORE (Epcoritamab) - (EPCORE NHL-2),Non-Hodgkin lymphoma (NHL)Â ,Phase 1b,12/9/2024,Phase 1b/2 overall response rate (ORR) of 61 percent and complete response (CR) rate of 39 percent in heavily pretreated patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) w,661.0,99192.69009,24.3986,1549.0,1561.5,1442.5,0.008037336,-0.071231842,0.017501464,0.045185613,0.0,0.06831,132.89146,2688,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
REGN,Pozelimab + Cemdisiran - (ACCESS-1),Paroxysmal Nocturnal Hemoglobinuria (PNH)Â ,Phase 3,12/9/2024,"Phase 3 data reported that 96% achieved adequate LDH control (â‰¤1.5 x ULN) across study visits, noted December 9, 2024.",105.0,84780.55043,25.314,778.0,788.0,724.87,0.012771566,-0.070734196,0.017501464,0.045185613,1.6599,0.14535,809.59278,2689,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1
GLPG,GLPG5101 - (ATALANTA-1),Relapsed/refractory Non-Hodgkin Lymphoma (rrNHL)Â ,Phase 1/2,12/9/2024,"Phase 1/2 data presented at ASH reported that all 8 of 8 efficacy-evaluable patients responded to treatment (ORR and CRR 100%), noted December 9, 2024.",65.0,1690.91884,33.2324,25.66,25.66,25.7,0.0,0.001557633,0.017501464,0.045185613,0.0,0.08066,2.78077,2690,1,0,0,0,0,1,0,0,0,0,1,0,3,0,0,1
MRK,NKTR-255 with BAVENCIO (avelumab) - (JAVELIN),Locally advanced or metastatic urothelial carcinoma (UC)Â ,Phase 2,12/9/2024,"Phase 2 trial data reported that 73% of the NKTR-255 treatment group compared to 50% of the placebo group achieved a complete response at 6 months, noted December 9, 2024.",0.0,262550.8836,24.0934,103.09,103.79,100.06,0.006767234,-0.029832387,0.017501464,0.045185613,1.04058,0.12559,1988.87245,2691,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1
NKTR,NKTR-255 with BAVENCIO (avelumab) - (JAVELIN),Locally advanced or metastatic urothelial carcinoma (UC)Â ,Phase 2,12/9/2024,"Phase 2 trial data reported that 73% of the NKTR-255 treatment group compared to 50% of the placebo group achieved a complete response at 6 months, noted December 9, 2024.",19.0,186.30286,69.7883,15.29999,15.14999,14.99999,-0.009852303,-0.01980264,0.017501464,0.045185613,2.77922,0.13776,1.17755,2692,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1
AMGN,BLINCYTO (blinatumomab) - (AALL1731),B-cell acute lymphoblastic leukemia (B-ALL)Â ,Phase 3,12/9/2024,"Phase 3 data reported that among SR-Average patients, 3-year DFS was 97.5% for patients treated with BLINCYTO compared to 90.2% for those treated with only chemotherapy, noted December 9, 2024.",538.0,149235.2099,24.6373,272.58,277.63,266.5,0.018357143,-0.022557905,0.017501464,0.045185613,1.82413,0.06513,894.65102,2693,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
INCY,Retifanlimab - (POD1UM-304),Non-small cell lung cancer (NSCLC)Â ,Phase 3,12/9/2024,"Phase 3 data reported that the trial met its primary endpoint of overall survival (OS) and all secondary endpoints, noted December 9, 2024.",196.0,13892.00946,34.6507,75.92,72.11,69.8,-0.051487423,-0.084046145,0.017501464,0.045185613,3.63131,0.08243,126.77839,2694,1,0,0,0,0,1,0,0,1,0,0,0,3,0,0,1
MGNX,Retifanlimab - (POD1UM-304),Non-small cell lung cancer (NSCLC)Â ,Phase 3,12/9/2024,"Phase 3 data reported that the trial met its primary endpoint of overall survival (OS) and all secondary endpoints, noted December 9, 2024.",63.0,218.4168,83.122,3.5,3.48,3.23,-0.005730675,-0.080280831,0.017501464,0.045185613,8.11795,0.02473,1.16907,2695,1,0,0,0,0,1,0,0,1,0,0,0,3,0,0,1
MRUS,Petosemtamab (MCLA-158) - (LiGeR-HN1),PD-L1+ recurrent/metastatic head and neck squamous cell carcinoma (r/m HNSCC)Â ,Phase 1/2,12/9/2024,"Phase 1/2 data reported that a confirmed overall response rate (ORR) 36%, noted December 9, 2024.",75.0,2994.60141,37.979,44.65,43.74,42.8,-0.020591292,-0.042316205,0.017501464,0.045185613,12.79469,0.08466,52.85253,2696,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
GMAB,Petosemtamab (MCLA-158) - (LiGeR-HN1),PD-L1+ recurrent/metastatic head and neck squamous cell carcinoma (r/m HNSCC)Â ,Phase 1/2,12/9/2024,"Phase 1/2 data reported that a confirmed overall response rate (ORR) 36%, noted December 9, 2024.",661.0,99192.69009,24.3986,1549.0,1561.5,1442.5,0.008037336,-0.071231842,0.017501464,0.045185613,0.0,0.06831,132.89146,2697,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ATHA,ATH-1105,Amyotrophic Lateral Sclerosis (ALS)Â ,Phase 1,12/9/2024,"Phase 1 data reported that treatment demonstrated neuroprotective activity through the MET receptor; following siRNA-mediated knockdown of MET, the neuroprotective effects of ATH-1105 on neuronal surv",3.0,24.0947,237.778,6.351,6.231,5.774,-0.019075447,-0.0952472,0.017501464,0.045185613,5.72852,0.11625,0.32516,2698,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1
JAZZ,Dordaviprone (ONC201) - (ACTION),H3 K27M-mutant diffuse midline gliomaÂ ,NDA Filing,12/9/2024,"Pre-NDA meeting with FDA showing clinical data highlighting a 28% objective response rate, median response duration of 10.4 months, and significant reduction of the hallmark mutation, noted December 1",60.0,7302.91471,28.9206,122.59,120.8,125.2,-0.014709169,0.021067005,0.017501464,0.045185613,6.31056,0.08934,56.21235,2699,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CPIX,Acetadote (N-acetylcysteine for injection) (IV),Prevent or lessen liver injury after toxic quantities of acetaminophen.Â ,Approved,12/9/2024,"FDA approved, noted December 9, 2024.",14.0,17.41246,54.6189,1.235,1.24,2.12,0.00404041,0.540345119,0.017501464,0.045185613,0.63813,0.0109,7.78565,2700,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
FATE,FT819,B-cell Leukemias and LymphomasÂ ,Phase 1b,12/9/2024,"Phase 1b data presented at ASH showed that all 3 patients treated in first dose cohort administered fludarabine-free conditioning and show rapid, deep, and sustained B-cell depletion with favorable sa",115.0,309.79259,92.5725,2.65,2.72,2.0,0.02607224,-0.281412459,0.017501464,0.045185613,9.12148,0.06965,7.42691,2701,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1
BMEA,BMF-500 - (COVALENT-103),Acute myeloid leukemia (AML)Â ,Phase 1,12/9/2024,"Phase 1 preliminary data supports BMF-500's potential as a transformative therapy for patients with FLT3 mutated relapsed or refractory (R/R) acute leukemia, noted December 9, 2024.",59.0,209.822,84.0818,6.1,5.79,5.85,-0.05215648,-0.04184711,0.017501464,0.045185613,25.95969,0.01999,5.35064,2702,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
NBTX,NBTXR3 (JNJ-1900) - (MD Anderson trial/NANORAY Pancreas),"Non-Small Cell Lung Cancer (NSCLC), Pancreatic cancerÂ ",Phase 1b,12/9/2024,"Phase 1b updated data from investigators concluded that the encouraging oncologic outcomes coupled with a favorable safety profile warrant further evaluation in a randomized trial, 23 months median Ov",47.0,146.57543,72.6976,3.0,3.0,3.49,0.0,0.151289448,0.017501464,0.045185613,0.0,0.0,1.13417,2703,0,0,0,1,0,1,0,0,0,0,0,0,2,0,0,1
PTGX,Rusfertide - (REVIVE),Polycythemia veraÂ ,Phase 2,12/9/2024,"Phase 2 final results presented at ASH showed that 54% of patients experience more than 2.5 years of durable hematocrit (Hct) control (<45%), decreased phlebotomy use, long-term tolerability, and impr",62.0,2413.71973,43.622,42.06,40.5,41.46,-0.037795196,-0.014368063,0.017501464,0.045185613,5.53879,0.15447,16.68381,2704,0,0,0,1,0,1,0,0,0,0,1,0,3,0,0,1
IRON,Bitopertin - (BEACON),Erythropoietic Protoporphyria (EPP)Â ,Phase 2,12/9/2024,"Phase 2 data presented at ASH showed that bitopertin significantly reduced protoporphyrin IX (PPIX) at low and high doses and in both adult and adolescent populations, noted December 9, 2024.",34.0,1924.13495,60.6604,64.82,64.66,66.18,-0.002471425,0.020764105,0.017501464,0.045185613,5.52203,0.18755,15.88974,2705,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1
IRON,Bitopertin - (HELIOS),Erythropoietic ProtoporphyriaÂ ,Phase 2,12/9/2024,"Phase 2 trial updated analysis presented at ASH showed that bitopertin reduced PPIX in all prespecified subgroups across demographic and baseline patient characteristics, noted December 9, 2024.",34.0,1924.13495,60.6604,64.82,64.66,66.18,-0.002471425,0.020764105,0.017501464,0.045185613,5.52203,0.18755,15.88974,2706,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1
CRSP,CTX112,Systemic lupus erythematosus (SLE)Â ,Phase 1/2,12/9/2024,"Preliminary data presented at ASH demonstrated that CTX112 has the potential to provide meaningful clinical benefit with a well-tolerated safety profile using a standard lymphodepletion protocol, note",90.0,4254.01739,50.3039,52.33,49.84,44.24,-0.048751946,-0.167940463,0.017501464,0.045185613,22.71793,0.16707,102.48744,2707,0,0,0,1,0,0,0,0,0,0,1,0,2,0,0,1
RIGL,R289,Myeloid dysplastic syndrome (MDS)Â ,Phase 1,12/9/2024,"Phase 1 initial data presented at ASH demonstrated signs of preliminary clinical activity in elderly heavily pretreated LR-MDS patients, RBC-TI/HI-E responses occurred in 40% of evaluable TD patients",17.0,407.96433,93.9023,25.45,23.16,19.14,-0.09428909,-0.284935357,0.017501464,0.045185613,2.62655,0.15044,6.72166,2708,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1
EDIT,Renizgamglogene autogedtemcel (reni-cel; EDIT-301) - (RUBY),Sickle Cell DiseaseÂ ,Phase 1/2,12/9/2024,Additional Phase 1/2 data presented at ASH was well-tolerated and continued to demonstrate a safety profile consistent with myeloablative busulfan conditioning and autologous hematopoietic stem cell t,89.0,184.08226,71.2509,2.14,2.23,1.48,0.041195756,-0.368763741,0.017501464,0.045185613,19.26822,0.12166,5.49228,2709,0,0,0,1,0,1,0,0,0,0,1,0,3,0,0,1
MGX,MGX-001,Hemophilia AÂ ,Preclinical,12/9/2024,"Preclinical data presented at ASH reported that the mean FVIII activity of months 13-16.5 following LNP dosing was 71%, 7%, and 27% compared to mean FVIII activity of months 3-6 of 76%, 8% and 30%, no",37.0,156.05773,144.1682,1.85,4.17,3.105,0.812730397,0.517828076,0.017501464,0.045185613,1.18524,0.09766,266.14846,2710,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1
LYEL,LYL314 (IMPT-314),Large B-cell lymphomaÂ ,Phase 1/2,12/9/2024,"Phase 1/2 trial data from ASH reported an objective response rate (ORR) of 94% and a complete response (CR) rate of 71%, noted December 9, 2024.",19.0,262.94548,117.428,18.084,18.0,13.408,-0.004655812,-0.299176026,0.017501464,0.045185613,3.28733,0.03061,0.61421,2711,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ONC,Sonrotoclax (BGB-11417),Chronic lymphocytic leukemia/small lymphocytic leukemiaÂ ,Phase 1b,12/9/2024,"Phase 1/1b data presented at ASH reported that the combination achieved a 99% overall response rate (ORR), noted December 9, 2024.",110.0,22075.50087,40.0044,205.62,207.62,176.33,0.009679681,-0.153672566,0.017501464,0.045185613,0.93994,0.09823,106.51778,2712,1,0,0,0,0,1,0,0,0,0,1,0,3,0,0,1
ONC,BGB-16673-101 - (CaDAnCe-101),Relapsed or refractory (R/R) CLL/SLLÂ ,Phase 1,12/9/2024,"Phase 1 data presented at ASH reported an ORR of 94% at the 200mg dose, noted December 9, 2024.",110.0,22075.50087,40.0044,205.62,207.62,176.33,0.009679681,-0.153672566,0.017501464,0.045185613,0.93994,0.09823,106.51778,2713,1,0,0,0,0,1,0,0,0,0,1,0,3,0,0,1
KROS,Elritercept with Ruxolitinib - (RESTORE),MyelofibrosisÂ ,Phase 2,12/9/2024,"Phase 2 data presented at ASH reported that 55.2% (n=48/87) of the mITT24 patients achieved an overall erythroid response over the first 24 weeks of treatment, noted December 9, 2024.",40.0,2719.66744,51.0376,70.0,67.14,19.42,-0.04171525,-1.282191779,0.017501464,0.045185613,5.49044,0.0014,41.90738,2714,0,0,0,0,1,1,0,0,0,0,1,0,3,0,0,1
NRIX,NX-5948,R/R Chronic Lymphocytic Leukemia (CLL)Â ,Phase 1a,12/9/2024,"Phase 1a/1b data presented at ASH reported an 75.5% Objective Response Rate which increased to 84.2% in patients with at least two disease assessments, noted December 9, 2024.",76.0,1463.47759,66.3778,21.37,20.66,20.81,-0.033788606,-0.026554429,0.017501464,0.045185613,13.55793,0.08601,20.07047,2715,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1
RXRX,REC-617 - (ELUCIDATE),CDK7 inhibitor; Advanced Solid TumorsÂ ,Phase 1,12/9/2024,"Phase 1 monotherapy safety and PK/PD initial data from the AACR Special Conference reported 1 cPR and 4 SD, noted December 9, 2024.",434.0,2372.15221,80.9701,8.01,8.27,7.44,0.031943748,-0.073819912,0.017501464,0.045185613,22.5121,0.19885,285.16475,2716,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
REGN,Odronextamab - (OLYMPIA),Non-Hodgkin Lymphoma (NHL)Â ,Phase 3,12/9/2024,"Phase 3 data presented at ASH reported an objective response rate (ORR) of 89% and 67% CR rate, noted December 9, 2024.",105.0,84780.55043,25.314,778.0,788.0,724.87,0.012771566,-0.070734196,0.017501464,0.045185613,1.6599,0.14535,809.59278,2717,1,0,0,0,0,1,0,0,0,0,1,0,3,0,0,1
ZLAB,Odronextamab - (OLYMPIA),Non-Hodgkin Lymphoma (NHL)Â ,Phase 3,12/9/2024,"Phase 3 data presented at ASH reported an objective response rate (ORR) of 89% and 67% CR rate, noted December 9, 2024.",109.0,3126.24512,55.1976,27.97,28.91,26.18,0.033055049,-0.066136747,0.017501464,0.045185613,4.51928,0.02846,22.57492,2718,1,0,0,0,0,1,0,0,0,0,1,0,3,0,0,1
OMER,Zaltenibart - (OMS906),Paroxysmal nocturnal hemoglobinuria (PNH)Â ,Phase 2,12/9/2024,"Phase 2 proof of concept results presented at ASH showed that clinical data support Phase 3 enrollment to commence in early 2025, noted December 9, 2024.",68.0,659.46827,111.5841,11.61,11.38,7.59,-0.020009367,-0.425035204,0.017501464,0.045185613,18.50758,0.01318,3.63162,2719,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1
CRIS,CA-4948 - (Take Aim Leukemia),Acute Myeloid Leukemia / Myelodysplastic Syndromes (MDS)Â ,Phase 1/2,12/9/2024,"Phase 1/2 triplet data presented at ASH reported 10 objective responses (6 CRs, 2 CRi/CRh, and 2 MLFS) among 19 evaluable relapsed/refractory AML patients with FLT3 mutations, treated with the RP2D of",12.0,35.0532,73.7791,3.86,4.14,3.48,0.070028604,-0.10363489,0.017501464,0.045185613,1.91925,0.02959,0.41955,2720,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1
ARTL,ART27.13 - (CAReS),Cancer-Related Anorexia and Weight LossÂ ,Phase 1,12/9/2024,"Phase 1 of CAReS, ART27.13 at one month of treatment, two-thirds of participants showed evidence the drug was impacting their weight loss with either stabilization or reversal of weight loss associate",1.0,3.74413,66.9375,7.35614,6.96,6.36,-0.055355864,-0.145506961,0.017501464,0.045185613,0.67286,0.019,0.2555,2721,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
SLN,Divesiran (SLN124) - (SANRECO),Polycythemia VeraÂ ,Phase 1,12/9/2024,"Phase 2 dosing commenced and Phase 1 data reported at ASH continue to show substantial reduction in phlebotomy frequency and lowering of hematocrit levels in PV patients, noted December 9, 2024.",46.0,377.24648,87.2804,8.52,7.99,6.74,-0.064225581,-0.234356416,0.017501464,0.045185613,0.80795,0.00709,5.91505,2722,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CRBP,CRB-601,Solid tumorsÂ ,Phase 1,12/9/2024,"Phase 1 clinical study initiated, noted December 9, 2024.",12.0,185.61531,155.7959,15.26,15.24,14.28,-0.001311476,-0.066375069,0.017501464,0.045185613,19.71872,0.0061,4.59131,2723,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
NAMS,Obicetrapib - (BROADWAY),Heterozygous Familial Hypercholesterolemia and/or Established Atherosclerotic Cardiovascular DiseaseÂ ,Phase 3,12/10/2024,"Phase 3 study achieved primary endpoint of LS mean reduction vs placebo in LDL-C on top of maximally tolerated lipid modifying therapies at day 84 with statistically significant reduction, noted Decem",112.0,2419.58599,74.293,18.52,26.19,26.61,0.346526429,0.362435856,0.013011812,0.037861702,2.80237,0.07731,251.4906,2724,1,0,1,0,0,1,0,0,0,0,0,0,3,0,0,1
CRVO,Neflamapimod - (RewinD-LB),Dementia with Lewy bodies (DLB)Â ,Phase 2b,12/10/2024,"Phase 2b topline data did not demonstrate statistically significant effects versus placebo on primary and secondary endpoints at 16 weeks, noted December 10, 2024.",9.0,17.82808,243.7278,10.25,2.16,1.94,-1.557169484,-1.664589733,0.013011812,0.037861702,23.20339,0.06014,17.95483,2725,1,0,0,0,0,1,0,0,1,0,1,0,4,0,0,1
APGE,APG777 + APG333,"Healthy volunteers, Respiratory diseasesÂ ",Preclinical,12/10/2024,"Preclinical proof-of-concept achieved for APG777 + APG333 combination with clinical trial planning underway in asthma and COPD patients, noted December 10, 2024.",59.0,2752.96279,59.9773,49.07,48.38,48.09,-0.014161345,-0.020173595,0.013011812,0.037861702,12.93584,0.06349,58.31851,2726,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1
OLMA,Palazestrant (OP-1250) and ribociclib - (OPERA-02),Breast CancerÂ ,Phase 2,12/10/2024,"Phase 1b/2 new data presented at SABCS demonstrated promising clinical activity, a safety profile consistent with ribociclib and endocrine therapy, and favorable tolerability, noted December 10, 2024",68.0,711.10779,67.0893,9.44,9.64,6.14,0.020965128,-0.430131238,0.013011812,0.037861702,13.5771,0.07652,10.71558,2727,0,0,0,1,0,1,0,0,0,0,1,0,3,0,0,1
QNTM,Lucid-21-302 - (Lucid-MS),"Healthy Volunteers, multiple sclerosisÂ ",Phase 1,12/10/2024,"Phase 1 safety review committee recommends commencing dosing of the second cohort, noted December 10, 2024.",3.0,11.65782,173.0114,5.7,6.05,5.94,0.059592097,0.041242959,0.013011812,0.037861702,0.0,0.01565,0.01057,2728,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
QURE,AMT-130,Huntington's diseaseÂ ,Phase 1/2,12/10/2024,"FDA agreed that data from ongoing Phase 1/2 studies compared to a natural history external control may serve as the primary basis for a Biologics License Application (BLA) for Accelerated Approval, no",54.0,745.77004,166.0986,7.295,15.3,16.46,0.740663646,0.813744013,0.013011812,0.037861702,6.66977,0.04128,947.50013,2729,0,0,0,0,0,1,1,1,0,0,0,0,3,0,0,1
ACIU,ACI-24 (anti-Abeta vaccine) - (ABATE),Down syndromeÂ ,Phase 1/2,12/10/2024,Phase 1/2 results were generally safe and well tolerated in individuals with Down syndrome with no serious adverse events related to the study drug. No cases of amyloid-related imaging abnormalities o,100.0,310.6725,57.6863,3.14,3.14,2.94,0.0,-0.065813219,0.013011812,0.037861702,1.03407,0.03243,0.18561,2730,0,0,0,1,0,1,0,0,0,0,0,0,0,0,2,0
TAK,ACI-24 (anti-Abeta vaccine) - (ABATE),Down syndromeÂ ,Phase 1/2,12/10/2024,Phase 1/2 results were generally safe and well tolerated in individuals with Down syndrome with no serious adverse events related to the study drug. No cases of amyloid-related imaging abnormalities o,0.0,6521432.964,18.2637,13.74,13.46,13.36,-0.020588963,-0.028046119,0.013011812,0.037861702,0.0,0.0,20.64065,2731,0,0,0,1,0,1,0,0,0,0,0,0,0,0,2,0
INAB,INB-100,"Allogeneic hematopoietic stem cell transplantation (HSCT), leukemias undergoing haploidentical stem cell transplantationÂ ",Phase 1,12/10/2024,Phase 1b data presented at ASH continues to demonstrate durable complete remissions (CR) with no relapses observed in any acute myeloid leukemia (AML) patients including those with high-risk disease a,4.0,22.10739,150.4975,10.08301,9.15001,8.64001,-0.097096857,-0.154448089,0.013011812,0.037861702,1.18546,0.09661,0.35778,2732,1,0,0,0,0,1,0,0,0,0,1,0,3,0,0,1
NVAX,COVID-19 vaccine (NVX-CoV2705),COVID-19-Influenza Combination (CIC) 2024-2025Â ,Phase 3,12/10/2024,"Phase 3 dosing initiated, noted December 10, 2024.",162.0,1404.8224,92.5583,9.07,8.77,9.0,-0.033635458,-0.007747687,0.013011812,0.037861702,24.83551,0.06271,21.91787,2733,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1
ATYR,Efzofitimod - (EFZO-FIT),Pulmonary sarcoidosisÂ ,Phase 3,12/10/2024,"Phase 3 DSMB recommended that the study continue without any modifications, noted December 10, 2024.",97.0,276.17052,73.3206,3.53,3.29,3.08,-0.070410306,-0.136368274,0.013011812,0.037861702,2.58966,0.0286,2.82015,2734,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
LSTA,CENDâ€1 - (CENDIFOX),Solid tumorsÂ ,Phase 1/2,12/10/2024,"Phase 1b/2a all cohorts enrollment completed December 10, 2024.",8.0,23.63165,53.2923,2.64,2.815,2.645,0.064183344,0.001892148,0.013011812,0.037861702,0.17975,0.00626,0.11427,2735,0,0,0,0,0,1,0,0,0,1,0,0,2,0,0,1
SLS,Galinpepimut-S - (REGAL),Acute Myeloid Leukemia (AML)Â ,Phase 3,12/10/2024,"Phase 3 study reached pre-specified threshold of 60 events (Deaths) initiating the interim analysis, noted December 10, 2024.",105.0,73.19726,62.8266,1.09,1.04,0.8817,-0.046956983,-0.212081113,0.013011812,0.037861702,12.85594,0.0168,3.0295,2736,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CLNN,CNM-Au8 - (HEALEY ALS),Amyotrophic Lateral Sclerosis (ALS)Â ,Phase 2,12/10/2024,Phase 2 FDA recommends that Clene leverage additional Neurofilament Light (NfL) data from its three Expanded Access Protocols (EAPs) and the HEALEY ALS Platform Trial to support earlier presented find,9.0,39.34005,109.2077,4.75,4.93,4.36,0.03719437,-0.085672561,0.013011812,0.037861702,1.35649,0.00901,2.61272,2737,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
IMMP,Eftilagimod alpha (efti) - (TACTI-004),1L Non-small cell lung cancer (NSCLC)Â ,Phase 3,12/10/2024,"Phase 3 initiated, noted December 10, 2024.",147.0,494.78781,83.6359,2.18,2.12,2.13,-0.027908788,-0.023202897,0.013011812,0.037861702,0.0,0.0,0.23341,2738,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
IMNN,IMNN-001 - (OVATION 2),Ovarian cancerÂ ,Phase 2,12/10/2024,"Updated Phase 2 data reported that the hazard ratio (HR) decreased from 0.74 to 0.69, with an increase in median overall survival (OS) from 11.1 to 13 months following treatment with IMNN-001 plus sta",2.0,13.03611,207.0059,11.21739,11.72608,11.3113,0.044350168,0.008336973,0.013011812,0.037861702,5.09374,0.03493,0.61549,2739,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
STRO,Luvelta - (REFRÎ±ME-O1),Platinum-resistant ovarian cancer (PROC)Â ,Phase 2/3,12/10/2024,"Phase 2/3 trial data reported an 32% objective response rate (ORR) in evaluable patients at the 5.2 mg/kg starting dose, noted December 10, 2024.",84.0,193.778,86.5136,2.81,2.35,2.09,-0.178769155,-0.296020417,0.013011812,0.037861702,2.49416,0.18237,8.53272,2740,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
TCRX,"TSC-100, TSC-101 - (ALLOHA)",Hematologic malignanciesÂ ,Phase 1,12/10/2024,"Phase 1 data presented at ASH reported that event-free survival strongly favors the treatment arm (HR=0.30; p=0.04), and treatment-arm patients trend towards lower probability of relapse (HR=0.28; p=0",56.0,188.16295,78.6775,4.64,3.33,2.97,-0.331742062,-0.446152413,0.013011812,0.037861702,4.10171,0.04637,6.48532,2741,0,1,1,0,0,1,0,0,0,0,1,0,4,0,0,1
SPRB,Tildacerfont - (CAHptain-205),Pediatric Classic Congenital Adrenal HyperplasiaÂ ,Phase 2,12/10/2024,"Phase 2 topline study indicated that higher doses and twice-daily (BID) dosing might improve efficacy, showing trends toward androgen level reduction, Spruce to halt investment in tildacerfont and exp",0.0,22.17954,55.0885,40.4401,40.2751,30.33008,-0.004088455,-0.287681908,0.013011812,0.037861702,0.07427,0.02151,2.50048,2742,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
SPRB,Tildacerfont - (CAHmelia-204),Congenital Adrenal Hyperplasia (good disease control)Â ,Phase 2b,12/10/2024,"Phase 2b study did not meet its primary endpoint of reducing glucocorticoid (GC) usage, with a placebo-adjusted reduction of only 0.7 mg/day. Spruce to halt investment in tildacerfont and explore stra",0.0,22.17954,55.0885,40.4401,40.2751,30.33008,-0.004088455,-0.287681908,0.013011812,0.037861702,0.07427,0.02151,2.50048,2743,1,0,0,0,0,1,0,0,0,0,0,0,0,2,0,-1
SIGA,Tecovirimat - (STOMP),Human Mpox VirusÂ ,Phase 3,12/10/2024,"Phase 3 interim analysis shows that tecovirimat did not improve time to lesion resolution compared to placebo in adults with mild to moderate clade II mpox, noted December 10, 2024.",71.0,461.98821,85.0479,6.94,6.47,6.09,-0.070125666,-0.130653693,0.013011812,0.037861702,5.18753,0.03109,8.57556,2744,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ALMS,izokibep,"Non-infectious, non-anterior uveitisÂ ",Phase 2/3,12/10/2024,"Phase 2b/3 trial of izokibep did not meet primary endpoint; secondary endpoints also did not achieve statistical significance, noted Decemeber 10, 2024. Based on these data, and previously announced g",104.0,456.47747,0.0,8.61,8.39,8.74,-0.025883798,0.014985871,0.013011812,0.037861702,4.46529,0.06304,1.48609,2745,1,0,0,0,0,1,0,0,1,0,0,0,0,3,0,-1
IMMX,NXC-201 (HBI10101) - (NEXICART-1),relapsed/refractory multiple myeloma and relapsed/refractory AL amyloidosisÂ ,Phase 1/2,12/10/2024,"Phase 1/2 data presented at ASH showed that therapy demonstrated a 94% overall response rate, a favorable safety profile, and no grade 4 cytokine release syndrome or neurotoxicity events, noted Novemb",28.0,60.24173,93.2034,2.54,2.19,2.29,-0.148262537,-0.103612263,0.013011812,0.037861702,1.711,0.14975,0.5906,2746,0,0,0,1,0,1,0,0,0,0,1,0,3,0,0,1
XNCR,MONJUVI (tafasitamab) with REVLIMID (lenalidomide) and RITUXAN (rituximab),Follicular lymphoma (FL) / marginal zone lymphoma (MZL)Â ,Phase 3,12/10/2024,"Phase 3 data presented at ASH showed that trial met its primary endpoint of progression-free survival (PFS) and key secondary endpoints, noted December 10, 2024.",71.0,1769.84554,52.0906,25.2,25.29,25.04,0.003565066,-0.006369448,0.013011812,0.037861702,6.37487,0.15617,12.52057,2747,1,0,0,0,0,1,0,0,1,0,1,0,4,0,0,1
NVS,MONJUVI (tafasitamab) with REVLIMID (lenalidomide) and RITUXAN (rituximab),Follicular lymphoma (FL) / marginal zone lymphoma (MZL)Â ,Phase 3,12/10/2024,"Phase 3 data presented at ASH showed that trial met its primary endpoint of progression-free survival (PFS) and key secondary endpoints, noted December 10, 2024.",0.0,2178.09011,51.0392,7.15,7.0,7.0,-0.021202208,-0.021202208,0.013011812,0.037861702,0.0,0.00714,0.10973,2748,1,0,0,0,0,1,0,0,1,0,1,0,4,0,0,1
INCY,MONJUVI (tafasitamab) with REVLIMID (lenalidomide) and RITUXAN (rituximab),Follicular lymphoma (FL) / marginal zone lymphoma (MZL)Â ,Phase 3,12/10/2024,"Phase 3 data presented at ASH showed that trial met its primary endpoint of progression-free survival (PFS) and key secondary endpoints, noted December 10, 2024.",196.0,13963.29005,34.5163,72.11,72.48,69.4,0.005117931,-0.038305863,0.013011812,0.037861702,3.10726,0.08243,174.44341,2749,1,0,0,0,0,1,0,0,1,0,1,0,4,0,0,1
NXTC,LNCB74,B7-H4 expressing cancersÂ ,IND-Enabling,12/10/2024,"IND cleared by the FDA, noted December 10, 2024.",2.0,31.64755,61.1252,13.92001,13.56001,10.8084,-0.026202353,-0.253003764,0.013011812,0.037861702,0.18009,0.01547,0.09451,2750,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
ALXO,Zanidatamab and Evorpacept (ALX148),HER2 Breast cancer and solid tumorsÂ ,Phase 1/2,12/10/2024,Phase 1b/2 data to be presented at SABCS suggest that HER2-positive patients whose cancer has been heavily pretreated may benefit from CD47 inhibition via evorpacept's unique mechanism when combined w,53.0,83.3341,114.2088,1.72,1.58,1.79,-0.084899444,0.039891329,0.013011812,0.037861702,13.59677,0.09236,1.988,2751,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1
ZYME,Zanidatamab and Evorpacept (ALX148),HER2 Breast cancer and solid tumorsÂ ,Phase 1/2,12/10/2024,Phase 1b/2 data to be presented at SABCS suggest that HER2-positive patients whose cancer has been heavily pretreated may benefit from CD47 inhibition via evorpacept's unique mechanism when combined w,75.0,899.54049,43.6284,13.14,13.06,13.37,-0.006106889,0.017352378,0.013011812,0.037861702,6.72575,0.15698,6.85133,2752,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1
IMMX,NXC-201 (HBI10101) - (NEXICART-2),Relapsed/refractory AL AmyloidosisÂ ,Phase 1/2,12/10/2024,"Phase 1b/2 data reported a 75% (12/16) complete response (CR) rate observed in standard of care (Dara-CyBorD) relapsed/refractory AL Amyloidosis patients with median 4 lines of prior therapy, noted De",28.0,60.24173,93.2034,2.54,2.19,2.29,-0.148262537,-0.103612263,0.013011812,0.037861702,1.711,0.14975,0.5906,2753,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
RLYB,RLYB212,Fetal and neonatal alloimmune thrombocytopenia (FNAIT)Â ,Preclinical,12/10/2024,"Preclinical data presented at ASH showed that treatment has the potential to be a safe and effective preventative therapeutic using innovative nonclinical models, noted December 10, 2024.",41.0,49.37023,59.7402,1.16,1.19,1.03,0.025533302,-0.118861203,0.013011812,0.037861702,0.8534,0.01022,0.20601,2754,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1
RLYB,RLYB332,Iron overloadÂ ,Preclinical,12/10/2024,"Preclinical data presented at ASH demonstrated that single intravenous injections of RLYB332 to humanized FcRn mice had rapid and sustained effects on pharmacodynamic (PD) parameters, including serum",41.0,49.37023,59.7402,1.16,1.19,1.03,0.025533302,-0.118861203,0.013011812,0.037861702,0.8534,0.01022,0.20601,2755,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1
RLAY,RLY-2608 + fulvestrant + ribociclib triplet combination - (ReDiscover),"PIK3CA (PI3KÎ±) mutant tumors, including HR+/HER2- breast cancerÂ ",Phase 1,12/11/2024,"Phase 1 efficacy data shared at SABCS reported a 39% confirmed ORR across all patients & 67% in patients with kinase mutations at RP2D, noted December 11, 2024.",172.0,833.56713,89.2758,4.43,4.98,4.2,0.117030307,-0.053315059,0.033611347,0.079999938,7.12769,0.12209,45.13863,2756,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
PHAR,Leniolisib - (pediactric),Activated phosphoinositide 3-kinase delta syndrome (APDS)Â ,Phase 3,12/11/2024,"Phase 3 data reported improvement in lymphoproliferation and immunophenotype correction were seen across the four dose levels being investigated, noted December 11, 2024.",68.0,91.76368,48.7655,0.229,0.222,0.21,-0.031044622,-0.086614473,0.033611347,0.079999938,0.0,0.01398,0.00119,2757,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CADL,CAN-2409 - (ULYSSES),Prostate Cancer (Active Surveillance)Â ,Phase 3,12/11/2024,Phase 2b clinical trial of monotherapy CAN-2409 in 190 patients with low-to-intermediate risk localized prostate cancer undergoing active surveillance showed numerical improvement in time to radical t,54.0,251.68541,105.7908,4.61,7.75,6.53,0.519464986,0.348179086,0.033611347,0.079999938,6.71023,0.00034,780.98909,2758,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CADL,CAN-2409 (aglatimagene besadenovec) combined with Valacyclovir,Prostate cancerÂ ,Phase 2,12/11/2024,"Phase 3 results for CAN-2409 viral immunotherapy in intermediate-to-high-risk localized prostate cancer, achieved its primary endpoint of significantly improved disease-free survival (DFS) when combin",54.0,251.68541,105.7908,4.61,7.75,6.53,0.519464986,0.348179086,0.033611347,0.079999938,6.71023,0.00034,780.98909,2759,1,0,0,0,0,1,0,0,0,0,0,0,2,0,0,1
ADCT,ZYNLONTA (Loncastuximab Tesirine-Ipyl) - (LOTIS-7),B-cell non-Hodgkin lymphomaÂ ,Phase 1b,12/11/2024,"Phase 1b data reported a clinically meaningful benefit with 94% best ORR and 72% CR rate, noted December 11, 2024.",112.0,214.65095,127.3844,3.48,2.22,1.91,-0.449525098,-0.599929052,0.033611347,0.079999938,3.11782,0.05734,12.49258,2760,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ARWR,ARO-CFB,Complement Mediated Kidney DiseaseÂ ,Phase 1/2,12/11/2024,"Phase 1/2a data reported dose dependent reductions in circulating CFB protein by up to 90% with greater than 3 months duration, noted December 11, 2024.",138.0,2828.39487,63.4606,23.92,22.73,20.36,-0.051029291,-0.161142737,0.033611347,0.079999938,8.09297,0.10278,35.63609,2761,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CELC,Gedatolisib with Palbociclib and Letrozole,Early-Stage Breast CancerÂ ,Phase 1b,12/11/2024,"Phase 1b trial presented at SABCS showed a median overall survival (OS) among patients with HR+, HER2- advanced breast cancer who were treatment-naÃ¯ve in the advanced setting was 77.3 months, while me",42.0,477.1148,48.9821,12.73,12.85,12.1,0.009382399,-0.05075596,0.033611347,0.079999938,7.73047,0.12608,2.04639,2762,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
PRLD,PRT2527,Solid tumors and hematological malignanciesÂ ,Phase 1,12/11/2024,"Phase 1 data reported an overall response rate (ORR) of 17.4% (4 of 23), with complete responses (CRs) observed in 3 patients (2 DLBCL, 1 MCL) and 2 partial responses (PRs) observed, noted December 11",56.0,71.31515,130.2163,0.97,0.94,0.9063,-0.031416196,-0.067925694,0.033611347,0.079999938,4.02895,0.00055,0.89254,2763,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
BPTH,BP1002,Refractory/relapsed lymphoma and chronic lymphocytic leukemiaÂ ,Phase 1,12/11/2024,"Phase 1 study enrollment discontinued, noted December 11, 2024.",8.0,3.07943,93.1923,0.74,0.715,0.669,-0.034367644,-0.100866126,0.033611347,0.079999938,0.71743,0.03037,0.5044,2764,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ATXS,Navenibart (STAR-0215) - (ALPHA-ORBIT),"Hereditary angioedema (HAE), healthy volunteersÂ ",Phase 1/2,12/11/2024,"Phase 1b/2 data results demonstrated reduction in the mean monthly attack rate of 90-95% at 6 months, favorable safety and tolerability profile, noted December 11, 2024.",56.0,592.5593,61.93,10.16,10.5,9.36,0.032916815,-0.082013152,0.033611347,0.079999938,5.57425,0.15108,8.26211,2765,0,0,0,1,0,1,0,0,0,0,0,0,2,0,0,1
ATXS,STAR-0310,Healthy volunteersÂ ,IND-Enabling,12/11/2024,"IND cleared by the FDA, noted December 10, 2024.",56.0,592.5593,61.93,10.16,10.5,9.36,0.032916815,-0.082013152,0.033611347,0.079999938,5.57425,0.15108,8.26211,2766,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
MBRX,"Annamycin (MB-106) in combination with Cytarabine - (Ara-C, MIRACLE)",Acute Myeloid Leukemia (AML)Â ,Preclinical,12/11/2024,"Preclinical data resulted in durable disease eradication up to 150 days post treatment in 20% of mice, noted December 11, 2024.",30.0,7.95502,98.4891,2.31,2.65,1.88,0.137312115,-0.205975748,0.033611347,0.079999938,0.68807,0.03454,0.77999,2767,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ANRO,ALTO-300,Major Depressive Disorder (MDD)Â ,Preclinical,12/11/2024,"New preclinical data presented at ACNP from a reverse translation study demonstrates the link between the mechanism of ALTO-300 and the EEG biomarker used for patient selection, noted December 11, 202",27.0,104.91395,188.2551,4.05,3.89,3.64,-0.040307723,-0.106733199,0.033611347,0.079999938,15.11659,0.08357,1.74258,2768,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
JNJ,CAPLYTA (Lumateperone) - (Study 501),Major depressive disorder (MDD)Â ,Phase 3,12/11/2024,"Phase 3 data reported that response rates for CAPLYTA were 45.6% vs. 24.0% for placebo (p<0.0001) and remission rates were 25.9% vs. 13.6% for placebo, noted December 11, 2024.",0.0,353053.8326,15.1378,149.23,146.64,144.75,-0.017508136,-0.030480623,0.033611347,0.079999938,0.77008,0.00046,1971.81764,2769,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
JNJ,CAPLYTA (lumateperone) - (Study 502),Major depressive disorder (MDD)Â ,Phase 3,12/11/2024,"Phase 3 data reported response rates for CAPLYTA were 40.1% vs. 25.3% for placebo (p<0.01) and remission rates were 25.0% vs. 13.5% for placebo, noted December 11, 2024.",0.0,353053.8326,15.1378,149.23,146.64,144.75,-0.017508136,-0.030480623,0.033611347,0.079999938,0.77008,0.00046,1971.81764,2770,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
BCTX,Bria-IMT - (BRIA-ABC),Advanced breast cancerÂ ,Phase 2,12/11/2024,"Phase 2 SABCS data reported a median overall survival (OS) to date of 13.4 months, noted December 11, 2024.",1.0,58.51833,148.2792,161.99992,164.99992,92.39995,0.018349148,-0.561469404,0.033611347,0.079999938,0.0,0.0,10.13496,2771,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
AZN,LYNPARZA (olaparib) - (OlympiA),Early Breast CancerÂ ,Phase 3,12/11/2024,"Phase 3 data reported that 87.5% of patients treated with LYNPARZA were alive at six-years vs. 83.2% in the comparator arm, noted December 11, 2024.",0.0,163372.4254,22.1881,105.12,105.38,103.52,0.00247031,-0.015337724,0.033611347,0.079999938,0.0,0.03907,322.25478,2772,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
MRK,LYNPARZA (olaparib) - (OlympiA),Early Breast CancerÂ ,Phase 3,12/11/2024,"Phase 3 data reported that 87.5% of patients treated with LYNPARZA were alive at six-years vs. 83.2% in the comparator arm, noted December 11, 2024.",0.0,252331.1556,24.2942,101.0,99.75,98.34,-0.012453461,-0.026689655,0.033611347,0.079999938,1.29616,0.12559,2155.89476,2773,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CORT,Dazucorilant (DAZALS),Amyotrophic Lateral Sclerosis (ALS)Â ,Phase 2,12/11/2024,"Phase 2 trial did not meet its primary endpoint, noted December 11, 2024.",105.0,6294.89023,41.8322,58.81,60.08,52.42,0.021365099,-0.115023711,0.033611347,0.079999938,16.27449,0.18646,32.819,2774,1,0,0,0,0,1,0,0,0,0,0,0,0,2,0,-1
ATOS,Z-Endoxifen - (Karisma),"Mammographic breast density (MBD), breast cancerÂ ",Phase 2,12/11/2024,"Phase 2 data showed that the 1 mg dose reduced MBD by 17.3 percentage points, while the 2 mg dose achieved a reduction of 23.5 percentage points, compared to a minimal change in the placebo group of 0",129.0,153.47753,57.789,1.26,1.22,0.99,-0.032260862,-0.241162057,0.033611347,0.079999938,9.22338,0.12994,1.28739,2775,0,0,1,0,0,1,0,0,0,0,0,0,2,0,0,1
GLUE,MRT-9643,HR-positive/HER2-negative breast cancerÂ ,Preclinical,12/11/2024,"Preclinical data demonstrated that the company has superior selectivity compared to clinical-stage CDK2 inhibitors and induced robust downstream CDK2 pathway suppression, noted December 11, 2024.",61.0,522.82135,132.8884,9.44,8.51,7.03,-0.103714038,-0.294769274,0.033611347,0.079999938,17.99426,0.02311,12.58118,2776,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
LLY,Inluriyo (imlunestrant),"ER+, HER2-, ESR1-mutated advanced or metastatic breast cancerÂ ",Phase 3,12/11/2024,"Phase 3 data presented at SABCS significantly reduced the risk of progression or death by 38% compared to standard endocrine therapy (ET) in patients with ESR1 mutations, noted December 11, 2024.",0.0,716770.92,33.4221,799.58,796.03,764.71,-0.004449716,-0.044589913,0.033611347,0.079999938,0.64822,0.18857,2794.76421,2777,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1
IMCR,KIMMTRAK (tebentafusp-tebn) - (ATOM),Uveal melanomaÂ ,Phase 3,12/11/2024,"Phase 3 trial initiated, noted December 11, 2024.",48.0,1539.50833,39.002,31.85,30.77,28.26,-0.034497193,-0.119590005,0.033611347,0.079999938,14.36528,0.15783,9.20014,2778,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
JAGX,Mytesi (crofelemer) - (OnTarget),Cancer Therapy-Related DiarrheaÂ ,Phase 3,12/11/2024,"Phase 3 subgroup results from SABCS reported that nearly half (47.1%) of crofelemer group patients were responders through 12 weeks, compared to 33.7% of those on placebo, noted December 11, 2024.",2.0,15.10179,150.3141,24.755,32.0,21.5,0.256708414,-0.140974554,0.033611347,0.079999938,4.36724,0.00605,2.82374,2779,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ARVN,Vepdegestrant (ARV-471) - (TACTIVE-U),Solid TumorsÂ ,Phase 1b,12/12/2024,"Phase 1b sub-study data reported a clinical benefit rate: 62.5%; overall response rate: 26.7%, noted December 12, 2024.",73.0,1356.39656,60.0611,22.54,19.74,17.83,-0.132644475,-0.234409077,0.037510307,0.076705325,13.12746,0.05708,49.08758,2780,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ATOS,(Z)-endoxifen with abemaciclib (VERZENIO) - (EVANGELINE),Pre-menopausal women w/ early-stage estrogen receptor positive and Human Epidermal Growth Factor Receptor 2 negative breast cancerÂ ,Phase 2,12/12/2024,Phase 2 data from SABCS reported that 50 percent of patients (3/6) in the group that received 80 mg of (Z)-endoxifen with goserelin met the target steady-state plasma concentrations (Css) of 500â€“1000,129.0,144.67144,58.2001,1.22,1.15,0.98,-0.059088916,-0.219053566,0.037510307,0.076705325,9.22338,0.12994,1.99994,2781,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1
LLY,(Z)-endoxifen with abemaciclib (VERZENIO) - (EVANGELINE),Pre-menopausal women w/ early-stage estrogen receptor positive and Human Epidermal Growth Factor Receptor 2 negative breast cancerÂ ,Phase 2,12/12/2024,Phase 2 data from SABCS reported that 50 percent of patients (3/6) in the group that received 80 mg of (Z)-endoxifen with goserelin met the target steady-state plasma concentrations (Css) of 500â€“1000,946.0,704453.0096,33.5028,796.03,782.35,757.54,-0.017334663,-0.049560532,0.037510307,0.076705325,0.64822,0.18857,2209.23122,2782,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1
KROS,Cibotercept (KER-012) - (TROPOS),Pulmonary arterial hypertension (PAH) and disorders associated with bone lossÂ ,Phase 2,12/12/2024,"Phase 2 trial voluntarily halted dosing in the 3.0 mg/kg and 4.5 mg/kg treatment arm due to the unanticipated observation of pericardial effusion adverse events in the trial, noted December 12, 2024.",40.0,746.55155,191.7574,68.65,18.43,16.92,-1.315041361,-1.400524778,0.037510307,0.076705325,5.42443,0.0014,269.91985,2783,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
GUTS,Rejuva (RJVA-001),Obesity and type 2 diabetes (T2D)Â ,Preclinical,12/12/2024,"Preclinical data shared at the WCIRDC was successfully delivered in large animal Yucatan pig models at a low total viral dose, noted on December 12, 2024.",50.0,106.05817,103.6705,2.28,2.205,1.82,-0.033447934,-0.225338942,0.037510307,0.076705325,4.64736,0.11025,0.81579,2784,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
TRVI,Haduvio - (CORAL),Chronic Cough in Idiopathic Pulmonary Fibrosis (IPF)Â ,Phase 2b,12/12/2024,"Phase 2b SSRE result reported that it was recommended that the CORAL trial should continue as planned to maintain the pre-specified conditional power of 80% or greater, noted December 12, 2024.",121.0,276.71656,82.0595,2.49,3.6,4.15,0.368651135,0.510825624,0.037510307,0.076705325,1.83861,0.00772,229.8707,2785,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ELTX,ELI-002 (AMPLIFY-201),Solid TumorsÂ ,Phase 2,12/12/2024,"Phase 2 data presented include a 16.3-month median recurrence-free survival (mRFS) and 28.9-month median overall survival (mOS) from full study population, noted ESMO-IO on December 12, 2024.",16.0,53.77659,109.263,5.32,4.99,5.075,-0.064037394,-0.047146778,0.037510307,0.076705325,0.55423,0.00768,0.06847,2786,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ANAB,ANB032 - (ARISE-AD),Atopic dermatitisÂ ,Phase 2b,12/12/2024,"Phase 2b did not meet the primary and secondary endpoints in any of the doses studied in the global, AD trial and all further investment in ANB032 will be discontinued, noted December 12, 2024.",28.0,457.0388,95.5593,15.51,15.02,15.0,-0.032102331,-0.033434776,0.037510307,0.076705325,23.33132,0.10335,12.2313,2787,1,0,0,0,0,1,0,0,1,0,0,0,0,3,0,-1
APRE,ATRN-119 - (ABOYA-119),Solid tumorsÂ ,Phase 1/2,12/12/2024,"Phase 1/2 dosing commenced, noted December 12, 2024.",5.0,19.12814,73.5815,3.6,3.5195,3.23,-0.022614911,-0.108451708,0.037510307,0.076705325,0.20208,0.02429,0.05387,2788,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
VRTX,Povetacicept (ALPN-303) - (RAINIER),"Lupus nephritis, IgA nephropathyÂ ",Phase 1/2,12/12/2024,"Phase 1b/2a data reported that 100% of patients achieved remission within 30 days, noted December 12, 2024.",256.0,119524.4941,23.1811,468.29,464.12,396.64,-0.008944623,-0.166058694,0.037510307,0.076705325,1.42556,0.29269,444.8994,2789,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1
ALPN,Povetacicept (ALPN-303) - (RAINIER),"Lupus nephritis, IgA nephropathyÂ ",Phase 1/2,12/12/2024,"Phase 1b/2a data reported that 100% of patients achieved remission within 30 days, noted December 12, 2024.",68.0,66.19524,20.6354,7.6,7.6,7.65,0.0,0.006557401,0.037510307,0.076705325,0.0,0.00943,0.0,2790,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1
PFE,IBRANCE (palbociclib) - (PATINA),"HR+, HER2+ Metastatic Breast CancerÂ ",Phase 3,12/12/2024,Phase 3 data reported that the median PFS was 44.3 months (95% CI: 32.4-60.9) for patients treated with IBRANCE in combination with anti-HER2 therapy (trastuzumab or trastuzumab plus pertuzumab) and e,0.0,143771.5372,21.7122,25.23,25.37,25.77,0.005533611,0.021177262,0.037510307,0.076705325,1.59492,0.00061,981.94818,2791,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
IMMP,Eftilagimod alpha (IMP321) and KEYTRUDA (pembrolizumab) - (TACTI-003),Head and neck squamous cell carcinoma (HNSCC)Â ,Phase 2b,12/12/2024,"Phase 2b data presented on ESMO IO reported that the median overall survival (OS) has not yet been reached and the 12-month OS rate is 67%, both well above historical controls, noted December 12, 2024",147.0,545.72185,84.904,2.36,2.235,2.12,-0.054420391,-0.10724553,0.037510307,0.076705325,0.0,0.0,0.74762,2792,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ALXO,Evorpacept with zanidatamab,Metastatic breast cancerÂ ,Phase 1/2,12/12/2024,"Phase 1b/2 data reported promising anti-tumor activity with an cORR of 55.6%, noted December 12, 2024.",53.0,74.89521,114.4824,1.51,1.42,1.48,-0.061452779,-0.020067563,0.037510307,0.076705325,13.59677,0.09236,3.74687,2793,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
JAZZ,Evorpacept with zanidatamab,Metastatic breast cancerÂ ,Phase 1/2,12/12/2024,"Phase 1b/2 data reported promising anti-tumor activity with an cORR of 55.6%, noted December 12, 2024.",60.0,7472.18757,28.9427,120.72,123.6,122.85,0.023576731,0.017490285,0.037510307,0.076705325,7.03541,0.08934,92.58814,2794,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
INTS,INT230-6 - (INVINCIBLE-2),Early stage breast cancerÂ ,Phase 2,12/12/2024,"Phase 2 results in tumors larger than 2 cm showed significant necrosis in 74% of subjects at the time of surgery, noted December 12, 2024.",47.0,31.17765,58.6207,2.35,2.0646,2.0,-0.129478825,-0.161268148,0.037510307,0.076705325,0.25611,0.02398,0.54887,2795,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
KRYS,KB408 - (SERPENTINE-1),Alpha-1 antitrypsin deficiency (AATD)Â ,Phase 1,12/12/2024,"Phase 1 data reported a clinically meaningful proportion of conducting airway epithelial cells were transduced following administration of a single dose of KB408, with the percentage of cells positive",28.0,4987.07902,38.7015,187.12,173.4,160.83,-0.076149058,-0.151402216,0.037510307,0.076705325,12.6913,0.13277,82.89092,2796,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
KRYS,KB407 - (CORAL-1),Cystic FibrosisÂ ,Phase 1,12/12/2024,"Phase 1 data reported that no serious adverse events have been reported, noted December 12, 2024.",28.0,4987.07902,38.7015,187.12,173.4,160.83,-0.076149058,-0.151402216,0.037510307,0.076705325,12.6913,0.13277,82.89092,2797,0,0,0,1,0,1,0,0,0,0,0,0,0,2,0,-1
BOLD,BBI-355/BBI-825 - (POTENTIATE),Resistance gene amplificationsÂ ,Phase 1/2,12/12/2024,"Company will not to continue dose escalation of Part 1 or to proceed into the Part 2 portion of the STARMAP trial, noted December 12, 2024.",22.0,65.78076,100.5225,3.38,2.95,2.52,-0.136070539,-0.293616808,0.037510307,0.076705325,0.81056,0.20982,0.17185,2798,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CORT,Korlym - (CATALYST),Hypercortisolism (Cushing's Syndrome) and Difficult-to-Control DiabetesÂ ,Phase 3,12/12/2024,"Phase 4 trial met primary endpoint, noted December 12, 2024.",105.0,5901.45959,42.9295,60.08,56.325,51.15,-0.064538521,-0.160914515,0.037510307,0.076705325,16.27449,0.18646,60.15595,2799,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1
BCYC,Bicycle Toxin Conjugates zelenectide pevedotin (BT8009) - (Duravelo-2),Solid tumorsÂ ,Phase 2/3,12/12/2024,"Data presented at SABCS reported an 60% overall response rate, noted December 12, 2024.",69.0,1388.51548,58.0136,21.09,20.11,15.0,-0.047581791,-0.340748793,0.037510307,0.076705325,4.90983,0.08986,6.19173,2800,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1
KZIA,Paxalisib - (A071701),Brain MetastasesÂ ,Phase 2,12/12/2024,"Phase 2 data presented reported minimal clinical activity, noted December 12, 2024.",1.0,15.98272,251.1149,18.35,18.35,15.15,0.0,-0.191629043,0.037510307,0.076705325,0.511,0.00365,0.113,2801,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
RPTX,Lunresertib (RP-6306) + Debio 0123 - (MYTHIC),Solid TumorsÂ ,Phase 1,12/13/2024,"Phase 1 trial achieved 25.9% overall response rate (ORR) in endometrial cancer and 37.5% in platinum-resistant ovarian cancer, noted December 13, 2024.",42.0,75.24395,133.9984,3.97,1.77,1.32,-0.807786548,-1.101134358,-0.005927198,0.031488476,1.35619,0.12353,8.31243,2802,1,0,0,0,0,1,0,0,0,0,0,0,2,0,0,1
FBIO,UNLOXCYT (cosibelimab-ipdl),Cutaneous squamous cell carcinoma (CSCC)Â ,Approved,12/13/2024,"Approved December 13, 2024.",29.0,53.55357,77.7319,1.99,1.94,1.72,-0.025446666,-0.145810348,-0.005927198,0.031488476,10.20224,0.04813,1.15238,2803,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1
ROIV,Tapinarof Cream 1%,Atopic dermatitis (AD)Â ,Approved,12/16/2024,"Approved December 16, 2024.",682.0,8808.1919,27.5577,11.84,12.1,11.97,0.021721823,0.01091989,-0.012660417,0.016299136,6.56723,0.05566,56.03557,2804,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1
OGN,Tapinarof Cream 1%,Atopic dermatitis (AD)Â ,Approved,12/16/2024,"Approved December 16, 2024.",259.0,3754.9168,35.389,15.3,14.58,14.7,-0.048202102,-0.040005335,-0.012660417,0.016299136,5.31066,0.00748,64.84884,2805,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1
MNKD,Afrezza (Technosphere Insulin) - (INHALE-1),Pediatric type 1/2 diabetesÂ ,Phase 3,12/16/2024,Phase 3 data reported that in the intent-to-treat population (ITT) found that the between-group difference in mean HbA1c change over 26 weeks exceeded the prespecified non-inferiority margin of 0.4% (,306.0,1729.12614,36.1749,6.54,6.27,7.02,-0.042160811,0.070826053,-0.012660417,0.016299136,15.12491,0.04753,31.56675,2806,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
FHTX,FHD-286,Acute myeloid leukemia (AML)Â ,Phase 1,12/16/2024,"Phase 1 dose escalation trial combination reported that objective clinical responses were observed by standard response criteria. However, the observed response rate did not meet the Company's thresho",56.0,306.31815,89.2537,5.3,5.51,4.93,0.038857803,-0.072367833,-0.012660417,0.016299136,1.59722,0.09491,3.98948,2807,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,-1
PRTC,Deupirfenidone (LYT-100) - (ELEVATE IPF),Idiopathic pulmonary fibrosis (IPF)Â ,Phase 2b,12/16/2024,"Phase 2b topline data reported a strong, consistent and durable efficacy with a treatment effect versus placebo of 80.9% with favorable tolerability, noted December 16, 2024.",24.0,407.01623,32.8292,1.628,1.7,1.564,0.043275983,-0.040105625,-0.012660417,0.016299136,0.0,0.04562,3.67089,2808,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
LRMR,Nomlabofusp (CTI-1601),Friedreichâ€™s ataxia (FA)Â ,Phase 2,12/16/2024,"Phase 2 data showed sustained increases in tissue frataxin (FXN) levels. Buccal cell FXN increased from 15% of healthy volunteer levels at baseline to 30% by Day 90, and skin cell FXN rose from 16% to",85.0,308.18601,87.4117,6.17,4.83,3.96,-0.24485237,-0.443454813,-0.012660417,0.016299136,6.07745,0.02265,29.44774,2809,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
MNMD,"MM120 (lysergide D-tartrate, LSD) - (Voyage)",Generalized Anxiety Disorder (GAD)Â ,Phase 3,12/16/2024,"Phase 3 dosing initiated, noted December 16, 2024.",75.0,542.65451,70.9346,7.16,7.4,7.08,0.032970019,-0.011236073,-0.012660417,0.016299136,13.23767,0.0198,9.3566,2810,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1
SNGX,HyBryte - (FLASH2),Cutaneous T-Cell LymphomaÂ ,Phase 3,12/16/2024,"Phase 3 18-week study initiated, noted December 16, 2024.",4.0,7.65422,215.3116,3.1601,3.0501,2.84,-0.035429296,-0.10679962,-0.012660417,0.016299136,1.46197,0.00504,0.32619,2811,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
BCAB,Mecbotamab Vedotin (BA3011),Solid TumorsÂ ,Phase 2,12/16/2024,"Phase 2 enrollment completed with a registrational trial planned for 2H 2024. Phase 2 1-year OS was 58% for mKRAS vs. 23% for wtKRAS patients with an ORR of 28.6%, active across 9 mKRAS variants, not",58.0,65.26652,99.3841,1.45,1.35,0.611,-0.071458964,-0.864221876,-0.012660417,0.016299136,8.23806,0.12155,0.8518,2812,0,0,0,0,0,1,0,0,0,1,0,0,2,0,0,1
ASND,TransCon hGH - (InsiGHTS),Turner SyndromeÂ ,Phase 2,12/16/2024,"Phase 2 topline results reported that all three TransCon hGH starting dose cohort showed a safety and tolerability profile comparable to daily somatropin, noted December 16, 2024.",60.0,8163.27255,44.1011,129.87,136.6,139.7,0.050522997,0.072963316,-0.012660417,0.016299136,6.30403,0.04809,77.7086,2813,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
EWTX,Sevasemten (EDG-5506) - (CANYON),Becker Muscular Dystrophy (BMD)Â ,Phase 2,12/16/2024,"Phase 2 trial met its primary endpoint of reduction in circulating levels of creatine kinase (CK), a biomarker associated with skeletal muscle damage, in the largest Becker interventional trial to dat",105.0,3095.36762,89.3328,27.62,32.69,29.98,0.168529073,0.081990345,-0.012660417,0.016299136,6.06511,0.17642,125.4298,2814,1,0,0,0,0,1,0,0,0,0,0,0,2,0,0,1
PEPG,PGN-EDO51 - (CONNECT2),Duchenne muscular dystrophy (DMD)Â ,Phase 2,12/16/2024,"Phase 2 trial received a clinical hold notice from the FDA regarding its IND application, noted December 16, 2024.",32.0,147.00677,96.9127,4.68,4.51,3.89,-0.037000956,-0.184888952,-0.012660417,0.016299136,2.3769,0.0878,2.11401,2815,0,0,0,0,0,1,0,1,0,0,0,0,0,2,0,-1
BHVN,BHV-1300,Healthy volunteersÂ ,Phase 1,12/16/2024,"Phase 1 achieved deep lowering of targeted IgG, with reductions > 60% in the lowest subcutaneous dose tested in the MAD, noted December 16, 2024.",105.0,4190.50587,54.3801,38.47,41.44,36.15,0.074367881,-0.062201768,-0.012660417,0.016299136,7.75421,0.12854,87.19594,2816,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1
BHVN,Troriluzole (BHV4157-206-RWE),Spinocerebellar AtaxiaÂ ,sNDA Filing,12/16/2024,"sNDA submitted to the FDA, noted December 16, 2024.",105.0,4190.50587,54.3801,38.47,41.44,36.15,0.074367881,-0.062201768,-0.012660417,0.016299136,7.75421,0.12854,87.19594,2817,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
RVPH,Brilaroxazine - (RECOVER),SchizophreniaÂ ,Phase 3,12/16/2024,"Phase 3 long-term topline data from OLE demonstrated favorable long-term safety and robust broad-spectrum efficacy sustained over 1-year, the treatment generally well-tolerated with low rates of adver",68.0,79.53216,135.0134,2.61,2.3,1.64,-0.126441098,-0.464653979,-0.012660417,0.016299136,17.81521,0.0121,22.22031,2818,0,0,0,1,0,1,0,0,0,0,1,0,3,0,0,1
SNY,MenQuadfi,Meningococcal diseaseÂ ,Approved,12/17/2024,"Approved December 17, 2024.",0.0,115004.5962,22.7225,45.89,48.94,48.29,0.06434783,0.050977271,0.052315789,0.029776217,0.0,0.0,328.29574,2819,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1
SNY,Duvakitug (TEV-'574/SAR447189) - (RELIEVE UCCD),Moderate-to-severe inflammatory bowel disease (IBD); this includes ulcerative colitis (UC) and Crohn's disease (CD)Â ,Phase 2b,12/17/2024,"Phase 2b topline data reported that the trial met its primary endpoints, noted December 17, 2024.",0.0,115004.5962,22.7225,45.89,48.94,48.29,0.06434783,0.050977271,0.052315789,0.029776217,0.0,0.0,328.29574,2820,1,0,0,0,0,1,0,0,0,0,1,0,3,0,0,1
TEVA,Duvakitug (TEV-'574/SAR447189) - (RELIEVE UCCD),Moderate-to-severe inflammatory bowel disease (IBD); this includes ulcerative colitis (UC) and Crohn's disease (CD)Â ,Phase 2b,12/17/2024,"Phase 2b topline data reported that the trial met its primary endpoints, noted December 17, 2024.",0.0,23690.28925,45.4783,16.51,20.88,22.42,0.234825505,0.30598716,0.052315789,0.029776217,1.97495,0.05568,1207.25838,2821,1,0,0,0,0,1,0,0,0,0,1,0,3,0,0,1
PSTV,REYOBIQ (rhenium Re186 obisbemeda) - (ReSPECT-LM),Leptomeningeal metastases (LM)Â ,Phase 1,12/17/2024,"Phase 1 data presented at SABCS reported that the best response rates (response only) were, CTC: 88% (7/8), noted December 17, 2024.",99.0,6.30908,87.5461,1.17,1.07,1.08,-0.0893451,-0.080042708,0.052315789,0.029776217,1.93279,0.05666,0.30255,2822,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1
TNYA,TN-201 - (MyPeak-1),Hypertrophic cardiomyopathy (HCM)Â ,Phase 1/2,12/17/2024,"Phase 1/2 preliminary data from three patients in the first dose cohort of 3E13 vg/kg (Cohort 1) showed that TN-201 was generally well tolerated, with readily detectable vector DNA in the heart, evide",162.0,111.70093,148.4895,2.88,1.41,1.66,-0.71420059,-0.550972692,0.052315789,0.029776217,17.73342,0.14615,59.86532,2823,0,0,0,1,0,1,0,0,0,0,0,0,2,0,0,1
TNXP,Tonmya (TNX-102 SL) - (RELIEF/RESILIENT),FibromyalgiaÂ ,NDA Filing,12/17/2024,"NDA accepted December 17, 2024.",8.0,62.40397,186.7357,53.0,33.39,38.53,-0.46203546,-0.318854755,0.052315789,0.029776217,0.85092,0.03311,340.01815,2824,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
BMEA,Icovamenib (BMF-219) - (COVALENT-111),Type 2 DiabetesÂ ,Phase 2,12/17/2024,"Phase 2 study met the primary endpoint, displaying a meaningful statistically significant placebo-corrected mean reduction in HbA1c in the prespecified per protocol patient population, noted December",59.0,168.14751,83.5268,5.85,4.64,4.01,-0.231727295,-0.37765042,0.052315789,0.029776217,27.36521,0.03017,29.30849,2825,1,0,0,0,0,1,0,0,0,0,0,0,2,0,0,1
IMMP,IMP761,Autoimmune diseasesÂ ,Phase 1,12/17/2024,"Phase 1 safety data reported no treatment related adverse events to date, noted December 17, 2024.",147.0,494.90046,84.7712,2.08,2.13,1.95,0.023754086,-0.064538521,0.052315789,0.029776217,0.0,0.0,0.14957,2826,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ACTU,Elraglusib (9-ING-41) - (Actuate-1902),Ewing Sarcoma (Pediatric)Â ,Phase 1,12/17/2024,"Phase 1 met primary endpoint of 1 year survival rate and median overall survival, noted December 17, 2024.",20.0,149.61233,0.0,8.69,7.66,7.53,-0.126160956,-0.143277897,0.052315789,0.029776217,0.19213,0.00211,2.76544,2827,1,0,0,0,0,1,0,0,0,0,0,0,2,0,0,1
LPCN,LPCN 1148,"Liver cirrhosis, specifically prevention of OHE recurrence and treatment of sarcopeniaÂ ",Phase 2,12/17/2024,"Fast track designation granted by the FDA, noted December 17, 2024.",5.0,27.86277,99.2465,4.99,5.21,4.8981,0.043143946,-0.018588535,0.052315789,0.029776217,1.15663,0.00238,0.42104,2828,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
CORT,Relacorilant - (GRADIENT),Cushingâ€™s syndromeÂ ,Phase 3,12/17/2024,"Phase 3 long term extension data demonstrated that patients treated with relacorilant experienced clinically meaningful and durable cardiometabolic improvements and relacorilant was well-tolerated, w",105.0,5777.30105,40.7396,55.43,55.14,52.17,-0.005245558,-0.060613346,0.052315789,0.029776217,16.27449,0.17925,34.06406,2829,0,0,0,1,0,1,0,0,0,0,0,0,2,0,0,1
SNTI,SN301A (SENTI-301A),Hepatocellular Carcinoma (HCC)Â ,Phase 1,12/17/2024,"Phase 1 dosing commenced in mainland China, noted December 17, 2024.",26.0,23.63152,249.1353,5.11,5.15,4.17,0.00779731,-0.203283368,0.052315789,0.029776217,1.28585,0.03268,0.98138,2830,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
GPCR,ACCG-2671,ObesityÂ ,Preclinical,12/17/2024,"Preclinical studies with ACCG-2671 demonstrate potent target engagement, robust weight loss, favorable safety profile and PK properties supportive of once-daily dosing in humans, noted December 17, 20",57.0,1802.56596,64.1041,31.0,31.48,28.25,0.015365219,-0.092893747,0.052315789,0.029776217,18.42778,0.06346,15.222,2831,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1
MRUS,Petosemtamab (MCLA-158),"Recurrent/metastatic (r/m) head and neck squamous cell carcinoma (HNSCC), Solid TumorsÂ ",Phase 2,12/17/2024,"Phase 2 OLE colorectal cancer cohort dosing commenced, noted December 17, 2024.",75.0,3074.01928,37.7655,42.8,44.9,42.41,0.047899692,-0.009153919,0.052315789,0.029776217,12.73779,0.08453,39.90972,2832,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
GMAB,Petosemtamab (MCLA-158),"Recurrent/metastatic (r/m) head and neck squamous cell carcinoma (HNSCC), Solid TumorsÂ ",Phase 2,12/17/2024,"Phase 2 OLE colorectal cancer cohort dosing commenced, noted December 17, 2024.",661.0,90680.47717,24.7021,1442.5,1427.5,1485.0,-0.010453057,0.029037053,0.052315789,0.029776217,0.0,0.12409,201.67292,2833,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
IMMX,NXC-201 (HBI10101) - (NEXICART-1),relapsed/refractory multiple myeloma and relapsed/refractory AL amyloidosisÂ ,Phase 1/2,12/17/2024,"Phase 1/2 data published at the JCO demonstrated compelling clinical activity, rapid and deep complete responses in frail and resistant relapsed/refractory AL Amyloidosis patients, noted December 17,",28.0,62.99249,97.0471,1.95,2.29,2.18,0.160722445,0.111495504,0.052315789,0.029776217,1.711,0.13798,0.67116,2834,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CTNM,PIPE-791,Osteoarthritis and low back painÂ ,Phase 1b,12/17/2024,"Phase 1b commenced, noted December 17, 2024",28.0,362.43577,77.5106,13.66,14.06,14.41,0.028862032,0.053450556,0.052315789,0.029776217,4.02621,0.26052,2.34578,2835,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
TLSA,Foralumab (Intranasal),Alzheimerâ€™s DiseaseÂ ,Phase 1,12/17/2024,"Phase 1 dosing commenced, noted December 17, 2024.",111.0,107.97323,101.8759,0.9294,0.9898,0.69,0.062963686,-0.297847619,0.052315789,0.029776217,0.19078,0.03705,0.9153,2836,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
MTVA,Vanoglipel (DA-1241),Metabolic dysfunction-associated steatohepatitis (MASH)Â ,Phase 2a,12/18/2024,"Phase 2a data reported that DA-1241 (100mg) demonstrated a statistically significant reduction in alanine transaminase (ALT) levels at weeks 4 and 8, with a near statistically significant reduction at",24.0,15.93962,75.2021,2.2486,1.85,1.62,-0.195122161,-0.327881651,0.051855435,0.0279806,0.25298,0.04808,9.03345,2837,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1
CGTX,Zervimesine (CT1812) - (SHIMMER),Dementia with Lewy Bodies (DLB)Â ,Phase 2,12/18/2024,"Phase 2 trial met its primary endpoint, noted December 18, 2024.",73.0,24.09784,134.9202,0.4549,0.58,0.648,0.242950489,0.353813082,0.051855435,0.0279806,6.45953,0.14382,167.85629,2838,1,0,0,0,0,1,0,0,0,0,0,0,2,0,0,1
CRVS,Soquelitinib - (CPI-818),Moderate to severe atopic dermatitisÂ ,Phase 1,12/18/2024,"Phase 1 data reported that the soquelitinib mean EASI score reduction was 55.9% at 28 days (n=12) compared to mean EASI reduction of 27.0% in placebo. At day 58, continued improvement in the soqueliti",74.0,302.00908,105.1457,7.39,4.7,4.9,-0.452565226,-0.41089253,0.051855435,0.0279806,5.46919,0.03344,66.15086,2839,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
QNRX,QRX003 - (open label),Netherton Syndrome (NS)Â ,Phase 1,12/18/2024,"Phase 1 data from the first subject being dosed twice daily is suggestive of clinical efficacy across a number of measured endpoints after six weeks of dosing with QRX003, which is the midpoint of tes",0.0,2.84046,125.1756,21.09102,19.68752,16.97852,-0.068862425,-0.216898342,0.051855435,0.0279806,1.88423,0.00108,3.29396,2840,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CHRS,Casdozokitug/toripalimab/bevacizumab,Unresectable locally advanced or metastatic hepatocellular carcinoma (HCC)Â ,Phase 2,12/18/2024,"Phase 2 data reported an objective response rate of 25.3% versus 6.1% in the sorafenib group, a median progression-free survival of 5.8 months, and a median overall survival of 20 months, compared to",116.0,180.88505,108.2226,1.71,1.57,1.47,-0.085417751,-0.15123097,0.051855435,0.0279806,26.66106,0.03588,4.95966,2841,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
KRYS,KB707 - (KYANITE-1),Solid TumorsÂ ,Phase 1,12/18/2024,"Phase 1 initial data reported an objective response rate (ORR) of 27% and disease control rate (DCR) of 73%, noted December 18, 2024.",28.0,4505.05224,40.7633,169.04,156.64,158.52,-0.076185195,-0.064254605,0.051855435,0.0279806,12.6913,0.13239,56.33432,2842,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
VSTM,VS-6766 and LUMAKRAS (Sotorasib) - (RAMP 203),KRAS mutant non-small cell lung cancer (NSCLC)Â ,Phase 1/2,12/18/2024,"Phase 1/2 data reported no dose-limiting toxicities (DLTs) have been observed in the triplet combination, noted December 18, 2024.",61.0,189.5978,96.1601,4.6,4.26,3.9,-0.076787143,-0.16507975,0.051855435,0.0279806,4.50276,0.06004,3.36849,2843,0,0,0,1,0,1,0,0,0,0,0,0,0,2,0,-1
AMGN,VS-6766 and LUMAKRAS (Sotorasib) - (RAMP 203),KRAS mutant non-small cell lung cancer (NSCLC)Â ,Phase 1/2,12/18/2024,"Phase 1/2 data reported no dose-limiting toxicities (DLTs) have been observed in the triplet combination, noted December 18, 2024.",538.0,139102.7181,24.7606,265.95,258.78,264.49,-0.027330041,-0.005504878,0.051855435,0.0279806,2.07196,0.0614,1059.3356,2844,0,0,0,1,0,1,0,0,0,0,0,0,0,2,0,-1
SVRA,MOLBREEVI (Molgradex) - (IMPALA-2),Autoimmune pulmonary alveolar proteinosis (aPAP)Â ,BLA Filing,12/18/2024,"Rolling BLA submission initiated December 18, 2024.",172.0,632.57157,62.2921,3.22,3.02,3.2,-0.064124528,-0.00623055,0.051855435,0.0279806,5.75939,0.14685,2.0937,2845,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
NBIX,"CRENESSITY (Crinecerfont) - (CAHtalyst, capsule formulation)",Congenital Adrenal Hyperplasia (CAH)Â ,Approved,12/19/2024,"Approved December 19, 2024.",99.0,13664.28311,40.2637,135.45,134.96,139.03,-0.00362413,0.026087169,-0.014900116,-0.029797363,3.86086,0.05753,132.69416,2846,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1
PRTA,Prasinezumab (PRX002) - (PADOVA),Parkinson's diseaseÂ ,Phase 2b,12/19/2024,"Phase 2b trial failed to meet its primary endpoint, noted December 19, 2024.",53.0,861.4778,79.7432,11.95,16.01,15.74,0.292482249,0.275473965,-0.014900116,-0.029797363,14.97397,0.06127,52.55444,2847,1,0,0,0,0,1,0,0,0,0,0,0,0,2,0,-1
MESO,RYONCIL (remestemcel-L),"Pediatric participants with acute graft versus host disease (aGVHD), following allogeneic hematopoietic stem cell transplant (HSCT)Â ",Approved,12/19/2024,"Approved December 19, 2024.",128.0,3480.78569,86.4962,12.25,16.76,18.29,0.313469158,0.400828525,-0.014900116,-0.029797363,0.0,0.0,66.81972,2848,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1
PLUR,RYONCIL (remestemcel-L),"Pediatric participants with acute graft versus host disease (aGVHD), following allogeneic hematopoietic stem cell transplant (HSCT)Â ",Approved,12/19/2024,"Approved December 19, 2024.",8.0,24.45106,71.0927,4.2,4.4,4.6,0.046520016,0.090971778,-0.014900116,-0.029797363,0.15375,0.00591,0.1552,2849,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1
VRTX,Suzetrigine,Painful Lumbosacral RadiculopathyÂ ,Phase 2,12/19/2024,"Phase 2 trial met its primary endpoint, noted December 19, 2024.",256.0,102146.4176,29.2005,447.5,396.64,410.65,-0.120647469,-0.085935268,-0.014900116,-0.029797363,1.42556,0.30722,3255.90551,2850,1,0,0,0,0,1,0,0,0,0,0,0,2,0,0,1
MRK,Doravirine/Islatravir (DOR/ISL) - (MK-8591A-051),HIV-1 InfectionÂ ,Phase 3,12/19/2024,Phase 3 trial topline srudy demonstrated non-inferiority of DOR/ISL to baseline antiretroviral therapy (bART) andbictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) in virologically suppress,0.0,251749.3394,24.5045,98.34,99.52,99.87,0.011927767,0.015438478,-0.014900116,-0.029797363,1.29616,0.12425,1205.26443,2851,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
OCGN,OCU410 - (ArMaDa),Geographic Atrophy (GA)Â ,Phase 1/2,12/19/2024,"Phase 1/2 DSMB review noted no serious adverse events, noted December 19, 2024.",292.0,223.70484,71.8422,0.7545,0.7679,0.8142,0.017604238,0.076150758,-0.014900116,-0.029797363,19.56445,0.03106,5.53218,2852,0,0,0,1,0,1,0,0,0,0,0,0,0,2,0,-1
BPTH,BP1001-A (Prexigebersen-A),Obesity in Type 2 diabetes patientsÂ ,Preclinical,12/19/2024,"Preclinical data reported that BP1001-A reduced Grb2 protein expression in myoblast cells, noted December 19, 2024.",8.0,6.41727,145.0869,0.669,1.49,1.35,0.800747339,0.702075811,-0.014900116,-0.029797363,0.71743,0.03109,169.42143,2853,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
MRK,Doravirine/Islatravir (DOR/ISL) - (MK-8591A-052),HIV-1 InfectionÂ ,Phase 3,12/19/2024,"Phase 3 met primary efficacy endpoint at Week 48, the study demonstrated to be non-inferior to BIC/FTC/TAF in double-blind trial. The superiority criteria were not met in trial MK-8591A-052. Primary s",0.0,251749.3394,24.5045,98.34,99.52,99.87,0.011927767,0.015438478,-0.014900116,-0.029797363,1.29616,0.12425,1205.26443,2854,0,0,0,0,0,1,0,0,0,0,0,1,2,0,0,1
REGN,REGN9933 - (ROXI-VTE-I),Venous thromboembolism (VTE)Â ,Phase 2,12/19/2024,"Phase 2 data reported that only 20 of 116 patients has VTE events, noted December 19, 2024.",105.0,76200.28533,26.1552,714.62,708.25,716.68,-0.008953794,0.002878504,-0.014900116,-0.029797363,1.67219,0.1465,769.65315,2855,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ACET,ADI-270,"Solid tumors CAR T, relapsed/refractory renal cell carcinoma (RCC)Â ",Phase 1,12/19/2024,"Phase 1 dosing commenced, noted December 19, 2024.",83.0,78.15507,68.9661,0.8954,0.8603,0.96,-0.03998938,0.069662739,-0.014900116,-0.029797363,3.29356,0.0328,0.8176,2856,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
REGN,REGN7508 (ROXI-VTE-II),0,Phase 2,12/19/2024,"Phase 2 data reported that 8 of 113 patients patients with VTE events, noted December 19, 2024.",105.0,76200.28533,26.1552,714.62,708.25,716.68,-0.008953794,0.002878504,-0.014900116,-0.029797363,1.67219,0.1465,769.65315,2857,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
GILD,Efarindodekin Alfa (XTX301),Solid tumorsÂ ,Phase 1,12/19/2024,"Phase 1 preliminary safety data demonstrated an improved tolerability profile over historical data for rhIL-12, with no dose-limiting toxicities, noted December 19, 2024.",0.0,113522.3569,24.8429,90.69,91.09,94.41,0.004400931,0.040199902,-0.014900116,-0.029797363,1.87869,0.06708,808.54107,2858,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
XLO,Efarindodekin Alfa (XTX301),Solid tumorsÂ ,Phase 1,12/19/2024,"Phase 1 preliminary safety data demonstrated an improved tolerability profile over historical data for rhIL-12, with no dose-limiting toxicities, noted December 19, 2024.",51.0,41.23267,96.1348,0.8665,0.938,0.975,0.07928784,0.117975362,-0.014900116,-0.029797363,0.39872,0.05764,4.44289,2859,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ARMP,AP-PA02 - (Tailwind),Non-cystic fibrosis bronchiectasis (NCFB)Â ,Phase 2,12/19/2024,"Phase 2 trial results demonstrated that inhaled AP-PA02 provides a durable reduction of Pseudomonas aeruginosa in the lung, with a favorable safety and tolerability profile, noted December 19, 2024.",36.0,71.64247,77.1137,1.95,1.98,2.02,0.015267472,0.035268139,-0.014900116,-0.029797363,0.00741,0.04578,0.04051,2860,0,0,0,1,0,1,0,0,0,0,0,0,2,0,0,1
PTN,Bremelanotide - (BREAKOUT),Diabetic Kidney DiseaseÂ ,Phase 2a,12/19/2024,"Phase 2a showed that bremelanotide therapy for six months, in patients with established Type II diabetic nephropathy, resulted in positive and beneficial results for the majority of patients related t",46.0,80.23249,56.1889,0.05,0.049,0.05,-0.020202707,0.0,-0.014900116,-0.029797363,0.0,0.01107,0.07332,2861,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
PHIO,PH-762,Cutaneous Squamous Cell CarcinomaÂ ,Phase 1b,12/19/2024,"Phase 1b demonstrated encouraging safety profile in 2nd cohort with recommendation to escalate to next dose concentration, noted December 19, 2024.",5.0,1.83608,109.3468,2.51,1.74,2.09,-0.36639764,-0.183118687,-0.014900116,-0.029797363,4.56057,0.11164,10.47054,2862,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
MRKR,Neldaleucel (MT-601) - (APOLLO),Lymphoma who have failed or are ineligible to receive anti-CD19 CAR T cell treatmentÂ ,Phase 1,12/19/2024,"Phase 1 showed that 78% of patients achieved objective response rates, with 44.4% demonstrating complete response (CR), noted December 19, 2024.",12.0,33.28462,110.7572,4.03,3.73,3.37,-0.077358142,-0.178853632,-0.014900116,-0.029797363,0.56135,0.04653,0.44466,2863,1,0,0,0,0,1,0,0,0,0,0,0,2,0,0,1
PTCT,Vatiquinone - (MOVE-FA),Friedreich ataxiaÂ ,NDA Filing,12/19/2024,"NDA submitted to the FDA, noted December 19, 2024.",79.0,3489.91272,57.9092,45.46,45.25,45.84,-0.004630148,0.008324254,-0.014900116,-0.029797363,5.95992,0.24653,26.03825,2864,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
CLDX,Barzolvolimab (CDX-0159),Atopic dermatitis (AD)Â ,Phase 2,12/19/2024,"Phase 2 dosing commenced, noted December 19, 2024.",66.0,1683.81671,58.3092,24.82,25.38,25.65,0.022311683,0.032893792,-0.014900116,-0.029797363,11.60909,0.03326,21.50727,2865,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
IMMX,NXC-201 (HBI10101) - (NEXICART-2),Relapsed/refractory AL AmyloidosisÂ ,Phase 1/2,12/19/2024,"Phase 1b/2 data reported that all four patients treated with NXC-201 normalized their disease markers within 30 days of dosing, of which, two are already classified as complete responders (CR), and th",28.0,61.06695,97.7001,2.1,2.22,2.1,0.055569851,0.0,-0.014900116,-0.029797363,1.711,0.13798,1.00343,2866,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
OMER,Narsoplimab,Hematopoietic stem cell-associated TMA (HSCT-TMA)Â ,Phase 3,12/19/2024,"Trial met primary endpoint, noted December 19, 2024.",68.0,593.40554,122.3248,7.46,10.24,10.46,0.316746205,0.338003044,-0.014900116,-0.029797363,15.39012,0.01732,61.49483,2867,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1
IONS,TRYNGOLZA (olezarsen),Familial Chylomicronemia Syndrome (FCS)Â ,Approved,12/19/2024,"Approved December 19, 2024.",159.0,5619.56444,41.0653,36.25,35.59,36.33,-0.018374682,0.002204465,-0.014900116,-0.029797363,6.61723,0.02142,67.42522,2868,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1
RARE,GTX-102 - (Aspire),Angelman SyndromeÂ ,Phase 3,12/19/2024,"Phase 3 dosing commenced, noted December 19, 2024.",96.0,4011.20925,37.1204,42.94,43.47,43.82,0.012267253,0.020286542,-0.014900116,-0.029797363,3.66192,0.09734,51.10398,2869,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ALMS,A-005,Central nervous system (CNS) penetrant TYK2 inhibitorÂ ,Phase 1,12/19/2024,"Phase 1 data demonstrated the ability to cross the human blood-brain barrier to address inflammation within the central nervous system (CNS), noted December 19, 2024.",104.0,469.53523,0.0,8.43,8.63,8.41,0.023447733,-0.002375298,-0.014900116,-0.029797363,4.46529,0.06848,1.96591,2870,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
NVO,AM833 (CagriSema) - (REDEFINE),ObesityÂ ,Phase 3,12/20/2024,"Phase 3 trial met its primary endpoint, noted December 20, 2024.",0.0,2616837.804,42.8504,103.44,85.0,87.37,-0.196340478,-0.16883976,-0.022895882,-0.017001955,0.0,0.0,4569.80791,2871,1,0,0,0,0,1,0,0,0,0,0,0,2,0,0,1
GSK,Zejula (niraparib) and Jemperli (dostarlimab) - (FIRST-ENGOT-OV44),First line advanced ovarian cancerÂ ,Phase 3,12/20/2024,"Phase 3 trial met primary endpoint, noted December 20, 2024.",0.0,53862.85521,19.0938,13.22,13.2,13.425,-0.001514005,0.015387806,-0.022895882,-0.017001955,0.0,0.07985,184.79789,2872,1,0,0,0,0,1,0,0,0,0,0,0,2,0,0,1
HUMA,SYMVESS (acellular tissue engineered vessel-tyod),Extremity Vascular TraumaÂ ,Approved,12/20/2024,"Approval announced December 20, 2024.",158.0,597.02177,102.7139,3.46,4.64,5.5,0.293445777,0.463479503,-0.022895882,-0.017001955,15.80334,0.00162,350.27901,2873,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
GALT,GR-MD-02 (belapectin) - (NAVIGATE),Non-alcoholic steatohepatitis (NASH) with cirrhosisÂ ,Phase 2/3,12/20/2024,"Phase 2b/3 topline data reported a statistically significant reduction (p-value < 0.05) in development of esophageal varices in 2mg/kg cohort compared to placebo, noted December 20, 2024.",64.0,65.2723,112.2514,2.0,1.04,1.15,-0.653926467,-0.553385238,-0.022895882,-0.017001955,9.33356,0.09276,9.63889,2874,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,1
RYTM,IMCIVREE (setmelanotide),"Obesity due to biallelic POMC, PCSK1, LEPR deficiency, or BBS (ages 2-6 years old)Â ",Approved,12/20/2024,"Approved December 20, 2024.",66.0,3448.97071,49.4786,55.48,56.12,55.59,0.01146966,0.001980734,-0.022895882,-0.017001955,10.3607,0.21222,85.30386,2875,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1
PFE,BRAFTOVI,BRAF V600E-Mutant Metastatic Colorectal CancerÂ ,Approved,12/20/2024,"Approved December 20, 2024.",0.0,149381.8573,22.7368,25.77,26.36,26.62,0.022636685,0.032451788,-0.022895882,-0.017001955,1.59492,2e-05,3066.72432,2876,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1
VRTX,ALYFTREK (vanzacaftor/tezacaftor/deutivacaftor),Cystic fibrosis (CF) ages 6 years and olderÂ ,Approved,12/20/2024,"FDA approved on December 20, 2024.",256.0,102308.661,29.1688,396.64,397.27,408.76,0.001587082,0.030099118,-0.022895882,-0.017001955,1.42556,0.32439,2464.31785,2877,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
LXRX,Zynquista (sotagliflozin),Type 1 Diabetes and chronic kidney disease (CKD)Â ,CRL,12/20/2024,"CRL issued by FDA on December 20, 2024.",363.0,258.35854,107.0384,0.7236,0.7147,0.7734,-0.012375879,0.066557626,-0.022895882,-0.017001955,8.72218,0.07182,5.26482,2878,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,-1
LLY,Zepbound (Tirzepatide) - (SURMOUNT-OSA),Obstructive Sleep Apnea (OSA)Â ,Approved,12/20/2024,"FDA Approved on December 20, 2024.",946.0,691315.7061,33.4427,757.54,767.76,783.17,0.013400843,0.033273445,-0.022895882,-0.017001955,0.64822,0.24127,7633.29487,2879,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
NBIX,CRENESSITY (Crinecerfont) - (oral solution formulation),Classic congenital adrenal hyperplasia (CAH)Â ,Approved,12/20/2024,"FDA Approved on December 20, 2024.",99.0,13710.85669,40.1246,134.96,135.42,139.44,0.003402622,0.032655963,-0.022895882,-0.017001955,3.86086,0.03353,306.80728,2880,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
BMY,Sotyktu (deucravacitinib) - (POETYK PsA-1),Psoriatic ArthritisÂ ,Phase 3,12/23/2024,"Phase 3 trial met its primary endpoint, noted December 23, 2024.",0.0,116782.4129,32.1034,57.33,57.58,56.06,0.004351238,-0.022401501,-0.007639457,0.015345005,1.26225,0.00318,543.0899,2881,1,0,0,0,0,1,0,0,0,0,0,0,2,0,0,1
BMY,Sotyktu (deucravacitinib) - (POETYK PsA-2),Psoriatic ArthritisÂ ,Phase 3,12/23/2024,"Phase 3 trial met its primary endpoint, noted December 23, 2024.",0.0,116782.4129,32.1034,57.33,57.58,56.06,0.004351238,-0.022401501,-0.007639457,0.015345005,1.26225,0.00318,543.0899,2882,1,0,0,0,0,1,0,0,0,0,0,0,2,0,0,1
WVE,NHBE GalNAc siRNA (WVE-007) - (INLIGHT),ObesityÂ ,IND-Enabling,12/23/2024,"CTA submitted, noted December 23, 2024.",159.0,2001.05938,121.0172,13.51,13.12,12.41,-0.029292368,-0.084927553,-0.007639457,0.015345005,4.54097,0.07234,11.34166,2883,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
IMCR,IMC-P115C (PRAME-A02 HLE),Solid tumorsÂ ,Phase 1,12/23/2024,"Phase 1 dosing commenced, noted December 23, 2024.",48.0,1407.92215,38.8739,28.325,28.14,29.03,-0.006552755,0.024584971,-0.007639457,0.015345005,14.36528,0.14097,33.185,2884,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
VYNE,VYN202,Moderate-to-severe plaque psoriasisÂ ,Phase 1a,12/23/2024,"Phase 1a topline results demonstrated a favorable safety and tolerability profile with no drug-related adverse events historically associated with earlier generation, less selective BET inhibitors, no",25.0,37.91118,71.3394,2.5,2.57,3.19,0.027615167,0.243730185,-0.007639457,0.015345005,0.43565,0.13324,0.64029,2885,0,0,0,1,0,0,0,0,0,0,1,0,2,0,0,1
ARWR,ARO-INHBE,ObesityÂ ,Phase 1/2,12/23/2024,"Phase 1/2a trial initiated, noted December 23, 2024.",138.0,2457.58023,62.4155,19.45,19.75,18.61,0.015306421,-0.044147999,-0.007639457,0.015345005,8.09297,0.10215,27.6356,2886,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
GKOS,Epioxa (Epi-on),Progressive keratoconusÂ ,NDA Filing,12/23/2024,"NDA filing submitted to the FDA, noted December 23, 2024.",57.0,8176.03489,34.5289,150.88,148.36,149.51,-0.016843066,-0.009121539,-0.007639457,0.015345005,4.83348,0.10755,66.29229,2887,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
XBIT,Natrunix,Rheumatoid ArthritisÂ ,Phase 2,12/23/2024,"Phase 2 trial did not meet its primary endpoint, noted December 23, 2024.",30.0,137.17567,91.3788,6.38,4.5,4.09,-0.349090701,-0.444623127,-0.007639457,0.015345005,2.63668,0.05491,2.13016,2888,1,0,0,0,0,1,0,0,0,0,0,0,0,2,0,-1
ASMB,ABI-4334,Hepatitis BÂ ,Phase 1b,12/26/2024,"Phase 1b initial data reported that a mean decline in HBV DNA of 2.9 log10 IU/mL was observed, noted December 26, 2024.",7.0,97.75968,69.2871,14.72,15.38,17.15,0.043860851,0.15279106,0.006872879,0.004904375,0.20952,0.06017,0.6054,2889,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
ONC,TEVIMBRA (tislelizumab-jsgr) - (RATIONALE 305),Gastric or gastroesophageal junction (G/GEJ) adenocarcinomaÂ ,Approved,12/27/2024,"FDA Approved on December 27, 2024.",110.0,19365.50563,40.7697,184.68,181.89,180.82,-0.015222489,-0.021122536,0.030242252,0.002593755,1.29179,0.10412,30.87892,2890,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
PRFX,PRF-110,BunionectomyÂ ,Phase 3,12/27/2024,"Phase 3 trial did not meet the primary 72-hour endpoint due to unresolved data from the final 24-hour period. However, the drug showed statistically significant pain reduction in the first 48 hours, n",1.0,3.06202,334.0346,4.9,3.5,3.32,-0.336472237,-0.389270422,0.030242252,0.002593755,5.42451,9e-05,3.32333,2891,0,0,0,0,0,1,0,0,0,0,0,1,1,1,0,-1
AXSM,AXS-05 (ADVANCE-2),Alzheimer's disease agitationÂ ,Phase 3,12/30/2024,"Phase 3 trial did not demonstrate statistical significance on primary endpoint, noted December 30, 2024.",49.0,4108.64024,35.6041,86.7,84.78,85.13,-0.022394218,-0.018274384,0.014222168,-0.009370302,13.44554,0.03844,299.57395,2892,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
NRXP,NRX-101,Bipolar Depression and Suicidal IdeationÂ ,NDA Filing,12/30/2024,"NDA initial section filed, noted December 30, 2024.",19.0,18.45296,78.0213,1.51,1.53,3.51,0.013158085,0.843506387,0.014222168,-0.009370302,4.97344,0.0484,1.90266,2893,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CORT,Relacorilant - (GRACE),Hypercortisolism (Cushing's Syndrome)Â ,NDA Filing,12/30/2024,"NDA filing submitted December 30, 2024.",105.0,5327.81572,41.6409,52.47,50.85,51.66,-0.031361455,-0.01555779,0.014222168,-0.009370302,14.99953,0.19532,30.32277,2894,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
NVS,Zolgensma Intravenous OAV101 (AVXS-101) - (STEER),Spinal muscular atrophy (SMA) Type 2Â ,Phase 3,12/30/2024,"Phase 3 trial met primary endpoint, noted December 30, 2024.",0.0,2146.97454,47.3646,6.81,6.9,7.42,0.013129291,0.085786937,0.014222168,-0.009370302,0.0,3e-05,0.37732,2895,1,0,0,0,0,1,0,0,0,0,0,0,2,0,0,1
PGEN,PAPZIMEOS (zopapogene imadenovec-drba),Recurrent Respiratory Papillomatosis (RRP)Â ,BLA Filing,12/30/2024,"BLA rolling submission completed, noted December 30, 2024. The submission is in the initial 60-day review period, during which time the FDA will decide whether to accept the BLA for further review and",297.0,273.27615,78.8783,0.7263,0.9331,1.27,0.250549224,0.558809027,0.014222168,-0.009370302,6.1053,0.19399,5.24143,2896,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
JAZZ,Dordaviprone (ONC201) - (ACTION),H3 K27M-mutant diffuse midline gliomaÂ ,NDA Filing,12/30/2024,"NDA submitted to FDA, noted December 30, 2024.",60.0,7434.10118,28.2961,124.6,122.97,121.82,-0.013168183,-0.022564061,0.014222168,-0.009370302,6.94663,0.08564,57.00238,2897,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
AXSM,Dextromethorphan-bupropion (AXS-05) - (ACCORD-2),Agitation in patients with Alzheimerâ€™s disease (AD)Â ,Phase 3,12/30/2024,"Phase 3 trial in Alzheimer's disease agitation achieves primary endpoint compared to placebo, noted December 30, 2024.",49.0,4108.64024,35.6041,86.7,84.78,85.13,-0.022394218,-0.018274384,0.014222168,-0.009370302,13.44554,0.03844,299.57395,2898,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
NMRA,Navacaprant (NMRA-140) - (KOASTAL-1),Major depressive disorderÂ ,Phase 3,1/2/2025,"Phase 3 KOASTAL-1 data reported that the trial did not meet its primary endpoint with statistical significance, noted January 2, 2025.",161.0,318.2753,245.3232,10.6,1.97,2.37,-1.682820458,-1.497964046,-0.025759083,-0.024676363,6.70534,0.15997,88.41075,2899,1,0,0,0,0,1,0,0,0,0,0,0,0,2,0,-1
ANIP,Prucalopride Tablets - (Motegrity generic),(RLD) Motegrity BiosimilarÂ ,Approved,1/2/2025,"FDA ANDA approved on January 2, 2025.",21.0,1082.45353,39.0241,55.28,55.44,54.16,0.002890175,-0.020468551,-0.025759083,-0.024676363,12.03895,0.07217,8.66982,2900,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1
KZIA,Paxalisib (GDC-0084) - (GBM AGILE),Glioblastoma multiformeÂ ,Phase 2/3,1/2/2025,"FDA feedback reported that data on OS would generally not be appropriate for accelerated approval, noted January 2, 2025.",1.0,7.59941,262.0674,8.85,8.725,8.45,-0.014224991,-0.046251018,-0.025759083,-0.024676363,0.38538,0.00623,0.42125,2901,1,0,0,0,0,0,0,1,0,0,0,0,2,0,0,1
COCP,CC-42344,Influenza AÂ ,Phase 2a,1/2/2025,"Phase 2a data reported no SAEs and no drug-related discontinuations by study participants, noted January 2, 2025.",10.0,23.60319,108.5562,2.02,2.32,2.407,0.138469674,0.175283647,-0.025759083,-0.024676363,0.17233,4e-05,0.34266,2902,0,0,0,1,0,1,0,0,0,0,0,0,2,0,0,1
PHIO,RXI-231,HyperpigmentationÂ ,Preclinical,1/2/2025,"Preclinical data reported that RXI-231 significantly reduced tyrosinase mRNA expression, and correspondingly reduced in melanin content in both normal human melanocytes and the 3D human epidermal cult",5.0,3.29158,115.1354,1.8,1.9,1.69,0.054067221,-0.063058136,-0.025759083,-0.024676363,2.29507,0.14382,0.52857,2903,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CAPR,Deramiocel (CAP-1002) - (HOPE-2),Duchenne Muscular Dystrophy (DMD)Â ,BLA Filing,1/2/2025,"BLA submission to the FDA completed, noted January 2, 2024.",45.0,680.22982,128.885,13.8,14.96,13.86,0.08071138,0.004338402,-0.025759083,-0.024676363,12.29795,0.01148,18.7839,2904,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1
KROS,Cibotercept (KER-012) - (TROPOS),Pulmonary arterial hypertension (PAH) and disorders associated with bone lossÂ ,Phase 2,1/5/2025,"Phase 2 trial voluntarily halted all dosing due to new observations of pericardial effusion adverse events, noted January 15, 2025.",40.0,652.16929,191.7289,16.1,16.1,14.56,0.0,-0.100541229,0.002166613,0.032667188,7.46812,0.03251,0.0,2905,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
OCS,OCS-05 - (ACUITY),Acute optic neuritisÂ ,Phase 2,1/6/2025,"Phase 2 trial met primary safety endpoint, noted January 6, 2025.",43.0,740.3289,42.3619,17.56,17.65,22.38,0.005112195,0.242544115,-0.004965468,0.03613922,0.05245,0.00211,2.98938,2906,0,0,0,1,0,1,0,0,0,0,0,0,2,0,0,1
IMAB,Uliledlimab (TJ004309),Solid tumorsÂ ,Phase 1,1/6/2025,"Development of uliledlimab is being paused, noted January 6, 2025.",81.0,87.94945,75.5089,0.9399,1.08,1.07,0.138942833,0.129640441,-0.004965468,0.03613922,0.84191,0.10754,3.39335,2907,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
VYNE,Repibresib Gel (VYN201),VitiligoÂ ,Phase 2b,1/6/2025,"Phase 2b enrollment completed, noted January 6, 2024.",25.0,59.00573,70.7955,3.46,4.0,3.02,0.145025772,-0.136011758,-0.004965468,0.03613922,0.42285,0.10982,1.13926,2908,0,0,0,0,0,1,0,0,0,1,0,0,2,0,0,1
TPST,Amezalpat (TPST-1120) and OPDIVO (nivolumab),"Hepatocellular Carcinoma (HCC), Solid tumorsÂ ",Phase 1/2,1/6/2025,"Orphan Drug Designation granted by the FDA, noted January 6, 2024.",4.0,41.42505,98.0907,12.3747,12.3396,11.9925,-0.002840463,-0.031372611,-0.004965468,0.03613922,7.39012,0.22592,4.42293,2909,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
